Volume 30

Annals of Oncology

Volume 30

1

Reply to the letter to the editor ‘Response to the effect of PD-L1 testing on the cost-effectiveness of immune checkpoint inhibitors’ by Ogale

de Lima Lopes, G, Aguiar, P

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 54 KB

english, 2019

2

9PSafety profile and therapeutic efficacy of one cycle of [177Lu]prostate-specific membrane antigen (PSMA) in end stage metastatic castration-resistant prostate cancer patients with low performance status

Gupta, M, Choudhury, P S, Rawal, S, Goel, H C, Talwar, V, Dutta, K D, Singh, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 110 KB

english, 2019

3

11PPhotosensitizer-based multimodal nanocomposites as a theranostic agent for near infrared (NIR)-guided cancer-targeting synergistic chemo-phototherapy

Ponraj, T, Vivek, R, Paulpandi1, M, Vimala, K, Vasanthakumar, A, Kannan, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

4

22PTherapeutic potential of connective tissue growth factor (CTGF) in triple-negative breast cancer

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 69 KB

english, 2019

5

Drug Index

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

6

14PButein inhibits solid tumors cell viability, colony, and tumor growth via STAT3 signaling pathway and enhance the anti-cancer effects of Frondoside-A and camptothecin

Attoub, S, Sulaiman, S, Arafat, K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

7

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer

Overman, M J, Adam, L, Raghav, K, Wang, J, Kee, B, Fogelman, D, Eng, C, Vilar, E, Shroff, R, Dasari, A, Wolff, R, Morris, J, Karunasena, E, Pisanic, T R, Azad, N, Kopetz, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

8

130PRelationship of clinicopathological characteristics, EGFR genotyping and prognosis in non-small cell lung cancer patients with malignant pleural effusion

Zhang, J, Zhou, Z S, Su, Y C, Yu, T Q

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

9

151PSafety and tolerability of pembrolizumab or placebo plus pemetrexed and platinum as first-line therapy in Japanese patients (PTS) with metastatic non-squamous non-small cell lung cancer (NSCLC) enrolled in the phase III KEYNOTE-189 study

Horinouchi, H, Nogami, N, Saka, H, Nishio, M, Tokito, T, Takahashi, T, Kasahara, K, Hattori, Y, Ichihara, E, Adachi, N, Sawada, T, Shimamoto, T, Noguchi, K, Pietanza, M C, Kurata, T

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 92 KB

english, 2019

10

3PNotable variation of molecular testing in metastatic lung cancer in the Netherlands

Kuijpers, C, Van den Heuvel, M, Overbeek, L, Lindert, A Van, Damhuis, R, Willems, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 107 KB

english, 2019

11

5PThe circular RNA circXPO1 promotes tumor growth in lung adenocarcinoma

Huang, Q, Qiu, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

12

7PImmunomodulatory effects of Tumor Treating Fields (TTFields) on lung cancer models

Weinberg, U, Kaynan, N, Voloshin Sela, T, Davidi, S, Porat, Y, Shteingauz, A, Munster, M, Schneiderman, R S, Tempel Brami, C, Zeevi, E, Gotlib, K, Cahal, S, Giladi, M, Kirson, E, Kinzel, A, Palti, Y

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 90 KB

english, 2019

13

10PThe prevalence and prognostic significance of JAK2 mutation subtypes in non-small cell lung cancer from Chinese populations

Wang, W, Xu, C, Zhang, Q, Zhuang, W, Zhu, Y, Huang, Z, Chen, G, Fang, M, Lv, T, Song, Y

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 86 KB

english, 2019

14

13PThe micro-environmental cross talk between mast cells and lung cancer cells through cell-to-cell contact

Shemesh, R, Gorzalczany, Y, Sagi-Eisenberg, R, Geva, S, Roisman, L R C, Peled, N

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

15

22PPaclitaxel/ carboplatin/ bevacizumab in non-small cell lung cancer patients induces peripheral effector CD8 T cell proliferation that could be prone for treatment with checkpoint inhibitors

Dumoulin, D, de Goeje, P, Poncin, M, Bezemer, K, Groen, H J M, Smit, E F, Dingemans, A-M C, Kunert, A, Hendriks, R, Aerts, J G

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 94 KB

english, 2019

16

147PImpact on KRAS-subtypes and TP53 mutations on the prognostic value of KRAS/KEAP1 comutations in non-small cell lung cancer (NSCLC)

Scheffler, M, Frank, R, Ihle, M A, Abdulla, D S, Koleczko, S, Nogova, L, Holzem, A, Chanra, T, Riedel, R, Michels, S, Fischer, R N, Kron, A, Merkelbach-Bruse, S, Buettner, R, Wolf, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

17

185TiPRATIONALE 001: Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)

Paz-Ares, L, Senan, S, Planchard, D, Wang, L, Cheong, A, Slepetis, R, Nguyen, M H, Vokes, E E

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 81 KB

english, 2019

18

45PTreatment (Tx) patterns and overall survival (OS) in patients (pts) with stage IIIB–IV NSCLC in Portugal: An IPO-PORTO database analysis from the I-O Optimise initiative

Soares, M A S, Antunes, L, Redondo, P, Borges, M, Hermans, R, Patel, D, Grimson, F, Munro, R, Chaib, C, Lacoin, L, Daumont, M, Penrod, J R, O’Donnell, J C, Bento, M J, Goncalves, F R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 95 KB

english, 2019

19

LBA2Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC)

Garassino, M C, Paz-Ares, L, Hui, R, Faivre-Finn, C, Spira, A, Planchard, D, Ozguroglu, M, Daniel, D B, Vicente, D, Murakami, S, Rydén, A, Zhang, Y, O’Brien, C, Dennis, P A, Antonia, S J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 91 KB

english, 2019

20

122POsimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts

Yang, J C-H, Ramalingam, S S, Lee, C K, Kurata, T, Kim, D-W, John, T, Nogami, N, Ohe, Y, Rukazenkov, Y, Murphy, M, Jänne, P A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 82 KB

english, 2019

21

27PComparison of three different gene panels for determination of tumor mutational burden by next generation sequencing

Pappesch, R, Heydt, C, Rehker, J, Merkelbach-Bruse, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

22

2ODifferentially regulated high-throughput CT imaging features correlate to distinct tumor immune contextures portraying a radiomic signature with prognostic impact on surgically resected NSCLC

Mazzaschi, G, Quaini, F, Milanese, G, Madeddu, D, Bocchialini, G, Ampollini, L, Gnetti, L, Lagrasta, C, Silva, M, Roti, G, Sverzellati, N, Tiseo, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 93 KB

english, 2019

23

200PImplementation of artificial intelligence (AI) for lung cancer clinical trial matching in a tertiary cancer center

Leventakos, K, Helgeson, J, Mansfield, A S, Deering, E, Schwecke, A, Adjei, A, Molina, J, Hocum, C, Halfdanarson, T, Marks, R, Parikh, K, Pomerleau, K, Coverdill, S, Rammage, M, Haddad, T

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 86 KB

english, 2019

24

189OEGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with multiple brain metastases

Jiang, T, Zhou, C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 109 KB

english, 2019

25

104OIMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations

Reck, M, Jotte, R, Mok, T S K, Lim, D W-T, Cappuzzo, F, Orlandi, F, Stroyakovskiy, D, Nogami, N, Rodríguez-Abreu, D, Moro-Sibilot, D, Thomas, C A, Barlesi, F, Finley, G, Nishio, M, Lee, A, Shankar, G,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 99 KB

2019

26

115OAfatinib in EGFR TKI-naïve patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: An interim analysis of a phase IIIB trial

Passaro, A, Laktionov, K K, Poltoratskiy, A, Egorova, I, Hochmair, M, Migliorino, M R, Metro, G, Gottfried, M, Tsoi, D, Ostoros, G, Rizzato, S, Mukhametshina, G Z, Schumacher, M, Novello, S, Dziadzius

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 102 KB

2019

27

48PEducation and lung cancer: A Mendelian randomisation study

Zhou, H, Zhang, Y, Liu, J, Yang, Y, Fang, W, Hong, S, Chen, G, Zhao, S, Zhang, Z, Shen, J, Xian, W, Huang, Y, Zhao, H, Zhang, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

28

49PA Mendelian randomization study of the effects of Crohn’s disease on lung cancer

Liu, J, Zhou, H, Zhang, Y, Fang, W, Yang, Y, Hong, S, Chen, G, Zhao, S, Shen, J, Xian, W, Huang, Y, Zhao, H, Zhang, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

29

60PNomogram for patients with stage I small cell lung cancer: A competing risk analysis

Liu, J, Zhou, H, Zhang, Y, Fang, W, Yang, Y, Hong, S, Chen, G, Zhao, S, Chen, X, Zhang, Z, Xian, W, Shen, J, Huang, Y, Zhao, H, Zhang, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

30

112OCirculating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC)

Horn, L, Whisenant, J G, Wakelee, H, Reckamp, K L, Qiao, H, Du, L, Hernandez, J, Huang, V, Waqar, S N, Patel, S, Sanborn, R E, Shaffer, T, Garg, K, Holzhausen, A, Harrow, K, Liang, C, Lim, L P, Li, M,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

31

114OPotential resistance mechanisms using next generation sequencing from Chinese EGFR T790M+ non-small cell lung cancer patients with primary resistance to osimertinib: A multicenter study

Xu, C, Wang, W, Zhu, Y, Yu, Z, Zhang, H, Wang, H, Zhang, J, Zhuang, W, Lv, T, Song, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

32

118O Blood tumor mutational burden as a predictor of clinical benefit in non-small cell lung cancer patients treated with docetaxel: Secondary analysis of the OAK and POPLAR randomized clinical trials

Nie, W, Qian, J, Han, B-H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

33

135P EGFR & PD L1: An (im)perfect union

Batra, U, Sharma, M, Jain, P, Bothra, S, Pasricha, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

34

137PDetection and clinicopathologic features of ctDNA in T790M-positive advanced lung adenocarcinomas patients after failure of treatment with first- and second-generation EGFR-TKIs

He, W, Zhou, Z S, Yu, T Q, Zhao, H W, Su, Y C, Zeng, P A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

35

139PReal-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United States

Pan, X, Lin, M M, Yin, Y, Hou, P, Baumann, P, Jahanzeb, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

36

150PCharacterization of patients with metastatic non-small cell lung cancer obtaining long term benefit from immunotherapy

Galli, G, Proto, C, Signorelli, D, Imbimbo, M, Ferrara, R, Prelaj, A, De Toma, A, Randon, G, Trevisan, B, Ganzinelli, M, Zilembo, N, Garassino, M C, Lo Russo, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

37

155PAssociation of immune-related adverse events (irAEs) and immunotherapy (IT) benefit in advanced non-small cell lung cancer (NSCLC)

Saavedra Serrano, C, Barquín García, A, Corral de la Fuente, E, Serrano Domingo, J J, Albarrán Artahona, V, Martin Huertas, R, Gómez Rueda, A, Olmedo García, M E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

38

156PPeripheral blood biomarkers as prognostic factors for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients

Prelaj, A, Rebuzzi, S E, Pizzutilo, P, Bilancia, M, Montrone, M, Pesola, F, Longo, V, Del Bene, G, Lapadula, V, Cassano, F, Petrillo, P, Bafunno, D, Varesano, N, Lamorgese, V, Mastranrdea, A, Ricci, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

39

159PInitial serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC

Lang, D, Horner, A, Brehm, E, Akbari, K, Hergan, B, Langer, K, Asel, C, Scala, M, Kaiser, B, Lamprecht, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

40

166PCorrelation of various clinical, imaging and laboratory parameters with outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): Results from a prospective, observational, single institution study

Rounis, K, Papadaki, C, Makrakis, D, Monastirioti, A, Vamvakas, L, Kalbakis, K, Mavroudis, D, Aggelaki, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

41

176PReal-world treatment patterns for metastatic non-small cell lung cancer at IRST Italy

Altini, M, Massa, I, Balzi, W, Gentili, N, Foca, F, Danesi, V, Manunta, S, Burgio, M A, Cravero, P, Ejzykowicz, F, Chandwani, S, Delmonte, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 102 KB

2019

42

179PTreatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice

Frueh, M, Rahma, O E, Pachynski, R K, Mazieres, J, Goldschmidt, J, Ton, T G N, Mhatre, S K, Chuo, C-Y, Martinalbo, J, Davies, J, Juergens, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

43

180TiPAn open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer

Spicer, J, Provencio, M, Garrido Lopez, P, Bosch-Barrera, J, de Castro Carpeño, F J, Felip, E, Trigo, J, Viteri, S, Coart, E, Schmidt, E, Christiansen, A V, Zocca, M-B, Andersen, M H, Ehrnrooth, E, Pa

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

44

102OFinal analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLC

Mok, T S K, Wu, Y-L, Kudaba, I, Kowalski, D M, Cho, B C, Turna, H Z, de Castro, G, Srimuninnimit, V, Laktionov, K K, Bondarenko, I, Kubota, K, Caglevic, C, Karaszewska, B, Dang, T, Yin, L, Penrod, J,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 112 KB

2019

45

69OComprehensive profiling of genomic and TCR repertoire in localized stage lung adenocarcinomas from a prospective cohort study

Chen, K, Bai, J, Zhao, H, Yang, F, Zhang, C, Wang, Y, Chang, L, Guan, Y, Yi, X, Feng, L, Zhang, K, Cheng, S, Wang, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

46

70ORadiomic-based quantitative CT analysis to predict the invasiveness of pure ground-glass lung adenocarcinoma

Xv, F, Zhu, W, Hu, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 108 KB

2019

47

81PHigher PD-L1 expression correlates with lymphocyte infiltration in early non-small cell lung cancer

Rocha, P, Rodrigo, M, Moliner, L, Hardy-Werbin, M, Casadevall Aguilar, D, Durán, X, Arpí, O, Clavé, S, Salido, M, Riera, X, Menendez, S, Taus, Á, Pijuan, L, Comerma, L, Arriola Aperribay, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

48

203PRetrospective study about lung carcinoid: Our experience in a Spanish hospital

Cabrero, D S, Cruz, P, de Castro, J, Higuera, O, Pertejo, A, Esteban, I, Gutierrez, L, Villamayor, J, Ostios, L, Viñal, D, Miranda, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

49

55ORadiogenomic signatures of NSCLC brain metastases: A potential non-invasive imaging marker for ALK mutation

Wadhwa, S, Krishna.b, G, Malhotra, M, Prabhash, K, Noronha, V, Joshi, A, Patil, V, Mahajan, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

50

87PTime-series of peripheral blood biomarkers as biomarkers for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients

Prelaj, A, Rebuzzi, S E, Pizzutilo, P, Bilancia, M, Montrone, M, Pesola, F, Longo, V, Del Bene, G, Lapadula, V, Cassano, F, Petrillo, P, Bafunno, D, Varesano, N, Lamorgese, V, Mastranrdea, A, Ricci, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

51

94PChallenges in the management of stage III non-small cell lung cancer (NSCLC) within multidisciplinary team (MDT): A lung cancer center experience

Harbegue, K, Mejri, N, El Benna, H, Labidi, S, Daoud, N, Boussen, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

52

42OImplementation of organized lung cancer screening program in Korea

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

53

64PTiming of treatment with concurrent chemoradiotherapy (CRT) and impact on progression free survival (PFS) in limited stage small cell lung cancer (LSSCLC)

McSorley, L M, Goggin, C M, Elhadi, N, O’Dea, P, Sui, J S Y, Kelly, D C, Brady, C, O’Mahony, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

54

66PTreatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice

Sebastian, M, Barlesi, F, Califano, R, Mansfield, A S, Blackhall, F H, Flahavan, E M, Davies, J, Arnold, P, Morris, S, Reck, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

55

4PCorrelation between folate receptor alpha (FRα) expression and clinicopathological features in lung adenocarcinoma

Tamura, N, Fujiwara, Y, Hashimoto, T, Shiraishi, H, Kitano, S, Shimizu, T, Yamamoto, N, Motoi, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

56

11PAutophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells

Liang, L, Hui, K, Hu, C, Wen, Y, Jiang, X

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

57

14PThe characteristics of MET exon 14 skipping mutations in Chinese non-small cell lung cancer: A retrospective analysis

Zhu, Y, Xu, C, Wang, W, Zhang, Q, Zhuang, W, Chen, G, Fang, M, Lv, T, Song, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

58

15PTTF1 status in non-small cell lung cancer adenocarcinoma: A prognostic factor

Cordoba Ortega, J F, Salud, A, Morales, S, Veas, J, Rodriguez, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

59

19PFOXP3Δ3, the major isoform of FOXP3, promotes proliferation, migration, and invasion in non-small cell lung cancer

Jia, H, Qi, H, Peng, J, Li, M, Chen, G G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

60

1OImpact of MET variants on PD-L1 expression in pleomorphic lung carcinoma

Januszewski, A, Zhang, Y Z, Chang, W-C, Laggner, U, Bowman, A, Adefila-Ideozu, T, Vivanco, I, Moffatt, M F, Cookson, W O, Gupta, N P, Nicholson, A G, Bowcock, A, Popat, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 99 KB

2019

61

24PA new bioinformatic pipeline allows the design of small, targeted gene panels for efficient TMB estimation

Manca, P, Mallona, I, Santini, D, Tonini, G, Rolfo, C D, Robinson, M D, Pantano, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

62

25PLung tumorspheres as a drug screening platform against cancer stem cells

Herreros Pomares, A, Amado, H, Calabuig Fariñas, S, Escorihuela, E, Murga, J, Torres, S, Durendez-Saez, E, Zhang, F, Blasco, A, Navarro, A, Sampedro, C, Jantus-Lewintre, E, Camps, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

63

29PPretreatment T790M mutation detection by ultrasensitive PCR assay as predictor of efficacy in non-small lung cancer (NSCLC) patients treated with 1st or 2nd generation EGFR tyrosine kinase inhibitors (TKIs)

Juan Vidal, O J, Simarro, J, Lorente Estelles, D, Pérez-Simó, G, Mancheno, N, Murria, R, Gomez Codina, J, Laiz, B, Palanca, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

64

31PDo two lungs form an integrated immune system? Learning from BALF examination in lung cancer

Domagala-Kulawik, J, Skirecki, T, Dziedzic, D, Polubiec-Kownacka, M, Kryczka, T, Kwiecien, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

65

32PExosomes in NSCLC: Analysis of its cargo as a source of biomarkers

Durendez-Saez, E, Calabuig Fariñas, S, Suarez, C, Mosqueda, M, Gallach, S, Escorihuela, E, Moreno, A, Dong, N, Herreros Pomares, A, de la Cueva, E, Martinez-Romero, A, Serna, E, Paramio, J M, Jantus-L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

66

36PCan a BALF profile distinguish hot vs cold lung tumors?

Domagala-Kulawik, J, Dziedzic, D, Polubiec-Kownacka, M, Kryczka, T, Kwiecien, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

67

41PDiagnostic accuracy of droplet digital PCR (ddPCR) and amplification refractory mutation system PCR (ARMS-PCR) for detecting EGFR mutation in cell-free DNA of advanced lung cancer: A meta-analysis

Li, C C, He, Q, Liang, H, He, J, Liang, W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

68

21OEPAC-Lung: Pooled analysis of circulating tumor cells in advanced non-small cell lung cancer

Lindsay, C R, Blackhall, F H, Carmel, A, Gazzaniga, P, Groen, H J M, Krebs, M G, Muinelo-Romay, L, Pantel, K, Rossi, E, Terstappen, L, Wikman, H, Soria, J-C, Farace, F F, Renehan, A, Dive, C, Besse, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

69

LBA1_PRNivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study

Owonikoko, T K, Kim, H R, Govindan, R, Ready, N, Reck, M, Peters, S, Dakhil, S R, Navarro, A, Rodriguez-Cid, J, Schenker, M, Lee, J S, Gutierrez, V, Percent, I, Morgensztern, D, Fairchild, J, Baudelet

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

70

142PClinical management of advanced lung adenocarcinoma with ALK rearrangement: Real-world treatment outcomes and long-term survival

Zhang, B, Wang, S, Xu, J, Zhang, Y, Zhang, X, Qian, J, Lu, J, Qiao, R, Nie, W, Zhang, L, Zhao, Y, Hu, M, Zhang, W, Han, B-H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 93 KB

english, 2019

71

164PPD-L1 expression affect the efficacy of pemetrexed maintenance therapy in real-world patients with advanced non-squamous NSCLC

Qin, Y, Jiang, L, Li, Y, Ren, L, Wang, Y, Gong, Y, Peng, F, Zhu, J, Ding, Z, Liu, Y, Yu, M, Lu, Y, Huang, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

72

183TiPA phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer

Planchard, D, Li, B T, Murakami, H, Shiga, R, Lee, C C, Wang, K, Jänne, P A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 93 KB

english, 2019

73

113OEntrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001

Paz-Ares, L, Doebele, R C, Farago, A F, Liu, S V, Chawla, S P, Tosi, D, Blakely, C M, Krauss, J C, Sigal, D, Bazhenova, L, John, T, Besse, B, Wolf, J, Seto, T, Chow-Maneval, E, Ye, C, Simmons, B, Deme

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 103 KB

english, 2019

74

39PHigh dose apatinib in the reversal of immunosuppressive tumor microenvironment for irradiation therapy in lung carcinoma

Liang, L, Hu, C, Wen, Y, Zhuang, W, Wang, L, Xia, Y, Hui, K, Jiang, X

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

75

200PImplementation of artificial intelligence (AI) for lung cancer clinical trial matching in a tertiary cancer center

Leventakos, K, Helgeson, J, Mansfield, A S, Deering, E, Schwecke, A, Adjei, A, Molina, J, Hocum, C, Halfdanarson, T, Marks, R, Parikh, K, Pomerleau, K, Coverdill, S, Rammage, M, Haddad, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

76

189OEGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with multiple brain metastases

Jiang, T, Zhou, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 109 KB

2019

77

123PLong term survival analysis of osimertinib in stage IV NSCLC patients harbored acquired EGFR T790M mutation: A real-word study in China

Wang, S, Han, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

78

107OCrizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001

Shaw, A, Riely, G J, Bang, Y-J, Kim, D-W, Camidge, D R, Shapiro, G I, Usari, T, Wang, S C, Wilner, K, Clark, J W, Ou, S-H I

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 91 KB

english, 2019

79

72OMulti-centre analysis of cardiac events following radical radiotherapy for lung cancer

Sun, F, Banfill, K, Lilley, J, Wheller, B, Murray, L, McWilliam, A, Van Herk, M, Abravan, A, Faivre-Finn, C, Franks, K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

80

38PHedgehog pathway activation might mediate pemetrexed resistance in NSCLC cells

Liu, Y, Kiefl, R, Huber, R M, Tufman, A, Kauffmann-Guerrero, D

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

81

106OBrigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial

Califano, R, Hochmair, M J, Gridelli, C, Delmonte, A, Garcia Campelo, M R, Bearz, A, Griesinger, F, Morabito, A, Felip, E, Ghosh, S, Tiseo, M, Haney, J, Kerstein, D, Popat, S, Camidge, D R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 85 KB

english, 2019

82

108OTreatment duration of brigatinib in patients enrolled in the international expanded access program (EAP)

Lin, M M, Pan, X, Hou, P, Allen, S, Baumann, P, Hochmair, M J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

83

119OEfficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): First results of the ongoing non-interventional study (NIS) VARGADO

Grohe, C, Gleiber, W, Haas, S, Mueller-Huesmann, H, Schulze, M, Atz, J, Kaiser, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 81 KB

english, 2019

84

120OThromboembolic events in advanced non-small cell lung cancer

Srinivasalu, V K, Subramaniam, N, Raghuram, S, Kolathu, S, Ponnada, B, Philip, A, Jose, W M, Pavithran, K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 96 KB

english, 2019

85

141PEffect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p)

Angelats, L, Garcia Campelo, M R, Bernabe Caro, R, Arriola Aperribay, E, Calvo de Juan, V, Barba Joaquín, A, Vinolas Segarra, N, Gil Moreno, M D L L, Vilà Martinez, L, Juan Vidal, O J, Vilariño Quinte

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

86

145PClinicopathological characteristics and outcome of advanced ROS1-positive non-small cell lung cancer in Asian patients

Kho, C Y X, Lim, D W-T, Tan, D S W, Tan, W L, Rajasekaran, T, Jain, A, Toh, C K, Ang, M-K, Tan, E H, Ng, Q S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

87

71OImpact of underlying pulmonary diseases on treatment outcomes in early stage non-small cell lung cancer treated with definitive radiotherapy

Kim, H, Yoo, H, Pyo, H, Park, H Y

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

88

75PThoracic ultrasound can be a trustable tool in untouchable lung nodule surgery

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

89

76PEndobronchial surgery and photodynamic therapy for early central lung cancer treatment

Pirogov, S S, Telegina, L, Sokolov, V, Karmakova, T, Filonenko, E, Pikin, O, Kaprin, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

90

79PTissue microarray analysis on prognostic value of coexpression of RUNX3 and trimethylated histone H3 lysine 27 in surgically resected patients with stage I non-small cell lung cancer

Chen, X, Deng, Y, Shi, Y

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

91

84OPhase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations

Creelan, B C, Yeh, T, Kim, S-W, Nogami, N, Kim, D-W, Chow, L Q, Kanda, S, Taylor, R, Tang, W, Tang, M, Angell, H K, Roudier, M P, Marotti, M, Gibbons, D L

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 111 KB

english, 2019

92

86OThe effect of prophylactic cranial irradiation (PCI) for young stage III NSCLC patients: Subgroup analyses of the NVALT-11/DLCRG-02 study

Witlox, W J A, Ramaekers, B, Groen, H J M, Dingemans, A-M C, Praag, J, Belderbos, J, Van der Noort, V, Van Tinteren, H, Joore, M A, De Ruysscher, D

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 100 KB

english, 2019

93

89PTreatment patterns and long-term survival for unresected stage III non-small cell lung cancer patients: A nationwide register study in Denmark

Green, A, Olsen, K E, Bliddal, M, Christensen, H N, Jakobsen, E

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

94

95PThe role of patient performance status and its changes before and after completion of multimodal treatment for inoperable stage III NSCLC

Käsmann, L, Taugner, J, Eze, C, Roengvoraphoj, O, Dantes, M, Gennen, K, Karin, M, Tufman, A, Belka, C, Manapov, F

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

95

101TiPPACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy

Girard, N, Mornex, F, Christoph, D C, Fietkau, R, Filippi, A R, Field, J, Garrido Lopez, P, McDonald, F, Peters, S, Klein, A B, Licour, M, Garassino, M C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

96

50PReduced-, and no-dose thin-section radiologic examinations: Comparison of capability for nodule detection in patients having pulmonary nodules

Tang, W, Peng, Q, Huang, Y, Wu, N, Ouyang, H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

97

53PPulmonary tuberculosis: A hurdle to overcome for early lung cancer diagnosis in TB burden countries

Akter, M S, Ahmed, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 68 KB

english, 2019

98

20PAtypical hyperplasia of bronchial epithelial cells induced by chronic exposure to PM 2.5 in mice

Hou, T F, Chen, Q H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 59 KB

english, 2019

99

26PPotentialities of liquid biopsy in advanced non-small cell lung cancer (aNSCLC): Early evaluation of sentinel mutations in plasma and outcome of patients treated with immunotherapy

Bonanno, L, Zulato, E, Attili, I, Pavan, A, Del Bianco, P, Nardo, G, Boscolo Bragadin, A, Pasqualini, L, Calabrese, F, Fassan, M, Pasello, G, Guarneri, V, Amadori, A, Conte, P, Indraccolo, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

100

30PPrognostic significance of IGF-1 signaling pathway in patients with advanced non-small cell lung cancer

Kotsantis, I, Economopoulou, P, Psyrri, A, Maratou, E, Pectasides, D, Gogas, H, Kentepozidis, N, Mountzios, G, Dimitriadis, G, Giannouli, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

101

34PImpacts of HDAC2 inhibition on lung cancer treatment

Yeh, Y-T, Wu, C-R, Lai, J-C, Huang, C-H, Wei, Y-F, Huang, M-S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

102

35PClinicopathological characteristics with genetic profiling and prognostic analysis of primary lymphoepithelioma-like carcinoma in Chinese south-eastern population

Shen, Y, Hu, F, Zhang, B, Han, B-H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

103

103O_PRSafety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1–positive advanced NSCLC: Pooled analysis from KEYNOTE-010, -024, and -042

Nosaki, K, Hosomi, Y, Saka, H, Baas, P, de Castro, G, Reck, M, Wu, Y-L, Brahmer, J R, Felip, E, Sawada, T, Noguchi, K, Han, S R, Piperdi, B, Kush, D A, Lopes, G

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 85 KB

english, 2019

104

109OEntrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2

Barlesi, F, Drilon, A, Braud, F De, Cho, B C, Ahn, M J, Siena, S, Krebs, M G, Lin, C C, John, T, Tan, D S W, Seto, T, Dziadziuszko, R, Arkenau, H-T, Rolfo, C, Wolf, J, Ye, C, Riehl, T, Eng, S, Doebele

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 108 KB

english, 2019

105

126PRegional retrospective analysis of outcomes of EGFR mutated non-squamous non-small cell lung cancer (NSCLC) patients in West Yorkshire

Sharma, D, Slevin, F, Clarke, K, Franks, K, Snee, M, Jain, P

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

106

128PFrequency and types of EGFR mutation in Moroccan patients with non-small cell lung cancer

Sow, M L, El Yacoubi, H, Moukafih, B, Balde, S, Akimana, G, Elkhoyaali, S, Abahssain, H, Mrabti, H, Elghissassi, I, Errihani, H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

107

133PA study evaluating the different treatment modalities for EGFR mutation positive advanced NSCLC patients that acquire c-MET amplification after EGFR TKI therapy resistant

Qu, J, Liu, L, Heng, J, Zhou, C, Xiong, Y, Jiang, W, Yang, N

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

108

140PBrigatinib experience on the ALK project

Gomes, F, Tokaca, N, Yip, K, Ghosh, S, Newsom-Davis, T, Greystoke, A, Mills, H, Ahmed, S, Harle, A S, Ayre, G, Shah, R, Popat, S, Blackhall, F H, Summers, Y

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

109

77PThe prognostic impact of the international association for the study of lung cancer (IASLC) definitions on completeness of surgical resection for non-small cell lung cancer (NSCLC)

Gagliasso, M, Cartia, C F, Maraschi, A, Rapanà, R, Sobrero, S, Sandri, A, Migliaretti, G, Ardissone, F

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

110

78PLung resection for cancer in patients with heart disease: Management and postoperative outcome

Caushi, F S, Skenduli, I, Hatibi, A, Mezini, A, Telo, S, Bala, S, Shima, E, Cani, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

111

80PHigh blood platelets levels (BPL): A prognostic factor in patients with early or locally advanced non-small cell lung cancer (NSCLC)

Cordoba Ortega, J F, Salud, A, Morales, S, Veas, J, Rodriguez, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

112

59PComparison of internal target volume delineation using CT datasets of four-dimensional computed tomography in lung cancer radiotherapy

Bushra, S, Tibdewal, A, Mummudi, N, Kinhikar, R, Ghadi, Y, Agarwal, J P

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

113

85OPrevalence of programmed death ligand-1 (PD-L1) by demographic, disease and sample characteristics in unresectable, stage III NSCLC (PACIFIC)

Planchard, D, Garassino, M C, Paz-Ares, L, Faivre-Finn, C, Spira, A, Gu, Y, Wadsworth, C, Whiteley, J, Scott, M, Boothman, A-M, Ratcliffe, M, Walker, J, Dennis, P A, Antonia, S J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 90 KB

english, 2019

114

90PReal-world treatment patterns, clinical practice and outcomes for locally advanced, non resectable, non-small cell lung cancer from the French ESME Lung database

Girard, N, Pérol, M, Simon, G, Audigier Valette, C, Gervais, R, Debieuvre, D, Schott, R, Quantin, X, Coudert, B, Lena, H, Carton, M, Robain, M, Filleron, T, Chouaid, C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

115

92PA prospective study on the association of dose-volume histogram parameters with oesophagitis, radiation pneumonitis, radiation induced pulmonary fibrosis after receiving chemoradiation for NSCLC

Bhowal, S, Chatterjee, K, Dey, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

116

93PHeterogeneity score in inoperable stage III non-small cell lung cancer patients treated with definitive chemoradiotherapy: A single centre analysis

Taugner, J, Käsmann, L, Eze, C, Dantes, M, Roengvoraphoj, O, Gennen, K, Karin, M, Tufman, A, Belka, C, Manapov, F

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

117

96PImpact of thrombocytosis and neutrophil-to-lymphocyte ratio before start of chemoradiotherapy on patient survival in inoperable stage III NSCLC

Hoffmann, M, Taugner, J, Roengvoraphoj, O, Eze, C, Käsmann, L, Belka, C, Manapov, F

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

118

97PPattern of first-site failure and salvage treatment in patients with inoperable stage III non-small cell lung cancer after chemoradiotherapy

Eze, C, Taugner, J, Käsmann, L, Roengvoraphoj, O, Schmidt-Hegemann, N-S, Dantes, M, Belka, C, Manapov, F

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

119

98PImplications for UK practice of the use of durvalumab in stage III NSCLC

Iqbal, M S, Atherton, P, Macgregor, C, Wieczorek, A, Singer, J, Walther, J, Little, F, Harden, S, Peedell, C, Cyriac, A, Chowdhury, S, Bayne, M, Yip, K, Britten, A, Powell, C, Brock, J, Datta, S, Sevi

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

120

99PEfficacy and safety of adjuvant chemotherapy in lung cancer: Real-world evidence

Roitberg, F S R, Neffá, M F B V, Bonadio, R R C C, Harada, G, Mendoza, E Z, Mak, M P, Takahashi, T K, Martins, R E, Mesquita, C, Santini, F C, de Araújo, P H X N, Lauricella, L L, Prado, G F, Takagaki

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

121

83OImpact of subsequent post-discontinuation immunotherapy on overall survival in patients with unresectable, stage III NSCLC from PACIFIC

Ouwens, M, Darilay, A, Zhang, Y, Mukhopadhyay, P, Mann, H, Ryan, J, Dennis, P A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 93 KB

english, 2019

122

43OBaseline results from a French pilot study on lung cancer screening by CT scan: DEP KP80

Leleu, O, Auquier, M-A, Chauffert, B, Berna, P, Petigny, V, Ait Addi, A, Basille, D, Jounieaux, V

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 89 KB

english, 2019

123

44PTemporal trends in treatment (Tx) and overall survival (OS) among patients (pts) with incident NSCLC in the UK: A real-oncology database analysis from the I-O Optimise initiative

Snee, M, Cheeseman, S, Thompson, M, Riaz, M, Lacoin, L, Sopwith, W, Chaib, C, Daumont, M, Penrod, J R, O’Donnell, J C, Hall, G

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 111 KB

english, 2019

124

47PTreatment (Tx) patterns and overall survival (OS) in patients (pts) with NSCLC in Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative

Ekman, S, Sørensen, J B, Brustugun, O T, Horvat, P, Patel, D, Rosenlund, M, Mette Kejs, A, Juarez-Garcia, A, Daumont, M, Lacoin, L, Penrod, J R, O’Donnell, J C, Planck, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

125

61PValue of post-radiotherapy for limited stage small cell lung cancer on basis of a prognostic scoring model

Yu, J, Ouyang, W, Hu, J, Zhang, J, Xie, C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 81 KB

english, 2019

126

63PReal-life experience with the implementation of DLL3 staining and the subsequent treatment with rovalpituzumab tesirine in heavily pretreated SCLC patients

Hochmair, M J, Weinlinger, C, Fabikan, H, Koger, R, Krenbeck, D, Huemer, F, Illini, O M, Kulaksiz, M, Valipour, A, Burghuber, O C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 81 KB

english, 2019

127

65PExperience of prophylactic cranial irradiation in extensive stage small cell lung cancer at a regional cancer center in India

Jat, R R, Rai, R K, Jakhar, S L, Beniwal, S K, Sharma, N, Kumar, H S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

128

18PImmunohistochemical expression of PD-L1 in early and late stage non-small cell lung cancer: Correlation with clinicopathological and molecular features

Kokkotou, E, Rapti, V, Grapsa, D, Bakakos, P, Papadopoulos, S, Bobos, M, Iliadis, K, Syrigos, K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

129

33PPrognostic value of CD8-positive tumor stroma-infiltrating lymphocytes and PD-L1 positive tumor cells at initial biopsy in patients with locally advanced NSCLC treated with chemoradiotherapy

Gennen, K, Käsmann, L, Eze, C, Dantes, M, Roengvoraphoj, O, Taugner, J, Neumann, J, Tufman, A, Orth, M, Reu, S, Belka, C, Manapov, F

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

130

37PGenetic variation of lymphotoxin beta receptor (LTβR) rs10849448 (A/G) is associated with risk for lung cancer and metastatic spread to adrenals

Dimitrakopoulos, F-I D, Antonacopoulou, A, Kottorou, A, Tzelepi, V, Panagopoulos, N, Kalofonou, M, Dougenis, D, Koutras, A, Makatsoris, T, Kalofonos, H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

131

40PThe metabolic phenotypes of non-small cell lung cancer cells in association with clinical treatment strategies

Kuo, T-C, Hsiao, T-H, Yang, P-C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

132

39PHigh dose apatinib in the reversal of immunosuppressive tumor microenvironment for irradiation therapy in lung carcinoma

Liang, L, Hu, C, Wen, Y, Zhuang, W, Wang, L, Xia, Y, Hui, K, Jiang, X

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

133

182TiPA phase II trial of tepotinib in patients with non-small cell lung cancer (NSCLC) harboring MET alterations: The VISION study

Paik, P, Cortot, A, Felip, E, Sakai, H, Mazieres, J, Horn, L, Griesinger, F, Bruns, R, Scheele, J, Straub, J, Veillon, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

134

173PCurrent treatment landscape in triple negative breast cancer: A systematic literature review

Fu, A Z, Kuang, Y, Fazeli, M S, Kumar, N, Davis, C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 91 KB

english, 2019

135

5OTILs in ER+/HER2- breast cancer

Criscitiello, C, Vingiani, A, Maisonneuve, P, Viale, G, Viale, G, Curigliano, G

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

136

17PAre single hormone receptor-positive phenotypes biologically and clinically distinct breast cancer? A population-based study

Li, Y, Wu, Y, Yang, D, Li, H, Ren, G

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 81 KB

english, 2019

137

59PMyeloid derived-suppressor cells in healthy women and in advanced breast cancer patients

Palazón Carrión, N, Sánchez León, M L, Jiménez Cortegana, C, Valdivia García, F J, Araujo Fernández, I, Henao Carrasco, F, Nieto García, M A, Sánchez Margalet, V, de la Cruz Merino, L

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 82 KB

english, 2019

138

117ORacial disparities in characteristics and prognosis in Asian versus white patients receiving atezolizumab: An ancillary analysis of POPLAR and OAK studies

Qian, J, Nie, W, Lu, J, Zhang, L, Zhang, Y, Zhang, B, Wang, S, Hu, M, Xu, J, Lou, Y, Dong, Y, Niu, Y, Yan, B, Zhong, R, Zhang, W, Chu, T, Zhong, H, Han, B-H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 82 KB

english, 2019

139

121PRisk of not receiving second-line therapy is high in EGFR mt+ patients: Real-world data of certified lung cancer centers on treatment sequence in EGFR mt+ patients

Roeper, J, Lueers, A C, Falk, M, Schatz, S, Tiemann, M, Wesseler, C, Wiest, G H, Sackmann, S, Ukena, D, Heukamp, L, Griesinger, F

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 81 KB

english, 2019

140

124PThe effect of proton pump inhibitors (PPI) on dacomitinib (DACO) pharmacokinetics and efficacy in non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutation

Li, J, Nickens, D J, Wilner, K, Tan, W

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

141

129PAnlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer

Lian, Z, Du, W, Zhu, J, Zeng, Y, Liu, Z, Huang, J-A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

142

134PMutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors

Wagener-Ryczek, S, Heydt, C, Sueptitz, J, Michels, S, Falk, M, Alidousty, C, Fassunke, J, Tiemann, M, Heukamp, L, Wolf, J, Buettner, R, Merkelbach-Bruse, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

143

136PCorrelation of molecular status and anatomic sites of metastases at diagnosis of EGFR positive non-small cell lung cancer (NSCLC): A single institution experience

Krpina, K, Budimir, B, Kukulj, S, Marušić, A, Jakopović, M, Samaržija, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

144

144PClinical and treatment features associated with improved 5-year survival rate in ALK-positive lung cancer treated with ALK-TKIs

Passaro, A, Prelaj, A, Spitaleri, G, Del Signore, E, Rossi, G, Guerini-Rocco, E, Barberis, M, Catania, C, de Marinis, F

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

145

146PClinical significance of ROS1 5’ deletions detected by FISH and response to crizotinib

Dall’Olio, F G, Lamberti, G, Capizzi, E, Gruppioni, E, Sperandi, F, Altimari, A, Giunchi, F, Fiorentino, M, Ardizzoni, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 101 KB

english, 2019

146

153PChemotherapy with immune-checkpoint inhibitors in first-line treatment metastatic NSCLC patients: Systematic review and literature-based meta-analysis

Addeo, A, Banna, G L, Metro, G, Di Maio, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

147

73PUtilization rates of stereotactic body radiation therapy for the treatment of stage I NSCLC in three European countries

Damhuis, R, Senan, S, Khakwani, A, Harden, S, Helland, A, Strand, T-E

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 89 KB

english, 2019

148

74PIs there any prognostic significance of the level of change in SUVmax after SBRT in patients with early stage NSCLC?

Yaprak, G, Ozen, A, Tugrul, F, Ozugur, S, Isik, N

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

149

68OElectromagnetic navigation bronchoscopy in the European cohort of the prospective, multicenter NAVIGATE study

Lau, K, Flandes, J, Christensen, M, Bezzi, M, Lamprecht, B, Salio, M, Vergnon, J M, Studnicka, M, Trigiani, M, Fernandez, I, Kropfmüller, R, Barisione, E, Viby, N-E, Khandhar, S, Folch, E

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 93 KB

english, 2019

150

57PNon-small cell lung carcinoma (NSCLC) patients with baseline brain imaging: A prospective observational study

Gundu, N, Malik, P S, Khurana, S, Pathy, S, Yadav, M, Jain, D, Kancharla, H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 88 KB

english, 2019

151

58PEvaluation of a care path for patients with lung tumors and co-existing interstitial lung disease

Ronden-Kianoush, M I, Nossent, E J, Dickhoff, C, Nijman, S F M, Bahce, I, Senan, S, Spoelstra, F O B

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

152

91PPrognosis of EGFR-mutant advanced lung adenocarcinoma patients with different intrathoracic metastatic patterns

Hu, F, Zhang, B, Li, C, Xu, J, Wang, H, Gu, P, Zheng, X, Nie, W, Shen, Y, Zhang, H, Hu, P, Zhang, X

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

153

100PA new PET-CT score for locally-advanced inoperable NSCLC stage III patients treated with chemoradiotherapy

Roengvoraphoj, O, Eze, C, Taugner, J, Gjika, A, Tufman, A, Käsmann, L, Hadi, I, Mille, E, Belka, C, Manapov, F

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

154

46PEvolution of overall survival (OS) in patients (pts) with incident NSCLC in Denmark and Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative

Sørensen, J B, Ekman, S, Brustugun, O T, Horvat, P, Patel, D, Rosenlund, M, Mette Kejs, A, Juarez-Garcia, A, Daumont, M, Lacoin, L, Penrod, J R, O’Donnell, J C, Planck, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 87 KB

english, 2019

155

52PConcordance, decision impact, and satisfaction for a computerized clinical decision support system in treatment of lung cancer patients

Lee, K A, Felix, W, Jackson, G

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 68 KB

english, 2019

156

8PRole of chemokines in resectable non-small cell lung cancer (NSCLC)

Drosslerová, M, Šterclová, M, Vašáková, M, Tašková, A, Hytych, V, Horažďovský, P, Richterová, E, Smětáková, M, Havel, L

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

157

17PREDOXI-miRNA of Keap1/Nrf2 axis in lung tumors

Fabrizio, F P, Sparaneo, A, Castellana, S, Mazza, T, Trombetta, D, Graziano, P, Rossi, A, Fazio, V M, Muscarella, L A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

158

23PImmunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts)

Ferrara, R, Naigeon, M, Auclin, E, Duchemann, B, Cassard, L, Medhi, J J, Boselli, L, Grivel, J, Desnoyer, A, Mezquita, L, Hendriks, L, Planchard, D, Caramella, C, Remon-Masip, J, Sangaletti, S, Garass

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 107 KB

english, 2019

159

69PLong duration of breastfeeding is associated to inflammatory breast (IBC) cancer

Mejri, N, El Benna, H, Rachdi, H, Labidi, S, Boussen, H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

160

116OHealth-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study

Pérol, M, Dixmier, A, Barlesi, F, Debieuvre, D, Raspaud, C, Auliac, J B, Benoit, N, Bombaron, P, Moro-Sibilot, D, Asselain, B, Cotté, F-E, Lamoureux, P, Karam, N, Ozan, N, Calvet, C, Bryan, B, Allan,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

161

132PNew insights into acquired resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor therapy in lung cancer

Fassunke, J, Heydt, C, Michels, S, Veggel, B Van, Müller, F, Keul, M, Dammert, M A, Schmitt, A, Smit, E F, Kast, S, Wolf, J, Buettner, R, Sos, M L, Rauh, D, Merkelbach-Bruse, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

162

6OUtility of early circulating tumour DNA dynamics as a surrogate for progression free survival in the BEECH phase I/II trial in metastatic breast cancer

Hrebien, S, Citi, V, Garcia-Murillas, I, Cutts, R, Kozarewa, I, Ratnayake, J, de Bruin, E C, Schiavon, G, Antunes De Melo e Oliveira, A M, Turner, N

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

163

184PCAM-H2 effectively targets and treats HER2 positive brain lesions: A comparative preclinical study with trastuzumab

Puttemans, J, D’Huyvetter, M, Windhorst, B, Lahoutte, T, Devoogdt, N

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

164

103O_PRSafety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1–positive advanced NSCLC: Pooled analysis from KEYNOTE-010, -024, and -042

Nosaki, K, Hosomi, Y, Saka, H, Baas, P, de Castro, G, Reck, M, Wu, Y-L, Brahmer, J R, Felip, E, Sawada, T, Noguchi, K, Han, S R, Piperdi, B, Kush, D A, Lopes, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

165

109OEntrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2

Barlesi, F, Drilon, A, Braud, F De, Cho, B C, Ahn, M J, Siena, S, Krebs, M G, Lin, C C, John, T, Tan, D S W, Seto, T, Dziadziuszko, R, Arkenau, H-T, Rolfo, C, Wolf, J, Ye, C, Riehl, T, Eng, S, Doebele

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 108 KB

2019

166

126PRegional retrospective analysis of outcomes of EGFR mutated non-squamous non-small cell lung cancer (NSCLC) patients in West Yorkshire

Sharma, D, Slevin, F, Clarke, K, Franks, K, Snee, M, Jain, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

167

128PFrequency and types of EGFR mutation in Moroccan patients with non-small cell lung cancer

Sow, M L, El Yacoubi, H, Moukafih, B, Balde, S, Akimana, G, Elkhoyaali, S, Abahssain, H, Mrabti, H, Elghissassi, I, Errihani, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

168

133PA study evaluating the different treatment modalities for EGFR mutation positive advanced NSCLC patients that acquire c-MET amplification after EGFR TKI therapy resistant

Qu, J, Liu, L, Heng, J, Zhou, C, Xiong, Y, Jiang, W, Yang, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

169

140PBrigatinib experience on the ALK project

Gomes, F, Tokaca, N, Yip, K, Ghosh, S, Newsom-Davis, T, Greystoke, A, Mills, H, Ahmed, S, Harle, A S, Ayre, G, Shah, R, Popat, S, Blackhall, F H, Summers, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

170

77PThe prognostic impact of the international association for the study of lung cancer (IASLC) definitions on completeness of surgical resection for non-small cell lung cancer (NSCLC)

Gagliasso, M, Cartia, C F, Maraschi, A, Rapanà, R, Sobrero, S, Sandri, A, Migliaretti, G, Ardissone, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

171

78PLung resection for cancer in patients with heart disease: Management and postoperative outcome

Caushi, F S, Skenduli, I, Hatibi, A, Mezini, A, Telo, S, Bala, S, Shima, E, Cani, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

172

80PHigh blood platelets levels (BPL): A prognostic factor in patients with early or locally advanced non-small cell lung cancer (NSCLC)

Cordoba Ortega, J F, Salud, A, Morales, S, Veas, J, Rodriguez, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

173

59PComparison of internal target volume delineation using CT datasets of four-dimensional computed tomography in lung cancer radiotherapy

Bushra, S, Tibdewal, A, Mummudi, N, Kinhikar, R, Ghadi, Y, Agarwal, J P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

174

85OPrevalence of programmed death ligand-1 (PD-L1) by demographic, disease and sample characteristics in unresectable, stage III NSCLC (PACIFIC)

Planchard, D, Garassino, M C, Paz-Ares, L, Faivre-Finn, C, Spira, A, Gu, Y, Wadsworth, C, Whiteley, J, Scott, M, Boothman, A-M, Ratcliffe, M, Walker, J, Dennis, P A, Antonia, S J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

175

90PReal-world treatment patterns, clinical practice and outcomes for locally advanced, non resectable, non-small cell lung cancer from the French ESME Lung database

Girard, N, Pérol, M, Simon, G, Audigier Valette, C, Gervais, R, Debieuvre, D, Schott, R, Quantin, X, Coudert, B, Lena, H, Carton, M, Robain, M, Filleron, T, Chouaid, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

176

92PA prospective study on the association of dose-volume histogram parameters with oesophagitis, radiation pneumonitis, radiation induced pulmonary fibrosis after receiving chemoradiation for NSCLC

Bhowal, S, Chatterjee, K, Dey, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

177

93PHeterogeneity score in inoperable stage III non-small cell lung cancer patients treated with definitive chemoradiotherapy: A single centre analysis

Taugner, J, Käsmann, L, Eze, C, Dantes, M, Roengvoraphoj, O, Gennen, K, Karin, M, Tufman, A, Belka, C, Manapov, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

178

96PImpact of thrombocytosis and neutrophil-to-lymphocyte ratio before start of chemoradiotherapy on patient survival in inoperable stage III NSCLC

Hoffmann, M, Taugner, J, Roengvoraphoj, O, Eze, C, Käsmann, L, Belka, C, Manapov, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

179

97PPattern of first-site failure and salvage treatment in patients with inoperable stage III non-small cell lung cancer after chemoradiotherapy

Eze, C, Taugner, J, Käsmann, L, Roengvoraphoj, O, Schmidt-Hegemann, N-S, Dantes, M, Belka, C, Manapov, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

180

98PImplications for UK practice of the use of durvalumab in stage III NSCLC

Iqbal, M S, Atherton, P, Macgregor, C, Wieczorek, A, Singer, J, Walther, J, Little, F, Harden, S, Peedell, C, Cyriac, A, Chowdhury, S, Bayne, M, Yip, K, Britten, A, Powell, C, Brock, J, Datta, S, Sevi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

181

99PEfficacy and safety of adjuvant chemotherapy in lung cancer: Real-world evidence

Roitberg, F S R, Neffá, M F B V, Bonadio, R R C C, Harada, G, Mendoza, E Z, Mak, M P, Takahashi, T K, Martins, R E, Mesquita, C, Santini, F C, de Araújo, P H X N, Lauricella, L L, Prado, G F, Takagaki

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

182

83OImpact of subsequent post-discontinuation immunotherapy on overall survival in patients with unresectable, stage III NSCLC from PACIFIC

Ouwens, M, Darilay, A, Zhang, Y, Mukhopadhyay, P, Mann, H, Ryan, J, Dennis, P A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

183

43OBaseline results from a French pilot study on lung cancer screening by CT scan: DEP KP80

Leleu, O, Auquier, M-A, Chauffert, B, Berna, P, Petigny, V, Ait Addi, A, Basille, D, Jounieaux, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

184

44PTemporal trends in treatment (Tx) and overall survival (OS) among patients (pts) with incident NSCLC in the UK: A real-oncology database analysis from the I-O Optimise initiative

Snee, M, Cheeseman, S, Thompson, M, Riaz, M, Lacoin, L, Sopwith, W, Chaib, C, Daumont, M, Penrod, J R, O’Donnell, J C, Hall, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 111 KB

2019

185

47PTreatment (Tx) patterns and overall survival (OS) in patients (pts) with NSCLC in Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative

Ekman, S, Sørensen, J B, Brustugun, O T, Horvat, P, Patel, D, Rosenlund, M, Mette Kejs, A, Juarez-Garcia, A, Daumont, M, Lacoin, L, Penrod, J R, O’Donnell, J C, Planck, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

186

61PValue of post-radiotherapy for limited stage small cell lung cancer on basis of a prognostic scoring model

Yu, J, Ouyang, W, Hu, J, Zhang, J, Xie, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

187

63PReal-life experience with the implementation of DLL3 staining and the subsequent treatment with rovalpituzumab tesirine in heavily pretreated SCLC patients

Hochmair, M J, Weinlinger, C, Fabikan, H, Koger, R, Krenbeck, D, Huemer, F, Illini, O M, Kulaksiz, M, Valipour, A, Burghuber, O C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

188

65PExperience of prophylactic cranial irradiation in extensive stage small cell lung cancer at a regional cancer center in India

Jat, R R, Rai, R K, Jakhar, S L, Beniwal, S K, Sharma, N, Kumar, H S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

189

18PImmunohistochemical expression of PD-L1 in early and late stage non-small cell lung cancer: Correlation with clinicopathological and molecular features

Kokkotou, E, Rapti, V, Grapsa, D, Bakakos, P, Papadopoulos, S, Bobos, M, Iliadis, K, Syrigos, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

190

33PPrognostic value of CD8-positive tumor stroma-infiltrating lymphocytes and PD-L1 positive tumor cells at initial biopsy in patients with locally advanced NSCLC treated with chemoradiotherapy

Gennen, K, Käsmann, L, Eze, C, Dantes, M, Roengvoraphoj, O, Taugner, J, Neumann, J, Tufman, A, Orth, M, Reu, S, Belka, C, Manapov, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

191

37PGenetic variation of lymphotoxin beta receptor (LTβR) rs10849448 (A/G) is associated with risk for lung cancer and metastatic spread to adrenals

Dimitrakopoulos, F-I D, Antonacopoulou, A, Kottorou, A, Tzelepi, V, Panagopoulos, N, Kalofonou, M, Dougenis, D, Koutras, A, Makatsoris, T, Kalofonos, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

192

40PThe metabolic phenotypes of non-small cell lung cancer cells in association with clinical treatment strategies

Kuo, T-C, Hsiao, T-H, Yang, P-C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

193

13PDynamic monitoring of ctDNA reveals that acquired NF2 mutations confer resistance to HER2 targeted therapy in HER2-mutant breast cancer

Li, X, Ma, J, Pan, B, Zhao, Z, Li, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

194

56PCT image standardization is superior to larger but heterogeneous data for robust radiomic models

Vuong, D, Bogowicz, M, Unkelbach, J, Foerster, R, Denzler, S, Xyrafas, A, Pless, M, Thierstein, S, Peters, S, Guckenberger, M, Tanadini-Lang, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 88 KB

english, 2019

195

4ORelationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial

Loi, S, Schmid, P, Aktan, G, Karantza, V, Salgado, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

196

131PUpfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma

Li, C, Guo, J, Zhao, L, Hu, F, Nie, W, Wang, H, Zheng, X, Shen, Y, Gu, P, Zhang, Y, Zhang, X

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

197

202PInformation for lung cancer patients and their caregivers: A systematic analysis of the online landscape

Naish, P, Purdy, E

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 86 KB

english, 2019

198

196OSTELLAR: Final updated results of a phase II trial of TTFields with chemotherapy for unresectable malignant pleural mesothelioma

Ceresoli, G L, Aerts, J G, Dziadziuszko, R, Cedres, S, Hiddinga, B, Meerbeeck, J P Van, Mencoboni, M, Planchard, D, Chella, A, Crinò, L, Krzakowski, M J, Madrzak, J, Ramlau, R, Grosso, F

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 91 KB

english, 2019

199

38PDefining the physiological miRNA landscape in nipple aspirate fluid

Patuleia, S I S, Moelans, C B, van Gils, C H, van Diest, P J, van der Wall, E

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

200

144PImmune cell dynamics induced by a single dose of pembrolizumab as revealed by single-cell RNA profiling

Vos, H, Bassez, A, Qian, J, Floris, G, Nevelsteen, I, Lambein, K, Neven, P, Wildiers, H, Lambrechts, D, Smeets, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 91 KB

english, 2019

201

105OOsimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study

Ahn, M-J, Chiu, C-H, Cheng, Y, Han, J-Y, Goldberg, S B, Greystoke, A, Crawford, J, Zhao, Y, Huang, X, Johnson, M, Vishwanathan, K, Mendoza-Naranjo, A, Mok, T S K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 69 KB

english, 2019

202

138PPD-L1 confers primary resistance to EGFR-TKI in EGFR mutant non-small cell lung cancer via inducing EMT phenotype

Zhang, Y, Liu, T, Zeng, Y, Zhu, J, Du, W, Liu, Z, Huang, J-A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

203

152PCorrelation among different KRAS alterations, genetic co-mutations and PD-L1 expression in patients treated with immunotherapy in metastatic NSCLC

Gianoncelli, L, Spitaleri, G, Passaro, A, Fumagalli, C, Trillo Aliaga, P, Del Signore, E, Stati, V, Ferraro, E, Guerini-Rocco, E, Catania, C M, Barberis, M, de Marinis, F

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

204

143PRole of radiotherapy in management of brain metastases in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC): A single-center retrospective study

Zhao, Y, Zhang, B, Zhang, Y, Wang, S, Qian, J, Han, B-H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

205

204PIncreased risk of breast cancer-specific mortality among women with second primary breast cancer: A SEER population-based study

Wang, C, Hu, K, Zheng, H, Lu, D

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

206

197TiPPhase III study of [fam-] trastuzumab deruxtecan vs investigator’s choice in T-DM1-pretreated HER2+ breast cancer

André, F, Shahidi, J, Lee, C, Wang, K, Krop, I

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

207

13PDynamic monitoring of ctDNA reveals that acquired NF2 mutations confer resistance to HER2 targeted therapy in HER2-mutant breast cancer

Li, X, Ma, J, Pan, B, Zhao, Z, Li, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

208

51PInvasive diagnostic investigation-related complications and its impact on treatment initiation in lung cancer patients in a rapid access lung lesion clinic in regional Australia

McCann, K, Faisal, W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

209

62PExternal validation of a survival score for limited stage small cell lung cancer treated with chemoradiotherapy

Käsmann, L, Abdo, R, Taugner, J, Eze, C, Dantes, M, Roengvoraphoj, O, Belka, C, Manapov, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

210

28PImpact of the 21-gene assay on treatment decisions in high-risk patients with ER-positive HER2-negative early breast cancer: Results of the KARMA Dx study

Llombart, A, Andrés, R, Anton Torres, A, Martinez, N, Rodriguez, C, Sánchez-Rovira, P, Rojas, B, Ruiz Borrego, M, Bermejo, B, Martinez de Dueñas, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

211

167PUtilization and outcomes of Eribulin Mesylate POst a cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i): An observational real-World study in UnitEd States community oncology pRactices (EMPOWER)

Mougalian, S, Wang, E, Alexis, K, Feinberg, B A, Nero, D, Miller, T, Laney, J, Chatterjee, D, Knoth, R, Kish, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

212

2OPrognostic value of endopredict for invasive lobular carcinomas in the combined ABCSG-6/8 and TransATAC trials

Sestak, I, Filipits, M, Buus, R, Rudas, M, Knauer, M, Kronenwett, R, Cuzick, J, Gnant, M I, Dowsett, M, Dubsky, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

213

3OComprehensive evaluation of methodology to assess abundance of immune infiltrates in breast cancer

Nederlof, I, de Bortoli, D, Bareche, Y, Hooijer, G K J, Sotiriou, C, van de Vijver, M J, Horlings, H M, Salgado, R, Biganzoli, E, Desmedt, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

214

7OPAM50MET: A prognostic model based on PAM50 and clinical variables in metastatic hormone receptor (HR)-positive/HER2 negative breast cancer

Prat, A, Tsai, Y-H, Pascual, T, Paré, L, Vidal, M, Adamo, B, Brase, J C, Johnston, S R D, Ciruelos, E M, Parker, J S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

215

8OThe mutational profile of IBC reveals higher mutational burden, deficiency of homologous recombination and NOTCH signalling

Van Laere, S J, Finetti, P, Rypens, C, Birnbaum, D, Vermeulen, P, Viens, P, Dirix, L Y, Bertucci, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

216

9OPara-necrotic expression of VEGFA metagene signature identified by single-cell profiling

Karn, T, Denkert, C, Weber, K E, Jank, P, El-Balat, A, Rody, A, Untch, M, Loibl, S, Pusztai, L, Holtrich, U

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

217

10OComparison of patient populations identified by different PD-L1 assays in in triple-negative breast cancer (TNBC)

Scott, M, Scorer, P, Barker, C, Al-Masri, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

218

11PMammographic density change and risk of breast cancer

Azam, S, Eriksson, M, Sjölander, A, Hellgren, R, Gabrielson, M, Czene, K, Hall, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

219

12PDuctal carcinoma in situ of the breast: Immune cell composition according to subtype

Agahozo, M C, Van Bockstal, M R, Groenendijk, F H, van den Bosch, T P P, Westenend, P, van Deurzen, C H M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

220

14POutcomes of women at high familial risk for breast cancer in Australia: An 8-year single-centre experience

Lammert, J, Skandarajah, A R, Shackleton, K, Calder, P, Thomas, S, Lindeman, G J, Mann, G B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

221

15PInfluence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: Pooled analysis of 484 patients from three prospective multicentre GBG trials

Jank, P, Loibl, S, Fasching, P A, Karn, T, Marmé, F, Mueller, V, Schem, C, Stickeler, E, Lederer, B, Denkert, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

222

16PLongitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer

Guan, X, Niu, Y, Liu, B, Li, C, Li, L, Yi, Z, Sun, X, Chen, H, Ma, F, Lu, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

223

18PSecondary mechanisms of anti-HER2 resistance in breast cancer: NF1 as an actionable target

Duso, B A, Poletti, C, Curigliano, G, Pelicci, P G, Mazzarella, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 98 KB

2019

224

19PThe clinical impact of substituting multigene assays: Comparative clinical analysis of PAM50-ROR versus 21-gene assay

Markopoulos, C J, Hochheiser, L, Hornberger, J, Hytopoulos, E, Stoppler, M C, Gitlin, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

225

20PERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC)

Griguolo, G, Brasó-Maristany, F, Pascual, T, Chic, N, Vidal, M, Adamo, B, Giarratano, T, Dieci, M V, Guarneri, V, Prat, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

226

21PCharacteristics of circulating tumor DNA (ctDNA) in patients with ER-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (MBC) on different lines of endocrine treatment

Bos, M K, Kruger, D T, Jansen, M P H M, Martens, J W M, Boven, E, Sleijfer, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

227

22PESR1 mutations are similarly prevalent in newly metastatic and loco-regional recurrence of endocrine-treated breast cancer patients and carry worse prognosis

Nili Gal Yam, E, Zundelevich, A, Dadiani, M, Itay, A, Sela, T, Gadot, M, Kahana, S, Pavlovsky, A, Barshack, I, Kaufman, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

228

23PDesign of a protein signature predicting response to neo-adjuvant treatment with chemotherapy combined with bevacizumab in breast cancer patients

Haugen, M H, Lingjærde, O C, Garred, Ø, Hedenfalk, I, Loman, N, Mills, G, Borresen-Dale, A-L, Naume, B, Mælandsmo, G M, Engebråten, O

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

229

24PA nomogram integrating reverse phase protein array based proteomic signature and clinical variables improves prognostic prediction in non-metastatic breast cancer after surgery

Junping, Y, Channan, Q

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

230

25PExpression of ER, PR, HER2 and Ki67 in the neoadjuvant GeparX trial: Comparison of central immunohistochemistry with an automated cartridge-based system for mRNA assessment (on behalf of the GBG neoadjuvant and translational subboard)

Denkert, C, Jank, P, Link, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

231

26PUtilization and performance of the Prosigna® breast cancer prognostic gene signature assay at the Medical University of Vienna

Tendl, K A, Monschein, L, Exner, R, Fitzal, F, Bergen, E S, Seifert, M, Singer, C F, Rudas, M, Müllauer, L, Bago-Horvath, Z A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

232

27PBiological features of estrogen receptor-positive breast cancer with elevated RANK (TNFRSF11A) expression

Casimiro, S, Gomes, I, Almeida, B, Alves, P, Félix, P, Vilhais, G, Mansinho, A B, Dionísio, M R, Barbosa-Morais, N, Costa, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

233

29PHeterozygous mutation in fanconi anemia genes associated with hereditary breast cancer

Gordiev, M, Brovkina, O, Shigapova, L H, Shagimardanova, E, Enikeev, R F, Nikitin, A, Petkau, V, Aksarin, A, Ovchinnikova, E, Sakaeva, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

234

30PUpdate on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer

Smyth, L M, Saura, C, Piha-Paul, S A, Lu, J, Mayer, I A, Brufksy, A M, Spanggaard, I, Arnedos, M, Cutler, R E, Hyman, D M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

235

31PThe spatial relations among immune cells are prognostic in inflammatory breast cancer

Van Berckelaer, C, Colpaert, C G, Rypens, C, Marien, K, Kockx, M, Waumans, Y, Vermeulen, P, Dirix, L Y, Van Laere, S J, Van Dam, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

236

32PMicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro

Svartdal, L G, Aure, M R, Leivonen, S-K, Haugen, M H, Hongisto, V, Kristensen, V N, Mælandsmo, G M, Sahlberg, K K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

237

33PGermline PALB2 heterozygous mutations in breast cancers: Haploinsufficiency paradigm

Ouyang, Q, Hu, Z-Y, Liu, L, Gao, J, Wu, H, Lu, J, Xie, N, Tian, C, Liu, Z, Xu, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

238

34PComparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor and synchronous axillary lymph node metastases in 159 breast cancer patients - indicating tumoral heterogeneity

Weydandt, L, Horn, L-C, Aktas, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

239

35PDownregulation of immune checkpoints by doxorubicin and carboplatin-containing neoadjuvant regimens in breast cancer: A new insight into the mechanism of induction of antitumor immunity

Sadighi, S, Sharifian, R, Kazemimanesh, M, Muhammadnejad, A, Amanpour, S, Muhammadnejad, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

240

36PEndocrine implications in male breast cancer in Bulgaria

Konsoulova-Kirova, A A, Kalchev, K, Yordanov, A, El Shemeri, S, Strashilov, S A, Maslyankov, S I, Angelov, K G, Kostova-Lefterova, D, Marincheva, Y, Vasileva, M B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

241

37PRNA signatures from tumor-educated platelets (TEP) enable detection of early-stage breast cancer

Liefaard, M C, Lips, E, Best, M, Sol, N, In ’T Veld, S, Rookus, M, Sonke, G S, Tannous, B A, Wesseling, J, Würdinger, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

242

40PWNT, Hedgehog and NOTCH signaling pathways in triple negative breast cancer with high and low content of cancer stem cells

Brilliant, A, Brilliant, Y, Sazonov, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

243

41PPrognostic significance of BCL-2 expression in triple negative breast cancer (TNBC)

Srinivasalu, V K, Susan, A, Jose, W M, Philip, A, N V, S, Nambiar, A, Pavithran, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

244

42P_PRPainting the global picture of HER2-testing for breast cancer. The ONCOLLEGE-001 survey study

Altuna, S C, Lengyel, C, Trapani, D, Elfaham, E M, Hussain, S, Petrillo, A, El Bairi, K, Mazher, S A, Habeeb, B S, Khan, S Z

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

245

43PCIP2A as a novel target to combat basal like breast cancer

Nagelli, S, Laine, A, Suomi, T, Elo, L, Westermarck, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

246

44PPrognostic value of Ki-67 in patients with triple-negative breast cancer receiving neo-adjuvant or adjuvant chemotherapy: A systematic review and meta-analysis

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

247

45P3D association of ER, PR and HER2 to aid sub-grouping of breast cancer patients

Zhang, J, Lv, J, Yu, G, Li, L, Zhang, Y, Tang, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

248

46PBRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience

Molinaro, E, Venturelli, M, Toss, A, Piombino, C, Barbieri, E, Marcheselli, L, Marchi, I, Tagliafico, E, Cascinu, S, Cortesi, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

249

47PPalbociclib-induced senescence upregulates the expression of IL-8 and may enhance the response to inmunotherapy

Martinez Bueno, A, Bertran Aramillo, J, Garcia Mosquera, J J, Gimenez Capitan, A, Codony-Servat, J, Aguilar, A, Garcia Román, S, Mayo de las Casas, C, Viteri, S, Molina, M A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

250

48PHereditary breast and ovarian cancer syndrome: Descriptive analysis of a familial cancer clinic

Amaral, S R, Cunha Pereira, T, Monteiro, A R, Garcia, A R, Pinto, L, Gonçalves, V, Mariano, M, Broco, S, Carvalho, T, Sousa, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

251

49PThe metastatic potential of grade I breast carcinoma of no special type: A deep insight into putative molecular mechanisms

Lessi, F, Scopelliti, C, Aretini, P, Menicagli, M, Franceschi, S, Mazzanti, C M, Naccarato, A G, Scatena, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

252

50PER pathway activity score as a predictive biomarker to improve stratification for neoadjuvant endocrine therapy

Keizer, D, Inda, M A, Clout, D, van de Stolpe, A, Fernando, A, Martinez-Perez, C, Dixon, J M, Sims, A H, Turnbull, A K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

253

51PHigher ER load is not associated with better outcome in stage I-III breast cancer

Noordhoek, I, de Groot, A F, Cohen, D, Liefers, G-J, Portielje, J E A, Kroep, J R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

254

52PThe early changes of ΔSUV is a predictive marker of response and outcome in everolimus treated patients with mBC

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

255

53PActivity of chemotherapy drugs in patient-derived xenografts (PDXs) from chemotherapy naïve local-regional triple negative breast cancer (LR-TNBC) patients

Martín, M, Ramos-Medina, R, Garcia Sáenz, J Á, del Monte-Millán, M, Cebollero, M, Moreno, F, Echavarria, I, Jerez, Y, Massarrah, T, Lopez-Tarruella Cobo, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

256

54PPrognostic and predictive value of phosphorylated HER2, HER3 and PTEN expression in patients with HER2-positive breast cancer treated with trastuzumab

Debska-Szmich, S, Kusinska, R, Krakowska, M, Czyzykowski, R, Czernek, U, Zadrozna, A, Potemski, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

257

55PTryptophan catabolism differentiates breast cancer patients from healthy controls but does not predict outcome

Onesti, C E, Boemer, F, Josse, C, Leduc, S, Poulet, C, Bours, V, Jerusalem, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

258

56PHER2-targeted antibody dependent cell-mediated cytotoxicity (ADCC) mediated by NK cells against tyrosine kinase inhibitor (TKI)-treated breast cancer (BC) cell lines

Collins, D M, Gaynor, N, Conlon, N T, O’Donovan, N, Crown, J P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

259

57PPrognostic role of microRNA 182 and microRNA 18a in locally advanced triple negative breast cancer

Bajaj, R, Doval, D, Tripathi, R, Sridhar, T, Korlimarla, A, Choudhury, K D, Suryavanshi, M, Mehta, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

260

58PSpindle cell carcinoma of the breast: Rare cancer with potentially targetable biomarkers

Gatalica, Z, Vranic, S, Stafford, P, Palazzo, J, Skenderi, F, Swensen, J, Xiu, J, Spetzler, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

261

60PAnti-inflammatory treatment and inhibition of B-cell activation in a nude mouse model of human breast cancer

Fernandez Madrid, F, Maroun, M-C, Long, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

262

61PFounder mutations BRCA2 c.156_157insAlu in Portuguese population

Macedo, F, Félix Soares, R, Cunha Pereira, T, Monteiro, A R, Bonito, N, Broco, S, Carvalho, T, Mariano, M, Sousa, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

263

62PGrowth inhibition of triple-negative breast cancer cells due to the lack of CD73

Petruk, N, Sandholm, J, Tuomela, J, Selander, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

264

63PControlling nutritional status (CONUT) score is a prognostic factor in patients with resected breast cancer

Li, W, Deng, Y, Ma, G, Wu, Q, Zhou, Q

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

265

64PIdentification of serum proteome signatures of male breast cancer

Zografos, E, Anagnostopoulos, A, Papadopoulou, A, Legaki, E, Zagouri, F, Marinos, E, Tsangaris, G, Gazouli, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

266

65PmiR-210 and miR-152 as biomarkers in invasive ductal carcinoma by liquid biopsy

Zuccari, D A P D C, Lopes, B C, Ventura, F V, Oliveira, J G, Braga, C Z, Kato-Junior, E M, Bordin-Junior, N A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

267

66PDual targeting of RANKL/RANK pathway and HER-2 as a novel treatment strategy in HER-2 positive (+) breast carcinomas (BC)

Zoi, I, Xingi, E, Thomaidou, D, Papavassiliou, A G, Karamouzis, M V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

268

67PDifferential regulation of glucocorticoid receptor signaling in luminal, triple negative and HER2+ breast cancer cells

Zhidkova, E, Maksimova, V, Lylova, E, Savinkova, A, Kuzin, K, Kirsanov, K, Yakubovskaya, M, Lesovaya, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

269

68PFunctional CRISPR knockout screens for modifiers of sensitivity to trastuzumab emtansine

Lipert, B, Siemens, K N, Khan, A, Barker, H R, Tsai, P, Ketela, T W, Bohlander, S K, Print, C G, Jamieson, S M F, Hunter, F W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

270

70PLong non-coding RNA PART1 contributes to cell proliferation and stem cell maintenance in triple-negative breast cancer

Cruickshank, B M, Vidovic, D, Dahn, M L, Sultan, M, Marcato, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

271

72PClinico-pathological relationship between androgen receptor (AR) and tumor infiltrating lymphocytes (TILs) in triple negative breast cancer (TNBC)

Elghazawy, H, Alorabi, M O, Helal, T, Aref, A, Kelany, M, Eid Abdallah, L A, Sayed, F, Ali, D, Zaki, D, Ahmed, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

272

74PInflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity

Rypens, C, Van Berckelaer, C, Billiet, C, Hauspy, J, Bertucci, F, Devi, G, Vermeulen, P, Dirix, L Y, Van Laere, S J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

273

76PPrognostic and predictive significance of the expression of the beta-2 adrenergic receptor in HER2-positive breast cancer

Richard, F, Bitton, R C, Sotiriou, C, de Azambuja, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

274

77PHep par 1 immunohistochemistry in glycogen-rich clear cell carcinoma of the breast

Chang, M C, Wu, J M, Bethune, G C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

275

78PAn in vivo genome-wide RNAi screen identifies novel mediators of paclitaxel response in breast cancer

Sultan, M, Cruickshank, B M, Huynh, T, Lamoureux, E, Vidovic, D, Dahn, M L, Giacomantonio, C, Langille, M, Marcato, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

276

79PThe adipokine receptor CAP1 regulates breast cancer cell proliferation

Bergqvist, M, Borgquist, S, Rosendahl, A H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

277

80PDNA methylation markers of breast cancer response to anthracycline based neoadjuvant chemotherapy

Sigin, V O, Strelnikov, V V, Litviakov, N V, Simonova, O A, Volodin, I V, Slonimskaya, E M, Tanas, A S, Zaletaev, D V, Kuznetsova, E B, Tsyganov, M M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

278

81PInotilone interferes with chromosome replication as an attractive anti-cancer drug target for breast cancer

Chen, L-C, Tu, S-H, Ho, Y-S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

279

82TiPSCAN-B-rec: Infrastructure, technology and clinical research platform to profile and monitor metastatic breast cancer

Bosch, A, Larsson, A-M, Holm, K, Borg, Å, Staaf, J, Saal, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

280

83TiPRESCUE: Reaching for evidence-based chemotherapy use in endocrine sensitive breast cancer - A prospective non-interventional study on risk assessment by the endopredict test and long-term patient outcome in early luminal breast cancer

Ettl, J, Blohmer, J-U, Denkert, C, Beier, L, Klein, E, Neuser, P, Keller, M, Untch, M, Wittenberg, M, Kiechle, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

281

84TiPHER-Seq: A blood-based genomic screening study to identify HER2 mutation-positive patients for enrollment into clinical trials with the pan-HER inhibitor neratinib

Tomasevic, Z, Smyth, L M, Saura, C, Boni, V, Garcia-Sáenz, J Á, Prat, A, Eli, L, Garza, S J, Lalani, A S, Crown, J P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

282

85TiPPhase II trial of HER2-PET/CT using 68Ga-anti-HER2 VHH1 for characterization of HER2 presence in brain metastases of breast cancer patients

Keyaerts, M, Xavier, C, Everaert, H, Vaneycken, I, Fontaine, C, Decoster, L, Vanhoeij, M, Caveliers, V, Lahoutte, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

283

1ODouble PIK3CA mutations in cis enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer

Vasan, N, Razavi, P, Johnson, J L, Shao, H, Reznik, E, Smith, M L, Sebra, R, Cantley, L C, Scaltriti, M, Baselga, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

284

87OImpact of older age on the locoregional and distant breast cancer recurrence risk: A large population-based study

de Boer, A Z, van der Hulst, H C, van der Plas-Krijgsman, W, de Glas, N A, Marang-van de Mheen, P J, Siesling, S, Liefers, G-J, Bastiaannet, E, Portielje, J E A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

285

88OValidation of the American Joint Committee on Cancer new prognostic stage groups for HER2-positive breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the prospective ShortHER trial

Dieci, M V, Bisagni, G, Brandes, A A, Frassoldati, A, Donadio, M, Garrone, O, Piacentini, F, Balduzzi, S, Guarneri, V, Conte, P F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 213 KB

2019

286

89OImpact of delayed adjuvant chemotherapy: The Royal Marsden Hospital (RMH) experience

Okines, A F C, Kipps, E, Irfan, T, Coakley, M, Aggelis, V, Asare, B, Johnston, S R D, Parton, M, Turner, N, Smith, I E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

287

90OThe role of dose-dense (DD) adjuvant chemotherapy (CT) in HER2-positive (HER2+) early breast cancer (BC) patients (pts) before and after the introduction of trastuzumab (T): Exploratory analysis of the GIM2 trial

Lambertini, M, Bruzzone, M, Poggio, F, Conte, B, de Azambuja, E, Bisagni, G, De Laurentiis, M, de Placido, S, Cognetti, F, Del Mastro, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

288

91OCirculating tumor DNA and disease recurrence in early stage breast cancer: From a case-control study to a prospective longitudinal trial

Di Cosimo, S, Appierto, V, Ortolan, E, Dell’Angelo, F, Silvestri, M, Bianchi, G, Folli, S, De Cecco, L, Pruneri, G, Daidone, M G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

289

92OValidating the CTS5 algorithm with the IDEAL study cohort

Noordhoek, I, Blok, E, Meershoek-Klein Kranenbarg, E, Putter, H, Duijm-De Carpentier, M, van de Velde, C, Liefers, G-J, Kroep, J R, Portielje, J E A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

290

93OImpact of tamoxifen (TAM) serum concentration on side effects among premenopausal patients (pts) with early breast cancer (BC) in the prospective multicenter CANTO cohort

Ferreira, A R, Paci, A, Meglio, A Di, André, F, Everhard, S, Martin, A-L, Fasse, L, Menvielle, G, Vaz-Luis, I, Pistilli, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

291

94PCholesterol-lowering medication: Impact on the clinical effect of adjuvant endocrine treatment in postmenopausal breast cancer

Harborg, K S, Heide-Jørgensen, U, Ahern, T P, Ewertz, M, Fenton, D Cronin, Borgquist, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

292

95PThe changing role of gene-expression profiling in the era of de-escalating adjuvant chemotherapy in early stage breast cancer

Steenhoven, J V, Kuijer, A, Schreuder, K, Elias, S, Diest, P V, Wall, E V D, Siesling, S, Dalen, T V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

293

96PAdjuvant radiotherapy induces secondary tumor events in breast cancer patients with Li-Fraumeni syndrome

Rounis, K, Koukaki, T, Christodoulou, C, Papadimitriou, C, Tryfonopoulos, D, Mavroudis, D, Aggelaki, S, Fostira, F, Saloustros, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

294

97PAdjuvant trastuzumab in stage I breast cancer with the tumour size < 1 cm: Our centre experience

Belikova, H, Alhasso, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

295

98PAdjuvant management of male breast cancer in Bulgaria

Konsoulova-Kirova, A A, Yordanov, A, Kostova-Lefterova, D, Shemeri, S El, Dimova, M, Strashilov, S A, Hristova, R H, Maslyankov, S I, Marincheva, Y, Vasileva, M B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

296

99PTalking about risk in the context of genomic tests (TARGET): Evaluation of an educational program

Jenkin, V A, Fallowfield, L J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

297

100PImproved survival of young patients with breast cancer ≤ 40 years of age at diagnosis

Dick, J El, Khalil, L E, Charafeddine, M, Tomb, P El, Fares, J, El Saghir, N S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

298

101P_PRBreast cancer in young women: A multi-center 10-year experience

Eiriz, I F, Pereira, N G, Neves, M T, Batista, M V, Tomás, T C, Braga, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

299

102P_PRBreast cancer early recurrences in young women

Cima, S, Cekani, E K, Valli, M, Richetti, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

300

103PAnti HER-2 therapies and left ventricular dysfunction: A prospective study

Daniele, A J, Gregorietti, V E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

301

104PFinal results of scalp cooling for hair preservation: A single-institution prospective study

Loparco, D, Orlando, L, Caloro, M, Chiara, C, Quaranta, A, Schiavone, P, Fedele, P, Rendini, M, Bonuso, V, Cinieri, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

302

105PSafe chemotherapy for treating early breast cancer in G6PD-deficient patients

Donisi, C, Atzori, F, Dessì, M, Persano, M, Scartozzi, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

303

106PMolecular sub types of breast cancer in a developing country. Classification immunohistochemical: Clinicopathologic feature and survival analysis

Castro, H R, Salazar, L, Garcia, L, Castro Sanchez, N, Ramos, P, Cruz, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

304

107PA comparative study of voluntary deep inspiration breath hold versus free breathing techniques in adjuvant left breast hypofractionated radiotherapy

Elkhouly, E A, Abdelbarry, N, Rashed, Y, Alhanafy, A, Shabaan, N A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

305

86ODose-dense adjuvant chemotherapy in early breast cancer: 15–year results of the phase III Mammella InterGruppo (MIG)-1 study

Blondeaux, E, Cantore, M, Michelotti, A, Conte, B, Benasso, M, Bighin, C, Lambertini, M, Poggio, F, Del Mastro, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

306

109PEarly prediction of non-pCR using ultrasound-guided serial core needle biopsy in HER2-positive breast cancer patients

Zhang, Y, Shen, J, Zhou, Y, Shao, Z-M, Liu, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 201 KB

2019

307

110PEvaluation of pathological complete response as a trial-level surrogate for long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant therapy

Huang, M, Qi, C Z, Ramsey, S, Briggs, A, Zhao, J, Haiderali, A, Karantza, V, Xie, J, Gu, C, Fasching, P A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 204 KB

2019

308

111PSubtype-guided 18F-FDG PET/CT in tailoring axillary surgery among node-positive breast cancer patients treated with neoadjuvant chemotherapy: A feasibility study

Wu, S, Wang, Y, Li, J, Zhang, N, Mo, M, Shen, J, Cheng, J, Liu, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

309

112PNomogram for predicting axillary lymph node pathological complete response after neoadjuvant chemotherapy in node-positive breast cancer patients

Wang, W, Wang, X, Liu, J, Wang, X

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

310

113PThe aromatase inactivator exemestane suppresses serum leptin levels significantly in vivo - in contrast to the aromatase inhibitor letrozole

Bahrami, N, Jabeen, S, Sauer, T, Kristensen, V N, Gundersen, J M, Geisler, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

311

114PThe incidence of metastases detected on a staging CT scan prior to neoadjuvant chemotherapy in early stage breast cancer

Broadbent, R, Ralston, S, Armstrong, A, O’Brien, C, Wardley, A M, Wilson, G, Howell, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

312

115PPathological complete response rates following neoadjuvant systemic therapy in 300 patients with early or locally advanced HER2 positive breast cancer: The Royal Marsden experience

Chaabouni, N, Battisti, N M L, True, V, Chopra, N R, Shepherd, S T C, Lee, K, Joshi, R, Kabir, M, Allen, M, Ring, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

313

117PThe prognostic and predictive role of the androgen receptor in TNBC treated with neo-adjuvant chemotherapy

Jongen, L, Floris, G, Laenen, A, Ardui, J, Smeets, A, Vergote, I, Berteloot, P, Wildiers, H, Neven, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

314

118PDose dense neoadjuvant and adjuvant chemotherapy in triple-negative breast cancer patients: Survival analysis

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

315

119PA systematic review of endocrine deprivation therapy administered in the neoadjuvant setting in double positive breast cancer

Smith, M A, Doran, P, Kelly, C M, McCaffrey, J, Vencken, S, Wallace, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

316

120PPathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy: Focus on Ki-67 and molecular subtypes

Rapoport, B L, Barnard-Tidy, J, Van Eeden, R I, Smit, T, Nayler, S, Benn, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

317

121TiPKEYNOTE-756: Randomized, double-blind, phase III study of pembrolizumab vs placebo + neoadjuvant chemotherapy (CT) and adjuvant endocrine therapy (ET) for high-risk, early-stage estrogen receptor–positive human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer (BC)

Cardoso, F, Jia, L, Hirshfield, K, Karantza, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

318

122TiPGeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo

Loibl, S, Jackisch, C, Rastogi, P, Seiler, S, Lucas, P C, Denkert, C, Costantino, J, Nekljudova, V, Wolmark, N, Geyer, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

319

108OFactors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy: Pooled analysis based on the GBG database

Huober, J, Schneeweiss, A, Blohmer, J-U, Denkert, C, Hanusch, C, Jackisch, C, Nekljudova, V, Seither, F, Loibl, S, Untch, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

320

124PLate-term effects in the arm and shoulder with hypofractionated regional nodal irradiation in patients with breast cancer

Yadav, B S, Bansal, A, Philip, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

321

125P Brazilian randomized study: Impact of preoperative magnetic resonance in the evaluation for breast cancer conservative surgery (BREAST-MRI Trial)

Mota, B S, Reis, Y N, Doria, M T, Ricci, M D, Shimizu, C, Ferreira, V, Tucunduva, T, de Barros, N, Baracat, E C, Filassi, J R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 212 KB

2019

322

126PClinical outcome of early stage breast cancer patients with 1 to 3 positive axillary lymph nodes: A single institution experience

Arjunan, A, Abbas, S, George, P S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

323

127PTreatment outcomes after post-operative radiotherapy in triple-negative breast cancer: Multi-institutional retrospective study (KROG 17-05)

Kim, J H, Byun, S J, Shin, K H, Kim, D-Y, Kim, T H, Kim, Y B, Lee, S-Y, Kim, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

324

128PRole of short-course radiotherapy in post-operative carcinoma of the breast

Behera, M K, Mittal, K, Dutta, S, Ansari, F A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

325

129PPerioperative factors and complications after delayed reconstruction in breast cancer patients in relation to outcome

Dillekås, H E, Kristoffersen, C M, Jensen, S A, Straume, O

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

326

130PIntraoperative radiotherapy with electronic brachytherapy system in breast cancer patients: Systematic review

Vasileva, M B, Kostova-Lefterova, D, Maslyankov, S I, Paycheva, T V, Vlahova, A I, Zahariev, Z I, Pavlov, V M, Todorov, G T, Angelov, K G, Konsoulova, A A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

327

131PA prospective comparative study of sentinel lymph node biopsy with indo-cyanine green (ICG) florescence technique versus dual dye technique for early breast cancer: Going beyond the horizon

Kr, A, Sp, S, Kumar, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 98 KB

2019

328

132PSurgical management of breast cancer in BRCA mutation carriers: A single centre experience

Fachinetti, A, Chiappa, C, Vischi, S, Roesel, R, Ambrosiani, L, Carnevali, I, Tibiletti, M G, Rovera, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

329

133PA nomogram for predicting the malignant diagnosis of BI-RADS US category 4A lesions in women with dense breast tissue

Yang, Y, Hu, Y, Shen, S, Jiang, X, Wang, H, Gu, R, Liu, F, Jia, H, Gong, C, Liu, Q

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

330

134PThe negative pressure therapy with PICO as a prevention of surgical site infection in high risk patients undergoing breast surgery

Fogacci, T, Cattin, F, Samorani, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

331

135PMulti-gene panel testing at the hereditary breast and ovarian cancer (HBOC) unit of the Hospital Clinic of Barcelona

Adamo, B, Moreno, L, Gaba, L, Vidal, M, Pascual, T, Chic, N, Alonso, I, Puig-Butillé, J A, Muñoz, M, Prat, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

332

136PDecisions for immediate breast reconstruction: Do surgeons make sensible choices?

Zaidi, M, Rezacova, M, Mansfield, L, Helme, S, Yiangou, C, Agrawal, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

333

137PCan sentinel node biopsy be considered in early breast cancer with axillary nodal disease?

May-Miller, P, Zaidi, M, Helme, S, Mansfield, L, Yiangou, C, Agrawal, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

334

138PEfficacy of using imprint and exfoliative cytology followed by frozen section as intraoperative margin assessment in breast conservation surgery

Tamanuki, T, Namura, M, Aoyagi, T, Shimizu, S, Suwa, T, Matsuzaki, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

335

139PRate of breast-conserving surgery vs mastectomy in developing countries

Kr, A, Sp, S, Kumar, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

336

140PEvaluation of intraoperative frozen section with final histopathology results for sentinel lymph node biopsy in breast cancer

Kr, A, Sp, S, Kumar, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

337

141PImplant-based breast cancer reconstruction with biological matric or synthetic mesh

Sukhotko, A, Zikiryahodjaev, A D, Ermoshchenkova, M V, Shirokih, I M, Tukmakov, A Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

338

142PRelapse after radical subcutaneous mastectomy with simultaneous reconstruction in patients with breast cancer

Rasskazova, E, Zikiryakhodzhaev, A, Khakimova, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

339

143PA systemic review of information requirements of young women with breast cancer undergoing mastectomy or breast conserving surgery

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

340

123OVariation in radiotherapy after breast conserving surgery in patients aged 75 years or older between hospitals is not reflected in the locoregional recurrence risk

de Boer, A Z, de Glas, N A, Marang-van de Mheen, P J, Dekkers, O M, Siesling, S, Portielje, J E A, Bastiaannet, E, Liefers, G-J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

341

145PImmune functions of follicular helper CD4+CXCR5+ T cells in human breast cancer

Langouo Fontsa, M, Noel, G, Garaud, S, de Wind, A, Van den Eynden, G, Boisson, A, Naveaux, C, Larsimont, D, Piccart, M, Willard-Gallo, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

342

146PExpression of immunomodulatory molecule, programmed death ligand-1 in triple negative invasive breast cancer in the Indian population

Gorijavolu, N B, Augustine, P, Subhadra Devi, L, Antony, G R, Kattoor, J, Mathew, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

343

147PClinical significance of BCL-2 with basal and non-basal triple negative breast cancer (TNBC)

Srinivasalu, V K, Susan, A, Philip, A, Jose, W M, N V, S, Nambiar, A, Pavithran, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 69 KB

2019

344

148PInvestigation on the MyD88 mediated TLR3 signaling via cell surface in breast cancer

Singh, A, Basu, A, Devkar, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 67 KB

2019

345

150O_PRPertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG)

Huober, J, Ribi, K, Weder, P, Li, Q, Vanlemmens, L, Gerard, M-A, Lemonnier, J, Thürlimann, B, Boven, E, Bonnefoi, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 208 KB

2019

346

151OSingle agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results from a phase I/II trial

Yonemori, K, Masuda, N, Takahashi, S, Kogawa, T, Nakayama, T, Yamamoto, Y, Takahashi, M, Toyama, T, Saeki, T, Iwata, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

347

152OFirst report of AURORA, the breast international group (BIG) molecular screening initiative for metastatic breast cancer (MBC) patients (pts)

Aftimos, P G, Antunes De Melo e Oliveira, A M, Hilbers, F, Venet, D, Vingiani, A, Nili Gal Yam, E, Martinez, J L, Ndozeng, J, Irrthum, A, Piccart, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

348

153OResponse rate by geographic region in patients with hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer from the SOLAR-1 trial

Loibl, S, Conte, P F, Campone, M, Mayer, I, Lu, Y-S, Denduluri, N, Wilke, C, Ridolfi, A, André, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

349

154OImpact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial

Fasching, P A, Quek, R G W, Bhattacharyya, H, Hurvitz, S A, Rugo, H S, Ettl, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

350

149OOutcome and mutational landscape of patients with PIK3CA-mutated metastatic breast cancer (mBC)

Mosele, M F, Lusque, A, Tran Dien, A, Droin, N, Le Tourneau, C, Lacroix, L, Bieche, I, Massard, C, Bertucci, F, André, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

351

Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer

Ricordel, C, Friboulet, L, Facchinetti, F, Soria, J -C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

352

181PA nationwide, multi-institutional retrospective study of efficacy and safety of eribulin in Korean breast cancer patients (REMARK)

Jeong, J, Park, M H, Lee, S J, Noh, W C, Jeon, C W, Lee, S W, Son, G S, Moon, B I, Lee, J S, Kang, S S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

353

204PIncreased risk of breast cancer-specific mortality among women with second primary breast cancer: A SEER population-based study

Wang, C, Hu, K, Zheng, H, Lu, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

354

P-012Weighted gene co-expression networks explored MiR-92b Implicated In esophageal squamous cell cancer

Wang, W, Fu, C, Liu, Y, Zhang, Q, Wang, C, He, Z, Pu, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

355

P-019Chemotherapeutic hyperthermic intraperitoneal perfusion following radical D2 resection in the treatment of advanced gastric cancer

Zhu, L, Wu, Z, Ma, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 87 KB

english, 2019

356

P-030Serglycin level in peripheral circulating blood cells has prognostic significance in patients with hepatocellular carcinoma

Chen, H, Li, Y, Chen, Y, Li, Y, McGowan, E, Lin, Y

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 85 KB

english, 2019

357

210TiPEvaluation of safety and efficacy of minocycline combined with tyrosine kinase inhibitors in patients of EGFR mutated metastatic lung cancer

Thottian, A G F, Babu, G K, Dasappa, L, Jacob, L A, Babu, S M, Lokesh, K N, Rudresha, A H, Saldanha, S, Gv, G, Lk, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

358

P-006miR381-3p inhibits migration and invasion in ESCC through downregulated FLVCR1

Ye, W, Zhou, S, Yang, H, Wang, W

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 70 KB

english, 2019

359

P-082Efficacy and safety of intermittent dosing schedule of apatinib for advanced gastric cancer in second-line setting

He, Y, Yan, Y, Wang, G, Sun, Y, Xu, T, Wu, S, Niu, J, Li, H, Xu, H, Luo, H, Ke, L, Chen, W, Cao, L, Hu, X, Ji, C, Hu, B

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 70 KB

english, 2019

360

P-081PKM2 expression as biomarker for resistance to oxaliplatin-based chemotherapy in colorectal cancer

Sfakianaki, M, Papadaki, C, Tzardi, M, Trypaki, M, Manolakou, S, Messaritakis, I, Saridaki, Z, Mavroudis, D, Georgoulias, V, Souglakos, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 90 KB

english, 2019

361

P-098TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)

Hammel, P, Feliu, J, Parner, V, Berardi, R, Van Cutsem, E, Greil, R, Wasan, H, Metges, J, Nygren, P, Osterlund, P, Seufferlein, T, Creemers, G, Biswas-Baldwin, N, Youssoufian, H, Gupta, A, Salesse, S,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

362

P-148High rates of hepatocellular carcinoma within two years of starting treatment for chronic hepatitis C with direct antiviral agents but not with PEG-interferon/ Ribavirin (HORRID Study)

Karbeyaz, F, Müllhaupt, B, Winder, T, Misselwitz, B, Mertens, J, Siebenhuener, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

363

P-393Role of stereotactic body radiation therapy in the management of oligometastatic pancreatic cancer: single institution experience

Scorsetti, M, Comito, T, Franzese, C, Franceschini, D, De Rose, F, Tomatis, S, D’alessio, A, Prete, M, Bozzarelli, S, Rimassa, L, Personeni, N, Santoro, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 70 KB

english, 2019

364

Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer

Ricordel, C, Friboulet, L, Facchinetti, F, Soria, J -C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

365

P-259A novel anti-tumorigenic mechanism by herbal extract saikosaponin-d through p-STAT3/C/EBPβ signaling suppression of COX-2 in liver cancer

Lin, Y, He, S, Li, Y, Chen, H, Zhu, X, McGowan, E

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

366

P-264Chinese herbal medicine Sijunzi decoction alleviates liver cancer cachexia through downregulating TGF-β and IGF 1 signaling pathways

Chen, Y, Chen, H, Sun, B, Chen, Z, Zhang, S, Lin, Y

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 83 KB

english, 2019

367

157PPrognostic impact of the use of antibiotics in patients with advanced non-small cell lung cancer (NSCLC) receiving PD-(L)1 targeting monoclonal antibodies

Schett, A, Rothschild, S I, Mauti, L A, Schmid, S, Appenzeller, C, Curioni-Fontecedro, A, Frueh, M, Joerger, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

368

P-003Perturbation of fatty acids of erythrocyte membranes and blood serum in patients with colorectal cancer: new opportunities for diagnostics

Kruchinina, M, Gromov, A, Prudnikova, I, Shashkov, M, Sokolova, A, Kruchinin, V, Yakovina, I, Bannova, N

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 83 KB

english, 2019

369

P-004Nine years of epidemiological changes of gastrointestinal cancer in Egypt

Aboelhassan, R, abdelMohsen, N, Ali, S, Garas, C, Taha, M, Ateya, K, Mahmoud, H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 94 KB

english, 2019

370

P-005Increased FLVCR1 expression predicts poor prognosis and enhances malignant phenotypes in esophageal squamous cell carcinoma

Zhou, S, Ye, W, Yang, H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 70 KB

english, 2019

371

P-007Rectal cancer in Albania: treatment outcome and prognostic factors of disease progression

Kozma, E, Mati, K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 70 KB

english, 2019

372

P-008Plasma cytokeratin-18 level of patients with esophagogastric cancer as a biomarker of tumour response

Fanipakdel, A, Javadinia, S, Memar, B, Homayundust, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

373

P-009Prognostic factors of untreated hepatocellular carcinoma on cirrhosis

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

374

P-010Glomerular filtration rate to liver transplantation

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

375

P-011The comparison between UGT1A1 single heterozygous and wild-type regarding the clinical outcomes of fixed-dose irinotecan monotherapy for advanced gastric cancer: a multicenter retrospective study

Ando, T, Nakano, S, Yuki, S, Sawada, K, Muranaka, T, Kawamoto, Y, Nakatsumi, H, Yoshita, H, Harada, K, Kobayashi, Y, Miyagishima, T, Hatanaka, K, Tanimoto, A, Ishiguro, A, Honda, T, Sasaki, T, Dazai,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

376

P-013Surgical and combined treatment for patients with cholangiocarcinoma: the experience of FSBI

Polyakov, A, Patutko, Y, Pokataev, I, Podluzhnyi, D, Sagaidak, I, Bazin, I, Chikhareva, Y, Syskova, A, Bazina, I, Yastrebova, A, Magomedov, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

377

P-014Associations between primary cancer site, metastatic site, comorbidity, and details of symptoms and treatment in advanced gastrointestinal cancer patients at end-of-life

Hiramoto, S, Kikuchi, A, Hori, T, Yoshioka, A, Nagashima, K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

378

P-015Association between prognosis and discontinuation by image diagnosis for advanced gastrointestinal cancer patients who received end-of-life chemotherapy

Hiramoto, S, Nagashima, K, Hori, T, Kikuchi, A, Yoshioka, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 88 KB

english, 2019

379

P-016Long-course chemoradiation in carcinoma rectum; is it really worth it? Perspectives from a developing nation

Chakrabarti, D, Rajan, S, Akhtar, N, Kumar, V, Kumar, R, Srivastava, K, Bhatt, M, Gupta, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

380

P-017Place of perioperative chemotherapy at the base of FOLFOX in the treatment of localized gastric cancers: a retrospective study of 31 cases

Jamal, S, El Alami, I, Tanz, R, Rouibaa, F, Aourarh, A, Ichou, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

381

P-020Surprisingly high prevalence of DPYD gene mutation in UK regional trust: implications for treatment

Kestenbaum, S, Hill, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 71 KB

english, 2019

382

P-021Efficient treatment policies and its impact on the economic burden for CRC in low-middle income countries: the Egypt Case

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 71 KB

english, 2019

383

P-022Which patients on chemotherapy for colorectal cancer should be anticoagulated?

Forner, S, Summers, J, Hill, M, Mikropoulos, C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 71 KB

english, 2019

384

P-025Toxicity syndromes, patient-related clinical indicator of toxicity burden induced by intensive triplet chemotherapy-based regimens in metastatic gastrointestinal cancers

Bruera, G, Mastropietro, S, Salisburgo, L Dari, Cosenza, P, Ricevuto, E

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 66 KB

english, 2019

385

P-026Prognostic role of hyponatremia in pancreatic cancer

Berardi, R, Rinaldi, S, Belfiori, G, Stefano, P, Crippa, S, Torniai, M, Massimo, F

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 67 KB

english, 2019

386

P-027Multidirectional colonoscopy quality improvement increases adenoma detection rate: results of the Seoul national university hospital healthcare system Gangnam center colonoscopy quality upgrade project (Gangnam-CUP)

Seo, J, Jin, E, Chung, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

387

P-028Long non-coding RNA Linc00525 is an unfavorable prognostic factor and regulates proliferation and apoptosis in colorectal cancer

Zheng, Q, Peng, P

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

388

P-029Impact on survival of local complications in Pancreatic Cancer: experience at the Ramón y Cajal University Hospital (HURyC)

Serrano Domingo, J, Martín Huertas, R, Corral de la Fuente, E, Barquín García, A, Saavedra Serrano, C, Albarrán Artahona, V, Reguera Puertas, P, Fuentes, R, Ferreiro Monteagudo, R, Olmos, V Pachón, Va

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

389

P-031Low level of centromere-associated protein E promotes growth of hepatocellular carcinoma and is associated with adverse clinical features

Lin, Y, He, P, Hu, P, Chen, H, Chen, Y, McGowan, E

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 69 KB

english, 2019

390

P-032Hypofractionated volumetric modulated arc therapy (VMAT) in the treatment of advanced oesophageal cancer

Deantonio, L, Richetti, A, Valli, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 69 KB

english, 2019

391

P-033Management of small intestine cancers

Rekai, K, Belkharoubi, K, Krelil, B, Larbaoui, B

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 69 KB

english, 2019

392

P-034PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer

Muro, K, Uetake, H, Tsuchihara, K, Shitara, K, Yamazaki, K, Ota, M, Oki, E, Sato, T, Naitoh, T, Komatsu, Y, Kato, T, Yamanaka, K, Mori, I, Soeda, J, Hihara, M, Yamanaka, T, Akagi, K, Ochiai, A, Yoshin

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

393

P-035Prognosis of gastric dysplasia according to mucin phenotype after complete resection with endoscopic procedures

Park, J, Lee, J, Kim, J, Kim, H, Lee, T, Jeon, S, Cho, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

394

P-036Multidisciplinary approach associated with improved overall survival in metastatic colorectal cancer

Zok, J, Radecka, B, Adamowicz, K, Korniluk, J, Bieńkowski, M, Duchnowska, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

395

P-037Doxycycline as a preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy: interim analysis to evaluate skin toxicities

Ramirez Daffos, P, González-Astorga, B, Jiménez, E, Rubiales, S, Bolaños, M, Ceballos, E, Rodríguez, J, Reina, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 94 KB

english, 2019

396

P-038Whole-exome sequencing: 13 primary liver cancer cell lines established in our laboratory

Akiba, J, Ogasawara, S, Fukushima, H, Oie, S, Yano, H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

397

P-039ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: results of a prospective single centre clinical utility study (PRECISE STUDY)

Lee, L, Starkey, T, Sivakumar, S, Fotheringham, S, Mozolowski, G, Shearwood, V, Palles, C, Camilleri, P, Kerr, R, Kerr, D

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

398

P-040Cost of metastatic colorectal cancer drugs per month of life gained in Spain

Vieitez de Prado, J, Encinas García, S, Grande Pulido, E, Sánchez Nieto, R, González Moreno, S, Garrán del Río, C, Alonso Casado, O, Ortega Pérez, G, Mombiedro Lozano, C, Grasso Cicala, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

399

P-041Predictivity of body mass index, age and tumor laterality for systemic therapy outcome in metastatic colorectal cancer patients

Radwi, A, Asiri, I, Asiri, M, Khudhayri, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 88 KB

english, 2019

400

P-042The clinical outcomes and feasibility of endoscopic full-thickness resection assisted laparoscopic surgery for duodenal neuroendocrine tumor

Cho, J, Cheung, D, Moon, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

401

P-043Scope position is a determining factor for diagnostic performance of EUS-FNA for mass lesions in the pancreas head and uncinate process

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

402

P-044Efficacy and safety of early administration of pegfilgrastim in patients with esophageal cancer treated by docetaxel, cisplatin, and 5-fluorouracil (DCF): a phase 2 prospective study

Ishikawa, T, Yasuda, T, Okayama, T, Konishi, H, Naito, Y, Taguchi, T, Itoh, Y

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

403

P-045Long-term results of endoscopic treatment vs. esophagectomy with lymphadenectomy in patients with high-risk early esophageal cancer including detailed analysis of lymph node micrometastases

Kollar, M, Krajciova, J, Prefertusova, L, Sticova, E, Maluskova, J, Pazdro, A, Haruštiak, T, Spicak, J, Vackova, Z, Martinek, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 85 KB

english, 2019

404

P-046Expression pattern of death receptors FasR and DR3 on NK and T cells defines the complexity of tumor-immune system interplay in esophageal cancer

Snajdauf, M, Strizova, Z, Vachtenheim, J, Biskup, J, Taborska, P, Stakheev, D, Lischke, R, Bartunkova, J, Smrz, D

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

405

P-047Finding the options of managing duodenal carcinoids in Pakistan. a retrospective study in a tertiary care setup

Fatima, A, Zaidi, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 71 KB

english, 2019

406

P-048Identifying the severity of psychosocial symptoms among patients diagnosed with gastric tumors. Do we really need emotional support groups?

Fatima, A, Zaidi, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

407

P-049Identifying the nature of perforation in patients diagnosed with gastrointestinal lymphoma. Do we need early interventions?

Fatima, A, Zaidi, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

408

P-050The Velindre cancer centre experience of panitumumab versus cetuximab in combination with chemotherapy for metastatic colorectal cancer: a comparison of toxicity and economic evaluation

Case, A, Arif, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

409

P-051Predictors of response to 3rd line TAS-102 chemotherapy in metastatic colorectal cancer

Angelis, V, Young, T, Vasiliadou, I, Hill, M, Summers, J, Raman, R, Mikropoulos, C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

410

P-052Is there an optimal choice in refractory colorectal cancer? A network meta-analysis

Casadei Gardini, A, Gelsomino, F, Spallanzani, A, Tamburini, E, Scartozzi, M, Cascinu, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

411

P-053Neoadjuvant rectal cancer (NAR) score as a prognostic factor in locally advanced rectal cancer patients in Assiut university hospital clinical oncology department

Khalil, M, Shehata, S, Essa, H, Mohamed, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 93 KB

english, 2019

412

P-054Retrospective analysis of the efficacy and safety of regorafenib in patients with advanced GIST

Nakatsumi, H, Komatsu, Y, Saito, R, Ito, K, Nakano, S, Kawamoto, Y, Yuki, S, Sakamoto, N

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

413

P-055Somatic and germline genetic variants of gastric cancer in Russian patients identified by NGS

Kalinkin, A, Tanas, A, Kuznetsova, E, Alekseeva, E, Bykov, I, Kchorobryh, T, Kirillova, K, Zaletaev, D, Strelnikov, V, Nemtsova, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

414

P-056Differential expression of CCR5, TIM3 and PD-1 on peripheral blood T and B lymphocytes from hepatitis C patients with hepatocellular carcinoma and their impact on treatment outcomes

Rayan, A, Zahran, A, El-Badawy, O, Soliman, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

415

P-057Interleukin-6 correlated with neutrophil-to-lymphocyte ratio in pancreatic cancer

Pop, V, Seicean, A, Soritau, O, Buiga, R, Barsan, M, Balacescu, L, Burz, C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 90 KB

english, 2019

416

P-058Trifluridine/tipiracil safety and efficacy in Russian patients with metastatic colorectal cancer and refractory or intolerant to standard chemotherapies: Results of the primary analysis

Fedyanin, M, Chekini, D, Chubenko, V, Tjulandin, S, Zhabina, A, Amellal, N, Aubel, P, Gandossi, E, Moiseenko, V

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

417

P-059SM-88 therapy in high-risk poor prognosis pancreatic cancer (PDAC)

Noel, M, Wang-Gillam, A, Ocean, A, Chawla, S, Chung, V, DelPriore, G, Picozzi, V

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

418

P-060Outcomes for 556 consecutive patients with stages I-III colon cancer managed in a single cancer center in Cyprus over 10 years

Papamichael, D, Kountourakis, P, Papanastasopoulos, P, Xenophontos, E, Constantinou, I, Vogazianos, P

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

419

P-062Predicting esophageal cancer outcome with positron emission tomography using deep convolutional neural network

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

420

P-063Role of maintenance gemcitabine in advanced and metastatic carcinoma gall bladder

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

421

P-064Self-expandable metal stent (SEMS) for esophageal-gastric junction versus pyloric area obstruction in advanced gastric cancer patients: a retrospective, comparative, single-center study

Moon, H, Jeong, H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

422

P-065A multicenter retrospective study of gemcitabine plus nab-paclitaxel or FOLFIRINOX in metastatic pancreatic cancer: NAPOLEON study

Nakazawa, J, Otsuka, T, Shimokawa, M, Koga, F, Ueda, Y, Otsu, S, Arima, S, Fukahori, M, Makiyama, A, Taguchi, H, Honda, T, Shibuki, T, Shirakawa, T, Mitsugi, K, Nio, K, Ide, Y, Ureshino, N

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 89 KB

english, 2019

423

P-066Neutrophil/lymphocyte ratio in metastatic colorectal cancer: real-world data for evidence of its prognostic role

Nogueira-Costa, G, Fernandes, I, Guerra-Pereira, N, Gameiro, R, Gramaça, J, Xavier, A, Pina, I

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 69 KB

english, 2019

424

P-067Can an undifferentiated type early gastric cancer be a candidate for endoscopic resection?

Choi, C, Kim, S, Kang, D, Park, S, Nam, H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 69 KB

english, 2019

425

P-069Acute pancreatitis after pressurized intraperitoneal aerosol chemotherapy oxaliplatin in an ongoing phase 1 study for peritoneal metastasis

Kim, G, Tan, H, Wang, L, Teo, S, Jang, C, Shabbir, A, Yong, W, So, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 87 KB

english, 2019

426

P-070Esophageal cancer: 5 years of experience in a Mexican oncology reference center

Salazar-Mejia, C, Burguete-Torres, A, Vidal-Gutierrez, O, Hernández Barajas, D, Borjas-Almaguer, O, Wimer-Castillo, B, Cessa-Zanatta, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

427

P-071Incidental gallbladder cancer: can we improve survival?

Galodha, S, Saxena, R, Singh, R, Aggrawal, J, Kapoor, V, Behari, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

428

P-072Effects of natural substances from Boswellia sacra and Nerium oleander (breastin) in colon and pancreatic cancer

Parsonidis, P, Vlachou, I, Apostolou, P, Papasotiriou, I

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

429

P-073Oxaliplatin-based chemotherapy in patients aged at least 75 years with metastatic colorectal cancer: a post-hoc subgroup analysis if three phase II studies

Rosati, G, Cordio, S, Reggiardo, G, Aprile, G, Butera, A, Avallone, A, Tucci, A, Novello, G, Blanco, G, Caputo, G, Bilancia, D, Bordonaro, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 90 KB

english, 2019

430

P-074A three-year study of epidemiological trends of gastrointestinal cancers in a Haitian cancer program

Bernard, J, Gilbert, D, Germain, R, Alexis, L, DeGennaro, V

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

431

P-075SBRT in primary and metastatic liver disease: analysis after implementation in our center

De la Pinta, C, Martín, M, Sancho, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

432

P-076Adjuvant chemotherapy for stage II colon cancer: the prognostic value of high-risk features

Cheong, C, Suh, K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

433

P-077Novel SN-38 double core-shell micelle formulation, SNB-101, enhanced anti-tumor effect and tolerance

Park, Y, Li, Y, Choi, M, Kim, J, Lee, D

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

434

P-079Circulating tumor cell detection and microsatellite instability status in predicting outcomes of advanced CRC patients

Messaritakis, I, Sfakianaki, M, Vogiatzoglou, K, Koulouridi, A, Dimitriou, O, Gouvas, N, Athanasakis, E, Tsiaoussis, I, Xynos, E, Mavroudis, D, Tzardi, M, Souglakos, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

435

P-080Regorafenib combined with irinotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase 2 trial (PRODIGE 58 – UCGI 35 – REGIRI)

Samalin, E, Turpin, A, Khemissa, F, Zaanan, A, Benabdelghani, M, Senellart, H, Gilabert, M, Evesque, L, Dahan, L, Sefrioui, D, Bouché, O, De la Fouchardière, C, Hennequin, A, Monard, L, Gourgou, S, Lo

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

436

P-083FLOT- or CROSS-protocol treatment in advanced adenocarcinoma of the esophagus: a retrospective single-center analysis

Herzberg, J, Jenner, R, Strate, T, Honarpisheh, H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 68 KB

english, 2019

437

P-085Rectal adenocarcinoma: clinical predictive factors for tumor response after chemoradiotherapy

De la Pinta, C, Martín, M, Sancho, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 85 KB

english, 2019

438

P-086EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment

Su, M, Chen, L, Hitre, E, Lee, W, Bai, L, Papai, Z, Kang, S, Dvorkin, M, Lee, M, Ludovic, E, Choi, H, Oh, S, Bodoky, G, Artru, P, Hwang, J, Bazin, I, Bosc, F, Bachet, J, Horváth, Z, Chang, C, Lin, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

439

P-088Radiology-guided oesophageal stenting for the palliation of dysphagia: a single center experience

Tralau-Stewart, L, Roy, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

440

P-089FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial

Fernández Montes, A, Martinez Lago, N, De la Cámara Gómez, J, Covela Rúa, M, Cousillas Castiñeiras, A, Gonzalez Villarroel, P, Méndez Méndez, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 85 KB

english, 2019

441

P-090North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: final analysis (NORTH/HGCSG1003)

Ishiguro, A, Yuki, S, Takahashi, N, Shichinohe, T, Nakatsumi, H, Kawamoto, Y, Kusumi, T, Harada, K, Iwanaga, I, Hatanaka, K, Oomori, K, Nakamura, M, Senmaru, N, Iwai, K, Koike, M, Sakamoto, N, Taketom

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

442

P-091Delta-radiomics signature predicts treatment outcomes after preoperative chemoradiotherapy in rectal cancer

Jeon, S, Song, C, Chang, W, Kim, Y, Kim, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

443

P-092Impact on survival of adjuvant chemotherapy following chemo-radiotherapy and surgery in locally advanced, non-metastatic rectal adenocarcinoma: a retrospective analysis among 331 patients

Sondag, M, Nguimpi Tambou, M, Schumacher, C, Reimund, J, Serfaty, L, Duclos, B

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

444

P-093Male gender and bone metastases linked to inferior survival in advanced biliary tract cancer

Oliveira, F, Riechelmann, R, Mello, C, Jesus, V, Felismino, T

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

445

P-094KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo-controlled phase 3 study

Chung, H, Bang, Y, Fuchs, C, Qin, S, Satoh, T, Shitara, K, Tabernero, J, Van Cutsem, E, Cao, Z, Chen, X, Kang, S, Shih, C, Janjigian, Y

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

446

P-095Gastroenteropancreatic neuroendocrine neoplasia G3 according to 2019 WHO classification: a comprehensive clinicopathological characterization including mismatch repair proteins and PDL1 expression in a large cohort of patients

Grasselli, J, Rizzolo, M, Ruiz, G, Salanova, R, Mariani, J, O’Connor, J, Luca, R, Cabanne, A, Mendez, G, Roca, E

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

447

P-096Pancreatic resection in elderly patients over the age of 70 with primary pancreatic cancer: a retrospective analysis

Tan, E, Sandroussi, C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 94 KB

english, 2019

448

P-097RGS5 overexpression worsens the prognosis of patients with hepatocellular carcinoma by enhancing cancer cell motility and proliferative activity

Fukushima, H, Ogasawara, S, Kobayashi, T, Akiba, J, Yano, H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

449

P-099Triplet chemotherapy plus cetuximab as first-line treatment in RAS wild-type metastatic colorectal carcinoma patients

Samalin, E, Mazard, T, Assenat, E, Rouyer, M, De la Fouchardière, C, Guimbaud, R, Smith, D, Portales, F, Ychou, M, Fiess, C, de Forges, H, Lopez-Crapez, E, Thézenas, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 92 KB

english, 2019

450

P-100Trifluridine-tipiracil for the treatment of metastatic colorectal cancer patients: UK multicentre real-world experience

Tilby, M, Escola, C, Ellison, C, Narramneni, L, King, M, Grumett, S, Jain, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

451

P-101A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy

Parisi, A, Cortellini, A, Roberto, M, Venditti, O, Santini, D, Dell’Aquila, E, Stellato, M, Marchetti, P, Occhipinti, M, Zoratto, F, Mazzuca, F, Tinari, N, De Tursi, M, Iezzi, L, Natoli, C, Ratti, M,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

452

P-102Phase II study of neoadjuvant chemotherapy with S-1 plus oxaliplatin at a dose of 130mg/m2 (nacG-SOX130) in clinical(c)Stage III gastric cancer

Konishi, S, Manaka, D, Ikeda, Y, Ota, T, Kudo, R, Ann, H, Kawaguchi, K, Sasaki, N, Hamasu, S, Nishitai, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 87 KB

english, 2019

453

P-103Prognostic implications of free cancer cells in gastric juice in gastric cancer patients who underwent surgery: a prospective cohort study

Manaka, D, Konishi, S, Kawaguchi, K, Ikeda, Y, Ota, T, Kudo, R, Ann, H, Sasaki, N, Hamasu, S, Nishitai, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 68 KB

english, 2019

454

P-104Potent anticolorectal cancer activity of 5-fluorouracil and laccaic acid combination via modulation of epigenetic regulation

Bhatt, L, Gupta, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 67 KB

english, 2019

455

P-108Quality of life assessment and reporting in colorectal cancer: a systematic review of phase 3 trials published between 2012 and 2018

Lombardi, P, Marandino, L, De Luca, E, Zichi, C, Pignataro, D, Di Stefano, R, Ghisoni, E, Mariniello, A, Reale, M, Trevisi, E, Gianmarco, L, Muratori, L, La Salvia, A, Sonetto, C, Leone, F, Aglietta,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 64 KB

english, 2019

456

P-112A retrospective study on treatment outcomes for patients with high grade neuroendocrine colorectal carcinoma

Piskilidis, D, Madi, D, Wong, D, McKay, M, Law, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 64 KB

english, 2019

457

P-113Evaluation of the mimetic peptide APOE COG1410 in the viability, migration, and apoptosis of the intestinal cells IEC-18 after injuries by 5-FU

Pessoa, T, Carneiro, I, Aguiar, P, Vieira, L, Guerrant, R, Vitek, M, Abreu Junior, J, Oria, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

458

P-114Relationship between peripheral neuropathy and effectiveness in second-line chemotherapy for unresectable advanced gastric cancer: a prospective, observational, multicenter study protocol

Tanioka, H, Nagasaka, T, Uno, F, Inoue, M, Okita, H, Katata, Y, Kanzaki, H, Kuramochi, H, Satake, H, Shindo, Y, Doi, A, Nasu, J, Yamashita, H, Yamaguchi, Y

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

459

P-115The onset of grade ≥ 3 neutropenia at the first cycle is associated with longer overall survival in metastatic colorectal cancer patients treated with trifluridine/tipiracil

Giuliani, J, Bonetti, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

460

P-116GRADE evaluation of the COLOFOL randomized clinical trial

Ceballos, E, Robles, G

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 88 KB

english, 2019

461

P-117Stage IIa colon cancer: adjuvant chemotherapy in real life

Cunha, R, Menezes, M, Fernandes, R, Oliveira, A, Carvalho, T, Inácio, M, Trinca, F, Bravo, E, Nogueira, A, Dinis, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 66 KB

english, 2019

462

P-118Treatment efficacy of endoscopic submucosal dissection for papillary adenocarcinoma-type early gastric cancer

Lee, H, Kim, J, Kang, S, Moon, H, Sung, J, Jeong, H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 66 KB

english, 2019

463

P-122Advocacy program for GI malignancy patients

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 67 KB

english, 2019

464

P-123What do you want me to know about you? A qualitative retrospective pilot study to pay more attention to patients’ personal life aspects upon admission to a palliative care ward

Kitta, A, Adamidis, F, Unseld, M, Watzke, H, Masel, E

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 67 KB

english, 2019

465

P-124Definitive chemoradiotherapy in oesophageal cancer: treatment outcomes from a regional cancer centre

Abdul-Latif, M, Bhuva, N, Harrison, M, Glynne-Jones, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 83 KB

english, 2019

466

P-125Total neoadjuvant treatment of “ugly” rectal cancers in Slovenia

Velenik, V, Boc, N, Ocvirk, J, Brecelj, E, Krebs, B, Anderluh, F, Jeromen, A, Oblak, I, Secerov-Ermenc, A, But-Hadzic, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

467

P-127Prognostic value of lymph node ratio in lymph node-invaded colon cancer

Elbaiomy, M, Waheed, A, Elkhodary, T

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

468

P-128Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease

Ghidini, M, Hahne, J, Senti, C, Lampis, A, Ratti, M, Pizzo, C, Gobbi, A, Tomasello, G, Passalacqua, R, Valeri, N

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 98 KB

english, 2019

469

P-129Expression of female sex hormone receptors, connective tissue growth factor, and HER2 in gallbladder cancer and adjacent normal tissue

Hryciuk, B, Pęksa, R, Bieńkowski, M, Szymanowski, B, Radecka, B, Perdyan, A, Winnik, K, Zok, J, Cichowska, N, Iliszko, M, Duchnowska, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 84 KB

english, 2019

470

P-130Factors associated with the efficacy of aflibercept in patients with metastatic colorectal cancer: results of the multicenter observational study

Fedyanin, M, Chubenko, V, Belonogov, A, Beluhin, S, Belyaeva, A, Bolotina, L, Vladimirova, L, Zhabina, A, Zagorskaya, L, Khalikova, L, Fakhrudinova, O, Moiseenko, F, Khasanova, A, Musaeva, H, Novikova

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 84 KB

english, 2019

471

P-132A novel LncRNA (LOC105371049) regulates colorectal cancer proliferation, metastasis and metabolism

Yu, H, Yao, X, Meng, X

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 97 KB

english, 2019

472

P-133A randomized, multicenter, open-label controlled phase 2 trial of Foxy-5 as neoadjuvant therapy in patients with WNT5A negative colon cancer

Vermorken, J, Cervantes, A, Morsing, P, Johansson, K, Andersson, T, Roest, N Lindland, Gullbo, J, Salazar, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

473

P-134Real-world guideline application in the management of pancreatic cancer patients: the Italian GARIBALDI study

Reni, M, Bergamo, F, Cavanna, L, Spada, M, Ghidini, M, Giommoni, E, Maiello, E, Artioli, F, Cardellino, G, Torri, V, Cinquini, M, Giugliano, V, Pinto, C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

474

P-135Efficacy and safety of apatinib for metastatic colorectal cancer in standard therapy failure

Sun, G, Gao, P, Jia, J, Zhang, L

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

475

P-136Effect of regorafenib in delaying definitive deterioration in health-related quality of life across three tumor types

Hofheinz, R, Marian, M, Bartsch, J, Odom, D

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

476

P-137Circulating T cell subsets differ in PDAC patients at initial diagnosis and after two months of treatment: a single institution prospective study

Tulyte, S, Sileikis, A, Tamulyte, I, Ranceva, A, Characiejus, D, Matuzeviciene, R, Janiulionienė, A, Zvirblis, T

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

477

P-138Alcohol consumption and tobacco smoking and selected gastrointestinal cancers morbidity rates in Poland

Jarosz, M, Rychlik, E

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

478

P-139Chemotherapy rechallenge or reintroduction, regorafenib, and TAS-102 for metastatic pretreated colorectal cancer patients: a propensity score analysis of treatment beyond the second line (PROSERpINA Study)

Calegari, M, Zurlo, I, Basso, M, Orlandi, A, Bensi, M, Camarda, F, Stefano, B Di, Vivolo, R, Pozzo, C, Sperduti, I, Bria, E, Salvatore, L, Tortora, G

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 89 KB

english, 2019

479

P-140Correlation between values of specific biomarkers and outcome in metastatic colorectal cancer patients treated with regorafenib

Ricci, V, Falletta, A, Granetto, C, Paccagnella, M, Abbona, A, Fea, E, Fabozzi, T, Lo Nigro, C, Merlano, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

480

P-141Detecting the disappearance of RAS-mutant clones in the plasma of patients with RAS-mutant mCRC to select patient candidates for anti-EGFR treatment and to monitor resistance to treatment

Raimondi, C, Loreni, F, Nicolazzo, C, Belardinilli, F, Wilson, A, Gradilone, A, Giannini, G, Gazzaniga, P, Cortesi, E

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

481

P-142Sunitinib rechallenge in pancreatic neuroendocrine tumors

Michalaki, V, Poydorou, A, Frangulidis, G, Vezakis, A, Theodosopoulos, T, Karvouni, E, Papadimitriou, C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 88 KB

english, 2019

482

P-143Gastric cancer: system approach

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

483

P-144Impact of ileostomy in the adjuvant treatment of colorectal cancer stages II-III

Calderillo-Ruiz, G, Lopez, H, Diaz, C, Ruiz-Garcia, E, Carbajal, B, Gomez, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

484

P-145Gastric cancer in young Latin women: bad prognostic factors and outcomes

Calderillo-Ruiz, G, Takahashi, A, Herrera, M, Padilla, A, Trejo, E, Ramos-Ramirez, M, Carbajal, B, Albarran, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

485

P-146Immune modulatory effects of ibrutinib in pancreatic ductal adenocarcinoma

Sinha, M, Griffith, M, Betts, C, Choe, G, Sivagnanam, S, Cheung, A, Tamaki, W, Liu, E, Sudduth-Klinger, J, Vaccaro, G, Lopez, C, Fong, L, Coussens, L, Tempero, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

486

P-147Surgery specialization as a prognostic factor in colon cancer

Calderillo-Ruiz, G, Lopez, H, Padilla, A, Diaz, C, Miranda, G, Lopez, A, Carbajal, B, Herrera, A, Meneses, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

487

P-149Obesity and hyperglycemia as a bad prognosis factor for recurrence and survival in colon cancer

Calderillo-Ruiz, G, Lopez, H, Herrera, M, Trejo, E, Carbajal, B, Ramos-Ramirez, M, Albarran, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 92 KB

english, 2019

488

P-150Perioperative FLOT experience: pathological regression and toxicity

Sánchez Vegas, A, Gil Torralvo, A, Fernández-Parra, E, Robles Barraza, C, Rodríguez de la Borbolla, M, López Ladrón, A, Rodríguez Hernández, J, Fuentes PRadera, J, López Álvarez, P, Chaves, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

489

P-151Circulating tumor cells levels correlate with carcinoembryonic antigen in patients with high-risk colon cancer who experienced disease progression

Abdallah, E, Souza, V, Silva, e, Aguiar, S, Takahashi, R, Flores, B, Braun, A, Alves, V, Rodríguez Tarazona, J, Chinen, L, Mello, C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

490

P-152A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: analysis of Glasgow prognostic score (GPS)

Harada, K, Nakano, S, Yuki, S, Sawada, K, Muranaka, T, Kawamoto, Y, Nakatsumi, H, Yoshita, H, Ando, T, Kobayashi, Y, Miyagishima, T, Hatanaka, K, Tanimoto, A, Ishiguro, A, Honda, T, Dazai, M, Sasaki,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

491

P-153Regorafenib in the third-line treatment of metastatic colorectal cancer: a retrospective study of 27 cases

Boudinar, F, Larbaoui, B

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 90 KB

english, 2019

492

P-154Correlation between neutrophil/lymphocyte ratio and postoperative infectious complications after pancreatoduodenectomy for carcinoma of the pancreas head

Romano, L, Schietroma, M, Giuliani, A, Vicentini, V, Carlei, F

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

493

P-155The management of hepatocellular carcinoma: a report of 19 cases

Boudinar, F, Larbaoui, B

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

494

P-156Treatment for esophageal and esophagogastric junction cancer with radical radiotherapy: a single-institution cohort study

Soce, M, Bisof, V, Rakusic, Z, Misir Krpan, A, Stancic-Rokotov, D, Sandrk, S, Juretic, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

495

P-157Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen

Martínez-Lago, N, Carmona Campos, M, Gonzalez Villarroel, P, Salgado Fernandez, M, De la Cámara Gómez, J, Romero Reinoso, C, Cousillas Castiñeiras, A, Méndez Méndez, J, Vidal Insua, Y, Reboredo Rendo,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 90 KB

english, 2019

496

P-158Patient understanding of the aim and duration of treatment during the consent process

Kumaran, G, Razzaq, M, Velikova, G, Papaxoinis, G, Corker, S, Fox, F, Peters, R, Kamposioras, K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

497

P-159Patterns and predictors of relapse following radical chemoradiotherapy delivered using intensity-modulated radiotherapy with a simultaneous integrated boost in anal squamous cell carcinoma

Shakir, R, Adams, R, Cooper, R, Downing, A, Geh, I, Gilbert, D, Jacobs, C, Jones, C, Lorimer, C, Namelo, W, Sebag-Montefiore, D, Shaw, P, Muirhead, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

498

P-160Updated results of a phase II randomized trial with high dose proton pump inhibitors and metronomic capecitabine as salvage treatment for patients with advanced gastrointestinal tumours

Roberto, M, Arrivi, G, Milano, A, D’Antonio, C, Romiti, A, Falcone, R, Mazzuca, F, Fais, S, Marchetti, P

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 89 KB

english, 2019

499

P-162Dose-escalated intensity-modulated radiotherapy (IMRT) using a simultaneous integrated boost (SIB) in rectal cancer

Owens, R, Mukherjee, S, Padmanaban, S, Hawes, E, Jacobs, C, Weaver, A, Betts, M, Muirhead, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

500

P-164Simple endoscopic scoring system for patients with rectal cancer after concurrent chemoradiation therapy

Im, H, Kim, J, Park, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

501

P-165Safety and effectiveness of direct oral anticoagulants for venous thromboembolism in patients with active cancer: a retrospective study

Ogata, M, Satake, H, Ama, Y, Hirabatake, M, Ogata, T, Yasui, H, Hashida, T

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

502

P-166Systemic inflammatory response index (SIRI) predicts poor survival in pancreatic cancer patients treated with FOLFIRINOX

Kamposioras, K, Razzaq, M, Ahmad, U, Damyanova, I, Papaxoinis, G

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

503

P-167Outcomes of pancreatic adenocarcinoma resection between initial resectable and borderline/unresectable patients undergoing neoadjuvant chemotherapy: a two-center study

Moreira-Pinto, J, Godinho, J, Simões, P, da Costa, L Leal, Mata, I, Branco, F, Pulido, C, Costa Santos, M, Cunha, C, Padrão, T, Lopes, F, Teixeira, J, Rodrigues, T, Casa-Nova, M, Maio, R, Passos-Coelh

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

504

P-001Paclitaxel for the treatment of anal cancer after cisplatin and 5-fluorouracil

Rekai, K, Belkharoubi, K, Larbaoui, B

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 82 KB

english, 2019

505

P-018Prediction of oncologic outcome using systemic neutrophil-to-lymphocyte ratio in stage II and III colon cancer

Park, Y, Lee, K, Lee, J, Oh, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

506

P-078Preoperative neutrophil to lymphocyte ratio as a prognostic factor for patients with colorectal cancer

Zarev, I, Maksimovic, M, Ljubisavljevic, R, Bozovic, M, Maksimovic, Z, Pavlovic, M, Veselinovic, Z, Kamidzorac, G, Curcic, A, Kosanin, Z

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

507

P-126The management of pancreatic adenocarcinoma in a hospitalized-based population (2015-2019)

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

508

P-131Cancer immunotherapy with STING agonist and PD-1 immune checkpoint inhibitor effectively suppresses peritoneal carcinomatosis of colon cancer

Kim, C, Kim, W, Han, Y, Kim, J, Chon, H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 83 KB

english, 2019

509

PD-017APC I1307K and risk of colorectal neoplasia in humans and mice

Gruber, S, Gruber, P, Capellá, G, Bowen, C, Rennert, G

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

510

LBA-006BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer

Kopetz, S, Grothey, A, Van Cutsem, E, Yaeger, R, Wasan, H, Yoshino, T, Desai, J, Ciardiello, F, Gollerkeri, A, Maharry, K, Loupakis, F, Hong, Y, Steeghs, N, Guren, T, Arkenau, H, García Alfonso, P, Sa

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

511

O-005Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT ‘basket’ trial

Harding, J, Cleary, J, Shapiro, G, Braña, I, Moreno, V, Quinn, D, Borad, M, Loi, S, Spanggaard, I, Stemmer, S, Dujka, M, Cutler, R, Xu, F, Eli, L, Macia, S, Lalani, A, Bryce, R, Bernstam, F Meric, Sol

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

512

P-012Weighted gene co-expression networks explored MiR-92b Implicated In esophageal squamous cell cancer

Wang, W, Fu, C, Liu, Y, Zhang, Q, Wang, C, He, Z, Pu, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

513

P-019Chemotherapeutic hyperthermic intraperitoneal perfusion following radical D2 resection in the treatment of advanced gastric cancer

Zhu, L, Wu, Z, Ma, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

514

P-030Serglycin level in peripheral circulating blood cells has prognostic significance in patients with hepatocellular carcinoma

Chen, H, Li, Y, Chen, Y, Li, Y, McGowan, E, Lin, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

515

O-012The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

516

P-318The role of interleukin-8 (IL-8) in predicting the outcome of metastatic colorectal cancer patients treated with aflibercept in combination to FOLFIRI: the FLIBER study

D’Arcangelo, M, Buonerba, C, Avallone, A, Dazzi, C, Frassineti, G, Tamberi, S, Tassinari, D, Aprile, G, Granetto, C, Bonetti, A, Vecchiarelli, S, Cappuzzo, F

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 101 KB

english, 2019

517

P-347The risk of hepatitis B virus (HBV) reactivation in patients with gastrointestinal stromal tumours (GIST) under imatinib mesylate treatment

Soufleris, K, Lazaraki, G, Pavlioglou, P, Stergiou, E, Paraskevaidou, K, Tzilves, D

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

518

P-181Efficacy of surgical resection in patients with recurrent tumor of intrahepatic cholangiocarcinoma

Arita, J, Ishizawa, T, Akamatsu, N, Kaneko, J, Hasegawa, K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

519

201PPsychosocial and financial impact on family of lung cancer patients: A cancer research center experience

Godara, S K, Beniwal, S K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 86 KB

english, 2019

520

PD-018Feasibility of next-generation sequencing of circulating tumor cells for predicting relapse after liver resection in metastatic colorectal cancer

Lam, K, Ko, J, Chan, A, Choi, H, Dai, W, Lau, K, Wu, S, So, T, Lam, T, Chiang, C, Chan, W, Chan, M, Chu, K, She, W, Ma, K, Cheung, T, Wong, T, Chok, K, Lam, C, Wong, V, Lee, V, Lung, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 94 KB

english, 2019

521

219TiPFeasibility of a self-screening for insomnia and acceptability of an online targeted video-based cognitive behavioral program in cancer outpatients: SLEEP-4-ALL-1 study design

Charles, C, Boinon, D, Fasse, L, Journiac, J, Pallubicki, G, Ninot, G, Ninot, E, Gouy, S, Savard, J, Dauchy, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

522

P-183Legumain is a predictive effector of peritoneal metastasis for diffuse gastric cancer patients

Wang, Y, Cui, Y, Wang, Z, Li, W, Liu, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

523

P-190Update of metastatic colorectal cancer metastases resection after FOLFIRI-aflibercept in oxaliplatin-refractory patients

de Toro Carmena, M, Ortega Morán, L, García Adrián, S, Castañón López, C, Molina Villaverde, R, Marrupe González, D, Lopez Muñoz, A, Alcaraz Nunes, D, Díaz Beveridge, R, López Alfonso, A, García Pared

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 104 KB

2019

524

P-371Feasibility of modulated electro-hyperthermia as a concomitant boost to preoperative radiotherapy in locally advanced rectal cancer: A phase 2 trial

Kim, S, You, S, Cha, J, Lee, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

525

P-308Role of TILS in predicting evolution of metastatic colorectal cancer

Ben Nasr, S, Alibi, S, Msekni, I, Zribi, A, Karrit, S, Fendri, S, Ayari, J, Balti, M, Bouzyani, A, Haddaoui, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

526

LBA-007Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable mCRC

Cremolini, C, Antoniotti, C, Lonardi, S, Rossini, D, Morano, F, Cordio, S, Bergamo, F, Marmorino, F, Maiello, E, Passardi, A, Masi, G, Tamburini, E, Santini, D, Grande, R, Zaniboni, A, Granetto, C, Mu

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

527

163PImmuno-oncological treatment and tumor load in non-small cell lung cancer (NSCLC): Case-control analysis of overall survival (OS) in routine clinical practice

Faehling, M, Schwenk, B, Kopp, M, Fallscheer, S, Kramberg, S, Eckert, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

528

186TiPAn open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy: EDEN trial

Gelsomino, F, Tiseo, M, Boni, L, Cavanna, L, Camerini, A, Chiari, R, Verusio, C, Tognetto, M, Ardizzoni, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 92 KB

english, 2019

529

P-263Over-expression of c-MET in Biliary Tract Cancer. Prevalence and Clinical-Molecular Correlation

Segovia, R, Arroyo, G, Ituarte, C, Inklemona, C, Rojo, S, Salvatierra, A, Berlinghieri, G, Saucedo, S, Monteros Alvi, M, lamas, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 83 KB

english, 2019

530

P-281Efficacy of a therapeutic exercise program on autonomic nervous system function, cardiac function and functional capacity in colorectal cancer survivors: a randomized controlled pilot study

Ruiz-Vozmediano, J, Gutiérrez-Martínez, À, Postigo-Martin, P, Cruz-Fernández, M, González-Flores, E, Cantarero-Villanueva, I

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

531

215PMale breast cancer, a heterogeneous entity: Experience from a cancer center

Carvalho, J C, Peixoto, M, Cunha Pereira, T, Garcia, A R, Mariano, M, Broco, S, Pazos, I, Carvalho, T, Ribeiro, J, Sousa, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

532

LBA4Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study

Reinmuth, N, Cho, B C, Lee, K H, Luft, A, Ahn, M-J, Schneider, J, Shepherd, F A, Geater, S L, Pápai-Székely, Z, Ngoc, T Van, Garassino, M C, Liu, F, Clemett, D, Thiyagarajah, P, Ouwens, M, Scheuring,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 89 KB

english, 2019

533

195TiPSYNERGY: Phase I and randomized phase II trial to investigate the addition of the anti-CD73 antibody oleclumab to durvalumab, paclitaxel and carboplatin for previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Maurer, C, Eiger, D, Velghe, C, Aftimos, P G, Maetens, M, Gaye, J, Paesmans, M, Ignatiadis, M, Piccart, M, Buisseret, L

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

534

188TiPMetformin +/- cyclic fasting mimicking diet in combination with platinum-pemetrexed chemotherapy for advanced LKB1 inactive lung adenocarcinoma: The FAME trial

Galli, G, Signorelli, D, Vernieri, C, Ganzinelli, M, Moro, M, Fabbri, A, Tamborini, E, Marabese, M, Caiola, E, Broggini, M, Hollander, L, Gallucci, R, Gavazzi, C, Rizzo, A M, Corsetto, P, Pruneri, G,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

535

P-186Perihilar and distal extrahepatic cholangiocarcinomas show different genetic profiles but share MYC copy gain and TP53 mutation as independent poor prognostic markers

Simbolo, M, Mafficini, A, Vicentini, C, Ruzzenente, A, Rusev, B, Brunelli, M, Pedron, S, Bertuzzo, F, Barbi, S, Fassan, M, Corbo, V, Bagante, F, Turri, G, Luchini, C, Lawlor, R, Guglielmi, A, Bassi, C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

536

P-212The use of oral capecitabine with irinotecan and cetuximab (mCAPIRI-C) among colorectal cancer patients with unresectable liver-only metastases

Wong, S, Chiang, C, Yeung, S, Lee, S, Lee, A, Wong, C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 84 KB

english, 2019

537

P-296Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience

Pretta, A, Lai, E, Liscia, N, Impera, V, Camera, S, Musio, F, Mariani, S, Soro, P, Persano, M, Donisi, C, Tolu, S, Balconi, F, Atzori, F, Dessì, M, Massa, E, Madeddu, C, Pusceddu, V, Astara, G, Demurt

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

538

P-385PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

539

LBA-002Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study

Tabernero, J, Van Cutsem, E, Bang, Y, Fuchs, C, Wyrwicz, L, Lee, K, Kudaba, I, Garrido, M, Chung, H, Castro Salguero, H, Mansoor, W, Braghiroli, M, Goekkurt, E, Chao, J, Wainberg, Z, Kher, U, Shah, S,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 111 KB

english, 2019

540

213PHIV infection in breast cancer patients from Mozambique: A prospective cohort study

Brandão, M D R A, Guisseve, A, Bata, G, de Morais, G, Alberto, M, Schmitt, F, Lorenzoni, C, Tulsidás, S, Lunet, N, Carrilho, C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

541

172PA multi-center, randomized, double-blind, parallel, two-group phase III clinical study on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in the first-line treatment of non-squamous non-small cell lung cancer

Han, B, Li, K, Chu, T, Bi, M, Zhang, H, Yu, Y, Shi, J, Zhang, X, Chen, Z, Han, C, Bai, T

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

542

158P_PRIntermittent versus continuous chemotherapy beyond first-line for patients with HER2-negative advanced breast cancer (BOOG 2010-02)

Erdkamp, F L G, Claessens, A K M, Lopez-Yurda, M, Bouma, J M, van Tinteren, H, Rademaker-Lakhai, J M, Honkoop, A H, de Graaf, H, Tjan-Heijnen, V C G, Bos, M M E M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 92 KB

english, 2019

543

159P_PRInfluence on quality of life of chemotherapy scheduling for patients with advanced HER2-negative breast cancer

Claessens, A K M, Timman, R, Busschbach, J J, Bouma, J M, Rademaker-Lakhai, J M, Erdkamp, F L G, Tjan-Heijnen, V C G, Bos, M M E M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

544

P-39115-PGDH regulated PD-1/PD-L1 immune checkpoint blockade immunotherapy in colon cancer is a TNF-α dependent phenomenon

Satapathy, S, Sjolander, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

545

O-011Randomized phase 2 trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12

Hofheinz, R, Fokas, E, Allgäuer, M, Polat, B, Klautke, G, Grabenbauer, G, Fietkau, R, Kuhnt, T, Staib, L, Brunner, T, Grosu, A, Schmiegel, W, Jacobasch, L, Weitz, J, Folprecht, G, Germer, C, Grützmann

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

546

P-297Serum level of miRNA-143 as a potential prognostic marker in patients with colorectal cancer and synchronous metastatic disease

Mihaylova, Z, Ivanova, D, Mihaylova, G, Tasinov, O, Nazifova-Tasinova, N, Petkova, D, Garev, A, Manev, R, Conev, N, Donev, I, Radanova, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 99 KB

english, 2019

547

169P_PRBenefit of immunotherapy (IT) in advanced non-small cell lung cancer (NSCLC) in elderly patients (EP)

Corral de la Fuente, E, Barquín García, A, Saavedra Serrano, C, Olmedo García, M E, Martin Huertas, R, Serrano Domingo, J J, Albarrán Artahona, V, Gómez Rueda, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 94 KB

english, 2019

548

P-262Percutaneous transhepatic biliary drainage in malignant biliary obstruction: complications and outcome

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 102 KB

english, 2019

549

P-261Poor prognosis of hypermutant colorectal cancer with KRAS mutations: A retrospective analysis of 1,052 Japanese colorectal cancer patients without treatment of immuno-checkpoint inhibitors

Nagasaka, T, Tanioka, H, Nyuya, A, Katata, Y, Okawaki, M, Yamamura, M, Kawai, T, Yasui, K, Toshima, T, Mori, Y, Umeda, Y, Tsuruta, A, Ueno, T, Yamaguchi, Y

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

550

201PPreventive bilateral mastectomy (PBS) in BRCA mutation carriers with ovarian cancer: Is it justified?

Safra, T, Waissengrin, B, Gerber, D, Bernstein-Molcho, R, Shaizaf, R, Taff, J, Mugia, F, Frey, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 110 KB

english, 2019

551

181TiP Phase II study of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study

Shimokawa, M, Nosaki, K, Seto, T, Ohashi, K, Morise, M, Fujiwara, Y, Sakakibara, J, Murakami, H, Yano, S, Satouchi, M, Matsumoto, S, Goto, K, Yoh, K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

552

190PNon-vigorous physical activity and the risk of breast cancer among Nigerian women

Azubuike, S O, Hayes, L, McNally, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

553

P-269PIPAC paclitaxel: A systematic and peritoneal tissue pharmacokinetic study in swine

Tan, H, Kim, G, Jang, C, Shabbir, A, Charles, C, Li, R, Wang, L, Goh, B, So, J, Yong, W

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

554

SO-007Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603)

Hara, H, Fukuoka, S, Takahashi, N, Kojima, T, Kawazoe, A, Asayama, M, Yoshii, T, Kotani, D, Tamura, H, Mikamoto, Y, Sugama, A, Wakabayashi, M, Nomura, S, Sato, A, Togashi, Y, Nishikawa, H, Shitara, K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

555

P-339Epidemiology, treatment modalities and prognostic factors of colon cancer in the central region of Tunisia

Belaid, I, Khechine, W, Saad, A, Fki, A, Makram, H, El Ghali, A, Chabchoub, I, Ezzairi, F, Ben Fatma, L, Ben Ahmed, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 98 KB

english, 2019

556

PD-012Emerging risk factors of recurrence and overall survival in a Swedish stage I-III colon cancer cohort

Osterman, E, Mezheyeuski, A, Sjöblom, T, Glimelius, B

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

557

SO-006Hafnium oxide nanoparticles activated by SBRT: a new interventional radiation therapy approach for the treatment of unresectable liver cancers

Baere, T De, Pracht, M, Rolland, Y, Nguyen, F, Bronowicki, J, Vendrely, V, Cunha, A Sa, Baumann, A, Croisé-Laurent, V, Rio, E, Sourd, S Le, Gustin, P, Perret, C, Peiffert, D, Deutsch, E, Chajon, E

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 95 KB

english, 2019

558

P-261Poor prognosis of hypermutant colorectal cancer with KRAS mutations: A retrospective analysis of 1,052 Japanese colorectal cancer patients without treatment of immuno-checkpoint inhibitors

Nagasaka, T, Tanioka, H, Nyuya, A, Katata, Y, Okawaki, M, Yamamura, M, Kawai, T, Yasui, K, Toshima, T, Mori, Y, Umeda, Y, Tsuruta, A, Ueno, T, Yamaguchi, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

559

201PPreventive bilateral mastectomy (PBS) in BRCA mutation carriers with ovarian cancer: Is it justified?

Safra, T, Waissengrin, B, Gerber, D, Bernstein-Molcho, R, Shaizaf, R, Taff, J, Mugia, F, Frey, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 110 KB

2019

560

181TiP Phase II study of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study

Shimokawa, M, Nosaki, K, Seto, T, Ohashi, K, Morise, M, Fujiwara, Y, Sakakibara, J, Murakami, H, Yano, S, Satouchi, M, Matsumoto, S, Goto, K, Yoh, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

561

PD-006A predictive model for endoscopic ultrasonography accuracy of invasion depth in early gastric cancer

Park, J, Choi, S, Kim, E

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 89 KB

english, 2019

562

P-178A nomogram to predict poor health-related quality of life in metastatic colorectal cancer patients

Formica, V, Nardecchia, A, Morelli, C, Lucchetti, J, Giuliano, G, Renzi, N, Gallo, C, Serci, C, Pellegrino, R, Massimiliani, V, Maiorino, L, Roselli, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

563

P-302Prospective evaluation of FOLFIRINOX in Neo-adjuvant treatment of gastro-oesophageal junction carcinomas

Dean, A, Peeperkorn, L, Armstrong, K, De Marie, A, Watanabe, Y, Tan, M, Travers, N

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 69 KB

english, 2019

564

SO-005A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer

Wainberg, Z, Boland, P, Lieu, C, Dayyani, F, Macarulla, T, Zhang, B, Belanger, B, Moore, Y, Wang, T, Maxwell, F, Dean, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 82 KB

english, 2019

565

75PPulse mode irradiation regimen of PDT results in high progression free and overall survival in mice with model tumour

Bogdanov, A, Klimenko, V, Verlov, N, Bogdanov, A, Knyazev, N

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

566

503PEPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer

Moigne, R Le, Banuelos, C A, Mawji, N R, Tam, T, Wang, J, Jian, K, Andersen, R J, Cesano, A, Sadar, M D, Zhou, H -J, Virsik, P

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 88 KB

english, 2019

567

573PRandomized phase II trial of CAPOX with planned oxaliplatin stop-and-go strategy as adjuvant chemotherapy after curative resection of colon cancer (CCOG-1302 study)

Yokoyama, H, Nakayama, G, Ishigure, K, Hayashi, N, Tanaka, K, Tsutsuyama, M, Hattori, N, Yamada, S, Kodera, Y

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 81 KB

english, 2019

568

649PDiet-derived metabolites and the risk of colorectal cancer: A nested case-control study in a population-based cohort, the Singapore Chinese health study

Chong, D Q, Lu, Y, Jin, A, Li, Z, Wang, R, Yuan, J M, Ong, C N, Koh, W P

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

569

660TiPBISQUIT: A randomized phase II study of the administration of prebiotics and probiotics during definitive treatment with chemotherapy-radiotherapy for patients with squamous cell carcinoma of the anal canal

Riechelmann, R P, Camandaroba, M, Mello, C A, Silva, V S, de Jesus, V H F, Barros, M, Rodrigues, N, Donadio, M D, Cavichiolli, M, Lima, V C C, Dias-Neto, E, Nunes, D N, Carraro, D, De Brot, L, Aguiar,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 83 KB

english, 2019

570

694PDiagnostic value of digital multiplexed detection of single nucleotide variants in pancreatic cancer specimens collected by endoscopic ultrasound fine-needle aspiration

Cazacu, I M, Semaan, A, Stephens, B M, Swartzlander, D B, Guerrero, P A, Singh, B S, Lungulescu, C V, Raileanu, S, Danciulescu, M M, Roy-Chowdhuri, S, Maitra, A, Saftoiu, A, Bhutani, M S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

571

1094PUse of droplet digital polymerase chain reaction for detecting minimal residual disease: A prospective, multi-institutional study

Park, H, Shin, D-Y, Kim, I, Sohn, S-K, Koh, Y, Lee, J-H, Lee, K-H, Kim, D-Y, Kim, H-J, Ahn, J-S, Lee, J-O, Bang, S-M, Cheong, J-W, Park, S-G, Park, S, Lee, Y J, Ahn, S-Y

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

572

1200PTumour stroma targeting and modulation by OMTX705 ADC, a novel and potent immunotherapeutic treatment of solid tumours

Fabre, M, Ferrer, C, Domínguez-Hormaetxe, S, Kontermann, R, Pfizenmaier, K, Seifer, O, Vivanco, M D, Lee, S-Y, López-Casas, P, Abbas, M, Richter, W, Simon, L, Hidalgo, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

573

1478OResults of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain

Chow, L Q, Barlesi, F, Bertino, E M, van den Bent, M J, Wakelee, H, Wen, P Y, Chiu, C-H, Orlov, S, Majem, M, Chiari, R, McKeage, M, Yu, C-J, Hurtado, F K, Arratia, P Cazorla, Song, Y, Branle, F, Shi,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 120 KB

english, 2019

574

1635PDAccessibility and affordability to trastuzumab for breast cancer patients: Voices of the global oncology community from ONCOLLEGE 001 survey, part 2

Altuna, S C, Trapani, D, Lengyel, C, Habeeb, B, Hussain, S, Mazher, S, Elfaham, E, Petrillo, A, El Bairi, K, Khan, S Z

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

575

1626OESMO-MCBS and health technology assessment (HTA): Does value for physicians correspond to value for payers?

Ambavane, A, Benedict, A, Rivolo, S, Rakonczai, P, Kapetanakis, V

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 93 KB

english, 2019

576

1824PA prospective study about the complementary medicine among patients with cancers

Ben Kridis, W, Mnif, A, Khanfir, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

577

CN52A pilot trial to investigate the impact of a personalised self-management lifestyle programme using mobile technology on the health and wellbeing of cancer survivors

Kelly, M G, Richmond, J, Singaroyan, N, Kerr, T, O’Donnell, A, Masterson, E, Haughey, C, Harney, O, Walsh, J, Groarke, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

578

P-361Laparoscopic liver resection in metastatic colorectal cancer

Kolesnik, O, Lukashenko, A, Ostapenko, Y, Chorna, N, Patsko, V

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

579

259PProgesterone receptor isoform ratio dictates antiprogestins/progestins effects on metastatic breast cancer models

Abascal, M F, Giulianelli, S, Alvarez, M, Sequeira, G, Vanzulli, S, Elia, A, Pataccini, G, Lombes, M, Lanari, C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

580

671OConversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (NEOLAP): Final results of a multicenter randomised phase II AIO trial

Kunzmann, V, Algül, H, Goekkurt, E, Siegler, G M, Martens, U M, Waldschmidt, D, Pelzer, U, Hennes, E, Fuchs, M, Siveke, J, Kullmann, F, Boeck, S, Ettrich, T J, Ferenczy, P, Keller, R, Germer, C-T, Ste

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 89 KB

english, 2019

581

1085PSafety and efficacy of bendamustine and rituximab (BR) regimen in Indian chronic lymphocytic leukemia patients

Gogia, A, Kumar, L, Sharma, A, Raina, V, Gupta, R, Rani, L

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

582

1534PTP53 mutations predicts worse prognosis in EGFR-mutated NSCLC patients receiving TKIs in first- or further line of treatment

Canale, M, Luigi, N De, Petracci, E, Delmonte, A, Ludovini, V, Dubini, A, Baglivo, S, Minenza, E, Chiadini, E, Landi, L, Papi, M, Bronte, G, Crinò, L, Ulivi, P

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

583

1806PSalivary cytokines and oral mucosa cells apoptosis in patients during hematopoietic cell transplantation: Possible relationship with oral mucositis

Corrêa, L, Bezinelli, L M, Rosin, F C P, Ferreira, M H, Carvalho, D L C, Lopes, R M D G, Hamerschlak, N, Eduardo, F D P

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

584

1753OLong term follow-up (F/U) report of symptomatic cardiac events (SCEs) in 2,809 breast cancer (BC) patients (pts) treated with adjuvant trastuzumab (T) in real world (RW) practice

Di Cosimo, S, Trama, A, Merlo, I, Minicozzi, P, Tarantini, L, Apolone, G, Corrao, G, Franchi, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 93 KB

english, 2019

585

CN77Effect of Kegel exercises on prevention of urinary and fecal incontinence in patients with prostate cancer undergoing radiotherapy

Uravylioglu, A E, Kutlutürkan, S, Kılıç, D

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

586

LBA2_PRPhase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev

Ray-Coquard, I L, Pautier, P, Pignata, S, Pérol, D, González-Martín, A, Sevelda, P, Fujiwara, K, Vergote, I B, Colombo, N, Mäenpää, J, Selle, F, Sehouli, J, Lorusso, D, Alia, E M Guerra, Lefeuvre-Ples

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 92 KB

english, 2019

587

P-346A single center experience with oral chemotherapy with capecitabine and temozolomide in metastatic neuroendocrine tumors

Rego, I, Pontes, F, Carvalho, J, Pratas, E, Chaves, A, Martins, R, Couto, J, Ribeiro, J, Rodrigues, F, Sousa, G

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 99 KB

english, 2019

588

PD-033A prospective cohort study on the effect of radiotherapy for rectal cancer on female sexual function

Svanström Röjvall, A, Buchli, C, Bottai, M, Ahlberg, M, Flöter-Rådestad, A, Martling, A, Segelman, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 83 KB

english, 2019

589

135PCan we improve patient selection for phase I clinical trials (phI1) based on immuno-oncology score prognostic index (VIO)?

Matos Garcia, I, Hierro, C, Martin-Liberal, J, VIAPLANA, C, Azaro, A, Brana, I, Vieito Villar, M, Saavedra, O, Gardeazabal, I, Ros, J, Prieto, P, Berché, R, Muñoz-Couselo, E, Oliveira, M, Elez Fernánd

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

590

1360PIntracranial anti-tumour activity in melanoma brain metastases with encorafenib plus binimetinib: A multicenter, retrospective analysis

Lutzky, J, Holbrook, K, Amin, A, Davis, J M, Davies, M A, Diab, A, Glitza, I C, Amaria, R N, Patel, S, Tawbi, H A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

591

1385PDNew circulating biomarkers in gastro-entero-pancreatic-neuroendocrine-tumours

Bocchini, M, Mazza, M, Foca, F, Nicolini, F, Calogero, R A, Severi, S, Paganelli, G

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 84 KB

english, 2019

592

CN1Patients’ usage and perception of an interactive app for symptom management and self-care during cancer treatment

Crafoord, M-T, Fjell, M, Nilsson, M I, Nilsson, M I, Sundberg, K, Langius-Eklöf, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 88 KB

english, 2019

593

149PEvaluation and diagnostic potential of plasma biomarkers in bladder cancer

Voronova, V, Peskov, K, Glybochko, P, Svistunov, A, Fomin, V, Kopylov, P, Enikeev, D, Gitel, E, Ragimov, A, Poddubskaya, E, Sekacheva, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 88 KB

english, 2019

594

177PDProspective, multicenter registry trial to evaluate the clinical feasibility of targeted axillary dissection (TAD) in patients (pts) with breast cancer (BC) and core biopsy proven axillary involvement (cN+)

Reinisch, M, Heil, J, Rüland, A, Seiberling, C, Harrach, H, Schindowski, D, Lubitz, J, Ankel, C, Graßhoff, S -T, Deuschle, P, Hanf, V, Holtschmidt, J, Traut, E, Kuehn, T, Kuemmel, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

595

262PGeriatric parameters predict both disease-related and patient-reported outcomes in older patients with breast cancer

van der Plas-Krijgsman, W, de Boer, A, de Jong, P, Bastiaannet, E, van den Bos, F, Liefers, G-J, Portielje, J E A, De Glas, N

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 84 KB

english, 2019

596

401PDGEINO 1402: A phase Ib dose-escalation study followed by an extension phase to evaluate safety and efficacy of crizotinib in combination with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed glioblastoma (GB)

Martinez Garcia, M, Gil, M J, Pineda, E, Martin Soberón, M C, Mesia Barroso, C, Foro, P, Capellades, J, Sarmiento, B, Bruna, J, Verger, E, Taus Garcia, A, Alameda, F, Hernandez Lain, A, Velasco, G, Se

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

597

417PEffect of cumulative dose of maintenance temozolomide on overall survival in patients with high grade glia tumours: A single institution analysis

Nerone, M, Caspani, F, Tralongo, A C, Tuzi, A, Pinotti, G

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

598

429POutcome of high-grade gliomas (HGGs) treated into immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience

Simonelli, M, Persico, P, Dipasquale, A, Lorenzi, E, Giordano, L, Pessina, F, Navarria, P, Scorsetti, M, Bello, L, Santoro, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 81 KB

english, 2019

599

442OTherapeutic drug monitoring of oral anticancer drugs - preliminary results of a prospective study

Groenland, S L, Van Eerden, R A G, Koolen, S L, Moes, D J A R, Desar, I M E, Touw, D J, Imholz, A L T, Reyners, A K L, Gelderblom, H, van Erp, N P, Mathijssen, R H J, Huitema, A D R, Steeghs, N

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

600

636PPrognostic and predictive impact on FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer

Hasegawa, H, Taniguchi, H, Kato, T, Fujii, S, Ebi, H, Shiozawa, M, Yuki, S, Masuishi, T, Kato, K, Izawa, N, Moriwaki, T, Kagawa, Y, Sakamoto, Y, Okamoto, W, Nakamura, Y, Yamazaki, K, Yoshino, T

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

601

847PDCentral, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study

de Bono, J S, Fizazi, K, Saad, F, Shore, N, Sandhu, S K, Mehra, N, Kolinsky, M, Roubaud, G, Özgüroǧlu, M, Matsubara, N, Gedye, C, Choi, Y D, Padua, C, Goessl, C, Kohlmann, A, Corcoran, C, Adelman, C A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 92 KB

english, 2019

602

865PTreatment outcomes of 3rd treatment in a real-world metastatic castration resistant prostate cancer (mCRPC) population: Results from the Dutch CAPRI-registry

Notohardjo, J C L, Kuppen, M C P, Westgeest, H M, van den Eertwegh, A J M, Moorselaar, J Van, Mehra, N, Coenen, J L, van Oort, I, van den Bergh, A C M, Aben, K K H, Somford, D M, de Wit, R, Bergman, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 94 KB

english, 2019

603

880PImpact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Data from the prospective PROREPAIR-B study

Cattrini, C, Laorden, N Romero, Castro, E, García-Carbonero, I, Piulats, J M, Puente, J, Valderrama, B P, Guzman, J C Villa, Billalabeitia, E Gonzalez, Barrera, R Morales, Mejorada, R Lozano, Luque, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 89 KB

english, 2019

604

881PImplications of single nucleotide polymorphisms (SNPs) in androgen related-genes in outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone (Abi) and enzalutamide (Enza)

Aragon, I M, Cendón, Y, Lorente, D, Mejorada, R Lozano, Laorden, N Romero, Colmenero, A Medina, Puente, J, Villatoro, R, Estevez, S Vazquez, Piulats, J M, Lainez, N, Fernandez-Parra, E, del Alba, A Go

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

605

897TiPA phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)

Chi, K N, Rathkopf, D, Attard, G, Smith, M R, Efstathiou, E, Olmos, D, Small, E J, Lee, J Y, Sieber, P, Dunshee, C, Ricci, D, Simon, J S, Zhao, X, Kothari, N, Cheng, S, Sandhu, S K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

606

954PSPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz)

Valderrama, B P, Perez Ramirez, S, Rodriguez-Vida, A, González del Alba, A, Mendez Vidal, M J, Vazquez Estevez, S, Martinez Ortega, E, Virizuela, J A, Fernández Calvo, O, Hernández Jorge, A, Vazquez M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 93 KB

english, 2019

607

1055PClinical impact of molecular profiling of cervical cancer (CC) patients (pts) in a dedicated phase I (P1) unit

Scaranti, M, Caldwell, R, Miralles, M Selvi, Shinde, R, Pal, A, Ang, J E, Biondo, A, Guo, C, Cojocaru, E, Gennatas, S, Lockie, F, Bertan, C, Baker, C, Carreira, S, Banerjee, S, Kaye, S, de Bono, J S,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

608

1084PSplenic marginal zone lymphoma: Clinical characteristics and prognostic factors in a series of 52 patients

Cengiz Seval, G, Topcuoglu, P, Arslan, O, Gurman, G, Demirer, T, Kuzu, I, Ozcan, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

609

1270PPembrolizumab in advanced rare cancers

Naing, A, Meric-Bernstam, F, Karp, D, Rodon, J A, Piha-Paul, S A, Subbiah, V, Hong, D S, Pant, S, Fu, S, Janku, F, Yap, T A, Tsimberidou, A M, Dumbrava, E E Ileana, Colen, R R, Hess, K R, Campbell, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 95 KB

english, 2019

610

1174OPembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies

Diaz, L A, Le, D, Maio, M, Ascierto, P A, Geva, R, Motola-Kuba, D, André, T, Van Cutsem, E, Gottfried, M, Elez, E, Delord, J-P, Jäger, D, Kim, T W, Guimbaud, R, Yoshino, T, Chen, M, Norwood, K, Marine

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 92 KB

english, 2019

611

1387PDifferences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumours (NETs)

Hernando Cubero, J, Grande, E, Castellano Gauna, D, Ibrahim, T, Fazio, N, Lopez, C, Teulé, A, Valle, J W, Alonso, V, Molina-Cerrillo, J, Tafuto, S, Custodio, A, Trejo, L, Casteras, A, Manneh Kopp, R,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

612

1399PHematologic malignancies in temozolomide-treated metastatic pancreatic neuroendocrine tumours

Balmaceda, N, Mouw, T, Abhyankar, S, Male, H, Woodroof, J, Williamson, S, Baranda, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

613

1998P The discovery of RNA-aptamers that selectively bind and inhibit glioblastoma stem cells by targeting EphA2

Affinito, A, Quintavalle, C, Esposito, C L, Roscigno, G, Vilardo, C, Nuzzo, S, Ricci Vitiani, L, De Luca, G, Minic, Z, Giannetti, S, Pallini, R, Berezovski, M V, Kichkailo, A S, Lapin, I N, Franciscis

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

614

1700POutcomes of metastatic soft tissue sarcoma treated with pazopanib from dedicated medical oncology sarcoma clinic: A holistic care approach from a developing country

Kapoor, A, Kumar, S M, Ghosh, J, Rekhi, B, Bajpai, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

615

1702PEfficacy and safety of apatinib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib: An open-label, multicenter, single-arm, phase II trial

Cai, Z, Zhang, B, Yin, Y, Cao, D

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

616

1703PLong-term outcome of neoadjuvant tyrosine kinase inhibitors (TKI) in locally advanced dermatofibrosarcoma protuberans (DFSP)

Beaziz, J, Battistella, M, Delyon, J, Maignan, C Le, Marco, O, Kérob, D, Laurent, C Pages, Da Meda, L, Farges, C, Basset-Seguin, N, Lebbe, C, Baroudjian, B

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

617

1705PGastrointestinal stromal tumours (GIST) in adolescents and young adults (AYA)

Ijzerman, N S, Drabbe, C, Den Hollander, D, Mohammadi, M, van Boven, H, Desar, I M E, Gelderblom, H, Grünhagen, D J, Reyners, A K L, Mathijssen, R H J, Steeghs, N, van der Graaf, W T A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

618

LBA79Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials

Herbst, R S, Lopes, G, Kowalski, D M, Nishio, M, Wu, Y-L, de Castro Junior, G, Baas, P, Kim, D-W, Gubens, M A, Cristescu, R, Aurora-Garg, D, Albright, A, Ayers, M, Loboda, A, Lunceford, J, Kobie, J, L

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 90 KB

english, 2019

619

12PEGFR-mediated PD-L1 upregulation in HER2+ breast cancer (BC) cell line models

Gaynor, N, Mc Dermott, M, Canonici, A, Crown, J, Collins, D M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

620

17PAberrant glycolysis associates with inflammatory tumour microenvironment and promotes metastasis in triple negative breast cancer

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

621

33PThe tyrosine kinase inhibitor dasatinib blocks tumour growth, invasion and recurrence potential by interrupting the communication between cancer cells and their surrounding microenvironment in triple negative breast cancer

Nuncia-Cantarero, M, Nieto-Jiménez, C, Burgos, M, Montero, J C, Ocaña, A, Galán-Moya, E M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

622

64PThe potential of neratinib plus dasatinib in overcoming and preventing neratinib resistance in HER2-positive breast cancer models

Conlon, N, Browne, A, Breen, L, Lowry, M, O’Driscoll, L, Cremona, M, Hennessy, B T, Eustace, A J, O’Donovan, N, Crown, J, Collins, D M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

623

201PFinal results of scalp cooling for hair preservation: A single- institution prospective study

Loparco, D, Orlando, L, Caloro, M, Caliolo, C, Quaranta, A, Schiavone, P, Fedele, P, Rendini, M, Varriano, R, Morleo, A, Falcone, L L, Lotti, G, Cinefra, M, Ferrara, P, Rizzo, P, Marino, A, Calvani, N

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

624

266PPathologic response and survival efficacy in patients with initial nodal involvement after neoadjuvant chemotherapy in early breast cancer

Murillo, S Morales, Cudos, A Gasol, Rodriguez, J Veas, Villellas, F Vilardell, Guzmán, D -R Sánchez, Morales, C Canosa, Olivé, J Melé, el Koulali, I, Martínez, E Iglesias

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

625

383TiPBintrafusp alfa (M7824) and eribulin mesylate in treating patients with metastatic triple negative breast cancer (TNBC)(NCT03579472)

Litton, J K, Damodaran, S, Wistuba, I I, Yang, F, Contreras, A, Tam, A, Ojalvo, L, Dussault, I, Helwig, C, Moulder, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 84 KB

english, 2019

626

438OMETEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours

Siu, L L, Rasco, D W, Vinay, S Postel, Romano, P Martin, Menis, J, Opdam, F L, Heinhuis, K M, Egger, J L, Gorman, S A, Parasrampuria, R, Wang, K, Kremer, B E, Gounder, M M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 94 KB

english, 2019

627

643PImpact of CCL4 knockout using CRISPR Cas-9 technology on colorectal tumour progression

Barakat, R H, Habashy, D A, Bahaa, A, Adwan, H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

628

663TiPA phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study

Barbera, M A, Corbelli, J, Papiani, G, Grassi, E, Ugolini, G, Montroni, I, Bartolomeo, M Di, Cascinu, S, Marzola, M, Bonetti, A, Frassineti, G L, Nanni, O, Zattoni, D, Ghignone, F, Taffurelli, G, Pint

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 81 KB

english, 2019

629

1033PPhase Ib/IIa study assessing the safety and efficacy of adding AL3818 (anlotinib) to standard platinum-based chemotherapy in subjects with recurrent or metastatic endometrial, ovarian or cervical carcinoma

Miller, D, Miller, D S, Cheung, E, Huang, M, Schlumbrecht, M, Garcia, A, Loch, M, Jernigan, A, Li, Z, Chen, M, Chen, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

630

1062TiPA phase II study of pembrolizumab in combination with doxorubicin in advanced, recurrent or metastatic endometrial cancer

Oaknin, A, Perez, M J Rubio, Madrid, L Fariñas, Redondo, A, Esteban, A Yubero, Martín, M Gil, Martín, A González, Romero, I, Garcia-Donas, J, Serrano, R, Martínez, A Gallego, Diez, M Ocariz, Lorenzo,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 91 KB

english, 2019

631

1079PDose adjustment of chemotherapy in aggressive lymphoma using automated and standardized analysis and evaluation of DNA double strand breaks

Schröder, J, Rödiger, S, Ruhe, M, Deckert, P M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

632

1108OChemotherapy plus local-regional radiotherapy versus chemotherapy alone in primary metastatic nasopharyngeal carcinoma: A randomized, open-label, phase III trial

Chen, M, You, R, You-Ping, L, Huang, P-Y, Zou, X, Shen, G-P, Zhang, H-D

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 91 KB

english, 2019

633

1862PDImpact of lung metastasis on overall survival (OS) in the phase III SELECT study with lenvatinib (LEN) in patients (pts) with radioiodine refractory differentiated thyroid cancer (RR-DTC)

Tahara, M, Kiyota, N, Hoff, A O, Badiu, C, Owonikoko, T K, Dutcus, C E, Suzuki, T, Ren, M, Misir, S, Wirth, L J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 94 KB

english, 2019

634

CN13Harnessing nurse leadership to implement a project for electronic scheduling of chemotherapy

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

635

EL6Cytotoxic Anticancer Agents

Takigawa, Nagio

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 66 KB

english, 2019

636

P2-060A case of recurrent HCC successfully treated with lenvatinib

Sugaya, Akinori, Takagi, Kaoruko, Murashita, Tetsuya, Hirose, Mitsuaki

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

637

LBA29Immune activation with a novel immune switch anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in phase I/II first-in-human MATINS trial in patients with advanced solid tumours

Bono, P, Hollmen, M, Jaakkola, P, Shetty, S, Thibault, A, de Jonge, M J A, Minchom, A R, Ma, Y T, Yap, C, Robbrecht, D, Pasanen, A, Jalkanen, S, Cruz, R, Pal, A, Karvonen, M K, Mandelin, J, Koivunen,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

638

LBA77Simultaneous multi-cancer detection and tissue of origin (TOO) localization using targeted bisulfite sequencing of plasma cell-free DNA (cfDNA)

Oxnard, G R, Klein, E A, Seiden, M V, Hubbell, E, Venn, O, Jamshidi, A, Zhang, N, Beausang, J F, Gross, S, Kurtzman, K N, Fung, E T, Allen, B, Fields, A P, Liu, H, Sekeres, M A, Richards, D A, Yu, P P

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 82 KB

english, 2019

639

166PPooled safety analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2– advanced breast cancer (ABC)

Tripathy, D, Hortobagyi, G N, Chan, A, Im, S-A, Chia, S, Yardley, D, Esteva, F J, Hurvitz, S A, Ridolfi, A, Slamon, D

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 83 KB

english, 2019

640

180PPalbociclib in daily clinical use: Real world experience of the breast center at the University Hospital Munich

Hester, A, Koenig, A, Dobler, F, Degenhardt, T, Heidegger-Steger, H, Kurt, A-G, Kahlert, S, Mahner, S, Harbeck, N, Wuerstlein, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

641

182PEfficacy and tolerability of neratinib in advanced HER-2 positive breast cancer: A single institution experience

Shepherd, S T C, Lee, K, Mohammed, K, Patel, K, Allen, M, Johnston, S R D, Parton, M, Ring, A, Turner, N, Okines, A F C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

642

P-249Right-sided versus left-sided metastatic colorectal cancer

Ben Kridis, W, Mnif, A, khmiri, S, Feki, J, Ayedi, I, Toumi, N, Boudawara, T, Mzali, R, Khanfir, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 81 KB

english, 2019

643

164PEffect of serum survivin on survival among non-small cell lung cancer patients: NCI experience

Rashed, R A, Rahouma, M, Abo Elfetouh, R, Aziz, H, Kamel, M K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 88 KB

english, 2019

644

298PTargeting CDCA3 to improve chemotherapy response in triple negative breast cancer patients

O’Byrne, K J, Adams, M N, Burgess, J, Richard, D J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

645

302PUsing nodal ratio to predict recurrence in patients with 4 or more positive lymph nodes early stage breast cancer

Graja, B, Nesrine, M, Ghorbel, A, Benna, H El, Berrazega, Y, Daoud, N, Labidi, S, Boussen, H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 68 KB

english, 2019

646

318PAssociation between PIK3CA mutation status and development of brain metastases in HR+/HER2- metastatic breast cancer

Fitzgerald, D M, Muzikansky, A, Pinto, C, Henderson, L, Walmsley, C, Allen, R, Ferraro, G B, Isakoff, S, Moy, B, Oh, K, Shih, H A, Dias-Santagata, D, Iafrate, A J, Bardia, A, Brastianos, P K, Juric, D

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

647

1131PTranscriptome signatures of treatment responses in a preoperative window of opportunity trial of nivolumab and tadalafil in resectable squamous cell carcinoma of the head and neck

Shukla, S, Johnson, J M, Curry, J M, Kim, Y, Argiris, A, Luginbuhl, A, Harshyne, L, Rodeck, U

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

648

1132PRisk and impact of renal impairment of locally advanced head and neck squamous cell carcinoma patients who received chemoradiotherapy with cisplatin

Patimarattananan, T, Pattaranutaporn, P, Unwanatham, N, Jiarpinitnun, C, Nongnuch, A, Ngamphaiboon, N

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

649

1318PPhase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)

Rischin, D, Lim, A M, Schmults, C D, Khushalani, N I, Hughes, B G, Schadendorf, D, Dunn, L A, Chang, A L S, Hauschild, A, Ulrich, C, Eigentler, T, Migden, M R, Pavlick, A C, Geiger, J, Stankevich, E,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 91 KB

english, 2019

650

1719PFusion of immortalized myoblasts induces genomic instability that drives tumour development and progression

Merle, C, Baud, J, Thebaud, N, Lesluyes, T, Pérot, G, Delespaul, L, Lartigue, L, Chibon, F

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 88 KB

english, 2019

651

LBA21KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)

Cortés, J, Lipatov, O, Im, S-A, Gonçalves, A, Lee, K S, Schmid, P, Tamura, K, Testa, L, Witzel, I, Ohtani, S, Zambelli, S, Harbeck, N, André, F, Dent, R, Zhou, X, Karantza, V, Mejia, J A, Winer, E P

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 83 KB

english, 2019

652

LBA41Phase III randomized study of neoadjuvant chemotherapy (CT) with docetaxel(D), oxaliplatin(O) and S-1(S) (DOS) followed by surgery and adjuvant S-1, vs surgery and adjuvant S-1, for resectable advanced gastric cancer (GC) (PRODIGY)

Kang, Y-K, Yook, J H, Park, Y-K, Kim, Y-W, Kim, J, Ryu, M-H, Rha, S Y, Chung, I-J, Kim, I-H, Oh, S C, Yoo, C-H, Choi, J-H, Zang, D Y, Kim, G, Lee, Y, Noh, S-H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 93 KB

english, 2019

653

LBA62Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358

Naumann, R W, Oaknin, A, Meyer, T, Lopez-Picazo, J M, Lao, C, Bang, Y-J, Boni, V, Sharfman, W H, Park, J C, Devriese, L A, Harano, K, Chung, C H, Topalian, S L, Zaki, K, Chen, T, Gu, J, Li, B, Barrows

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 90 KB

english, 2019

654

LBA5_PROsimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis

Ramalingam, S S, Gray, J E, Ohe, Y, Cho, B C, Vansteenkiste, J, Zhou, C, Reungwetwattana, T, Cheng, Y, Chewaskulyong, B, Shah, R, Lee, K H, Cheema, P, Tiseo, M, John, T, Lin, M C, Imamura, F, Hodge, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 89 KB

english, 2019

655

1631PD_PRClinical benefit and prices of cancer drugs in the US and Europe

Vokinger, K N, Hwang, T, Tibau, A, Rosemann, T J, Kesselheim, A S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 82 KB

english, 2019

656

162PHospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA

Ettl, J, Quek, R G W, Hurvitz, S A, Goncalves, A, Tudor, I C, Rugo, H S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 82 KB

english, 2019

657

P-252Gemcitabine induced haemolytic uremic syndrome: The big unknown

Cidon, E Una, Alonso, P

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

658

77PRed-blood-cell-membrane-enveloped magnetic nanoclusters as a biomimetic theranostic nanoplatform for bimodal imaging guided cancer photothermal therapy

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 93 KB

english, 2019

659

146PDiscovery of an immunotranscriptomics signature in blood for early colorectal cancer detection

Angelino, P, Hosseinian Ehrensberger, S, Ciarloni, L, Despraz, J, Dorta, G, Perez-Uribe, A, Morgenthaler, S, Delorenzi, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

660

147PSerum netrin-1 as a biomarker for colorectal cancer detection

Zhu, J, Xi, L, Wu, A, Ma, X, Zhang, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 108 KB

english, 2019

661

310PDThe importance of primary surgery in patients with de novo stage IV BC surviving at least 5 years: Protocol MF07-01 randomized clinical trial

Ozmen, V, Ozbas, S, Karanlik, H, Muslumanoglu, M, Igci, A, Canturk, Z, Utkan, Z, Ozaslan, C, Evrensel, T, Uras, C, Aksaz, E, Soyder, A, Ugurlu, U M, Col, C, Cabioglu, N, Bozkurt, B, Uzunkoy, A, Sezgin

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

662

750PA phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL

Pinato, D J, Cole, T, Bengsch, B, Tait, P, Sayed, A A, Abomeli, F, Gramenitskaya, D, Allara, E, Thomas, R, Ward, C, Wong, C N, Akarca, A U, Miguens Blanco, J, Marafioti, T, Marchesi, J, Sharma, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

663

833TiPPhase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy

Rimassa, L, Cheng, A-L, Braiteh, F, Chaudhry, A, Benzaghou, F, Thuluvath, P, Hazra, S, Borgman-Hagey, A E, Tan, B, Kayali, Z K, Zhu, A X, Kelley, R K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 84 KB

english, 2019

664

844ODocetaxel for hormone-naïve prostate cancer: Results from long-term follow-up of metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476) and sub-group analysis by metastatic burden

Clarke, N W, Ali, A, Ingleby, F C, Hoyle, A, Calvert, J, Attard, G, Chowdhury, S, Dearnaley, D, Douis, H, Gillessen, S, Jones, R, Malik, Z, Mason, M D, Millman, R, Parker, C, Rush, H L, Omlin, A G, Sy

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 106 KB

english, 2019

665

932PHyperphosphatemia due to erdafitinib (a pan-FGFR Inhibitor) and anti-tumour activity among patients (Pts) with advanced urothelial carcinoma (UC)

Tagawa, S, Siefker-Radtke, A, Dosne, A -G, Zhong, B, Qi, K, Shalaby, W, O’Hagan, A, De Porre, P, Mahadevia, P, Loriot, Y

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

666

1030PImpact of prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer (ROC): Sub-group analysis from a randomized, open-label study comparing trabectedin (T) and PLD versus PLD alone in ROC (ET743-OVC-3006)

Monk, B J, Herzog, T J, Triantos, S, Maul, S, Wang, G, Valero, M J Pontes, McGowan, T, Shalaby, W S, Coleman, R L

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 92 KB

english, 2019

667

1179PDNatural dendritic cell vaccinations generate immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

Creemers, J, Westdorp, H, van Oort, I, Schreibelt, G, Gorris, M, Mehra, N, Simons, M, de Goede, A, van Rossum, M, Croockewit, S, Figdor, C, Witjes, J A, Aarntzen, E, Mus, R, Gotthardt, M, Barentsz, J,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

668

1345POutcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)

Knispel, S, Gassenmaier, M, Menzies, A M, Loquai, C, Johnson, D B, Franklin, C, Gutzmer, R, Hassel, J C, Weishaupt, C, Eigentler, T, Schummer, P, Kiecker, F, Owen, C, Schmidgen, M I, Kähler, K C, Cann

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 94 KB

english, 2019

669

1372TiPA phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)

Rischin, D, Fury, M G, Lowy, I, Stankevich, E, Li, S, Han, H, Porceddu, S V

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

670

1443PCharacterization of lung tumourspheres reveals cancer stem-like cells potential targets and prognostic markers in non-small cell lung cancer

Herreros Pomares, A, Jantus-Lewintre, E, Calabuig-Fariñas, S, de-Maya-Girones, J D, Lucas, R, Blasco, A, Guijarro, R, Martorell, M, Escorihuela, E, Alonso, S, Chiara, M D, Duréndez, E, Gandia, C, Sire

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

671

1449PAnalysis of immunosuppressive factors produced by tumorspheres in NSCLC: Prognostic value of galectin-3 in adenocarcinoma

Torres Martinez, S, Herreros Pomares, A, Zhang, F, Calabuig-Fariñas, S, González, Á, Sirera, R, Moreno-Manuel, A, Mosqueda, M, Escorihuela, E, Duréndez, E, Gallach, S, Garde, J, Guijarro, R, Jantus-Le

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

672

1928PAntecedent of cancer and mortality after the first ST segment elevation acute myocardial infarction treated with primary coronary angioplasty. A prospective cohort study

Sillero, I D, López Flores, M, Sánchez-Cousido, L F, Rojas Piedra, M, Prieto-Salvador, I, López González, A, Castañón González, C, García-Palomo, A, Fernández Vazquez, F, Iglesias, I

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

673

1950PEffect of selumetinib plus AZD8186 treatment on cabazitaxel sensitivity in docetaxel-acquired resistant metastatic prostate cancer cell lines

Ruiz de Porras, V, Laguía, F, Marín-Aguilera, M, Jiménez, N, Mellado, B, Ramirez, J L, Martinez-Balibrea, E, Font, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

674

LBA7_PROverall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

Slamon, D J, Neven, P, Chia, S, Fasching, P A, De Laurentiis, M, Im, S-A, Petrakova, K, Bianchi, G V, Esteva, F J, Martin, M, Nusch, A, Sonke, G S, De la Cruz-Merino, L, Beck, J T, Pivot, X, Sondhi, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 105 KB

english, 2019

675

LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

Yau, T, Park, J W, Finn, R S, Cheng, A-L, Mathurin, P, Edeline, J, Kudo, M, Han, K-H, Harding, J J, Merle, P, Rosmorduc, O, Wyrwicz, L, Schott, E, Choo, S P, Kelley, R K, Begic, D, Chen, G, Neely, J,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 85 KB

english, 2019

676

LBA48_PRAdjuvant or salvage radiotherapy for the treatment of localised prostate cancer? A prospectively planned aggregate data meta-analysis

Vale, C L, Brihoum, M, Chabaud, S, Cook, A, Fisher, D, Forcat, S, Fraser-Browne, C, Herschtal, A, Kneebone, A, Nénan, S, Parker, C, Parmar, M K B, Pearse, M, Richaud, P, Rogozińska, E, Sargos, P, Syde

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

677

LBA63Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy

Creutzberg, C L, Leon-Castillo, A, de Boer, S M, Powell, M E, Mileshkin, L R, Mackay, H J, Leary, A, Nijman, H W, Singh, N, Pollock, P, Fyles, A, Haie-Meder, C, Smit, V T H B M, Edmondson, R J, Putter

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 83 KB

english, 2019

678

151PPeripheral cytotoxic T cell correlates with tumor mutational burden and is predictive for progression free survival in advanced breast cancer

Liu, X-R, Song, G, Jiang, H, Di, L-J, Yu, J, Jia, S, Li, H, Liang, X

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

679

200PEffects of delayed initiation of adjuvant trastuzumab for non-metastatic, HER2 positive breast cancer in a limited resources setting: ML25232 study final results

Beslija, S, Ceric, T, Hasanbegovic, B, Skenderi, F, Alidžanović, J, Kopric, D, Marjanović, I, Mekic-Abazovic, A, Sisic, I S, Hammami, M, Pasic, A, Rasic, A, Kapisazović, E

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

680

424PPreclinical study of novel tetracyclic small molecule, CC12, for brain cancer

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

681

681PDLow-dose aspirin and risk of gastric and oesophageal cancer: A population-based study

Garcia Rodriguez, L, Vora, P, Soriano-Gabarró, M, Cea Soriano, L

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 91 KB

english, 2019

682

721PEfficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications

Droz Dit Busset, M, Braun, S, El-Rayes, B, Harris, W P, Damjanov, N, Masi, G, Rimassa, L, Bhoori, S, Niger, M, Personeni, N, Braiteh, F, Lonardi, S, Engelhardt, M, Saulay, M, Schwartz, B, Shaib, W L,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 92 KB

english, 2019

683

1548PCrizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trial – Updated progression-free survival, overall survival and mechanisms of resistance

Michels, S, Massuti Sureda, B, Schildhaus, H-U, Franklin, J, Sebastian, M, Felip, E, Grohe, C, Rodríguez-Abreu, D F, Bischoff, H, Carcereny Costa, E, Corral Jaime, J, Insa, A, Reck, M, Scheffler, M, K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 88 KB

english, 2019

684

1972PIn vitro functional interrogation of viable circulating tumor associated cells (C-TACs) for evaluating platin resistance

Schuster, S, Akolkar, D, Patil, S, Patil, D, Datta, V, Srinivasan, A, Datar, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

685

1976PGeneral methodology to optimize tumor treating fields delivery utilizing numerical simulations

Urman, N, Bomzon, Z, Hershkovich, H S, Kirson, E D, Naveh, A, Shamir, R, Fedorov, E, Wenger, C, Weinberg, U

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

686

JSJS-1Management of older cancer patients: updated recommendations of the International Society of Geriatric Oncology (SIOG)

Brain, Etienne G C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 71 KB

english, 2019

687

56PcRGDfK (cRGD) conjugated pyropheophorbide-a (Pyro), a new tumour photodynamic agent, is highly accumulated and specific in tumour cell killing

Wang, F, Tan, S, Hong, Z

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

688

238PElderly patients in the Japanese breast cancer registry

Sawaki, M, Yamada, A, Kumamaru, H, Miyata, H, Shimizu, C, Miyashita, M, Honma, N, Taira, N, Saji, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 88 KB

english, 2019

689

358PComplete responses in patients with second-line or greater metastatic triple negative breast cancer (TNBC) following first-in-human immunotherapy combining NK and T cell activation with off-the-shelf high-affinity CD16 NK cell line (haNK)

Nangia, C, Soon-Shiong, P, Rabizadeh, S, Lee, J H, Sender, L, Jones, F, Kistler, M, Niazi, K, Seery, T, Rock, A, Jafari, O

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

690

305OOverall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)

Emens, L A, Esteva, F J, Beresford, M, Saura, C, De Laurentiis, M, Kim, S-B, Im, S-A, Wang, Y, Mani, A, Shah, J, Liu, H, de Haas, S, Patre, M, Loi, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 112 KB

english, 2019

691

414PCharacteristics, incidence, and survival of primary cerebral lymphoma: A population based study

Ghozy, S, Dibas, M, Afifi, A M, Hashim, M A, Abbas, A S, Abdel-Daim, M M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

692

639PMicrosatellite instability detection in colorectal cancer: 44-Center comparison between the Idylla MSI assay and routine molecular and immunohistochemistry tests on formalin-fixed paraffin-embedded tissue

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

693

901OEV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma

Hoimes, C J, Rosenberg, J E, Srinivas, S, Petrylak, D P, Milowsky, M, Merchan, J R, Bilen, M A, Gupta, S, Carret, A-S, Yuan, N, Melhem-Bertrandt, A, Flaig, T

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 91 KB

english, 2019

694

1405PValidation of a tumour mutational burden workflow on routine histological samples of colorectal cancer and assessment of a cohort with synchronous hepatic metastases

Mafficini, A, Cantù, C, Antonello, D, Simbolo, M, Piredda, L, Lever, V, Rusev, B, Pecori, S, Milella, M, Lawlor, R T, Scarpa, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 90 KB

english, 2019

695

480PDrug-drug interaction profile of tepotinib with CYP3A and P-gp substrates

Yalkinoglu, Ö, Heuer, J, Becker, A, Krebs-Brown, A, Strotmann, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 91 KB

english, 2019

696

1597PDEmergency admissions and bad news disclosure as precipitators of suicide: A territory-wide cohort analysis of 458 oncology patients who completed suicides

Lam, T C, Kwan, E, Luo, H, Yip, P S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 89 KB

english, 2019

697

AOJS-2An overview of innovative cancer drug clinical development in China

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

698

MO2-3-5Awareness Towards Breast and Cervical Cancer Risk factors and its prevention among students and patients in Bangladesh

Islam, Md Shariful, Sultana, Farzana, Islam, A k m Nazrul, Alam, Nur-E-, Ullah, Hedayet, Molla, tarek, Khatun, Mst Mahmuda, Mohiuddin, A k m

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

699

MO2-7-1Efficacy of information prescription booklet and video material on patient adherence for chemothrapy induced dermopathy

Sato, Junya, Ishikawa, Hiroshi, Yasuda, Yoko, Yamawaki, Yuki, Endo, Megumi, Nakajima, Kazuko, Kiyohara, Akio, Shino, Michihiro

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

700

MO2-7-2ALOE VERA: AS A NATURAL MEDICAMENT IN PALLIATIVE CARE PATIENTS

Acharya, Jitendra

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

701

MO1-1-3Awareness about Cervical Cancer and Its Prevention among the Female Respondents of General Hospital in Bangladesh

Alam, Nur-E-, Khatun, Mst Mahmuda, Molla, Tarek, Ullah, Hedayet, Akter, Sumaiya, Ifa, Humaira Nur, Akter, Salma, Shifat, Siratul Kubra, Rayyan, Fabia, Ali, Rayhan, Sen, Tapon Chandra, Sultana, Farzana

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 91 KB

english, 2019

702

P2-228 [Encore]Randomised Phase 3 Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) - INTEGRATE II

Chua, Yu Jo, Pavlakis, Nick, Sjoquist, Katrin M, Martin, Andrew J, Tsobanis, Eric, Yip, Sonia, Bang, Yung-Jue, Alcindor, Thierry, O’callaghan, Christopher J, Bekaii-Saab, Tanios S, Grothey, Axel, Chen

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

703

DL2Precision Medicine in Triple Negative Breast Cancer: The Future is Coming

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 69 KB

english, 2019

704

178PIntrahepatic mitomycin C infusion in breast cancer liver metastases

Aarts, B, Klompenhouwer, E, Dresen, R, Laenen, A, Beets-Tan, R, Punie, K, Neven, P, Maleux, G, Wildiers, H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 83 KB

english, 2019

705

199OLong-term cardiac outcomes of HER2+ breast cancer patients treated in the ALTTO trial

Eiger, D, Ponde, N F, Agbor-Tarh, D, Korde, L A, Moreno Aspitia, A, Rodeheffer, R J, Ewer, M, Suter, T, Piccart, M, de Azambuja, E

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 215 KB

english, 2019

706

LBA 1miRNA expression profiles in BRCA1-associated breast cancers reveal upregulation of specific miRNAs in tumors lacking a clear second hit in a large proportion of the tumour

Heetvelde, M Van, Bockstal, M R Van, Dorpe, J Van, Leeneer, K De, Vral, A, Claes, K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

707

P-238Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy

Rimassa, L, Cheng, A, Braiteh, F, Benzaghou, F, Hazra, S, Borgman, A, Sinha, R, Kayali, Z, Zhu, A, Kelley, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 100 KB

english, 2019

708

P-353Neurotoxicity of oxaliplatin in patients treated for colorectal cancer: FOLFOX versus XELOX

Aliane, H, Ghomari-Bezzar, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

709

P-400ANCHOR CRC: a phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC)

Grothey, A, Yaeger, R, Paez, D, Tabernero, J, Taïeb, J, Yoshino, T, Groc, M, Vedovato, J, Chetaille, E, Van Cutsem, E

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

710

14PApplication of sonoporation to increase anticancer drug efficacy in 2D and 3D NSCLC cell cultures

Petrikaite, V, Paškevičiūtė, M, Raišutis, R, Sakalauskienė, K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 91 KB

english, 2019

711

95PEvaluation of markers associated with efficacy of abiraterone acetate plus prednisone (AAP) in patients (pts) with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study

Chi, K N, Thomas, S, Gormley, M, Shen, D, Joshi, S, Tran, N, Smith, M, Ricci, D, Fizazi, K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

712

198PA multicentre, international neoadjuvant (NA), randomized, double-blind phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib in patients with operable luminal breast cancer (SAFIA Trial)

Nabholtz, J-MA, Alsaleh, K A, Bounedjar, A, Oukkal, M, El-Zawahry, H M, Bouzid, K, Razek, H Abdel, Mahfouf, H, Bensalem, A, Saadeddin, A, Filali, T, Larbaoui, B, Abulkhair, O, Al-Foheidi, M, Boussen,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

713

469PSafety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti‐PD‐L1 antibody, in patients (pts) with advanced cancers

Clingan, P R, Mant, A M, Richardson, G E, Kowalski, D M, Koralewski, P, Lugowska, I, Dechaphunkul, A, Charoentum, C, Sookprasert, A, Sriuranpong, V, Akopov, A, Kozlov, V, Fadeeva, N, Kasparov, B, Kova

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 82 KB

english, 2019

714

476PUpdated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumors: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

Rolfo, C, Dziadziuszko, R, Doebele, R C, Demetri, G, Simmons, B, Huang, X, Ye, C, Paz-Ares, L

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

715

525OACHIEVE-2 trial: A randomized phase III trial investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with high-risk stage II colon cancer (CC)

Yoshino, T, Yamanaka, T, Shiozawa, M, Manaka, D, Kotaka, M, Gamoh, M, Shiomi, A, Makiyama, A, Munemoto, Y, Rikiyama, T, Fukunaga, M, Ueki, T, Shitara, K, Shinkai, H, Tanida, N, Yamazaki, K, Sunami, E,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

716

757PEfficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase III trials (REACH and REACH-2)

Kudo, M, Galle, P R, Motomura, K, Assenat, E, Merle, P, Brandi, G, Daniele, B, Okusaka, T, Tomasek, J, Borg, C, Zagonel, V, Morimoto, M, Pracht, M, Finn, R S, Llovet, J, Homma, G, Jen, M-H, Shinozaki,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

717

883PAndrogen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN

Chi, K N, Thomas, S, Agarwal, N, Feng, F, Attard, G, Wyatt, A W, Gormley, M, Ricci, D S, Lopez-Gitlitz, A, Deprince, K, Larsen, J, Chen, W, Miladinovic, B, Naini, V, Chowdhury, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 89 KB

english, 2019

718

888PCirculating tumour cell (CTC) genomic landscape in neuroendocrine prostate cancer (NEPC) by single cell copy number analysis

Conteduca, V, Ku, S-Y, Wang, Y, Fernandez, L, Kearney, M, Lee, J, Jiles, R, Rodriguez, A, Nanus, D M, Tagawa, S T, Dittamore, R, Beltran, H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

719

891TiPKEYNOTE-921: Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Petrylak, D P, Li, B, Schloss, C, Fizazi, K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

720

998PDAnalysis of tumour samples from SOLO1: Frequency of BRCA specific loss of heterozygosity (LOH) and progression-free survival (PFS) according to homologous recombination repair deficiency (HRD)-LOH score

Gourley, C, Brown, J S, Lai, Z, Lao-Sirieix, P, Elks, C E, McGarvey, H, French, T, Milenkova, T, Bloomfield, R, Rowe, P, Hodgson, D, Barrett, J C, Moore, K, DiSilvestro, P, Harrington, E A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

721

1148PACCURACY a phase (P) II trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notch act mut): Preliminary safety and efficacy data

Ferrarotto, R, Ho, A, Wirth, L J, Muzaffar, J, Rodriguez, C, Dekel, E, Walker, R M, Nadri-Shay, C, Vergara-Silva, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 105 KB

english, 2019

722

1176OArtificial intelligence combining radiomics and clinical data for predicting response to immunotherapy

Ligero, M, Garcia-Ruiz, A, Viaplana, C, Raciti, M V, Matos, I, Liberal, J Martín, Hierro, C, Gonzalez, M, Barrera, R Morales, Suárez, C, Elez, E, Brana, I, Muñoz-Couselo, E, Oaknin, A, Felip, E, Taber

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 69 KB

english, 2019

723

1220PPhase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumours

Luke, J J, Fong, L, Chung, K, Tolcher, A W, Kelly, K, Hollebecque, A, Le Tourneau, C, Subbiah, V, Tsai, F, Kao, S, Cassier, P, Khasraw, M, Allaire, K, Fan, F, Fang, H, Patel, M, Henner, W, Hayflick, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 87 KB

english, 2019

724

1326PExternal validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC) using the surveillance, epidemiology and end results (SEER) program

Tjokrowidjaja, A, Browne, L, Soudy, H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

725

1431PPrediction of benign and malignant breast masses using digital mammograms texture features

Yanhua, C, Li, Y, Zhu, J, Dong, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

726

1561PIncidence of T790M in NSCLC patients progressed to gefitinib, erlotinib, and afatinib: A study on circulating tumour DNA

Danesi, R, Petrini, I, Mazzoni, F, Valleggi, S, Gianfilippo, G, Pozzessere, D, Crucitta, S, Restante, G, Chella, A, Garassino, M C, Miccoli, M, Re, M Del

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

727

1873OPARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors

Pellegrino, B, Llop-Guevara, A, Pedretti, F, Cruz, C, Castroviejo, M, Cedro-Tanda, A, Fasani, R, Mateo, F, Musolino, A, Pujana, M A, Nuciforo, P G, Gros, A, Balmana, J, O’Connor, M J, Serra Elizalde,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 94 KB

english, 2019

728

2002PCXCR4, CCR2 and CCR5 expression in subsets of tumor cells with stem and/or EMT features

Savelieva, O E, Tashireva, L A, Kaigorodova, E V, Tarabanovskaya, N A, Perelmuter, V M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

729

CN33Patient safety and the power of nursing presence

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 90 KB

english, 2019

730

SY5-5The role of immuno-checkpoint inhibitors in Hodgkin lymphoma

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 69 KB

english, 2019

731

SY10-5Novel treatment strategies for EGFR mutant lung cancer

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

732

MO1-3-4Rare cancers are also not rare in Asia: The rare cancer burden in East Asia

Matsuda, Tomohiro, Won, Young-Joo, Chiang, Ruru Chun-Ju, Lim, Jiwon, Saika, Kumiko, Trama, Annalisa

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 91 KB

english, 2019

733

MO1-9-6Characteristics and Treatment Patterns for Non-Metastatic Castration Resistant Prostate Cancer Patients in Japan

Shah, Ruchitbhai, Ledesma, Dianne, Ikeme, Shelly, Botteman, Marc, Waldeck, Reg

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

734

MO2-6-3Matrisomal abnormality: a predictive biomarker for cancer immunotherapy

Lim, Su Bin, Lim, Chwee Teck, Lim, Darren Wan-Teck

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

735

MO2-10-5TSGA10 and H2AX competition over binding HIF-1 in breast cancer

Mansouri, Kamran, Jahani, Mozhgan, Yarani, Reza, Chehri, Javad

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

736

MO2-11-1 [Encore]Biomarkers and clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma in CheckMate 040

Melero, Ignacio, Neely, Jaclyn, Sangro, Bruno, Finn, Richard S, Abou-Alfa, Ghassan K, Cheng, Ann-Lii, Yau, Thomas, Furuse, Junji, Park, Joong-Won, Wadhawan, Samir, Tang, Hao, Anderson, Jeffrey, Boyd,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

737

O1-4-2 [Encore]Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK+ NSCLC from ALTA-1L

Yang, James C H, Kim, Hye R, Ahn, Myung-Ju, Han, Ji-Youn, Hochmair, Maximilian J, Lee, Ki H, Delmonte, Angelo, Campelo, Maria R Garcia, Kim, Dong-Wan, Felip, Enriqueta, Califano, Raffaele, Spira, Alex

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 81 KB

english, 2019

738

O2-4-2Influence of physical symptoms on distress in patients with colorectal cancer undergoing outpatient chemotherapy

Aoki, Miwa, Arao, Harue, Hatakeyama, Akiko, Minamiguchi, Yoko, Toki, Masayo, Fujikawa, Naomi, Asano, Kota, Takao, Ayumi, Tatsumi, Yukiko

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

739

P1-105Multiple Myeloma in Patient with Co-existing Chronic Renal Failure on Hemodialysis: A Case Report

Sutandyo, Noorwati, Novianti, Nia

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

740

P1-116The prognostic value of nadir PSA level and time to nadir in high risk mHNPC patients

Asai, Akihiro, Shirosima, Itsuho, Imasato, Yushi, Furukawa, Masataka

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

741

P2-206Companion diagnosis by BRACAnalysis CDxTM and therapeutic experience of Olaparib for HER2-negative breast cancer

Kimura, Yuri, Itagaki, Tomoko, Ohara, Masahiro

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

742

SY15-2New BCR-ABL inhibitors in chronic myeloid leukemia

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

743

WS1-5Recent advances in systemic therapy for hepatocellular carcinoma

Ikeda, Masafumi

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

744

LBA47Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

Kaseb, A, Duda, D G, Tran Cao, H S, Abugabal, Y I, Vence, L M, Rashid, A, Carmagnani Pestana, R, Blando, J M, Singh, S, Vauthey, J N, Chun, Y S, Tzeng, C-W D, Sakamuri, D, Wolff, R A, Yao, J C, Alliso

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 69 KB

english, 2019

745

LBA49_PRTiming of radiotherapy (RT) after radical prostatectomy (RP): First results from the RADICALS RT randomised controlled trial (RCT) [NCT00541047]

Parker, C, Clarke, N W, Cook, A, Kynaston, H G, Meidahl Petersen, P, Cross, W, Persad, R, Catton, C, Logue, J, Payne, H, Saad, F, Brasso, K, Lindberg, H, Zarkar, A, Raman, R, Roder, M A, Heath, C, Par

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 85 KB

english, 2019

746

LBA54ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC)

Motzer, R J, Lee, C-H, Emamekhoo, H, Matrana, M, Percent, I, Hsieh, J J, Hussain, A, Vaishampayan, U N, Graham, R, Liu, S, McCune, S, Shaheen, M, Parmar, H, Shen, Y, Whiting, S H, Tannir, N M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 88 KB

english, 2019

747

LBA3VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)

Coleman, R L, Fleming, G F, Brady, M F, Swisher, E, Steffensen, K D, Friedlander, M, Okamoto, A, Moore, K, Ben-Baruch, N, Werner, T L, Oaknin, A, Nam, J-H, Leath, C A, Nicum, S, Cella, D, Sullivan, D

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 85 KB

english, 2019

748

LBA80Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407

Paz-Ares, L, Langer, C J, Novello, S, Halmos, B, Cheng, Y, Gadgeel, S M, Hui, R, Sugawara, S, Borghaei, H, Cristescu, R, Aurora-Garg, D, Albright, A, Loboda, A, Kobie, J, Lunceford, J, Ayers, M, Lubin

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 85 KB

english, 2019

749

LBA83Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

Socinski, M, Velcheti, V, Mekhail, T, Chae, Y K, Leal, T A, Dowell, J E, Tsai, M L, Dakhil, C S, Stella, P, Shen, V, Hu, S, Paul, S M, Shames, D S, Schleifman, E, Fabrizio, D A, Nowicki, M, Yun, C, Ph

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 84 KB

english, 2019

750

1629O_PRThe price of added value for new anti-cancer drugs in France 2004-17

Marino, P, Jalbert, A-C, Duran, S, Mancini, J, Gonçalves, A, Rodwin, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 85 KB

english, 2019

751

145PBreast cancer in young women of Kazakh population depending on germline mutations: Results of next-generation sequencing

Kaidarova, D, Omarbayeva, N, Zhunussova, G, Abdrakhmanova, A, Chingissova, Z, Djansugurova, L

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

752

210PImpact of delayed neoadjuvant systemic chemotherapy on survival among breast cancer patients

Gregor, M Chavez Mac, Lei, X, Gagliato, D, Valero, V, Barcenas, C, Hortobagyi, G N, Giordano, S H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 82 KB

english, 2019

753

760PPembrolizumab vs chemotherapy in patients with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line therapy: Analysis of the Chinese subgroup in KEYNOTE-181

Chen, J, Luo, S, Qin, S, Cheng, Y, Li, Z, Fan, Y, Yuan, X, Li, W, Sun, Y, Yin, X, Lin, X, Bai, Y, Liu, T, Zhang, J, Cui, Y, Bhagia, P, Kang, S P, Lu, W, Zhou, Y, Shen, L

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 81 KB

english, 2019

754

1754OPrediction of serious complications in patients with cancer and pulmonary embolism: Validation of the EPIPHANY index in a prospective cohort of patients from the PERSEO study

Sanchez Canovas, M, Fernández Montes, A, Morales Giménez, R, Cejuela Solís, M, Casado Elia, D, Coma Salvans, E, Gómez Sánchez, D, Sánchez Cendra, C, Sequero López, S, Orrillo Sarmiento, M, Arrazubi Ar

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 93 KB

english, 2019

755

1844ODurable anti-tumor activity of the multi-targeted inhibitor lenvatinib in patients with advanced or metastatic thymic carcinoma: Preliminary results from a multicenter phase II (REMORA) trial

Itoh, S, Satouchi, M, Sato, J, Okuma, Y, Niho, S, Mizugaki, H, Murakami, H, Fujisaka, Y, Kozuki, T, Nakamura, K, Nagasaka, Y, Kawasaki, M, Yamada, T, Kuchiba, A, Yamamoto, N

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 93 KB

english, 2019

756

LBA78IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC

Spigel, D, de Marinis, F, Giaccone, G, Reinmuth, N, Vergnenegre, A, Barrios, C H, Morise, M, Felip, E, Andric, Z G, Geater, S, Özgüroğlu, M, Mocci, S, McCleland, M, Enquist, I, Komatsubara, K M, Deng,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 85 KB

english, 2019

757

LBA27Drug Rediscovery Protocol: Expanded use of existing anticancer drugs

Voest, E E, van der Velden, D L, Hoes, L, Van Der Wijngaart, H, Van Berge Henegouwen, M, Van Werkhoven, E, Roepman, P, Huitema, A D R, van Herpen, C, de Groot, D J, Devriese, L, de Jonge, M J A, Chala

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 99 KB

english, 2019

758

PD-030Final results of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC)

Geissler, M, Tannapfel, A, Reinacher-Schick, A, Martens, U, Ricke, J, Riera-Knorrenschield, J, Kanzler, S, Held, S, Heinemann, V, Seufferlein, T, Modest, D

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 95 KB

english, 2019

759

115PEvaluation of microsatellite instability testing through cell-free DNA sequencing

Zhang, S, LoCoco, J S, Mentzer, A, Crain, B M, Katz, S, Berry, G, Fu, Y, Jiang, T, Zhao, C, Bilke, S, Pawlowski, T, Kruglyak, K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

760

116PLongitudinal changes in cell-free DNA (cfDNA) methylation levels identify early non-responders to treatment in advanced solid tumours

Davis, A A, Iams, W, Chan, D, Oh, M S, Lentz, R W, Srivas, R, Lambert, N, Robertson, A, Peterman, N, Shah, A, Wilson, T, Close, J, George, P, Wood, H, Wong, B, Tezcan, A, Spinosa, J C, Tezcan, H, Chae

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

761

89PDPrognostic and predictive impact of high tumor mutation burden (TMB) in solid tumors: A systematic review and meta-analysis

McNamara, M G, Jacobs, T, Frizziero, M, Pihlak, R, Lamarca, A, Hubner, R, Valle, J W, Amir, E

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 93 KB

english, 2019

762

747PA phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results

Llovet, J, Shepard, K V, Finn, R S, Ikeda, M, Sung, M, Baron, A D, Kudo, M, Okusaka, T, Kobayashi, M, Kumada, H, Kaneko, S, Pracht, M, Mamontov, K, Meyer, T, Mody, K, Kubota, T, Saito, K, Siegel, A B,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 92 KB

english, 2019

763

840TiPA phase Ib/II study of AK104, a PD-1/CTLA-4 bispecific antibody, combined with mXELOX as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma

Ji, J, Shen, L, Li, Z, Gao, X, Gong, J, Liu, D, Wu, X, Xu, S, Jin, X, Li, B, Wang, M, Xia, Y

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

764

LBA55Initial results from TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients (Pts) with metastatic urothelial cancer (mUC) after failure of platinum-based regimens (PLT) or immunotherapy

Tagawa, S T, Balar, A, Petrylak, D P, Grivas, P, Agarwal, N, Sternberg, C N, Hong, Q, Gladden, A, Kanwal, C, Siemon-Hryczyk, P, Goswami, T, Itri, L M, Loriot, Y

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 85 KB

english, 2019

765

P-339Epidemiology, treatment modalities and prognostic factors of colon cancer in the central region of Tunisia

Belaid, I, Khechine, W, Saad, A, Fki, A, Makram, H, El Ghali, A, Chabchoub, I, Ezzairi, F, Ben Fatma, L, Ben Ahmed, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 98 KB

2019

766

PD-012Emerging risk factors of recurrence and overall survival in a Swedish stage I-III colon cancer cohort

Osterman, E, Mezheyeuski, A, Sjöblom, T, Glimelius, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

767

SO-006Hafnium oxide nanoparticles activated by SBRT: a new interventional radiation therapy approach for the treatment of unresectable liver cancers

Baere, T De, Pracht, M, Rolland, Y, Nguyen, F, Bronowicki, J, Vendrely, V, Cunha, A Sa, Baumann, A, Croisé-Laurent, V, Rio, E, Sourd, S Le, Gustin, P, Perret, C, Peiffert, D, Deutsch, E, Chajon, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

768

845PDCDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors

Antonarakis, E S, Velho, P Isaacsson, Agarwal, N, Santos, V Sacristan, Maughan, B L, Pili, R, Adra, N, Sternberg, C N, Vlachostergios, P J, Tagawa, S T, Bryce, A H, McNatty, A L, Reichert, Z R, Dreice

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 87 KB

english, 2019

769

993OOCTOPUS: A randomised, multi-centre phase II umbrella trial of weekly paclitaxel+/- novel agents in platinum-resistant ovarian cancer: Vistusertib

Banerjee, S, Lewsley, L-A, Clamp, A R, krell, J, Herbertson, R, Glasspool, R M, Orbegoso, C, Green, C, Kristeleit, R S, Gourley, C, Cambell, C, Banerji, U, Shepherd, C, Brugger, W, Chudleigh, L, Hanif

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 109 KB

english, 2019

770

1203PPreliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumours

Massard, C, Cassier, P, Bendell, J C, Marie, D B, Blery, M, Morehouse, C, Ascierto, M, Zerbib, R, Mitry, E, Tolcher, A W

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

771

1798PInfection-related mortality in different types of cancers

Gouda, M A, Gouda, A A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

772

2037PA challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience

Pauli, C, Bochtler, T, Mileshkin, L, Baciarello, G, Losa, F, Ross, J, Pentheroudakis, G, Zarkavelis, G, Yalcin, S, Özgüroğlu, M, Beringer, A, Foser, S, Scarato, J, Mueller-Ohldach, M, Moch, H, Krämer,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 94 KB

english, 2019

773

P1-185Liquid biopsy for detection of actionable mutation in various cancer patients

Takahashi, Shunji, Ohtaki, Masumi, Tomomatsu, Junichi, Ono, Makiko, Yunokawa, Mayu, Ito, Yoshinori, Shibayama, Tomoko, Kobayashi, Kokoro, Sasahira, Naoki, Ozaka, Masato, Chin, Keisho, Yamaguchi, Kense

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 82 KB

english, 2019

774

P-361Laparoscopic liver resection in metastatic colorectal cancer

Kolesnik, O, Lukashenko, A, Ostapenko, Y, Chorna, N, Patsko, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

775

259PProgesterone receptor isoform ratio dictates antiprogestins/progestins effects on metastatic breast cancer models

Abascal, M F, Giulianelli, S, Alvarez, M, Sequeira, G, Vanzulli, S, Elia, A, Pataccini, G, Lombes, M, Lanari, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

776

671OConversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (NEOLAP): Final results of a multicenter randomised phase II AIO trial

Kunzmann, V, Algül, H, Goekkurt, E, Siegler, G M, Martens, U M, Waldschmidt, D, Pelzer, U, Hennes, E, Fuchs, M, Siveke, J, Kullmann, F, Boeck, S, Ettrich, T J, Ferenczy, P, Keller, R, Germer, C-T, Ste

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

777

1085PSafety and efficacy of bendamustine and rituximab (BR) regimen in Indian chronic lymphocytic leukemia patients

Gogia, A, Kumar, L, Sharma, A, Raina, V, Gupta, R, Rani, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

778

1534PTP53 mutations predicts worse prognosis in EGFR-mutated NSCLC patients receiving TKIs in first- or further line of treatment

Canale, M, Luigi, N De, Petracci, E, Delmonte, A, Ludovini, V, Dubini, A, Baglivo, S, Minenza, E, Chiadini, E, Landi, L, Papi, M, Bronte, G, Crinò, L, Ulivi, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

779

1806PSalivary cytokines and oral mucosa cells apoptosis in patients during hematopoietic cell transplantation: Possible relationship with oral mucositis

Corrêa, L, Bezinelli, L M, Rosin, F C P, Ferreira, M H, Carvalho, D L C, Lopes, R M D G, Hamerschlak, N, Eduardo, F D P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

780

1753OLong term follow-up (F/U) report of symptomatic cardiac events (SCEs) in 2,809 breast cancer (BC) patients (pts) treated with adjuvant trastuzumab (T) in real world (RW) practice

Di Cosimo, S, Trama, A, Merlo, I, Minicozzi, P, Tarantini, L, Apolone, G, Corrao, G, Franchi, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

781

CN77Effect of Kegel exercises on prevention of urinary and fecal incontinence in patients with prostate cancer undergoing radiotherapy

Uravylioglu, A E, Kutlutürkan, S, Kılıç, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

782

LBA2_PRPhase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev

Ray-Coquard, I L, Pautier, P, Pignata, S, Pérol, D, González-Martín, A, Sevelda, P, Fujiwara, K, Vergote, I B, Colombo, N, Mäenpää, J, Selle, F, Sehouli, J, Lorusso, D, Alia, E M Guerra, Lefeuvre-Ples

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

783

P-346A single center experience with oral chemotherapy with capecitabine and temozolomide in metastatic neuroendocrine tumors

Rego, I, Pontes, F, Carvalho, J, Pratas, E, Chaves, A, Martins, R, Couto, J, Ribeiro, J, Rodrigues, F, Sousa, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 99 KB

2019

784

PD-033A prospective cohort study on the effect of radiotherapy for rectal cancer on female sexual function

Svanström Röjvall, A, Buchli, C, Bottai, M, Ahlberg, M, Flöter-Rådestad, A, Martling, A, Segelman, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

785

135PCan we improve patient selection for phase I clinical trials (phI1) based on immuno-oncology score prognostic index (VIO)?

Matos Garcia, I, Hierro, C, Martin-Liberal, J, VIAPLANA, C, Azaro, A, Brana, I, Vieito Villar, M, Saavedra, O, Gardeazabal, I, Ros, J, Prieto, P, Berché, R, Muñoz-Couselo, E, Oliveira, M, Elez Fernánd

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

786

1360PIntracranial anti-tumour activity in melanoma brain metastases with encorafenib plus binimetinib: A multicenter, retrospective analysis

Lutzky, J, Holbrook, K, Amin, A, Davis, J M, Davies, M A, Diab, A, Glitza, I C, Amaria, R N, Patel, S, Tawbi, H A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

787

1385PDNew circulating biomarkers in gastro-entero-pancreatic-neuroendocrine-tumours

Bocchini, M, Mazza, M, Foca, F, Nicolini, F, Calogero, R A, Severi, S, Paganelli, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

788

CN1Patients’ usage and perception of an interactive app for symptom management and self-care during cancer treatment

Crafoord, M-T, Fjell, M, Nilsson, M I, Nilsson, M I, Sundberg, K, Langius-Eklöf, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

789

149PEvaluation and diagnostic potential of plasma biomarkers in bladder cancer

Voronova, V, Peskov, K, Glybochko, P, Svistunov, A, Fomin, V, Kopylov, P, Enikeev, D, Gitel, E, Ragimov, A, Poddubskaya, E, Sekacheva, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

790

177PDProspective, multicenter registry trial to evaluate the clinical feasibility of targeted axillary dissection (TAD) in patients (pts) with breast cancer (BC) and core biopsy proven axillary involvement (cN+)

Reinisch, M, Heil, J, Rüland, A, Seiberling, C, Harrach, H, Schindowski, D, Lubitz, J, Ankel, C, Graßhoff, S -T, Deuschle, P, Hanf, V, Holtschmidt, J, Traut, E, Kuehn, T, Kuemmel, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

791

262PGeriatric parameters predict both disease-related and patient-reported outcomes in older patients with breast cancer

van der Plas-Krijgsman, W, de Boer, A, de Jong, P, Bastiaannet, E, van den Bos, F, Liefers, G-J, Portielje, J E A, De Glas, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

792

401PDGEINO 1402: A phase Ib dose-escalation study followed by an extension phase to evaluate safety and efficacy of crizotinib in combination with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed glioblastoma (GB)

Martinez Garcia, M, Gil, M J, Pineda, E, Martin Soberón, M C, Mesia Barroso, C, Foro, P, Capellades, J, Sarmiento, B, Bruna, J, Verger, E, Taus Garcia, A, Alameda, F, Hernandez Lain, A, Velasco, G, Se

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

793

417PEffect of cumulative dose of maintenance temozolomide on overall survival in patients with high grade glia tumours: A single institution analysis

Nerone, M, Caspani, F, Tralongo, A C, Tuzi, A, Pinotti, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

794

429POutcome of high-grade gliomas (HGGs) treated into immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience

Simonelli, M, Persico, P, Dipasquale, A, Lorenzi, E, Giordano, L, Pessina, F, Navarria, P, Scorsetti, M, Bello, L, Santoro, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

795

442OTherapeutic drug monitoring of oral anticancer drugs - preliminary results of a prospective study

Groenland, S L, Van Eerden, R A G, Koolen, S L, Moes, D J A R, Desar, I M E, Touw, D J, Imholz, A L T, Reyners, A K L, Gelderblom, H, van Erp, N P, Mathijssen, R H J, Huitema, A D R, Steeghs, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

796

636PPrognostic and predictive impact on FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer

Hasegawa, H, Taniguchi, H, Kato, T, Fujii, S, Ebi, H, Shiozawa, M, Yuki, S, Masuishi, T, Kato, K, Izawa, N, Moriwaki, T, Kagawa, Y, Sakamoto, Y, Okamoto, W, Nakamura, Y, Yamazaki, K, Yoshino, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

797

847PDCentral, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study

de Bono, J S, Fizazi, K, Saad, F, Shore, N, Sandhu, S K, Mehra, N, Kolinsky, M, Roubaud, G, Özgüroǧlu, M, Matsubara, N, Gedye, C, Choi, Y D, Padua, C, Goessl, C, Kohlmann, A, Corcoran, C, Adelman, C A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

798

865PTreatment outcomes of 3rd treatment in a real-world metastatic castration resistant prostate cancer (mCRPC) population: Results from the Dutch CAPRI-registry

Notohardjo, J C L, Kuppen, M C P, Westgeest, H M, van den Eertwegh, A J M, Moorselaar, J Van, Mehra, N, Coenen, J L, van Oort, I, van den Bergh, A C M, Aben, K K H, Somford, D M, de Wit, R, Bergman, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

799

880PImpact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Data from the prospective PROREPAIR-B study

Cattrini, C, Laorden, N Romero, Castro, E, García-Carbonero, I, Piulats, J M, Puente, J, Valderrama, B P, Guzman, J C Villa, Billalabeitia, E Gonzalez, Barrera, R Morales, Mejorada, R Lozano, Luque, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

800

881PImplications of single nucleotide polymorphisms (SNPs) in androgen related-genes in outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone (Abi) and enzalutamide (Enza)

Aragon, I M, Cendón, Y, Lorente, D, Mejorada, R Lozano, Laorden, N Romero, Colmenero, A Medina, Puente, J, Villatoro, R, Estevez, S Vazquez, Piulats, J M, Lainez, N, Fernandez-Parra, E, del Alba, A Go

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

801

897TiPA phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)

Chi, K N, Rathkopf, D, Attard, G, Smith, M R, Efstathiou, E, Olmos, D, Small, E J, Lee, J Y, Sieber, P, Dunshee, C, Ricci, D, Simon, J S, Zhao, X, Kothari, N, Cheng, S, Sandhu, S K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

802

954PSPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz)

Valderrama, B P, Perez Ramirez, S, Rodriguez-Vida, A, González del Alba, A, Mendez Vidal, M J, Vazquez Estevez, S, Martinez Ortega, E, Virizuela, J A, Fernández Calvo, O, Hernández Jorge, A, Vazquez M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

803

1055PClinical impact of molecular profiling of cervical cancer (CC) patients (pts) in a dedicated phase I (P1) unit

Scaranti, M, Caldwell, R, Miralles, M Selvi, Shinde, R, Pal, A, Ang, J E, Biondo, A, Guo, C, Cojocaru, E, Gennatas, S, Lockie, F, Bertan, C, Baker, C, Carreira, S, Banerjee, S, Kaye, S, de Bono, J S,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

804

1084PSplenic marginal zone lymphoma: Clinical characteristics and prognostic factors in a series of 52 patients

Cengiz Seval, G, Topcuoglu, P, Arslan, O, Gurman, G, Demirer, T, Kuzu, I, Ozcan, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

805

1270PPembrolizumab in advanced rare cancers

Naing, A, Meric-Bernstam, F, Karp, D, Rodon, J A, Piha-Paul, S A, Subbiah, V, Hong, D S, Pant, S, Fu, S, Janku, F, Yap, T A, Tsimberidou, A M, Dumbrava, E E Ileana, Colen, R R, Hess, K R, Campbell, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

806

1174OPembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies

Diaz, L A, Le, D, Maio, M, Ascierto, P A, Geva, R, Motola-Kuba, D, André, T, Van Cutsem, E, Gottfried, M, Elez, E, Delord, J-P, Jäger, D, Kim, T W, Guimbaud, R, Yoshino, T, Chen, M, Norwood, K, Marine

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

807

1387PDifferences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumours (NETs)

Hernando Cubero, J, Grande, E, Castellano Gauna, D, Ibrahim, T, Fazio, N, Lopez, C, Teulé, A, Valle, J W, Alonso, V, Molina-Cerrillo, J, Tafuto, S, Custodio, A, Trejo, L, Casteras, A, Manneh Kopp, R,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

808

1399PHematologic malignancies in temozolomide-treated metastatic pancreatic neuroendocrine tumours

Balmaceda, N, Mouw, T, Abhyankar, S, Male, H, Woodroof, J, Williamson, S, Baranda, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

809

1998P The discovery of RNA-aptamers that selectively bind and inhibit glioblastoma stem cells by targeting EphA2

Affinito, A, Quintavalle, C, Esposito, C L, Roscigno, G, Vilardo, C, Nuzzo, S, Ricci Vitiani, L, De Luca, G, Minic, Z, Giannetti, S, Pallini, R, Berezovski, M V, Kichkailo, A S, Lapin, I N, Franciscis

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

810

1700POutcomes of metastatic soft tissue sarcoma treated with pazopanib from dedicated medical oncology sarcoma clinic: A holistic care approach from a developing country

Kapoor, A, Kumar, S M, Ghosh, J, Rekhi, B, Bajpai, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

811

1702PEfficacy and safety of apatinib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib: An open-label, multicenter, single-arm, phase II trial

Cai, Z, Zhang, B, Yin, Y, Cao, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

812

1703PLong-term outcome of neoadjuvant tyrosine kinase inhibitors (TKI) in locally advanced dermatofibrosarcoma protuberans (DFSP)

Beaziz, J, Battistella, M, Delyon, J, Maignan, C Le, Marco, O, Kérob, D, Laurent, C Pages, Da Meda, L, Farges, C, Basset-Seguin, N, Lebbe, C, Baroudjian, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

813

1705PGastrointestinal stromal tumours (GIST) in adolescents and young adults (AYA)

Ijzerman, N S, Drabbe, C, Den Hollander, D, Mohammadi, M, van Boven, H, Desar, I M E, Gelderblom, H, Grünhagen, D J, Reyners, A K L, Mathijssen, R H J, Steeghs, N, van der Graaf, W T A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

814

LBA79Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials

Herbst, R S, Lopes, G, Kowalski, D M, Nishio, M, Wu, Y-L, de Castro Junior, G, Baas, P, Kim, D-W, Gubens, M A, Cristescu, R, Aurora-Garg, D, Albright, A, Ayers, M, Loboda, A, Lunceford, J, Kobie, J, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

815

162PHospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA

Ettl, J, Quek, R G W, Hurvitz, S A, Goncalves, A, Tudor, I C, Rugo, H S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

816

P-252Gemcitabine induced haemolytic uremic syndrome: The big unknown

Cidon, E Una, Alonso, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

817

77PRed-blood-cell-membrane-enveloped magnetic nanoclusters as a biomimetic theranostic nanoplatform for bimodal imaging guided cancer photothermal therapy

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

818

146PDiscovery of an immunotranscriptomics signature in blood for early colorectal cancer detection

Angelino, P, Hosseinian Ehrensberger, S, Ciarloni, L, Despraz, J, Dorta, G, Perez-Uribe, A, Morgenthaler, S, Delorenzi, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

819

147PSerum netrin-1 as a biomarker for colorectal cancer detection

Zhu, J, Xi, L, Wu, A, Ma, X, Zhang, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 108 KB

2019

820

310PDThe importance of primary surgery in patients with de novo stage IV BC surviving at least 5 years: Protocol MF07-01 randomized clinical trial

Ozmen, V, Ozbas, S, Karanlik, H, Muslumanoglu, M, Igci, A, Canturk, Z, Utkan, Z, Ozaslan, C, Evrensel, T, Uras, C, Aksaz, E, Soyder, A, Ugurlu, U M, Col, C, Cabioglu, N, Bozkurt, B, Uzunkoy, A, Sezgin

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

821

750PA phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL

Pinato, D J, Cole, T, Bengsch, B, Tait, P, Sayed, A A, Abomeli, F, Gramenitskaya, D, Allara, E, Thomas, R, Ward, C, Wong, C N, Akarca, A U, Miguens Blanco, J, Marafioti, T, Marchesi, J, Sharma, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

822

833TiPPhase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy

Rimassa, L, Cheng, A-L, Braiteh, F, Chaudhry, A, Benzaghou, F, Thuluvath, P, Hazra, S, Borgman-Hagey, A E, Tan, B, Kayali, Z K, Zhu, A X, Kelley, R K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

823

844ODocetaxel for hormone-naïve prostate cancer: Results from long-term follow-up of metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476) and sub-group analysis by metastatic burden

Clarke, N W, Ali, A, Ingleby, F C, Hoyle, A, Calvert, J, Attard, G, Chowdhury, S, Dearnaley, D, Douis, H, Gillessen, S, Jones, R, Malik, Z, Mason, M D, Millman, R, Parker, C, Rush, H L, Omlin, A G, Sy

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 106 KB

2019

824

932PHyperphosphatemia due to erdafitinib (a pan-FGFR Inhibitor) and anti-tumour activity among patients (Pts) with advanced urothelial carcinoma (UC)

Tagawa, S, Siefker-Radtke, A, Dosne, A -G, Zhong, B, Qi, K, Shalaby, W, O’Hagan, A, De Porre, P, Mahadevia, P, Loriot, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

825

1030PImpact of prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer (ROC): Sub-group analysis from a randomized, open-label study comparing trabectedin (T) and PLD versus PLD alone in ROC (ET743-OVC-3006)

Monk, B J, Herzog, T J, Triantos, S, Maul, S, Wang, G, Valero, M J Pontes, McGowan, T, Shalaby, W S, Coleman, R L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

826

1179PDNatural dendritic cell vaccinations generate immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

Creemers, J, Westdorp, H, van Oort, I, Schreibelt, G, Gorris, M, Mehra, N, Simons, M, de Goede, A, van Rossum, M, Croockewit, S, Figdor, C, Witjes, J A, Aarntzen, E, Mus, R, Gotthardt, M, Barentsz, J,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

827

1345POutcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)

Knispel, S, Gassenmaier, M, Menzies, A M, Loquai, C, Johnson, D B, Franklin, C, Gutzmer, R, Hassel, J C, Weishaupt, C, Eigentler, T, Schummer, P, Kiecker, F, Owen, C, Schmidgen, M I, Kähler, K C, Cann

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

828

1372TiPA phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)

Rischin, D, Fury, M G, Lowy, I, Stankevich, E, Li, S, Han, H, Porceddu, S V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

829

1443PCharacterization of lung tumourspheres reveals cancer stem-like cells potential targets and prognostic markers in non-small cell lung cancer

Herreros Pomares, A, Jantus-Lewintre, E, Calabuig-Fariñas, S, de-Maya-Girones, J D, Lucas, R, Blasco, A, Guijarro, R, Martorell, M, Escorihuela, E, Alonso, S, Chiara, M D, Duréndez, E, Gandia, C, Sire

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

830

1449PAnalysis of immunosuppressive factors produced by tumorspheres in NSCLC: Prognostic value of galectin-3 in adenocarcinoma

Torres Martinez, S, Herreros Pomares, A, Zhang, F, Calabuig-Fariñas, S, González, Á, Sirera, R, Moreno-Manuel, A, Mosqueda, M, Escorihuela, E, Duréndez, E, Gallach, S, Garde, J, Guijarro, R, Jantus-Le

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

831

1928PAntecedent of cancer and mortality after the first ST segment elevation acute myocardial infarction treated with primary coronary angioplasty. A prospective cohort study

Sillero, I D, López Flores, M, Sánchez-Cousido, L F, Rojas Piedra, M, Prieto-Salvador, I, López González, A, Castañón González, C, García-Palomo, A, Fernández Vazquez, F, Iglesias, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

832

1950PEffect of selumetinib plus AZD8186 treatment on cabazitaxel sensitivity in docetaxel-acquired resistant metastatic prostate cancer cell lines

Ruiz de Porras, V, Laguía, F, Marín-Aguilera, M, Jiménez, N, Mellado, B, Ramirez, J L, Martinez-Balibrea, E, Font, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

833

LBA7_PROverall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

Slamon, D J, Neven, P, Chia, S, Fasching, P A, De Laurentiis, M, Im, S-A, Petrakova, K, Bianchi, G V, Esteva, F J, Martin, M, Nusch, A, Sonke, G S, De la Cruz-Merino, L, Beck, J T, Pivot, X, Sondhi, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 105 KB

2019

834

LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

Yau, T, Park, J W, Finn, R S, Cheng, A-L, Mathurin, P, Edeline, J, Kudo, M, Han, K-H, Harding, J J, Merle, P, Rosmorduc, O, Wyrwicz, L, Schott, E, Choo, S P, Kelley, R K, Begic, D, Chen, G, Neely, J,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

835

LBA48_PRAdjuvant or salvage radiotherapy for the treatment of localised prostate cancer? A prospectively planned aggregate data meta-analysis

Vale, C L, Brihoum, M, Chabaud, S, Cook, A, Fisher, D, Forcat, S, Fraser-Browne, C, Herschtal, A, Kneebone, A, Nénan, S, Parker, C, Parmar, M K B, Pearse, M, Richaud, P, Rogozińska, E, Sargos, P, Syde

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

836

LBA63Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy

Creutzberg, C L, Leon-Castillo, A, de Boer, S M, Powell, M E, Mileshkin, L R, Mackay, H J, Leary, A, Nijman, H W, Singh, N, Pollock, P, Fyles, A, Haie-Meder, C, Smit, V T H B M, Edmondson, R J, Putter

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

837

P-211A nomogram to predict neutropenia in metastatic pancreatic cancer patients treated with gemcitabine/nab-paclitaxel

Morelli, C, Formica, V, Nardecchia, A, Lucchetti, J, Tisone, G, Anselmo, A, Del Vecchio Blanco, G, Benassi, M, Palmieri, G, Argiró, R, Roselli, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 106 KB

2019

838

58PIKS01, a next generation antibody drug conjugate (ADC) designed to be efficacious in tumors with low and moderate levels of folate receptor expression

Thirlway, J, Lodge, A, Pelava, A, Williamson, D J, Carta, D, Nakeeb, M Al, Mysliwy, J, Jackson, P J M, Thurston, D E, Lutz, R J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

839

527PDTrastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial

Strickler, J H, Zemla, T, Ou, F-S, Cercek, A, Wu, C, Sanchez, F A, Hubbard, J, Jaszewski, B, Bandel, L, Schweitzer, B, Niedzwiecki, D, Kemeny, N, Boland, P M, Ng, K, Bekaii-Saab, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

840

1748PPhase I open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer

Calvo, E, Spira, A, Prenen, H, Ohe, Y, Rottey, S, Gazzah, A, Millward, M, Moreno, V, Italiano, A, Alanko, T, Yoh, K, Cassier, P A, Seto, T, Afar, D, Englert, S, Komarnitsky, P, Lambert, S, Parikh, A,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 116 KB

2019

841

1951PAnti-tumor activity of cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, in pancreatic ductal adenocarcinoma cells

Momeny, M, Alishahi, Z, Eyvani, H, Hamzelou, S, Ghaffari, S H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

842

1692PTreatment outcomes for adult patients with localized osteosarcoma treated with chemotherapy without methotrexate

Silva, M P M, Bonadio, R R D C C, Matos, G D R, Camargo, V P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

843

LBA11Nivolumab versus chemotherapy in advanced esophageal squamous cell carcinoma (ESCC): The phase III ATTRACTION-3 study

Cho, B C, Kato, K, Takahashi, M, Okada, M, Lin, C-Y, Chin, K, Kadowaki, S, Ahn, M-J, Hamamoto, Y, Doki, Y, Yen, C-C, Kubota, Y, Kim, S-B, Hsu, C-H, Holtved, E, Xynos, I, Kodani, M, Kitagawa, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

844

LBA12_PRPROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations

Hussain, M, Mateo, J, Fizazi, K, Saad, F, Shore, N D, Sandhu, S, Chi, K N, Sartor, O, Agarwal, N, Olmos, D, Thiery-Vuillemin, A, Twardowski, P, Mehra, N, Goessl, C, Kang, J, Burgents, J, Wu, W, Kohlma

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 105 KB

2019

845

LBA1Niraparib therapy in patients with newly diagnosed advanced ovarian cancer (PRIMA/ENGOT-OV26/GOG-3012 study)

González Martín, A, Pothuri, B, Vergote, I B, Christensen, R D, Graybill, W, Mirza, M R, McCormick, C, Lorusso, D, Hoskins, P, Freyer, G, Backes, F, Baumann, K, Redondo, A, Moore, R G, Vulsteke, C, O’

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

846

2OStrategic inhibition of CEP55 in aggressive breast cancer leads to mitotic catastrophe

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

847

413PDevelopment and validation of novel nomograms predicting survival of malignant ependymoma patients: A population-based study

Abbas, A S, Dibas, M, Ghozy, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

848

698PA protein level signature of four selected genes associated with survival outcomes of patients with pancreatic ductal adenocarcinoma

Hua, J, Wei, M, Shi, S, Xu, J, Yu, X

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

849

764PA novel nomogram and risk classification system predicting radiation pneumonitis in patients with esophageal cancer receiving radiotherapy

Wang, L, Meng, X, Yu, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

850

1119PDInducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results from INDUCE-1 expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC)

Rischin, D, Groenland, S L, Lim, A M L, Martin-Liberal, J, Moreno, V, Trigo Perez, J M, Le Tourneau, C, Mathew, M, Cho, D C, Hansen, A R, Vincente-Baz, D, Maio, M, Italiano, A, Bauman, J R, Chisamore,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

851

1243PTumour mutation burden (TMB), PD-L1, IFN-γ signaling identify subgroups of patients (pts) who benefit from durvalumab (D, anti-PDL1) or D and tremelimumab (T, anti-CTLA4) treatment in urothelial bladder cancer (UC)

Massard, C, Si, H, Zhang, Q, Higgs, B, Raja, R, Abdullah, S E, Gupta, A, Li, W, van der Heijden, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

852

1736OIMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)

Reck, M, Liu, S V, Mansfield, A S, Mok, T S K, Scherpereel, A, Reinmuth, N, Garassino, M C, Carpeno, J De Castro, Califano, R, Nishio, M, Orlandi, F, Alexander, J A Alatorre, Leal, T A, Cheng, Y, Lee,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 134 KB

2019

853

LBA8_PRKEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)

Schmid, P, Cortés, J, Dent, R, Pusztai, L, McArthur, H L, Kuemmel, S, Bergh, J, Denkert, C, Park, Y H, Hui, R, Harbeck, N, Takahashi, M, Foukakis, T, Fasching, P A, Cardoso, F, Jia, L, Karantza, V, Zh

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 108 KB

2019

854

LBA40FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)

Vogel, A, Sahai, V, Hollebecque, A, Vaccaro, G, Melisi, D, Al-Rajabi, R, Paulson, A S, Borad, M J, Gallinson, D, Murphy, A G, Oh, D-Y, Dotan, E, Catenacci, D V, Van Cutsem, E, Lihou, C F, Zhen, H, Fél

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

855

LBA86Mirtazapine in cancer-associated anorexia cachexia: A randomised, double-blind, placebo-controlled trial

Hunter, C N, Faheem, D E E D, El-Sherief, W A, Abdel Aal, H H, Alsirafy, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

856

LBA87INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753)

von Mehren, M, Serrano, C, Bauer, S, Gelderblom, H, George, S, Heinrich, M, Schöffski, P, Zalcberg, J, Chi, P, Jones, R L, Reichardt, P, Attia, S, D’Amato, G, Meade, J, Shi, K, Ruiz-Soto, R, Blay, J-Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 102 KB

2019

857

120PEarly on-treatment vs pre-treatment tumour transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer

Pernas, S, Goel, S, Johnson, N T, Harrison, B T, Guerriero, J L, Hu, J, Winship, G, Sokolov, A, Regan, M M, Mittendorf, E A, Overmoyer, B

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

858

511TiPA phase I, open-label study of GSK1795091 administered in combination with immunotherapies in participants with advanced solid tumours (NCT03447314)

Hansen, A R, Strauss, J, Chaves, J, Piha-Paul, S A, Park, H, Garralda, E, Matheny, C J, Carver, J, Moore, A, Hug, B A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

859

576PImpact of prophylactic systemic antibiotics (SA) on outcome of patients (pts) with RAS-wildtype (RAS-wt) metastatic colorectal carcinoma (mCRC) treated with cetuximab-based first-line therapy. Subgroup analysis of the german non-interventional study ERBITAG

Sahm, S W, Zahn, M-O, Maintz, C, Goehler, T, Janssen, J, Hering-Schubert, C, Rubanov, O, Zander, I, Stenzel, K G, Overkamp, F

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 81 KB

english, 2019

860

789PApatinib combined with docetaxel in second-line treatment of advanced gastric cancer: A prospective clinical study (data updated)

Yang, M, Gao, J, Liu, X, Xu, Z, Lu, H, Yang, W, Li, H, Li, Y

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 729 KB

english, 2019

861

1208PSafety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumours: Preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts

Conter, H J, MacDonald, L D, Fiset, S, Bramhecha, Y M, Chaney, M, Rosu, G N

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

862

1590TiPSafety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study

Reckamp, K L, Akerley, W, Calvo, E, Clarke, J, Edelman, M J, He, K, Moreno, V, Neal, J W, Owonikoko, T K, Patel, J D, Patel, S P, Riess, J W, Sacher, A G, Turcotte, S, Villaruz, L C, Zauderer, M G, Fa

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 89 KB

english, 2019

863

1831PUpdate of the registry of young women with cancer by the International Network of Cancer, Infertility and Pregnancy

Maggen, C, Van Calsteren, K, Cardonick, E, Shmakov, R G, Gziri, M, Garcia, A C, Fruscio, R, Lok, C A R, Halaska, M, Boere, I A, Zola, P, Ottevanger, P, de Groot, C J M, Scarfone, G, Fumagalli, M, Pain

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

864

2016PModulation of TLR9-dependent autophagy response via inhibition of c-Met signaling influences the survival of HT29 cancer cells

Sipos, F J, Nagy, L, Barta, B, Simon, Á, Dankó, T, Sebestyén, A, Kiss, A L, Műzes, G

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 69 KB

english, 2019

865

CN111Cancer patient participation and compliance in microbiome sample collection: An oncology research nurse’s experience

Malo, J, Messaoudene, M, Cauchois, F, Belkaid, W, Frizon-Peresa, D, Ikene, S, Rousseau, L, Lattouf, J-B, Elkrief, A, Mezquita, L, Derosa, L, Besse, B, Blais, N, Alameddine, R, Tehfe, M, Florescu, M, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

866

Introduction

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 65 KB

english, 2019

867

JS3-1A case of heart failure after radiation therapy for mediastinum

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

868

PSY1-3Precision Medicines in Oncology, European Regulator’s Views

Démolis, Pierre

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 71 KB

english, 2019

869

PSY2-4 [Encore]Establishing Comprehensive Cancer Care in Cambodia

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 82 KB

english, 2019

870

SY11-5Current status, issue and future perspectives for biosimilars in Japan from the viewpoint of cost-effectiveness

Nanbu, Yoshihiro

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

871

MO1-2-1Temozolomide monotherapy in patient of neuroendocrine carcinoma with resistant to platinum chemotherapy (Final Report)

Kobayashi, Noritoshi, Takeda, Yuma, Tokuhisa, Motohiko, Hiroshima, Yukihiko, Goto, Ayumu, Ichikawa, Yasushi

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 90 KB

english, 2019

872

MO1-8-4Baseline neutrophil to lymphocyte ratio is predictor of longer OS of metastatic BC patients treated with eribulin

Kusuhara, Shota, Kogawa, Takahiro, Shimokawa, Mototsugu, Shingaki, Sumito, Fujimoto, Yumi, Harano, Kenichi, Matsubara, Nobuaki, Naito, Yoichi, Hosono, Ako, Mukai, Hirofumi, Mukohara, Toru

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

873

MO1-9-2Immune microenvironment in clear cell type renal cell carcinoma with loss of PBRM1 protein expression

Miura, Yuji, Motoshima, Takanobu, Inoshita, Naoko, Okaneya, Toshikazu, Takano, Toshimi, Komohara, Yoshihiro

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

874

MO1-11-5Factors that could potentially impact on the initiation time of oncology clinical trials at investigational sites

Sano, Ayaka, Sasamoto, Hiromi, Nakamura, Mitsuyoshi, Ando, Koji, Shimada, Naomi, Kondo, Yayoi, Sawa, Junichiro, Ebisawa, Ryuichi, Suzuki, Hajime, Maruhashi, Akihiro, Tsuda, Takanori, Qiu, Xinbin, Shig

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 89 KB

english, 2019

875

MO1-11-6The health-related quality of life and Economic burden on Cancer Patients in Japan

Ohno, Shinya, Chen, Yirong, Sakamaki, Hiroyuki, Tsukamoto, Katsura

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

876

MO1-15-2Safety and efficacy of irinotecan administered after nivolumab for advanced gastric cancer

Sasaki, Akinori, Kawazoe, Akihito, Eto, Tetsuya, Mishima, Saori, Kotani, Daisuke, Nakamura, Yoshiaki, Kuboki, Yasutoshi, Taniguchi, Hiroya, Kojima, Takashi, Doi, Toshihiko, Yoshino, Takayuki, Shitara,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

877

MO1-16-1Update on JACCRO CC-11 trial of 1st-line modified-FOLFOXIRI plus bevacizumab for RAS mutant metastatic colorectal cancer

Nakamura, Masato, Sunakawa, Yu, Okuyama, Hiroyuki, Matsuura, Masato, Negoro, Yuji, Yabuno, Taichi, Takahashi, Takao, Tamura, Takao, Takeuchi, Nobumichi, Satake, Hironaga, Miyamoto, Yuji, Kataoka, Masa

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

878

MO2-1-4 [Encore]Association between preanalytical factors and tumor mutational burden estimated by NGS-based multiplex gene panel assay

Nguyen, Quy Pham, Kanai, Masashi, Kou, Takayuki, Kondo, Tomohiro, Yamamoto, Yoshihiro, Matsubara, Junichi, Hiroshima, Akinori, Mochizuki, Hiroaki, Sakuma, Tomohiro, Fukuyama, Keita, Matsumoto, Shigemi

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

879

MO2-7-5Quality of medical care in end-of-life lung cancer patients previously received immunotherapy

Kubo, Emi, Ishiki, Hiroto, Yokota, Sayuri, Shimizu, Masaki, Kiuchi, Daisuke, Satomi, Eriko

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

880

MO2-8-5A pharmacokinetics study of edoxaban in NSCLC patients harboring an EGFR mutation combined with venous thromboembolism

Hotta, Takamasa, Tsubata, Yukari, Ishikawa, Nobuhisa, Tanino, Akari, Kobayashi, Misato, Sugisaka, Jun, Nakamura, Atsushi, Okuno, Takae, Umemoto, Junro, Nakao, Mika, Hamaguchi, Megumi, Hamaguchi, Shuni

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 90 KB

english, 2019

881

MO2-15-4The different frequencies of histologic transformation after different EGFR-TKIs in EGFR-mutant adenocarcinomas

Kang, Jin, Chen, Jun Hua, Yang, Ji Jin, Yi Wu, Long

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 83 KB

english, 2019

882

MO3-2-1Correlation between Ghrelin and gastrointestinal stromal tumors/Study on mechanism of Ghrelin regulating GISTs growth

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

883

O1-2-1Phase 1 study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma

Tahara, Makoto, Okano, Susumu, Enokida, Tomohiro, Ueda, Yuri, Fujisawa, Takao, Biel, Merrill

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 91 KB

english, 2019

884

O1-2-4Efficacy of nivolumab for head and neck cancer arising from subsites which were not included in CheckMate 141

Ueda, Yuri, Fujisawa, Takao, Ito, Kazue, Enokida, Tomohiro, Okano, Susumu, Tahara, Makoto

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

885

O2-3-2Phase 1 to 3 of the update of the EORTC Quality of Life Gastric module QLQ-STO22

Terada, Mitsumi, Sodergren, Samantha, Blazeby, Jane, Singer, Susanne, Yoshikawa, Takaki, Terashima, Masanori, Lordick, Florian, Vassiliou, Vassilios

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

886

O2-4-4Improvement quality of life in elderly metastatic colorectal cancer patients receiving ambulatory chemotherapy

Chansriwong, Phichai, Sirilerttrakul, Suwannee, Wannakansophon, Nopakan, Tangteerakoon, Patamaporn, Vongterapak, Suluck, Jirajarus, Manmana, Ckumdee, Sineenuch, Muntham, Dittapol, Sirachainan, Ekaphop

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 92 KB

english, 2019

887

O3-1-1Pembrolizumab vs chemotherapy as 2L therapy for advanced esophageal cancer: Japanese Subgroup Analysis in KEYNOTE-181

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

888

P1-012Primary tumor location and benefit of anti-EGFRs as second or later line treatment in RAS-RAS wild type mCRC patients

Saito, Ayumi, Fukuda, Misao, Ashimine, Hiroya, Miyaji, Yasutomo, Chi, Sunngi, Oyama, Yu

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

889

P1-026Efficacy of nivolumab for advanced gastric cancer

Moriyama, Ichiro, Kawakami, Koshi, Ikejiri, Fumiyoshi, Takahashi, Fumimasa, Matsuda, Shinichiro, Ugata, Norimi, Shimasaki, Yasumasa, Fujii, Yusuke, Tsukano, Kousuke, Yamanouchi, Satoshi, Kusunoki, Ryu

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

890

P1-103Study Pharmacokinetic Behavior of MTX-HD and Rescue with Leucovorine in Human Plasma LC and RMNC13, Children Hospital

Rocabado Calizaya, Guillermo O, Riveros, Astrid S, Leyton Omar, Almazan

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

891

P1-254Expectations and challenges for TeamOncology workshops

Kondoh, Chihiro, Ichinari, Yoko, Morita, Hajime, Suyama, Hisashi, Yoshii, Yumi, Ezura, Mio, Fujisawa, Yoko, Iihara, Hirotoshi, Kariya, Mitsuki, Matsumoto, Natsumi, Nakajima, Sanae, Osato, Yoichi, Tera

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 90 KB

english, 2019

892

P1-267Cost-effectiveness of pegfilgrastim in prostate cancer patients receiving cabazitaxel

Kondo, Yu, Sakakibara, Takayoshi, Furuta, Misato, Hiraiwa, Izumi, Kato, Jun, Kato, Aki, Miyake, Yoshio

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

893

P2-199A retrospective study of immune-related adverse events in various solid tumors

Shimozaki, Keitaro, Sukawa, Yasutaka, Beppu, Noriko, Kurihara, Isao, Suzuki, Shigeaki, Asoda, Seiji, Ozawa, Hiroyuki, Mizuno, Ryuichi, Funakoshi, Takeru, Ikemura, Shinnosuke, Tsugaru, Kai, Togasaki, K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 87 KB

english, 2019

894

P2-274Prevalance Geriatric in Hospitilized Cancer Patient

Gunarsa, Ralph, Tryanni, Vania, Iranwan, Cosphiadi

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

895

P2-310Two cases of congestive heart failure during osimertinib treatment for EGFR mutant NSCLC

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 71 KB

english, 2019

896

P3-030C-reactive protein predicts recurrence after postoperative chemotherapy using S-1 in advanced gastric cancer patients

Shimizu, Takayuki, Ishizuka, Mitsuru, Arakawa, Takao, Suzuki, Takashi, Tago, Kazuma, Hachiya, Hiroyuki, Harada, Yasuhiro, Park, Kyunghwa, Shiraki, Takayuki, Sakuraoka, Yuhki, Mori, Shozo, Abe, Akihito

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

897

P3-130Prevalence of BRCA 1 and BRCA 2 in Breast Cancer Patients in India

Pathak, Abhishek

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

898

SY16-4Countermeasures against delirium during cancer treatment-from the standpoint of a physical therapist-

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 70 KB

english, 2019

899

DL3Breast Cancer in Young and Premenopausal Women

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 70 KB

english, 2019

900

EL30Treatment of Multiple Myeloma: Current Status and a Future Perspective

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 69 KB

english, 2019

901

PS1-3Alpelisib (ALP)+fulvestrant (FUL) in patients from Japan with advanced breast cancer: Subgroup analysis of SOLAR-1 trial

Iwata, Hiroji, Yamashita, Toshinari, Inoue, Kenichi, Takahashi, Masato, Masuda, Norikazu, Yamauchi, Teruo, Yamamoto, Yutaka, Takano, Toshimi, Niikura, Naoki, Nakayama, Takahiro, Takashima, Seiki, Mats

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 94 KB

english, 2019

902

SY2-3Investigator-Initiated Registration Directed Trials, or Advanced Medical Care conducted by GOTIC and NRG-Oncology Japan

Fujiwara, Keiichi

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

903

SY18-4Chemotherapy for patients with cancer and pulmonary comorbidities

Takiguchi, Yuichi

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

904

WS2-1Support for working cancer survivors: toward collaboration among stakeholders in hospitals, workplaces, and communities

Takahashi, Miyako

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 81 KB

english, 2019

905

P-182Clinical importance of colonoscopy in patients with gastric cancer

Yang, H, Park, J, Ryu, S, Lee, S, Kim, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

906

SO-009Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR-T therapy in metastatic colorectal cancer

Cutsem, E Van, Machiels, J, den Eynde, M Van, Prenen, H, Hendlisz, A, Shaza, L, Carrasco, J, Canon, J, Sotiropoulou, P, Breman, E, Alcantar, E, Flament, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 84 KB

english, 2019

907

107PHigh proportion of multiple KRAS mutations in circulating tumour DNA and tumour tissue of pancreatic ductal adenocarcinoma

Kim, M K, Woo, S M, Kim, Y H, Park, B, Joo, J N, Yoon, K -A, Park, S J, Kong, S -Y

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

908

158PPlasma KIM-1 is associated with clinical outcomes after resection for localized renal cell carcinoma: A trial of the ECOG-ACRIN Research Group (E2805)

Xu, W, Puligandla, M, Haas, N B, Flaherty, K T, Uzzo, R G, Sabbisetti, V, Dutcher, J J, DiPaola, R S, Bhatt, R S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 3.80 MB

english, 2019

909

273PA nomogram to predict pathologic complete response of neoadjuvant chemotherapy in triple-negative breast cancer based on simple blood indicators

Zhang, F, Huang, M, Zhou, H, Chen, K, Jin, J, Ding, X, Su, D, Zou, D

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 4.47 MB

english, 2019

910

274PIdentification of GSTP1 transferred by extracellular vesicles responsible for adriamycin-resistance in breast cancer cells

Yang, S, Tang, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

911

288TiPA randomized phase II study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy

McArthur, H L, Comen, E A, Bryce, Y, Solomon, S B, Leal, J H S, Rodine, M, Abaya, C D, Patil, S, Page, D B, Norton, L

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 82 KB

english, 2019

912

408PWhole brain radiotherapy plus simultaneous in-field boost versus whole brain radiotherapy plus fractionated stereotactic radiotherapy for multiple brain metastases of non-small cell lung cancer

Li, L, Feng, M, Xu, P, Yin, J, Huang, Y, Peng, X, lang, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

913

484PThe addition of metformin to systemic anticancer therapy

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

914

501POncogenic mutations at the dimer interface of EGFR lead to formation of covalent homo-dimers and allosteric activation of the kinase domain: A mechanism which alters the selectivity profile of oncogenic EGFR

Buck, E, O’Connor, M, Flohr, A, Iacone, R, Nicolaides, T, Zhang, J, Mayweg, A V, Epstein, D M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

915

543PThe impact of completeness of chemotherapy on the efficacy of irinotecan in the preoperative chemoradiotherapy of (CRT) locally advanced rectal cancer

Wang, J, Fan, J, Li, C, Shen, L, Yang, L, Xia, F, Wan, J, Zhang, Z, Zhu, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 6.31 MB

english, 2019

916

609PRomidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and exerts synergistic anti-tumour activity with an anti-PD-1 antibody in colon cancer

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 677 KB

english, 2019

917

727PThe clinical outcomes of systemic chemotherapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinoma (HCC-CCA): Retrospective study of 120 patients

Kim, E, Yoo, C, Ryoo, B-Y

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 1.40 MB

english, 2019

918

862PRetrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE

Mintz, H P, Amos, C, Brannan, R, Brawley, C, Calvert, J, Gannon, M R, Hounsome, L, Ingleby, F C, McPhail, S, Parmar, M K B, Parsons, H M, Patel, P, Rauchenberger, M, Sydes, M R, Wu, H, James, N D

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 82 KB

english, 2019

919

885PSpatial-temporal change in quantitative total bone imaging (QTBI) and circulating tumour cells (CTCs) in metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA)

Liu, G, Kyriakopoulos, C E, Lang, J M, Sperger, J M, Singh, A, Heath, E I, Perlman, S, Mayer, T, Modelska, K, Porcari, A, Duggan, W, Jeraj, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 2.01 MB

english, 2019

920

903ORedefining the IGCCCG classification in advanced non-seminoma

Gillessen, S, Collette, L, Daugaard, G, de Wit, R, Tryakin, A, Albany, C, Stahl, O, Fizazi, K, Gietema, J A, De Giorgi, U F F, Hansen, A R, Feldman, D, Cafferty, F, Tandstad, T, Garcia del Muro, X, Hu

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 93 KB

english, 2019

921

1164PDevelopment and validation a nomogram based on pathological microscopic features to predict survival in nasopharyngeal carcinoma and guide treatment decision

Liu, K, Lv, X, Guo, X, Li, Y, Li, C, Cheng, H, Qiang, M, Chen, X, Zhang, T

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 1.26 MB

english, 2019

922

1404TiPHORMONET: Study of tamoxifen in well differentiated neuroendocrine tumours and hormone receptor positive expression

Barros, M, Felismino, T C, de Jesus, V H F, Mello, C A, Silva, V S, Camandaroba, M, Rodrigues, N, Donadio, M D, Nobrega, E, Chinen, L, De Brot, L, Weschenfelder, R F, Rego, J F, Carvalheira, J B, Riec

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 64 KB

english, 2019

923

1740PDDifferential expression of B7-H4, VISTA, B7-H6, HHLA2, IDO-1, PD-L1 and CD8 in EGFR mutant and wild-type lung adenocarcinoma

Yu, S, Shi, M, Feng, J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

924

1475PImpact of plasma EGFR mutation fractions on response to first generation tyrosine-kinase inhibitor in treatment of naïve non-small cell lung cancer patients

Wang, X, Liu, Y, Meng, Z, Wu, Y, Wang, S, Jin, G, Qin, Y, Wang, F, Wang, J, Wang, L, Bai, J, Shi, X, Wen, Z, Jia, X, Fu, X, Wang, X, Qin, Q, Gao, Y, Guo, W, Lu, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

925

1498PReal-world effectiveness of nivolumab monotherapy after prior systemic therapy in advanced non-small cell lung cancer (NSCLC) in the United States

Stenehjem, D D, Lubinga, S J, Gupte-Singh, K, Zhang, Y, Trong, K Le, Penrod, J R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 87 KB

english, 2019

926

1513PAtezolizumab in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs)

Mogollon-Duffo, F, Sultan, A, Swarup, S, Jahan, N, Tun, A M, Win Htut, T, Naing, T W, Naing, P T, Mon Myat, Y, Hardwicke, F, Rehman, S, Tijani, L, D’Cunha, N, Thein, K Z

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

927

1649PHealth status of middle-aged and older cancer survivors in China: Results from the China Health and Retirement Longitudinal Study (CHARLS)

Li, J, Zhao, L, Bai, C, Pang, H, Sun, Z

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 375 KB

english, 2019

928

1764PA phase III trial evaluating olanzapine 5 mg for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin: J-FORCE study

Hashimoto, H, Abe, M, Nakao, M, Mizutani, H, Sakata, Y, Fujita, Y, Nishimura, T, Hirano, K, Okada, H, Inui, N, Sakata, Y, Iihara, H, Zenda, S, Uchitomi, Y, Yamaguchi, T, Hoshina, Y, Yanai, T, Iwasa, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 5.79 MB

english, 2019

929

1875PDTargeting molecular mediators of T cell exclusion for effective immunotherapy in ovarian cancer

Wang, Y, Desbois, M, Udyavar, A, Ryner, L, Kozlowski, C, Guan, Y, Dürrbaum, M, Lu, S, Fortin, J-P, Koeppen, H, Ziai, J, Chang, C-W, Lo, A, Keerthivasan, S, Plante, M, Bais, C, Hegde, P, Daemen, A, Tur

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 794 KB

english, 2019

930

1899PThe clinical and transcriptional signatures of human CD204 reveal an applicable marker for tumor associated macrophage in breast cancer

He, Y, Tang, J, Yang, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 90 KB

english, 2019

931

1730PInfluence of eribulin on proliferation, migration and invasion properties of leiomyosarcoma cell line models

Mendiola, M, Heredia-Soto, V, Escudero, J, Crespo, R, Ruiz, P, Martínez, A Gallego, Martínez-Marin, V, Pozo, J J, Berjón, A, Ortiz-Cruz, E, Bernabeu, D, Redondo, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

932

MO2-18-6Real-World Effectiveness and Safety of Nivolumab in NSCLC pts in Japan: A Multicenter-Retrospective Observational Study

Saito, Haruhiro, Morita, Ryo, Okishio, Kyoichi, Shimizu, Junichi, Sakai, Hiroshi, Kim, Young Hak, Hataji, Osamu, Yomota, Makiko, Nishio, Makoto, Aoe, Keisuke, Kanai, Osamu, Kumagai, Toru, Kibata, Kayo

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

933

PD5-2Medical Cooperation and Total Care for Pediatric Cancer

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 81 KB

english, 2019

934

ME13Interpretation the Results of Adjuvant Chemotherapy in Curatively Resected Pancreatic Cancer

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 71 KB

english, 2019

935

LBA32Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)

Tabernero, J, Grothey, A, Van Cutsem, E, Yaeger, R, Wasan, H, Yoshino, T, Desai, J, Ciardiello, F, Loupakis, F, Hong, Y Sang, Steeghs, N, Guren, T K, Arkenau, H-T, García-Alfonso, P, Gollerkeri, A, Pi

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

936

LBA82Pembrolizumab (pembro) + chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407

Paz-Ares, L, Vicente, D, Tafreshi, A, Robinson, A, Soto Parra, H, Mazières, J, Hermes, B, Cicin, I, Medgyasszay, B, Beatrix, B, Rodríguez Cid, J, Okamoto, I, Lee, S, Ramlau, R, Vladimirov, V, Cheng, Y

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 91 KB

english, 2019

937

JS1-2Work-sharing between radiotherapy and chemotherapy for the treatment of bone metastasis

Shibata, Hiroyuki

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 71 KB

english, 2019

938

MO2-15-1 [Encore]Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions

Jänne, Pasi A, Neal, Joel W, Camidge, D R, Spira, Alexander, Piotrowska, Zofia, Horn, Leora, Costa, Daniel B, Tsao, Anne, Patel, Jyoti, Gadgeel, Shirish, Bazhenova, Lyudmila, Zhu, Viola W, West, Howar

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 84 KB

english, 2019

939

MO3-8-3Revisit the risk factors of recurrence in node involved HER2-positive breast cancer

Hasegawa, Yoriko, Kogawa, Takahiro, Shimokawa, Mototsugu, Kusuhara, Syota, Fujimoto, Yumi, Harano, Kennichi, Mastubara, Nobuaki, Naito, Yoichi, Hosono, Ako, Mukai, Hirofumi, Mukohara, Toru

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

940

P3-124Analysis of treatment and outcomes in locally advanced breast cancer

Taji, Tomoe, Okada, Yuki, Yamaguchi, Ai, Suwa, Hirofumi

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

941

MS2-1Integrating precision medicine into the treatment of colorectal cancer

Marshall, John L

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

942

154PRenal toxicity from platinum/pemetrexed and pembrolizumab in the era of combination therapy

Dumoulin, D, Visser, S, Cornelissen, R, Aerts, J G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

943

158PImmune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC): Platelet-to-lymphocyte ratio (PLR) predicts the risk of development and relapse

Pavan, A, Calvetti, L, Dal Maso, A, Attili, I, Pasello, G, Aprile, G, Guarneri, V, Conte, P, Bonanno, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

944

160PEPSILoN score: Validation cohort of a prognostic score in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy

Prelaj, A, Lo Russo, G, Signorelli, D, Ferrara, R, Imbimbo, M, Galli, G, De Toma, A, Randon, G, Brambilla, M, Trevisan, B, Ganzinelli, M, Zilembo, N, De Braud, F, Garassino, M C, Proto, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

945

162PMonitoring of blood serum amyloid (SAA) to predict outcome of first-line pembrolizumab (P) in patients (pts) with advanced non-small cell lung cancer (ANSCLC)

Di Noia, V, D’Argento, E, Vita, E, Ferrara, M, Damiano, P, Ribelli, M, Cannella, A, Virtuoso, A, Tortora, G, Bria, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

946

165PClinical benefit of anti PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment in advanced non-small cell lung cancer: A meta-analysis

Landre, T, Des Guetz, G, Vergnenegre, A, Chouaid, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

947

167PPrognostic significance of neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small cell lung cancer

Rapoport, B L, Vorobiof, D A, Langenhoven, L, Hall, J M, Van Eeden, R I, Smit, T, Chan, S W, Botha, M C, Raats, J I, De Necker, M, Duvenhage, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

948

168PDynamic changes of patelet-to-lymphocyte ratio predict efficacy of PD-1/PD-L1 inhibitors in NSCLC

Zhou, F, Xiong, A, Zhou, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

949

170PAdvanced non-small cell lung cancer patients with low tumor mutation burden might derive benefit from anti-programmed cell death (PD)-1 and anti-programmed deathligand 1 (PD-L1) blockade

Nie, W, Xu, M-D, Gan, L, Zhang, Y, Han, B-H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 3.04 MB

2019

950

171PPrevious exposure to bevacizumab indicated inferior benefits from PD-1/PD-L1 inhibitors in nonsquamous NSCLC

Zhou, F, Pan, Y, Zhou, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

951

173PStereotactic radiotherapy concurrent to immune or targeted therapy for oligometastatic NSCLC: Clinical scenarios affecting survival

Kroeze, S G C, Fritz, C, Kaul, D, Blanck, O, Kahl, K, Roeder, F, Siva, S, Verhoeff, J J C, Grosu, A L, Schymalla, M M, Glatzer, M, Szuecs, M, Geier, M, Skazikis, G, Sackerer, I, Lohaus, F, Eckert, F,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

952

174PNSCLC stages IIa-IIIc: Tumor related IGRT yields better local control than kV-guidance to anatomic structures

Zehentmayr, F, Karner, J, Wurstbauer, K, Wass, R E, Fastner, G, Rettenbacher, L, Studnicka, M, Pirich, C, Sedlmayer, F, Kopp, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

953

175PPermanent pleural catheter (PPC) for malignant pleural effusion (PE) in advanced non-small cell lung cancer (NSCLC)

Martinez Kareaga, M, Urbieta-Macazaga, N, Sanchez-Vieco, C, Tomás-López, L, Intxaurbe-Etxebarria, I, Mareque, B, Torrego, N, Narro, A, Puntí, L, Guillen, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

954

177PReal-world experience of ALK positive NSCLC from India

Malhotra, M, Noronha, V, Joshi, A, Patil, V, Wadhwa, S, Prabhash, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

955

178PFeasibility of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET for treatment monitoring of brain metastases in lung cancer patients

Abdulla, D S, Ruge, M, Scheffler, M, Nogova, L, Koleczko, S, Persigehl, T, Grau, S, Drzezga, A, Kobe, C, Buettner, R, Galldiks, N, Wolf, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

956

184TiPFIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered squamous NSCLC

Nogova, L, Malchers, F, Hillmer, A, Merkelbach-Bruse, S, Pinto, A, Woempner, C, Riedel, R, Scheffler, M, Michels, S, Porre, P De, Santiago-Walker, A, Fischer, R N, Abdulla, D S, Thomas, R, Buettner, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

957

187TiPTumor treating fields concurrent with standard of care therapy for stage IV NSCLC following platinum failure: Phase III LUNAR study

Weinberg, U, Farber, O, Giladi, M, Bomzon, Z, Kirson, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

958

204PDiagnostic value of concomitant use of radial probe endobronchial ultrasound with guide sheath and transbronchial biopsy in lung cancer

Lee, S C, Kwak, S, Park, M S, Kim, Y S, Chang, J, Lee, S H, Han, C H, Lee, S M, Kim, C J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

959

205PNon-small cell lung cancer in the elderly: A retrospective study comparing first-line treatment with single-agent vs combination chemotherapy vs tyrosine kinase inhibitor

Cipriano, É, Tavares, A, Soares, A, Estevinho, F, Sottomayor, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

960

206PImplementation of PD-L1 analysis among patients with non-small cell lung cancer in a single center

Tsiouprou, I, Tsartsianidou, V, Papaemmanouil, S, Pastelli, N, Lampaki, S, Eleftheriadou, E, Domvri, K, Kontakiotis, T, Spyratos, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

961

207PPrimary mucinous carcinomas of the lung: Clinical characteristics and treatment outcomes

Thottian, A G F, Babu, G K, Dasappa, L, Jacob, L A, Babu, S M, Lokesh, K N, Rudresha, A H, Rajeev, L K, Saldanha, S, Gv, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

962

208PSarcopenia as prognostic factor in lung cancer patients: A systematic review and meta-analysis

Büntzel, J, Heinz, J, Röver, C, Bleckmann, A, Bauer, C, Emmert, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

963

209PFeasibility and utility of transbronchial cryobiopsy in primary lung cancer: Prospective, single arm study

Kirita, K, Udagawa, H, Matsumoto, S, Yoh, K, Niho, S, Goto, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

964

190PERGR-TKIs combined with chemotherapy delays intracranial progression in EGFR-mutant lung adenocarcinoma patients

Li, C, Zhang, B, Guo, J, Hu, F, Nie, W, Zheng, X, Lou, Y, Shen, Y, Zhang, X

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

965

191PAssessment of toxicity and clinical outcomes with SBRT in lung metastases: A single institute experience

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

966

192PCharacterization and potential role of PD-L1 positive lung cancer stem cells in lymph nodes metastasis

Raniszewska, A, Rutkowska, E, Sokolowski, R, Domagala-Kulawik, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

967

193PManagement of cN2 NSCLC patients treated with radical radiotherapy: Relapse with or without brain metastases

McKay, F, Ansel, S, Lowrie, C, McLoone, P, Mohammed, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

968

195TiPPhase III METIS study: Tumor treating fields (150 kHz) and radiosurgery for supra- and/or infratentorial brain metastases (1-10) from non-small cell lung cancer (NSCLC)

Mehta, M, Gondi, V, Ahluwalia, M, Brown, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

969

197PEffect of surgical treatment on the survival in patients with malignant pleural mesothelioma

Baez-Saldana, R, Marmolejo-Torres, M T, Iñiguez-García, M, Berrios Mejía, J A, Rumbo-Nava, U, Arrieta-Rodríguez, O

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

970

198PEfficacy of 150 kHz tumor treating fields (TTFields) and cisplatin or pemetrexed for the treatment of mesothelioma cells in vitro

Weinberg, U, Munster, M, Gotlib, K, Schneiderman, R S, Porat, Y, Voloshin Sela, T, Davidi, S, Shteingauz, A, Kaynan, N, Zeevi, E, Giladi, M, Kirson, E, Kinzel, A, Palti, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

971

199PSafety meta-analysis of clinical trials delivering TTFields to the upper torso

Ceresoli, G L, Pless, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 65 KB

2019

972

Drug Index

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

973

Translational Research Index

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

974

LBA3Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC

Cho, B C, Reinmuth, N, Lee, K H, Ahn, M-J, Luft, A, den Heuvel, M Van, Dols, M Cobo, Smolin, A, Vicente, D, Moiseyenko, V, Antonia, S J, Moulec, S Le, Robinet, G, Natale, R, Garon, E B, Nakagawa, K, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

975

155PPooled efficacy analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2: Advanced breast cancer (ABC)

Tripathy, D, Hortobagyi, G N, Chan, A, Im, S-A, Chia, S, Yardley, D, Esteva, F J, Hurvitz, S A, Ridolfi, A, Slamon, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

976

156PPalbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study

Welt, A, Welslau, M K, Lüftner, D, Deryal, M, Liersch, R, Sahlmann, J, Houet, L, Vannier, C, Marschner, N, Potthoff, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

977

157PDifferences between breast cancer subtypes in developing metastatic disease

Wildiers, H, van Mechelen, M, van Herck, A, Lobelle, J-P, Smeets, A, Neven, P, Punie, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

978

160PCDK 4/6 inhibitors plus endocrine therapy in ER positive metastatic breast cancer (MBC): Systematic review and meta-analysis of randomized clinical trials

D’Avanzo, F, Saggia, C, Rossi, V, Siffredi, G, Barone Adesi, F, Gennari, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

979

161PBRCA status, treatment patterns and outcomes in HER2- advanced breast cancer (ABC): A multi-country real-world study

Niyazov, A, Quek, R G W, Lewis, K, Kemp, J, Rider, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

980

163PSAKK 21/12: A stratified, multicenter phase II trial of transdermal CR1447 in endocrine responsive-HER2 negative and triple negative-androgen receptor positive metastatic or locally advanced breast cancer

Vetter, M H F, Rothgiesser, K, Li, Q, Hawle, H, Schönfeld, W, Ribi, K, Riniker, S, von Moos, R, Müller, A, Thürlimann, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

981

164PLocoregional therapy targeted at the primary tumour improves overall survival in patients with stage IV metastatic breast cancer: A systematic review and meta-analysis with 185942 patients

Gera, R, Mokbel, K, El Hage Chehade, H, Wazir, U, Tayeh, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

982

165PPrevalence of risk factors for QT prolongation and torsades de pointes among women with HR+/HER2– advanced or metastatic breast cancer treated in real-world settings in Italy and Germany

Harbeck, N, Law, E H, Ajmera, M, Mitra, D, Davis, K, Brucker, S, De Laurentiis, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

983

168PAssociation of serum IGF1 and adiponectin in prognosis of breast cancer metastasis

Akter, S, Faruque, M, Nahar, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

984

169PImpact of BRCA1/2 mutations status on patient reported outcomes in HER2- advanced breast cancer: Results from a multi-country real-world study

Rider, A, Quek, R G W, Lewis, K, Kemp, J, Niyazov, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

985

170PReal world patterns of use and value of pertuzumab in the treatment of HER2+ metastatic breast cancer in Singapore: The National Cancer Centre Singapore experience

Rahardja, S, Tan, R Y C S, Sultana, R, Leong, F L, Lim, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

986

171PGastrointestinal symptoms & health-related quality of life among women with HR+/HER2– advanced or metastatic breast cancer treated in real-world settings in Italy and Germany

Brucker, S, Law, E H, Ajmera, M, Mitra, D, Davis, K, Harbeck, N, De Laurentiis, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

987

172PBreast cancer specific graded prognostic assessment (BC-GPA) score and outcome of HER 2 positive breast cancer patients with brain metastases: A single centre retrospective analysis

Kate, S, Paleja, N, Patil, R, Bhalerao, S, Dhande, S, Palve, V, Targe, M, Nagarkar, R, Fernandes, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

988

174PThe outcome of patients with metastatic breast cancer with lung metastasis treated with fulvestrant is superior to that of those with liver metastasis

He, M, Li, J-J, Zuo, W-J, Ji, L, Hu, X-C, Wang, Z-H, Shao, Z-M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

989

175PA four-year study of epidemiological trends of breast cancer in a Haitian cancer program

Bernard, J J, Alexis, L G, Degennaro, V J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

990

176PBrain metastasis of breast cancer: A 10-year single institution retrospective analysis

Batista, M Vaz, Tomás, T C, Eiriz, I F, Almeida, S B, Vitorino, M, Atalaia, G, del Rio, A, Braga, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

991

177PPertuzumab (P) as ≥ second-line therapy for HER2-positive metastatic breast cancer (mBC): Swiss clinical experience

Biskup, E M, Montavon Sartorius, C, Müller, A, Leo, C, Uhlmann Nussbaum, C, Koychev, D, Schreiber, A, Taverna, C, Thorn, D, Vetter, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

992

183PCD146 suppresses breast tumor via its novel downstream signaling pathway, Latexin/Akt/NFκB

Ouhtit, A, Fernando, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

993

185PClinical, biological and histological features predictive of response to everolimus in metastatic breast cancer patients

Van den bossche, V, Jadot, G, Augusto, D, Samartzi, V, Castela, S, Lejeune, S, Seront, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

994

186PHER2-positive breast cancer and CNS metastases: Prognostic factors and clinical outcome

Agostinetto, E, Masci, G, Giordano, L, Losurdo, A, De Sanctis, R, Torrisi, R, Zuradelli, M, Scorsetti, M, Santoro, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

995

187PSensitivity and dynamic range of CellSearch based CSF DTC enumeration in patients with breast cancer related leptomeningeal metastases (LM)

Van Goethem, A, Rypens, C, Rutten, A, Van den Mooter, T, Erven, K, Van Havenbergh, T, Prové, A, Van Laere, S J, Vermeulen, P, Dirix, L Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

996

188PEfficacy of trastuzumab-emtansina (T-DM1) in HER2-positive breast cancer (BC) with brain metastases (BM): A single institution experience

Martin Huertas, R, Lopez Miranda, E, Corral de la Fuente, E, Serrano Domingo, J J, Fernandez Abad, M, Martinez, N, Guerra, E M, Cortes Salgado, A, Gion Cortes, M, Carrato Mena, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

997

191PImaging-proven venous thromboembolism among breast cancer patients in a tertiary hospital in the Philippines from 2010-2015

Gerona, A T B, Gorospe, A E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

998

192PPredictive role of derived neutrophil to lymphocyte ratio on platinum-based chemotherapy in triple-negative breast cancer

Marra, A, Viale, G, Trapani, D, Nicolò, E, Morganti, S, Esposito, A, Minchella, I, Criscitiello, C, Curigliano, G, Locatelli, M A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

999

193PPALBOCOMP: Retrospective observational analysis of palbociclib treatment in patients with advanced breast cancer within a compassionate use program in Spain

Manso, L, Bermejo, B, Delgado, I, Aguirre, E, Oltra, A, Gonzalez, M, Malón, D, Ales, J E, Rodriguez, C, Moreno, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1000

194TiPPhase III study of [fam-] trastuzumab deruxtecan (DS-8201a) vs T-DM1 for HER2-positive breast cancer

Verma, S, Shahidi, J, Lee, C, Wang, K, Cortes, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1001

196TiPSGNLVA-002: Single arm, open label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer

Boni, V, Alemany, C, Meisel, J L, Sinha, R, Sterrenberg, D, Tkaczuk, K H R, Wang, Y, Wang, Z, Han, H S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1002

198TiPA randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB)

Paplomata, E, Bachelot, T, Mueller, V, Murias, C, Murthy, R K, Okines, A F C, Wardley, A M, Walker, L N, Antunes De Melo e Oliveira, A M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1003

200PNon-invasive and low-cost technique for early detection of clinically relevant breast lesions using a handheld point-of-care medical device (iBreast): Prospective three-arm triple-blinded comparative study for breast cancer screening in low resource setting countries

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 97 KB

2019

1004

202P_PRAdherence to dietary guidelines (DG) and body weight change (BWC) in early-stage breast cancer (EBC): A prospective trial in patients submitted to nutrition evidence-based educational intervention

Carbognin, L, Trestini, I, Sperduti, I, Fiorio, E, Tregnago, D, Pilotto, S, Scambia, G, Tortora, G, Milella, M, Bria, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1005

203PThe analysis of statistics of breast cancer in Cherkassy region before and after Chernobyl disaster

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

1006

205PA prospective, multicentre, randomized trial comparing vascular access strategies for patients receiving non-trastuzumab containing chemotherapy for early stage breast cancer

Awan, A A, Basulaiman, B, Robinson, A, Stober, C, Fergusson, D, Joy, A A, Vandermeer, L, Mallick, R, Saunders, D, Clemons, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1007

206PProtroca: A non-interventional study on prophylaxis of chemotherapy induced neutropenia using lipegfilgrastim in non-selected breast cancer patients

Wuerstlein, R, Harbeck, N, Grischke, E-M, Forstmeyer, D, von Schumann, R, Krabisch, P, Nitz, U, Gluz, O, Kates, R E, Graeser, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1008

207PAfter breast cancer: A nurse practitioner led model of care for women on adjuvant endocrine treatment

Shenkier, T, Lohrisch, C, Simmons, C, Dotts, A, McTaggart-Cowan, H, Houlihan, E, Johnston, C, Le, D, Gelmon, K, Chia, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1009

208PSecond malignancies with breast cancer: An audit

Srinivasalu, V K, Subramaniam, N, K S, S, V, A, Kolathu, S, D K, V K, Philip, A, Jose, W M, Kunheri, B, Pavithran, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1010

209PCompromised cancer-specific survival among under-insured Chinese patients with breast cancer: A prospective cohort study

Xie, Y, Valdimarsdóttir, U, Gou, Q, Wang, C, Hu, K, Tamimi, R, Zheng, H, Lu, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 68 KB

2019

1011

211PA cost-utility analysis of administration schedules of G-CSF for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer: Economic evaluation alongside the REaCT-G trial

Basulaiman, B, Awan, A A, Hilton, J, Fergusson, D, Stober, C, Vandermeer, L, Saunders, D, Clemons, M, Thavorn, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 68 KB

2019

1012

212PPatient-reported health problems and health care use after treatment for early breast cancer

de Ligt, K M, Heins, M, Verloop, J, Smorenburg, C H, Korevaar, J C, Siesling, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1013

214PTrastuzumab related cardiotoxicity in nonmetastatic breast cancer: A real-world scenario

Shrivastva, S, Prasad, S K, Chennamaneni, R, Stalin, B, Konatam, M L, Gundeti, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1014

216PThe predictive value of NHS PREDICT for triple negative breast cancer

Sobočan, M, Belak, U, Sikošek Čas, N, Kozar, N, Krajnc, K K, Takac, I, Arko, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1015

217PFeasibility of quantitative sensory testing (QST) in clinical routine as a tool to evaluate chemotherapy-induced peripheral neuropathy (CIPN) amongst breast cancer patients treated with taxanes

Ioannou, I, Utpadel-Fischler, D, Tölle, T, Kiechle, M, Ettl, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

1016

218PFeasibility study of using an app-based mHealth group challenge to improve physical activity (PA) and fatigue after breast cancer (BC)

Martin, E, Di Meglio, A, Charles, C, Ferreira, A R, Gbenou, A, Blond, M, Fagnou, B, Pistilli, B, Saghatchian, M, Vaz-Luis, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

1017

LBA 2Everolimus plus aromatase inhibitors vs aromatase inhibitors as maintenance therapy after first-line chemotherapy in HR+/HER2- metastatic breast cancer: Final results of the phase III randomized MAIN-A trial

Guarneri, V, Cinieri, S, Orlando, L, Bengala, C, Mariani, G, Bisagni, G, Frassoldati, A, Zamagni, C, Salvo, G De, Conte, P F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1018

LBA 3A pragmatic, randomised, multicentre trial comparing 4-weekly vs. 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases

Clemons, M, Stober, C, Mates, M, Joy, A A, Robinson, A, Hilton, J, Blanchette, P, Aseyev, O, Pond, G, Fergusson, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1019

Drug Index

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1020

Translational Research Index

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1021

Author Index

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 184 KB

2019

1022

O-002Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study

Tempero, M, Oh, D, Macarulla, T, Reni, M, Cutsem, E Van, Hendifar, A, Waldschmidt, D, Starling, N, Bachet, J, Chang, H, Maurel, J, Lonardi, S, Coussens, L, Fong, L, Tsao, L, Cole, G, James, D, Taberne

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

1023

O-003Exploratory analysis based on tumor location of REACHIN, a randomized, double-blinded, placebo-controlled phase 2 trial of regorafenib after failure of gemcitabine and platinum-based chemotherapy for advanced/metastatic biliary tract tumors

Demols, A, Borbath, I, den Eynde, M Van, Houbiers, G, Peeters, M, Marechal, R, Delaunoit, T, Goeminne, J, Laurent, S, Holbrechts, S, Paesmans, M, Laethem, J Van

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1024

O-004Applied precision cancer medicine in advanced biliary tract cancer

Taghizadeh, H, Müllauer, L, Kieler, M, Prager, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1025

O-006Genomic profiling of diffuse gastric carcinoma (DGC)

Hemmerich, A, Madison, R, Klempner, S, Sokol, E, Severson, E, Miller, V, Lee, J, Ou, S, Alexander, B, Schrock, A, Ross, J, Ali, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1026

O-007ZEBRA: an ACCRU/IRCI multicenter phase 2 study of pembrolizumab in patients with advanced small bowel adenocarcinoma (SBA)

Pedersen, K, Foster, N, Overman, M, Boland, P, Kim, S, Arrambide, K, Jaszewski, B, Welch, J, Wilson, R, McWilliams, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1027

O-008Proof of concept of the abscopal effect in MSS GI cancers: A phase 2 study of ipilimumab and nivolumab with radiation in metastatic pancreatic and colorectal adenocarcinoma

Parikh, A, Clark, J, Wo, J, Yeap, B, Allen, J, Blaszkowsky, L, Ryan, D, Giantonio, B, Weekes, C, Zhu, A, Seventer, E Van, Ly, L, Matlack, L, Foreman, B, Drapek, L, Ting, D, Corcoran, R, Hong, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1028

O-009Landscape of FMS-like tyrosine kinase 3 (FLT3) and associated molecular alterations in 44,766 gastrointestinal (GI) cancers

Salem, M, Juckett, L, Schrock, A, Ross, J, Puccini, A, Grothey, A, Lee, J, Miller, V, Madison, R, Ali, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1029

O-010VOLTAGE: Investigator-initiated clinical trial of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable locally advanced rectal cancer

Yoshino, T, Bando, H, Tsukada, Y, Inamori, K, Yuki, S, Komatsu, Y, Homma, S, Uemura, M, Kato, T, Kotani, D, Fukuoka, S, Sasaki, T, Nishizawa, Y, Nakamura, N, Wakabayashi, M, Kojima, M, Togashi, Y, Sat

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1030

O-013Impact of age and gender on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies

Zucchelli, G, Marmorino, F, Rossini, D, Aprile, G, Casagrande, M, Lonardi, S, Murgioni, S, Dell’Aquila, E, Tomasello, G, Moretto, R, Antoniotti, C, Borelli, B, Urbano, F, Ronzoni, M, Zaniboni, A, Mang

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1031

O-014Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer: a Danish randomized trial

Pfeiffer, P, Yilmaz, M, Möller, S, Zitnjak, D, Maltha, L, Krogh, M, Winther, S, Petersen, L, Hejlersen, F, Thomsen, K, Qvortrup, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1032

O-015Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results

Pfeiffer, P, Glimelius, B, Winther, S, Qvortrup, C, Yilmaz, M, Berglund, À, Vistisen, K, Kersten, C, Liposits, G, Sorbye, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1033

O-016Serial assessment of cell-free circulating tumor DNA (ctDNA) to assess treatment effect and minimal residual disease during neoadjuvant and adjuvant therapy in colorectal cancer

Parikh, A, Seventer, E Van, Boland, G, Hartwig, A, Jaimovich, A, Raymond, V, Talasaz, A, Corcoran, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1034

O-017SUNRISE-DI study: decision impact of the 12-gene recurrence score (12-RS) assay on adjuvant chemotherapy recommendation for stage II and IIIA/B colon cancer

Watanabe, J, Sato, T, Kagawa, Y, Oki, E, Kuboki, Y, Ikeda, M, Ueno, H, Kato, T, Kusumoto, T, Masuishi, T, Yamaguchi, K, Kanazawa, A, Nishina, T, Uetake, H, Yamanaka, T, Yoshino, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1035

O-018Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study

Elizabeth, A, Jansen, L, Hendrik, B, Kloor, M, Tagscherer, K, Roth, W, Boakye, D, Herpel, E, Grüllich, C, Chang-Claude, J, Brenner, H, Hoffmeister, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1036

O-019Comprehensive genomic profiling (CGP) defines the genomic landscape of colorectal cancer (CRC) in individuals of African ancestry

Myer, P, Lee, J, Madison, R, Newberg, J, Ross, J, Chung, J, Albacker, L, Alexander, B, Miller, V, Schrock, A, Mitchell, E, Frampton, G, Ali, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1037

O-020Copy number variation in longitudinal liver metastases biopsies in colorectal cancer identifies biomarker candidates of resistance to standard chemotherapy

Gambaro, K, Marques, M, McNamara, S, du Tertre, M Couetoux, Hoffert, C, Srivastava, A, Samson, B, Lesperance, B, Ko, Y, Dalfen, R, St-Hilaire, E, Sideris, L, Couture, F, Burkes, R, Harb, M, Camlioglu,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1038

O-022Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)

Miksad, R, Cicin, I, Chen, Y, Klumpen, H, Kim, S, Lin, Z, Youkstetter, J, Sen, S, Cheng, A, Meyer, T, Kelley, R, Abou-Alfa, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1039

O-023Significant differences in outcome between Immunoscore categories in stage I colon cancer patients

Galon, J, Hermitte, F, Mlecnik, B, Marliot, F, Bifulco, C, Lugli, A, Nagtegaal, I, Hartmann, A, den Eynde, M Van, Roehrl, M, Ohashi, P, Zavadova, E, Torigoe, T, Patel, P, Wang, Y, Kawakami, Y, Marinco

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1040

O-024Entrectinib in NTRK-fusion positive gastrointestinal cancers: integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1, and ALKA-372-001)

Siena, S, Demetri, G, Doebele, R, Chae, Y, Conkling, P, Garrido-Laguna, I, Garrido, P, Rolfo, C, Sigal, D, Eng, S, Simmons, B, Ye, C, Ciardiello, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1041

O-025A randomized, multicenter, phase 2 trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients

Pietrantonio, F, Lobefaro, R, Antista, M, Miceli, R, Raimondi, A, Lonardi, S, Rimassa, L, Saggio, S, Capone, I, Farina, G, Longarini, R, Mosconi, S, Bianchi, A Sartore, Tomasello, G, Petrelli, F, Murg

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1042

O-026Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC)

Argiles, G, Margalef, N Mulet, Valladares-Ayerbes, M, de Prado, J Vieitez, Grávalos, C, Alfonso, P García, Santos, C, Tobeña, M, Sastre, J, Benavides, M, Cano, T, Loupakis, F, Garrote, M Rodriguez, Ri

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1043

O-027Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240

Finn, R S, Ryoo, B-Y, Merle, P, Kudo, M, Bouattour, M, Lim, H-Y, Breder, V, Edeline, J, Chao, Y, Ogasawara, S, Yau, T, Garrido, M, Chan, S L, Knox, J, Daniele, B, Ebbinghaus, S W, Chen, E, Siegel, A B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1044

O-001An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes

Reni, M, Riess, H, O’Reilly, E, Santoro, A, Park, J, Bekaii-Saab, T, Tempero, M, Shan, Y, Macarulla, T, Cutsem, E Van, Noel, M, Berlin, J, Biankin, A, Dhani, N, Frassineti, G, Goldstein, D, Romano, A,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

1045

P-168Maximum tolerated radiation dose for unresectable thoracic esophageal squamous cell carcinoma: both acute and late toxicities matter

Yu, W, Fu, X, Cai, X, Feng, W, Liu, M, Gao, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

1046

P-169Apatinib as non-first-line treatment in patients with advanced cholangiocarcinoma

Lin, J, Yang, X, Mao, J, Yang, X, Wang, D, Zhang, L, Bai, Y, Bian, J, Long, J, Xie, F, Huang, H, Sang, X, Zhao, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1047

P-170Nutritional index differential as a prognostic factor for recurrence in patients with locally advanced rectal cancer

Ramos-Ramirez, M, Diaz, C, Calderillo-Ruiz, G, Navia, L, Herrera, M, Espinosa-Ramirez, J, Ruiz-Garcia, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1048

P-171The prognostic effect of immunohistochemical staining of biomarkers

Chung, W, Kim, Y, Kim, D, Kim, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1049

P-172Outcomes of laparoscopic liver resection versus percutaneous radiofrequency ablation in patients with hepatocellular carcinoma and liver cirrhosis: 10 years analysis in a single center

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1050

P-173Impact of proteinuria on long-term renal function in patients with gastrointestinal cancer treated with ramucirumab

Hirata, T, Okada, Y, Nozaki, M, Tashiro, H, Nakano, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1051

P-174Proposal of optimal cut-off of preoperative serum tumor marker levels to predict postoperative recurrences of gastric cancer

Sato, B, Kanda, M, Ito, S, Teramoto, H, Mochizuki, Y, Ishigure, K, Murai, T, Asada, T, Ishiyama, A, Matsushita, H, Tanaka, C, Kobayashi, D, Fujiwara, M, Kodera, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1052

P-175The optimal time interval between self-expandable metallic stent placement and elective operation in patients with obstructive colon cancers: a multicenter retrospective analysis

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

1053

P-176Multicenter phase 2 trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil-resistant advanced gastric cancer (HGCSG1502)

Ueda, A, Muranaka, T, Kawamoto, Y, Sawada, K, Nakatsumi, H, Harada, K, Kobayashi, Y, Miyagishima, T, Hatanaka, K, Dazai, M, Kawahata, S, Sasaki, T, Sasaki, Y, Kato, S, Shinada, K, Tsuji, Y, Yuki, S, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1054

P-177Accuracy of clinical staging for rectal cancer

Hernández Benitez, J, Camacho Elizondo, K, de la Cruz de la Cruz, C, Gallegos Arguijo, D, Ruiz Sánchez, D, Hernández Barajas, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1055

P-179Retrospective analysis of 18 cases of gastric cancer with peritoneal metastases resulting in successful conversion surgery

Honma, R, Takayama, T, Sugiyama, J, Hirayama, M, Tsuji, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1056

P-180A phase 2 study of capecitabine plus oxaliplatin therapy (XELOX) for patients with inoperable/advanced gastric cancer who were resistant/intolerable to fluoropyrimidine, CDDP, taxane, and CPT-11 (OGSG1403)

Kawada, J, Sugimoto, N, Hirokazu, T, Ueda, S, Murakami, K, Nishikawa, K, Kurokawa, Y, Fujitani, K, Kawakami, H, Sakai, D, Shimokawa, T, Satoh, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1057

P-184Calcium and vitamin D intake and colorectal cancer morbidity rates in Poland

Jarosz, M, Rychlik, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1058

P-185Is intra-arterial hepatic chemotherapy painful?

Kerbage, F, Grinda, T, Smolenschi, C, Boige, V, Malka, D, Burtin, P, Perret, A, Abdullah, J, Berthou, H, Hollebecque, A, Ducreux, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1059

P-187A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence after curative hepatic resection

Knox, J, Cheng, A, Cleary, S, Galle, P, Kokudo, N, Lencioni, R, Park, J, Zhou, J, Mann, H, Morgan, S, Liu, X, Chin, S, Vlahovic, G, Fan, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1060

P-188Hepatic sinusoidal obstruction syndrome (HSOS) in cStage III gastric cancer patients undergoing neoadjuvant chemotherapy with oxaliplatin: a retrospective cohort study

Kawaguchi, K, Manaka, D, Konishi, S, Ikeda, Y, Ota, T, Kudo, R, Sasaki, N, Hamasu, S, Nishitai, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1061

P-189The validity and safety of 1st-line chemotherapy with capecitabine/oxaliplatin for advanced gastric cancer in Japanese patients over 70 years old

Shindo, Y, Yoshida, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1062

P-191Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND)

Aparicio, J, Virgili, A, Capdevila, J, Muñoz Boza, F, Álvarez, R, Bosch, C, Cámara, J, Fernandez-Martos, C, Fernandez-Plana, J, Gallego, J, Gallego, R, Hernández-Yagüe, X, Macías Declara, I, Rodríguez

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1063

P-192Complete peritonectomy versus selective peritonectomy in peritoneal carcinomatosis secondary to colorectal cancer: a prospective comparative analysis of outcomes

Kr, A, P, S S, Kumar C, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1064

P-193FOLFIRINOX after first-line gemcitabine-based chemotherapy in metastatic pancreatic cancer: a mono-institutional experience

Foschini, F, Formisano, L, Marciano, R, Mozzillo, E, Carratù, A, Napolitano, F, Santaniello, A, Placido, P De, Cascetta, P, Servetto, A, Bianco, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

1065

P-194Right vs left-sided RAS wild-type metastatic colorectal cancer treated with EGFR inhibitors: prognostic differences

Duarte, S, Grilo, I, Ladeira, K, Pimenta, J, Liu, P, Sarmento, T, Barbosa, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

1066

P-195Coffee and alcohol consumption and trends in colorectal cancer morbidity in Poland

Jarosz, M, Rychlik, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

1067

P-196Total mesorectal excision for rectal cancer patients: a comparative triple arm study of surgical results in open vs laparoscopic vs robotic-assisted surgery

KR, A, Kumar C, R, P, S S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 97 KB

2019

1068

P-197VOYAGER: an open-label, randomised, phase 3 study of avapritinib vs regorafenib in patients with locally advanced metastatic or unresectable gastrointestinal stromal tumour

Bauer, S, George, S, Kang, Y, Jones, R, Mir, O, Tap, W, Doyle, A, Picazio, N, Zhou, T, Roche, M, Heinrich, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1069

P-198Predictors of morbidity and mortality for patients with peritoneal carcinomatosis secondary to colorectal cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Kr, A, P, S S, Kumar C, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1070

P-199Role of robotic surgery for rectal cancer: short-term, functional, and oncological outcomes for 150 consecutive patients

Kr, A, P, S S, Kumar C, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1071

P-200Assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer

Kr, A, P, S S, Kumar C, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1072

P-201Treatment of relapsed oesophagogastric adenocarcinoma after perioperative chemotherapy and surgery

Davidson, M, Butler, C, Butters, O, Fong, C, Turkes, F, Cafferkey, C, Kouvelakis, K, Cunningham, D, Watkins, D, Rao, S, Starling, N, Chau, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1073

P-202Search for new predictive/prognostic biomarkers in potentially resectable pancreatic ductal adenocarcinoma

González Borja, I, Viudez, A, Goñi, S, Pérez Sanz, J, Santamaria, E, López-López, C, Pazo, R, Fonseca, P Jimenez, Arévalo, S, Feliu, J, Fernández Irigoyen, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1074

P-203The role of combined treatment of metastatic colorectal cancer in patients with liver metastases

Gridnev, D, Trandofilov, M, Zhevelyuk, A, Islamova, D, Makarov, V, Popov, A, Vozny, E, Kudryavtseva, A, Kostyrev, S, Rudakova, M, Ryabov, K, Sizova, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1075

P-204Procalcitonin can be used to predict not only postoperative infectious complications but also prognosis in colorectal cancer patients

Bae, J, Kye, B, Lee, Y, Lee, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1076

P-205Hepatocellular carcinoma: characteristics, outcomes, and prognostic fators

Soares, A, Quintela, C, Rodrigues, D, Magalhães, H, Mesquita, A, Faria, G, Salgado, M, Sottomayor, C, Andrade, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1077

P-206Prognostic factors of metastatic colorectal cancer patients undergoing first-line chemotherapy plus bevacizumab

Bousahba, A, Behourah, Z

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1078

P-207Clinical and molecular characteristics of biliary tract carcinoma using next-generation sequencing

Ceniceros, L, Álvarez, R, Muñoz, C, Sanz-García, E, Ugidos, L, Rodriguez-Pascual, J, Hernandez, S, Gomez, P, Garcia-Rico, E, Cubillo, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1079

P-208Phase II study in progress to verify improved response with mFOLFOX6 after exposure to an immune checkpoint inhibitor in advanced gastric cancer

Ann, H, Manaka, D, Konishi, S, Ikeda, Y, Ota, T, Kudo, R, Kawaguchi, K, Sasaki, N, Hamasu, S, Nishitai, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1080

P-210Cytosponge™ for post‐chemoradiation surveillance of oesophageal cancer: a feasibility study

Levy, S, Moschandreas, J, Debiram-Beecham, I, O’Donovan, M, Brooks, C, Bailey, A, Hawkins, M, Kadri, S, de Caestecker, J, Crosby, T, Fitzgerald, R, Mukherjee, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1081

P-213CA19-9 decrease and predictive value for response in patients with metastatic pancreatic cancer treated with FOLFIRINOX

Rodríguez Hernández, J, Gil Torralvo, A, Chaves, M, Beltrán Guerra, I, Lourenzo Aguilera, G, Garcia Rodríguez, S, López Ladrón, A, Robles Barraza, C, Sánchez Vegas, A, Rodríguez de la Borbolla, M, Lóp

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

1082

P-214Does PICC side matter? The experience at our hospital

Gil Torralvo, A, Ladrón, A López, Rodríguez Hernández, J, Garcia Rodríguez, S, Vegas, A Sánchez, de la Borbolla, M Rodríguez, Barraza, C Robles, Fernández-Parra, E, PRadera, J Fuentes, Jimenez-Vilches

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 100 KB

2019

1083

P-215Recurrence rate in colorectal adenocarcinoma patients receiving adjuvant capecitabine monotherapy: do the number of chemotherapy cycles and relative dose intensity of the drug play a role?

Sgouros, J, Spathas, N, Gkoura, S, Kanellopoulou, S, Lambropoulou, D, Belechri, M, Miaris, N, Kozompoli, D, Tsoukra, M, Stamoulis, G, Aravantinos, G, Samantas, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1084

P-216Neo-adjuvant Chemo-Radiation for Resectable Esophageal Carcinoma – is Oral Capecitabine Non-Inferior to Paclitaxel – Carboplatin Combination?

Dastidar, A Ghosh, Saha, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1085

P-217A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2

Knox, J, Cheng, A, Cleary, S, Galle, P, Kokudo, N, Lencioni, R, Park, J, Zhou, J, Mann, H, Morgan, S, Liu, X, Chin, S, Vlahovic, G, Fan, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 103 KB

2019

1086

P-218L1CAM expression in colorectal cancer identifies patients prone to metastasis already in early-stage disease

Tampakis, A, Tampaki, E, Nonni, A, Patsouris, E, von Flüe, M, Kontzoglou, K, Kouraklis, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1087

P-219Is there any affordable and reliable score in local gastric cancer?

Cousillas Castiñeiras, A, Gallardo Martin, E, Fernández Montes, A, Covela Rúa, M, Carmona Campos, M, Salgado Fernandez, M, Pellón Augusto, M, Vidal Insua, Y, Gonzalez Villarroel, P, Martínez-Lago, N,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

1088

P-220Perioperative chemotherapy with FLOT vs other regimens for resectable gastric cancer

Esakia, T, Metonidze, B, Turkiashvili, L, Dgebuadze, E, Katselashvili, L, Melkadze, T, Kiladze, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1089

P-221Locally advanced unresectable or metastatic pancreatic adenocarcinoma in patients under 65 years with good performance status (PS) at Ramón y Cajal University Hospital in Madrid

Martín Huertas, R, Longo Muñoz, F, Serrano Domingo, J, Corral de la Fuente, E, Pachón Olmos, V, Rodriguez Garrote, M, Fuentes, R, Ferreiro Monteagudo, R, Vaz, M, Carrato, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1090

P-223Quality of life and preoperative chemotherapy in gastric cancer in Chile: results from the observational study of perioperative chemotherapy in gastric cancer (PRECISO)

Betancour, P, Mueller, B, Sola, J, Arancibia, J, Ascui, R, Araya, I, Cerda, M, Miranda, J, Strube, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1091

P-224Phase 2 HEPANOVA trial of tumor treating fields concomitant with sorafenib for advanced hepatocellular carcinoma

Grosu, A, Gkika, E, Brunner, T, Strouthos, J, Weinberg, U

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 103 KB

2019

1092

P-225Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial

Javle, M, Borbath, I, Clarke, S, Hitre, E, Louvet, C, Macarulla, T, Oh, D, Spratlin, J, Valle, J, Weiss, K, Berman, C, Howland, M, Ye, Y, Cho, T, Moran, S, Abou-Alfa, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1093

P-227Real World Data (RWD) of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): clinical benefit from a Spanish single institution

Sánchez-Camacho, A, Herrero Rivera, D, Carrasco, I, Limón, M, Jimenez, J, Benavent, M, Gallego Jimenez, I, Martínez, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1094

P-229The value of alfa-fetoprotein and neutrophil/lymphocyte ratio (NLR) in the prognosis of patients with hepatocellular carcinoma

Quintela, C, Soares, A, Rodrigues, D, Faria, G, Andrade, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1095

P-230Effectiveness of CA 19.9 in predicting prognosis in metastatic pancreatic cancer patients treated with nab-paclitaxel plus gemcitabine

Mariani, S, Soro, P, Liscia, N, Balconi, F, Camera, S, Donisi, C, Impera, V, Musio, F, Persano, M, Pireddu, A, Pretta, A, Tolu, S, Pusceddu, V, Lai, E, Faloppi, L, Demurtas, L, Ziranu, P, Puzzoni, M,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1096

P-231Proinflammatory cytokines as predictive factors for response to chemotherapy or mental disorders present in colorectal cancer patients

Burz, C, Bojan, A, Balacescu, L, Lisencu, C, Puscas, E, Pop, V, Cainap, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 101 KB

2019

1097

P-232RENCA macrobead therapy (RMB): A biological-systems approach to metastatic colorectal cancer [U.S. FDA BB-IND 10091]

Nazarian, A, Sureshbabu, S, Berman, N, Wolf, D, Gazda, L, Fahey, T, Ocean, A, Smith, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1098

P-233Disparities in clinical outcomes across age, sex and race among patients with pancreatic adenocarcinoma: a single center experience

Paluri, R, Behring, M, Jacob, R, Al-diffalha, S, Smith, C, Williams, G, Gbolahan, O, Manne, U

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1099

P-234The T cell architecture of pancreatic ductal adenocarcinoma

Sivakumar, S, Abu-Shah, E, Ahern, D, Mangal, N, Reddy, S, Rendek, A, Silva, M, Soonawalla, Z, Middleton, M, Dustin, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1100

P-235Induction Chemotherapy with Taxane versus Anthracycline-based Triplet for Locally Unresectable Nonmetastatic Gastric Cancer

Borges, C, Simões, J, Lemos, C, Costa, A, Águas, L, Damasceno, M, Almeida, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 99 KB

2019

1101

P-236Histological patterns and clinical characteristics of metastatic gastric adenocarcinoma, single institutional experience in the eastern province of Saudi Arabia

Bukhari, N, Taha, W, Zahralliyali, A, Shahrani, S, AlSelwi, W, AlSowayigh, A, AlAbdulhadi, D, Ibnshamsah, F, Rahal, M, Halawani, H, Al-Saif, O, Mashhour, M, Al-Hashmi, H, Latif, M, Azam, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1102

P-237Does metastatic colorectal cancer in elderly patients have specific features: the final results of a prospective phase II study of bevacizumab in combination with capecitabine as first-line treatment?

Omrcen, T, Katic, A, Tomic, S, Eterovic, D, Vrdoljak, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1103

P-239Sorafenib for advanced hepatocellular carcinoma (HCC) in the public health setting in Brazil: a cost-effectiveness analysis

Sasse, A, Carmo, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1104

P-240Outcomes of Gastrointestinal cancers treated on Phase 1 clinical trials at O’Neal Comprehensive Cancer Center

Paluri, R, Naik, G, Li, P, Mcardle, T, Anderson, A, Young, M, Saleh, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1105

P-241Epidemiological study of gall bladder cancer

Abdelkader El Hakim, B, Caid, N, Braneci, F, Boudjemaa, M, Bouaaza, H, Dekkar, N, Mouaici, A, Smaili, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1106

P-242Preventing oral mucositis by using its chronology in prior cycle and a special mouthwash

Una Cidon, E, Alonso, P, Hickish, T, Tyler, A, Goulbourne, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

1107

P-244Therapeutic aspects of gallbladder cancer

Abdelkader El Hakim, B, Braneci, F, Caid, N, Dekkar, N, Boudjemaa, M, Bouaaza, H, Mouaici, A, Smaili, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1108

P-245Neoadjuvant modified FOLFIRINOX or gemcitabine-nab paclitaxel followed by stereotactic body radiotherapy for patients with locally advanced pancreatic cancer

Paluri, R, Manne, U, Williams, G, Rose, B, Heslin, M, Reddy, S, Kyanam Kabir Baig, K, Vickers, S, Ali, A, Gbolahan, O, Smith, C, Jacob, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1109

P-246The importance of laterality in colorectal cancer predicting response to therapeutics – retrospective study evaluating differences between right and left colon in stage IV colon cancer

Cipriano, À, Tavares, A, Soares, A, Mesquita, A, Salgado, M, Sottomayor, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 99 KB

2019

1110

P-247Splanchnic vein thrombosis in cholangiocarcinoma. A retrospective observational study. Donostia University Hospital

Landa, A, Sánchez, B, Diaz, M, Otaño, M, Medina, A, Catalán, C Fernández, Santos, A, Izquierdo, L, La Casta Muñoa, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1111

P-248Futility and utility of two-stage hepatectomy

Cunha, M, Barros, I, Marreiros, A, Martins, A, Pinto Marques, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1112

P-250The combined treatment of 150 kHz Tumor Treating Fields (TTFields) and sorafenib shows In vitro and in vivo efficacy in hepatocellular carcinoma

Davidi, S, Gotlib, K, Zeevi, E, Shnaiderman, R, Voloshin, T, Giladi, M, Kinzel, A, Weinberg, U, Kirson, E, Palti, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1113

P-251FLOT versus ECF/ECX peri-operative regimens in real life setting for patients with resectable gastric adenocarcinoma

Graça, J, Pinto, M, Alberca, D, Chitonho, P, Matos, A, Barata, J, Neves, M, Alves, F, Martins, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1114

P-253Age vs performance status - which is worst for surgery outcome?

Amorim, E, Cunha, M, Rachadell, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1115

P-254Liquid biopsy for RAS mutational status analysis in metastatic colorectal cancer

Marinho, J, Neto, E, Leão, I, Silva, J, Cardoso, L, Gonçalves, S, Capela, A, Costa, T, Moreira Pinto, A, Custódio, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 101 KB

2019

1116

P-255Outcomes of treatment for non-metastatic rectal cancer; a ten year single institute experience at the Bank of Cyprus Oncology Centre (BOCOC)

Konstantinou, I, Xenophontos, E, Papanastasopoulos, P, Vassiliou, V, Kountourakis, P, Vogazianos, P, Papamichael, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1117

P-256Locally advanced unresectable and metastatic pancreatic cancer – predictors of survival

Cipriano, À, Soares, A, Tavares, A, Mesquita, A, Sottomayor, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1118

P-257Single-center experience treating gastric cancer with liver metastasis

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1119

P-258Computational simulations to determine the effectiveness and thermal safety of tumor treating fields with delivery to the abdomen

Weinberg, U, Bomzon, Z, Naveh, A, Yesharim, O, Faber, O, Kirson, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 99 KB

2019

1120

P-260PANOVA-3: A phase 3 study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma (LAPC)

Picozzi, V, Weinberg, U, Giladi, M, Bomzon, Z, Kirson, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1121

P-265Retroperitoneal lymph node metastases as a prognosis factor in overall survival in metastatic colorectal cancer

Calderillo-Ruiz, G, Heredia, D, Lopez, H, Carbajal, B, Itzel, V, Herrera, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1122

P-266Metastatic pancreatic cancer: Characteristics of long-term survivors

Mandelson, M, Picozzi, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1123

P-267Clinical experience: ramucirumab with FOLFIRI/XELIRI as a second line for patients with metastatic gastric cancer

Titova, T, Besova, N, Artamonova, E, Stroyakovskiy, D, Perminova, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1124

P-268Association between primary perioperative CEA ratio, tumor site, and overall survival in patients with colorectal cancer

Odeny, T, Farha, N, Hildebrand, H, Allen, J, Vazquez, W, Martinez, M, Saeed, A, Paluri, R, Kasi, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1125

P-271Efficacy and tolerability of the combination of Liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic cancers: post-approval clinic experience

Paluri, R, Kasi, A, Mcginnis, T, Smith, C, Williams, G, Jacob, R, Manne, U, Gbolahan, O, Naik, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1126

P-273Mini-invasive interventions in acute cholangitis malignant and benign etiology

Tashbulov, I, Uktamovna, N, Nazirov, F, Matmuradov, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 97 KB

2019

1127

P-275Immune-inflammatory and clinicopathologic prognostic factors in a Western cohort of resected gastric cancers (GCs)

Salati, M, Pipitone, S, Rimini, M, Gelsomino, F, Gardini, A Casadei, Andrikou, K, Schipilliti, F, Cortesi, G, Cassanelli, L, Caffari, E, Serra, F, Ricciardolo, A, Ruvo, N De, Gelmini, R, Cascinu, S, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1128

P-276Neoantigen-reactive T cells combined with chemotherapy and radiation improved survival in advanced pancreatic cancer

Liu, Q, Kong, W, Chen, F, Meng, F, Wei, J, Zou, Z, Liu, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1129

P-277Clinicopathologic difference according to gender in gastric cancer

Hassan, S, D, L, Jacob, L, Babu, S, Kn, L, Ah, R, Lk, R, Saldanha, S, Thottian, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 98 KB

2019

1130

P-279Characterization of mismatch repair deficiency in biliary tract cancer

Vivaldi, C, Ugolini, C, Orsi, G, Formica, V, Catanese, S, Andrea, C, Andrikou, K, Doldo, E, Pecora, I, Campani, D, Bonetti, L Reggiani, Pasquini, G, Salani, F, Massa, V, Niccoli, C, Lencioni, M, Vasil

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1131

P-280Clinicopathologic difference according to gender in gastric cancer

Han, S, Chung, J, Kim, Y, Kim, K, Park, D, Kwon, K, Kim, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1132

P-282Is additive treatment necessary for patients with a positive lateral margin after endoscopic submucosal dissection of early gastric cancer?

Cho, Y, Chung, I, Nam, J, Jung, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1133

P-283Predictors of oxaliplatin-induced hepatotoxicity: Increase in spleen volume or liver fibrosis and steatosis?

Kreidieh, M, El Chami, A, Haddadin, F, Al Darazi, M, Charafeddine, M, Haydar, A, Muallem, N, Ershaid, F, Faraj, W, Khalifeh, M, Mukherji, D, Temraz, S, Dbouk, H, Shamseddine, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1134

P-284Gevokizumab, an interleukin-1β (IL-1β) monoclonal antibody (mAb), in metastatic colorectal cancer (mCRC), metastatic gastroesophageal cancer (mGEC) and metastatic renal cell carcinoma (mRCC): “first-in-cancer” phase Ib study

Van Cutsem, E, Shitara, K, Deng, W, Vaury, A, Tseng, L, Wang, X, Millholland, J, Shilkrut, M, Mookerjee, B, Jonasch, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 105 KB

2019

1135

P-285The role of active nutritional intervention in patients receiving chemoradiation (CRT) for oesophageal cancer

Howard, A, Banks, S, Owens, R, Ward, L, Warner, N, Mukherjee, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

1136

P-286The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an Austrian multicenter, non-interventional study

Riedl, J, Posch, F, Prager, G, Eisterer, W, Öhler, L, Thamer, S, Wilthoner, K, Petzer, A, Pichler, P, Hubmann, E, Winder, T, Burgstaller, S, Korger, M, Andel, J, Greil, R, Pecherstorfer, M, Philipp-Ab

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

1137

P-287Compression therapy of both hands is safely applicable for the prevention of oxaliplatin-induced neuropathy

Kawakami, K, Koyama, Y, Morioka, M, Tobaru, Y, Sakura, Y, Fukumoto, M, Nagamine, A, Hattori, K, Taira, I, Shimada, N, Okuno, E, Tsuyuki, S, Kanazawa, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 101 KB

2019

1138

P-288The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA)

Basile, D, Pelizzari, G, Di Nardo, P, Corvaja, C, Ongaro, E, Garattini, S, Gerratana, L, Lisanti, C, Michele, B, Bortot, L, Buriolla, S, Garutti, M, Curtolo, G, Bonotto, M, Da Ros, L, Torrisi, E, Miol

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1139

P-289Incidence and severity of cancer-related fatigue in gastric cancer patients

Alexa Stratulat, T, Gaina, S, Marinca, M, Afrasanie, V, Paduraru, M, Miron, L, Gafton, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1140

P-290Comparative analyses between younger and older patients with pancreatic adenocarcinoma: differences in clinicopathological features, treatment patterns, and outcomes

Salem, M, Kadakia, K, Trufan, S, Hwang, J, Nazemzadeh, R, Jagosky, M, Worrilow, W, Coley, H, Al Hallak, M, Gower, N, Philip, P, O’Reilly, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 101 KB

2019

1141

P-292Prognostic role white blood cell levels in patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy

Ioannou, A, Demiri, S, Papaxoinis, G, Rapti, V, Klouva, E, Sarris, E, Baxevanos, P, Garefalakis, G, Goumas, G, Gouveris, P, Kourakos, P, Koumakis, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1142

P-293Evaluation of neoangiogenesis in locally advanced gastric cancer before and after neoadjuvant radiochemotherapy by probe confocal laser endomicroscopy (PCLE)

Cannizzaro, R, Magris, R, Fornasarig, M, Pivetta, E, Maiero, S, Mongiat, M, De Re, V, Canzonieri, V, De Paoli, A, Turriziani, V, Guarnieri, G, Buonadonna, A, Belluco, C, Serraino, D, Spessotto, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

1143

P-294Role of chemoradiation (CRT) in the adjuvant treatment of radically resected pancreatic cancer (PC) patients (pts): a mono-institutional retrospective analysis

Salvatore, L, Mattiucci, G, Bensi, M, Stefano, B Di, Cellini, F, Bagalà, C, Zurlo, I, Reina, S, Masiello, V, De Franco, P, Quero, G, Giuliante, F, Alfieri, S, Valentini, V, Tortora, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1144

P-295Endoscopic submucosal dissection using an detachable robotic assitive device in a live porcine model

Kim, E, Jeon, H, Choi, S, Kim, S, Lee, J, Choi, H, Keum, B, Chun, H, Lee, H, Kim, C, Jang, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1145

P-298Directed differentiation of human pluripotent stem cells into hepatic tissue with gallbladder and bile ducts organoids in vitro

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1146

P-299Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients

Catanese, S, Aringhieri, G, Cappelli, C, Vivaldi, C, Vitali, S, Pecora, I, Salani, F, Pasquini, G, Balducci, F, Piercarlo, R, Lencioni, M, Vasile, E, Massa, V, Falcone, A, Caramella, D, Fornaro, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1147

P-300Pancreatic Cancer resection in elderly patients: Analysis of outcomes

Cuadrado-García, A, Fernandez, R, Ortega, I, Zorrilla, L, Garcia-Virosta, M, Nuñez O’Sullivan, S, Picardo, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1148

P-303Third-line re-treatment of advanced pancreatic adenocarcinoma with gemcitabine and nab-paclitaxel

Das, A, Dean, A, McNulty, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 69 KB

2019

1149

P-304Modified FOLFIRINOX as a second-line treatment in pancreatic adenocarcinoma following gemcitabine plus nab-paclitaxel failure in patients with performance status two or less

Das, A, Dean, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

1150

P-305K-Ras mutation in liquid biopsy and tumor tissue correlation in patients with pancreatic cancer

Perdomo Zaldivar, E, Inga, E, Cano, T, Gómez, M, Toledano Fonseca, M, Saavedra Garcia, G, Rodriguez Alonso, B, Rodriguez Alonso, R, Rodriguez Ariza, A, Aranda, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1151

P-306Anal cancer outcomes and human immunodeficiency virus: a single-center experience

Garcia Duran, C, Rodriguez Alonso, R, Moreno-Olmedo, E, Rodriguez Alonso, B, Ortiz, M, Cano, T, Rodriguez Liñan, M, Garcia Cabezas, S, Gómez, M, Aranda, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1152

P-307Epidemiology, treatment and prognostic factors of colorectal cancers in Tunisia: compliance with recommendations and therapeutic results

Karrit, S, Ayari, J, Fendri, S, Zribi, A, Ben Nasr, S, Balti, M, Haddaoui, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1153

P-310Efficacy of FOLFIRI as a second-line in extrapulmonary poorly-differentiated neuroendocrine carcinoma

Fabregat Franco, C, Nieva Muñoz, M, Pérez Martín, F, Ruffinelli, J, Santos Vivas, C, Sánchez, C, Salazar, R, Teule, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 70 KB

2019

1154

P-312The survival of patients with pancreatic cancer in Jeju Island may be related to blood type

Han, S, Jo, J, Rhee, J, Kim, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1155

P-313Chemoradiation with capecitabine and mitomycin-C for locally advanced anal squamous cell carcinoma: experience of a single Portuguese institution

Miguel, I, Monteiro, A, Oliveira, I, Marques, T, Rosa, I, Limbert, M, Fernandez, G, Barroca, R, Marques, I, Fonseca, R, Mirones, L, Ferreira, T, Venâncio, J, Moreira, A, Freire, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1156

P-314Do we need adjuvant therapy in patients with rectal cancer and pathologic complete response, after conventional preoperative chemoradiation and laparoscopic (LapTME) or Transanal total mesorectal excision (TaTME)?

Reyes, R, Ayuso, J, Pagés, M, Conill, C, Darnell, A, Pineda, E, Gines, A, Fernández-Esparrach, M, Cuatrecasas, M, Moreno, R, Lacy, A, Pellisé, M, Maurel, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1157

P-315ΔNp73 and Δ133p53 in liquid biopsy as early diagnostic markers for colorectal cancer

Rodriguez-Cobos, J, Viñal, D, Poves, C, Fernández-Aceñero, M, Santos-Lopez, J, Carnicero, P, Amor, A, Peinado, H, Barderas, R, Rodríguez-Salas, N, Domínguez, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 99 KB

2019

1158

P-316Outcomes of gastrointestinal tumours in the tyrosine kinase inhibitor era: 15 years of experience from a single tertiary care centre in India

Bhargava, P, Ramaswamy, A, Panda, G, Patil, P, Ostwal, V, Shetty, O

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1159

P-317Clinical, pathological, and prognostic features of rare BRAF mutations in metastatic colorectal cancer: a bi-institutional retrospective analysis (REBUS study)

Bensi, M, Calegari, M, Basso, M, Orlandi, A, Boccaccino, A, Lombardo, F, Zurlo, I, Stefano, B Di, Camarda, F, Vivolo, R, Cocomazzi, A, Martini, M, Auriemma, A, Pozzo, C, Bria, E, Salvatore, L, Tortora

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1160

P-319Longitudinal evaluation of angiogenesis-related circulating biomarkers during second-line treatment with paclitaxel and ramucirumab in advanced gastroesophageal cancer

Fornaro, L, Vivaldi, C, Orlandi, P, Musettini, G, Pecora, I, Gentile, D, Catanese, S, Lencioni, M, Salani, F, Pasquini, G, Massa, V, Di Desidero, T, Falcone, A, Vasile, E, Bocci, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1161

P-321Young onset rectal cancer: a therapeutic challenge

Mondal, D, Biswas, S, Basu, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 97 KB

2019

1162

P-322Changes in the exchange of minerals during mechanical jaundice of tumor etiology

Tashbulov, I, Uktamovna, N, Nazirov, F, Matmuradov, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1163

P-323Is FNA always necessary in submucosal lesion miming GIST?

Guarnieri, G, Magris, R, Maiero, S, Fornasarig, M, Belluco, C, Canzonieri, V, Cannizzaro, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1164

P-324Stereotactic body radiotherapy in locally advanced pancreatic adenocarcinoma: A single institution experience

Jacob, R, McDonald, A, Manne, U, Reddy, S, Vickers, S, Heslin, M, Kyanam Kabir Baig, K, Smith, C, Williams, G, Ali, A, Gbolahan, O, Rose, B, Everett, A Ashlyn, Kasi, A, Paluri, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1165

P-325Outcomes of combined modality neoadjuvant chemoradiotherapy (CRT) and surgery in resectable esophageal carcinoma patients treated at a tertiary cancer care centre

Pant, S, Yadav, R, Singh, S, Singh, R, Kumar, S, Misra, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

1166

P-326Clinical practice use of liquid biopsy to identify RAS/BRAF mutational status in patients with metastatic colorectal cancer: A single institution experience

Falco, V De, Vitiello, P, Giunta, E, Ciardiello, D, Stefania, N, Cardone, C, Vitale, P, Zanaletti, N, Terminiello, M, Poliero, L, Borrelli, C, Caputo, V, Arrichiello, G, Mattera Iacono, V, Marrone, F,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1167

P-327Exploration of alternative regorafenib regimens to manage hand-foot-skin-reaction

Ploeger, B, Hoefman, S, Ruppert, M, Vis, P, Zisowsky, J, Grothey, A, Van Cutsem, E, Dochy, E, Cleton, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1168

P-328Treatment of Metastatic Colorectal Cancer in the Real World (mCRC): Final Results from a European Survey

Maravic, Z, Benedict, À, Komlos, K, Lemmens, L, Rawicka, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 99 KB

2019

1169

P-329Gemcitabine-based chemotherapy after FOLFIRINOX: a Portuguese retrospective multicenter analysis

Neves, M, Alves, F, Barata, J, Graça, J, Matos, A, Eiriz, I, Vitorino, M, Nogueira-Costa, G, Coelho, A, Pinto, M, Martins, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1170

P-330Retrospective study of Regorafenib versus Trifluridine/Tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: a single Italian institution real-life clinical data

Vitale, P, Zanaletti, N, Vitiello, P, martinelli, e, Ciardiello, D, Falco, V De, Giunta, E, Poliero, L, Terminiello, M, Borrelli, C, Caputo, V, Arrichiello, G, Martini, G, Stefania, N, Famiglietti, V,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1171

P-331Paclitaxel plus ramucirumab combination therapy as second-line therapy in elderly patients with metastatic advanced gastric cancer: A single-center retrospective study

Kashiwada, T, Nishioka, A, Aragane, N, Kimura, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1172

P-332A new prognostic score for biliary tract cancer: a multicenter experience

Ziranu, P, Lai, E, Casadei Gardini, A, Pretta, A, Faloppi, L, Andrikou, K, Astara, G, Orsi, G, Impera, V, Mariani, S, Liscia, N, Soro, P, Musio, F, Camera, S, Tolu, S, Madeddu, C, Massa, E, Pusceddu,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

1173

P-333Early fluorescence detection of oropharengeal and esophageal cancer

Sadykov, R, Sadykov, R, Karimov, M, Mahmudov, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1174

P-334Functionalized nanoparticles as tools in anti-cancer treatment

Kędzierska, M, Tyliszczak, B, Drabczyk, A, Kudłacik–Kramarczyk, S, Potemski, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

1175

P-335FOLFIRINOX versus Nab-paclitaxel plus gemcitabine in the first-line chemotherapy for patients with advanced pancreatic ductal adenocarcinoma: a multivariate analysis of prognostic factors in a national cohort (Comunica-TTD working group)

Longo Muñoz, F, Castillo Trujillo, O, Serrano Domingo, J, Martín Huertas, R, Corral de la Fuente, E, San Juan, A, Portela, J, Cano, J, Reguera Puertas, P, Rodriguez Garrote, M, Izquierdo Manuel, M, Ji

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 98 KB

2019

1176

P-336Retrospective study of TAS-102 plus bevacizumab for patients with metastatic colorectal cancer in salvage therapy

Hisamatsu, A, Ikusue, T, Toshima, H, Kobayashi, K, Shimada, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1177

P-337Prospective clinical study phase IIa open-label and not randomized of efficacy and toxicity of weekly paclitaxel chemotherapy in patients with advanced esophagogastric adenocarcinoma

Diaz, C, Calderillo-Ruiz, G, Herrera, M, Ramos-Ramirez, M, Ruiz-Garcia, E, Takahashi, A, Calderillo, V, Horacio, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1178

P-338Liver resection in elderly patients over the age of 70 with primary liver cancer: A retrospective analysis

Tan, E, Sandroussi, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1179

P-341Health disparities and gastric cancer survival in Cali, Colombia: a hospital-based study

Parra-Lara, L, Falla-Martinez, J, Bravo, J, Bravo, L, Zambrano, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1180

P-342Impact of KRAS mutations in clinical features and survival in pancreatic cancer patients: a single institution experience

Inga, E, Perdomo Zaldivar, E, Gómez, M, Cano, T, Rodriguez Alonso, B, Ortiz, M, Rodriguez Alonso, R, Toledano Fonseca, M, Rodriguez Ariza, A, Aranda, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1181

P-343Association of Prognostic Nutritional Index as a predictive factor of survival in patients with colorectal cancer in a Mexican population

Diaz, C, Calderillo-Ruiz, G, Ramos-Ramirez, M, Herrera, M, Manuel, F, Horacio, L, Ruiz-Garcia, E, Itzel, V, Ruan, J, Miranda, G, Gomez, A, Meneses, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1182

P-344Survival analysis of gastric cancer in a Hispanic population: 15-years of experience at a specialized cancer center

Falla-Martinez, J, Parra-Lara, L, Bravo, J, Bravo, L, Zambrano, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1183

P-345Turnaround time < 7 days with a fully automated assay for RAS mutations in metastatic colorectal cancer: a pilot project in real-life conditions

Rossat, S, Lefevre, M, Le Berre, N, Dorel, M, Triby, S, Sabourin, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1184

P-350Management of gallbladder cancer - experience of medical oncology department about 140 cases

Nouikh, L, Oualla, K, Berrad, S, Erraichi, H, Benbrahim, Z, Arifi, S, Mellas, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1185

P-351Pancreatic Cancer Europe heatmap: a comparative presentation of inequalities

Stunt, A, Malats, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1186

P-352Prognostic value, clinicopathologic features and diagnostic accuracy of interleukin-8 in colorectal cancer: A prospective study in 60 patients in Tunisia

Ayari, J, Karrit, S, Guesmi, R, Zribi, A, Fendri, S, Nasr, S Ben, Balti, M, Haddaoui, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1187

P-354Survival and prognostic factors of localized gastric carcinomas (about 50 cases). Experience of the medical oncology department of Hassan II University of Fez

Erraichi, H, Berrad, S, Nouikh, L, Messoudi, K, Oualla, K, Benbrahim, Z, Arifi, S, Mellas, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

1188

P-355To investigate the role of PGD2 and its receptor signalling in colon cancer pathophysiology

Dash, P, Topi, G, Sjolander, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1189

P-356Colorectal cancer in young Tunisian patients: clinical, histopathological and RAS testing data

Guettiti Tounsi, H, Wider, D, Ben Ayed, I, Habbachi, A, Jaballah, A, Boubaker, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1190

P-357The place of oncogeriatric evaluation in the therapeutic management and the prediction of the toxicity of the specific medical treatment of elderly patients with colorectal cancer

Aliane, H, Ghomari-Bezzar, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1191

P-358Simultaneous lungs and liver resections in metastatic colorectal cancer patients

Lukashenko, A, Kolesnik, O, Chorna, N, Ostapenko, Y, Patsko, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

1192

P-360Pancreatic neuroendocrine tumors

Kolesnik, O, Lukashenko, A, Chorna, N, Ostapenko, Y, Patsko, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1193

P-362Reasons for chemotherapy discontinuation and end of life in gastro-intestinal cancers: a multicentric prospective AGEO study

Palmieri, L, Dubreuil, O, Hautefeuille, V, Bachet, J, Trouilloud, I, Locher, C, Coriat, R, Moryoussef, F, Landi, B, Perkins, G, Doat, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 100 KB

2019

1194

P-363Gallbladder cancer in Morocco: the epidemiological evidence

Haimer, A, Habib, F, Soulaymani, A, Mokhtari, A, Hami, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1195

P-364High expression of estrogen receptor beta correlates with anti-tumorigenic and anti-proliferative inflammatory proteins in colorectal cancer patients

Topi, G, Satapathy, S, Dash, P, Ehrnstrom, R, Lydrup, M, Sjolander, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1196

P-365Baseline 18F-FDG-PET and Dynamic Contrast Enhanced (DCE)-MRI for assessment of lymph node metastatic potential of oesophageal adenocarcinoma

Owczarczyk, K, Withey, S, Kozarski, R, Winfield, J, Siddique, M, Maisey, N, Gossage, J, Davies, A, Cook, G, Goh, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1197

P-366Diagnostic and prognostic value of P53 and the human Programmed cell death 4 (PDCD-4) genes in colorectal cancer

Elkhouly, E, Gohar, S, Abelela, D, Fakhry, T, Abdelazim, W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

1198

P-367Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in malignant peritoneal disease: a review on outcomes for colorectal cancer

Simões, J, Fernandes, C, Borges, C, Melo, R, Sarmento, C, Meireles, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1199

P-368Chemoradiation and surgery versus chemoradiation followed by neoadjuvant chemotherapy and surgery in locally advanced rectal cancer: A retrospective analysis of a single center experience

Lima, B, Oliveira, L, Rolo, A, Carvalho, C, Faustino, I, Teixeira, A, Coutinho, C, Carvalho, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1200

P-369Home chemotherapy in colorectal cancer: First experience in Argentina

Streich, G, Batagelj, E, Dimase, F, Martinez, D, Sanguinetti, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1201

P-370Role of radiotherapy in local control of metastatic rectal cancer: A single-center experience

Afonso, A, Sousa, F, Reis, I, Gomes, D, Sousa, N, Sousa, O

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 98 KB

2019

1202

P-372WNT / β-catenin pathway in recovering IEC-6 intestinal cells after 5-FU induced injury and treatment with mimetic peptide APOE COG133

Pessoa, T, Carneiro, I, Aguiar, P, Vieira, L, Vitek, M, Guerrant, R, Oria, R, Abreu Junior, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1203

P-374Krukenberg tumors arising from gastric cancer: a report of 6 cases

Messoudi, K, Oualla, K, Amaadour, L, Benbrahim, Z, Arifi, S, Mellas, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1204

P-375Palliative management of malignant biliary obstruction in patients with advanced biliary tract cancers

Berrad, S, Oualla, K, Nouikh, L, Erraichi, H, Messoudi, K, Mellas, N, Benbrahim, Z

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1205

P-376Primary malignant tumors of the small intestine: clinical and therapeutic aspects

Berrad, S, Oualla, K, Erraichi, H, nouiyakh, l, Messoudi, K, Benbrahim, Z, Arifi, S, Mellas, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1206

P-378Clinico-epidemiological profile of colorectal cancer in Algerian patients age 40 and under: Alarming increase in incidence

Bekouaci, S, Smaili, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

1207

P-379Are hepatic metastases of colorectal cancer more chemosensitive than other metastatic sites?

Bekouaci, S, Smaili, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1208

P-380Skin toxicity of cetuximab in patients with metastatic colorectal carcinoma (mCRC)

Bekouaci, S, Smaili, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1209

P-381The management of neuroendocrine gastroenteropancreatic tumors

Berrad, S, Erraichi, H, Nouikh, L, Messoudi, K, Oualla, K, Benbrahim, Z, Arifi, S, Mellas, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1210

P-382Clinicopathologic feature of microsatellite stable early-onset colorectal cancer

Shin, R, Park, J, Jeong, S, Heo, S, Lee, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1211

P-383Survival and prognostic factors for stage II colon cancer

Berrad, S, Oualla, K, nouiyakh, l, Erraichi, H, benbrahim, Z, Arifi, S, Mellas, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

1212

P-384Anal Carcinoma A comparative analysis of the standard treatment vs An hypofractionated schedule (the Tlalpan Regime) experience at the Instituto Nacional de Cancerología, México

Zamora Moreno, J, Macario-Pixcar, B, García Pantoja, B, Estrada, G, Sebastian Barajas, G, Naranjo Ornelas, E, Aiello-Crocifoglio, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1213

P-386Interleukin-6 induced Lipocalin 2 promotes tumorigenesis from colitis to colorectal cancer

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 1.73 MB

2019

1214

P-387Final results of neoadjuvant photodynamic therapy (PDT) on the indices of T- and B-cellar immune answer in the surgical treatment of patients with gastric cancer

Myasnyankin, M, Anisimov, V, Drozd, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1215

P-388Prospective randomized comparison between 5-fluorouracil, leucovorin and etoposide plus best supportive care with best supportive care in advanced gastric cancer

Khatri, P, Samdariya, S, Kumari, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1216

P-389Clinical significance of BRAF mutations in colorectal cancer: A retrospective study of one institution in a real-life population

Carnerero Córdoba, L, González Cebrián, I, Rodríguez González, C, González-Flores, E, Conde, V, Delgado Ureña, M, Jurado García, J, González-Astorga, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1217

P-3905-fluorouracil and cisplatin regulated with leucovorin for locally advanced esophageal cancer

Khatri, P, Kumari, P, Samdariya, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1218

P-392Minimally invasive surgical approach for the treatment of esophageal cancer as a component of multimodal treatment

Abzalbek, Y, Dauletbayev, D, Zhetkergen, A, Izhanov, E, Zhandossov, O, Utelbayeva, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

1219

P-395Expression of MMR in women high grade carcinoma of unknown primary

Howells, J, Khoury, E, Hack, J, Yeoh, C, Rahimi, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

1220

P-396Pancreatic cancer: Experience of Medical Oncology Department, University-Hospital Center of Tizi Ouzou, Algeria

Sedkaoui, C, Ammour, H, Ouikene, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

1221

P-398The use of first, second and beyond line chemotherapy for metastatic pancreatic ductal adenocarcinoma at the Royal Marsden Hospital

Butters, O, Swann, F, Leslie, I, Young, K, Kouvelakis, K, Watkins, D, Rao, S, Chau, I, Cunningham, D, Starling, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1222

P-399How does adjuvant chemotherapy for stage II colon cancer impact survival in regard of prognostic factors? A report of 147 Tunisian cases

Sghaier, S, Rachdi, H, Mejri, N, Graja, B, Labidi, S, Boussen, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1223

PD-002CCL5 is associated with poor prognosis in locally advanced pancreatic cancer (LAPC): biomarker analysis from the randomised phase II SCALOP trial

Willenbrock, F, Cox, C, Wilhelm-benartzic, C, Owens, R, Sabbagh, A, Abraham, A, Maughan, T, Hurt, C, O’Neill, E, Mukherjee, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

1224

PD-003Identification of a nanostring signature that differentiates early pancreatic cancers according to stromal composition and predicts clinical outcome

Sclafani, F, Cascione, L, Cunningham, D, Young, K, Carotenuto, P, Fassan, M, Salati, M, Lanese, A, Berenguer Pina, J, Kouvelakis, K, Vendrell, I, Said-Huntingford, I, Previdi, M, Begum, R, Gillbanks,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 111 KB

2019

1225

PD-004Time to CA19.9 nadir: a clue for defining treatment duration of primary chemotherapy in resectable PDAC

Peretti, U, Reni, M, Zanon, S, Macchini, M, Mazza, E, Balzano, G, Tamburrino, D, Arcidiacono, P, Massimo, F, Gianni, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1226

PD-005Analysis of weight loss as a prognostic factor in patients with advanced gastric cancer from the Phase 3 RAINBOW study

Mansoor, W, Roeland, E, Abraham, M, Wei, R, Chatterjee, A, Sashegyi, A, Desai, A, Abada, P, Chaudhry, A, Klempner, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1227

PD-007Surgical Indication for advanced gallbladder cancer considering the optimal preoperative carbohydrate antigen 19-9 cut-off value

Yamamoto, Y, Sugiura, T, Okamura, Y, Ito, T, Ashida, R, Ohgi, K, Uesaka, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1228

PD-008Serial circulating tumor DNA (ctDNA) monitoring to predict response to treatment in metastatic gastrointestinal cancers

Parikh, A, Kanter, K, Mojtahed, A, Schneider, J, Seventer, E Van, Fish, M, Allen, J, Blaszkowsky, L, Wo, J, Clark, J, Giantonio, B, Goyal, L, Hong, T, Nipp, R, Roeland, E, Weekes, C, Zhu, A, Ryan, D,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1229

PD-009Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

Kaseb, A, Vence, L, Blando, J, Yadav, S, Ikoma, N, Pestana, R, Vauthey, J, Cao, H, Chun, Y, Sakamura, D, Wolff, R, Yao, J, Allison, J, Sharma, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1230

PD-010Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: results of INNOVATE study

Casadei Gardini, A, Marisi, G, Dadduzio, V, Ielasi, L, Vivaldi, C, Rizzato, M, Fornaro, L, Lonardi, S, Gramantieri, L, Pecora, I, Foschi, F, Silvestris, N, Fornari, F, Orsi, G, Rovesti, G, Santini, D,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1231

PD-011Mutational profile of non-metastatic anal squamous cell carcinoma: a restrictive high impact genetic variants analysis

Trilla, L, Ghanem, I, Gámez, A, Maurel, J, Campos-Barros, À, G-Pastrián, L, Mendiola, M, Peña, C, Cuatrecasas, M, García Alfonso, P, Fresno, J, Feliu, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1232

PD-013RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC)

Sunakawa, Y, Nakamura, M, Ishizaki, M, Kataoka, M, Satake, H, Kitazono, M, Yanagisawa, H, Kawamoto, Y, Kuramochi, H, Ohori, H, Nakamura, M, Takahashi, K, Maeda, F, Komeno, C, Takeuchi, M, Fujii, M, Yo

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1233

PD-015Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies

Rossini, D, Sbrana, A, Bergamo, F, Manai, C, Santini, D, Ghidini, M, Antoniotti, C, Moretto, R, Marmorino, F, Urbano, F, Ronzoni, M, Noventa, S, Randon, G, Carlomagno, C, Latiano, T, Cordio, S, Granet

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1234

PD-016Health-related quality of life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study

Raimondi, A, Di Maio, M, Peverelli, G, Morano, F, Corallo, S, Bergamo, F, Cremolini, C, Smiroldo, V, Amatu, A, Tampellini, M, Fanchini, L, Murialdo, R, Clavarezza, M, Noventa, S, Adamo, V, Ratti, M, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1235

PD-019Optimizing treatment with anti-epidermal growth factor receptor drugs for patients with metastatic colorectal cancer: novel mechanisms of resistance beyond RAS

Cardone, C, Blauensteiner, B, Moreno-Viedma, V, Paul, M, Martini, G, Troiani, T, Vitiello, P, Ciardiello, D, Poliero, L, Borrelli, C, Rachiglio, A, Rizzi, D, Maiello, E, Latiano, T, Normanno, N, Sibil

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1236

PD-020Bayesian machine learning on CALGB/SWOG 80405 (Alliance) and PEAK data identify a heterogeneous landscape of clinical predictors of overall survival (OS) in different populations of metastatic colorectal cancer (mCRC)

Das, R, Ou, F, Washburn, C, Innocenti, F, Nixon, A, Lenz, H, Blanke, C, Niedzwiecki, D, Khalil, I, Harms, B, Venook, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1237

PD-021Bevacizumab (BV) maintenance after first-line chemotherapy plus BV for metastatic colorectal cancer patients: a meta-analysis of individual patients data from 3 phase III studies

Salvatore, L, Bria, E, Sperduti, I, Hinke, A, Hegewisch-Becker, S, Aparicio, T, Le Malicot, K, Boige, V, Koeberle, D, Baertschi, D, Dietrich, D, Tortora, G, Arnold, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1238

PD-022PARP-ness in metastatic colorectal cancer

Mauri, G, Kanter, K, Fish, M, Horick, N, Allen, J, Blaszkowsky, L, Clark, J, Ryan, D, Nipp, R, Giantonio, B, Goyal, L, Dubois, J, Murphy, J, Roeland, E, Weekes, C, Wo, J, Hong, T, Zhu, A, Van Seventer

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1239

PD-023Survey on the Unmet Needs of Patients Living with mCRC – Learnings from an International Study

Maravic, Z, Rawicka, I, Lemmens, L, Bokros, J, González de Pedro, C, Stanisic Trenevski, J, Méndez Otero, M, Rial, O, Ferro, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1240

PD-024Exploratory analysis of the effect of FTD/TPI in mCRC patients treated in RECOURSE by different prognostic factors: impact on ECOG PS

Argiles, G, Tabernero, J, Sobrero, A, Ohtsu, A, Mayer, R, Vidot, L, Moreno Vera, S, Van Cutsem, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1241

PD-025Hand-foot syndrome is a biomarker of improved survival following treatment with capecitabine

Jandu, H, Church, D, Paul, J, Tomlinson, I, Iveson, T, Kerr, R, Kerr, D, Palles, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1242

PD-026Quality of life in patients treated with aflibercept and FOLFIRI for metastatic colorectal cancer: interim analysis with focus on therapy lines of the non-interventional study QoLiTrap (AIO-LQ-0113)

Hofheinz, R, Scholten, F, Derigs, H, Thaler, J, von Moos, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1243

PD-027Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis

Rossini, D, Pagani, F, Pellino, A, Dell’Aquila, E, Liscia, N, Bensi, M, Germani, M, Masi, G, Moretto, R, Santini, D, Salvatore, L, Scartozzi, M, Lonardi, S, Zucchelli, G, Puglisi, F, Vannini, F, Colom

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1244

PD-028Pattern and dynamics of metastatic sites during course of metastatic colorectal cancer (mCRC) trajectory in 1086 Finnish patients in the nationwide prospective RAXO study

Osterlund, P, Lamminmäki, A, Soveri, L, Ålgars, A, Salminen, T, Kallio, R, Ristamäki, R, Halonen, P, Osterlund, E, Rajanen, A, Lantto, E, Ovissi, A, Nordin, A, Murashev, M, Aroviita, L, Jekunen, A, Li

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1245

PD-029Regorafenib dose escalations in the prospective, observational CORRELATE study in patients with metastatic colorectal cancer

Ducreux, M, O’Connor, J, Dochy, E, Fiala-Buskies, S, Cervantes, A, Falcone, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1246

PD-031Immune signatures identify three immune clusters in mCRC, with potential clinical implications

Pedrosa, L, Moreno, R, Esposito, F, Jares, P, Cuatrecasas, M, Pineda, E, Español, M, Paré, L, De la Iglesia, N, Benitez, D, Camps, J, Church, S, Cascante, M, Thomson, T, Prat, A, Maurel, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1247

PD-032Comparison of surgical data and survival outcome of rectal cancer patients that need upfront surgery after chemoradiotherapy versus salvage surgery after watch-and-wait

Bulens, P, Debucquoy, A, Joye, I, Wolthuis, A, D’Hoore, A, Van Cutsem, E, Dekervel, J, Sagaert, X, Dresen, R, Vandecaveye, V, Deroose, C, Haustermans, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1248

PD-034Clinical outcomes of rectal neuroendocrine tumors less than 20 mm: a single institutional analysis of 371 patients

Choi, C, Kang, D, Kim, H, Park, S, Kim, S, Nam, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 59 KB

2019

1249

PD-001Analysis of patient screening in the phase III, international, randomized, open-label APACT trial

Reni, M, Winter, J, Tortora, G, Pelzer, U, Riess, H, Chang, H, O’Reilly, E, Oh, D, Diaz, I Alés, Milella, M, Bendell, J, Garlipp, B, Tempero, M, Macarulla, T, Van Cutsem, E, Berlin, J, Goldstein, D, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

1250

SO-002Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF)

Chau, I, Bendell, J, Soriano, A, Arkenau, H, Cultrera, J, Santana-Davila, R, Calvo, E, Tourneau, C Le, Zender, L, Mi, G, Schelman, W, Ferry, D, Herbst, R, Fuchs, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1251

SO-003Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: preliminary results

Matos, I, Goyal, L, Cleary, J, Voss, M, Oh, D, Bernstam, F Meric, Ng, C, Iyer, G, Ishii, N, Hu, Y, Chessex, A Vaslin, Pokorska-Bocci, A, Nicolas, V, Kirpicheva, Y, Zanna, C, Flaherty, K, Tabernero, J,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 112 KB

2019

1252

SO-008Ramucirumab plus merestinib in previously treated metastatic colorectal cancer: safety, pharmacokinetic, and preliminary efficacy findings from a Phase 1 study

Saleh, M, Cassier, P, Eberst, L, Naik, G, II, V Morris, Pant, S, Terret, C, Gao, L, Long, A, Mao, H, McNeely, S, Carlesi, R, Fu, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1253

SO-010Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors

Garralda, E, Fiedler, W, Matos, I, Rolling, C, Kebenko, M, Klinghammer, K, Conte, G, Raspagliesi, F, Habel, B, Baumeister, H, Ochsenreither, S, Zurlo, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 63 KB

2019

1254

SO-001Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer

Kadowaki, S, Izawa, N, Minashi, K, Nishina, T, Yamanaka, T, Muro, K, Sunakawa, Y, Hironaka, S, Kajiwara, T, Kawakami, Y, Nakajima, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1255

LBA-003A phase III study of TAS-118 plus oxaliplatin versus S-1 plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer (SOLAR study)

Kang, Y, Chin, K, Chung, H, Kadowaki, S, Oh, S, Nakayama, N, Lee, K, Hara, H, Chung, I, Tsuda, M, Park, S, Hosaka, H, Hironaka, S, Miyata, Y, Ryu, M, Takeuchi, M, Baba, H, Hyodo, I, Bang, Y, Boku, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1256

LBA-004Phase 2 study results of murlentamab, a monoclonal antibody targeting the Anti-Mullerian-Hormone-Receptor II (AMHRII), acting through Tumor-Associated Macrophage engagement in advanced/metastatic colorectal cancers

Van Cutsem, E, Melichar, B, Van den Eynde, M, Prausova, J, Geboes, K, Dekervel, J, Vitaskova, D, De Cuyper, A, Linke, Z, Van Acker, N, Frenois, F, Noel, G, Prost, J, Barret, J, Jean, B, Tabah-Fisch, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1257

P-401(late submission poster) The tumor burden rise at radiological disease progression associates with poor overall survival in advanced colorectal cancer

Kogan, Yuri, Elishmereni, Moran, Taub, Eldad, Agur, Zvia

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1258

P-402(late submission poster) Incidence and mortality rates of cholangiocarcinoma in England

Genus, Tracey, Tataru, Daniela, Morement, Helen, Toledano, Mireille, Khan, Shahid

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

1259

LBA-001Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial

Golan, T, Hammel, P, Reni, M, Van Cutsem, E, Macarulla, T, Hall, M, Park, J, Hochhauser, D, Arnold, D, Oh, D, Reinacher-Schick, A, Tortora, G, Algül, H, O’Reilly, E, McGuinness, D, Cui, K, Schlienger,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1260

3OSystemic gut microbial metabolites limit the anti-tumour effect of CTLA-4 blockade in hosts with cancer

Coutzac, C, Jouniaux, J -M, Paci, A, Asvatourian, V, Saulnier, P, Lacroix, L, Carbonnel, F, Ascierto, P A, Robert, C, Chaput, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 105 KB

2019

1261

4ONovel dendritic cell based immunotherapy for advanced cancer

Kaur, A P, Adhikaree, J, Franks, H, Patel, P, Jackson, A M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1262

5PDThe role of EGFR inhibitor (EGFRi) in immune cell infiltration and CD8+ T-cell activation in EGFR mutant lung cancer

Li, F, Lizee, G, Hwu, P, Du, X, Deng, L, Talukder, A, Katailiha, A, Zou, Q, Roszik, J, Hawke, D, Jackson, K, Bradley, S, Wang, Y, Ataullakhanov, R, Bagaev, A, Kotlov, N, Svekolkin, V, Miheecheva, N, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1263

6PDThe mutational signature of spontaneously developing tumours in MLH1-/- mice: Potential consequences for immunotherapeutic approaches

Maletzki, C, Gladbach, Y, hamed, M, Junghanss, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1264

7PDSynergistic anti-cancer activity of auranofin with anti-PD-L1 therapy in triple negative breast cancer

Raninga, P, Lee, A, Sinha, D, Shin, Y-Y, Mittal, D, Kalimutho, M, Khanna, K K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1265

8PDAutomatic interpretation of cancer genomes creates the largest repository of tumour genetic driver events

Martínez Jiménez, F, Muiños, F, Pich, O, González-Perez, A, López-Bigas, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1266

9PDAurora-B mediated snail phosphorylation is essential for mitotic spindle checkpoint and for preventing chromosomal instability in breast cancer

Xu, B, Xiao, M, Li, X

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 3.96 MB

2019

1267

11PTriple blockade of EGFR, MEK and PD-L1 as effective antitumor treatment in PD-L1 overexpressing, MEK inhibitor resistant colon cancer cells

Matrone, N, Napolitano, S, Belli, V, Barra, G, Giunta, E F, De Falco, V, Terminiello, M, Vitiello, P P, Ciardiello, D, Turano, M, Furia, M, Muddassir, A S, Kopetz, S, Martinelli, E, Ciardiello, F, Tro

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1268

13PThe impact of cortisol on immune cells and its effect on cancer-immune cells co-culture in a 3D spheroid of ovarian cancer

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1269

15PTr1-like cells in human peripheral blood are part of the T effector memory pool and are preferentially stimulated via CD55

Charles, I A, Ramage, J M, Spendlove, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1270

16PFunctional analysis of tumour infiltrating lymphocytes in triple negative breast cancer focusing on granzyme B

Kawaji, H, Kubo, M, Motoyama, Y, Shimazaki, A, Hayashi, S, Kurata, K, Yamada, M, Kaneshiro, K, Kai, M, Nakamura, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1271

18PAnti-cancer effects of differentiation-inducing factor-1 in triple negative breast cancer

Tetsuo, F, Arioka, M, Takahashi, F Y, Nishimura, F, Sasaguri, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1272

19PThe inhibitory effect in oral squamous cell carcinoma cells by knocking down matrix metalloproteinase 9

Zhang, X, Wen, J, Yin, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1273

20PMatrix metalloproteinases and their tissue inhibitors genes abnormal DNA methylation in breast cancer

Simonova, O, Kuznetsova, E, Tanas, A S, Rudenko, V, Poddubskaya, E, Kekeeva, T, Chesnokova, G, Kutsev, S, Zaletaev, D V, Nemtsova, M V, Strelnikov, V V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

1274

21PUveal melanoma cell lines depend on multiple signaling pathways for survival

Park, J J, Stewart, A, Irvine, M, Pedersen, B, Kefford, R, Diefenbach, R, Carlino, M S, Rizos, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

1275

22PXAF1 and ZNF313 complex stimulates ER stress-induced apoptosis via direct GRP78 inhibition

Jang, S, Lee, K-W, Magdalene, T K, Ahn, J, Lee, M-G, Chi, S-G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 64 KB

2019

1276

23PXAF1 assembles a destructive complex to induce BRCA1-mediated apoptosis via suppressing ERa and switching estrogen function

Jang, S-H, Lim, J-S, Jang, S, Lee, M, Chi, S-G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 64 KB

2019

1277

24PCancer associated fibroblasts promote cancer progression via Wnt2 secretion in colorectal cancer

Karasawa, H, Aizawa, T, Sato, K, Suzuki, H, Kajiwara, T, Yamamura, A, Kamei, T, Naitoh, T, Unno, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1278

25PPaired-related homeobox 1 overexpression promotes invasion and metastasis and is a prognostic factor for worse disease-free survival in patients with lung cancer

Hung, J-J, Kao, Y-S, Hsu, W-H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1279

27PLncRNA-GC1 contributes to gastric cancer chemo-resistance through inhibition of miR-551b-3p and the overexpression of dysbindin

Guo, X, Wang, X, Li, S, Lu, Y, Xie, T, Qiu, Z, Wu, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1280

28PGLPG 1790, a new selective EPHA2 inhibitor, is active in colorectal cancer cell lines belonging to the CMS4/mesenchymal-like subtype

Vitiello, P P, Mele, L, Prisco, C, Cardone, C, Ciardiello, D, Poliero, L, Borrelli, C, Zanaletti, N, Vitale, P, Tirino, V, Papaccio, G, Troiani, T, Ciardiello, F, Marampon, F, Desiderio, V, Martinelli

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1281

29PCharacterisation of growth hormone signal transduction in primary melanoma cell lines

Sousa, K S, Tran, K, Kolekar, S, Jain, L, Wang, Y, Shepherd, P R, Perry, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1282

30PLAPTM5 protein can regulate TGF-β mediated MAPK and smad signaling pathways in ovarian cancer cell

Gao, Y, Chen, Q, Yue, W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1283

31PEffects of novel targeted anticancer drugs on cytotoxicity, apoptosis, angiogenesis, EMT, drug resistance and autophagic mechanism

Aydinlik, S, Uvez, A, Armutak, E İ, Dere, E, Ulukaya, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1284

32PDelineating the mechanisms of alpha 1-3 fucosyltransferase FUT11 in ovarian cancer

Chen, Q, Gao, Y, Yue, W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1285

34PNORE1A induces a feedback termination of TNF signaling by antagonizing TNFR1 through ITCH-mediated destruction complex

Ahn, J, Ko, K-P, Lee, M, Chi, S-G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1286

35PHsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small cell cell lung cancer cell models

Codony-Servat, J, Codony-Servat, C, Viteri, S, Ito, M, Chaib, I, Bracht, J, Molina-Vila, M A, Karachaliou, N, Rosell, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1287

36PExpression of IL-17RA promotes cancer stem-like properties of colorectal cancer cells by Stat3 activation

Yang, C-Y, Lin, C-H, Jiang, J-K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1288

37PAdaption of pancreatic cancer cells to AKT1 inhibition induces the acquisition of cancer stem-cell like phenotype through upregulation of mitochondrial functions

Arasanz, H, Zuazo, M, Santamaría, E, Bocanegra, A I, Gato-Cañas, M, Fernández-Hinojal, G, Hernández-Saez, C, Fernández-Irigoyen, J, Santamaria, E, Rodríguez-Ortigosa, C, Kochan, G, Vera, R, Escors, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1289

38PBub3 is phosphorylated by the ataxia-telangiectasia mutated kinase in mitosis and required for activation of the mitotic spindle checkpoint in breast cancer

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1290

39PThe regulation of INK4 locus by long non-coding RNAs

Kotake, Y, Matsunaga, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

1291

40PVascular endothelial growth factor in colorectal cancer pathology, survival and treatment

Baker, L, Robinson, N, Wilson, D, Tabaqchali, M, Leaper, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

1292

41PLCSCAF1 maintains cancer stem-like traits by stabilizing c-Myc protein and promotes metastasis and recurrence in lung cancer

Guo, T, Zhao, L, Zhao, S, Gu, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

1293

43PXAF1 enhances temozolomide induced autophagic cell death through AMPK signaling pathway

Lee, M, Ko, K-P, Chi, S-G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

1294

44PThe effect of cortisol on methylation patterns in breast cancer cell lines

Intabli, H, Flint, M S, Qattan, A, Allen, M, Yeoman, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1295

45PGlobal and sex-specific epigenome-wide association studies for the identification of the main methylated loci related to smoking in a mediterranean population

Ramirez Sabio, J B, Coltell, O, Asensio, E M, Ortega-Azorín, C, Portoles, O, Gonzalez-Monje, I, Corella, D, Sorlí, J V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1296

46PWhole transcriptomics analyses of mimicking circulating tumor cells (CTCs) by single-cell RNA sequencing (scRNAseq)

Garcia, J, Monjaret, F, Geiguer, F, Aurel, J-P, Puisieux, A, Morel, A P, Bardel, C, Vilchez, G, Brigitte, M, Couraud, S, Vigneron, A, Tourniaire, G, Payen-Gay, L F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1297

47PComparison of enzymatic-and bisulfite conversion to map the plasma cell-free methylome in cancer

Lambert, N, Robertson, A, Srivas, R, Peterman, N, Close, J, Wilson, T, George, P, Wood, H, Wong, B, Tezcan, A, Tezcan, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1298

48PDetection of low mutations in hepatocellular carcinoma by using circulating tumour DNA

Kim, E, Choi, J R, Lee, S -T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1299

49PVariants in the JAK1 and JAK2 genes in the risk and prognosis of patients with cutaneous melanoma

Carvalho, B F, Gomez, G V B, Lourenço, G J, Moraes, A M D, Passos Lima, C S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1300

50PP-Rex1 expression in breast cancer patients

Lara Montero, A, Gonzalez, N, Cicinelli, K, Acosta, G, Vornetti, S, Leguina, L, Maltagliatti, D, Sanchotena, V, Carrasco, M, Flaks, D, Temple, C, Costa, F, Gon, C, Cuneo, N, Abba, M, Kordon, E, Lorenz

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1301

51PModulation of risk of cutaneous melanoma patients by variants in STAT3 gene and functional analysis

Gomez, G V B, Monteiro, L M O, Rocha, R S, Lourenço, G J, Lima, C S P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1302

52PSpectrum of pathogenic germline mutations in Chinese lung cancer patients through next-generation sequencing

Huang, Y, Tian, P, Zhang, Y, Zhao, Z, Cai, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1303

53PPoor prognostic impact of NTRK2 gene variation in esophageal squamous cell carcinoma

Chen, Y, Jiang, D, Chen, W, Zhang, X, Luan, L, Xu, J, Su, J, Gao, F, Ni, Z, Wang, H, Tan, L, Hou, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1304

55PSynergistic activity between niraparib and chemotherapy in colorectal cancer: Molecular determinants from a preclinical model

Vitiello, P P, Ciardiello, D, Cardone, C, Martini, G, Belli, V, Borrelli, C, Poliero, L, Arrichiello, G, De Falco, V, Giunta, E F, Terminiello, M, Troiani, T, Ciardiello, F, Martinelli, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1305

57PThe expression of MMR, CD133 and the presence of p53 wt predict the response to cabazitaxel in malignant neural tumours cell lines

Doello, K, Mesas, C, Perazzoli, G, García-Collado, C, Gándara, M J, García-Fumero, R, Fuel, M, Luque, R, Ortiz, R, Melguizo, C, Prados, J C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1306

59PNovel non-camptothecin compounds with antiproliferative activities against breast cancer cells

Li, W-S, Wu, H-C, Yeh, C-T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1307

60PSensitization of estrogen receptor-positive breast cancer cells to tamoxifen by novel epi-oligomycin A

Yastrebova, M A, Omelchuk, O, Lysenkova, L, Mikhaevich, E, Scherbakov, A M, Shchekotikhin, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1308

61PAutophagy inhibition enhances leflunomide-induced cytotoxicity in human bladder cancer cells

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1309

62PmTOR inhibition in the treatment of resistant breast cancer

Rodriguez, M J, Perrone, M C, Riggio, M, Novaro, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1310

63PStudy of photodynamic therapy in vitro

Jiménez Munguía, I, Meshkov, I, Gorbunova, Y, Sokolov, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1311

65PNovel HDACi, MHY446, induces apoptosis via regulation of mitochondria-endoplasmic reticulum interaction in HCT116 human colorectal cancer cells

Kim, N D, Ahn, Y R, Kang, Y J, Sung, B, Jang, J Y, Kim, M J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1312

66PDual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer

Ciardiello, D, Belli, V, Cardone, C, Vitiello, P P, Martini, G, Poliero, L, Borrelli, C, Arrichiello, G, Ciaramella, V, Matrone, N, Barra, G, De Falco, V, Giunta, E F, Morgillo, F, Troiani, T, Termini

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

1313

67PPARP inhibition enhances cisplatin sensitivity in cervical cancer by modulating β-catenin signaling

Mann, M, Kumar, S, Sharma, A, Chauhan, S S, Bhatla, N, Kumar, S, Bakhshi, S, Gupta, R, Kumar, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

1314

68PSynergistic effect of DSF combined treatment with cisplatin in atypical teratoid/rhabdoid tumors (AT/RT)

Choi, S A, Jangra, A, Kim, S-K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1315

69PReactive oxygen species induced by OSU-A9 inhibit the growth of duodenal cancer and gastric cancer cells through dephosphorylating intranuclear pyruvate kinase muscle isozyme M2

Bai, L-Y, Wu, C-Y, Chu, P-C, Weng, J-R, Chiu, C-F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1316

70PNew therapy for intrahepatic cholangiocarcinoma targeted to cancer associated fibroblasts

Yamanaka, T, Harimoto, N, hoshino, K, Muranushi, R, Hagiwara, K, Gantumur, D, Ishii, N, Tsukagoshi, M, Igarashi, T, Watanabe, A, Kubo, N, Araki, K, Shirabe, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1317

71PMacrophage-cancer cell fusion is mediated by phosphatidylserine-CD36 receptor interaction and induced by ionizing radiation

Shabo, I, Midtbö, K M, Hedayati, E, Garvin, S, Lindström, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1318

72PEffects of three products in the prevention and treatment of chemotherapy and radiation therapy-induced oral mucositis

Zannier, F, Di Bella, S, Della Torre, S, Candido, P, Pelliccione, M, Della Vedova, A, Cozzi, C, Bollina, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1319

73PBoiling histotripsy-induced mechanical ablation modulates tumour microenvironment by promoting immunogenic cell death of cancers

Shin, C-H, Pahk, K J, Kim, S-H, Kim, H, Oh, S J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

1320

74PThe bacterial receptor NOD2 mediates LGR5+ intestinal stem cells protection against irradiation via mitophagy activation

Levy, A, Deutsch, E, Sansonetti, P, Nigro, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1321

76PProton-sensitizing effect of small molecule inhibitor of P300 histone acetyltransferase C646 in human pancreatic cancer cells

Shin, S, Choi, C, Kim, S-Y, Park, H C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1322

78PUrine cell-free and extracellular vesicle cargo miRNAs as biomarkers for prostate cancer diagnosis

Zaporozhchenko, I A, Bryzgunova, O E, Konoshenko, M Y, Lekchnov, E A, Amelina, E V, Pashkovskaya, O A, Yarmoschuk, S V, Zheravin, A A, Rykova, E Y, Laktionov, P P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1323

79PParkin, APEX1 and BCL2L1 tissue expression in southern Brazilian patients with different breast cancer molecular subtypes

Cabral, B B, Riva, F V, Rabinovich, Í, Olandoski, M, Noronha, L, Sotomaior, V S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1324

80PObesity and prognosis in breast cancer

Ibrahim, N Y, Talima, S M, Naguib, D Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1325

81PSIPA1 is a modulator of HGF induced tumour metastasis via the regulation of tight junctions in lung adenocarcinoma cells

Liu, C, Jiang, W G, Hargest, R, Martin, T A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1326

82PDose differential modulation of the autophagic behaviour of estrogen expressing breast carcinoma cells

Fouad, M A, Kamel, M W, Sawalhi, M El, Shouman, S A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1327

83PSynthetic peptide of tumour–associated antigen L6 formulated with polymer-based adjuvant enhances anti-tumour effects in mice

Liu, S-J, Lin, S-I, Huang, M-H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1328

85PImproving detection level of somatic mosaicism in neurofibromatosis type 1

Karandasheva, K, Pashchenko, M, Tanas, A S, Strelnikov, V V, Kuznetsova, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1329

88PTranscription factors of snail family in the regulation of resistance of breast cancer cells to hypoxic conditions

Khamidullina, A I, Yastrebova, M A, Scherbakov, A M, Tatarskiy, V V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 70 KB

2019

1330

90PDComparison of platforms for determining tumour mutational burden (TMB) in patients with non-small cell lung cancer (NSCLC)

Baden, J, Zhao, C, Pratt, J, Kirov, S, Pant, S, Seminara, A, Green, G, Bilke, S, Deras, I, Fabrizio, D A, Pawlowski, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

1331

92PDComprehensive pan-cancer analysis of KRAS genomic alterations (GA) including potentially targetable subsets

Ou, S -H I, Sokol, E S, Madison, R, Chung, J, Ross, J S, Miller, V A, Alexander, B M, Ali, S M, Schrock, A B, Ramalingam, S S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1332

93PDAnalysis of the androgen receptor status in liquid biopsy to predict the outcome to abiraterone and enzalutamide in CRPC patients

Del Re, M, Conteduca, V, Crucitta, S, Gurioli, G, Casadei, C, Restante, G, Schepisi, G, Lolli, C, Morganti, R, Danesi, R, De Giorgi, U F F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1333

94PTwo years of BRCA1 and BRCA2 somatic external quality assessment with Gen&Tiss scheme in France

Dufraing, K, Garrec, C, Egele, C, Keppens, C, Chiesa, J, Lamy, A, Lacroix, L, Harlé, A, Pascal, R, Van Casteren, K, Fetique, D, Dequeker, E, Bellocq, J -P, Rouleau, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1334

97PReanalysis of the efficacy of molecular targeted agents (MTAs) given in the randomized trial SHIVA01 according to the ESMO ESCAT scale of actionability

Moreira, A, Vacher, S, Lecerf, C, Frelaut, M, Sablin, M P, Loirat, D, Ricci, F, Hescot, S, Borcoman, E, Torossian, N, Masliah-Planchon, J, Callens, C, Salomon, A, Bieche, I, Le Tourneau, C, Kamal, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

1335

99PComparison of platforms for determining tumor mutational burden (TMB) from blood samples in patients with non-small cell lung cancer (NSCLC)

Baden, J, Chang, H, Greenawalt, D M, Kirov, S, Pant, S, Seminara, A, Srinivasan, S, Green, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1336

101PPan-cancer genomic landscape of the cyclin D1/FGF3,4,19 (11q13) amplicon including associations with HPV status, and ESR1 and AR alterations

Schrock, A B, Miller, V A, Alexander, B M, Ross, J S, Chung, J, Ali, S M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1337

102PCo-occurrence of NTRK fusions with other genomic biomarkers in cancer patients

Jiao, X, Lokker, A, Snider, J, Castellanos, E, Nanda, S, Fisher, V, Zong, J, Keating, K, Fellous, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1338

103PProspective comparative study of next-generation sequencing on fine needle aspirations versus core needle biopsies in cancer patients included in SHIVA02 trial

Masliah-Planchon, J, Kamal, M, Borcoman, E, Girard, E, Gestraud, P, Bataillon, G, Vincent-Salomon, A, Lecerf, C, Callens, C, Antonio, S, Franck, C, Mariani, O, Bieche, I, Le Tourneau, C, Servois, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1339

104PFirst national external quality assessment for the interpretation of somatic variants: Assessment of 25 variants in colorectal, lung, ovarian cancers and melanoma in France

Rouleau, E, Leroy, K, Dufraing, K, Harlé, A, Lacroix, L, Vanwelden, K, Denis, M G, Lamy, A, Dequeker, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1340

106PElevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer

De Laere, B, Crippa, A, Ghysel, C, Ost, P, Rajan, P, Eklund, M, Dirix, L, Grönberg, H, Lindberg, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1341

108PBiological difference of tumour mutational burden (TMB) and microsatellite instability (MSI) status in patients (pts) with somatic vs germline BRCA1/2-mutated advanced gastrointestinal (GI) cancers using cell-free DNA (cfDNA) sequencing analysis in the GOZILA study

Kawamoto, Y, Nakamura, Y, Ikeda, M, Bando, H, Esaki, T, Ueno, M, Nishina, T, Kagawa, Y, Oki, E, Denda, T, Mizukami, T, Takahashi, N, Okano, N, Miki, I, Sakamoto, Y, Lefterova, M I, Odegaard, J I, Tani

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1342

109PCell-Free DNA to detect focal versus non-focal MET amplification in metastatic colorectal cancer patients: Combined analysis from Japan and the United States

Saori, M, Kawazoe, A, Nakamura, Y, Odegaard, J I, Lefterova, M I, Lanman, R, Yoshino, T, Strickler, J H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1343

110PPresence of circulating tumour DNA in surgically resected renal cell carcinoma is associated with advanced disease and poor patient prognosis

Correa, A, Connolly, D C, Balcioglu, M, Wu, H-T, Dashner, S, Shchegrova, S, Kalashnikova, E, Pawar, H, Uzzo, R G, Gong, Y, Kister, D, Collins, M, Donovan, M, Winters, R, Aleshin, A, Sethi, H, Salari,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1344

111PCombined genomic and epigenomic assessment of cell-free circulating tumour DNA (cfDNA) for cancer diagnosis and recurrence-risk assessment in early-stage lung cancer

Lee, Junghee, Kim, Il-Jin, Cho, Jong Ho, Kim, Hong Kwan, Lee, Jinseon, Lee, Se-hoon, Shultz, Matthew, Jaimovich, Ariel, Odegaard, Justin, Olsen, Steve, Talasaz, AmirAli, Kim, Jhingook

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

1345

113PBespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P)

Yang, C, Iafolla, M A, Dashner, S, Xu, W, Hansen, A R, Bedard, P, Lheureux, S, Spreafico, A, Razak, A A, Wu, H -T, Shchegrova, S, Liu, Z A, Ohashi, P S, Torti, D, Louie, M, Sethi, H, Aleshin, A, Siu,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

1346

114PDynamic changes in whole-genome cell-free DNA (cfDNA) to identify disease progression prior to imaging in advanced solid tumours

Davis, A A, Iams, W, Chan, D, Oh, M S, Lentz, R W, Peterman, N, Robertson, A, Shah, A, Srivas, R, Lambert, N, Wilson, T, George, P, Wong, B, Close, J, Wood, H, Tezcan, A, Spinosa, J C, Tezcan, H, Chae

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1347

117PMultigene panel testing results for hereditary breast cancer in 1325 individuals: Implications for gene selection and considerations for guidelines

Tsaousis, G N, Tsoulos, N, Papadopoulou, E, Agiannitopoulos, K, Pepe, G, Diamantopoulos, N, Floros, T I, Iosifidou, R, Markopoulos, C, Papazisis, K, Venizelos, V, Xepapadakis, G, Banu, E, Eniu, D T, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1348

118PPIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors

Quintanilha, J C F, Racioppi, A, Wang, J, Denning, S, Etheridge, A S, Peña, C E, Crona, D J, Lin, D, Innocenti, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1349

119PERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): A retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials

Chic, N, Pascual, T, Brasó-Maristany, F, Villagrasa Gonzalez, P, Pare Brunet, L, Schettini, F, Conte, B, Adamo, B, Vidal, M, Muñoz, M, Martínez, O, Gonzalez-Farre, B, Cortés, J, Llombart-Cussac, A, Ro

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

1350

121PAXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)

Cardone, C, Blauensteiner, B, Moreno-Viedma, V, Vitiello, P P, Martini, G, Ciardiello, D, Simeon, V, Rachiglio, A M, Rizzi, D, Maiello, E, Latiano, T, Cremolini, C, Argiles Martinez, G, Elez, E, Falco

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 111 KB

2019

1351

122PPrevalence of EGFR mutations and its correlation with Egyptian patients’ human kinetics (PEEK Study)

Ibrahim, A K, Youssef, M W, Helal, A, Waguih, S, Khalifa, M, Aziz, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1352

123PEvaluation of tumour microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)

Rutella, S, Church, S E, Vadakekolathu, J, Reeder, S, Sullivan, A H, Warren, S, Baughman, J, Muth, J, Park, H, Uronis, H, Kang, Y -K, Ng, M C H, Enzinger, P, Lee, K W, Huber, K, Wynter-Horton, A, Li,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1353

124PClinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt)

Rousseau, BJ-C, Cohen, J, Calderaro, J, Dupuy, A, Bourgoin, R, Tournigand, C, Baumgaertner, I, Ropert, S, Thirot Bidault, A, Klotz, C, Le Foll, C, Boussion, H, Diaz, L A, Ollier, M, Pujals, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1354

125PTumour mutation burden and microsatellite instability in colorectal cancer

Fenizia, F, Esposito Abate, R, Pasquale, R, Roma, C, Lambiase, M, Chicchinelli, N, Graziano, P, Botti, G, Tatangelo, F, Scognamiglio, G, Pietrantonio, F, Normanno, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1355

126PPredictors of response to checkpoint inhibitors in naïve and ipilimumab-refractory melanoma

Mallardo, D, Ong, S, Capone, M, Madonna, G, Warren, S, Cesano, A, Beechem, J M, Ascierto, P A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1356

128PMultiplex chromogenic Immunohistochemistry (IHC) for spatial analysis of checkpoint-positive tumour infiltrating lymphocytes (TILs)

Ely, S, Lee, G, Menard, L, Yan, J, Fischer, P, Kakrecha, B, Locke, D, Patah, P, Urbanska, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1357

129PThe role of PD-L1 expression as a predictive biomarker in advanced renal cell carcinoma: A meta-analysis of randomized clinical trials

Carretero-Gonzalez, A, Martín Sobrino, I, Sáez Sanz, I, Castellano Gauna, D, De Velasco Oria de Rueda, G A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1358

130PRadiomic features as a non-invasive biomarker to predict response to immunotherapy in recurrent or metastatic urothelial carcinoma

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1359

131PIntegrative combination of high-plex digital profiling techniques and cluster analysis to reveal complex immune biology in the tumour microenvironment of mesothelioma

Ballesteros-Merino, C, Herz, T, Church, S E, Widmaier, M, Budco, A, Medrikova, D, Kanchev, I, Spitzmueller, A, Shaepe, A, White, A, Reeves, J, Sullivan, A H, Bailey, M, Jensen, S, Handy, J, Sanborn, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1360

132PPredictive factors of response to immunotherapy in 198 patients with metastatic non-microcytic lung cancer (mNSCLC): Real world data from 2 university hospitals in Spain

Cordoba Ortega, J F, Gasol Cudos, A, Morales Murillo, S, Pallise, O, Salud Salvia, M A, Brunet Vidal, J, Pla Juher, H, Carbó Bagué, A, Porta Balanya, R, Izquierdo Font, A, Hernández Martínez, A, Franq

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1361

133PEvaluating lung ct density changes among patients with extensive stage small cell lung cancer (ES-SCLC) treated with thoracic radiotherapy (TRT) alone or TRT followed by combined ipilimumab (IPI) and nivolumab (NIVO)

Latifi, K, Kim, S, Dilling, T J, Rosenberg, S A, Gray, J E, Antonia, S J, Perez, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

1362

134PImmuno-oncology therapy biomarkers differences between polyoma-virus positive and negative Merkel cell carcinomas

Gatalica, Z, Xiu, J, Contreras, E, Swensen, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1363

137PBiomarkers predictive of overall survival in advanced cancer patients treated with a peptide-based cancer vaccine

Suekane, S, Noguchi, M, Terasaki, M, Yutani, S, Narita, Y, Yamada, A, Shichijo, S, Igawa, T, Itoh, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1364

138PExpression of PD-L1 in plasma exosomes of NSCLC patients and its associations with PD-L1 expression of corresponding tumour tissues

Yu, S, Shi, M, Feng, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1365

139PPatient’s perspective on digital biomarkers in advanced urologic malignancies

Rodler, S, Buchner, A, Schott, M, Schulz, G, Stief, C G, Staehler, M, Casuscelli, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1366

141PA comprehensive pan-cancer study of FGFR aberrations in Chinese cancer patients

Gao, Y, Zhu, W, He, Q, Liu, Y, Chen, X, Xiao, D, Han-Zhang, H, Lin, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1367

144PCirculating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel)

Pavan, A, Calvetti, L, Dal Maso, A, Fabozzi, A, Piccin, L, Chiarion-Sileni, V, Pasello, G, Aprile, G, Guarneri, V, Conte, P F, Bonanno, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1368

148PSalivary metabolomics for colorectal cancer detection

Kuwabara, H, Iwabuthi, A, Soya, R, Enomoto, M, Ishizaki, T, Tsuchida, A, Nagakawa, Y, Katsumata, K, Sugimoto, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1369

150PLiquid biopsy assays using combined circulating tumour cells and circulating tumour DNA in the same patients for the diagnosis of primary lung cancer

Suh, Y, Bae, J-S, Lee, H S, Moon, J-M, Kwon, H-J, Kim, J, Moon, S M, Jeong, B-H, Lee, K, Lee, M-S, Jeon, B H, Lee, S, Park, J C, Um, S-W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1370

154PSplenic metabolic activity as biomarker in cervical cancer

De Jaeghere, E A, Laloo, F, Lippens, L, De Man, K, Van Bockstal, M, Van de Vijver, K, Tummers, P, Makar, A, De Visschere, P, De Wever, O, Amant, F, Denys, H, Vandecasteele, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1371

155PIdentification of distinct subtypes revealing prognostic and therapeutic relevance in diffuse type gastric cancer

Kim, S-K, Park, J-R, Kim, H-J, Kim, J-H, Kim, S-Y, Lee, S-I, Song, K-S, Kim, W-H, Kim, Y S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1372

156PRecurrence risk evaluation in stage IB/IIA gastric cancer with TP53 codon 72 polymorphisms

Nishizuka, S S, Ohmori, Y, Iwaya, T, Koeda, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1373

157PIdentification and validation of a prognostic 4 genes signature for hepatocellular carcinoma: Integrated ceRNA network analysis

Yan, Y, Mao, K, Huang, P, Wang, J, Xiao, Z

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1374

159PPrognostic immunoprofiling of muscle invasive bladder cancer (MIBC) patients in a multicentre setting

Nekolla, K, Brieu, N, Gavriel, C G, Widmaier, M, Budco, A, Medrikova, D, Kanchev, I, Testori, M, Chan, J, Dundee, P, Anderson, P, Lawrentschuk, N, Wong, L -M, Phan, P, Gibbs, P, Harrison, D J, Baehner

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 104 KB

2019

1375

161PDifferential expression of various miRNAs in pediatric cytogenetically normal acute myeloid leukemia (CN-AML)

Gaur, V, Chaudhary, S, Tyagi, A, Bakhshi, S, Sharma, P, Kumar, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

1376

162PCirculating tumour cells in head and neck and non-small cell lung cancer

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

1377

163POX40/OX40L protein expression in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers

Zhang, X, He, Y, Hirsch, F R, Zhou, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

1378

167PAscites-derived circulating microRNAs as potential diagnostic biomarkers of gastric cancer-associated malignant ascites

Han, H S, Chae, H B, Yun, J, Kim, H J, Go, S-I, Lee, W S, Bae, W K, Cho, S H, Song, E -K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

1379

168PResults from TRIO030, a pre-surgical tissue-acquisition study to evaluate molecular alterations in human breast cancer tissue following short-term exposure to the androgen receptor antagonist darolutamide

Chen, H-W, Von Euw, E, Millan, P, Fresco, R, Carrez, S, Afenjar, K, Fung, H, Burton, M, Santiago, A, Guzman, R, Villalobos, I, Press, M, Eiermann, W, Slamon, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1380

169PJMJD2A is a novel epigenetic factor of chemotherapeutic susceptibility in gastric cancer

Sato, Y, Nakagawa, T, Tanahashi, T, Kitamura, S, Miyamoto, H, Okamoto, K, Muguruma, N, Takayama, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1381

171TiPPhase II study of olaparib in previously treated advanced solid tumours with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002

Hyman, D, Hendifar, A, Cheol Chung, H, Maio, M, Leary, A, Spanggaard, I, Rhee, J, Marton, M, Chen, M, Krishnan, S, Shapira, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

1382

172TiPThe K-BASKET trial: A prospective phase II biomarker-driven multiple basket trial in Korean solid cancer patients

Kim, S G, Choi, H J, Kim, M H, Jung, M, beom, S -H, Kim, G M, Shin, S J, Chung, H C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

1383

173TiPCambridge liquid biopsy “CALIBRATION” study: Can changes in circulating tumour DNA (ctDNA) predict durable tumour responses in patients with advanced oesophageal cancer receiving MEDI4736?

Linossi, C, Williams, A, Baird, R, Dovedi, S, Fitzgerald, R, Pacey, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

1384

175OPrognostic value of tumour infiltrating lymphocytes (TILs) in patients with early-stage triple negative breast cancers (TNBC) in the absence of chemotherapy

Park, J H, Jonas, S F, Dieci, M V, Bataillon, G, Criscitiello, C, Viale, G, Salgado, R F, Lee, H J, Loi, S, Kim, S -B, Curigliano, G, Vincent-Salomon, A, André, F, Michiels, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

1385

176OMachine learning-assisted prognostication based on genomic expression in the tumour microenvironment of estrogen receptor positive and HER2 negative breast cancer

Abdou, Y, Baird, A, Dolan, J, Lee, S, Park, S, Lee, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 110 KB

2019

1386

178PDLong-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the HER2-positive subgroup

D’Hondt, V, Canon, J -L, ROCA, L, Levy, C, Pierga, J -Y, Du, F Le, Campone, M, Desmoulins, I, Viens, P, Debled, M, Ferrero, J -M, Serin, D, Bessard, A -C Hardy, Brain, E, Dohollou, N, Orfeuvre, H, Lem

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1387

179PDTumor size and overall survival in a cohort of young (≤40 years), nodenegative, systemically untreated breast cancer patients; by the PARADIGM study group

De Jong, V, ter Hoeve, N D, Opdam, M, Vreuls, W, Koop, E, Varga, Z, Willems, S M, van Deurzen, C H M, Cordoba, A, Broeks, A, Stathonikos, N, Voogd, A, Jozwiak, K, Hauptmann, M, Sonke, G S, van der Wal

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1388

180PDImpact of chemotherapy-induced ovarian failure (CIOF) on disease-free survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC)

Furlanetto, J, Nekljudova, V, Schneeweiss, A, Thode, C, Denkert, C, Untch, M, Bassy, M, Karn, T, Fasching, P A, Stickeler, E, Schem, C, Marmé, F, Grischke, E -M, van Mackelenbergh, M, Strik, D, Schmat

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 99 KB

2019

1389

181PDImproved survival of older patients with advanced breast cancer due to an increase in systemic treatments – a population-based study

De Glas, N, Bastiaannet, E, de Boer, A, Siesling, S, Liefers, G -J, Portielje, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

1390

182PDUtility of the CPS+EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy

Marmé, F, Solbach, C, Michel, L, Fasching, P A, Schneeweiss, A, Blohmer, J -U, Rezai, M, Huober, J, Jackisch, C, Nekljudova, V, Link, T, Rhiem, K, Denkert, C, Hanusch, C, Tesch, H, Lederer, B, Loibl,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 104 KB

2019

1391

183PDNeoadjuvant endocrine therapy with palbociclib in patients with high-risk breast cancer

Lønning, P E, Clausen, C, Blix, E S, Lundgren, S, Vagstad, G, Espelid, H, Gilje, B, Janssen, E A, Geisler, J, Aas, T, Aase, H, Knappskog, S, Eikesdal, H P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1392

184PDNeoadjuvant olaparib monotherapy in primary triple negative breast cancer

Eikesdal, H P, Yndestad, S, Blix, E S, Lundgren, S, Vagstad, G, Espelid, H, Gilje, B, Janssen, E A, Geisler, J, Aas, T, Aase, H, Knappskog, S, Lønning, P E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1393

185PDImmunological differences between immune-rich estrogen receptor-positive and -negative breast cancers

O’Meara, T, Marczyk, M, Blenman, K, Yaghoobi, V, Pelenkanou, V, Rimm, D, Pusztai, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 102 KB

2019

1394

186PEfficacy of dose-dense (DD) adjuvant chemotherapy (CT) in hormone receptor positive/HER2-negative early breast cancer (BC) patients (pts) according to immunohistochemically (IHC) defined luminal subtypes: An exploratory analysis of the GIM2 trial

Conte, B, Bruzzone, M, Lambertini, M, Poggio, F, Blondeaux, E, De Laurentiis, M, Valle, E, Cognetti, F, Nisticò, C, De Placido, S, Merlano, M C, Gamucci, T, Montemurro, F, Ceppi, M, Del Mastro, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1395

187PHigh dose neo-adjuvant chemotherapy in triple-negative breast cancer with evidence of homologous recombination deficiency (HRD)

Vliek, S B, Van Werkhoven, E, Mandjes, I, Westphal, T, Lips, E H, Mulder, L, Loo, C, Russel, N, Holtkamp, M, Schot, M, Baars, J, Karger, M, Honkoop, A H, Bos, M E M M, Imholz, A L T, Vrijaldenhoven, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 100 KB

2019

1396

188PRisk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials

Werutsky, G, Untch, M, Hanusch, C, Fasching, P A, Blohmer, J -U, Seiler, S, Denkert, C, Tesch, H, Jackisch, C, Gerber, B, Schneeweiss, A, Link, T, Huober, J, Rhiem, K, Vladimirova, V, Nekljudova, V, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1397

189PEstimating radiotherapy-induced cardiovascular mortality in female breast cancer patients

De Ridder, M, Mulliez, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1398

190P3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)

Stebbing, J, Baranau, Y, Baryash, V, Manikhas, A, Moiseyenko, V, Dzagnidze, G, Zhavrid, E, Boliukh, D, Stroyakovskiy, D, Pikiel, J, Eniu, A, Komov, D, Lee, S J, Kim, M J, Kim, S, Park, S, Bae, J H, Es

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

1399

191PAdjuvant chemotherapy in elderly breast cancer patients: Pattern of use and impact on overall survival

Berthelot, A, De Nonneville, A, Classe, J -M, Cohen, M, Reyal, F, Mazouni, C, Chauvet, M P, Martinez, A, Chopin, N, Daraï, E, Coutant, C, Rouzier, R, Azuar, A -S, Guimbergues, P, De Lara, C Tunon, Vil

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

1400

192PCarboplatin-containing neoadjuvant chemotherapy for triple negative breast cancer (TNBC): A propensity score-matched study

Dieci, M V, Giorgi, C A, Griguolo, G, Angelini, S, Miglietta, F, Giarratano, T, Falci, C, Faggioni, G, Tasca, G, Mioranza, E, Vernaci, G, Menichetti, A, Mantiero, M, Genovesi, E, Frezzini, S, Saibene,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1401

193PImpact of adjuvant trastuzumab emtansine (T-DM1) on incidence of metastatic breast cancer (mBC): An epidemiological model of patients with HER2-positive breast cancer (BC) who did not achieve pathological complete response (pCR) after neoadjuvant treatment (non-pCR)

Williamson, M Y, Tomar, A, Jhuti, G S, Revil, C, Kotzeva, A, Gururaj, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

1402

195PChemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study

Tesch, H, Loibl, S, Kast, K, Jackisch, C, Möbus, V, Buchen, S, Untch, M, Hanusch, C, Seiler, S, Weigel, M, Fasching, P A, Rhiem, K, Huober, J, Blohmer, J -U, Solbach, C, Denkert, C, Nekljudova, V, Lin

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

1403

196PThe clinical impact of adjuvant dose-dense sequential chemotherapy (dds-CT) in patients with high-risk operable breast cancer (BC): Pooled analysis of 6 clinical trials

Fountzilas, E, Koliou, G -A, Zagouri, F, Pentheroudakis, G, Christodoulou, C, Koutras, A, Pectasides, D G, Bafaloukos, D, Samantas, E, Aravantinos, G, Papakostas, P, Psyrri, A, Kosmidis, P A, Koumaria

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

1404

197PThe efficacy of preoperative breast cancer chemotherapy without anti-HER2-targeted treatment: Single center experience in setting of no reimbursement in Poland (2011-2015)

Badora-Rybicka, A, Polakiewicz-Gilowska, A, Leśniak, A, Bal, W, Kubeczko, M, Świderska, K, Mianowska-Malec, M, Grandys, B D, Stobiecka, E, Chmielik, E, Kuś, A, Tarnawski, R, Jarzab, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 102 KB

2019

1405

202PAdjuvant systemic therapy in women with early breast cancer and intermediate prosigna ROR scores: Is chemotherapy use declining? Evidence from a large practice

Hart, L L, den Bergh, M V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1406

203PManagement of early breast cancer in women over 90: A 10 year experience

Coffey, E, Shaker, H, Absar, M, Nasir, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

1407

204PEvolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer

Reinhorn, D J, Amir, E, Yerushalmi, R, Goldvaser, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1408

205PHepatitis B screening and incidence of flare among non-metastatic breast cancer patients treated with anthracyclines

Zhang, Z, Lian, W, Lim, E, Kumar, R, Wong, F Y, Tang, T, Dent, R, Tan, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1409

206PEffect of denosumab on low bone mineral density in postmenopausal Japanese early breast cancer patients receiving aromatase nhibitors: 36-month results

Sakaguchi, K, Nakatsukasa, K, Koyama, H, Matsuda, T, Kato, M, Ouchi, Y, Morita, M, Taguchi, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1410

207PEfficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL study

Fabbri, M A, Botticelli, A, Omarini, C, Cretella, E, Fabi, A, Alesini, D, Pizzuti, L, Piesco, G, Vaccaro, A, Atzori, F, Piacentini, F, Moscetti, L, Orlandi, A, Sini, V, Mercanti, A, Framarino, M L, Pe

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1411

208PReal-world comparison of the impact of adjuvant capecitabine in women with high-risk triple-negative breast cancer after neoadjuvant chemotherapy

Vilbert, M T S, Corassa, M P, Saleh, R R, Coelho, R L, Teixeira, M R D J, Amir, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1412

209PInfluence of age on the indication of adjuvant chemotherapy in early breast cancer using Oncotype DX. An analysis of 240 patients treated in the Institut Catala d’Oncologia (ICO) hospitals

Recalde, S, Quiroga, V, del Barco, S, Falo, C, Dorca, J, Margeli, M, Stradella, A, Soler, T, García, I Teruel, Viñas, G, Fernandez, A, Vázquez, R Villanueva, Vethencourt, A, Marin, M Romeo, Gil-Gil, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 114 KB

2019

1413

211PClinical confirmation of higher exposure to niraparib in tumour vs plasma in patients with breast cancer

Spring, L, Shan, M, Liu, M C, Hamilton, E, Santa-Maria, C A, Irie, H, Isakoff, S, Reeves, J, Ellisen, L W, Liem, A, Naraine, A Milillo, Nangia, J, Page, D, Pan, P, Sun, K, Graham, J R, Han, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1414

212PThe rationale for the effectiveness of systemic treatment of breast cancer depending on the body weight index

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1415

213PResponse to neoadjuvant chemotherapy in HER2 non-overexpressing breast cancer subtypes

Ilie, S M, Desmoulins, I, Hennequin, A, Courèche-Guillaume, K, Arnould, L, Nathalie, B, Bertaut, A, Ladoire, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1416

214PPre-specified interim analysis of the SAFE trial (NCT2236806): A 4-arm randomized, double-blind, controlled study evaluating the efficacy and safety of cardiotoxicity prevention in non-metastatic breast cancer patients treated with anthracyclines with or without trastuzumab

Livi, L, Barletta, G, Martella, F, Desideri, I, Scotti, V, Becherini, C, Saieva, C, Terziani, F, Bacci, C, Airoldi, M, Allegrini, G, Amoroso, D, Venditti, F, Tarquini, R, Orzalesi, L, Sanchez, L, Bern

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1417

215PSafety of hypofractionated whole breast irradiation after conservative surgery for patients aged less than 60 years: A multi-center comparative study

Meattini, I, Livi, L, Kim, K, Kim, J, Jung, W, Olmetto, E, Desideri, I, Saieva, C, Becherini, C, Salvestrini, V, Fourquet, A, Kirova, Y, Poortmans, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1418

216PUsefulness of NT-ProBNP as a biomarker of cardiotoxicity in breast cancer patients treated with trastuzumab

Blancas, I, Martín, C, Martín-Pérez, F J, Legerén, M, Martos, M, Sequero, S, Carnenero, S, Pérez-García, M E, Rodríguez-González, C J, Jurado, J M, Delgado, M, González-Astorga, B, González-Cebrián, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 100 KB

2019

1419

217PThe routine use of sentinel lymph node biopsy in high risk DCIS lesions is not justified

Preat, F, Bohlok, A, Donckier, V, Nogaret, J M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 66 KB

2019

1420

218POncological impact of re-excision for positive margin status after breast conserving surgery in invasive breast cancer

Jimbo, K, Watase, C, Nakadaira, U, Murata, T, Shiino, S, Takayama, S, Suto, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1421

219PPneumonitis and fibrosis after breast cancer radiation

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1422

220PPrognosis of mastectomy with reconstruction after neoadjuvant chemotherapy: A nationwide study of the Korean Breast Cancer Society

Park, S, Bae, S Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1423

221PA negative prognosis of radiotherapy-induced lower lymphocyte to monocyte ratio in patients with breast cancer

Yoon, C-I, Bae, S J, Cha, C H, Park, S E, Ahn, S G, Jeong, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1424

223PPatient data to monitor clinical patterns in early and advanced breast cancer in Europe

Giusti, F, Martos, C, Crocetti, E, Dimitrova, N, Randi, G, Neamtiu, L, Carvalho, R N, Dyba, T, Flego, M, Nicholson, N, Bettio, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1425

225PPredictors of adherence among post-menopausal women receiving adjuvant endocrine therapy for breast cancer in Ontario, Canada

Blanchette, P, Lam, M, Richard, L, Allen, B, Shariff, S, Vandenberg, T, Pritchard, K, Chan, K, Louie, A, Desautels, D, Raphael, J, Earle, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1426

226PEvaluation of endocrine therapy and patients preferences in early breast cancer: Results of Elena study

Montagna, E, Pagan, E, Bagnardi, V, Colleoni, M A, Cancello, G, Munzone, E, Dellapasqua, S, Bianco, N, Campennì, G M, Iorfida, M, Mazza, M, De Maio, A, Milano, M, Veronesi, P, Sangalli, C, Scateni, B,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

1427

227PBaseline quality of life (QoL) and chemotherapy related toxicities (CRT) in localized breast cancer (BC) patients (pts): The French multicentric prospective CANTO cohort study

Licaj, I, Dabakuyo, S, Dauchy, S, Vaz Luis, I, Charles, C, Lemogne, C, Tredan, O, Vanlemmens, L, Jouannaud, C, Levy, C, Rigal, O, Fournier, M, Petit, T, Dalenc, F, Rouanet, P, Arnaud, A, Lemonnier, J,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1428

228PEffects of aerobic and resistance exercise on android: Gynoid fat ratio in breast cancer survivors

Dieli-Conwright, C, Sami, N, Lee, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1429

229PImpact of education for breast self examination in rural Indian women on early detection: Results of POC study

Parchuri, S S, Palanki, S Dattatreya, Nirni, S S, Atilli, S S, Andra, V V, Ch, V M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

1430

230PBreast cancer incidence and survival in renal transplant patients: 35-year experience

Kontos, M, Riza, E, Tsiampalis, T, Kirkilesis, G, Bokos, I, Moris, D, Darema, M, Andriopoulos, A, Varletzidou, A, Vernadakis, S, Nikolaidis, C, Lionaki, S, Sarantzi, X, Anagnostopoulou, C, Boletis, I,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1431

231PThe changing landscape of breast cancer incidence after treatment for Hodgkin’s disease

Benjamin, A J, Cleator, S, Thiruchelvam, P T R, Gujral, D M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1432

233PNumber of deliveries as a prognostic factor in different breast cancer subtypes

Jääskeläinen, A, Roininen, N, Jukkola, A, Karihtala, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1433

234PEffects of supervised and adapted exercise program in the quality of life and strength of breast cancer survivors: MAMA MOVE Gaia trial

Joaquim, A, Antunes, P, Garcia, C, Afreixo, V, Amarelo, A, Duarte, B, Vieira, M, Lopes, R, Leão, I, Baptista Capela, A, Helguero, L, Alves, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

1434

236PClinical decision making and multidisciplinary team meetings (MDMs) in early breast cancer. Is the agreement between planned and applied therapeutic program?

Giavarra, M, Bertoli, E, Buoro, V, Zara, D, Targato, G, Palmero, L, Vitale, M G, Pelizzari, G, Basile, D, Gerratana, L, Bonotto, M, Andreetta, C, Cinausero, M, Pascoletti, G, Poletto, E, Russo, S, Pug

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1435

237PThe value of genetic counselling in breast cancer genetic testing and clinical management

Kiesel, V, Wishart, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

1436

239PTumour-infiltrating lymphocytes and BRCA-like status in stage III breast cancer patients treated with intensified carboplatin-based chemotherapy

Boo, L De, Cimino-Mathews, A, Lubeck, Y, Daletzakis, A, Opdam, M, Sanders, J, Hooijberg, E, van Rossum, A G J, Loncova, Z, Rieder, D, Trajanoski, Z, Vollebergh, M, Sobral-Leite, M, Van de Vijver, K, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1437

240PUnravelling the biological characteristics of MammaPrint extreme risk subgroups

Bhaskaran, R, Griffioen, C, Wehkamp, D, Mittempergher, L, Glas, A M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1438

241PResidual cancer burden as a prognostic factor in a large series of neoadjuvant chemotherapy. Subgroup analysis per molecular surrogated subtypes

Falo, C, Fernández, S, Garrigós, E, Casado, A C Vethencourt, Vázquez, S, Stradella, A, Recalde, S, Pla, M J, Campos, M, Gumà, A, Ortega, R, Petit, A, Soler, T, Perez, J, Fernandez, E, Bergamino, M S,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1439

242PClinical validation of CanAssist breast in a Spanish cohort

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1440

243PMeta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer

Fasching, P A, Huang, M, Cortés, J, Zhao, J, O’Shaughnessy, J, Hu, P, Haiderali, A, Karantza, V, Aktan, G, Briggs, A, Ramsey, S, Qi, C Z, Xie, J, Gu, C, Qian, K, Yuan, M, Wu, E Q

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1441

244PImmune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial

Griguolo, G, Dieci, M V, Paré, L, Miglietta, F, Generali, D G, Frassoldati, A, Bisagni, G, Piacentini, F, Tagliafico, E, Cagossi, K, Ficarra, G, Prat, A, Conte, P F, Guarneri, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1442

245PFrequency of germline mutations in women’s cancer susceptibility genes in a large cohort of Chinese breast cancer patients

Liao, N, Chen, B, Zhang, G, Ren, C, Wang, Y, Guo, L, Cao, L, Wen, L, Li, K, Jia, M, Li, C, Mok, H, Chen, X, Wei, G, Lin, J, Zhang, Z, Hou, T, Shi, X, HanZhang, H, Liu, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1443

246PTriple blinded prospective study assessing the impact of genomics & artificial intelligence Watson for oncology (WFO) on MDT’s decision of adjuvant systemic therapy for hormone receptor positive early breast carcinoma

Prasannakumar, S Sampige, Ramya, Y, Rohit, C K, Ashwin, K, Patil, P, Rauthan, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1444

247PPrognostic significance of progesterone receptor levels in luminal-like Her2- early breast cancer patients. A retrospective single cancer center analysis

Diana, A, Carlino, F, Franzese, E, Centonze, S, Guerrera, L P, Perrone, A, Vita, F De, Ciardiello, F, Orditura, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1445

248PPAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: A meta-analysis

Schettini, F, Pascual, T, Chic, N, Conte, B, Martínez, O, Adamo, B, Vidal, M, Muñoz, M, Fernández-Martínez, A, Griguolo, G, Guarneri, V, Conte, P F, De Placido, S, Carey, L, Perou, C M, Prat, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1446

249PAssessment of CPS+EG, neo-bioscore and modified neo-bioscore in breast cancer patients treated with preoperative systemic therapy: A multicenter cohort study

XU, L, Liu, Y, Fan, Z, Jiang, Z, Liu, Y, Ling, R, Zhang, J, Yu, Z, Jin, F, Wang, C, Cui, S, Wang, S, Mao, D, Xiang, Q, Zhang, Z, Zhou, B, Liu, Z, Ma, C, Duan, X, Cui, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 107 KB

2019

1447

250PThe concordance of treatment decision guided by oncotype and the PREDICT tool in early stage breast cancer

Goldvaser, H, Yerushalmi, R, Shochat, T, Sarfaty, M, Goldstein, D, Mayer, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

1448

251PInfluence of first treatment delay on survival among breast cancer subtypes

Pedrinaci, I Zarcos, Perez, D, Rivas-Ruiz, F, Sala, M, Padilla-Ruiz, M, Alcaide-Garcia, J, Perez-Ruiz, E, Villatoro, R, Navarro, V, Redondo, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 99 KB

2019

1449

252PClinical features of early-stage (I-III) triple-negative breast cancer (TNBC) patients with tumours exhibiting low-overall change in molecular profile after neoadjuvant therapy

Abuhadra, N, Seth, S, Moulder, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 105 KB

2019

1450

253PMeta-analysis in HER2+ early breast cancer therapies and cost-effectiveness in a Brazilian perspective

Magalhaes, M, Aguiar, P, Haaland, B, del Giglio, A, Lopes, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

1451

254PAnti-mullerian hormone (AMH) levels and antral follicle counts (AFC) may predict ovarian reserves before systemic chemotherapy (SC) in women with breast cancer (BC): A prospective clinical study

Ordu, C, Gachayev, F, Elbuken, F, Baysal, B, Pilanci, K N, Alco, G, Ilgun, A S, Ucuncu, M, Ozturk, A, Erdogan, Z, Agacayak, F, Ozdem, G, Kayan, T, Uyar, T, Hocaoğlu, E, Soybir, G, Aktepe, F, Ozmen, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 112 KB

2019

1452

255PPrognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy

Cancello, G, Montagna, E, Pagan, E, Bagnardi, V, Munzone, E, Dellapasqua, S, Iorfida, M, Mazza, M, De Maio, A P, Viale, G, Mazzarol, G, Veronesi, P, Galimberti, V, Santomauro, G, Colleoni, M A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1453

256PNovel blood based circulating tumour cell biomarker for breast cancer detection

Liu, C -Y, Tsai, Y -F, Lin, F -M, Wu, J -C, Lin, Y -S, Chao, T -C, King, K -L, Lien, P -J, Wang, J, Lin, Y -H, Lai, Y -C, Hsieh, H B, Saklecha, A, Lai, J -M, Chang, S -E, Javey, M, Watson, D, Mei, R,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1454

257PMulti-gene prognostic signatures and prediction of pathological complete response of ER-Positive HER2-negative breast cancer patients to neo-adjuvant chemotherapy

Mazo, C, Barron, S, Mooney, C, Gallagher, W M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1455

258PImpact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy

Papakonstantinou, A, Matikas, A, Hellström, M, Johansson, H, Steger, G, Greil, R, Loibl, S, Gnant, M, Moebus, V, Untch, M, Foukakis, T, Bergh, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

1456

260PPAM50 and CGH-array genomic characterization of HER2-equivocal breast cancers defined by the 2018 ASCO/CAP recommendations

Ngo, C, Borcoman, E, Rapinat, A, Simaga, F, Mouterfi, N, Mariani, O, Fuhrmann, L, Jeannot, E, Lae, M, Pierga, J -Y, Gentien, D, Pierron, G, Morel, P, Brauer, H A, Vincent-Salomon, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1457

261POncotypeDX® predictive nomogram for recurrence score output: A machine learning system based on quantitative immunochemistry analysis - ADAPTED01

Marazzi, F, Masiello, V, Barone, R, Magri, V, Mulé, A, Santoro, A, Cacciatori, F, Boldrini, L, Franceschini, G, Moschella, F, Naso, G, Tomao, S, Mantini, G, Masetti, R, Smaniotto, D, Valentini, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 104 KB

2019

1458

263PPatients with a 21-gene assay in South East London differ from the TAILORx trial population

Gousis, C, Sylva, R, Kristeleit, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1459

264PPredictive tools in adjuvant breast cancer: What is the standard of evidence supporting their utility? A literature review examining validation of Adjuvant!, Cancermath and NHS Predict

Loft, A R, Strother, R M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1460

265POncologic outcome of invasive lobular carcinoma: Is it different from that of invasive ductal carcinoma?

Choi, H J, Kim, S W, Ryu, J M, Nam, S J, Yu, J, Lee, S K, Lee, J E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1461

267PChemotherapy-induced amenorrhea: Prognostic impact on premenopausal Egyptian patients with breast cancer

Karim, K Abdel, Al, D A G Abdel, Reda, C, Nohran, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1462

269PPredicting the presence of breast cancer using circulating small RNA in the serum

Koi, Y, Tsutani, Y, Nishiyama, Y, Sasada, S, Akita, T, Masumoto, N, Kadoya, T, Takahashi, R-U, Okada, M, Tahara, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1463

270PEvaluation of germ line mutational status among women with triple-negative breast cancer in Russia

Shagimardanova, E, Shigapova, L H, Nikitin, A, Enikeev, R F, Druzhkov, M, Gusev, O, Gordiev, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1464

271PAssociation of derived neutrophil-to-lymphocyte ratio (dNLR) with pathological complete response (pCR) after neoadjuvant chemotherapy (CT)

Ocaña, A, Chacón, JIL-M, Calvo, L, Antón, A, Mansutti, M, Alba, E, Lluch, A, Lahuerta, A, Bisagni, G, Bermejo, B, Semiglazov, V, Thill, M, Chan, A, Morales, S, Albanell, J, Herranz, J, Trias Bes, I Tu

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1465

272PCompeting nomogram for late-period breast cancer-specific death in patients with early-stage hormone receptor-positive breast cancer

Fu, J, Li, D, Wu, L, Yu, K, Du, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1466

275PExpression of x-linked inhibitor of apoptosis protein (XIAP) and its association with clinicopathological parameters in invasive breast cancers

Devi, G, Finetti, P, Geradts, J, McCall, S, Morse, M, Van Laere, S J, Bertucci, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

1467

276PThe prognostic significance of preoperative tumour marker (CEA, CA15-3) elevation in breast cancer patients

Bae, S Y, Lim, W, Jeong, J, Lee, S, Choi, J, Park, H, Jung, Y S, Jung, S P, Nam, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1468

277PCorrelation of clinical and pathological features with the tumour microenvironment in DCIS: An institutional experience

Eapen, A, Lyou, Y, Eisenbud, L, Mehta, R, Lane, K, Lama, T T, Daroui, P, Lin, E, Ziogas, A, Parajuli, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1469

278PCorrelation between radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer and pathologic complete response and their impact in recurrence-free survival

Cudos, A Gasol, Murillo, S Morales, Rodriguez, J Veas, Ortega, J F Córdoba, García, M I Gil, Morales, C Canosa, Olivé, J Melé, el Koulali, I, Martínez, E Iglesias

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1470

279PRing-like uptake appearance on dedicated breast positron emission tomography before chemotherapy predicts outcome of neoadjuvant chemotherapy in breast cancer

Masumoto, N, Kadoya, T, Nishina, M, Kimura, Y, Amioka, A, Itagaki, T, Sasada, S, Emi, A, Okada, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1471

280PDefining a SUV decrease cut-off in PET/CT response monitoring after one cycle of preoperative breast cancer chemotherapy

Kubeczko, M, Świderska, K, d’Amico, A, di Pietro, M, Chrabański, O, Polakiewicz-Gilowska, A, Mianowska-Malec, M, Bal, W, Badora-Rybicka, A, Leśniak, A, Pasierbek, A, Kuś, A, Tarnawski, R, Bobek-Billew

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1472

282PIdentification of ultralow risk breast cancer patients (probable overdiagnosis)

Casado, S Gamez, Gómez, M Bernal, Bermejo, A Campini, Perez, L Rodriguez, Quilez, A, Candenas, J Calvete, Bernal, G Martínez, Rodríguez, E Benítez, Baena-Canada, J M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1473

283PPrevalence of vitamin D3 deficiency among women with early breast cancer receiving chemotherapy in an oncology dayward

Finstad, W, Murphy, K, Markey, G, Connor, D O, Murphy, C G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1474

284PChanges in ER pathway activity score during neoadjuvant letrozole to assess therapy response and predict disease free survival (DFS) in ER positive breast cancer patients

Turnbull, A K, Inda, M A, van de Stolpe, A, Keizer, D, Clout, D, van Zon, H, Akse, M, Fernando, A, Martinez-Perez, C, Dixon, J M, Sims, A H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1475

285PSecond primary malignancies in patients with breast cancer

Lecuona, C Erasun, Hardy-Werbin, M, Falgas, E Felip, Mosquera, J J García, Salamero, M Cucurull, García, I Teruel, Vila, M Margeli

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1476

286TiPPhase II randomized trial of neoadjuvant trastuzumab and pertuzumab (TP) with either palbociclib + letrozole (Pal+L) or paclitaxel (Pac) for elderly patients with estrogen receptor & HER2 positive (ER+/HER2+) breast cancer (BC) (International Breast Cancer Study Group IBCSG 55-17, TOUCH)

Biganzoli, L, Brain, E, Malorni, L, Risi, E, Regan, M M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1477

287TiPNeoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial

McArthur, H L, Leal, J H S, Page, D B, Bardia, A, Spring, L, Abaya, C D, Basho, R K, Ristow, L, Coleman, H, Shiao, S, Knott, S, Tighiouart, M, Dadmanesh, F, Verma, S, Giuliano, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

1478

289TiPALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer

Ignatiadis, M, McArthur, H L, Bailey, A, Martinez, J, de Azambuja, E, Metzger, O, Lai, C, Franzoi, M A, Goulioti, T, Daly, F, Bouhlel, A, Balta, V, Maetens, M, Viale, G, André, B, DuFRane, C, Nguyen,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1479

290TiPRole of individualized intervention(s) on quality of life (QoL) and adherence to adjuvant endocrine therapy in premenopausal women with early-stage breast cancer (bc): MyChoice study

Ahmed, S, Chalchal, H I, Dwernychuk, L, Iqbal, N, Salim, M, Gowan-Moody, D, Asif, T, Khan, M, Lim, J, Bulych, D, Ahmed, O, Sami, A, Kontulainen, S, Leis, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1480

291TiPCorrelation between the density of tumour-infiltrating lymphocytes, immune cell subsets in tumour stroma and response to systemic therapy in breast cancer

Kuhar, C Grasic, Gersak, K, Gazic, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1481

174OPredictive and prognostic value of B-cell gene-expression signatures and B-cell receptor (BCR) repertoire in HER2+ breast cancer: A correlative analysis of the CALGB 40601 clinical trial (Alliance)

Fernandez-Martinez, A, Tanioka, M, Fan, C, Parker, J S, Hoadley, K A, Krop, I, Partridge, A, Carey, L, Perou, C M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

1482

294PNeoadjuvant endocrine therapy in combination with melatonin and metformin in locally advanced breast cancer

Semiglazova, T Y, Osipov, M, Krivorotko, P, Protsenko, S, Semiglazov, V, Donskih, R, Klimenko, V, Tsirlina, E, Berstein, L, Anisimov, V, Semiglazov, V, Belyaev, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 104 KB

2019

1483

295PMelatonin and metformin in neoadjuvant chemotherapy in locally advanced breast cancer

Semiglazova, T Y, Osipov, M, Krivorotko, P, Semiglazov, V, Protsenko, S, Berstein, L, Tsirlina, E, Klimenko, V, Donskih, R, Anisimov, V, Belyaev, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1484

296PPatient-tailored tamoxifen dosing based on an increased quantitative understanding of its complex pharmacokinetics: A novel integrative modelling approach

Mueller-Schoell, A, Klopp-Schulze, L, Huisinga, W, Joerger, M, Neven, P, Koolen, S L, Mathijssen, R H J, Schmidt, S, Kloft, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1485

297PLack of benefit of neoadjuvant pertuzumab in high risk HER2 positive breast cancer: A retrospective case-control study of 355 cases with biomarker analysis

Tiako Meyo, M, Lavigne, M, Leclerc, P, Tanguy, M -L, Kirova, Y, Hurgon, A, Lalli, A, Fourchotte, V, Vincent-Salomon, A, Escalup, L, Cottu, P H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

1486

299PActivity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer

Noblejas López, M D M, Nieto-Jiménez, C, Galán-Moya, E M, Burgos, M, Montero, J C, Gómez-Juárez, M, Pandiella, A, Ocaña, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1487

300POutcome of triple negative inflammatory breast cancers (TNIBC) treated with dose dense neoadjuvant epirubicin cyclophosphmide, prognostic impact of pre and post neoadjuvant chemotherapy (NAC) tumour infiltrating lymphocytes (TIL) and post NAC lymphovascular invasion

Campedel, L, Blanc-Durand, P, Binasker, A, Bécourt, S, Ledoux, F, Cuvier, C, Gardair, C, Teixeira, L, De Roquancourt, A, Lehmann Che, J, Espié, M, Giacchetti, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1488

301PA novel PET parameter for cancer stem cell metabolism: Early prediction of chemosensitivity to neoadjuvant chemotherapy in locally advanced breast cancer

Kim, C, Choi, H J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1489

303PRe-sentinel node biopsy for local recurrence after breast-conserving surgery

Matsubara, Y, Yamanaka, T, Yamashita, T, Okamoto, S, Toda, S, Kohagura, K, Sugawara, Y, Yamanaka, A, Suganuma, N, Nakayama, H, Yoshida, T, Iwasaki, H, Rino, Y, Masuda, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1490

304PAssessment of prognostic and therapeutic factors in men with breast cancer

Herrero Rivera, D, Morales Herrero, M D R, Almeida González, C, Sánchez Camacho-Mejías, A, Carrasco García, I, Benedetti Pedroza, J, Falcon Gonzalez, A, Montaño Periáñez, Á, Salvador Bofil, F J, Ruiz

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 67 KB

2019

1491

292PBRCA1/2 testing in HER2- advanced breast cancer (ABC): Results from the European component of a multi-country real-world study

Lux, M P, Lewis, K, Rider, A, Niyazov, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 107 KB

2019

1492

306PDPIK3CA alterations in metastatic breast cancer (mBC)

Albanell, J, Casadevall, D, Sokol, E S, Albacker, L A, Elvin, J A, Vergilio, J-A, Killian, J K, Ngo, N, Lin, D, Ramkissoon, S, Severson, E, Ali, S M, Schrock, A B, Chung, J, Reddy, P, Miller, V A, Ale

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 119 KB

2019

1493

307PDEmergence of ESR1 mutation in cell-free DNA during first line aromatase inhibitor and palbociclib: An exploratory analysis of the PADA-1 trial

Bidard, F-C, Callens, C, Pistilli, B, Dalenc, F, de La Motte Rouge, T, Sabatier, R, Frenel, J -S, Ladoire, S, Dubot, C, Ferrero, J-M, Clatot, F, Nierges, D, Everhard, S, Lemonnier, J, Bieche, I, Pradi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

1494

308PDUpdated overall survival (OS) and quality of life (QoL) in premenopausal patients (pts) with advanced breast cancer (ABC) who received ribociclib (RIB) or placebo (PBO) plus goserelin and a nonsteroidal aromatase inhibitor (NSAI) in the MONALEESA-7 (ML-7) trial

Lu, Y-S, Bardia, A, Vázquez, R V, Colleoni, M A, Wheatley-Price, P, Im, Y-H, Babu, G, Tripathy, D, Lanoue, B R, Chandiwana, D, Ridolfi, A, Hughes, G, Zarate, J P, Gounaris, I, Harbeck, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1495

311PDLeuprorelin (LEUP) combined with Letrozole (LET) with/without everolimus (EVE) in ovarian suppressed premenopausal women with hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC): Primary analysis of LEO Trial (NCT02344550)

Jeong, J, Kim, J E, Ahn, J -H, Jung, K H, Koh, S -J, Cheon, J, Sohn, J, Kim, G M, Lee, K S, Park, I H, Sim, S H, Kim, S -B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1496

312PGenomic profiling of Chinese breast cancer patients

Tao, Z, Li, T, Feng, Z, Li, B, Zhang, H, Zhang, J, Hu, X

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1497

313PGenome copy number alteration burden represents predictor of response in long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer

Walsh, N, Furney, S J, Quinn, C, Gullo, G, Crown, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1498

314PNext-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations

Turner, N C, Laird, A D, Telli, M L, Rugo, H S, Mailliez, A, Ettl, J, Grischke, E -M, Mina, L A, Balmaña, J, Fasching, P A, Hurvitz, S A, Albacker, L A, Frampton, G M, Chelliserry, J, Bycott, P, Conte

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

1499

315PFGFR1 and CCND1 gene amplifications are associated with breast cancer resistance to aromatase inhibitors

Imyanitov, E, Kramchaninov, M, Akhapkina, T, Sokolova, T, Aleksakhina, S, Togo, A, Iyevleva, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1500

316PClinicopathologic features of BRCA mutated breast cancer patients: Hacettepe experience

Aksoy, S, Degirmenciler, R F, Aktas, B Y, Guven, D C, Aktepe, O H, Guner, G, Taban, H, Kertmen, N, Arik, Z, Dizdar, O

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

1501

317PNovel fusion genes identified from matched primary and recurrent breast cancers by RNA-sequencing

Choi, S, Kim, J, Chung, I Y, Jo, W G, Yun, K W, Park, H J, Lee, S B, Kim, H J, Ko, B S, Lee, J W, Son, B H, Ahn, S H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

1502

319PThe role of AXL as mechanism of resistance to trastuzumab and a prognostic factor in breast cancer HER2 positive: A translational approach

Adam-Artigues, A, Tormo, E, Rojo, F, Perez-Fidalgo, J A, Zazo, S, Gonzalez-Alonso, P, Hernando, C, Martínez, M T, Gambardella, V, Poveda, J, Simón, S, Moragon, S, Alonso, E, Rovira, A, Albanell, J, Bu

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1503

320PUntargeted assessment of tumour fractions in plasma for monitoring and prognostication from metastatic breast cancer patients undergoing systemic treatment

Balic, M, Suppan, C, Brcic, I, Tiran, V, Mueller, D H, Posch, F, Ulz, P, Heitzer, E, Dandachi, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

1504

321PClinical application of mutational analysis in breast cancer patients: The relevance of PIK3CA analysis for precision medicine

Cejalvo, J M, Moragon, S, Ortega, B, Hernando, C, Martínez, M, Gambardella, V, Tarazona Llavero, N, Roda, D, Burgues, O, Alonso, E, Simón, S, Poveda, J, Rentero, P, Zuñiga, S, Bermejo, B, Lluch, A, Ce

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1505

322PA retrospective gene expression analysis of surgically-removed breast cancer brain metastasis (BCBM)

Mallafré-Larrosa, M, Pascual, T, Chic, N, Martínez, O, Galvan, P, Gonzalez-Farre, B, Vidal, M, Muñoz, M, Adamo, B, Prat, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1506

323PEndocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials

Omarini, C, Sperduti, I, Barbolini, M, Isca, C, Bocconi, A, Toss, A, Cortesi, L, Barbieri, E, Piacentini, F, Cascinu, S, Moscetti, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

1507

324PAlpelisib (ALP) + fulvestrant (FUL) for patients with hormone receptor–positive (HR+), HER2− advanced breast cancer (ABC): Management and time course of key adverse events of special interest (AESIs) in SOLAR-1

Rugo, H S, André, F, Yamashita, T, Cerda, H, Toledano, I, Stemmer, S, Cruz Jurado, J, Juric, D, Mayer, I, Ciruelos, E M, Iwata, H, Conte, P F, Campone, M, Wilke, C, Mills, D, Lorenzo, I, Miller, M, Lo

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 100 KB

2019

1508

325PChanges in hormone-receptor status in luminal breast cancers between primary tumour and metastases: Results of the observational cohort GIM-13 AMBRA study

Cazzaniga, M E, Pronzato, P, Del Mastro, L, Natoli, C, Montemurro, F, Bisagni, G, Blasi, L, Turletti, A, Giordano, M, Biganzoli, L, Michelotti, A, Garrone, O, Marchetti, P, Riccardi, F, Bernardo, A, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 100 KB

2019

1509

326PMONARCH 3: Updated time to chemotherapy and disease progression following abemaciclib plus aromatase inhibitor (AI) in HR+, HER2- advanced breast cancer (ABC)

Martín, M, Johnston, S, Huober, J, Di Leo, A, Sohn, J, Andre, V A, Martin, H R, Hardebeck, M C, Goetz, M P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 106 KB

2019

1510

327PPalbociclib plus an aromatase inhibitor as first-line therapy for metastatic breast cancer in US clinical practices: Real-world progression-free survival analysis

Torres, M, Liu, X, Mardekian, J, McRoy, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 98 KB

2019

1511

328PRibociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from the CompLEEment-1 trial

Campone, M, De Laurentiis, M, Zamagni, C, Kudryavcev, I, Agterof, M, Brown-Glaberman, U, Palácová, M, Chatterjee, S, Menon-Singh, L, Wu, J, Zhou, K, Martin, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1512

329PComparative effectiveness of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US real-world clinical practices

Layman, R M, Liu, X, Mardekian, J, McRoy, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 103 KB

2019

1513

330PPharmacokinetics (PK), safety, and efficacy of [fam-] trastuzumab deruxtecan with OATP1B/CYP3A inhibitors in subjects with HER2-expressing advanced solid tumours

Bang, Y-J, Karayama, M, Takahashi, M, Watanabe, J, Minami, H, Yamamoto, N, Kinoshita, I, Lin, C -C, Im, Y -H, Fujiki, T, Achiwa, I, Kamiyama, E, Okuda, Y, Lee, C, Takahashi, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 111 KB

2019

1514

331PA phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to non-small cell lung cancer (NSCLC) or melanoma (MEL)

Sahebjam, S, Le Rhun, E, Queirolo, P, Jerusalem, G, Subramaniam, D, Bear, M, Yang, Z, Chen, Y, Conte, P F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1515

332PRibociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial

De Laurentiis, M, Ring, A, Campone, M, Bachelot, T, Jacot, W, Marchetti, P, Timcheva, C, De Valk, B, Gombos, A, Menon-Singh, L, Wu, J, Zhou, K, Neven, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

1516

333PRibociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Cottu, P H, De Laurentiis, M, Marchetti, P, Coltelli, L, Califaretti, N, Debled, M, Patil, S, Evron, E, Duhoux, F P, Menon-Singh, L, Wu, J, Zhou, K, Salvador Bofill, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1517

334PClinical outcome and toxicity data in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy in a real-world clinical setting

Fountzilas, E, Koliou, G -A, Rapti, V, Nikolakopoulos, A, Christopoulou, A, Moirogiorgou, E, Binas, I, Aravantinos, G, Kostadima, L, Nikolaidi, A, Karteri, S, Zagouri, F, Saridaki, Z, Molfeta, A, Oiko

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1518

335PSafety and efficacy of ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study

De Laurentiis, M, Mazza, M, Mansutti, M, Masetti, R, Ballatore, Z, Torrisi, R, Michelotti, A, Zambelli, A, Ferro, A, Generali, D, Vici, P, Coltelli, L, Fabi, A, Marchetti, P, Ballestrero, A, Spazzapan

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

1519

336PInterim results from CompLEEment-1 (A phase IIIb study of ribociclib and letrozole as first-line therapy for advanced breast cancer in an expanded population): Spanish cohort results

Salvador, J, Ciruelos, E M, Jiménez-Rodríguez, B, De La Cruz, L, Villanueva Vázquez, R, De Toro, R, Antón, A, Moreno, F, Álvarez, I, Quiroga, V, de la Haba, J, González-Santiago, S, Díaz, N, Barnadas,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

1520

337PFirst Canadian interim analysis from the phase IIIb CompLEEment-1 ribociclib + letrozole HR+ HER2- advanced breast cancer trial

Ferrario, C, Warner, E, Califaretti, N, Joy, A A, Chia, S, Wu, J, Zarate, J P, Lakshmi, M, Perri, S R, Haftchenary, S, Dent, S F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1521

338PReal-world effectiveness of first-line palbociclib + letrozole for metastatic breast cancer 4 years post approval in the US

Kish, J, Trocio, J, Miller, T, Nero, D, Liassou, D, Liu, X, McRoy, L, Feinberg, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1522

339PPalbociclib-fulvestrant (PALBO-FUL) and everolimus -exemestane (EVE-EXE) for second line hormonal treatment (HT) of metastatic breast cancer (MBC) with lobular histology: A propensity score matched analysis of a multicenter ‘real-world’ patients (pts) series

Orlandi, A, Iattoni, E, Pizzuti, L, Fabbri, M A, Botticelli, A, Di Dio, C, Palazzo, A, Garufi, G, Indellicati, G, Alesini, D, Carbognin, L, Paris, I, vaccaro, A, Moscetti, L, Cassano, A, Vici, P, Gian

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1523

340PDose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC)

Dees, E C, Aftimos, P G, Menke-van der, C W, van Oordt, Houven, De Vries, E G E, Neven, P, Pegram, M D, Iqbal, R, Boers, J, Xiao, J, Sipes, C, Li, C, Sorrentino, J A, Malik, R, Beelen, A P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1524

341PFinal results of the STEM trial: SFX-01 in the treatment and evaluation of ER+ Her2- metastatic breast cancer (mBC)

Howell, S J, Campone, M, Cortés, J, Duhoux, F P, Ross, S, Morris, T, Franklin, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1525

342PAlpelisib (ALP) + fulvestrant (FUL) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis by presence of visceral metastasis (VM) in the SOLAR-1 trial

Campone, M, Rugo, H S, Rubovszky, G, André, F, Loibl, S, Iwata, H, Conte, P F, Mayer, I, Juric, D, Yamashita, T, Lorenzo, I, Ridolfi, A, Ciruelos, E M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 97 KB

2019

1526

343PPhase I dose escalation study of a selective androgen receptor modulator RAD140 in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer (BC)

Hamilton, E, Vidula, N, Ma, C, LoRusso, P, Bagley, R G, Yu, Z, Annett, M, Weitzman, A, Conlan, M G, Weise, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1527

344PA phase I study of XZP-3287, a novel oral CDK4/6 Inhibitor, administered on a continuous dosing schedule, in patients with advanced solid tumours

Xu, B, Wang, J, Liu, X, Fang, J, Yao, Z, Wang, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1528

345PPhase I dose-escalation and expansion study of the PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumours

Li, H, Xu, J, shao, B, Liu, R, ran, R, Song, G, Jiang, H, Wang, K, Shi, Y, Liu, J, Hu, W, Chen, F, Zhang, G, Wang, Y, Zhao, C, Ru, J, wang, Q, Rugo, H S, Li, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1529

346PPhase II study of DHP107 oral paclitaxel in first-line, HER2 negative recurrent/metastatic breast cancer (OPTIMAL study, NCT03315364)

Ahn, J-H, Lee, K S, Lee, K-H, Seo, J H, KANG, S Y, Sohn, J, Yang, Y, Park, K H, Moon, Y W, Lim, S T, Yoon, K E, Cho, H J, Kim, S -B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1530

347PMulticenter phase I trial of trastuzumab emtansine (T-DM1) in combination with non-pegylated liposomal doxorubicin (NPLD) in HER2[+] metastatic breast cancer (MBC). THELMA study

López-Miranda, E, Di Cosimo, S, Brain, E, Ravnik, M, Escrivá-de-Romaní, S, Vidal, M, Gligorov, J, Borstnar, S, Calabuig, L, Sampayo, M, Pérez-García, J M, Riva, F, Malfettone, A, Llombart Cussac, A, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1531

348PPhase I study of liposomal formulation of eribulin (E7389-LF) in patients (pts) with advanced solid tumours: Primary results of dose-escalation part

Yamamoto, N, Sato, J, Koyama, T, Iwasa, S, Shimomura, A, Kondo, S, Kitano, S, Yonemori, K, Fujiwara, Y, Tamura, K, Suzuki, T, Takase, T, Nishiwaki, Y, Nakai, K, Shimizu, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1532

349PPolo-like kinase 1 inhibitor onvansertib synergizes with paclitaxel in breast cancer carrying p53 mutation

Giordano, A, Liu, Y, Kappler, C, Park, Y, Yeh, E, Erlander, M, Ethier, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1533

350PPhase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173)

Wesolowski, R, Brufsky, A M, Chambers, M, Bhattacharya, S, Lustberg, M, VanDeusen, J B, Sardesai, S, Williams, N, Noonan, A M, Phelps, M, Grever, M, Stephens, J, Carson, W, Ramaswamy, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1534

351PImpact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: Results from the AGMT_MBC-registry

Gampenrieder, S P P, Rinnerthaler, G, Petzer, A, Tinchon, C, Fuchs, D, Balic, M, Heibl, S, Rumpold, H, Egle, D, Zabernigg, A F, Singer, C F, Andel, J, Hubalek, M, Knauer, M, Greil, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

1535

352PClinical profile and outcome of HER2 positive breast cancer patients with brain metastases treated with HER2 targeted therapy: Real-world experience

Bhargava, P G, Shenoy, R, Rathnasamy, N, Gulia, S, Bajpai, J, Ghosh, J, Rath, S, Budrukkar, A, Shet, T, Patil, A, Nair, N, Popat, P, Wadasadawala, T, Sarin, R, Kannan, S, Badwe, R, Gupta, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 70 KB

2019

1536

353PPertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer: Results of single arm phase IV COMACHI study

Masuda, N, Ohtani, S, Nagai, S, Takashima, S, Yamaguchi, M, Tsuneizumi, M, Komoike, Y, Osako, T, Ito, Y, Ikeda, M, Ishida, K, Nakayama, T, Takashima, T, Asakawa, T, Matsumoto, S, Shimizu, D, Takahashi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 107 KB

2019

1537

354PAnti-HER-2 therapies and left ventricular dysfunction the renaissance study

Daniele, A J, Gregorietti, V, Aguilar, A, Almada, C, Lopez, V, Savignano, M, Roganovich, G, Kassis, N, Ortencio, A D´, Daniele, S, Cáceres, M V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

1538

355PSafety and efficacy of T-DM1 in 128 patients with advanced HER2+ breast cancer: The Royal Marsden experience

Battisti, N M L, Lee, K A, Shepherd, S, Rogerson, F, Mohammed, K, Allen, M, Ring, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

1539

357PPatient Reported Outcomes (PRO) in patients (pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: A focus on subgroups with/ without visceral disease

Ettl, J, Quek, R G W, Bhattacharyya, H, Rugo, H S, Hurvitz, S A, Gonçalves, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1540

359PReproducibility and concordance of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays in triple negative breast cancer (TNBC)

Noske, A, Ammann, J, Wagner, D-C, Denkert, C, Lebeau, A, Sinn, P, Kreipe, H -H, Baretton, G, Steiger, K, Kiechle, M, Hieke-Schulz, S, Roth, W, Weichert, W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 108 KB

2019

1541

360PSystemic therapy in second-line metastatic triple negative breast cancer (mTNBC): A systematic literature review (SLR) and meta-analysis (MA) of efficacy

Kaufman, P A, Kwon, C S, Feliciano, J, Westley, T, Forsythe, A, Garfin, P, Brown, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

1542

361PCisplatin given at three divided doses for three consecutive days in metastatic breast cancer: An alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia

Chen, Y, Zhang, J, Zhang, J, Hu, X

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 2.35 MB

2019

1543

363PMaintenance chemotherapy is effective in patients with metastatic triple negative breast cancer after first-line platinum-based chemotherapy

Zhang, J, Chen, Y, Hu, X

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1544

364PUsing the patient-reported outcomes measurement information system (PROMIS) to investigate symptom burden enrichment in stage IV patients at an academic center

Matthys, M, Dempsey, A, Basu, A, Dreher, N, Esserman, L, van ’t Veer, L, Melisko, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1545

365PMeasures of functional status in adults aged ≥70 years with advanced breast cancer (ABC) receiving palbociclib (PAL) combination therapy in POLARIS

Karuturi, M S, Blum, J L, Wallmark, J, McCune, S, Lakhanpal, S, Telivala, B, Tsai, M, Rakowski, T, Bardia, A, Cappelleri, J C, Richardson, E, Wang, Y, Tripathy, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1546

366PReal-world 1-year survival analysis of patients with metastatic breast cancer with liver or lung metastasis treated with eribulin, gemcitabine or capecitabine

Kazmi, S M, Chatterjee, D, Alexis, K, Raju, D, Wang, E, Knoth, R L, Hauser, R S, Kaufman, P A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1547

367PPrognostic impact of body mass index (BMI) on overall survival in patients with metastatic breast cancer

Saleh, K, Carton, M, Dieras, V C, Heudel, P -E, Brain, E, Firmin, N, Mailliez, A, Patsouris, A, Mouret Reynier, M A, Gonçalves, A, Ferrero, J -M, Petit, T, Levy, C, Uwer, L, Cottu, P H, Veron, L, Delu

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1548

368PClinicopathological characteristics, survival and prognostic factors of breast cancer-related microangiopathic haemolytic anemia: A multicenter study

Alhenc Gelas, M, Bidard, F C, Heudel, P -E, Pierga, J -Y, Cabel, L, Delaloge, S, Frenel, J -S, Levy, C, Dalenc, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1549

369PMetabolic tumour volume by 18F-FDG PET/CT is an independent prognostic factor in metastatic breast cancer

Ahn, H, Hyun, S H, Park, S, Lee, S J, Kim, J Y, Ahn, J S, Im, Y -H, Park, Y H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1550

370PPatient preferences for breast cancer treatments: A discrete choice experiment from four European countries

Konstantopoulou, T, Stamuli, E, Ross, D, Pacheco, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1551

371PPalbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study

Lüftner, D, Welslau, M K, Liersch, R, Deryal, M, Brucker, C, Rauh, J, Welt, A, Zaiss, M, Sahlmann, J, Houet, L, Vannier, C, Potthoff, K, Marschner, N W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1552

372PVentriculoperitoneal shunt for CNS metastasis in breast cancer: Clinical outcomes based on intrinsic subtype

Kim, H K, Park, Y H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

1553

373PAdministration of chemotherapy for metastatic breast cancer near the end of life: A population registry study

Edman Kessler, L, Sigfridsson, J, Bergh, J, Foukakis, T, Matikas, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1554

374PPrognostic value of histological growth pattern in patients operated for breast cancer liver metastases

Bohlok, A, Botzenhart, L, Lucidi, V, Noël, J C, Demetter, P, Larsimont, D, Donckier, V, Vermeulen, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1555

375PIllness perceptions, quality of life and mood in metastatic breast cancer patients

Domingues, I, Carvalho, J, Pratas, E A, Pinheiro, S, Amaral, S, Pereira, T, Pontes, F, Félix, R, Chaves, A, Mariano, M, Carvalho, T, Madeira, P, Pêgo, A, Broco, S, Garcia, R, Pazos, I, Pais, A, Sousa,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1556

376PMultidisciplinary treatments increase overall survival in patients with newly diagnosed stage IV breast cancer: An analysis of 2010–2014 SEER data

Zhang, J, Li, M, Gong, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1557

377PCorrelation of radiotherapy with the prognosis of elderly patients with hormone receptor-positive breast cancer according to immunohistochemical subtyping

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1558

378PReal-world treatment sequencing patterns in secondary breast cancer (SBC): Pathway visualisation using national datasets

Horne, A W B, McMenemy, M, Holly, E, Rigglesford, N, Linksted, P, Murdoch, L, Oikonomidou, O, Michie, C, Hayward, L, Lilley, C, Hall, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1559

379PUtilization pattern of bone targeting agents in patients with solid tumour in Taiwan, Hong Kong and Korea

Lai, S J J, Au, P C M, Baek, Y H, Cheung, C L, Gao, S N, Yang, Y H Kao, Kleinman, N, Kim, J H, Lange, J, Liao, T C, Lin, T C, Man, K K, Shin, J Y, Sing, C W, Wong, I C K, Lai, E C C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1560

380PClinico-pathological features and prognosis of patients with pregnancy associated breast cancer: A matched case control study

Zhang, R, Liu, X -R, Li, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1561

381TiPTRYbeCA-2: A randomized phase II/III study of eryaspase in combination with gemcitabine and carboplatin chemotherapy versus chemotherapy alone as first-line treatment in patients with metastatic or locally recurrent triple-negative breast cancer

Awada, A H, Cortés, J, Slater, S, Macpherson, I, Csoszi, T, Bertrand, J -B, Clermont, A -S, Pollard, R, Chrestia-Blanchine, R, Biswas-Baldwin, N, Youssoufian, H, El-Hariry, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1562

382TiPCONTESSA TRIO: A multinational, multicenter, phase II study of tesetaxel plus 3 different PD-(L)1 inhibitors in patients with metastatic triple negative breast cancer (TNBC) and tesetaxel monotherapy in elderly patients with her2- metastatic breast cancer (MBC)

Tolaney, S M, Blum, J L, Bondarenko, I, Chan, A, DaCosta, N, Feng, Y -H, Izarzugaza, Y, Kim, S -B, Liu, M -C, Oliveira, M, Ow, S G W, Pavic, M, Peréz Lopéz, M E, Rugo, H S, Schwartzberg, L, Stradella,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

1563

384TiPEffectiveness of olaparib plus trastuzumab in HER2[+], BRCA–mutated (BRCAm) or homologous recombination deficient (HRD) advanced breast cancer (ABC) patients (pts). The OPHELIA study

Alés-Martínez, J E, Morales, S, Fernández Abad, M, Sánchez-Rovira, P, Salvador Bofill, F J, Lahuerta, A, García-Sáenz, J A, Garau Llinas, I, Díaz Redondo, T, Ferrer, N, Carañana, V, López, R, Alonso S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 99 KB

2019

1564

385TiPRIBOB: A study on the efficacy and safety of ribociclib in combination with letrozole in older women (≥70 years) with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior systemic therapy for advanced disease

Kenis, C, Ponde, N F, Decoster, L, de Azambuja, E, Jerusalem, G, Neven, P, Dal Lago, L, Denys, H, Vuylsteke, P, Duhoux, F P, Wildiers, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1565

386TiPRIbociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2– inoperable locally advanced or metastatic breast cancer: RIGHT choice study

El Saghir, N, Malwinder, S, Azim, H, Eralp, Y, Im, S-A, Yap, Y S, Delgar Alfaro, T, Gao, M, Lu, Y-S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 97 KB

2019

1566

387TiPPalbociclib rechallenge in hormone receptor (HR)[+]/HER2[-] advanced breast cancer (ABC). PALMIRA trial

Llombart Cussac, A, Medioni, J, Colleoni, M A, Ettl, J, Schmid, P, Macpherson, I, Gligorov, J, Albanell, J, Bellet Ezquerra, M, Fernández, A, Ruiz Borrego, M, Gavilá-Gregori, J, Wheatley, D, Zamora, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1567

388TiPAlpelisib (ALP) + endocrine therapy (ET) by last prior therapy in patients (pts) with PIK3CA-mutated hormone-receptor positive (HR+) human epidermal growth factor receptor-2-Negative (HER2–) advanced breast cancer (ABC): Additional study cohort in BYLieve

Ciruelos, E, Lerebours, F, Ruiz Borrego, M, Bachelot, T, Polikoff, J, Chia, S, Juric, D, Turner, N, Ridolfi, A, Sophos, N, Cooper, B, Thuerigen, A, Rugo, H S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1568

389TiPPRECYCLE: Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy

Degenhardt, T, Fasching, P A, Lüftner, D, Müller, V, Thomssen, C, Schem, C, Witzel, I, Decker, T, Tesch, H, Kuemmel, S, Uleer, C, Wuerstlein, R, Riese, C, Schinköthe, T, Kates, R E, Schumacher, J, Har

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1569

391OPrognostic role of the EANO ESMO classification of leptomeningeal metastases

Le Rhun, E, Devos, P, Weller, J, Seystahl, K, Mo, F, Compter, A, Berghoff, A S, Jongen, J, Wolpert, F, Rudà, R, Brandsma, D, Preusser, M, van den Bent, M J, Herrlinger, U, Weller, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1570

392OA phase 0/II clinical trial of a CDK4/6 inhibitor in aggressive meningioma patients

Sanai, N, Tien, A -C, Li, J, Bao, X, DeRogatis, A, Fujita, Y, Pennington-Krygier, C, Kim, S, Mehta, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1571

393OIs immuno-oncology therapy effective in hypermutator glioblastomas with somatic or germline mutations?

Kamiya-Matsuoka, C, Metrus, N, Weathers, S-P, Ross, J, Shaw, K, Penas-Prado, M, Loghin, M, Alfaro-Munoz, K, O’Brien, B, Harrison, R, Sadighi, Z, Majd, N, Yung, W, Meric-Bernstam, F, Hambardzumyan, D,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1572

395PDCirculating PD-L1 levels vary across brain tumour entities and are oppositely linked to survival in glioblastoma and lower grade glioma patients

Mair, M, Ilhan-Mutlu, A, Pajenda, S, Widhalm, G, Dieckmann, K, Hainfellner, J A, Marosi, C, Wagner, L, Preusser, M, Berghoff, A S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1573

396PDCharacterization of a novel BBB-permeable mutant IDH1 inhibitor, DS-1001b

Matsunaga, H, Machida, Y, Nakagawa, M, Yamaguchi, M, Ogawara, Y, Shima, Y, Yamagata, K, Katsumoto, T, Hattori, A, Itoh, M, Seki, T, Nishiya, Y, Nakamura, K, Suzuki, K, Imaoka, T, Suzuki, M, Sampetrean

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

1574

397PDPrecision medicine for patients with primary brain tumours: Molecular screening for cancer treatment optimization (MOSCATO) prospective trial

Boulfoul, W, Baldini, C, Borget, I, Martin Romano, P, Verlingue, L, Lacroix, L, Angevin, E, Rouleau, E, Varga, A, Postel Vinay, S, Gazzah, A, Bahleda, R, Marabelle, A, Ribrag, V, Vuagnat, P, Champiat,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1575

399PDAssociation of systemic inflammation with local tumour characteristics and survival in glioma patients

Mir Seyed Nazari, P, Ay, C, Preusser, M, Riedl, J, Marosi, C, Moik, F, Ricken, G, Hainfellner, J A, Pabinger-Fasching, I, Berghoff, A S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1576

400PDCharacteristics and patterns of care of high-grade IDH-mutant gliomas in elderly patients: A French POLA network study

Montégut, C, Guillamo, J -S, Ducray, F, Dehais, C, Chinot, O, Cohen-Jonathan Moyal, E L, Le Rhun, E, Loiseau, H, Appay, R, Figarella-Branger, D, Delattre, J -Y, Tabouret, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1577

402PDImpact of neurological symptom burden on the survival prognosis in a real-life cohort of patients with non-small cell lung cancer brain metastases

Steindl, A, Yadavalli, S, Gruber, K A, Seiwald, M, Frischer, J M, Gatterbauer, B, Dieckmann, K, Marosi, C, Widhalm, G, Preusser, M, Berghoff, A S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1578

403PDTumour mutational burden and immune infiltrates in primary renal cell carcinoma and matched brain metastases

Steindl, A, Bergen, E S, Alpar, D, Gatterbauer, B, Dieckmann, K, Widhalm, G, Hainfellner, J A, Schmidinger, M, Bock, C, Müllauer, L, Preusser, M, Berghoff, A S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1579

404PRadiographic phenotyping to identify intracranial disseminated recurrence in brain metastases treated with radiosurgery using contrast-enhanced MR imaging

Hsu, C, Kuo, S -H, Wang, W, Chen, T W -W, Lee, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1580

406PResponse assessment of melanoma brain metastases treated by stereotactic radiotherapy or immunotherapy or both: A comparison of RECIST 1.1, RANO and iRANO criteria

Le Rhun, E, Wolpert, F, Fialek, M, Devos, P, Andratschke, N, Reyns, N, Dummer, R, Mortier, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1581

409P3D based texture analysis serving as potential diagnostic factor in discriminating primary central nervous system lymphoma from metastatic brain tumours: A preliminary study

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1582

410PGlobal trends in population-based survival for 303,169 adults diagnosed with glioblastoma in 44 countries during 2000-2014 (CONCORD-3)

Girardi, F, Fersht, N, Coleman, M P, Allemani, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1583

411PSpanish survey of treatment recommendations for elderly patients with glioblastoma

Vaz Salgado, M Á, Rodríguez Sánchez, Á, Fernandez Perez, I, Quintanar, T, Navarro Martin, M, Vieito Villar, M, Cano, J M, Gonzalez, S, Ros, S, Herrero Ibañez, A, Ivars, M A, Lloret, M, Alonso, M, Moya

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 109 KB

2019

1584

412PUpdated analysis of the national registry of nervous system tumours in Spain (RETSINE). RETSINE: National registry of nervous system tumours of the Spanish research group in neuro-oncology (GEINO) and Spanish infrequent and orphan tumours group (GETHI)

Ceballos Lenza, I, Perez Segura, P, Salgado, M A V, del barco, S, Gallego, O, Quintanar, T, Ivars, M A, Fernandez Perez, I, García-Piñon, F, de las Penas Bataller, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1585

416PMeta of classical chemotherapy compared with high-dose chemotherapy combined with autologous stem cell transplantation in newly diagnosed medulloblastoma patients after radiotherapy

Zhang, M, Liu, C, Xue, X, Zhou, H, Wang, W, Wang, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1586

418PMarkers of systemic inflammation correlate with survival prognosis in patients with newly diagnosed brain metastases

Starzer, A M, Deischinger, C, Steindl, A, Mair, M, Widhalm, G, Frischer, J M, Gatterbauer, B, Marosi, C, Dieckmann, K, Preusser, M, Berghoff, A S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1587

419PVenous thromboembolism and intracranial hemorrhage in patients with high-grade glioma

Borges, C, Simões, J, Reis, J, Costa, I, Lemos, C, Soares, P, Silva, R, Carvalho, B, Fernandes, C, Costa, A, Caeiro, C, Sarmento, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1588

420PComprehensive geriatric assessment (CGA) can categorize elderly glioblastoma (GBM) patients into three groups predicting survival: A monoinstitutional study

Bergo, E, Caccese, M, Padovan, M, Bellu, L, Brunello, A, Zagonel, V, Lombardi, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1589

421PTriggering anti-GBM immune response with EGFR-mediated photoimmunotherapy

Kramer-Marek, G, Maczynska, J, Raes, F, Malarz, K, Da Pieve, C, de Mezer, M, Niedbala, M, Harrington, K J, Kaspera, W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1590

422PUpregulation of sFRP3 circulating expression levels correlates survival outcomes in glioblastoma

Bruixola, G, Dolz, S, Sanmartín, E, Fleitas, T, Font de Mora, J, Reynés, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1591

423PCharacterization and pre-clinical modeling of genetic aberrations in pediatric gliomas

Moshe, I P, Zohar, O, Ismer, B, Rousso-Noori, L, Jones, D, Friedmann-Morvinski, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1592

425PCHLOROBRAIN phase IB trial: The addition of chloroquine, an autophagy inhibitor, to concurrent radiation and temozolomide for newly diagnosed glioblastoma

Compter, I, Eekers, D, Hoeben, A, Rouschop, K, Reymen, B J, Ackermans, L, Beckervordersantforth, J, Bauer, N, Anten, M, Wesseling, P, Postma, A, De Ruysscher, D, Lambin, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

1593

426PA phase II clinical trial evaluating the efficacy and safety of apatinib combined with dose-dense temozolomide in recurrent glioblastoma

Wang, Y, Tao, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 7.01 MB

2019

1594

427PPhase 0 trial of ceritinib in brain metastases and recurrent glioblastoma

Mehta, S, Fiorelli, R, Li, J, Bao, X, DeRogatis, A, Pennington-Krygier, C, Kim, S, Sanai, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1595

428PPembrolizumab (Pem) in recurrent high-grade glioma (HGG) patients with mismatch repair deficiency (MMRd): An observational study

Caccese, M, Simonelli, M, Fassan, M, Padovan, M, Persico, P, Bellu, L, Dipasquale, A, Gardiman, M P, Indraccolo, S, Zagonel, V, Lombardi, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1596

430PTolerability of PCV in low grade glioma: A real world experience

Aslam, R, Keogh, R, Hennessy, M, Coyne, Z, Hennessy, B T, Breathnach, O S, Grogan, L, Morris, P G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

1597

431PMolecular EGFR/PD-L1 profile of glioblastoma: Hints for therapeutic strategies

Szopa, W, Czekaj, P, Malarz, K, Mrozek-Wilczkiewicz, A, Plewka, D, Niedbała, M, de Mezer, M, Kramer-marek, G, Kaspera, W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1598

432PRole of Intraoperative MRI (iMRI) in neurosurgery, potential imaging tool for maximizing gross total resection (GTR) rate of CNS tumours

Wadhwa, S, Malhotra, M, Walia, B, Kumar, A, Aggarwal, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1599

433PTumour related impairments of neurocognitive functions in patients with brain metastases

Wen, L, Li, S, Lai, M, Zhen, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1600

434PIs radiation therapy influencing alzheimer’s in brain and head and neck cancers?

Saad, A M M, Alfaar, A S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1601

435PMature treatment results of 120 cases of acoustic neuroma treated with cyberknife at a single institution

Malone, S, Zheng, J, Sinclair, J, Alkherayf, F, Malone, J, Nair, V, Szanto, J, Gratton, J, Gaviolli, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1602

436TiPA phase II/III trial of high-dose, intermittent sunitinib in patients with recurrent glioblastoma: The STELLAR study

Brahm, C G, van Linde, M E, Labots, M, Kouwenhoven, M C M, Sanchez Aliaga, E, Enting, R H, Appelman, A P A, Nuver, J, Walenkamp, A M E, Verheul, H M W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1603

437TiPCNS penetration and preliminary efficacy of sacutizumab govitecan in breast brain metastasis and glioblastoma: A surgical study

Brenner, A J, Floyd, J, Surapaneni, P, Kaklamani, V, Madhusudanan-Kunnuparampil, V, Tiziani, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1604

439OA first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors

Cassier, P, Eberst, L, Garin, G, Courbebaisse, Y, Terret, C, Robert, M, Frenel, J -S, Depil, S, Delord, J -P, Perol, D, Ray-Coquard, I L, Bidaux, A -S, Tabone-Eglinger, S, Gilles-Afchain, L, Treilleux

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

1605

440OPhase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours

Naing, A, Bauer, T, Papadopoulos, K P, Rahma, O, Tsai, F, Garralda, E, Naidoo, J, Pai, S, Gibson, M K, Rybkin, I, Wang, D, McDermott, D F, Fasolo, A, de Miguel, M, Shaheen, M, Jenkins, Y, Kallender, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1606

441OA platform trial with a registry study for rare cancers: MASTER KEY project

Narita, S N, Okuma, H S, Yonemori, K, Sukigara, T, Hirakawa, A, Munakata, W, Okita, N, Shimizu, T, Shibata, T, Kawai, A, Yamamoto, N, Izutsu, K, Muto, M, Akita, H, Baba, E, Nakamura, K, Mano, H, Nishi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1607

443PDGenomic characteristics and predicted ancestry of NTRK1/2/3 and ROS1 fusion-positive tumours from >165,000 pan-solid tumours

Wilson, T R, Sokol, E S, Trabucco, S E, Newberg, J Y, Simmons, B, Riehl, T, Maund, S L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1608

444PDSafety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)

Drilon, A, Cho, B C, Kim, D -W, Lee, J, Lin, J J, Zhu, V, Camidge, R D, Stopatschinskaja, S, Cui, J J, Hyman, D M, Ou, S -H, Shaw, A T, Doebele, R C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1609

445PDDurability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer

Hyman, D M, van Tilburg, C M, Albert, C M, Tan, D S W, Geoerger, B, Farago, A F, Laetsch, T W, Kummar, S, Doz, F, Lassen, U N, DuBois, S G, McDermott, R, Mascarenhas, L, Berlin, J D, Rudzinski, E R, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1610

446PDPhase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours

Govindan, R, Fakih, M G, Price, T J, Falchook, G S, Desai, J, Kuo, J C, Strickler, J H, Krauss, J C, Li, B T, Denlinger, C S, Durm, G, Ngang, J, Henary, H, Ngarmchamnanrith, G, Rasmussen, E, Morrow, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 110 KB

2019

1611

447PDPhase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours

Corcoran, R B, Do, K T, Cleary, J M, Parikh, A R, Yeku, O O, Weekes, C D, Veneris, J, Ahronian, L G, Mauri, G, Seventer, E E Van, Fetter, I J, Gurski, J M, Matulonis, U A, Juric, D, Flaherty, K T, Sul

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1612

448PDGenomic profiling of three pathways through molecular profiling-based assignment of cancer therapy (NCI- MPACT)

Chen, A, Kummar, S, Khan, S S, Moore, N, Rubinstein, L, Coyne, G O’Sullivan, Zhao, Y, Palmisano, A, Williams, P, Datta, V, Sims, D, Karlovich, C, Lih, C -J, Raghav, K P S, Meric-Bernstam, F, Leong, S,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1613

449PDPrecision medicine: Preliminary results from the initiative for molecular profiling and advanced cancer therapy 2 (IMPACT 2) study

Tsimberidou, A M, Hong, D S, Fu, S, Karp, D, Piha-Paul, S A, Kies, M, Ravi, V, Subbiah, V, Patel, S, Tu, S -M, Janku, F, Heymach, J, Johnson, A, Zhao, L, Zhang, J, Berry, D A, Vining, D, Futreal, A, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1614

450PDA phase I study of ATR inhibitor, AZD6738, as monotherapy in advanced solid tumours (PATRIOT part A, B)

Dillon, M, Guevara, J, Mohammed, K, Smith, S A, Dean, E, McLellan, L, Boylan, Z, Spicer, J, Forster, M D, Harrington, K J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1615

451PDUpdated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumours

Stradella, A, Johnson, M L, Goel, S, Chandana, S R, Galsky, M D, Calvo, E, Moreno, V, Park, H, Arkenau, H -T, Cervantes, A, Madrid, L Fariñas, Mileshkin, L, Plummer, R, Evans, J, Horvath, L, Prawira,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1616

452PDSafety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results

Voskoboynik, M, Mileshkin, L, Gan, H, Millward, M, Au-Yeung, G, Meniawy, T M, Kichenadasse, G, Zhang, K, Zhang, M, Mu, S, Lickliter, J D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1617

454PDFirst in human, a phase I study of ISU104, a novel ErbB3 monoclonal antibody, in patients with advanced solid tumours

Kim, S -B, Keam, B, Shin, S, Chae, Y S, Kim, T M, Kim, M -S, Kim, J G, Park, K, Ahn, J S, Park, L C, Lee, E, Juhn, J, Kim, S, Hong, S -B, Ahn, M -J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

1618

455PDFirst-in-human, first-in-class phase I study of MTL-CEBPA, a RNA oligonucleotide targeting the myeloid cell master regulator C/EBP-α, in patients with advanced hepatocellular cancer (HCC)

Sarker, D, Plummer, R, Basu, B, Meyer, T, MA, Y -T, Evans, J, Palmer, D H, Huang, K -W, Chee, C E, Spalding, D, Sodergren, M, Habib, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

1619

456PFirst-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumours

Yunokawa, M, Takahashi, S, Aoki, D, Yonemori, K, Hara, H, Hasegawa, K, Takehara, K, Harano, K, Nomura, H, Noguchi, E, Horie, K, Ogasawara, A, Okame, S, Doi, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1620

457PFirst-in-human study of ABBV-621 in patients (pts) with previously treated sold tumours: Dose-optimization cohorts

Calvo, E, de Jonge, M J A, Rasco, D W, Moreno, V, Chang, Y -W, Chiney, M, Motwani, M, Penugonda, S, Petrich, A M, Ratain, M J, LoRusso, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

1621

458PSafety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours

Wick, W, Tabatabai, G, Schuler, M, Rorhberg, K, Chawla, S P, Janku, F, Schiff, D, Heinemann, V, Narita, Y, Ando, Y, Lenz, H J, Ikeda, M, Genvresse, I, Rentzsch, C, Reschke, S, Cyris, C, Cai, C, Jeffer

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1622

459PProof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer

Hidalgo, M, Bazan-Peregrino, M, Laquente, B, Gallego, R Alvarez, Mato-Berciano, A, Giménez-Alejandre, M, Maliandi, V, Martinez, M C Riesco, Moreno, R, Morell, M, Perez-Carreras, M, Gornals, J, Prados,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1623

460PA phase Ia/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumours

Sarantopoulos, J, Fotopoulos, G, Tsai, F Y -C, Beg, M S, Adjei, A A, Lou, Y, Seetharam, M, Villalona-Calero, M A, Melear, J, Janat-Amsbury, M, Beever, H, Mouritsen, L, Wade, M, Bryan, B V, Bearss, D J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1624

461PFirst in human phase I/IIa study of PEN-866, a heat shock protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumours: Phase I results

Bendell, J C, Falchook, G, Sen, S, Johnson, M L, Jerkovic, G, Sarapa, N, Vilimas, R, Kriksciukaite, K, Mei, L, Wooster, R, Bloss, J, Thomas, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

1625

462PA phase I open-label, non-randomized study of recombinant super-compound interferon (rSIFN-co) in patients with advanced solid tumours

Seet, A, Macapagal, M C F, Ahmad, A, Li, G, Goh, M L, Ng, M C H, Tan, T, Tan, D S W, Choo, S P, Lim, W T D, Tai, D W M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1626

463PEvaluation of pharmacodynamic (PD) biomarkers in advanced cancer patients treated with oxidative phosphorylation (OXPHOS) inhibitor, OPC-317 (OPC)

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1627

465PA phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumours

Harb, W, Patnaik, A, Mahalingam, D, Liu, J, Wen, P Y, Shapiro, G I, Bullock, A J, Juric, D, Zheng, L, Moore, K, Patel, M, Guttendorf, R, Wang, S, Kerstein, K, Berk, G, Cieslewicz, M J, Watnick, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1628

466PInterim results from trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumours

Wang, J, Barve, M, Chiorean, E, LoRusso, P, Courtney, K, Qi, D, Bullington, J, Sardone, M, Chen, J, Brooks, C, Shemesh, S, Bauer, T M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1629

467PPhase I trial of fruquintinib in patients with advanced solid tumors: Results of the dose escalation phase

Wang-Gillam, A, Yeckes-Rodin, H, Kosmo, M A, Stanton, T, Park, H, Songhua, F, Sauter, N P, Kania, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1630

468PA phase I, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-601 in patients with advanced solid tumours

Tolcher, A W, Falchook, G, Bendell, J C, Ungar, D, Boni, J, Chao, G, Patel, M R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

1631

470PA phase I study of tinostamustine in patients (pts) with advanced solid tumours

Mita, A, Loeffler, M, Bui, N, Remmy, D, Mehrling, T, Mita, M, Rimel, B J, Natale, R B, Kummar, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1632

471PLurbinectedin (LUR) in combination with irinotecan (IRI) in patients (pts) with advanced solid tumours

Aix, S Ponce, Flor, M J, Falcón, A, Simón, I Sánchez, Jimenez, E, Coté, G, Nuñez, R, Siguero, M, Insa, M, Cullell-Young, M, Kahatt, C, Zeaiter, A, Paz-Ares, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1633

472PA phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumours

Tan, A C, Seet, A O L, Choo, S P, Tai, D W M, Lam, Y C J, Teng, W T, Lim, C, Lim, K H, Ng, M C H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1634

473PPhase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer

Huijberts, S C F A, van Brummelen, E, van Geel, R, Opdam, F L, Marchetti, S, Steeghs, N, Pulleman, S, Thijssen, B, Rosing, H, Monkhorst, K, Huitema, A D R, Beijnen, J H, Bernards, R, Schellens, J H M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

1635

474PPharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy

Hao, D, Ellis, P M, Laurie, S A, Juergens, R A, Mates, M, Bradbury, P A, Tsao, M, Tehfe, M, Kollmannsberger, C K, Goffin, J R, Wheatley-Price, P, Hilton, J, Robinson, A G, Brown-Walker, P, Tu, D, Smor

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

1636

475PA phase IIa clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumours harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification

Meric-Bernstam, F, Somaiah, N, DuBois, S G, Dumbrava, E E Ileana, Shapiro, G I, Patel, M R, Goel, S, Bauer, T, Pinchasik, D, Annis, A, Aivado, M, Vukovic, V, Saleh, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 97 KB

2019

1637

477PAn international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumours

Jackson, C G C A, Deva, S, Bayston, K, McLaren, B, Barlow, P, Hung, N A, Clarke, K, Segelov, E, Chao, T -Y, Dai, M -S, Yen, H -T, Cutler, D, Kramer, D, Zhi, J, Chan, W -K, Kwan, M -F R, Hung, C -T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 107 KB

2019

1638

478PClinical evaluation of drug-eluting bead transcatheter arterial chemoembolization(D-TACE) versus conventional TACE in treatment of unresectable hepatocellular carcinoma

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1639

479PSafety profile of tepotinib in patients with advanced solid tumors: Pooled analysis of phase I and II data

Decaens, T, Ryoo, B -Y, Falchook, G S, Veillon, R, Doi, T, Yamazaki, K, Hong, D, Qin, S, Scheele, J, Bruns, R, Berghoff, K, Faivre, S, Paik, P P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 108 KB

2019

1640

481PBioavailability of tepotinib: Impact of omeprazole and food

Strotmann, R, Heuer, J, Becker, A, Krebs-Brown, A, Mammasse, N, Yalkinoglu, Ö

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1641

482PTislelizumab exposure-response analyses of efficacy and safety in patients with advanced tumors

Wu, C-Y, Budha, N, Gao, Y, Castro, H, Nkobena, A, Ben, Y, Sahasranaman, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1642

483PPopulation pharmacokinetics of tislelizumab in patients with advanced tumors

Wu, C-Y, Tang, T, Liu, L, Ben, Y, Sahasranaman, S, Gao, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1643

485PGrowth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients

Italiano, A, Nanda, S, Keating, K, Childs, B H, Fellous, M, Drilon, A, Hyman, D M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 108 KB

2019

1644

486PAnalysis of the overall survival and main surrogates used for FDA approvals in solid and haematological malignancies

Kleniewska-Wieczor, M, Mendoza, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1645

487PComparison of intratumoral docetaxel exposure in cancer patients between nanoparticle entrapped docetaxel (CPC634) and conventional docetaxel (Cd): The CriTax study

Eerden, R A G Van, Atrafi, F, van, M A M, Vlieg, Hylckama, Oomen-de Hoop, E, de Bruijn, P, Moelker, A, Lolkema, M P, Rijcken, C J F, Hanssen, R, Eskens, F A, Mathijssen, R H J, Koolen, S L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1646

488PCorrelation of progression free survival-2 and overall survival in solid tumours

Mainwaring, P N, Zhang, L, Mundle, S D, Liu, K, Pollozi, E, Gray, A, Wildgust, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

1647

489PHigh performance of serial tumour biopsies in first in human (FIH) phase I trials

Sato, J, Koyama, T, Shimizu, T, Yamamoto, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1648

490PResponse rates and lesion-level progression patterns of solid tumor patients in an academic phase I program: implications for tumour heterogeneity

Chen, C, Pinto, C, Walmsley, C, Allen, R, Muzikansky, A, Henderson, L, Broudo, M, Wolfgang, J, Fitzgerald, D M, Hong, T, Juric, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1649

491PClinical benefit and response rate in early phase clinical trials: First report from a single-institution study

Marra, A, Ferraro, E, Repetto, M, Nicolò, E, D’Amico, P, Marrucci, E, Caramella, I, Tarantino, P, Morganti, S, Viale, G, Trapani, D, Curigliano, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

1650

492PPatient (pt) selection for immunotherapeutic early-phase clinical trials (ieCTs): A single phase I unit experience

Simonelli, M, Lorenzi, E, Dipasquale, A, Persico, P, Ninatti, G, Giordano, L, Bertossi, M, Santoro, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1651

493PImproving patient selection for immuno-oncology phase I trials: An external validation of five prognostic scores at Claudius Regaud Institute of Toulouse, Oncopôle (IUCT-O)

Darazi, G Al, Martin, E, Delord, J-P, Korakis, I, Betrian, S, Poublanc, M, Ollivier, F, Filleron, T, Gomez-Roca, C A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1652

494PDemonstrating the changing trends in phase I clinical trials

Guo, C, Kelly, R, Desai, J, Tran, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 104 KB

2019

1653

495PParticipation of women in phase I oncology clinical trials

Vidal, L, Berg, R, Yang, Z, Moss, K R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

1654

496PPredictors for early trial discontinuation of patients with cancer participating in phase I clinical trials

Douma, J A J, Buffart, L M, Labots, M, Menke-van der, C W, van Oordt, Houven, Skardhamar, M, Verheul, H M W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1655

497PSafety of tumour treating fields delivery to the torso: Meta analysis from TTFields clinical trials

Grosso, F, Pless, M, Ceresoli, G L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1656

498PProteomic profiling identifies molecular basis of adverse event to BPM31510 exposure: Rationale for comprehensive molecular pharmacodynamics (PD) in phase I clinical trial design

Subbiah, V, Granger, E, Kiebish, M, Zinner, R, Hong, D S, Miller, G, Zhang, L, Vemulapalli, V, Rodrigues, L, Narain, N, Sarangarajan, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1657

499PIdentification of first-in-class, naturally occurring LAG3 checkpoint inhibitor

Bratslavsky, G, Tsimafeyeu, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1658

500PAre epigenetic therapies modifying sensitivity to conventional chemotherapy?

Bizot, A, Romano-Martin, P, Baldini, C, Champiat, S, Varga, A, Gazzah, A, Bahleda, R, Vuagnat, P, Hollebecque, A, Michot, J -M, Ribrag, V, Massard, C, Vinay, S Postel

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

1659

502PBasic selective estrogen receptor degraders (B-SERDs) in combination with novel BET inhibitors in ER+ breast cancer

Xiong, R, Li, Y, Zhao, J, Huang, F, Shen, Z, Lu, Y, Gutgesell, L, Tonetti, D A, Thatcher, G R J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1660

504PAVID200 neutralizes TGF-beta1 and -beta3, the principal immunosuppressive TGF-beta isoforms overexpressed by tumours, and sensitizes tumours to immune checkpoint inhibitors

Gruosso, T, O’Connor, M, Denis, J -F, Figueredo, R, Koropatnick, J, Tremblay, G, Tikhomirov, I A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1661

505PHigh NAMPT expression and anti-tumour activity of NAMPT inhibitor in adult T-cell leukemia/lymphoma

Kozako, T, Ohsugi, T, Uchida, Y -I, Yoshimitsu, M, Ishitsuka, K, Kato, N, Sato, K, Aikawa, A, Honda, S-I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1662

506PTPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers

Drilon, A, Rogers, E, Zhai, D, Deng, W, Zhang, X, Lee, D, Ung, J, Whitten, J, Zhang, H, Liu, J, Hu, T, Zhuang, H, Lu, Y, Huang, Z, Graber, A, Zimmerman, Z, Xin, R, Cui, J J, Subbiah, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

1663

507PIn vivo evaluation of cisplatin-loaded PEG-PCL block copolymeric nanoparticles for anticancer drug delivery

Yen, Y, Yu, L, Qian, H, Wang, L, Liu, B, Li, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1664

508PInhibition of Rspo-Wnt pathway facilitates checkpoint blockade therapy by anti-RSPO3 antibody (DBPR117)

Hsu, J T-A, Hung, H -C, Chen, C -T, Yen, W -C, Chang, T -Y, Chao, P -K, Chin-Ting, H, Yen, K -J, Tsai, Y -R, Chang, C -Y, Fang, M -Y, Lai, Y -L, Shih, J C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1665

509TiPA phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours

Krauss, J, Eigentler, T, Schreiber, J, Weishaupt, C, Terheyden, P, Heinzerling, L, Mohr, P, Weide, B, Ochsenreither, S, Gutzmer, R, Becker, J C, Kiecker, F, Funkner, F, Heidenreich, R, Kays, S-K, Klin

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1666

510TiPPhase I/II study of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory haematological malignancies or solid tumours

Carneiro, B, Cavalcante, L, Munster, P, de Souza, A, Safran, H P, Giles, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1667

513PThe expression of versican and its role in pancreatic neuroendocrine tumour

Sun, Z, Gao, H, Cheng, Y, Bai, C, Chen, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1668

514PCharacteristics of patients with thyroid carcinoma in the United States

El-Habashy, D M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1669

515PThe discrimination of pituitary adenomas and craniopharyngioma on MRI: From image features to texture features

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

1670

516PProportion of peripheral lymphocyte subsets correlates with the progression-free survival and metastatic status of pancreatic neuroendocrine tumour patients

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

1671

517PImmunohistochemical expression of ER-α and PR in papillary thyroid carcinoma

Elkhouly, E A, Abdelraziq, E, Rageh, T, Serag, M, Abdou, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1672

518PSILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus

De Jesus-Acosta, A, Crespo Herrero, G, Gómez-Dorronsoro, M L, Alonso, V, Riesco Martinez, M C, Custodio, A, Lopez, C, Benavent, M, Carmona Bayonas, A, Jimenez-Fonseca, P, Llanos, M, López De San Vicen

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1673

519PCarcinoid heart disease (CHD): the CRUSOE-NETs, a prospective cohort study from the French group of endocrine tumours (GTE)

Dekeister Geoffroy, K, Francois, L, Walter, T, Hentic Dhome, O, Cachier, A, Cadiot, G, Nazeyrollas, P, Afchain, P, Ederhy, S, Lepage, C, Eicher, J -C, Coriat, R, Cabanes, L, Baudin, E, Dominguez, S, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1674

520PSafety of high doses of somatostatin analogs in well differentiated NENs in elderly

Cani, M, Incorvaia, L, Fanale, D, De Luca, I, Gelsomino, F, Ibrahim, T, Pusceddu, S, Riccardi, F, Tafuto, S, Lamberti, G, Faggiano, A, La salvia, A, Albertelli, M, Massironi, S, Rinzivillo, M, butturi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 100 KB

2019

1675

512OMalignant non-adrenal paraganglioma (mPara) and adrenal pheochromocytoma (mPheo) a comparative comprehensive genomic profiling (CGP) study

Bratslavsky, G, Sokol, E S, Necchi, A, Shapiro, O, Jacob, J, Liu, N, Elvin, J A, Vergilio, J-A, Killian, J K, Ngo, N, Lin, D, Ramkissoon, S, Severson, E, Ali, S M, Schrock, A B, Chung, J, Reddy, P, Al

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 105 KB

2019

1676

523OFOxTROT: An international randomised controlled trial in 1053 patients evaluating neoadjuvant chemotherapy (NAC) for colon cancer. On behalf of the FOxTROT Collaborative Group

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

1677

524ONext-generation sequencing (NGS) in metastatic colorectal cancer (mCRC): Novel mutated genes and their effect on response to therapy (Alliance)

Innocenti, F, Rashid, N, Wancen, M, Ou, F-S, Qu, X, Denning, S, Bertagnolli, M, Blanke, C D, Venook, A, Kabbarah, O, Lenz, H J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 108 KB

2019

1678

526PDTRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study

Nakamura, Y, Okamoto, W, Kato, T, Hasegawa, H, Kato, K, Iwasa, S, Esaki, T, Komatsu, Y, Masuishi, T, Nishina, T, Nomura, S, Fukui, M, Matsuda, S, Sato, A, Fujii, S, Odegaard, J I, Olsen, S, Yoshino, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

1679

528PDImpact of clonality and DNA repair mutations on plasma tumour mutation burden (pTMB) and immunotherapy efficacy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) in CCTG CO.26

Loree, J M, Jonker, D J, Feilotter, H, Kennecke, H F, Brohawn, P Z, Banks, K, Quinn, K, Tu, D, O’Callaghan, C, Chen, E X

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

1680

529PDEarly identification of treatment effect by methylated circulating tumour DNA in metastatic colorectal cancer

Thomsen, C B, Hansen, T F, Andersen, R F, Jensen, L H, Jakobsen, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1681

530PDAssociation between transit-amplifying signature and outcomes of patients treated with anti-epidermal growth factor receptor (EGFR) therapy in colorectal cancer

Fontana, E, Nyamundanda, G, Cunningham, D, Jonker, D J, Siu, L L, Tu, D, Sclafani, F, Eason, K V, Ragulan, C, Hulkki-Wilson, S, Loree, J M, Giordano, M, Lawrence, P V, Shapiro, J, Cremolini, C, Starli

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1682

531PDSequential RAS mutation testing in cfDNA in RAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pt) treated with panitumumab (P) and chemotherapy (CT) in first-line (1L): PERSEIDA study

Valladares-Ayerbes, M, García-Alfonso, P, Luengo, J Muñoz, Cáceres, P Pimentel, Viéitez, J M, Cruz-Hernández, J J, Llanos, M, Girón, C Garcia, Cirera, L, Vila, A Lloansí

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1683

532PDPre-operative FOLFOX chemotherapy in advanced colon cancer: Pathology analysis of the FOxTROT trial

West, N, Murakami, K, Magill, L, Gray, R, Handley, K, Seymour, M T, Morton, D, Quirke, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1684

533PDBACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study

Mettu, N B, Twohy, E, Ou, F-S, Halfdanarson, T R, Lenz, H J, Breakstone, R, Boland, P M, Crysler, O, Wu, C, Grothey, A, Nixon, A B, Bolch, E, Niedzwiecki, D, Fruth, B, Schweitzer, B, Elsing, A, Hurwit

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1685

534PUpdated data of epitopes-HPV02 trial and external validation of efficacy of DCF in prospective epitopes-HPV01 study in advanced anal squamous cell carcinoma. Pooled analysis of 115 patients

Kim, S, Meurisse, A, Stouvenot, M, Jary, M, Hon, T Nguyen Tan, Francois, E, Buecher, B, Andre, T, Samalin, E, Boulbair, F, Bari, B De, Almotlak, H, Klajer, E, Calcagno, F, Chatillon, E, Spehner, L, Ja

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 19.31 MB

2019

1686

535PPre-specified pilot analysis of a randomised pilot/phase II/III trial comparing standard dose vs dose-escalated concurrent chemoradiotherapy (CRT) in anal cancer (PLATO-ACT5)

Gilbert, A, McParland, L, Webster, J, Bell, S, Copeland, J, Adams, R A, Harrison, M, Muirhead, R, Renehan, A, Sebag-Montefiore, D, Hawkins, M A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

1687

537PTiming to achieve complete response (CR) after definitive chemoradiotherapy (ChRT) in patients with squamous cell carcinoma of the anal (SCCAC) with and without HIV infection: A multicenter retrospective study

Camandaroba, M P G, Iseas, S, Taboada, R G, Oliveira, C P, Mauro, C D C, Xerfan, M P, Barros, M, de Jesus, V H F, Felismino, T C, Mello, C A, Riechelmann, R P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

1688

538PPlanned organ preservation for T2 T3 M0 rectal adenocarcinoma: A possible option using chemoradiotherapy (CRT) and contact X-ray brachytherapy (CXB). A French multicenter study

Gérard, J-P, Benezery, K, Barbet, N, Montagne, L, Hannoun-Levi, J-M, Francois, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1689

540PA phase Ib study of E7046 (AN0025) in combination with radiotherapy/chemoradiotherapy (RT/CRT) in preoperative treatment of rectal cancer

Wyrwicz, L, Saunders, M P, Hall, M, Ng, J, Prasad, V Bhagawati, Lautermilch, N, Rashford, M M, Jin, J, Formenti, S, Glynne-Jones, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1690

541PUpfront radical surgery with total mesorectal excision (TME) versus preoperative chemoradiotherapy followed by TME in clinical stage II/III patients with rectal cancer: A propensity score analysis

Ham, A, Kim, H S, Chang, J S, Shin, S J, beom, S-H, Koom, W S, Kim, T, Hur, H, Min, B S, Lee, K Y, Kim, N K, Lim, J S, Ahn, J-B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1691

542PNeoadjuvant chemoradiotherapy with/without lateral lymph node dissection for low rectal cancer: Which patients can benefit?

Nishizaki, D, Hida, K, Sumii, A, Sakai, Y, Konishi, T, Akagi, T, Yamaguchi, T, Akiyoshi, T, Fukuda, M, Yamamoto, S, Maruyama, S, Okajima, M, Miyakura, Y, Okamura, R, Arizono, S, Yamamoto, M, Kawada, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1692

544PFeasibility of robot-assisted surgery in elderly patients with rectal cancer

Su, W-C, Huang, C-W, Ma, C-J, Po-Jung, C, Tsai, H-L, Chang, T-K, Chen, Y-C, Li, C-C, Yeh, Y-S, Wang, J-Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1693

545PFeasibility of chemoradiotherapy in rectal cancer patients with peritumoral abscesses and fistulas: A case-control non-inferiority trial

Ivanov, V, Gordeyev, S, Mamedli, Z, Chernykh, M, Perevoschikov, A, Surayeva, Y, Bulychkin, P, Haqverdiyeva, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1694

546PDifferential of the nutritional index before and after neoadjuvant chemoradiotherapy as a prognostic factor of recurrence in patients with locally advanced adenocarcinoma of the rectum

Navia-Ortuño, L, Díaz, M C, Ramos Ramirez, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1695

547PShort-term clinical outcomes of robotic-assisted total mesorectal excision in rectal cancer after concurrent chemoradiotherapy

Chen, P, Wang, J-Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

1696

548PLocal immune status in cancer cell nests can be a predictor of survival for rectal cancer with neoadjuvant radiotherapy

Lin, X, Lin, F, Zhuang, Q, Zhang, X, Huang, Y, Tang, L, Li, J, Junxin, W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1697

549PImpact of concomitant medications on disease free survival (DFS) and overall survival (OS) in patients from the PETACC8 study

Clémence, B, Taieb, J, Boulin, M, Malicot, K Le, Dourthe, L M, Avisse, B, Laplaige, P, Borel, C, Arsene, D, Kikolski, F, Denis, B, Geoffroy, P, Coriat, R, Piot, G, Lepage, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1698

550PUpdated results of NORDIC 8, a randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer

Pfeiffer, P, Bjerregaard, J K, Qvortrup, C, Sorbye, H, Glimelius, B, Kersten, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1699

551PClinical impact of mucinous and poorly differentiated tumours on the outcome of patients with stage II colon cancer: A TOSCA subgroup analysis

Rosati, G, Galli, F, Cantore, M, Lonardi, S, Banzi, M, Zampino, M G, Mattioli, R, Pella, N, Ronzoni, M, Bartolomeo, M Di, Tamberi, S, Marchetti, P, Bozzarelli, S, Corsi, D C, Bochicchio, A M, Artioli,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1700

552PExercise improved adjuvant treatment completion rates and treatment-related toxicities in colorectal cancer: A prospective pilot study

Kim, H J, Shim, Y J, Kim, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1701

553PBevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (CC): Updated analysis of stage II disease from the AVANT phase III randomized trial by the GERCOR group

Gramont, A De, Henriques, J, Baruch, B, Kim, T W, Martinez-Villacampa, M, Gallego-Plazas, J, Cervantes, A, Shim, K, Jonker, D J, Guerin-Meyer, V, Mineur, L, Banzi, M, Dewdney, A, Dejthevaporn, T Siris

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1702

554PMulticenter validation of the postoperative carcinoembryonic antigen combined prognostic model for stage III colon cancer

Zhu, J, Liu, Y, Zhang, R, Fan, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1703

555PImpact of the IDEA study on clinical practice for stage III colon cancer patients: A French GERCOR - FFCD - GI UNICANCER national survey

Ouali, K, Cohen, R, Turpin, A, Neuzillet, C, Rousseau, B, Garcia-Larnicol, M-L, Tournigand, C, Samalin, E, Taieb, J, André, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1704

556PSex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer

Falk, P, Severin, M, Guren, M Gronlie, Österlund, P, Hofsli, E, Giwercman, A, Eberhard, J, Sorbye, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1705

557PLoss of CDX-2 expression is an independent poor prognostic biomarker in colorectal cancer

Korphaisarn, K, Pongpaibul, A, Sukhokanjanachusak, K, Akewanlop, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1706

558PRobot-assisted natural orifice specimen extraction surgery for radical resection of colorectal cancer

Niu, Z, Wei, Y, Feng, Q, Zhu, D, Xu, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

1707

559PBevacizumab as adjuvant treatment for colon cancer: Updated results from the AVANT phase III study by the GERCOR group

André, T, Vernerey, D, Im, S -A, Bodoky, G M, Buzzoni, R, Reingold, S, Rivera, F, McKendrick, J, Scheithauer, W, Geva, R, Fountzilas, G, Yong, W P, Isaacs, R, Österlund, P, Liang, J -T, Creemers, G -J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1708

560PReal world data on adjuvant chemotherapy for high-risk stage II colorectal cancer: The role of tumour side

de Carvalho, C S Araujo, Moniz, C M V, Watarai, G Y, Crespo, J A R, Nogueira, P V D S, Martinez, J K, Moraes, P M G D, Bonadio, R R D C C, Braghiroli, M I F M, Sabbaga, J, Hoff, P M G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1709

561POncological outcome and safety of bevacizumab (BV) therapy in patients with occlusive colon cancer and self-expandable metal stents (SEMS)

Pacheco-Barcia, V E, Mondejar, R, Martinez-Saez, O, Munoz, F Longo, Monteagudo, J A Moreno, Rogado, J, Donnay, O, Santander, C, Mena, A Carrato, Bosch, R Colomer

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1710

562PActive chronic hepatitis B increases the risk of liver metastasis of colorectal cancer: A retrospective clinical study of 7187 consecutive cases of newly diagnosed colorectal cancer

Zhao, L, Song, L, Cao, J, Yang, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1711

563PComprehensive evaluation of recurrence risk (CERR) score for colorectal liver metastases: Development and validation

Ye, W, Chen, Y, Xu, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1712

564PBRAF-mutated colorectal metastases: What is the benefit of liver surgery? Results from a cohort of 91 patients

Javed, S, Benoist, S, Fouchardiere, C De La, Truant, S, Sefrioui, D, Galais, M P, Hautefeuille, V, Artru, P, Guimbaud, R, Cohen, R, Lievre, A, Edeline, J, Bachet, J-B, Gelli, M, Herrero, A, Marchese,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1713

565PThe smallest colorectal liver metastasis size as a prognosis factor after laparoscopic liver resection

Cervantes, B, Gayet, B, Frosio, F, Tabchouri, N, Bennamoun, M, Alexandra, N, Louvet, C, Fuks, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1714

566PValidation of GAME score risk groups in resected colorectal cancer liver metastases and the prognostic relevance of KRAS, NRAS and BRAF mutation analysis

Martin-Cullell, B, Fumagalli, C, Teres, R, Melo, P Gallardo, Garcia, A Sebio, Manrique, A C Virgili, Mirallas, O, Cabús, S Sánchez, Molina, V, Szafranska, J, Bravo, D Paez Lopez

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1715

567PPredictive factors and survival outcomes with stereotactic body radiation therapy in treatment of oligometastases in colorectal cancer

Pareek, V, Bhalavat, R, Chandra, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 97 KB

2019

1716

568PFactors of importance in procuring tumoroids from colorectal liver metastasis biopsies for precision medicine

Jensen, L H, Dam, C, Hagel, G, Vagn-Hansen, C, Harling, H, Havelund, B M, Jakobsen, A, Lindebjerg, J, Rafaelsen, S R, Thastrup, O, Hansen, T F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1717

569PFUSAFE individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting grade 4-5 fluoropyrimidine (FP) toxicity

Etienne-Grimaldi, M-C, Cozic, N, Boyer, J-C, Boige, V, Diasio, R B, Taieb, J, Meulendijks, D, Palles, C, Zanger, U, Deenen, M, Largiader, C, Boisdron-Celle, M, Marinaki, A, Jennings, B, Gross, E, Thom

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1718

570PTreatments (tx) after progression to first-line FOLFOXIRI + bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and TRIBE-2 studies by GONO

Rossini, D, Lonardi, S, Antoniotti, C, Santini, D, Tomasello, G, Aprile, G, Moretto, R, Prete, A A, Granetto, C, Urbano, F, Borelli, B, Zaniboni, A, Randon, G, Buonadonna, A, Ritorto, G, Barbara, C, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

1719

571PRandomized phase III study of sequential treatment with capecitabine or 5-fluorouracil (FP) plus bevacizumab (BEV) followed by the addition with oxaliplatin (OX) versus initial combination with OX+FP+ BEV in the first-line chemotherapy for metastatic colorectal cancer: The C-cubed study

Nagasaka, T, Inada, R, Ojima, H, Noura, S, Tanioka, H, Munemoto, Y, Shimada, Y, Ishibashi, K, Shindo, Y, Kagawa, Y, Tomibayashi, A, Okamoto, K, Tsuji, A, Tsuji, Y, Yamaguchi, S, Sawaki, A, Mishima, H,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 98 KB

2019

1720

572PEarly tumour shrinkage (ETS), depth of response (DpR) and associated survival outcomes in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC) classified according to Köhne prognostic category: Retrospective analysis of the panitumumab (Pmab) PRIME study

Sartore-Bianchi, A, Peeters, M, Geissler, M, Taieb, J, García-Alfonso, P, Price, T, Burdon, P, Zhang, Y, Koehne, C-H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1721

574PA metabolomic recurrence score for risk-stratification of elderly patients (pts) with early colorectal cancer (eCRC)

Donato, S Di, Vignoli, A, Mori, E, Tenori, L, Malorni, L, Cantafio, S, Mottino, G, Becheri, D, Mccartney, A, Biagioni, C, Monte, F Del, Leo, A Di, Luchinat, C, Biganzoli, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1722

575PRAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first-line treatment in metastatic colorectal cancer

Martini, G, Elez, E, Mancuso, F M, España, M A Gomez, Caratù, G, Matito, J, Martinez, G Argiles, Margalef, N Mulet, Morales, M J Ortiz, Montana, F J Ros, Garcia, A, Comas, R, Vivas, C Santos, Perez-Lo

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1723

577PIntraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): A randomized, multicenter, prospective, phase III trial

Zhang, R, Wu, X-J, Wan, D, Lin, J, Ding, P, Lei, J, Lu, Z, Li, L, Chen, G, Kong, L, Wang, F, Zhang, D, Fan, W, Jiang, W, Zhou, W, Li, C, Li, Y, Li, X, Pan, Z

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1724

578PPrognostic and predictive role of body mass index (BMI) in metastatic colorectal cancer (mCRC): A pooled analisys of TRIBE and TRIBE-2 studies by GONO

Dell’Aquila, E, Rossini, D, Stellato, M, Bergamo, F, Aprile, G, Morano, F, Intini, R, Fea, E, Ronzoni, M, Libertini, M, Buonadonna, A, Fanchini, L, Marcucci, L, Maiello, E, Marmorino, F, Boccaccino, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

1725

579PDrug holidays and overall survival in patients treated for metastatic colorectal cancer

Garattini, S K, Bonotto, M, Basile, D, Porcu, L, Ongaro, E, Gerratana, L, Cortiula, F, Pelizzari, G, Parnofiello, A, bertoli, E, Corvaja, C, Lisanti, C, Casagrande, M, Iacono, D, Cardellino, G G, Buon

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1726

580PQuality of life during 1st-line FOLFOXIRI+/- panitumumab in RAS wild-type metastatic colorectal cancer: Results from the randomized VOLFI trial (AIO KRK-0109)

Geissler, M, Klingler, T, Modest, D, Knorrenschild, J Riera, Ettrich, T J, Kanzler, S, Heinemann, V, Held, S, Martens, U M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1727

581PA biomarker combination indicating resistance to FOLFOX plus bevacizumab in metastatic colorectal cancer: Results of phase I of the PERMAD trial

Seufferlein, T, Ettrich, T J, Stein, A, Arnold, D, Prager, G, Kasper, S, Niedermeier, M, Mueller, L, Kubicka, S, König, A-O, Büchner-Steudel, P, Wille, K, Kestler, A, Hann, A, Perkhofer, L, Berger, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

1728

582PMicrosatellite Instability (MSI) status and prognosis in colorectal cancer: Meta-analysis

Toh, J, Spring, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1729

583PChoosing the right strategy based on individualized treatment effect predictions: Combination versus sequential chemotherapy in patients with metastatic colorectal cancer

Koopman, M, Kwakman, J J, van Kruijsdijk, R C M, Elias, S G, Seymour, M T, Meade, A M, Visseren, F, Punt, C J A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1730

584PNoninferiority on overall survival of every-2-weeks vs weekly schedule of cetuximab for first-line treatment of RAS wild-type metastatic colorectal cancer

Kasper, S, Cheng, A-L, Overkamp, F, Rouyer, M, Foch, C, Lamy, F-X, Esser, R, Messinger, D, Rothe, V, Chen, W, Brodowicz, T, Zielinski, C C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

1731

585PPOLAF study: Efficacy and safety of FOLFIRI/aflibercept in a phase II trial in patients with metastatic colorectal cancer: Results of plasmatic prognostic and predictive markers

Fernandez, M E Elez, Gómez-España, M A, Grávalos, C, García-Alfonso, P, Rodríguez, B, Losa, F, Ales-Diaz, I C, Suarez, B Graña, Toledano, M, Valladares-Ayerbes, M, Marques, E Polo, Fernandez, M Salgad

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1732

586PThe accuracy of the clinical PCI score in patients with peritoneal carcinomatosis of colorectal cancer

Boer, N L De, Brandt-Kerkhof, A, Madsen, E, Verhoef, K, Burger, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

1733

587PThe impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC)

Kawakami, T, Masuishi, T, Kawamoto, Y, Go, H, Shirasu, H, Kato, K, Kumanishi, R, Sawada, K, Yamamoto, K, Yuki, S, Komatsu, Y, Yasui, H, Muro, K, Yamanaka, T, Yamazaki, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1734

588PEfficacy and safety of FOLFIRI/Aflibercept (FA) in elderly population with mCRC after failure of oxaliplatin-based chemotherapy

Lago, N Martinez, Campos, M Carmona, Villarroel, P Gonzalez, Fernandez, M Salgado, la, J De, Gomez, Camara, Reinoso, C Romero, Castiñeiras, A Cousillas, Insua, Y Vidal, Mendez, J C Mendez, Rendo, C Re

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1735

589PFluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: Preliminary data from the prospective observational CHECKPOINT trial (NCT02665312)

Lombardi, P, Aimar, G, Depetris, I, Bonzano, A, Filippi, R, Fenocchio, E, Quarà, V, Milanesio, M, Ferraris, R, Cagnazzo, C, Neia, C Peraldo, Basiricò, M, Cavalloni, G, Aglietta, M, Leone, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

1736

590PComparable survival outcome between Thai patients with sporadic young adult and adult onset colorectal cancer

Sukhokanjanachusak, K, Korphaisarn, K, Akewanlop, C, Pongpaibul, A, Nimmannit, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1737

592PUndetectable RAS mutant clones in plasma: Possible implication for therapy and prognosis in the patient with RAS mutant metastatic colorectal cancer?

Bouchahda, M, Karaboué, A, Saffroy, R, Hamelin, J, Bosselut, N, Lemoine, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

1738

593PDihydropyrimidine dehydrogenase (DPD) determination prior the administration of medicines containing fluorouracil: A single Spanish hospital experience

Rambla, M D Mediano, Marcos, J A, Carrillo, R, Espinosa, M, Sanchez, F, Alvardado, M D, Rendon, L, Zoilo, J J Reina, Albero, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1739

594PDifferences in survival between right and left-sided colorectal cancer (CRC) in every stage, a CARESS-CCR group study

Alcaide-Garcia, J, Rivas-Ruiz, F, Quintana, J M, Perez-Ruiz, E, Redondo, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1740

595PQuality of life (QoL) in patients with aflibercept (AFL) and FOLFIRI for metastatic colorectal cancer (mCRC): Interim analysis with focus on mutational status of the non-interventional study QoLiTrap (AIO-LQ-0113)

von Moos, R, Scholten, F, Derigs, H-G, Grünberger, B, Thaler, J, Hofheinz, R D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

1741

596PThe cost of adverse event management in patients with RAS wild-type metastatic colorectal cancer treated with first-line cetuximab and panitumumab: An Italian healthcare payer perspective

Patterson, K, Bhattacharyya, S, Personeni, N, Gebbia, V, Novelli, P, Matteo, S Di, Colombo, G, Pescott, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1742

597PMeta-analysis of KRAS mutation as prognostic factor in patients (pts) with resection of colorectal (CRC) liver metastases: Tumour burden and Sidedness analysis

Luca, M R, Angel, M, Esteso, F, Mariani, J, Loria, F Sanchez, Chacon, M, Connor, J M Ó

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1743

598PClinical implications of regorafenib-induced hypothyroidism in metastatic colorectal cancer refractory to standard therapies: A prospective evaluation

Kim, J H, Kim, J E, Kim, S Y, Kim, K-P, Hong, Y S, Kim, T W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1744

599PClinical impact of BRAF V600E mutations in patients (pts) with resectable solitary colorectal liver metastases (CRLM)

Kobayashi, S, Takahashi, S, Kojima, M, Sugimoto, M, Konishi, M, Ito, M, Yoshino, T, Gotohda, N, Taniguchi, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1745

600PTrifluridine/tipiracil in metastatic colorectal cancer: An updated multicentre real-world analysis on efficacy, safety and predictive factors

Stavraka, C, Pouptsis, A, Synowiec, A, Aggelis, V, Satterthwaite, L, Khan, S, Chauhan, M, Holden, C E, Young, S, Karampera, C, Martinou, M, Mills-Baldock, T, Baxter, M, Eccles, B K, Iveson, T J, Shiu,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1746

601PCorrelation between p53 expression and clinical outcome in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan-cetuximab

Lai, E, Schirripa, M, Puzzoni, M, Loupakis, F, Ziranu, P, Pretta, A, Giampieri, R, Mariani, S, Liscia, N, Soro, P, Pusceddu, V, Astara, G, Impera, V, Camera, S, Musio, F, Zaniboni, A, Fassan, M, Lonar

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1747

602PSafety and effectiveness of aflibercept + FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC): OZONE secondary analyses

Chau, I, Fakih, M G, García-Alfonso, P, Linke, Z, Ruiz-Casado, A, Marques, E Polo, Picard, P, Celanovic, M, Cartwright, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1748

603PA phase Ib study of the safety and efficacy of atezolizumab (atezo) + bevacizumab (bev) + cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)

Bendell, J, Lieu, C, Raghav, K P S, Argilés, G, Cubillo, A, Qu, X, Yan, Y, Merchant, M, Zeuner, H, Gallo, J D, Segal, N H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

1749

604PDevelopment and validation of a metastasis-associated immune prognostic model for concurrent metastatic colorectal cancer

Luo, Z, Zhao, H, Li, Z, Mao, R, Zhao, J, Ge, D, Zhang, F, Zhou, Y, Chen, X, Cai, J, Bi, X

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1750

605PPrognostic role of blood cell count-based immuno-inflammatory parameters in the Valentino trial

Fuca, G, Guarini, V, Corallo, S, Lonardi, S, Raimondi, A, Peverelli, G, Rimassa, L, Antoniotti, C, Murialdo, R, Zaniboni, A, Sartore-Bianchi, A, Tomasello, G, Racca, P, Clavarezza, M, Adamo, V, Prisci

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

1751

606PEvaluation of safety, immunogenicity and preliminary efficacy of PolyPEPI1018 vaccine in subjects with metastatic colorectal cancer (mCRC) with a predictive biomarker

Hubbard, J, Cremolini, C, Graham, R P, Moretto, R, Mitchell, J, Wessling, J, Tőke, E R, Csiszovszki, Z, Lorincz, O, Molnar, L, Somogyi, E, Megyesi, M, Pántya, K, Toth, J, Pales, P, Miklos, I, Falcone,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1752

607PMorphology of tumour-associated macrophages dictates the prognosis of patients with colorectal liver metastases

Donadon, M, Tommaso, L Di, Cortese, N, Soldani, C, Franceschini, B, Carriero, R, Barbagallo, M, Rigamonti, A, Anselmo, A, Colombo, F, Maggi, G, Roncalli, M, Torzilli, G, Mantovani, A, Marchesi, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1753

608PPembrolizumab (pembro) plus mFOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC): KEYNOTE-651 cohorts B and D

Kim, R, Chaves, J, Kavan, P, Fakih, M, Kortmansky, J, Spencer, K, Wong, L, Tehfe, M, Li, J J, Lee, M, Mayo, C, Marinello, P, Chiorean, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

1754

610PPrognostic significance of circulating regulatory T lymphocytes (Tregs) in patients with metastatic colorectal cancer (mCRC) under treatment with first-line chemotherapy

Zafeiriou, Z, Koutoulaki, A, Koinis, F, Aggouraki, D, Vardakis, N K, Vetsika, E K, Kotta, K, Mavroudis, D, Georgoulias, V, Kotsakis, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1755

611PThe SAFFO study: Sex-related prognostic role and cut-oFf deFinition of monocyte-to-lymphocyte ratio (MLR) in metastatic colOrectal cancer

Lisanti, C, Basile, D, Garattini, S K, Parnofiello, A, Corvaja, C, Cortiula, F, Pelizzari, G, Cattaneo, M, Andreotti, V J, Bertoli, E, Ongaro, E, Iacono, D, Foltran, L, Casagrande, M, Miolo, G, Cardel

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

1756

612PSPICE, a phase I study of enadenotucirev in combination with nivolumab in tumours of epithelial origin: Analysis of the metastatic colorectal cancer patients in the dose escalation phase

Fakih, M G, Wang, D, Harb, W, Rosen, L, Mahadevan, D, Berlin, J D, Basciano, P, Brown, R, Arogundade, O, Cox, C, Genova, G Di, Krige, D, McElwaine-Johnn, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1757

613PPhase I/II study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer

Halama, N, Prüfer, U, Froemming, A, Beyer, D, Eulberg, D, Jungnelius, J U, Mangasarian, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1758

614PMicrosatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer

Okamoto, W, Nakamura, Y, Shiozawa, M, Komatsu, Y, Denda, T, Hara, H, Kagawa, Y, Narita, Y, Kawakami, H, Esaki, T, Nishina, T, Izawa, N, Ando, K, Moriwaki, T, Kato, T, Nagashima, F, Satoh, T, Nomura, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

1759

615PPhase II trial of trametinib (T) and panitumumab (Pmab) in RAS/RAF wild type (wt) metastatic colorectal cancer (mCRC)

Alshammari, K, Aung, K L, Zhang, T, Albiruni, A R R, Serra, S, Stockley, T, Wang, L, Nguyen, J, Spreafico, A, Hansen, A R, Zwir, D, Siu, L L, Bedard, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

1760

616PMicrosatellite instability and immunogenicity in colorectal cancer: Do resident memory Tcells (Trm) play a role in colorectal cancer?

Toh, W T, Toh, J, Ferguson, A, Spring, K, Mehajan, H, Palendira, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1761

618PUpdated survival analysis of the randomized phase III trial comparing S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (SALTO) by the Dutch colorectal cancer group

Kwakman, J J, Werkhoven, E Van, Simkens, L H, van Rooijen, J M, van de Wouw, A, Tije, A J Ten, Creemers, G-J, Hendriks, M P, Los, M, van Alphen, R, Polee, M B, Muller, E W, der Velden, A Van, Voorthui

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1762

619PJFMC51-1702-C7: Phase II study investigating efficacy and safety of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) in patients (pts) with metastatic colorectal cancer (mCRC) refractory or intolerant to standard chemotherapies

Kazama, K, Nakamura, M, Tanaka, R, Ojima, H, Makiyama, A, Matsuhashi, N, Kagawa, Y, Okuda, H, Asayama, M, Yuasa, Y, Negoro, Y, Mushiake, H, Manaka, D, Oba, K, Yoshino, T, Yoshida, K, Maehara, Y, Yamaz

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1763

620PBevacizumab plus trifluridine/tipiracil in elderly patients with previously untreated metastatic colorectal cancer (KSCC 1602): A single-arm, phase II study

Makiyama, A, Oki, E, Miyamoto, Y, Kotaka, M, Kawanaka, H, Miwa, K, Kabashima, A, Noguchi, T, Yuge, K, Kashiwada, T, Shimokawa, M, Saeki, H, Akagi, Y, Baba, H, Mori, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1764

621PBiweekly TAS-102 and bevacizumab as a third-line chemotherapy for metastatic colorectal cancer: A phase II multicenter clinical trial (TAS-CC4 study)

Yoshida, Y, Yamada, T, Matsuoka, H, Hirata, K, Kuramochi, H, Kosugi, C, Takahashi, M, Fukazawa, A, Sonoda, H, Matsuda, A, Watanabe, T, Koizumi, M, Aisu, N, Hasegawa, S, Yoshida, H, Sakamoto, K, Ishida

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

1765

622PLiquid biopsy concordance based on clonality and timing of testing in patients with metastatic colorectal cancer

Kasi, P M, Kamatham, S, Shahjehan, F, Li, Z, Johnson, P W, Merchea, A, Colibaseanu, D T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1766

623PPlasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer

Moati, E, Blons, H, Taly, V, Garlan, F, Shu-Fang, W-R, Pietrasz, D, Didelot, A, Garrigou, S, Saint, A, Pernot, S, Taieb, J, Laurent-Puig, P, Zaanan, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1767

624PHigh circulating miR-1247 is a marker for poor prognosis in patients with metastatic colorectal cancer treated with chemotherapy and cetuximab

Schou, J V, Sztupinszki, Z, Johansen, J S, Nielsen, D L, Glimelius, B, Qvortrup, C, Sorbye, H, Jensen, B Vittrup, Pfeiffer, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1768

625PClinical relevance of circulating tumour (ct)DNA genotyping for first-line cetuximab-based treatment monitoring in metastatic colorectal cancer (mCRC): A prospective multicentric study

Barrull, J Vidal, Casadevall, D, Fernandez, M C, Castro-Henriques, M, García-Alfonso, P, Martin-Cullell, B, Alonso-Orduna, V, Alonso, R M Rodríguez, Benavides, M, Vivas, C Santos, Fernández, E Elez, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

1769

626PClonal hematopoiesis mutations in plasma cfDNA RAS/BRAF genotyping of metastatic colorectal cancer

Wang, B, Huang, F, Shen, M, Wu, S, Wang, H, Jiang, H, Yu, Y, Yu, Q, Yang, Y, Zhao, Y, Zhou, Y, Pan, B, Liu, T, Guo, W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1770

627PImmune status of patients with different stages of colorectal cancer with and without circulating tumour cells

Sitkovskaya, A O, Zlatnik, E Y, Novikova, I A, Bondarenko, E S, Sagakyants, A B, Kit, O I, Vladimirova, L Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1771

629PDetection of 5-hydroxymethylcytosine in circulating-free DNA for prediction of the efficacy of conversion therapy for colorectal cancer liver metastases

Chang, W, Liu, T, Ye, W, Ren, L, He, G, Xu, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1772

630PmCRC gene profiling using the Idylla platform

Bricogne, C, Rodriguez-Justo, M, Agarwal, A, Khan, S, Patel, D, Bhuva, N, Brown, S, Wikinson, R, Shiu, K-K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1773

632PPatient-derived xenografts (PDX) identify JMJD6 inhibitor as an effective therapeutic medicine in colorectal cancer

Ye, F, You, J, Xia, L, Lian, J, Xiao, R, Ran, T, Gao, X, Li, J, Zhao, X, Gao, J, Lin, H, Zheng, J, Liu, W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1774

633PDACH1 induced stemness of intestinal organoids by directly suppressing bone morphogenetic proteins (BMP) signaling and contributes to intestinal tumorigenesis

Hu, X, Cai, S-J, Peng, J-J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1775

634PmiR-148a inhibits early relapsed colorectal cancers and the secretion of VEGF by indirectly targeting HIF-1α under non-hypoxia/hypoxia conditions

Tsai, H-L, Huang, C-W, Su, W-C, Li, K-L, Wang, J-Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1776

635PLong noncoding RNA CASC21 promotes cell proliferation and metastasis in colon cancer

Zhang, Q, Bian, Y, Hu, J, Li, L, Yang, M, Liu, B, Qian, X

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1777

638PDevelopment of a living organoid biobank derived from colorectal cancer patients: Towards personalized medicine

Papaccio, F, Gutierrez-Bravo, M F, Cabeza-Segura, M, Gambardella, V, Huerta, M, Ciarpaglini, C Martinez, Keranen, S Rosello, Gimeno-Valiente, F, Fleitas, T, Llavero, N Tarazona, Roda, D, Cervantes, A,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1778

640PExpression profile of EPHB3 and its prognostic significance in colorectal cancer progression (Running head: Prognostic value of EPHB3 in colorectal cancers)

Jang, B, Kim, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1779

642PFrequent BRAF, GNAS and SMAD4 mutations identified in colorectal mucinous carcinomas

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1780

645PWRN mutated colorectal cancer (CRC) is characterized by a distinct molecular and immunological profile

Seeber, A, Puccini, A, Xiu, J, Baca, Y, Spizzo, G, Zimmer, K, Lenz, H J, Battaglin, F, Goldberg, R M, Grothey, A, Shields, A F, Salem, M E, Marshall, J L, Korn, W M, Wolf, D, Kocher, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1781

646PMutation analysis of B2M gene in colorectal cancer patients with microsatellite instability

Kašubová, I, Sňahničanová, Z, Kalman, M, Plank, L, Lasabová, Z

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1782

647PSelective Wnt/β-catenin small-molecule inhibitor CWP232228 impairs tumour growth of colon cancer

Kim, J Y, Lee, K K, Jung, E H, Ha, E, Krishnan, M, Chun, K-S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1783

648PFeasibility and impact of prospective DPYD screening in the Irish population

Zameer, M Z, Iqbal, S, Macanovic, B, Clarke, D Bracken, Joyce, C, O’Reilly, S, Bambury, R M, Power, D, Collins, D C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1784

650PLoss of subcutaneous adipose tissue during chemotherapy predicts reduced survival in patients with incurable colorectal cancer undergoing palliative therapy

Sullivan, E S, Daly, L E, Bhuachalla, É B Ní, Cushen, S J, Ryan, A M, Power, D G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

1785

651PObese and overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab

Cybulska-Stopa, B, Regulski, K, Wiśniowski, R, Rajczykowski, M, Suwinski, R, Domagała-Haduch, M, Piejko, K, Drosik, A P, Bar-Letkiewicz, I, Rauch, L, Szczęsny, T, Ziobro, M, Mackiewicz, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

1786

652PPatient characteristics associated with poor performance status, ECOG 2-3, and effect on survival in 1086 Finnish metastatic colorectal cancers (mCRC) nationwide (prospective RAXO study)

Österlund, P J, Salminen, T, Algars, A, Soveri, L-M, Ristamäki, R, Kallio, R S, Lamminmäki, A, Halonen, P M, Poussa, T, Lantto, E, Ovissi, A, Nordin, A, Nyandoto, P, Kononen, J T, Aroviita, L J, Jekun

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1787

653PDiscovery and diagnosis of metastatic colorectal cancer (mCRC) in the real world: Final results from a European survey

Rawicka, I M, Maravic, Z, Lemmens, L, Benedict, A, Komlos, K, Rakonczai, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1788

654PAdherence to recommended intake of calcium and colorectal cancer risk in the HEXA study

Lee, J, Shin, A, Choi, J-Y, Kang, D, Lee, J-K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 1.88 MB

2019

1789

655PBody size, sex and sidedness of incident colorectal cancer in a prospective Swedish cohort study

Siesing, C, Berntsson, J, Brändstedt, J, Jirström, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1790

656PMiddle East & North Africa registry to characterize RAS mutation status and tumour specifications in recently diagnosed patients with metastatic colorectal cancer (MORE-RAS Study)

Oukkal, M, Bouzid, K, Bounedjar, A, Alnajar, A, Taleb, F Abou, Alsharm, A, Mahfouf, H, Larbaoui, B, Abdelaziz, A, Ouamer, A, Bashir, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1791

657PPatient demographics and management landscape of metastatic colorectal cancer in the third-line setting: Real-world data in an Australian population

Min, S Tun, Roohullah, A, Tognela, A, Jalali, A, Lee, M, Wong, R, Shapiro, J, Burge, M, Yip, D, Nott, L, Zimet, A, Lee, B, Dean, A, Steel, S, Wong, H-L, Gibbs, P, Lim, S H-S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1792

658PExploration of efficacious alternative regorafenib regimens to manage hand-foot-skin-reaction (HFSR)

Grothey, A, Hoefman, S, Ruppert, M, Vis, P, Zisowsky, J, Fiala-Buskies, S, Van Cutsem, E, Dochy, E, Cleton, A, Ploeger, B A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1793

659PQuality of life (QoL) in metastatic colorectal cancer (mCRC) in the real world: Final results of a European survey

Maravic, Z, Rawicka, I M, Lemmens, L, Benedict, A, Rakonczai, P, Komlos, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1794

661TiPiSCORE: Immunotherapy sequencing in colon and rectal cancer

Turkes, F S, Crux, R, Cunningham, D, Athauda, A, Kalaitzaki, E, Musallam, A, Begum, R, Paepe, K De, Fotiadis, N, Riddell, A, Loga, K Von, Kinross, J, Marchesi, J R, Teare, J, Morganstein, D, Rao, S, W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1795

662TiPPhase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA Study

Salvatore, L, Bensi, M, Pietrantonio, F, Boccaccino, A, Barbara, C, Auriemma, A, Ratti, M, Tamburini, E, Bordonaro, R, Clavarezza, M, Avallone, A, Bergamo, F, Granetto, C, Bustreo, S, Fabio, F Di, Smi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1796

664TiPOpen label phase III study of arfolitixorin vs leucovorin in mFOLFOX-6 for first-line treatment of metastatic colorectal cancer: AGENT

Tabernero, J, Prager, G, Stintzing, S, Lenz, H J, Nygren, H P, Papadimitriou, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1797

665TiPSOLSTICE, a phase III, randomized, open label study of trifluridine/tipiracil+bevacizumab (bev) versus capecitabine+bev for the 1L treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not candidates for intensive therapy

Andre, T, Saunders, M P, Kanehisa, A, Gandossi, E, Fougeray, R, Causse-Amellal, N, Falcone, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1798

666TiPA phase Ib/ II trial to assess the safety and efficacy of CXD101 in combination with the PD-1 inhibitor nivolumab in patients with metastatic, previously-treated, microsatellite-stable (MSS) colorectal carcinoma (short title CAROSELL)

Saunders, M P, Graham, J, Cunningham, D, Plummer, R, Cook, S, Church, D, Kerr, R, Thangue, N La, Kerr, D J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1799

667TiPA phase Ib/II study of onvansertib (PCM-075) in combination with FOLFIRI and bevacizumab for second-line treatment of metastatic colorectal cancer in patients with a KRAS mutation

Lenz, H J, Ahn, D, Erlander, M, Barzi, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1800

668TiPPhase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) colon

Martinelli, E, Troiani, T, Cardone, C, Ciardiello, D, Zanaletti, N, Borrelli, C, Terminiello, M, Avallone, A, Falcone, A, Maiello, E, Bordonaro, R, Santini, D, Garufi, C, Pietrantonio, F, Pinto, C, Sa

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1801

669TiPThe ORCHESTRA trial; A phase III trial of adding tumour debulking to systemic therapy versus systemic therapy alone in multi-organ metastatic colorectal cancer (mCRC)

Bakkerus, L, Gootjes, E C, van der Stok, E P, Buffart, T E, Zonderhuis, B M, Tuynman, J B, Meijerink, M R, van de Ven, P M, Haasbeek, C J, Tije, A J Ten, de Groot, J W, Radema, S A, Hendriks, M P, Hel

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1802

670TiPEMERGE: Epigenetic modulation of the immune response in gastrointestinal cancers

Cartwright, E, Turkes, F, Saffery, C, Kalaitzaki, E, Powell, R, Wotherspoon, A, Paepe, K De, von Loga, K, Hubank, M, Rao, S, Watkins, D, Chau, I, Starling, N, Cunningham, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1803

673PDNab-paclitaxel (Nab) plus gemcitabine (G) is more effective than G alone in locally advanced, unresectable pancreatic cancer (LAUPC): The GAP trial, a GISCAD phase II comparative randomized trial

Cascinu, S, Berardi, R, Bianco, R, Bilancia, D, Zaniboni, A, Ferrari, D, Mosconi, S, Spallanzani, A, Cavanna, L, Leo, S, Negri, F, Beretta, G D, Sobrero, A, Banzi, M, Morabito, A, Bittoni, A, Marciano

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 107 KB

2019

1804

674PDPerioperative FLOT + anti-PD-L1 avelumab (FLOT-A) chemo-immunotherapy in resectable oesophagogastric adenocarcinoma (OGA): Safety and biomarker data from the ICONIC trial safety run-in

Davidson, M, Mansukhani, S, Starling, N, Chau, I, Watkins, D, Cunningham, D, Rao, S, Lazaro-Alcausi, R, Griffiths, B, Barber, L, Morganstein, D, Forster, M D, Davies, S, Begum, R, Gillbanks, A, Kalait

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1805

675PDPOLO: Health-related quality of life (HRQoL) of olaparib maintenance treatment versus placebo in patients with a germline BRCA mutation and metastatic pancreatic cancer (mPC)

Hammel, P, Kindler, H L, Reni, M, Van Cutsem, E, Macarulla Mercade, T, Hall, M J, Park, J O, Hochhauser, D, Arnold, D, Oh, D-Y, Reinacher-Schick, A, Tortora, G, Algül, H, O’Reilly, E M, McGuinness, D,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1806

676PDHealth-related quality of life (HRQoL) impact of pembrolizumab (pembro) versus best supportive care (BSC) in previously systemically treated patients (pts) with advanced hepatocellular carcinoma (HCC): KEYNOTE-240

Merle, P, Kulkarni, A S, Ryoo, B-Y, Cheng, A-L, Kudo, M, Bouattour, M, Lim, H Y, Breder, V, Edeline, J, Chao, Y, Ogasawara, S, Yau, T, Garrido, M, Chan, S, Daniele, B, Norquist, J, Chen, E, Siegel, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1807

677PDComprehensive genomic profiling (CGP) of mixed hepatocellular cholangiocarcinomas (cHCC-CCA)

Murugesan, K, Javle, M, Schrock, A B, Ngo, N, Frampton, G M, Alexander, B M, Miller, V A, Bekaii-Saab, T, Albacker, L A, Ross, J S, Ali, S M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1808

679PDLarge-scale analysis of CDH1 mutations define a distinctive molecular subset in gastric cancer (GC)

Wang, J, Xiu, J, Arai, H, Battaglin, F, Poorman, K, Tokunaga, R, Zhang, W, Korn, W M, Lenz, H J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

1809

682PPhase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses

Tempero, M A, Reni, M, Riess, H, O’Reilly, E M, Krishnamurthi, S, Österlund, P, Ales-Diaz, I C, Milella, M, Siena, S, Tabernero, J, Van Cutsem, E, Philip, P A, Goldstein, D, Berlin, J D, Li, M, Ferrar

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

1810

683PFOLFIRINOX in locally advanced (LA) and borderline resectable (BR) pancreatic adenocarcinoma: Update of the AGEO cohort

Auclin, E, Marthey, L, Mas, L, Francois, E, Sa Cunha, A, Bachet, J-B, Tougeron, D, Vienot, A, Lecomte, T, Hautefeuille, V, Forestier, J, Collins, M, Abdallah, R, Coriat, R, Pointet, A-L, Leroy, F, Kso

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1811

684PImpact of adjuvant treatment with nab-paclitaxel and gemcitabine (nab-P+GEM) vs gemcitabine alone (GEM) on health-related quality of life (QoL) in patients (pts) with surgically resected pancreatic adenocarcinoma (PA) in the adjuvant pancreatic adenocarcinoma clinical trial (APACT)

Riess, H, Braverman, J, Reni, M, Dueck, A C, Hendifar, A, Oh, D-Y, Li, C-P, Mercade, T Macarulla, Shah, A, Joshi, N, Botterman, M, Mantovani, E, Lu, B, Tempero, M A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 112 KB

2019

1812

687PEvaluation of minimal important difference (MID) for the European organisation for research and treatment of cancer (EORTC) pancreatic cancer module (PAN26) in patients with surgically resected pancreatic adenocarcinoma

Reni, M, Braverman, J, Hendifar, A, Li, C-P, Macarulla Mercade, T, Oh, D-Y, Riess, H, Tempero, M A, Lu, B, Marcus, J, Joshi, N, Botterman, M, Dueck, A C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1813

688PMultispectral analysis of lymphocyte complexity in periampullary adenocarcinoma

Lundgren, S, Elebro, J, Heby, M, Nodin, B, Leandersson, K, Micke, P, Jirström, K, Mezheyeuski, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1814

689PPhase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC)

Jeong, J H, Yoo, C, Kim, K-P, Chang, H-M, Ryoo, B-Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1815

690PPrognostic factors for predicting early recurrence within the first year of surgery in pancreatic ductal adenocarcinoma

Kim, N, Shin, S H, Ryu, Y, Han, I W, Heo, J S, Choi, D W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1816

691PIntegrated population pharmacokinetic modelling of liposomal irinotecan in patients with various tumour types, including untreated metastatic pancreatic cancer (mPC)

Macarulla, T, Brendel, K, Lieu, C, Wainberg, Z, Dayyani, F, Zhang, B, Belanger, B, Moore, Y, Pedret-Dunn, A, Maxwell, F, Dean, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1817

692PExpression of long noncoding RNA and clinical outcomes of pancreatic cancer patients who received adjuvant chemotherapy by S-1 or GEM after curative resection

Kamiya, M, Miyagi, Y, Kamioka, Y, Yotsumoto, H, Inoue, H, Murakawa, M, Nakamura, Y, Yoshihara, M, Yamada, T, Yamamoto, N, Oshima, T, Shiozawa, M, Yukawa, N, Rino, Y, Masuda, M, Morinaga, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1818

693PPOLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC)

Van Cutsem, E, Golan, T, Hammel, P, Reni, M, Macarulla, T, Hall, M J, Park, J O, Hochhauser, D, Arnold, D, Oh, D-Y, Reinacher-Schick, A, Tortora, G, Algül, H, O’Reilly, E M, McGuinness, D, Cui, K Y, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

1819

695PPhase I/II study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer

Pijnappel, E N, Klaassen, R, van der Lee, K S, Pleunis - van Empel, M, Richel, D, Legdeur, M, Nederveen, A, van Laarhoven, H W M, Wilmink, H W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1820

696PEfficacy of platinum-containing chemotherapy and prognosis of pancreatic cancer patients with homologous recombination deficiency: Meta-analysis of published clinical studies

Polyanskaya, E, Pokataev, I, Fedyanin, M, Popova, A, Agafonova, Y, Tryakin, A, Tjulandin, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

1821

697PPlasmatic CXCL8 is a marker for TGFß-activated kinase 1 (TAK1) activation which may predict resistance to nanoliposomal irinotecan (nal-IRI) in gemcitabine-refractory pancreatic cancer (PC) patients

Merz, V, Zecchetto, C, Santoro, R, Simionato, F, Piro, G, Sabbadini, F, Cavaliere, A, Casalino, S, Auriemma, A, Melisi, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1822

699PPre-treatment serum 25-hydroxyvitamin D levels and survival in a Danish cohort of patients with pancreatic cancer

Rasmussen, L S, Yilmaz, M, Falkmer, U G, Poulsen, L Ø, Bojesen, S E, Vittrup Jensen, B, Johansen, A Z, Chen, I M, Hansen, C P, Hasselby, J P, Pfeiffer, P, Bjerregaard, J K, Nielsen, S E, Andersen, F Z

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

1823

700PSTAR-PAC: Phase I clinical trial repurposing all trans retinoic acid (ATRA) as stromal targeting agent in a novel drug combination for pancreatic cancer

Kocher, H M, Basu, B, Froeling, F E M, Sarker, D, Slater, S, Carlin, D, Coetzee, C, de Souza, N, Goulart, M, Hughes, C, Imrali, A, Lawrence, C, Mousa, K, North, B, Prendergast, A, Roberts, R, Sasieni,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1824

701POutcomes of first-line FOLFIRINOX (FFX) versus gemcitabine and nab-paclitaxel (GN) in patients with advanced pancreatic cancer: Multi-Institutional Canadian sites experience

Papneja, N, Ahmed, S, Mondal, P, Barrera, I, Papneja, A, Batist, G, Kavan, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1825

702PEffect of prior cancer on survival outcomes for patients with pancreatic adenocarcinoma

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1826

704PResults from phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel as first-line treatment of unresectable pancreatic cancer

Hashimoto, Y, Hijioka, S, Hirooka, Y, Ohno, E, Ioka, T, Kobayashi, S, Okusaka, T, Maruki, Y, Yashika, J, Ashida, R, Furuse, J, Ikeda, M, Kasuya, H, Tanaka, M, Ueno, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1827

705PMulticenter retrospective study of gemcitabine plus nab-paclitaxel for elderly patients with advanced pancreatic cancer

Ozaka, M, Kobayashi, S, Ikeda, M, Ueno, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1828

706PIrinotecan combined with oxaliplatin and S1 in patients with metastatic pancreatic adenocarcinoma

Nie, K, Guo, X, Zhou, X, Zhang, Z, Zhang, C, Lan, K, Ji, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1829

707PCancer-associated thrombosis in patients with pancreatic cancer and its correlation with plasma tissue factor level: A Japanese prospective cohort study

Kobayashi, S, Koizume, S, Miyagi, Y, Ueno, M, Morimoto, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1830

708PA phase I/Ib, multi-center trial of ARQ-761 (Beta-Lapachone) with gemcitabine/nab-paclitaxel in patients with advanced pancreatic cancer

Beg, M S, Boothman, D, Khosama, L, Arriaga, Y, Verma, U, Sanjeeviaiah, A, Kazmi, S, Fattah, F, Pilarski, S, Rodriguez, M, Lindsey, D, Linden, S, Schwartz, B, Laheru, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1831

711PThe analysis of genomic signatures of head and body/tail of pancreatic cancer in Chinese patients

Ling, Q, Huang, H, Zhang, X, Rui, T, Feng, S, Wang, Q, Huang, Y, Zhang, S, Wang, A, Yao, M, Wang, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1832

712PMGMT methylation in metastatic pancreatic cancer (mPAC): A single center experience

Niger, M, Morano, F, Manglaviti, S, Nichetti, F, Perrone, F, Tamborini, E, Marcuzzo, M, Raimondi, A, Peverelli, G, Brambilla, M, Pagani, F, Torchio, M, Prisciandaro, M, Antista, M, Pietrantonio, F, Pu

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1833

713PAdvantage of three-dimensional image analysis of pancreatic cancer using computed tomography

Yoon, S B, Choi, M H, Lee, I S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1834

714PPhase I study of the oncolytic viral immunotherapy agent canerpaturev (C-REV) with S-1 in patients with stage IV pancreatic cancer

Hijioka, S, Ueno, M, Ioka, T, Hirooka, Y, Ohno, E, Okusaka, T, Maruki, Y, Kobayashi, S, Ashida, R, Yashika, J, Furuse, J, Ikeda, M, Kasuya, H, Tanaka, M, Hashimoto, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1835

715PImpact of anatomic site of biliary tract tumour origin and conditional probability of survival (CS): Results from 15 prospective advanced first-line clinical trial

McNamara, M G, Lopes, A, Wasan, H, Malka, D, Goldstein, D, Shannon, J, Okusaka, T, Knox, J J, Wagner, A D, Andre, T, Cunningham, D, Moehler, M, Jensen, L H, Koeberle, D, Bekaii-Saab, T, Bridgewater, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1836

716PFOLFOXIRI versus FOLFIRINOX in first-line chemotherapy in patients with advanced pancreatic cancer: A propensity score analysis

Vienot, A, Chevalier, H, Bolognini, C, Gherga, E, Meurisse, A, Vernerey, D, Borg, C, Turpin, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1837

717PCell-free tumour-DNA (cfDNA) as a very early predictor of therapeutic outcome in pancreatic ductal adenocarcinoma (PDAC)

Payr, S, Bergelin, J, Beck, J, Dragovich, T, Azizian, A, Brunner, M, König, U, Naraev, B, Ellenrieder, V, Gaedcke, J, Schütz, E, Kundranda, M N, König, A-O

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

1838

718PComprehensive genomic profiling (CGP) of gall bladder adenocarcinoma (GBAC) in patients from distinct ancestral populations

Javle, M, Akumalla, S, Madison, R, Verma, A, Abdel-Wahab, R, Newburg, J, Alexander, B M, Chung, J, Miller, V A, Lee, J, Ross, J S, Schrock, A B, Frampton, G M, Ali, S M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1839

719PPhase II monotherapy efficacy of cancer metabolism targeting SM-88 in heavily pre-treated PDAC patients

Ocean, A, Noel, M, Wang-Gillam, A, Chawla, S, Chung, V, Pant, S, Korn, R, Priore, G Del, Picozzi, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1840

720PComprehensive genomic profiling and clinical outcomes in patients (pts) with fibroblast growth factor receptor rearrangement-positive (FGFR2+) cholangiocarcinoma (CCA) treated with pemigatinib in the fight-202 trial

Hollebecque, A, Silverman, I, Owens, S, Féliz, L, Lihou, C, Zhen, H, Newton, R, Burn, T, Melisi, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1841

722PIt’s not only about weight loss: Tackling pancreatic cancer-associated cachexia

Matos, A L V, Fernandes, L, Cunha, H, Graca, J A, Barata, J, Neves, M T, Alves, F R, Pereira, J, Ferreira, F A S, Freire Coelho, A, Malheiro, M, Mesquita Pinto, M S, Fontes e Sousa, M, Placido, A, Hen

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1842

723PFrequency and clinicopathological characteristics of biliary tract carcinomas harboring the FGFR2-fusion gene: A prospective observational study (PRELUDE study)

Ikeda, M, Maruki, Y, Ueno, M, Ioka, T, Naganuma, A, Furukawa, M, Mizuno, N, Uwagawa, T, Nakai, Y, Kanai, M, Asagi, A, Shimizu, S, Miyamoto, A, Yukisawa, S, Kadokura, M, Yamanaka, T, Arai, Y, Shibata,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1843

724PPost-hoc analyses of a subgroup of patients with advanced biliary tract cancer (BTC) who crossed over to treatment with etoposide toniribate (EDO-S7.1) in a randomized phase II study

Pape, U-F, Kasper, S, Meiler, J, Sinn, M, Vogel, A, Mueller, L, Burkhard, O, Caca, K, Heeg, S, Rodriguez Laval, V, Kuhl, A A, Arsenic, R, Jansen, H, Mehrling, T, Hilgier, K, Wagner, I, Utku, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

1844

725PCapecitabine +best supportive care (BSC) or erlotinib +BSC has overall survival (OS) benefit over BSC alone in unresectable/metastatic gall bladder cancer (GBC) patients with ECOG PS-III. Results from a phase II randomised controlled trial (RCT)

Kataria, B, Sharma, A, Mishra, S, Bhatnagar, S, Thulkar, S, Yadav, M, Sahoo, R K, Pramanik, R, Prasad, C P, Sreenivas, V, S, M K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1845

726PFGFR2 fusions and its effect of patient (pt) outcomes in intrahepatic cholangiocarcinoma (iCCA)

Almquist, D R, Javle, M, Ciombor, K K, Roth, M, Abdel-Wahab, R, Ou, F-S, Wolfe, E, Mody, K, Mahipal, A, Borad, M J, Bekaii-Saab, T, Ahn, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1846

728PHigh PD-L1 expression is associated with treatment response to pembrolizumab in patients with advanced biliary tract cancer

Kim, G, Ahn, S, Hwang, J-H, Lee, J-C, Kim, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

1847

729PGenomic profiling in Chinese biliary tract cancer patients with PI3K/AKT/mTOR pathway and RAS gene mutations

Cao, J, Guo, W, Niu, Z, Wang, Z, Hu, W, Ma, X, Liu, D, Shi, J, Yao, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1848

730PPhase II trial of trifluridine/tipiracil (TAS-102) in patients with advanced refractory biliary tract cancer (BTC)

Chakrabarti, S, Zemla, T, Ou, F-S, Fruth, B, Ahn, D, Borad, M J, Hartgers, M L, Wessling, J, Walkes, R L, Alberts, S, McWilliams, R R, Liu, M C, Mahipal, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1849

731PLiver metastases (LM) from intrahepatic cholangiocarcinoma (iCCA): Outcomes from the European Network for the study of cholangiocarcinoma (ENS-CCA) registry and implications on current American Joint Committee on Cancer (AJCC) staging

Lamarca, A, Santos, A, Utpatel, K, La Casta, A, Stock, S, Forner, A, Adeva Alfonso, J, Folseraas, T, Fabris, L, Macias, R, Krawczyk, M, Krawczyk, M, Cardinale, V, Braconi, C, Alvaro, D, Evert, M, Baña

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

1850

732PIs MGMT methylation a new therapeutic target for biliary tract cancer?

Niger, M, Morano, F, Manglaviti, S, Nichetti, F, Tamborini, E, Perrone, F, Marcuzzo, M, Peverelli, G, Brambilla, M, Pagani, F, Torchio, M, Ottini, A, Antista, M, Pietrantonio, F, Pusceddu, S, Pruneri,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1851

733PBiliary tract cancers in Portuguese families with BRCA gene mutation: A retrospective study

Pereira, P, Oliveira, I, Fernandes, S, Clara, A, Miguel, I, Bento, S, Fragoso, S, Santos, S, Rodrigues, P, Parreira, J, Rodrigues, F, Silva, I, Louro, P, Vaz, F, Luis, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1852

734PSelection of patients with hepatocellular carcinoma for selective internal radiation therapy based on tumour burden and liver function: A post-hoc analysis of the SARAH trial

Palmer, D H, Hawkins, N S, Vilgrain, V, Pereira, H, Chatellier, G, Ross, P J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

1853

735PSecond-line chemotherapy (SLC) in patients with advanced biliary tract and gallbladder cancers (ABGC) prolongs survival: A retrospective population-based cohort study

Zaidi, A, Chandna, N, Narasimhan, G, Moser, M, Haider, K, Chalchal, H I, Shaw, J, Ahmed, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1854

736POverall survival of patients with hepatocellular carcinoma receiving sorafenib versus selective internal radiation therapy with predicted osimetry in the SARAH trial

Hawkins, N S, Ross, P J, Palmer, D H, Chatellier, G, Pereira, H, Vilgrain, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1855

737PMulticenter phase II trial of axitinib monotherapy for advanced biliary tract cancer refractory to gemcitabine-based chemotherapy

Okano, N, Ueno, M, Morizane, C, Yamanaka, T, Ojima, H, Ozaka, M, Sasaki, M, Takahara, N, Kobayashi, S, Morimoto, M, Hosoi, H, Nakai, Y, Ikeda, M, Maeno, S, Nagashima, F, Okusaka, T, Furuse, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1856

738PSoluble programmed death-ligand 1 indicate poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization

Ma, X, Qu, X, Yang, W, Wang, H, Wang, B, Shen, M, Zhou, Y, Zhang, C Y, Sun, Y, Chen, J, Hu, B, Gong, Z, Zhang, X, Pan, B, Zhou, J, Fan, J, Yang, X, Guo, W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1857

739PThe prognostic nutritional index (PNI) is an independent predictor of survival in advanced biliary cancers (ABC) receiving first-line chemotherapy (1L)

Caputo, F, Salati, M, Cerma, K, Spallanzani, A, Andrikou, K, Gelsomino, F, Orsi, G, Rovesti, G, Riggi, M L, Molinaro, E, Santini, C, Bardasi, C, Rimini, M, Pipitone, S, Cortesi, G, Schipilliti, F M, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1858

740PImpact of centralisation of national cancer services on patient outcomes for hepatobiliary cancers in Ireland 2000-2016

O Reilly, D E, Deady, S, Walsh, P, Lowery, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1859

741PGenomic analysis of hepatobiliary lithiasis associated cholangiocarcinoma revealed a distinct subtype feature

Gu, L, Wang, Y, Deng, J, Chen, X, Zhou, J, Yang, X

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1860

742PComparison of the impact of stereotactic body radiation therapy vs radiofrequency ablation on liver function in patients with single hepatocellular carcinoma: A propensity score matching analysis

Ueno, M, Takabatake, H, Sue, M, Kayahara, T, Morimoto, Y, Mizuno, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1861

743PExploratory analysis based on tumour location and early metabolic tumour response of REACHIN, a randomized double-blinded placebo-controlled phase II trial of regorafenib after failure of gemcitabine/platinum-based chemotherapy for advanced and metastatic biliary tract tumours

Demols, A, Borbath, I, Guillaume, L, Van Laethem, J L, Goldman, S, Lhommel, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1862

745PPreliminary safety and pharmacokinetics of a new lysosomotropic oral agent, GNS561, in a first-in-human study in advanced primary liver cancer patients

Awada, A H, Harding, J J, Kotecki, N, Aftimos, P G, Decaens, T, Dreyer, C, Ansaldi, C, Rachid, M, Serdjebi, C, Halfon, P, Abou-Alfa, G K, Raymond, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1863

748PMulticentric prospective study of validation of angiogenesis-related gene polymorphisms in HCC patients treated with sorafenib: Final results of INNOVATE study

Casadei-Gardini, A, Marisi, G, Dadduzio, V, Faloppi, L, Ielasi, L, Vivaldi, C, Rizzato, M D, Fornaro, L, Lonardi, S, Gramantieri, L, Pecora, I, Silvestris, N, Fornari, F, Orsi, G, Rovesti, G, Santini,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1864

749PPrognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)

Meyer, T, Kelley, R K, Mangeshkar, M, Cheng, A-L, El-Khoueiry, A B, Abou-Alfa, G K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1865

751PAnlotinib for advanced hepatocellular carcinoma: Interim results from the phase II ALTER0802 study

Zhou, A, Sun, Y, Zhang, W, Jiang, Z, Chen, B, Zhao, J, Li, Z, Wang, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

1866

752PThe efficacy and safety of lenvatinib in patients who did not meet the inclusion criteria of the phase III trial (REFLECT trial) and those with BCLC Stage B hepatocellular carcinoma: A nationwide multicenter study in Japan

Sakamoto, A, Kurosaki, M, Tsuchiya, K, Abe, T, Ogawa, C, Soda, T, Kimura, H, Kondo, M, Tsuji, K, Koichiro, F, Shigeno, M, Jyoko, K, Narita, R, Uchida, Y, Yoshida, H, Akahane, T, Kobashi, H, Mitsuda, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1867

754PEffect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QTWiST analysis from the CELESTIAL study

Freemantle, N, Abou-Alfa, G K, Cheng, A-L, Kelley, R K, Valcheva, V, Benzaghou, F, Mollon, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

1868

755PAlpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase III RESORCE trial

Bruix, J, Reig, M, Merle, P, Kudo, M, Meinhardt, G, Zhang, M, Ozgurdal, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1869

756PPhase I/II trial of NBTXR3 activated by SBRT in patients with hepatocellular carcinoma or liver metastasis

Pracht, M, Chajon, E, Rolland, Y, de Baere, T, Nguyen, F, Bronowicki, J-P, Vendrely, V, Sa Cunha, A, Baumann, A-S, Croisé-Laurent, V, Rio, E, Said, P, Le Sourd, S, Gustin, P, Perret, C, Peiffert, D, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1870

758PRamucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysis

Llovet, J, Kudo, M, Kang, Y-K, Yen, C-J, Finn, R S, Galle, P R, Assenat, E, Motomura, K, Okusaka, T, Berg, T, Hsu, C-H, Ikeda, M, Hsu, Y, Liang, K, Widau, R, Schelman, W, O’Brien, L, Gao, L, Zhu, A X

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 100 KB

2019

1871

759POutcomes of hepatocellular carcinoma (HCC) patients treated with nivolumab: The Mount Sinai Hospital experience

Dharmapuri, S, Özbek, U, Lin, J-Y, Schwartz, M, Branch, A, Ang, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1872

761PA national comparative effectiveness study to assess definitive chemoradiation regimens in proximal oesophageal squamous cell cancer

de Vos-Geelen, J, Hoebers, F J P, Geurts, S M E, Hoeben, A, de Greef, B T A, Voncken, F E M, Bogers, J A, Braam, P M, Muijs, C T, de Jong, M A, Kasperts, N, Rozema, T, Jeene, P M, Blom, G J, Hulshof,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1873

762PPrognostic value of metabolic response assessed by 18FDG-PET after induction chemotherapy and after chemoradiotherapy (CRT) in localized esophageal squamous cell carcinoma (ESCC) patients (pts) receiving definite CRT (dCRT)

Bang, Y, Jeong, H, Im, H-S, Park, S R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1874

763PComprehensive genomic profiling of early-stage esophageal squamous cell carcinoma

Zuo, J, Fan, Z, Jia, Y, Wang, Y, Wang, L, Lizaso, A, Li, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1875

765PDrinking alcohol, smoking, multiple dysplastic lesions and the risk of field cancerization of squamous cell carcinoma in the esophagus and head and neck region

Katada, C, Yokoyama, T, Yano, T, Oda, I, Shimizu, Y, Doyama, H, Koike, T, Takizawa, K, Hirao, M, Okada, H, Ishikawa, H, Yokoyama, A, Muto, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1876

766PNeoadjuvant chemotherapy can eliminate the negative impact of postoperative infectious complications on recurrence in patients with esophageal cancer

Kano, K, Ogata, T, Komori, K, Watanabe, H, Shimoda, Y, Kumazu, Y, Fujikawa, H, Yamada, T, Oshima, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1877

767PComparison of chemoradiotherapy (CRT) followed by consolidation with cisplatin and 5-fluorouracil (CF) versus definitive CRT with carboplatin and paclitaxel (CP) in esophageal cancer

Cesca, M G, Pandolfi, N C, Barros, M, de Jesus, V H F, Silva, V S, Camandaroba, M, Felismino, T C, Rodrigues, N, Riechelmann, R P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1878

768PPaclitaxel in combination with cisplatin and 5-fluorouracil (TPF) induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: A phase II clinical trial

Li, Y, Wang, Z, Yang, H, Li, Q, Liu, H, Wang, D S, Xi, S Y, Qiu, M Z, Ren, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 3.82 MB

2019

1879

769PPrognosis of esophageal squamous cell carcinoma based on local immunity evaluation

Zlatnik, E Y, Kit, O I, Bazaev, A L, Novikova, I A, Demidova, A A, Vladimirova, L Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1880

770PImpact of sarcopenia and adiposity in survival of metastatic esophageal cancer (MEC)

Fares, A F, Taylor, K, Bajwa, J, Dong, G, Araujo, D V, Hueniken, K, Patel, D, Chen, E X, Knox, J J, Jang, R W-J, Wong, R, Darling, G, Elimova, E, Xu, W, Rozenberg, D, Liu, G, Mcinnis, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

1881

771PPALAESTRA: A phase II trial with short-course radiotherapy followed by chemotherapy as palliative treatment in esophageal adenocarcinoma

Borg, D, Sundberg, J, Brun, E, Kjellén, E, Petersson, K, Hermansson, M, Johansson, J, Eberhard, J, Johnsson, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1882

772PPrognostic factors analysis of 343 patients with adenocarcinoma of esophagogastric junction

Lu, Y, Wang, X, Xie, T, Li, S, Qiu, Z, Guo, X, Wu, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1883

774PThe prognostic value of higher absolute lymphocyte counts for patients with surgically resected non-advanced gastric cancer

Park, S J, Kim, I-H, Lee, J, Kim, H, Shin, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1884

775PTrastuzumab and pertuzumab added to neoadjuvant chemoradiotherapy in resectable HER2+ esophageal adenocarcinoma patients: An update on survival and predictive biomarkers in the TRAP study

Stroes, C I, Creemers, A, Bennink, R J, Schokker, S, Verhoeven, R H A, Meijer, S L, Krisnadath, K K, van Oijen, M, Creemers, G-J, van der Sangen, M J C, Beerepoot, L V, Heisterkamp, J, Los, M, Slinger

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1885

776PInterim analysis of a phase II trial of perioperative chemotherapy plus avelumab in esophagogastric and gastric adenocarcinoma

Alcindor, T, Opu, T, Mueller, C, Marcus, V, Fiset, P-O, Camilleri-Broet, S, Artho, G, Asselah, J, Vanhuyse, M, Hickeson, M, Awan, A, Koulouris, Z, Ferri, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1886

777PEvaluation of the introduction of primary G-CSF prophylaxis to the FLOT chemotherapy regimen

Crampton, K-M, Wood, J, Wong, H, McKay, M, Madi, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1887

778PSubgroup analyses of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with 2 and 4 courses of cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) as neoadjuvant chemotherapy for locally advanced gastric cancer

Hayashi, T, Yoshikawa, T, Sakamaki, K, Nishikawa, K, Fujitani, K, Tanabe, K, Ito, Y, Matsui, T, Miki, A, Fukunaga, T, Nemoto, H, Kimura, Y, Hirabayashi, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1888

779PHER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric cancer

Liu, Z, Shi, M, Song, S, Gao, J, Li, H, Han-Zhang, H, Ye, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

1889

780PEffect of neoadjuvant chemotherapy on the programmed death-1 pathway in esophageal and gastric cancer

Svensson, M C, Lindén, A, Nygaard, J, Hedner, C, Nodin, B, Borg, D, Leandersson, K, Jirström, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1890

781PA user-friendly nomogram to predict relapse-free survival (RFS) in western patients with resected gastric cancer (GC)

Salati, M, Pipitone, S, Rimini, M, Gelsomino, F, Casadei-Gardini, A, Andrikou, K, Schipilliti, F M, Cortesi, G, Cassanelli, L, Caffari, E, Serra, F, Ricciardolo, A, De Ruvo, N, Gelmini, R, Cascinu, S,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1891

782PEfficacy and toxicity of weekly carboplatin and paclitaxel as induction or palliative treatment in advanced esophageal cancer patients

de Man, F M, Van Eerden, R A G, Oomen-de Hoop, E, Veraart, J N, van Doorn, N, van Doorn, L, van der Gaast, A, Mathijssen, R H J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1892

783PPerioperative chemotherapy with docetaxel, oxaliplatin, fluorouracil and leucovorin (FLOT) versus epirubicin, platinum and capecitabine or flourouracil (EOX/ECF) in resectable gastric or gastroesophageal junction adenocarcinoma: Safety and response data from India

Chawla, T, Thambudorai, R, Ashok, A, Roy, B, Ghosh, J, Ganguly, S, Roy, P, Mallath, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1893

784PPhase II study of preoperative radiotherapy combined with S-1 plus cisplatin in clinically resectable type 4 or large type 3 gastric cancer: OGSG1205

Endo, S, Imano, M, Furukawa, H, Yokokawa, M, Nishimura, Y, Shinkai, M, Yasuda, T, Nakagawa, T, Adachi, S, Lee, S W, Goto, M, Kii, T, Uchiyama, K, Kawakami, H, Shimokawa, T, Sakai, D, Kurokawa, Y, Sato

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1894

785PObservational study of the peritoneal washing cytology positive gastric cancer without gross peritoneal metastasis underwent radical D2 gastrectomy

Hwang, J E, Kim, H, Shim, H-J, Bae, W K, Cho, S-H, Chung, I-J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1895

786PPrimary results of multicenter phase II study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PII)

Miki, A, Satake, H, Watanabe, T, Tanaka, N, Hirata, K, Shimozaki, K, Tanioka, H, Matsuura, M, Kyogoku, T, Tatsumi, M, Matoba, K, Oka, Y, Adachi, S, Yasui, H, Kotaka, M, Kato, T, Tsuji, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

1896

787PMulticenter phase I/II feasibility study of adjuvant treatment with S-1 in patients after R0-resection of adenocarcinoma of the stomach and esophagogastric junction (GMBH-STO-0114)

Heinrich, K, Heinemann, V, Müller, L, Büchner-Steudel, P, Ettrich, T J, Stintzing, S, Schulz, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1897

788PA phase I study of docetaxel/oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction

Hosoda, K, Azuma, M, Katada, C, Ishido, K, Niihara, M, Ushiku, H, Sakuraya, M, Washio, M, Wada, T, Watanabe, A, Harada, H, Tanabe, S, Koizumi, W, Yamashita, K, Hiki, N, Watanabe, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1898

790PA multicenter phase II study of TAS-114 in combination with S-1 in patients with pre-treated advanced gastric cancer (EPOC1604)

Takahari, D, Kawazoe, A, Nakamura, Y, Tamura, H, Fukutani, M, Hirano, N, Wakabayashi, M, Nomura, S, Sato, A, Shitara, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

1899

791PImpact of pembrolizumab (pembro) versus paclitaxel on health-related quality of life (HRQoL) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer that has progressed after first-line chemotherapy (KEYNOTE-061)

Van Cutsem, E, Amonkar, M, Fuchs, C S, Alsina, M, Özgüroğlu, M, Bang, Y-J, Chung, H C, Muro, K, Goekkurt, E, Benson, A, Sun, W, Wainberg, Z A, Norquist, J, Chen, X, Shih, C-S, Shitara, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1900

792PDoes nutritional status affect treatment tolerability, response and survival in metastatic gastric cancer patients? Results of prospective multicenter study

Karabulut, S, Doğan, I, Ak, N, Usul Afsar, C, Karabulut, M, Taştekin, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1901

793PRamucirumab use in patients with advanced gastric cancer (AGC) or gastro-oesophageal junction (GEJ) adenocarcinoma in Spain: RAMIS observational study

Longo Munoz, F, Jorge Fernandez, M, Yaya Tur, R, Diaz, S, Ortega, M, Dilla, T, Molero, A, Cervera, J M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1902

794PGastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor: Exploratory analysis in the patients who were enrolled in JCOG0705/KGCA01 phase III trial (REGATTA) and could continue chemotherapy

Yoshikawa, T, Fujitani, K, Yang, H-K, Mizusawa, J, Terashima, M, Tsujinaka, T, Nakamura, K, Katayama, H, Jin, S-H, Kong, S-H, Iwasaki, Y, Kim, H-H, Takagane, A, Lee, S-H, Bae, J-M, Noh, S H, Sasako, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1903

797PRamucirumab in the treatment of refractory metastatic gastric cancer: Results from the RamSelGa trial

Tryakin, A, Perminova, E, Stroyakovsky, D, Titova, T, Yukalchuk, D, Ponomarenko, D, Beliak, N, Teletaeva, G M, Ratner, E, Mochalova, A, Gordeeva, O O, Meshcheryakov, A, Zhabina, A S, Gamayunov, S, Smo

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1904

798PRegorafenib in combination with paclitaxel for beyond first-line treatment of advanced esophagogastric cancer (REPEAT): A phase Ib trial with expansion cohort

Khurshed, M, Stroes, C I, Schokker, S, van der Woude, S, Mathôt, R, Slingerland, M, de Vos-Geelen, J, van Oijen, M, van Delden, O, Weterman, M, Punt, C J A, Bijlsma, M, van Laarhoven, H W M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1905

799PThe relationship between the survival and fixed dosing of S-1 in advanced gastric cancer patients by pooled analysis using individual data from four Japanese randomized phase III trials

Ichikawa, W, Takeuchi, M, Sunakawa, Y, Shitara, K, Oba, K, Yamada, Y, Koizumi, W, Sakata, Y, Furukawa, H, Takeuchi, M, Fujii, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1906

800PA phase Ib study of oraxol in combination with ramucirumab in patients with gastric or esophageal cancers who failed previous chemotherapy

Chen, M H, Chao, Y, Tenner, L, Hung, N A, Cutler, D, Kramer, D, Kwan, M-F R, Hung, C-T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1907

801PEfficacy and safety of trifluridine/tipiracil (FTD/TPI) in European patients with heavily pretreated metastatic gastric cancer (mGC): An analysis of the TAGS study

Alsina, M, Tabernero, J, Arkenau, H-T, Squadroni, M, Doi, T, Faustino, C, Ghidini, M, Mansoor, W, Shitara, K, Van Cutsem, E, Causse-Amellal, N, Leger, C, Skanji, D, Ilson, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1908

802PClinical experience: Ramucirumab with FOLFIRI/XELIRI as a second-line for patients with metastatic gastric cancer

Titova, T, Besova, N, Artamonova, E, Perminova, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1909

803PEfficacy and safety of apatinib for the treatment of AFP-producing gastric cancer

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1910

805PParameters of local cellular immunity in metastatic gastric cancer

Sagakyants, A B, Kit, O I, Samoylenko, N S, Novikova, I A, Zlatnik, E Y, Frantsiyants, E M, Bondarenko, E S, Vladimirova, L Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1911

806PGermline pathogenic mutations in Chinese patients with gastric cancer identified by next-generation sequencing (NGS)

Zhang, X, Zhou, J, Zhao, Z, Zhang, Y, Cai, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1912

807PInhibition of the PI3K pathway in HER2-positive gastric cancer

Toomey, S, Mezynski, M J, Farrelly, A, Armstrong, P, McAuley, J, Holohan, C, Elamin, Y Y, Rafee, S, Workman, J, Cremona, M, Grogan, L, Breathnach, O S, Morris, P G, Fay, J, Kay, E, Hennessy, B T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1913

808PInvestigation on gastric cancer susceptibility genes in Chinese early-onset diffuse gastric cancer

Feng, Y, Zhang, M, Xing, X, Chen, W, Li, W, Jia, S, Su, L, Yang, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1914

810PPhase I study of apatinib combined with POF (paclitaxel plus FOLFOX) in patients (pts) with treatment-naïve advanced gastric cancer (TNAGC)

Lin, R, Zhao, S, Fan, N, Li, H, Liu, J, Yu, J, Zhao, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1915

811PSecond-line palliative systemic treatment for synchronous metastatic esophagogastric cancer: A population-based study

Dijksterhuis, W P M, Verhoeven, R H A, Slingerland, M, Haj Mohammad, N, de Vos-Geelen, J, Beerepoot, L V, Van Voorthuizen, T, Creemers, G-J, van Oijen, M, van Laarhoven, H W M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1916

812PSTING agonist, ADU-S100, yields potent anti-tumour activity and therapeutically favorable immune profile in an esophageal adenocarcinoma model

Zaidi, A H, Omstead, A N, Chowdhury, N, Kosovec, J E, Zheng, P, Salvitti, M S, Gorbunova, A, Babar, L, Kelly, R J, Jobe, B A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1917

813PIncreased assessment of HER2 in metastatic gastroesophageal cancer patients: A nationwide population-based cohort study

Dijksterhuis, W P M, Verhoeven, R H A, Meijer, S L, Slingerland, M, Haj Mohammad, N, de Vos-Geelen, J, Beerepoot, L V, Van Voorthuizen, T, Creemers, G-J, van Oijen, M, van Laarhoven, H W M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1918

815PA new docetaxel (DOC)-based triplet regimen does not improve the outcome of metastatic (M) or locally advanced (LA) gastric cancer (GC) as compared with an epirubicin (EPI) standard triplet regimen: A GISCAD trial

Labianca, R, Rosati, G, Fazio, N, Cavanna, L, Ferrari, D, Bartolomeo, M Di, Mosconi, S, Giordano, M, Silvestris, N, Artioli, F, Iaffaioli, R V, Veltri, E A, Amoroso, D, Ciarlo, A, Barni, S, Cascinu, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

1919

816PThe analysis of T cell subsets and clinical efficacy of immune checkpoint blockades in patients with advanced gastric cancer using multiplex immunohistochemistry

Kim, T-Y, Lee, D-W, Oh, D-Y, Kwak, Y, Lee, H S, Kim, W-H, Bang, Y-J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1920

817PFirst-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma

Janjigian, Y Y, Maron, S, Chou, J F, Gabler, A R, Simmons, M Z, Momtaz, P, Shcherba, M, Ku, G Y, Won, E, Sanchez-Vega, F, Gerdes, H, Kelsen, D P, Ilson, D H, Solit, D, Schultz, N, Shah, P M, Capanu, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1921

818PMonitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in locally advanced gastric cancer

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

1922

819PGastric cancer screening in BRCA 2 gene mutation carriers: Should it be recommended?

Oliveira, I C, Fernandes, S, Pereira, P, Fragoso, S, Santos, S, Rodrigues, P, Parreira, J, Louro, P, Coelho, I, Rodrigues, F, Clara, A, Luís, A, Vaz, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1923

820PInterim analysis of an observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial)

Sunakawa, Y, Takahashi, Y, Inoue, E, Sakamoto, Y, Kawabata, R, Yabusaki, H, Matsuyama, J, Ishiguro, A, Takahashi, M, Akamaru, Y, Kito, Y, Makiyama, A, Yasui, H, Kawakami, H, Nakajima, T E, Muro, K, Ma

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1924

821PPrediction of S-1 adjuvant chemotherapy efficacy in stage II/III gastric cancer treatment based on comprehensive gene expression analysis

Terashima, M, Nakamura, K, Hatakeyama, K, Furukawa, K, Fujiya, K, kamiya, S, Hikage, M, Tanizawa, Y, Bando, E, Oshima, K, Urakami, K, Machida, N, Yasui, H, Yamaguchi, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1925

822PAssessing the clinical utility of circulating tumour DNA through longitudinal liquid biopsy sampling in oesophageal adenocarcinoma

Ococks, E, Frankell, A, Masque-Soler, N, Northrop, A, Devonshire, G, Hughes, C, Grehan, N, Smyth, E, Blasko, A, Fitzgerald, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1926

823PMolecular subtypes of metastatic (met) gastric cancer (GC) (MoTriGastric): New biomarkers closer to the clinics

Alsina Maqueda, M, Ruiz, F, Landolfi, S, Viaplana, C, Miquel, J M, Jimenez, J, Diez, M, Gullo, I, Mirallas, O, Tabernero, J, Carneiro, F, Nuciforo, P G, Vivancos, A, Dienstmann, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1927

824PExploring candidate signal transduction pathways for targeted therapy in esophageal cancer

Creemers, A, Meijer, S L, Holtzer, L, Stoffels, M, van Ooijen, H, van Brussel, A G C, Aussems-Custers, E M G, van Berge Henegouwen, M I, Hulshof, M, Krishnadath, S K, van de Stolpe, A, Bijlsma, M F, v

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1928

825PClinical implication of CLDN18, RhoGAP, and E-cadherin in gastric signet ring cell carcinoma

Kim, H, Kim, S, Park, J M, Lee, H H, Song, K Y, Kim, S-Y, Kim, J-O, Lee, S H, Kim, I-H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1929

826PIdentification of a spectrum of germline mutations for hereditary diffuse gastric cancer in the Russian population by next-generation sequencing

Efimova, I U, Ignatova, E, Bykov, I, Kalinkin, A I, Tanas, A S, Alekseeva, E A, Strelnikov, V V, Alakunov, A, Kuznetsova, E, Nemtsova, M V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1930

827PThe molecular profiling and prognostic value of Chinese gastric signet ring cell carcinoma patients

Wei, J, wang, Y, Liu, L, Qiao, C, Hu, J, Wang, W, Wang, J, Yao, M, Wang, K, Liu, B, Cui, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1931

828TiPSimultaneous resection of pancreatic cancer and liver oligometastases after induction chemotherapy in stage IV patients: An open-label prospective randomized multicenter phase III trial (CSPAC-1)

Wei, M, Shi, S, Xu, J, Shen, B, Mou, Y, Qin, R, Fang, W, Chen, R, Wang, W, Shao, C, Yu, X

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1932

829TiPMulticenter randomized phase II trial of 5-fluorouracil/leucovorin (5-FU/LV) with or without liposomal irinotecan (nal-IRI) in metastatic biliary tract cancer (BTC) as second-line therapy after progression on gemcitabine plus cisplatin (GemCis): NIFTY trial

Yoo, C, Jeong, J H, Kim, K-P, Cheon, J, Kim, I, Kang, M, Ryu, H, Kang, B W, Ryoo, B-Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1933

830TiPA randomized phase II study of maintenance therapy with multiepitope vaccine tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM – PRODIGE 63 GERCOR study)

Neuzillet, C, Hautefeuille, V, Lambert, A, Garcia-Larnicol, M-L, Vernerey, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

1934

831TiPA phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1

Oh, D-Y, Chen, L-T, He, A R, Okusaka, T, Qin, S, Chin, S, Rokutanda, N, Uchinda, H, Vogel, A, Valle, J W, Kim, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1935

832TiPInfigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial

Abou-Alfa, G K, Borbath, I, Clarke, S J, Hitre, E, Louvet, C, Macarulla, T, Oh, D-Y, Spratlin, J L, Valle, J W, Weiss, K H, Berman, C, Howland, M, Ye, Y, Cho, T, Moran, S, Javle, M M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

1936

834TiPA randomized controlled, open label, adaptive phase III Trial to evaluate safety and efficacy of endoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment

Chen, L-T, Hitre, E, Lee, W-J, Bai, L-Y, Papaï, Z, KANG, S Y, Dvorkin, M, Choi, H J, Oh, S C, Artru, P, Bachet, J-B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1937

835TiPModified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase II trial of the German Gastric Group of the AIO

Lorenzen, S, Pauligk, C, Goetze, T O, Riera Knorrenschild, J, Goekkurt, E, Kullmann, F, Pink, D, Ettrich, T J, Homann, N, Angermeier, S, Thuss-Patience, P C, Lindig, U, Bitzer, M, Dechow, T, Schuch, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1938

836TiPGLOW: Randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2+/HER2− locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Shah, M, Ajani, J A, Al-Batran, S-E, Bang, Y-J, Catenacci, D V, Enzinger, P, Ilson, D, Kim, S, Lordick, F, Shitara, K, Cutsem, E Van, Arozullah, A, Park, J W, Xu, R-H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

1939

837TiPPRODIGE67_UCGI33 ARION: Association of radiochemotherapy and immunotherapy for the treatment of unresectable oesophageal cancer: A comparative randomized phase II trial

Guimbaud, R, Quero, L, Vendrely, V, Tougeron, D, Benerezy, K, Samalin, E, Aparicio, T, Zitvogel, L, Selves, J, Otal, P, Cohen-Jonathan Moyal, E L, Delord, J-P, Pezzella, V, Filleron, T, Modesto, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1940

838TiPRandomized phase II trial of weekly paclitaxel + ramucirumab versus weekly nab-paclitaxel + ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy: WJOG10617G/P-SELECT

Hirata, K, Hamamoto, Y, Tsuchihashi, K, Kondoh, C, Yamazaki, K, Hironaka, S, Ando, M, Imamura, C K, Yoshimura, K, Muro, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1941

839TiPFRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for locally advanced esophageal carcinoma

Yamamoto, S, Kato, K, Daiko, H, Kojima, T, Hara, H, Abe, T, Tsubosa, Y, Nagashima, K, Kitagawa, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1942

841TiPPerioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK

Al-Batran, S-E, Pauligk, C, Hofheinz, R D, Lorenzen, S, Wicki, A, Siebenhuener, A R, Schenk, M, Thuss-Patience, P C, Kretzschmar, A, Bolling, C, Eigendorff, E, Angermeier, S, Pink, D, Geissler, M, Goe

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1943

842TiPNal-iri/lv5-fu versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study

Randrian, V, Adenis, A, Desrame, J, Barbier, E, Di Fiore, F, Lievre, A, Dahan, L, Laurent-Puig, P, Mineur, L, Breysacher, G, Roquin, G, Louafi, S, Lopez, A, Louvet, C, Borg, C, Metges, J-P, Faroux, R,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

1944

848PDPhase II study of pembrolizumab with enzalutamide (Enz) in metastatic, castration-resistant prostate cancer (mCRPC): 30 patient expansion with examination of tumour-infiltrating immune cells and fecal microbiota

Graff, J N, Moran, A E, Slottke, R E, Thomas, G V, Alumkal, J J, Thompson, R F, Wood, M A, Peiffer, L B, Bergan, R C, Sfanos, K S, Beer, T M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1945

849PDPreliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)

Tagawa, S T, Osborne, J R, Hackett, A, Niaz, M J, Cooley, V, Christos, P, Vlachostergios, P J, Thomas, C, Gracey, L, Beltran, H, Molina, A M, Nanus, D M, Babich, J, Vallabhajosula, S, Sartor, O, Ballm

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 97 KB

2019

1946

850PDBenefit of prostate radiotherapy for patients with lymph node only or

Ali, S A, Hoyle, A, James, N D, Parker, C, Brawley, C, Attard, G, Douis, H, Mason, M D, Parmar, M K B, Sydes, M R, Clarke, N W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1947

851PDPatient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)

Agarwal, N, McQuarrie, K, Bjartell, A, Chowdhury, S, Gomes, A J P D S, Chung, B H, Özgüroğlu, M, Soto, Á Juárez, Merseburger, A, Uemura, H, Ye, D, Given, R, Miladinovic, B, Dearden, L, Deprince, K, Na

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 98 KB

2019

1948

855PDDocetaxel for hormone-naïve prostate cancer (PCa): Results from long-term follow-up of non-metastatic (M0) patients in the STAMPEDE randomised trial

James, N D, Ingleby, F C, Clarke, N W, Amos, C, Attard, G, Cross, W, Dearnaley, D, Gilbert, D, Jones, R, Langley, R, Mason, M D, Matheson, D, Parker, C, Ritchie, A, Rush, H L, Russell, M, Pereira Mest

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1949

852POverall survival (OS) and metastasis-free survival (MFS) in men with biochemically relapsed (BCR) prostate cancer after radical prostatectomy (RP) managed with deferred androgen deprivation treatment (ADT): A combined Johns Hopkins and CPDR study

Marshall, C H, Chen, Y, Cullen, J, Rosner, I, Markowski, M, Trock, B, Eisenberger, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

1950

853PARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups

Stenzl, A, Szmulewitz, R Z, Petrylak, D P, Holzbeierlein, J, Villers, A, Azad, A A, Alcaraz, A, Alekseev, B Y, Iguchi, T, Shore, N D, Rosbrook, B, Baron, B, Haas, G P, Morlock, R, Ramaswamy, K, Armstr

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

1951

854PUpdated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study)

Caffo, O, Palesandro, E, Nole, F, Gasparro, D, Mucciarini, C, Aieta, M, Zagonel, V, Iacovelli, R, Giorgi, U F F De, Rossetti, S, Fratino, L, Ermacora, P, Nicodemo, M, Giordano, M, Sartori, D, Scapoli,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

1952

856PReal-world analysis of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence

Morgans, A K, Divan, H A, Birtle, A J, Dorff, T, Ozatilgan, A, Graff, J N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1953

857PBaseline fracture risk in men with prostate cancer starting the STAMPEDE trial

Brown, J E, Handforth, C, Walsh, J, Pezaro, C, Sydes, M R, Clarke, N W, James, N D, McCloskey, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

1954

858PRisk of falls and fractures in patients with castration resistant prostate cancer (CRPC) treated with new hormonal agents: A meta-analysis of randomized controlled trials

Mariano, R Coutinho, Gomes, L M, Oliveira, C, Galdino, A C, Araújo, J A P, Vargas, D, Maluf, F C, De Velasco Oria de Rueda, G A, Schutz, F A B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1955

859PPain progression at initiation of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: A post-hoc analysis of FIRSTANA

Delanoy, N, Robbrecht, D, Fizazi, K, Mercier, F, Sartor, O, Wit, R De, Oudard, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1956

860PPain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study

Palmedo, H, Eschmann, S, Werner, A, Selinski, I, Möllers, M-O, Kalinovsky, J, Benson, A, Poeppel, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1957

861PTime to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders

Conteduca, V, Caffo, O, Scarpi, E, Sepe, P, Galli, L, Fratino, L, Maines, F, Chiuri, V E, Santoni, M, Zanardi, E, Massari, F, Toma, I, Schepisi, G, Sbrana, A, Kinspergher, S, Cursano, M C, Modonesi, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

1958

863PCabazitaxel for octogenarian patients with metastatic castration-resistant prostate cancer (MCRPC)

Tralongo, P, Bordonaro, S, Lorenzo, G Di, Borsellino, N, Facchini, G, Rossetti, S, Martelli, V, Longo, V, Tralongo, A C, Caspani, F, Tuzi, A, Spada, M, Calvani, N, Carlini, P, Giorgi, U F F De

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1959

864PExternal validation of a prognostic score in first-line metastastic castration-resistant prostate cancer (mCRPC)

Lorente, D, Mejorada, R Lozano, de Rueda, G A De Velasco Oria, Hernandez, A Sanchez, Aliaga, M Rodrigo, Iglesias, Á Sánchez, Campayo, M de Julián, Campos, F Lopez, Laorden, N Romero, Castro, E, Hidalg

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

1960

866PPelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion>5%: A propensity score matching analysis from SEER database

Chen, J, Wang, Z, Zhao, J, Zhu, S, Sun, G, Liu, J, Zhang, H, Zhang, X, Shen, P, Zeng, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1961

867PMulti-institutional evaluation of therapeutic management for oligometastatic cancer prostate recurrence with choline-PET/CT

Guibert-broudic, M, Dubergé, T, Autret, A, Carrier, P, Salem, N, Walz, J, Brenot-Rossi, I, Gravis, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1962

868PSafety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): A network meta-analysis of randomized controlled trials (RCT)

Altavilla, A, Maio, M Di, Tucci, M, Lolli, C, Schepisi, G, Buttigliero, C, Vignani, F, Giorgi, U De

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1963

869PReal-world use of radium-223 for treatment of metastatic castration resistant-prostate cancer (mCRPC): Results from the Dutch CAPRI registry

Kuppen, M C P, Westgeest, H M, van den Eertwegh, A J M, Moorselaar, J Van, Mehra, N, Coenen, J L, van Oort, I, van den Bergh, A C M, Lavalaye, J, Aben, K K H, Somford, D M, de Wit, R, Bergman, A M, Uy

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1964

870PA phase IIa study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)

Petrylak, D P, Vaishampayan, U N, Patel, K R, Higano, C S, Albany, C, Dawson, N A, Mehlhaff, B A, Quinn, D I, Nordquist, L T, Wagner, V J, Shen, J, Trandafir, L, Sartor, O

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1965

872PSafety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA

Tauber, R L, Feuerecker, B, Knorr, K, Beheshti, A, Seidl, C, D’Alessandria, C, Bruchertseifer, F, Retz, M, Gschwend, J E, Weber, W, Morgenstern, A, Eiber, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1966

873PPhase II trial of SM 88 in non-metastatic biochemical recurrent prostate cancer

Gartrell, B, Del Priore, G, Retter, A, Chen, W-T, Sokol, G H, Vandell, A, Roach, M, Scher, H I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1967

874PA phase I study of Ad5 PSA/MUC-1/brachyury vaccine in patients with metastatic castration resistant prostate cancer (mCRPC)

Bilusic, M, Madan, R A, Karzai, F H, McMahon, S, Donahue, R N, Strauss, J, Gatti-Mays, M E, Redman, J, Cordes, L M, Palena, C, Gabitzsch, E S, Jones, F R, Balint, J P, Soon-Shiong, P, Rabizadeh, S, Po

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

1968

875PMulticenter phase I trial of a DNA vaccine encoding the androgen receptor ligand binding domain (pTVG-AR, MVI-118) in patients with metastatic prostate cancer

McNeel, D G, Saraiya, B, Schweizer, M, Eickhoff, J, Wargowski, E, Lesniewski, R, Olson, B, Kyriakopoulos, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1969

876PImpact of germline mutations in homologous recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC)

Castro, E, Mejorada, R Lozano, Saez, M, De Giorgi, U F F, Aragón, I, Laorden, N Romero, De Velasco Oria de Rueda, G A, Magraner, L, Pacheco, M I, Puente, J, del Alba, A González, Garcia, P Borrega, Co

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

1970

877PSerum biomarkers of bone metabolism in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra223): Results from a prospective multicentre study

Laorden, N Romero, Mejorada, R Lozano, Jorge, A Hernández, Lainez, N, Casado, E Almagro, Calvo, O Fernández, Hernando, S, Freire, A Fernández, Billalabeitia, E Gonzalez, Chirivella, I, Domínguez, R Ga

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1971

878PPrognostic value of tumour suppression genes (TP53, PTEN, Rb) in metastatic hormone sensitive prostate cancer

Velez, M G Gonzalez, Kosiorek, H E, Egan, J, Bryce, A H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1972

879PGermline sequencing of advanced prostate cancer patients in the BARCODE2 trial

Benafif, S, Rageevakumar, R, Whitmore, I, Cieze-Borrella, C, Saunders, E, Kote-Jarai, Z, Eeles, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1973

882PActivating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC)

Fu, S Y F, Murtha, A, Herberts, C, Yip, S, Angeles, A, Hotte, S J, Alshangiti, A, Tran, B, Taavitsainen, S, Annala, M, Saad, F, Iqbal, N N, Wyatt, A W, Chi, K N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1974

884P68Ga-PSMA guided bone biopsies for molecular diagnostics in metastatic castration resistant prostate cancer patients

de Jong, A C, Segbers, M, Smits, M, Brabander, T, de Wit, R, Mehra, N, der Veldt, A A M Van, Lolkema, M P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1975

886PEfficacy of enzalutamide in hormone-sensitive metastatic prostate cancer: Clinical utility of 18F-choline PET and whole body MRI

Osanto, S, Alvarez, C, Bloem, H, van der Hulle, T, Jonker, M, Ozdemir, M, Goossens, K, Wijffelman, M, Pelger, R, Poppel, H Van, Burggraaf, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1976

887PUrine extracellular vesicle GATA2 mRNA alone and in a multigene test predicts initial prostate biopsy result

Woo, J, Santasusagna, S, Banks, J, Dominguez-Andres, A, Yadav, K, Pippa, R, Carceles-Cordon, M, Lallas, C D, Luyao, G, Rodriguez-Bravo, V, Tewari, A, Pastor-Lopez, S, Kelly, W K, Leiby, B E, Prats, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

1977

889PCirculating tumour cells (CTC) count and prostate-specific antigen (PSA) response measures in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (Doc)

Mejorada, R Lozano, Lorente, D, Castro, E, Bianchini, D, Nombela, P, Sandhu, S K, Laorden, N Romero, Cendón, Y, Sharp, A, Casado, E Almagro, Pacheco, M I, Rescigno, P, LLácer, C, Saez, M, Rivera, L, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1978

890PAssessing the clinical relevance of drug-drug interactions (DDI) with darolutamide (DARO)

Zurth, C R, Fizazi, K, Fricke, R, Gieschen, H, Graudenz, K, Koskinen, M, Ploeger, B A, Prien, O, Smith, M R, Tammela, T, Shore, N D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1979

892TiPKEYNOTE-641: Phase III study of pembrolizumab (pembro) plus enzalutamide for metastatic castration-resistant prostate cancer (mCRPC)

Graff, J N, Burgents, J, Liang, L W, Stenzl, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

1980

893TiPKEYLYNK-010: Phase III study of pembrolizumab (pembro) plus olaparib (OLA) vs enzalutamide (ENZA) or abiraterone (ABI) in ENZA- or ABI-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who had progression on chemotherapy (CTx)

Yu, E, Xu, L, Kim, J, Antonarakis, E S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

1981

894TiPPROSTRATEGY: A Spanish Genitourinary Oncology Group (SOGUG) multi-arm multistage (MAMS) phase III trial of immunotherapy strategies in high-volume metastatic hormone-sensitive prostate cancer

Arija, J A Arranz, Valderrama, B P, Gordoa, T Alonso, Diaz, E Gallardo, Sanchez, J M Sepulveda, Fernandez-Parra, E, Piulats, J M, Vidal, M J Mendez, González, N Sala, Estevez, S Vazquez, Lainez, N, Za

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1982

895TiPA phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Tran, B, Kouros-Mehr, H, Fermin, A, Horvath, L, Roncolato, F, Rettig, M, Dorff, T, Tagawa, S T, Subudhi, S K, Antonarakis, E S, Armstrong, A J, Petrylak, D P, Fizazi, K, Salvati, M E, Scher, H I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1983

896TiPProBio: An outcome-adaptive, multi-arm, open-label, multiple assignment randomised controlled biomarker-driven trial in patients with metastatic castration-resistant prostate cancer

Lindberg, J, Laere, B De, Crippa, A, Eklund, M, Grönberg, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

1984

898TiPThe extended/phase II study of safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate resistant prostate cancer (mCRPC) who failed either abiraterone (Abi) or enzalutamide (Enza)

Vogelzang, N J, Gabrail, N, Malik, Z, Volterra, F, Nordquist, L T, Levin, R, Zhang, P, Zhou, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

1985

899TiPAddition of an oral docetaxel treatment (ModraDoc006/r) to androgen deprivation therapy (ADT) and intensity-modulated radiation therapy (IMRT) in patients with high risk N+M0 prostate cancer

Vermunt, M A C, Janssen, J M, Vrijenhoek, G L, van der Poel, H G, Thijssen, B, Beijnen, J H, van Triest, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

1986

900TiPA phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy with LHRH agonist or antagonist versus anti-androgen therapy with apalutamide in patients with biochemical progression after radical prostatectomy

Dirix, P, Strijbos, M, Fransis, K, Liefhooghe, N, Bruwaene, S Van, Uvin, P, Ghysel, C, Ost, D, Engels, B, den Begin, R Van, Otte, F-X, Roumeguere, T, Palumbo, S, Neybuch, Y, Fonteyne, V, Renard, L, Ev

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

1987

902OAn adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies

Powles, T, Balar, A, Gravis, G, Jones, R, Ravaud, A, Florence, J, Grivas, P, Petrylak, D P, Galsky, M, Carles, J, Sridhar, S, Arkenau, H-T, Carroll, D, DeCesare, J, Mercier, F, Hodgson, D, Stone, J, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 109 KB

2019

1988

904PDPre-operative ipilimumab and nivolumab in locoregionally advanced, stage III, urothelial cancer (NABUCCO)

Van der Heijden, M S, van Dijk, N, Smit, L, Hendricksen, K, de Feijter, J M, Bekers, E, Hooijberg, E, van Rooijen, C C N, Broeks, A, Lubeck, Y, Sikorska, K, Schumacher, T N, Kvistborg, P, Boellaard, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1989

905PDMultiple-cohort analysis investigating FGFR3 alteration as a predictor of non-response to neoadjuvant pembrolizumab (pembro) in muscle-invasive bladder cancer (MIBC)

Necchi, A, Madison, R, Chung, J, Raggi, D, Briganti, A, Montorsi, F, Boormans, J L, Liu, Y, De Jong, J J, Chung, J, Black, P C, Ross, J S, Ali, S M, Davicioni, E, Gibb, E A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

1990

906PDPhase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Comprehensive tumour genomic and transcriptomic analyses

Ravaud, A, Martini, J-F, Ching, K, Staehler, M, Magheli, A, Escudier, B, Mu, X J, Valota, O, Lin, X, Motzer, R J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

1991

907PDADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma

Au, L, Litchfield, K, Rowan, A, Horswell, S, Byrne, F, Nicol, D, Fotiadis, N, Salgado, R F, Hazell, S, Lopez, J I, Hatipoglu, E, Del Rosario, L, Pickering, L, Gore, M, Chain, B, Quezada, S, Larkin, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

1992

908PDPrimary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)

Albiges, L, Rini, B I, Haanen, J B A G, Motzer, R J, Kollmannsberger, C K, Negrier, S, Nole, F, Bedke, J, Bilen, M A, Nathan, P, Tomita, Y, Huang, B, Ching, K A, Chudnovsky, A, Robbins, P B, di Pietro

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

1993

909PDNIVOREN GETUG-AFU 26 translational study: CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N)

Vano, Y, Rioux-Leclercq, N, Dalban, C, Sautès-Fridman, C, Bougoüin, A, Chaput, N, Chouaib, S, Beuselinck, B, Chevreau, C M, Gross-Goupil, M, Negrier, S, Laguerre, B, Borchiellini, D, Colina-Moreno, I,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

1994

911PDA first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC

Jonasch, E, Plimack, E R, Bauer, T, Merchan, J R, Papadopoulos, K P, McDermott, D F, Michaelson, M D, Appleman, L J, Thamake, S, Zojwalla, N, Choueiri, T K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

1995

912PDResults of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or metastatic renal cell carcinoma (mRCC)

Choueiri, T K, Kocsis, J, Pachynski, R K, Poprach, A, Deshazo, M, Zakharia, Y, Lara, P N, Pal, S K, Geczi, L, Ho, T H, Mangel, L, Redman, B, Ryan, C W, Olencki, T, Simpson, B E, Adams, B, Robertson, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

1996

913PDAPACHE: An open label, randomized, phase II study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with refractory germ cell tumours (GCT): Results from the expanded combination therapy cohort

Farè, E, Raggi, D, Giannatempo, P, Colecchia, M, Calareso, G, Ali, S M, Chung, J, Ross, J S, Necchi, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

1997

914PDPrognostic factors in metastatic seminomatous germ cell tumours and elevated human chorionic gonadotrophin (HCG): A study of the G3

Seidel, C, Daugaard, G, Nestler, T, Tryakin, A, Fankhauser, C D, Hermanns, T, Aparicio, J, Heinzelbecker, J, Pfaffenholz, P, De Giorgi, U, Cathomas, R, Lorch, A, Fingerhut, A, Gayer, F, Bremmer, F, Gi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 97 KB

2019

1998

915PDDiagnosis, management, and burden of renal cell carcinomas: Results from a global patient survey in 43 countries

Giles, R, Maskens, D, Bick, R, Martinez, R, Packer, M, Bex, A, Heng, D Y C, Larkin, J M G, Maclennan, S J, Jewett, M, Jonasch, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

1999

916PHealth-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG)

de Wit, R, Kulkarni, G S, Uchio, E, Boormans, J L, Roumiguié, M, Krieger, L E M, Singer, E A, Bajorin, D F, Kamat, A M, Grivas, P, Seo, H K, Nishiyama, H, Konety, B R, Saretsky, T, Li, H, Nam, K, Sbar

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

2000

918PAtezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): A long-term overall survival (OS) and safety update from the phase III IMvigor211 study

Van der Heijden, M S, Loriot, Y, Duran, I, Ravaud, A, Retz, M M, Vogelzang, N J, Nelson, B, Wang, J, Shen, X, Powles, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2001

919PThree-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)

Necchi, A, Fradet, Y, Bellmunt, J, de Wit, R, Lee, J-L, Fong, L, Vozelgang, N J, Climent, M A, Petrylak, D P, Choueiri, T K, Gerritsen, W R, Gurney, H, Quinn, D I, Culine, S, Sternberg, C N, Nam, K, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 97 KB

2019

2002

920PFirst report of efficacy and safety from a phase II trial of tislelizumab, an anti-PD-1 antibody, for the treatment of PD-L1+ locally advanced or metastatic urothelial carcinoma (UC) in Asian patients

Ye, D, Liu, J, Zhou, A, Zou, Q, Li, H, Fu, C, Hu, H, Huang, J, Zhu, S, Jin, J, Ma, L, Guo, J, Xiao, J, Park, S H, Zhang, D, Qiu, X, Bao, Y, Zhang, L, Shen, W, Feng, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

2003

921PQuality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a checkpoint inhibitor (CPI): Data from EV-201 cohort 1

McGregor, B A, O’Donnell, P H, Balar, A, Petrylak, D P, Rosenberg, J E, Yu, E, Quinn, D I, Shah, S N, Pinelli, J, Hepp, Z, Galsky, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

2004

922PSafety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma

Loriot, Y, Sternberg, C N, Castellano Gauna, D, Dumez, H, Huddart, R, Vianna, K M, Alonso Gordoa, T, Skoneczna, I A, Fay, A, Sacco, C S P, Nole, F, Massari, F, Brasiuniene, B, Maroto, P, Oosting, S F,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

2005

923PValidation of the VIO prognostic index in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors

Morales Barrera, R, Matos, I, Gonzalez, M, Suárez, C, Ros, J, Valverde, C, Fernandez, C, Hierro, C, Serra, E, Mateo, J, Gutierrez, S, Martín Liberal, J, Quintana, A, Dienstmann, R, Serrano, C, Garrald

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

2006

924PPathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer

Matulay, J T, Campbell, M T, Narayan, V M, Seif, M A, Lim, A H, Shah, A Y, Msaouel, P, Gao, J, Siefker-Radtke, A O, Dinney, C P N, Kamat, A M, Navai, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2007

925PAnalysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients (pts) with metastatic urothelial carcinoma (mUC)

Siefker-Radtke, A, Zhong, B, Qi, K, Shalaby, W, De Porre, P, O’Hagan, A, Mahadevia, P, Loriot, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2008

926PErdafitinib (erda) versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison

Loriot, Y, Van Sanden, S, Diels, J, Rahhali, N, Seshagiri, D, Kowalski, B, Fleming, S, De Porre, P, Siefker-Radtke, A O

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2009

928PNational small cell bladder cancer audit: Results from 26 UK institutions

Chau, C, Rimmer, Y, Law, A, Leaning, D, Lim, J H, Young, T, Hafeez, S, Mitchell, D, McGrane, J, Beresford, M, Vasudev, N, Sim, V-R, Koutalopoulou, A, Hilman, S, Manetta, C, Rajagopalan, S, Sharma, A,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2010

929PBiomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase III study

van der Heijden, M, Powles, T, Petrylak, D, de Wit, R, Chi, K, Necchi, A, Sternberg, C N, Matsubara, N, Nishiyama, H, Castellano, D, Hussain, S, Bamias, A, Hozak, R, Rhodes, R, Xia, M S, Rasmussen, E,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

2011

930PComparison of immuno-oncology (IO) biomarkers in adenocarcinoma (ACB), urothelial carcinoma (UCB) and squamous cell carcinoma (SCCB) of the bladder, with interim results from PURE01

Raggi, D, Ross, J S, Ali, S M, Chung, J, Schrock, A B, Madison, R, Alexander, B M, Grivas, P, Necchi, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2012

931PPotential role of a clinical, taxonomical classification and RNA expression integrated signature to predict response to neoadjuvant platinum-based chemotherapy in muscle-invasive bladder cancer (MIBC) patients

Font, A, Domenech, M, Ramirez, J L, Gago, J, Carrato, C, Cadenas, B, Benítez, R, Lobato, T, Pineda, S, Ruiz de Porras, V, Calle, M L, Malats, N, Real, F X

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2013

933PPrognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting

Roghmann, F, Wirtz, R, Jarczyk, J, Kriegmair, M C, Worst, T S, Sikic, D, Wach, S, Taubert, H, Wullich, B, Weyerer, V, Stoehr, R, Zengerling, F, Bolenz, C, Breyer, J, Burger, M, Porubsky, S, Hartmann,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2014

934PCirculating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)

Lavoie, J-M, Vandekerkhove, G, Annala, M, Taavitsainen, S, Sundahl, N L, Walz, S, Sano, T, Khalaf, D, Todenhöfer, T, Ost, P, Kollmannsberger, C K, Chi, K N, Black, P C, Wyatt, A W, Eigl, B J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2015

936PComparative analysis of tumour mutational burden (TMB) prediction methods and its association with determinants of the tumour immune microenvironment of urothelial bladder cancer (UBC)

Eckstein, M, Hartmann, A, Strissel, P, Strick, R, Wach, S, Taubert, H, Wullich, B, Geppert, C, Weyerer, V, Stoehr, R, Rübner, M, Fasching, P A, Rabizadeh, S, Benz, S, Haller, F, Moskalev, E, Toegel, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

2016

937PThe immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: Clinical significance for pathological response and survival

Nassif, E F, Mlecnik, B, Thibault, C, Barthere, X, Auvray, M, Bruni, D, Comperat, E, Colau, A, Hermitte, F, Camparo, P, Colin, P, Bruno, D, Bennamoun, M, Audenet, F, Mejean, A, Verkarre, V, Zakopoulou

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

2017

938PGenomic analysis of urothelial cancer and associations with treatment choice and outcome

Sarid, D L, Berger, R, Levertovsky, M, Gadot, M, Maurice-Dror, C, Peer, A, Perets, R, Purim, O, Sarfaty, M, Rosenbaum, E, Neiman, V, Ligumsky, H, Rouvinov, K, Romanov, E, Marmelstein, W, Shani-Shrem,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

2018

940PcfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)

Pal, S K, Bajorin, D F, Hoffman-Censits, J H, Quinn, D I, Petrylak, D P, Galsky, M D, Vaishampayan, U N, De Giorgi, U, Gupta, S, Burris, H A, Soifer, H S, Li, G, Dambkowski, C L, Moran, S, Wang, H, Da

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

2019

941PEfficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial

Jarczyk, J, Wirtz, R, Roghmann, F, Juette, H, Kriegmair, M C, Worst, T S, Sikic, D, Wach, S, Taubert, H, Wullich, B, Weyerer, V, Stoehr, R, Zengerling, F, Bolenz, C, Breyer, J, Burger, M, Porubsky, S,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2020

942PA differential bladder microbiota composition is associated with tumour grade in bladder cancer

Parra-Grande, M, Oré-Arce, M, Sánchez-Hellín, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2021

943PMolecular characterization of metastatic urothelial carcinoma (mUC) in prior or current smokers (PCS) vs non-smokers (NS)

Sacristan Santos, V, Esther, J, Maughan, B L, Wesolowski, S, Lin, E, Hahn, A, Sirohi, D, Rathi, N, Swami, U, Nussenzveig, R, Agarwal, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2022

945PGenomic characterization of non-schistosomiasis-related squamous cell carcinoma (NSR-SCC) of the urinary bladder: A retrospective study of potential prognostic and predictive biomarkers

Al-ezzi, E M, Veitch, Z W, Salah, S, Van der Kwast, T, Stockley, T, Malone, E, Sridhar, S, Sacher, A G, Fallah-rad, N, Kulkarni, G, Zlotta, A, Finelli, A, Hansen, A R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2023

947PTiNivo: Tivozanib combined with nivolumab results in prolonged progression free survival in patients with metastatic renal cell carcinoma (mRCC): Final results

Barthelemy, P, Escudier, B, Negrier, S, Ravaud, A, Needle, M N, Albiges, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

2024

948PFirst-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B

Suárez, C, Lee, J-L, Ziobro, M, Gafanov, R A, Matveev, V B, Donskov, F, Pouliot, F, Alekseev, B Y, Wiechno, P J, Tomczak, P, Climent, M A, Shin, S J, Kloss Silverman, R, Perini, R F, Schloss, C, McDer

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2025

949PFirst-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A

Larkin, J M G, Tykodi, S S, Donskov, F, Lee, J-L, Szczylik, C, Malik, J, Alekseev, B Y, Matveev, V B, Gafanov, R A, Tomczak, P, Geertsen, P F, Wiechno, P J, Shin, S J, Pouliot, F, Alonso Gordoa, T, Kl

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2026

950PAssociation between depth of response and overall survival: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214

Grünwald, V, Choueiri, T K, Rini, B I, Powles, T, George, S, Grimm, M-O, McHenry, M B, Maurer, M, Motzer, R J, Hammers, H J, Tannir, N M, Albiges, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2027

951PQuality of life in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214: Updated results

Cella, D, Escudier, B, Ivanescu, C, Mauer, M, Lord-Bessen, J, Gooden, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2028

952PResults of phase I clinical trial of high doses of seleno-l-methionine (SLM) in sequential combination with axitinib in previously treated and relapsed clear cell renal carcinoma (ccRCC) patients

Zakharia, Y, Garje, R, Brown, J, Nepple, K, Bellizzi, A, Bonner, J, Parr, D, Born, J, Sieren, J, Park, J, Milhem, M, Rustum, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2029

953PSafety and efficacy of CDX-014, an antibody-drug conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced renal cell carcinoma

McGregor, B A, Agarwal, N, Gordon, M, George, S, Quinn, D I, Rogalski, M, Keler, T, Hawthorne, T, Choueiri, T K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2030

955PEffect of antacid intake on the therapeutic efficacy of sunitinib (SUN) in metastatic renal cell carcinoma (mRCC) patients (pts): A sub-analysis of the STAR-TOR registry

Schlack, K, Boegemann, M, Woike, M, Krekeler, G, Fischer, T, Bergmann, L, Rink, M, Schmid, M, Strauss, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2031

956PRandomized phase III trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis

Uemura, M, Tomita, Y, Miyake, H, Hatakeyama, S, Kanayama, H-O, Numakura, K, Takagi, T, Kato, T, Eto, M, Obara, W, Uemura, H, Motzer, R J, Fujii, Y, Kamei, Y, Oya, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2032

957POverall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)

Finek, J, Poprach, A, Melichar, B, Kopecky, J, Zemanova, M, Buchler, T, Kopeckova, K, Mlcoch, T, Dolezal, T, Fiala, O

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2033

958PCombination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials

Thein, K Z, Mogollon-Duffo, F, Swarup, S, Sultan, A, Yendala, R, Jahan, N, Quirch, M, Ball, S, Htut, T Win, D’Cunha, N, Rehman, S, Hardwicke, F, Awasthi, S, Tijani, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2034

959PA phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH)

Grünwald, V, Grüllich, C, Ivanyi, P, Wirth, M, Staib, P, Schostak, M, Dargatz, P, Müller, L, Metz, M, Bergmann, L, Welslau, M K, Schütt, P, Rafiyan, M-R, Hellmis, E, Hinke, A, Meiler, J, Kretz, T, Loi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2035

960PNivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)

Hans, S, Simonaggio, A, Hamidatou, K, Fournier, L, Thibault, C, Elaidi, R-T, Oudard, S, Vano, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2036

961PFirst results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES study

Masini, C, Ciammella, P, Timon, G, Gnoni, R, De Giorgi, U F F, Bellia, S R, Buti, S, Salaroli, F, Milella, M, Mazzarotto, R, Mucciarini, C, Vitale, M G, Bruni, A, Procopio, G, Kinspergher, S, Nole, F,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2037

962PReal world experience of nivolumab therapy in metastatic renal cancer patients: A 3 year multi-centre review

Hack, J, Hill, S L, Broadfoot, J, Chau, C, Geldart, T, Gale, J, Fife, K, Wheater, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2038

963PA pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC)

Campbell, M T, Martin, S, Tam, A L, Sheth, R A, Singh, S, Ahrar, K, Slack Tidwell, B, Rao, P, Karam, J A, Wood, C G, Tannir, N M, Jonasch, E, Gao, J, Shah, A Y, Blando, J M, Duan, F, Basu, S, Allison,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

2039

964PLenvatinib (Len) alone or in combination with everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience

Wiele, A J, Ross, J, Chahoud, J, Lim, Z, Xiao, L, Campbell, M T, Shah, A Y, Zurita Saavedra, A, Jonasch, E, Tannir, N M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2040

965PWeight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC)

Colomba, E, Alves Costa Silva, C, Le Teuff, G, Benchimol-Zouari, A, Guida, A, Derosa, L, Raynard, B, Escudier, B, Albiges, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2041

966PImpact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma

Lefort, F, Dalban, C, Gross-Goupil, M, Laguerre, B, Barthelemy, P, Sarradin, V, Chanez, B, Negrier, S, Geoffrois, L, Gillon, P, De Vries, M, Ladoire, S, Bolognini, C, Laramas, M, Priou, F, Oudard, S,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2042

967PSkeletal muscle loss as an adverse event during cabozantinib treatment in patients with metastatic renal cell carcinoma

Alves Costa Silva, C, Afonso, D, Colomba, E, Le Teuff, G, Derosa, L, Raynard, B, Guida, A, Benchimol-Zouari, A, Escudier, B, Bidault, F, Albiges, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2043

968PLong term relative survival (RS) in patients with primary metastatic kidney cancer (primary mRCC): An analysis of 2,167 patients from the Austrian National Cancer Registry (ANCR)

Hackl, M, Karim-Kos, H, Madersbacher, S, Rauchenwald, M, Marszalek, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2044

969PAdvanced renal cell carcinoma: First results from the prospective research platform CARAT for patients with mRCC in Germany

Goebell, P J, Mueller, L, Grüllich, C, Reichert, D, Bögemann, M, Dörfel, S, von der Heyde, E, Binninger, A, Jänicke, M, Merling, M, Marschner, N W, Staehler, M, Grünwald, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2045

970PAre immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? Transcriptomic characterization of the immune infiltrate

De Vries-brilland, M, Menand, E, Seegers, V, Dauvé, J, Passot, C, Marion, J-M, Chauvet, P, Morel, A, Gross-Goupil, M, Ravaud, A, Boughalem, E, Escudier, B, Albiges, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2046

971PTreatment-free survival, with and without toxicity, as a novel outcome applied to immuno-oncology agents in advanced renal cell carcinoma

Regan, M M, Atkins, M B, Powles, T, Werner, L, Mantia, C, Yang, S, Johansen, J L, Rao, S, Gooden, K M, McDermott, D F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2047

972PFresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: Association with toxicity and treatment outcome

Desnoyer, A, Larive, A, Drubay, D, Lanoy, E, Vano, Y, Rioux-Leclercq, N, Chouaib, S, Beuselinck, B, Tantot, F, Escudier, B, Chaput, N, Albiges, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2048

973PAdvanced clear-cell renal cell carcinoma (accRCC): Association of microRNAs (miRNAs) with molecular subtypes, mRNA targets and outcome

Verbiest, A T L, Van Hoef, V, Lambrechts, D, Rodriguez Antona, C, Grana-Castro, O, Inglada-Perez, L, Albersen, M, Baldewijns, M, Laenen, A, Schoeffski, P, Wozniak, A, Couchy, G, Caruso, S, Zucman-Ross

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2049

974PPrior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients

Iebba, V, Albiges, L, Alla, L, Colomba, E, Alves Costa Silva, C, Pons, N, Baciarello, G, Le Chatelier, E, Fizazi, K, Routy, B, Escudier, B, Zitvogel, L, Derosa, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

2050

975PmTOR mutations are not associated with shorter PFS and OS in patients treated with mTOR inhibitors

Suarez Rodriguez, C, Arranz Arija, J A, Morales Barrera, R, Puente, J, Reig, O, Faez, L, González del Alba, A, Valderrama, B P, Gallardo, E, Mellado, B, Esteban, E, Jimenez, J, Vivancos, A, Carles, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2051

976PEfficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in advanced renal cell carcinoma (RCC)

Lalani, A-K A, Bakouny, Z, Farah, S, Xie, W, Flippot, R, Steinharter, J A, Nuzzo, P V, Fleischer, J, Pal, S K, Rathi, N, Hansen, A R, Donskov, F, Dudani, S, Yuasa, T, Vaishampayan, U, Subasri, M, Well

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2052

977PFinding the right biomarker for renal cell carcinoma (RCC): Nivolumab treatment induces the expression of specific peripheral lymphocyte microRNAs in patients with durable and complete response

Incorvaia, L, Fanale, D, Badalamenti, G, Iovanna, J L, Corsini, L, Simonato, A, Bazan, V, Porta, C G, Russo, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2053

978PAlgorithms derived from quantitative pathology can be a gatekeeper in patient selection for clinical trials in localised clear cell renal cell carcinoma (ccRCC)

Um, I H, Scott-Hayward, L, MacKenzie, M, Tan, P H, Kanesvaran, R, Choudhury, Y, Tan, M-H, O’Donnell, M, Caie, P D, Stewart, G D, Harrison, D J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2054

979PHigh baseline blood volume is an independent favorable prognostic factor for overall and progression-free survival in patients with metastatic renal cell carcinoma

Drljevic-Nielsen, A, Rasmussen, F, Mains, J R, Thorup, K, Donskov, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2055

981PTERT gene fusions characterize a subset of metastatic Leydig cell tumours

Kruslin, B, Gatalica, Z, Hes, O, Xiu, J, Florento, E, Swensen, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2056

983PDifferential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy

Nappi, L, Thi, M, Eigl, B J, Chi, K N, Gleave, M E, So, A, Black, P C, Hamilton, R, Daneshmand, S, Nichols, C R, Kollmannsberger, C K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

2057

984PPrognosis of anaemia in disseminated testicular germ cell tumours. On behalf of the Spanish Germ Cell Cancer Group (SGCCG)

Garcia Torralba, E, Castellano Gauna, D, Sobrevilla, N, Guma, J, Luengo, M I, Aparicio, J, Sanchez-Muñoz, A, Mellado, B, Saenz, A, Valverde, C, Fernández, A, Margeli, M, Duran, I, Fernandez, S, Sastre

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

2058

985PThe effects of primary testicular tumour localization on prognosis in patients with nonseminomatous testis cancer

Yildiz, B, Esin, E, Basgoz, B B, Erturk, I, Acar, R, Karadurmuş, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

2059

986PInitial results of a phase II study of nivolumab and ipilimumab in metastatic adrenal tumours

Campbell, M T, Xie, W, Shah, A Y, Habra, M A, Jimenez, C, Venkatesan, A M, Bubley, G, McKay, R R, Choueiri, T K, McGregor, B A, Killbridge, K L, Mortazavi, A, Bilen, M A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

2060

987TiPNEMIO: A randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma

Thibault, C, Audenet, F, Borchiellini, D, Huillard, O, Barthelemy, P, Pouessel, D, Flechon, A, Blons, H, Sautès-Fridman, C, Sun, C-M, Verkarre, V, Pallet, N, Mejean, A, Rouabah, M, Helali, I, Elaidi,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

2061

988TiPKEYNOTE-866: Phase III study of perioperative pembrolizumab (pembro) or placebo (pbo) in combination with neoadjuvant chemotherapy in cisplatin (cis)-eligible patients (pts) with muscle-invasive bladder cancer (MIBC)

Siefker-Radtke, A O, Steinberg, G, Bedke, J, Nishiyama, H, Martin, J, Kataria, R, Frenkl, T L, Hoimes, C J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2062

989TiPKEYNOTE-905: A phase III study of cystectomy plus perioperative pembrolizumab versus cystectomy alone in cisplatin (cis)-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC)

Galsky, M, Necchi, A, Shore, N D, Witjes, F, Nam, K, Godwin, J L, Frenkl, T L, Plimack, E R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2063

990TiPPhase III LEAP-011 trial: First-line pembrolizumab with lenvatinib in patients with advanced urothelial carcinoma ineligible to receive platinum-based chemotherapy

Loriot, Y, Balar, A, de Wit, R, Garcia, J A, Grivas, P, Matsubara, N, Frenkl, T L, Sbar, E, Jia, X C, Fouad, T, Siefker-Radtke, A O

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

2064

991TiPPULSE: A single arm trial assessing the activity and safety of avelumab immunotherapy maintenance among patients with locally advanced or metastatic squamous cell penile carcinoma (mSCPC)

Gassian, N, Mouillet, G, Vernerey, D, Manseur, O, Frontczak, A, Meurisse, A, Berthod, D, Robert, E, Calcagno, F, Thiery-Vuillemin, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 67 KB

2019

2065

994OLenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)

Makker, V, Taylor, M H, Aghajanian, C, Oaknin, A, Mier, J, Cohn, A L, Marin, M Romeo, Lorenzo, R Bratos, Brose, M S, DiSimone, C, Messing, M J, Stepan, D E, Dutcus, C E, Wu, J, Schmidt, E V, Orlowski,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2066

995PDTime to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial

Oaknin, A, Moore, K, Colombo, N, Scambia, G, Kim, B-G, Friedlander, M, Lisyanskaya, A, Floquet, A, Leary, A, Sonke, G S, Gourley, C, Banerjee, S, Oza, A M, González-Martín, A, Aghajanian, C, Bradley,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2067

996PDPatient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)

Friedlander, M L, Moore, K, Colombo, N, Scambia, G, Kim, B-G, Oaknin, A, Lisyanskaya, A, Floquet, A, Leary, A, Sonke, G S, Gourley, C, Banerjee, S, Oza, A, González-Martín, A, Aghajanian, C, Bradley,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2068

997PDValidation of the geriatric vulnerability score (GVS) in older ovarian cancer (oOC) patients: An analysis from the GCIG-ENGOT-GINECO EWOC-1 study

Tinquaut, F, Freyer, G, Pommeret, F, Gladieff, L, Lorusso, D, Reynier, M A Mouret, D’Hondt, V, Mollon-Grange, D, Floquet, A, Lacourtoisie, S Abadie, Brachet, P E, Stefani, L, Rousseau, F, Frenel, J-S,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2069

999PDImmune-related gene expression signatures (irGES) in patients (pts) with ovarian clear cell carcinomas (OCCC): A multicenter analysis

Heong, V, Tan, T Z, Ye, J, Miwa, M, Lim, D, Herrington, C S, Iida, Y, Okamoto, A, Low, J, Ng, J, Lim, S E, Lim, Y W, Gourley, C, Hasegawa, K, Tan, D S, Huang, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2070

1000PEfficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and platinum sensitive recurrent ovarian cancer

Li, N, Wu, L, Zhang, Y, Liu, J, Zhou, Q, Zhu, J, Yin, R, Wang, L, Li, G, Wu, X, Pan, H, Yao, S, Wu, Q, Gu, K, Zhang, H, Wan, X, An, R, Zou, J, Wang, Q

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2071

1001PEffect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase III study ARIEL3 of rucaparib maintenance treatment

Ledermann, J A, Oza, A M, Lorusso, D, Aghajanian, C, Oaknin, A, Dean, A, Colombo, N, Weberpals, J I, Clamp, A R, Scambia, G, Leary, A, Holloway, R W, Gancedo, M Amenedo, Fong, P C, Goh, J C, O’Malley,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2072

1002PIntegrated safety analysis of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and maintenance settings

Kristeleit, R S, Oza, A M, Oaknin, A, Aghajanian, C, Tinker, A V, Tredan, O, O’Malley, D M, Leary, A, Konecny, G E, Lorusso, D, Weberpals, J I, Goble, S, Maloney, L, Cameron, T, Swisher, E, McNeish, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

2073

1003PClinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers

Labidi-Galy, S I, de, T, Rouge, La Motte, Derbel, O, Wolfer, A, Kalbacher, E, Olivier, T, Combes, J-D, Hu-Heimgartner, K, Tredan, O, Guevara, H, Heinzelmann-Schwarz, V, Fehr, M, de Castelbajac, V, Vaf

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

2074

1004PA prospective evaluation of tolerability of niraparib dosing based on baseline body weight (BW) and platelet (plt) count: Blinded pooled interim safety data from the NORA study

Wu, X, Zhu, J, Yin, R, Yang, J, Wu, L, Liu, J, Liu, Z, Wang, J, Gao, Y, Wang, D, Lou, G, Yang, H, Kong, B, Huang, Y, Zhou, Q, Wen, H, Hou, J, Zhang, C, Hei, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

2075

1005PEvaluation of niraparib 200 mg/d as maintenance therapy in recurrent ovarian cancer and associated thrombocytopenia in a real-world US setting

Thaker, P, Travers, K, Karki, C, Patel, R P, Krebsbach, C, Harrow, B, Westin, S N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2076

1006PNiraparib initial dose and its’ management in patients with recurrent high-grade serous ovarian cancer

Grabowski, J P, Glajzer, J, Braicu, E I, Sehouli, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2077

1007PResults of the 3rd interim analysis of C-Patrol: A non-interventional study on olaparib in German routine clinical practice

Sehouli, J, Hilpert, F, Welslau, M K, Grabowski, J P, Seitz, J, El-Balat, A, Hartkopf, A, Glowik, R, Marmé, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2078

1008PA real-world analysis of the treatment of advanced ovarian cancer with PARPIs

de Pinillos, A Martinez, Anger, C, Mendoza, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2079

1009PIncidence of tumour BRCA1/2 variants in relapsed, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer

Morgan, R D, Bulman, M, Clamp, A R, MacMohon, S, Thompson, L, Ribeiro, S, Davies, A, Best, R, Palmer-Smith, S, Frugtniet, B, Evans, D G R, Jayson, G C, Wallace, A J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2080

1010PFrequency of mutations in 21 hereditary breast and ovarian cancer susceptibility genes among 882 high-risk individuals

Liu, J, Shao, D, Cheng, S, Guo, F, Yuan, Y, Hu, K, Wang, Z, Meng, X, Jin, X, Yun, X, Chai, X, Li, H, Zhang, Y, Zhang, H, Ye, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2081

1011PBRCA testing of 1,284 Brazilian patients for hereditary breast and ovarian cancer in a routine diagnostic setting

Milanezi, F, Silva, J S, de Marsillac, S M, Monfredini, P M, Nakano, V, D’Andrea, M G, Guarischi-Sousa, R, Schnabel, B, Correia, W D, Campana, G A, da Fonseca, G G, Perrone, E, Zalcberg, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2082

1012PA multi-center integrative study on cancer predisposition genes in Chinese patients with epithelial ovarian carcinoma

Zhu, C, Li, L, Shao, D, Lang, J H, Ma, S, Tan, X, Zhong, S, Wu, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2083

1013PIncidental early occult ovarian cancer after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers followed in a community public hospital

Suarez, B Grana, Molina, A, Prato, J, Czestokowa, C, Conde, C, Rendo, C Reboredo, Quindos, M, Perez, E, Mellid, R Lesta, Cordeiro, P, Gomez-Randulfe, I, Antolin, S, Calvo, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2084

1014PResponse to chemotherapy in ovarian cancer (OC) patients with or without prior breast cancer (BC), stratified by BRCA mutation (BRCAm) status

George, A, Chilcott, F, Pate, C, Banerjee, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2085

1015PAdvanced ovarian cancer: Is residual disease after debulking surgery affected by genetics factors involved in angiogenesis and immunity pathways?

Bartoletti, M, Gagno, S, Poletto, E, Garziera, M, Scalone, S, Dreussi, E, Zanusso, C, Roncato, R, Cecchin, E, De Mattia, E, Sorio, R, Giorda, G, Quartuccio, L, De Vita, S, Romualdi, C, Puglisi, F, Tof

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2086

1016PSurrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study

Lecuru, F, Pujade-Lauraine, E, Hamizi, S, Caumont-Prim, A, Raban, N, Malaurie, E, Pautier, P, Kaminsky-Forrett, M-C, Meunier, J, Alexandre, J, Berton-Rigaud, D, Dohollou, N, Dubot, C, Floquet, A, Favi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2087

1017PImmune-related gene expression profiling after neoadjuvant chemotherapy (NACT) of ovarian high-grade serous carcinoma

Manso, L M, Lodewijk, I, Hertfelder, E Bernal, Suárez-Cabrera, C, Garcia, J L, Wang, S, Paramio, J M, Dueñas, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2088

1018PTumour-infiltrating lymphocytes (TILs) in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy: A retrospective study

Giovannoni, S, Garbi, A, Parma, G, Lapresa, M, Zaccarelli, E, Vingiani, A, Ardoino, I, Pruneri, G, Colombo, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2089

1019PPrognostic significance of elements of the adaptive immunity in the microenvironment of epithelial ovarian cancer

Foukas, P, Koliou, G-A, Papoudou-Bai, A, Charchanti, A, Vrettou, E, Poulios, C, Chatzopoulos, K, Kotoula, V, Fountzilas, E, Zakopoulou, R, Visvikis, A, Pentheroudakis, G, Pectasides, D G, Aravantinos,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2090

1020PNeutrophil-to-lymphocyte ratio predicts platinum sensitivity in epithelial ovarian cancer patients: A MITO24 retrospective study

Farolfi, A, Scarpi, E, Greco, F, Bergamini, A, Longo, L, Pignata, S, Casanova, C, Vecchio, V Del, Bologna, A, Orditura, M, Zavallone, L, Ventriglia, J, Gallà, V, Franzese, E, Pigozzi, E, Loizzi, V, Gi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2091

1022PTP53 hotspot mutations as immunoreactive neoantigens define a signature with differential survival outcomes in advanced ovarian cancer

Garziera, M, Cecchin, E, Polesel, J, Canzonieri, V, Sorio, R, Gagno, S, Scalone, S, Roncato, R, De Mattia, E, Poletto, E, Giorda, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2092

1023PUse of bevacizumab (Bev) in real life for first-line (fl) treatment of ovarian cancer (OC)/ The GINECO ENCOURAGE cohort of 500 French patients

Berton-Rigaud, D, Floquet, A, Mollon-Grange, D, Dechartres, A, Lescaut, W, Kaminsky-Forrett, M-C, Tredan, O, Largillier, R, Savoye, A M, Alexandre, J, Delbaldo, C, Malaurie, E, Barletta, H, Bosacki, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2093

1024PPhase II study: Letrozole maintenance therapy after first-line chemotherapy in patients with advanced serous and endometrioid ovarian cancer

Tyulyandina, A, Rumyantsev, A, Pokataev, I, Nechushkina, V, Morkhov, K, Sergeev, Y, Mochalnikova, V, Bulanov, A, Stenina, M, Tjulandin, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2094

1025PBaseline IPI (immune prognostic index) predicts survival in patients with advanced cervical cancer treated with immune checkpoint inhibitors (ICI)

Blanc-Durand, F, Richardson, M, Vuagnat, P, Pautier, P, Hollebecque, A, Varga, A, Massard, C, Leary, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

2095

1026PPreselecting tumour-infiltrating lymphocyte subsets to implement adoptive immunotherapy in ovarian cancer

Salas-Benito, D, De Andrea, C, Aramendia, J M, Mancheño, U, Elizalde, E, Conde, E, Tamayo, I, Guillén, F, Jurado, M, Mínguez, J Á, Martín, A González, Ponz-Sarvise, M, Hervás-Stubbs, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

2096

1027PEarly prediction of the platinum-resistant relapse risk using the CA125 modeled kinetic parameter KELIM: A pooled analysis of AGO-OVAR 7 & 9; ICON 7 (AGO/GINECO/ MRC CTU/GCIG trials)

Colomban, O, Tod, M, Leary, A, Ray-Coquard, I L, Lortholary, A, Hardy-Bessard, A-C, Pfisterer, J, Du Bois, A, Kurzeder, C, Burges, A, Peron, J, Freyer, G, You, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

2097

1028PMirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a phase Ib study in patients (pts) with ovarian cancer

O'Malley, D, Richardson, D, Vergote, I B, Gilbert, L, Martin, L P, Mantia-Smaldone, G M, Castro, C, Provencher, D, Matulonis, U A, Malek, K, Moore, K N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

2098

1029PResponse to pegylated liposomal doxorubicin (PLD) and weekly paclitaxel (wpac) in platinum resistant (PR) ovarian cancer (OC) by BRCA mutation status

Bremer, L C, Pate, C L, Banerjee, S, George, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2099

1031POCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer

McNeish, I A, Moreno, V, Jayson, G, Roxburgh, P, Ginesta, M P Barretina, Garcia-Donas, J, Torres, A Anton, Michael, A, Brown, R, Krige, D, Bendall, J, Di Genova, G, McElwaine-Johnn, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 70 KB

2019

2100

1032PPhase I study of low dose whole abdominal radiation therapy (LDWART) in combination with weekly paclitaxel (wP) for platinum resistant ovarian cancer (PROC)

Ngoi, N Y L, Heong, V Y M, Kumarakulasinghe, N B, Phyu, P S, Peh, E Y, Lim, S E, Lim, Y W, Tang, J, Choo, B A, Koh, V, Ilancheran, A, Low, J, Ng, J, Thian, Y L, Tan, D S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2101

1034PPhase I study of intraperitoneal TRX-E-002-1 in subjects with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer: Three-month follow-up results of the dose escalation phase

Coward, J, Kichenadasse, G, Harnett, P, Moore, K, Barve, M, Berg, D, Garner, J, Dizon, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2102

1035PHybrid capture-based genomic profiling of circulating tumour DNA (ctDNA) from patients with ovarian cancer

Yang, M, Jiang, Z, Zhang, Y, Cai, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2103

1036PTumour microvessel density for predicting nintedanib activity: Data from the randomized CHIVA trial (a GINECO study)

Villemin, M, Elie, N, Blanc-Fournier, C, De Rauglaudre, G, Raban, N, Chevalier, A, Ferron, G, Kaminsky-Forrett, M-C, Beurrier, F, Hamizi, S, Combe, P, Lacourtoisie, S Abadie, Meunier, J, Floquet, A, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2104

1038PThe feasibility and efficacy of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian insufficiency in patient with malignant ovarian germ cell tumours

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2105

1039PEx vivo cytotoxicity and in vivo anti-tumour activity of a novel highly selective STAT3 inhibitor YHO-1701 for ovarian and endometrial cancer

Hasegawa, K, Taniguchi, K, Sato, S, Yoshinaga, A, Tsugane, M, Nishiyama, M, Fujiwara, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2106

1040PMutational landscapes and tumour mutational burden expression in endometrial cancer

Zhang, Y, Zhang, J, Shao, Z, Zhao, L, Zhang, Y, Zhang, S, Zhao, S, Guo, F, Pang, F, Zhang, L, Dong, X, Wang, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2107

1041PClinical features and frequency of mismatch repair protein deficiency in ovarian clear cell and endometrioid carcinoma patients

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2108

1042PProspective study evaluating white adipose tissue inflammation and clinicopathologic features in endometrial cancer

Moukarzel, L A, Stylianou, A, Wu, M, Nobre, S P, Abu-Rustum, N R, Broach, V, Giri, D D, Iyengar, N M, Weigelt, B, Makker, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2109

1043PCancer-specific survival with or without adjuvant chemotherapy in high-risk stage I endometrial cancer

Ko, J, Lester, B, Le, N, Bowering, G, Rugayan, C, Kumar, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2110

1044PPembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study

O'Malley, D, Marabelle, A, De Jesus-Acosta, A, Piha-Paul, S A, Arkhipov, A, Longo, F, Motola-Kuba, D, Shapira-Frommer, R, Geva, R, Rimel, B J, Lopez-Martin, J A, Hansen, A R, Mehnert, J M, Chen, X, Ji

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

2111

1045PWho drops out of cervical cancer screening? Results from the EDIFICE 6 survey

de La Motte Rouge, T, Eisinger, F, Couraud, S, Greillier, L, Touboul, C, Lhomel, C, Rouprêt, M, Viguier, J, Morere, J-F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2112

1046PIdentification of a RNA-Seq based signature to improve prognostic for uterine sarcoma

Zhou, J-G, Ma, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2113

1047PThe effect of multiple interventions for women at risk for cervical cancer on their health responsibility, beliefs regarding cervical cancer, and having screening: A randomized controlled experiment

Altinel, B, Akin, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2114

1048PQuantifying the effects of the Korean national cancer screening program on cervical cancer mortality

Bui, N C, Choi, E, Suh, M, Jung, K-W, Jun, J K, Choi, K S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2115

1049PSpread of tumour and adverse events after modified radical hysterectomy for FIGO Stage IB1 cervical cancer patients with tumour diameter preoperatively estimated 2 cm or less: Japan Clinical Oncology Group trial (JCOG1101); exploratory analysis before primary analysis

Arimoto, T, Takahiro, K, Toita, T, Kobayashi, H, Machida, R, Mizutani, T, Onda, T, Mizuno, M, Yokota, H, Kamiura, S, Takehara, K, Takano, H, Saito, T, Mandai, M, Satoh, T, Yamaguchi, S, Nakamura, T, U

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2116

1050PImpact of combined interstitial and intracavitary brachytherapy in locally advanced cervical cancer: A survival and toxicity profile assessment

Pareek, V, Chandra, M, Bhalavat, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2117

1051PChemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2118

1052PDisparities starting adjuvant chemotherapy for locally advanced cervix cancer in the international, academic, randomised, phase III OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274)

Mileshkin, L, Barnes, E, Moore, K N, Gebski, V, King, M, Narayan, K, Kolodziej, I K, Sjoquist, K, Fyles, A, Small, W, Gaffney, D, Quinn, M, Andrews, J, Thompson, S, Huh, W, Carlson, M, Disilvestro, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2119

1053PPrimary results from CECILIA, a global single-arm phase II study evaluating bevacizumab (BEV), carboplatin (C) and paclitaxel (P) for advanced cervical cancer (aCC)

Redondo, A, Colombo, N, Dreosti, L M, McCormack, M, Rodrigues, A Nogueira, Scambia, G, Roszak, A, Donica, M, Ulker, B, Martín, A González

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2120

1054PPrognostic and clinicopathological significance of PD-L1 in patients with cervical cancer: A meta-analysis

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2121

1056PComparative proteomic profiles of cervical cancer and paried paracancerous tissue and the potential effects of DUSP7 over-expression through inhibiting RAS pathway on the biological characteristics of human cervical cancer cell line SIHA

Jiang, X, Bai, H, Zhang, Z

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2122

1057PMolecular profiling reveals novel targetable biomarkers in neuroendocrine carcinoma of the uterine cervix

Vranic, S, Arguello, D, Contreras, E, Cimic, A, Gatalica, Z

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

2123

1058PChanges in clinico-pathological characteristics of vulvar cancer in Japan: Increasing oldest-old, stage-shifting, and decreasing cohort-level survival

Nishio, S, Matsuo, K, Shibata, T, Yamaguchi, S, Kanao, H, Takehara, K, Kado, N, Tozawa, A, Tokunaga, H, Matsunaga, T, Kato, H, Horie, K, Kikuchi, A, Enomoto, T, Mikami, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

2124

1059TiPTumour treating fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: Phase III INNOVATE-3/ENGOT-ov50 study

Vergote, I B, Copeland, L, Monk, B J, Coleman, R L, Cibula, D, Sehouli, J, Samartzis, E P, Radoslaw, M, Martín, A González, Korach, J, Salutari, V, Witteveen, P O, O’Malley, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

2125

1060TiPRandomized, phase Ib/II study of M6620 + avelumab + carboplatin vs standard care (sc) in patients (pts) with platinum-sensitive poly (ADP-ribose) polymerase inhibitor-(PARPi)-resistant ovarian cancer

Banerjee, S, Vergotte, I, Colombo, N, Barve, M, Grisham, R, Mehr, K T, Falk, M, Beier, F, Hennessy, M, Schroeder, A, Birrer, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

2126

1061TiPAn umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: A Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION

Lee, J-Y, Kim, J W, Kim, B G, Kim, S, Kim, H S, Choi, C H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2127

1063TiPENGOT-EN9/LEAP-001: A phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer

Marth, C, Vulsteke, C, Rubio, M J, Makker, V, Braicu, E I, McNeish, I A, Radoslaw, M, Ayhan, A, Hasegawa, K, Wu, X, Dutta, L, Xu, C, Keefe, S M, Lee, J, Pignata, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2128

1064TiPPhase I/II trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8)

Vergote, I B, Concin, N, Mirza, M R, Malmberg, A, Eaton, L, Nicacio, L, Lorusso, D, Soumaoro, I, Monk, B J, O’Malley, D M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

2129

992OFORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

Moore, K, Oza, A, Colombo, N, Oaknin, A, Scambia, G, Lorusso, D, Farias-Eisner, R, Banerjee, S, Murphy, C, Tanyi, J, Hirte, H, Konner, J, Lim, P, Hayes, M Prasad, Monk, B, Kim, S, Wang, J, Pautier, P,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

2130

1066OPolo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with low-dose cytarabine or decitabine in patients with relapsed/refractory acute myeloid leukaemia in phase Ib

Zeidan, A, Becker, P, Patel, P, Schiller, G, Tsai, M L, Lin, T, Wang, E, Erlander, M, Cortes, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2131

1068PDNon-Hodgkin lymphoma in HIV-positive patients treated with antiretroviral therapy and chemotherapy: A single institution retrospective study

Dalu, D, Fasola, C, De Francesco, D, Bombonati, G, Ammoni, L, La Verde, N M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2132

1069PDObstetric and maternal outcome of 134 patients with Hodgkin lymphoma diagnosed during pregnancy: Results from the INCIP registry

Amant, F, Maggen, C, Dierickx, D, Lugtenburg, E, Laenen, A, Cardonick, E, Shmakov, R G, Bellido Casado, M, Garcia, A C, Gziri, M, Halaska, M, Ottevanger, P, Van Calsteren, K, L’Hauglin, A, Polushkina,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2133

1070PDTreatment outcomes and pattern of failure in primary gastric diffuse large B cell lymphoma with complete remission following R-CHOP chemotherapy

Kang, H J, Choi, B-O, Jung, S-E, Park, K-S, O, J-H, Lee, H H, Jeon, Y-W, Cho, S-G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2134

1071PDTreatment outcome for Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma

Lim, S-N, Ko, S, Sohn, B S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

2135

1072PDMutational profiling through exome sequencing along with MYD88 L265P analysis could facilitate the diagnosis of vitreoretinal lymphoma

Lee, H, Kim, B, Lee, S-T, Choi, J R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

2136

1073PPrognostic factors influencing outcome after therapy with brentuximab vedotin in patients with relapsed or refractory Hodgkin’s lymphoma

Goranova-Marinova, V S, Ignatova, K, Ganeva, P, Spasov, E, Arnaudov, G, Micheva, I, Gercheva, L, Radinov, A, Petrova, R, Tzvetkova, G, Hadzhiev, E, Bogdanov, L, Tzvetkov, N, Spasov, B, Grudeva-Popova,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

2137

1074PDPrognostic value of microRNA-21/ Ki-67 in non-Hodgkin's lymphoma: NCI experience

Rahouma, M, Rashed, R A, Asker, H A, Abdel-Azim, L R, Naguib, E, Khaled, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

2138

1075PPhase I study of CC-90010 in patients with advanced solid tumours and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)

Moreno, V, Brana, I, Sepulveda Sanchez, J M, Vieito Villar, M, Hernández-Guerrero, T, Doger, B, Saavedra, O, Italiano, A, Michot, J-M, Musuraca, G, Asierto, P A, Carlo-Stella, C, Sarmiento, R, De Alva

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2139

1076PPretreatment coagulation factors related to prognosis in patients with natural killer/T cell lymphoma

Chai, Y, Dong, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2140

1078PMIPI as a superior prognostic tool in mantle cell lymphoma compared to monocyte-lymphocyte, neutrophil-lymphocyte and platelet-lymphocyte ratios

Macedo, F, Monteiro, A R, Coelho, D, Luis, D, Guilherme, R, Gomes, M, Ribeiro, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2141

1080PA new population model validated pharmacokinetic similarity of HLX01 and rituximab in B-cell lymphoma

Shi, Y, Dan, Y, Hong, Y, Guo, J, Zhao, S, Zeng, X, Hu, P, Jiang, W, Liu, S, Zhang, X, Luk, A, Chai, K, Liu, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2142

1081PEfficacy of salvage therapy in the treatment of Helicobacter pylori-positive gastric low-grade mucosa-associated lymphoid tissue lymphoma

Lim, S-N, Ko, S, Sohn, B S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2143

1082PMutational analysis of extranodal marginal zone lymphoma using next generation sequencing

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2144

1083PClinical features, treatment and outcomes of colon and rectum mucosa-associated lymphoid tissue (MALT) lymphoma: Literature reviews published in English between 1993 and 2017

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 423 KB

2019

2145

1086PN-terminal B-type natriuretic peptide (NT-proBNP) as an independed prognostic marker for patients with newly diagnosed multiple myeloma complicated by dialysis-dependent renal failure

Semochkin, S V, Zhelnova, E I, Misyurina, E N, Cherkasova, A V, Gagloeva, D E, Kotenko, O N, Ushakova, A I, Arefeva, N A, Tolstykh, T N, Baryakh, E A, Yatskov, K V, Sinyavkin, D O, Samsonova, I V, Lys

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2146

1087PThe first-line effect of bortezomib-based therapy on clinical outcomes for Taiwanese patients with multiple myeloma

Ho, C-L, Chen, J-H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

2147

1088PImpact of donor lymphocyte infusion in relapsing myeloid neoplasms post allogeneic hematopoietic stem cell transplantation

Hafez, H, Abdalla, A, Hammad, M, Hamdy, N, Elsharkawy, N, Khaled, M, Elhaddad, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2148

1089PInvasive fungal diseases in patients with Hodgkin’s lymphoma before and after allogeneic hematopoietic stem cell transplantation

Popova, M, Rogacheva, Y, Volkova, A, Markova, I, Nikolaev, I, Ignatieva, S, Bogomolova, T, Kozlov, A, Lepik, K, Stelmakh, L, Beynarovich, A, Borzenkova, E, Darskaya, E, Kondakova, E, Mikhailova, N, Bo

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2149

1090PInvasive fungal diseases caused by rare pathogens in patients after hematopoietic stem cell transplantation (HSCT) & chemotherapy

Rogacheva, Y, Popova, M, Volkova, A, Frolova, A, Markova, I, Nikolaev, I, Ignatieva, S, Bogomolova, T, Gevorgian, A, Paina, O, Bykova, T, Darskaya, E, Goloshchapov, O, Morozova, E, Vladovskaya, M, Bon

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2150

1091PSafety and pharmacokinetics of novel CXCR4 antagonist YF-H-2015005 in the mobilization of hematopoietic stem cells in patients with non-Hodgkin’s lymphoma

Liu, W, Xie, Y, Ping, L, Jiang, M, Zhang, G, Cui, Y, Xu, J, Wu, M, Leng, X, Wang, X, Wang, S, Zhang, G, Zhu, J, Song, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2151

1092PChemotherapy associated hyponatremia in hematological malignancies: A retrospective study of 189 patients treated in a single medical center

Lesan, V, Schmit, D, Bewarder, M, Assmann, G, Stilgenbauer, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2152

1093PRisk factors for bacteremia-associated mortality of Aeromonas sobria in hematologic malignancies

De la Cruz-Kú, G, Valcarcel, B S, Luján, M, Saavedra, A, Luque, R, Eyzaguirre, E, Sultanov, M B, Morante, Z, Quintana, S, Neciosup Delgado, S P, Holguín Ruíz, A, Vicente, W, Enriquez, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2153

1095PRUBIH2 - Use of NGS in haematological malignancies: From real world data to national recommendations, an innovative program to evaluate the impact of healthcare technology on patient care

Coquerelle, S, Darlington, M, Durand-Zaleski, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2154

1096POutcomes of chronic myeloid leukemia with T315I mutation in the absence of targeted therapy or hematopoietic stem cell transplantation

Palukuri, N R, Stalin, B, Chennamaneni, R, Prasad, S K, Konatam, M L, Gundeti, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2155

1097PIs bone marrow examination indispensable in chronic myeloid leukemia at diagnosis?

Palukuri, N R, Prasad, S K, Chennamaneni, R, Stalin, B, Konatam, M L, Gundeti, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2156

1098PIncidence of imatinib resistance in chronic myeloid leukemia (CML) patients: Experience from resource poor center of eastern India

Bhattacharyya, D, Ghosh, R, Gupta, P, Gupta, A, Roychoudhury, S, Nath, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2157

1099PBCR-ABL transcript variant’s significance in chronic myeloid leukemia in chronic phase: Institutional experience from a developing country

Prasad, S K, Chennamaneni, R, Stalin, B, Konatam, M L, Gundeti, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

2158

1100PInterleukin-6 as a predictive marker for early response to induction chemotherapy in acute myeloblastic leukaemia

Khallaf, S M, Abdelhafez, Z A A, Ahmed, T S, Abdou, M A A, Mansour, S M, Salah Eldeen, M M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

2159

1101PImpact of FLT3-ITD mutation on post-transplant outcome of adult acute myeloid leukemia (AML) is modified by the concomitant NPM1 mutation and pre-transplant remission status: A report from Taiwan Bone Marrow Transplant Registry (TBMTR)

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2160

1102PEfficacy endpoints studied in clinical trials for early-onset leukaemia

Said, D, Borg, J J, Attard Pizzuto, M, Serracino-Inglott, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2161

1104PHigh triglyceride is a major risk factor of DIC and differentiation syndrome in acute promyelocytic leukemia

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2162

1105TiPDREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)

Trudel, S, Nooka, A, Fecteau, D, Talekar, M, Jewell, R C, Williams, D, Evans, J, Opalinska, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2163

1106TiPA phase I study of HMPL-523, a selective oral anti-spleen tyrosine kinase inhibitor, in patients with relapsed or refractory lymphoma

Fowler, N, Jurczak, W, Cordoba Mascunano, R, Abrisqueta Costa, P, Strati, P, Yang, C, Kania, M, Kauh, J, Ferreri, A J M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2164

1107TiPA phase I study of HMPL-689, a selective oral phosphoinositide 3-kinase-delta inhibitor, in patients with relapsed or refractory lymphoma

Cohen, J, Cordoba Mascunano, R, Ferreri, A J M, Yang, C, Kania, M, Kauh, J, Ghosh, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 279 KB

2019

2165

1065OInterim evaluation of a targeted radiotherapeutic, CLR 131, in relapsed/refractory diffuse large B-cell lymphoma patients (R/R DLBCL)

Longcor, J, Oliver, K, Friend, J, Callandar, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2166

1109OA phase II study of monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)

Galot, R, Le Tourneau, C, Saada-Bouzid, E, Daste, A, Even, C, Debruyne, P R, Henry, S, Zanetta, S, Rutten, A, Licitra, L F, Canon, J-L, Kaminsky-Forrett, M-C, Specenier, P, Rottey, S, Dirix, L, Ravelo

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 104 KB

2019

2167

1110OPersonalized treatment according to geriatric assessment in first-line recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC) patients aged 70 or over: ELAN (ELderly heAd and Neck cancer) FIT and UNFIT trials

Guigay, J, Auperin, A, Mertens, C, Even, C, Geoffrois, L, Cupissol, D, Rolland, F, Sire, C, Fayette, J, Peyrade, F, Blot, E, Debourdeau, P, Bozec, L, Capitain, O, Pointreau, Y, Brard, C, Michel, C, Sc

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2168

1111OCisplatin reduces costs and provides more quality adjusted life years (QALYs) than cetuximab in chemoradiotherapy for patients with HPV-positive oropharyngeal cancer (HPV+OPC)

Jones, D A, Mehanna, H, Mistry, P, Dalby, M, Fulton-Lieuw, T, Kong, A H, Dunn, J, Gray, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2169

1112PDEfficacy evaluation of optimal patient selection for hypopharyngeal cancer organ preservation therapy using MRI-derived radiomic signature: Bi-institutional propensity score matched analysis

Lin, S-M, Hsu, C, Lee, Y, Li, T-C, Kuo, S-H, Wang, W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 233 KB

2019

2170

1113PDSurvival and prognostic factors of nasopharyngeal cancer patients in non-endemic countries: A large multicentric database analysis

Bossi, P, Grisanti, S, Mohamad, I, Linares Galiana, I, Ozyar, E, Franco, P, Vecchio, S, Livi, L, Cirauqui Cirauqui, B, El-Sherify, M, Ursino, S, Argiris, A, Pan, J, Wittekindt, C, D’angelo, E, Buglion

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2171

1114PDHigh immunoscore is associated with good response to neo-adjuvant chemotherapy and prolonged survival in advanced head and neck cancer patients

Mirghani, H, Mure, C, Mlecnik, B, Hermitte, F, Martel, E, Casiraghi, O, Iacob, M, Even, C, Galon, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2172

1116PDA window of opportunity trial of preoperative nivolumab with or without tadalafil in squamous cell carcinoma of the head and neck (SCCHN): Safety, clinical, and correlative outcomes

Luginbuhl, A J, Johnson, J M, Harshyne, L, Tuluc, M, Mardekian, S, Leiby, B E, Curry, J M, Cognetti, D M, Kim, Y, Mannion, K, Rodeck, U, Argiris, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2173

1117PDPembrolizumab and radiotherapy for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) with contraindication to cisplatin therapy

Sheth, S, Bauman, J R, Deal, A, Chera, B, Shen, C, Galloway, T, Hackman, T, Blumberg, J, Yarbrough, W, Weissler, M, Hilliard, C, Mehra, R, Grilley-Olson, J, Weiss, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2174

1118PDAvelumab-cetuximab-radiotherapy versus standards of care (SoC) in patients (pts) with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Safety phase of randomized trial GORTEC 2017-01 (REACH)

Tao, Y, Auperin, A, Sun, X, Sire, C, Martin, L, Coutte, A, Lafond, C, Miroir, J, Liem, X, Rolland, F, Maillard, A, Colin-Barailhou, N, Michel, C, Thariat, J, Guigay, J, Bourhis, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2175

1120PDBuparlisib (BKM120) in refractory head and neck squamous cell carcinoma harbouring or not a PI3KCA mutation: A phase II multicenter trial

Fayette, J, Digue, L, Ségura-Ferlay, C, Treilleux, I, Wang, Q, Lefebvre, G, Daste, A, Even, C, Couchon Thaunat, S, Guyennon, A, Peyrade, F, Cupissol, D, You, B, Le Tourneau, C, Jaouen, L, Grinand, E,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2176

1121PNimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV-negative oropharyngeal cancer

Prabhash, K, Patil, V M, Noronha, V, Joshi, A P, Bhattacharjee, A, Mathrudev, V, Bhelekar, A, Nawale, K, Agarwal, J P, Ghosh-Laskar, S, Budrukkar, A, Mahajan, A, Agarwal, A, Purandare, N, Chaturvedi,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2177

1122PInterim analysis of a single arm phase II study of adjuvant nivolumab after salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy

Wise-Draper, T, Haque, S, Steele, A, Desai, S, Harris, T, Riaz, M K, Morris, J C, Takiar, V, Nagasaka, M, Jandarov, R, Sukari, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2178

1123PA phase I study of the CDK4/6 inhibitor, palbociclib in combination with cetuximab and intensity modulated radiation therapy (IMRT) for locally advanced squamous cell carcinoma of the head and neck (SCCHN); A result of dose escalation cohort

Ngamphaiboon, N, Jiarpinitnun, C, Siripoon, T, Lukerak, S, Jinawath, A, Jinawath, N, Arsa, L, Konmun, J, Kongsuphon, N, Sankaseam, N, Sirachainan, E, Witoonpanich, P, Kositwattanarerk, A, Pattaranutap

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2179

1124PSingle cycle induction treatment with cisplatin/docetaxel plus durvalumab/tremelimumab in stage III-IVB head and neck squamous cell cancer (CheckRad-CD8 trial)

Hecht, M, Gostian, A-O, Eckstein, M, Rutzner, S, von der Grün, J, Illmer, T, Hautmann, M G, Brunner, T, Laban, S, Klautke, G, Tamaskovics, B, Frey, B, Hartmann, A, Rödel, C, Budach, W, Gaipl, U, Iro,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2180

1125PRadiotherapy plus cisplatin (CDDP) or cetuximab (C225) in human papilloma-virus (HPV)-associated oropharyngeal cancer (OPC)? A dilemma finally resolved. An updated meta-analysis

Suton, P, Skelin, M, Luksic, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2181

1126PTreatment outcomes of head and neck cancer patients 70 years and older receiving different chemo-radiation combinations

Issa, M, Mousa, L, Blakaj, D, Klamer, B, Pan, J, Old, M, Kang, S, Rupert, R, Mitchell, D, Ozer, E, Agrawal, A, Bhateja, P, Gamez, M, Miller, E, Jhawar, S, Carrau, R, Rocco, J, Bonomi, M R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2182

1127PBrachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs

Yu, J, Tsay, C, Sasaki, C, Son, Y, Decker, R, Mehra, S, Burtness, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2183

1128PFinal results of a phase II study of induction chemotherapy (CT) with paclitaxel (PTX) and panitumumab (P) followed by radiotherapy (RT) and P in patients (pts) with locally advanced head and neck cancer (LAHNC) no candidates to platinum: Study PANTERA

Martinez Trufero, J, Mesia Nin, R, Ortega Izquierdo, M E, Lozano, A, Cirauqui Cirauqui, B, Rubió Casadevall, J, Taberna Sanz, M, Pastor Borgoñon, M, Lambea Sorrosal, J, Iglesias, L, Vázquez, S, del Ba

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

2184

1129PWindow of opportunity for durvalumab (MEDI4736) plus metformin trial in squamous cell carcinoma of the head and neck (SCCHN): Interim safety analysis

Richa, T, Johnson, J M, Cognetti, D M, Argiris, A, Luginbuhl, A, Zinner, R, Axelrod, R, Bar-Ad, V, Goldman, R, Rodeck, U, Martinez-Outschoorn, U, Curry, J M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

2185

1133PSystemic bevacizumab for the treatment of recurrent respiratory papillomatosis: A retrospective analysis from an academic tertiary care center

Trivedi, S, Steuer, C E, Tkaczuk, A T, Shin, D M, Klein, A, Saba, N F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

2186

1134PMonalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data

Cohen, R B, Lefebvre, G, Posner, M R, Bauman, J R, Salas, S, Even, C, Saada-Bouzid, E, Seiwert, T, Colevas, D, Calmels, F, Zerbib, R, André, P, Boyer-Chammard, A, Fayette, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2187

1135PUpdated results of a phase II study evaluating accelerator-based boron neutron capture therapy (AB-BNCT) with borofalan(10B) (SPM-011) in recurrent squamous cell carcinoma (R-SCC-HN) and recurrent and locally advanced non-SCC (R/LA-nSCC-HN) of the head and neck

Hirose, K, Konno, A, Yoshimoto, S, Ono, K, Otsuki, N, Hatazawa, J, Hiratsuka, J, Takai, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2188

1136PPhase III KEYNOTE-048 study of first-line (1L) pembrolizumab (P) for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Asia vs non-Asia subgroup (subgrp) analysis

Tahara, M, Hong, R-L, Wan Ishak, W Z, Yen, C-J, Sriuranpong, V, Takahashi, S, Srimuninnimit, V, Yeh, S-P, Oridate, N, Yang, M-H, Tanaka, K, Nohata, N, Koh, Y, Roy, A, Gumuscu, B, Swaby, R F, Ngamphaib

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2189

1137PIntegrated data review evaluating safety, pharmacokinetics (PK) and immunogenicity of RM-1929 photoimmunotherapy (PIT) in subjects with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC)

Johnson, J M, Cognetti, D M, Curry, J M, Mott, F E, Kochuparambil, S T, McDonald, D R, Fidler, M J, Vasan, N R, Razaq, M A, Tahara, M, Biel, M A, Tello, M, Garcia-Guzman, M, Sun, E, Gillenwater, A M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

2190

1138PFirst-line versus second-line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck

Even, C, Torossian, N, Ibrahim, T, Martin, N, Mayache Badis, L, Ferrand, F R, Iacob, M, Guigay, J, Tourneau, C Le, Daste, A, Saada-Bouzid, E, Saleh, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2191

1139PSensitizing HRAS overexpressing head and neck squamous cell carcinoma (HNSCC) to chemotherapy

Rampias, T, Hoxhallari, L, Avgeris, M, Kanaki, Z, Telios, D, Giotakis, E, Giotakis, I, Scorilas, A, Psyrri, A, Klinakis, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2192

1140PA single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck

Bossi, P, Merlano, M C, Ghi, M G, Rinaldi, G, Caponigro, F, Morelli, F, Airoldi, M, Farnesi, A, Cassano, A, Ferrari, D, Mirabile, A, Tosoni, A, Galizia, D, Moretti, G, Sponghini, A P, Calareso, G, Vin

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2193

1141PLong-term results of phase II trial of reduced modified clinical target volume in low-risk nasopharyngeal carcinoma treated with intensity modulated radiotherapy

Miao, J, Di, M, Cao, Y, Wang, L, Xiao, W, Zhu, M, Chen, B, Huang, S, Han, F, Deng, X, Xiang, Y, Chua, M L K, Guo, X, Zhao, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2194

1142PTo compare two oral mucosa contouring methods in predicting acute oral mucocitis in nasopharyngeal carcinoma treated with helical tomotherapy

Chen, Y-Y, Li, P-J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 4.54 MB

2019

2195

1143PInduction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC)

Kaval, G, Altun, M, Ibis, K, Ozkaya, K, Meral, R, Karadeniz, A N, Sarı, M, Ekenel, M, Basaran, M, Bavbek, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2196

1144PEfficiacy of different nutritional intervention on nutritional status and quality of life for local advanced nasopharyngeal carcinoma patients: A prospective clinical trial

Chen, Y-Y, Huang, S, Chen, X, Hu, Q

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2197

1145PApatinib in treating patients with platinum-resistant or platinum-refractory recurrent or metastatic nasopharyngeal carcinoma

Tao, C, Chen, X

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

2198

1146PImpact of tumour site and adjuvant radiotherapy on survival in adenoid cystic carcinoma: A SEER database analysis

Tasoulas, Jason, Divaris, Kimon, Theocharis, Stamatios, Farquhar, Douglas, Hackman, Trevor, Amelio, Antonio L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2199

1147PEfficacy and safety of anlotinib for patients with recurrent and/or metastatic salivary gland carcinomas

Jiang, W, Dou, S, Li, R, Zhang, L, Zhu, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2200

1149PPathologic staging changes in oral cavity squamous cell carcinoma: Stage migration and implications for adjuvant treatment

Husain, Z, Lee, N C-J, Eskander, A, Park, H, mehra, S, Burtness, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2201

1150PExpression of immune response biomarkers in head and neck squamous cell carcinoma (HNSCC) in irradiated area

Pflumio, C, Thomas, J, Salleron, J, Faivre, J-C, Borel, C, Dolivet, G, Sastre-Garau, X, Geoffrois, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2202

1151PHLA-ligandome analysis reveals target antigens of oropharyngeal squamous cell carcinoma

Laban, S, Eziç, J, Bichmann, L, Mytilineos, D, Fürstberger, A, Kestler, H, Schuler, P J, Hoffmann, T K, Rammensee, H-G, Stevanovic, S, Mühlenbruch, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2203

1152PTopographical distribution of sentinel lymph nodes in early tongue squamous cell carcinomas

Goda, H, Nakashiro, K-I, Uchida, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2204

1153PRole of follow-up (FU) FDG-PET/CT (FU-FDG-PET/CT) in patients with locoregionally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) treated with chemotherapy and radiotherapy (RT), either concurrent (CRT) or sequential (ST)

Van Den Heuvel, B, Van Laer, C, Specenier, P M C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2205

1154PExpression of estrogen receptor and programmed cell death-ligand 1 can be complementary prognostic factors in HPV-positive oropharyngeal squamous cell carcinoma

Kwon, S, Kim, E S, Ahn, S-H, Jeong, W-J, Jung, Y H, Paik, J H, Kim, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2206

1155PReal-world data of clinicopathologic characteristics of young oropharyngeal cancer patients

Nieva, M, Fabregat, C, Tous, S, Mena, M, Teulé, A, Lozano, A, León, X, Guix, M, Bonfill, T, Mesía, R, Alemany, L, Taberna, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2207

1156PThe clinical significance and biological mechanisms of miR-499a in high-tobacco exposed head and neck squamous cell carcinoma

Gong, S, Xu, M, Xiang, M, Shan, Y, Zhang, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2208

1157PLiquid biopsy for mutational profiling of locoregional recurrent and/or metastatic squamous cell carcinoma of the head and neck

Galot, R, Van Marcke de Lummen, C, Helaers, R, Mendola, A, Goebbels, R-M, Caignet, X, Ambroise, J, Wittouck, K, Vikkula, M, Limaye, N, Machiels, J-P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

2209

1158PBlood-based testing of mutations in patients with head and neck squamous cell carcinoma (HNSCC) using highly sensitive SafeSEQ technology

Fostira, F, Oikonomopoulou, P, Kladi, A, Edelstein, D, Stieler, K, Heim, D, Gkotzamanidou, M, Anastasiou, M, Kotsantis, I, Kavourakis, G, Gavrielatou, N, Kousidou, E, Vagia, E V, Holtrup, F, Psyrri, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2210

1159PThe head and neck lung immune prognostic index (HN-LIPI): A prognostic score for immune checkpoint inhibitors (ICI) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients

Herrera Gomez, R G, Mezquita, L, Auclin, E, Heraudet, L, Plana, M, Salas, S, Cristina, V, Garcia Castano, A, Arrazubi, V, Grau, J J, Saleh, K, Cirauqui Cirauqui, B, Mesia Nin, R, Even, C, Taberna, M,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2211

1160PImmune-related adverse events (irAEs) and outcome in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts) treated by immune-checkpoints inhibitors (ICI)

Baste Rotllan, N, Auperin, A, Iacob, M, Sampetrean, A, Bouguetta, D, Mayache Badis, L, Ferrand, F R, Casiraghi, O, Blanchard, P, Bidault, F, Gorphe, P, Temam, S, Champiat, S, Even, C, Marabelle, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2212

1161PIntratumoral and peripheral exploratory biomarker analysis in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC) treated with RM-1929 photoimmunotherapy

Bui, J D, Suslov, N, Yadav, D, Fong, J, Sun, E, Haedo, M, Garcia-Guzman, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2213

1162PA nomogram based prognostic score to predict overall survival (OS) in recurrent-metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts) treated with immune checkpoint inhibitors (ICI)

Mousa, L, Issa, M, Klamer, B, Pan, J, Old, M, Kang, S, Agrawal, A, Ozer, E, Carrau, R, Bhateja, P, Rupert, R, Jhawar, S, Mitchell, D, Gamez, M, Rocco, J, Blakaj, D, Bonomi, M R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2214

1165PDeep learning in nasopharyngeal carcinoma: A retrospective cohort study of 3D convolutional neural networks on magnetic resonance imaging

Qiang, M Y, Lv, X, Li, C F, Liu, K Y, Chen, X, Guo, X

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2215

1166PCombined androgen blockade in patients with advanced androgen receptor-positive salivary gland carcinoma: Exploratory biomarker analyses

Fushimi, C, Kawakita, D, Takahashi, H, Nagao, T, Hirai, H, Saigusa, N, Masubuchi, T, Matsuki, T, Okada, T, Baba, D, Miura, K, Saotome, T, Tada, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2216

1167PClassification of esthesioneuroblastoma (ENB) based on chromosome (chr) arm gain and loss (CNA) in the setting of a hypomutated genomic landscape

Madison, R, Pavlick, D C, Johnson, J M, Khan, S, Lee, J, Ross, J S, Miller, V A, Alexander, B M, Chung, J, Schrock, A B, Ali, S M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2217

1168PTrastuzumab plus docetaxel in patients with advanced HER2-positive salivary duct carcinoma: Exploratory biomarker analyses

Takahashi, H, Kawakita, D, Fushimi, C, Nagao, T, Hirai, H, Saigusa, N, Masubuchi, T, Matsuki, T, Okada, T, Baba, D, Miura, K, Saotome, T, Tada, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2218

1169PDevelopment and characterization of salivary gland cancer organoid cultures

Boxtel, W V, Aalders, T M W, Lassche, G, van Engen - van Grunsven, I C H, Verhaegh, G W, van Herpen, C, Schalken, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

2219

1170PA parent-of-origin effect of the RB1 mutations in retinoblastoma with low penetrance and variable expressivity

Alekseeva, E A, Babenko, O V, Kozlova, V M, Ushakova, T L, Kazubskaya, T P, Sahakyan, S V, Tanas, A S, Zaletaev, D V, Strelnikov, V V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2220

1171PThe humanistic burden reported by patients diagnosed with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) in Europe

Singh, P, Bennett, B, Bailey, T, Taylor-Stokes, G, Hennessy, L, Rajkovic, I, Contente, M C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

2221

1173TiPA randomized phase II study on the OPTimization of Immunotherapy in squamous carcinoma of the head and neck (SCCHN) - OPTIM (AIO-KHT-0117)

Grünwald, V, Hahn, D, Alt, J, Schuch, G, Ivanyi, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 68 KB

2019

2222

1177PDClinical study of personalized neoantigen peptide vaccination in advanced NSCLC patients

Du, X, Li, F, Lizee, G, Hwu, P, Deng, L, Talukder, A, Hawke, D, Zou, Q, Roszik, J, Stairs, M, Feng, W, Jackson, K, Chen, C, Zhang, M, Huo, C, Chiu, Y, Wang, Y, Zhou, S, Zhang, Y, Xu, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2223

1178PDA phase I trial of GEN-009, a neoantigen vaccine using ATLAS™, an autologous immune assay, to identify immunogenic and inhibitory tumour mutations

Twardowski, P, Johnson, M L, Stein, M, Vaishampayan, U, Gillison, M L, McNeil, L, Dowal, L, DeOliveira, D, Jain, M, Price, J, Hernandez, R, DeCillis, A, Singh, N, Davis, T, Flechtner, J, Cohen, R B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2224

1180PDActive immunization with immune checkpoint inhibitors-mimotope elicits strong anti-tumour effect against HER-2/neu-expressing tumours

Tobias, J, Battin, C, Linhares, A De Sousa, Lebens, M, Baier, K, Ambroz, K, Högler, S, Inic-Kanada, A, Garner-Spitzer, E, Preusser, M, Kenner, L, Kundi, M, Zielinski, C C, Steinberger, P, Wiedermann,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2225

1182PDA novel affinity-enhanced NY-ESO-1-targeting TCR-redirected T cell transfer exhibited early-onset cytokine release syndrome and subsequent tumour responses in synovial sarcoma patients

Hattori, H, Ishihara, M, Kitano, S, Miyahara, Y, Kato, H, Mishima, H, Yamamoto, N, Funakoshi, T, Kojima, T, Sasada, T, Sato, E, Okamoto, S, Tomura, D, Chono, H, Nukaya, I, Mineno, J, Ikeda, H, Watanab

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2226

1183PDAdoptive T cell therapy with TBI-1301 results in gene-engineered T cell persistence and anti-tumour responses in patients with NY-ESO-1 expressing solid tumours

Butler, M O, Sotov, V, Saibil, S, Bonilla, L, Boross-Harmer, S, Fyrsta, M, Gray, D, Nelles, M, Le, M, Lemiashkova, D, Liu, D, Sacher, A G, Trang, A, Vakili, K, As, B Van, Scheid, E, Nguyen, L, Takahas

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2227

1185PDParallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted chimeric antigen receptor-T cells for B-cell non-Hodgkin lymphoma

Ying, Z, He, T, Wang, X, Zheng, W, Lin, N, Tu, M, Xie, Y, Ping, L, Zhang, C, Liu, W, Deng, L, Qi, F, Lu, X, Ding, Y, Song, Y, Zhu, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2228

1186PDSafety and efficacy of the oral CXCR4 inhibitor X4P-001 + axitinib in advanced renal cell carcinoma patients: An analysis of subgroup responses by prior treatment

McDermott, D F, Vaishampayan, U, Matrana, M, Rha, S Y, Saavedra, A Zurita, Ho, T, Keam, B, Lee, J-L, Joseph, R, Ali, S, Stadler, W, Haas, N B, Sundararajan, S, Park, S H, Mowat, R, Picus, J, Dudek, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

2229

1188PDMargetuximab (M) + pembrolizumab (P) for treatment of patients (pts) with HER2+ gastroesophageal adenocarcinoma (GEA) post-trastuzumab (T): Survival analysis

Catenacci, D V, Park, H, Uronis, H, Kang, Y-K, Ng, M C H, Enzinger, P, Lee, K W, Lim, K H, Gold, P J, Lacy, J, Park, S H, Huber, K, Wynter-Horton, A, Nordstrom, J, Wu, T, Wigginton, J, Baughman, J, Ro

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2230

1189PDDeterminants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T)

Park, H, Uronis, H, Kang, Y-K, Ng, M C H, Enzinger, P, Lee, K W, Rutella, S, Church, S E, Nordstrom, J, Knutson, K, Erskine, C, Wu, T, Yen, J, Franovic, A, Muth, J, Rosales, M, Vadakekolathu, J, David

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2231

1190PDPhase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Drew, Y, Kaufman, B, Banerjee, S, Lortholary, A, Hong, S H, Park, Y H, Zimmermann, S, Roxburgh, P, Ferguson, M, Alvarez, R H, Domchek, S, Gresty, C, Angell, H K, Ros, V Rocher, Meyer, K, Lanasa, M, He

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2232

1191OPhase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

Domchek, S, Postel-Vinay, S, Im, S-A, Park, Y H, Delord, J-P, Italiano, A, Alexandre, J, You, B, Bastian, S, Krebs, M G, Wang, D, Waqar, S, Lanasa, M, Angell, H K, Lai, Z, Gresty, C, Opincar, L M, Her

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2233

1193PDAnalysis of tumour hyperprogression (HP) with nivolumab (Nivo) in randomized, placebo (Pbo)-controlled trials

Reck, M, Feng, Y, Kim, H R, Plautz, G, Kang, Y-K, Owonikoko, T K, Nghiem, P, Sheng, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2234

1194PDEarly peripheral T-cell responses predict oncological outcome to checkpoint immune blockade in metastatic melanoma

Fairfax, B, Taylor, C A, Watson, R A, Nassiri, I, Fang, H, Mahe, E, Cooper, R, Danielli, S, Woodcock, V K, Traill, Z, Knight, J C, Payne, M, Middleton, M R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2235

1196PPhase I dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumours: Updated results

Borazanci, E, Schram, A, Brana, I, Villar, M Vieito, Garralda, E, Spreafico, A, Oliva, M, Lakhani, N, Wasserman, R, Hoffman, K, Hallett, R, Anido, J, Giblin, P, Pandya, N, Kelly, A, Seoane, J, Von Hof

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2236

1197PA phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)

Spreafico, A, Janku, F, Rodon, J A, Tolcher, A W, Chandana, S R, Oliva, M, Musalli, S, Knauss, L, Kragh, M, Alifrangis, L, Fröhlich, C, Melander, M C, Blondal, T, Pedersen, M W, Lantto, J, Wood, D, Na

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

2237

1198PFPA150 (B7-H4 antibody) phase I update in advanced solid tumours: Monotherapy and in combination with pembrolizumab

Wainberg, Z A, Sachdev, J C, Bauer, T, Pant, S, Chawla, S, Marina, N, Xiang, H, Deng, W, Schmidt, M, Patnaik, A, LoRusso, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2238

1199PMG1124, a novel CEACAM1-targeted monoclonal antibody, has therapeutic potential as a combination partner of PD-1 inhibitors in NSCLC patients

Lee, E H, Lee, J, Hur, M, Park, H-Y, Yum, H I, Nam, H, Oh, M-Y, Choi, H, Kim, J, Cho, B C, Lim, Y, Won, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2239

1201PDurvalumab + monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC)

Cho, M, Bendell, J C, Han, S-W, Naidoo, J, Lieu, C, Carneiro, B A, Varga, E, Li, X, Kourtesis, P, Abdullah, S E, Patel, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2240

1202PPhase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy

Mach, N, Curigliano, G, Santoro, A, Kim, D-W, Tai, D W M, Hodi, S, Wilgenhof, S, Doi, T, Longmire, T, Sun, H, Xyrafas, A, Gutzwiller, S, Manenti, L, Lin, C-C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2241

1204PGOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis

Correale, P, Staropoli, N, Pastina, P, Giannicola, R, Botta, C, Francini, E, Ridolfi, L, Mini, E, Ciliberto, D, Agostino, R M, Strangio, A, Azzarello, D, Nardone, V, Falzea, A, Tassone, P, Giordano, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2242

1205PImmune correlates in peripheral blood samples in a preoperative window of opportunity randomized trial of nivolumab with or without tadalafil in resectable squamous cell carcinoma of the head and neck (SCCHN)

Harshyne, L, Luginbuhl, A, Curry, J M, Kim, Y, Argiris, A, Shukla, S, Rodeck, U, Johnson, J M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2243

1206PPhase I evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies

Powderly, J, Spira, A, Gutierrez, R, DiRenzo, D, Udyavar, A, Karakunnel, J J, Rieger, A, Colabella, J, Lai, D W, de Souza, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2244

1207PPhase I trial of CV301 in combination with anti-PD-1 therapy in non-squamous NSCLC

Rajan, A, Gray, J E, Devarakonda, S, Gurtler, J, Birhiray, R, Paschold, E, Dasgupta, A, Heery, C, Pico-Navarro, C, Piechatzek, M, Wagner, E, Menius, E, Donahue, R N, Schlom, J, Gulley, J L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2245

1209PExcellent CBR and prolonged PFS in non-squamous NSCLC with oral CA-170, an inhibitor of VISTA and PD-L1

Radhakrishnan, V, Banavali, S, Gupta, S, Kumar, A, Deshmukh, C D, Nag, S, Beniwal, S K, Gopichand, M, Naik, R, Lakshmaiah, K C, Mandavia, D, Ramchandra, M, Prabhash, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2246

1210PPhase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers

Le Tourneau, C, Delord, J-P, Cassier, P, Loirat, D, Tavernaro, A, Bastien, B, Bendjama, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2247

1211PInduction of tumour-infiltrating functional CD8 positive cells and PD-L1 expression in esophageal cancer by S-588410

Kojima, T, Marafioti, T, Fujiwara, T, Shirakawa, Y, Nakatsura, T, Kato, K, Puccio, I, Hikichi, T, Yoshimura, S, Nakagawa, T, Furukawa, M, Stoeber, K, Nagira, M, Ide, N, Daiko, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2248

1212PComprehensive results of a phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer

Wiedermann, U, Garner-Spitzer, E, Chao, Y, Bulat, I, Dechaphunkul, A, Arpornwirat, W, Charoentum, C, Yen, C J, Yau, T, Maglakelidzde, M, Tanasanvimon, S, Maneechavakajorn, J, Sookprasert, A, Bai, L-Y,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2249

1213PSingle intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumour immunity

Samson, A, West, E, Turnbull, S, Scott, K, Tidswell, E, Kingston, J, Johnpulle, M, Bendjama, K, Stojkowitz, N, Lusky, M, Toogood, G, Twelves, C J, Ralph, C, Anthoney, A, Melcher, A, Collinson, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2250

1214PRandomized phase II clinical trial of NY-ESO-1 protein vaccine combined with cholesteryl pullulan (CHP-NY-ESO-1) in resected esophageal cancer patients

Kageyama, S, Nagata, Y, Ishikawa, T, Abe, T, Murakami, M, Kojima, T, Taniguchi, K, Shimada, H, Hirano, S, Ueda, S, Kanetaka, K, Wada, H, Yamaue, H, Sato, E, Miyahara, Y, Goshima, N, Ikeda, H, Yamada,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2251

1215PT cell repertoire sequencing reveals dynamics of response to dendritic cell vaccine plus dasatinib for checkpoint blockade resistant metastatic melanoma

Quagliata, L, Looney, T, Storkus, W, Taylor, J, Topacio-Hall, D, Lowman, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2252

1217PAnti-CSPG4 DNA vaccination as a promising strategy for the treatment of CSPG4+ tumours: A comparative oncology trial

Riccardo, F, Tarone, L, Barutello, G, Arigoni, M, Giacobino, D, Iussich, S, Occhipinti, S, Ferrone, S, Buracco, P, Cavallo, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2253

1218PAntitumor activity, immunogenicity and safety of a novel PD-1 vaccine in combination with two chimeric HER-2 peptide vaccine in syngeneic Balb/c, C57Bl/6 models and in beagle dogs

Kaumaya, P T P, Overholser, J, Guo, L, Yang, Y, Penichet, M, Sayanjali, B, Ede, N, Chong, L, Bekaii-Saab, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2254

1219PMaternal immunization against ALK as a weapon to fight neuroblastoma

Barutello, G, Riccardo, F, Voena, C, Chiarle, R, Cavallo, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2255

1221PAnti-PD-L1/IL-15 fusion protein generates robust adaptive immune gene signatures in tumours leading to tumour inhibition and memory responses

Martomo, S, Feng, X-J, Lu, D, Polonskaya, Z, Luna, X, Poyurovsky, M V, McCracken, K, Miyara, F, Li, L, Aggarwal, S, Patel, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

2256

1222PEvaluation of the anti-tumour efficacy and immune effects of N-809, a novel IL-15 superagonist/anti-PD-L1 bispecific agent

Hicks, K C, Knudson, K M, Ozawa, Y, Schlom, J, Gameiro, S R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2257

1223PGI101, a novel triple-targeting bispecific CD80-IgG4-IL2variant fusion protein, elicits synergistic anti-tumour effects in preclinical models

Park, J C, Pyo, K H, Song, Y J, Lee, W J, Kim, J, Ji, H N, Park, S S, Koh, Y J, Lee, K, Cho, B, Chun, B-H, Oh, Y M, Yang, B-G, Nam, S Y, Jang, M H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2258

1224PPhase Ib, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumours

Strauss, J, Vugmeyster, Y, Sznol, M, Pachynski, R K, Trang, K, Chennoufi, S, Gulley, J L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2259

1226PA phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells

Curioni, A, Britschgi, C, Hiltbrunner, S, Bankel, L, Gulati, P, Weder, W, Opitz, I, Lauk, O, Caviezel, C, Knuth, A, Münz, C, Renner, C, Stahel, R A, Petrausch, U

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2260

1227PHPV16 E6-specific TCR-T armored with checkpoint blockade in the treatment of cervical cancer

Bryson, P, Jia, Q, Chen, G, li, S, Fang, J, Zhao, L, Wolff, B, Chen, R, Wan, Y, Li, Q-J, Zhu, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2261

1228PThe mutant neoantigen specific T cell is a personalized immunotherapy in refractory solid tumour

Song, Q, Zhang, T, Li, J, Sheng, W, Wang, J, Gan, Q, Han, L, Sun, Q, Zhou, N, Zhou, X, Zhou, Y, Wu, L, LI, J, Chang, L, Zhou, Z, Song, Y, Zhang, L, Jiao, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2262

1229PNY-ESO-1 and LAGE1A: An emerging target for cell therapies in solid tumours

Eleftheriadou, I, Brett, S, Domogala, A, Patasic, L, Kijewska, M A, Soor, K, Georgouli, M, Dopierala, J, Fisher, P, Jing, J, Euesden, J, Auger, K R, Roberts, R, O’Sullivan, S, Castelletti, L, Damm, M,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

2263

1230PTargeting myeloid-derived suppressor cells and T cells: Combination treatment with MTL-CEBPA and PD-1 antibody in a mouse syngeneic CT26 model

Sodergren, M, Tan, C, Reebye, V, Habib, R, Blakey, D, Habib, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

2264

1231PMaster checkpoint Cbl-b inhibition: Anti-tumour efficacy in a murine colorectal cancer model following siRNA-based cell therapy

Thell, K, Urban, M, Harrauer, J, Haslinger, I, Kuttke, M, Brunner, J S, Vogel, A, Schabbauer, G, Penninger, J, Gaweco, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

2265

1232PFunctional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy

Zuazo, M, Arasanz, H, Granda, M J García, Bocanegra, A I, Fernández-Hinojal, G, Gato-Cañas, M, Aguillo, M Martínez, Marín, B Hernández, Teijeira, L, Ruiz, I Morilla, Vera, R, Kochan, G, Escors, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2266

1233PLandscape of PD-L1 expression status in Chinese solid tumour patients

Zhong, Y, Zhou, Y, Bai, Y, Zhang, B, Zhang, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2267

1234PAnti-cancer and immunomodulatory effects of cobimetinib in triple negative breast cancer

Liu, C-Y, Lau, K-Y, Chen, J-L, Chu, P-Y, Huang, C-T, Wang, W-L, Lien, P-J, Tseng, L-M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 1.15 MB

2019

2268

1236PInsights into the tumour immune microenvironment using tissue phenomics to drive cancer immunotherapy

Groher, M, Zimmermann, J, Musa, H, Ackermann, A, Surace, M, Rodriguez-Canales, J, Rebelatto, M, Steele, K, Kapil, A, Brieu, N, Rognoni, L, Segerer, F, Spitzmüller, A, Tan, T-H, Schäpe, A, Schmidt, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2269

1237PImmune competent somatic mosaic model of colorectal cancer

Napolitano, S, Carbone, F, Menter, D G, Troiani, T, Genovese, G, Kopetz, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2270

1238PGenomic correlates of response to anti-PDL1 atezolizumab in non-small cell lung cancer OAK and POPLAR trials

Singhal, H, Ekinci, O, Alcorn, C, Gandara, D R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2271

1239PHigh level of activity of nivolumab anti-PD-1 immunotherapy and favorable outcome in metastatic/refractory MSI-H non-colorectal cancer: Results of the MSI cohort from the French AcSé program

Tournigand, C, Flechon, A, Oudard, S, Saada-Bouzid, E, Pouessel, D, Tourneau, C Le, Augereau, P, Beylot-Barry, M, Grob, J J, Chibaudel, B, Soria, J-C, Simon, C, Couch, D, Hoog-Labouret, N, Tiffon, C,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2272

1240PTP53 and ATM co-mutation predicts response to immune checkpoint inhibitors in non-small cell lung cancer

Chen, Y, Chen, G, Li, J, Huang, C, Li, Y, Lin, J, Chen, L Z, Lu, J P, Wang, Y Q, Wang, C X, Pan, L K, Xia, X F, Yi, X, Chen, C B, Zheng, X W, Guo, Z Q, Pan, J J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2273

1241PImmune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients

Laza-Briviesca, R, Cruz-Bermudez, A, Casarrubios, M, Nadal, E, Molla, M A Insa, García-Campelo, M-R, Huidobro, G, Gomez, M Domine, Tarruella, M Majem, Abreu, D Rodriguez, Martinez-Marti, A, Carpeno, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2274

1244PThe decrease of TMB, TNB and HLA expression are the mechanism of drug resistance of NSCLC to immunosuppressive PD-1/PD-L1

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 1.32 MB

2019

2275

1245PEosinophilia during treatment of immune checkpoint inhibitors (ICIs) predicts succeeding onset of immune-related adverse events (irAEs)

Kizawa, R, Miura, Y, Oda, Y, Nagaoka, Y, Masuda, J, Ozaki, Y, Kondoh, C, Moriguchi, S, Takahashi, Y, Ogawa, K, Hashimoto, Y Tanabe, Taniguchi, S, Okaneya, T, Kishi, A, Hayashi, N, Takaya, H, Takano, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2276

1247PA transcriptomic immunologic signature predicts favorable outcome in neoadjuvant chemotherapy treated triple negative breast tumours

Pérez-Peña, J, Fekete, J T, Páez, R, García-Sáenz, J A, García-Barberán, V, Pérez-Segura, P, Pandiella, A, Gyorffy, B, Ocaña, A, Manzano, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2277

1248PAlterations of TMB and TCR repertoires during chemotherapy in East Asian lung cancer patients without TKI-related driver gene mutations

Song, L, He, Y, Li, X, Zhou, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2278

1249PAssociation of SCFA in gut microbiome and clinical response in solid cancer patients treated with andi-PD-1 antibody

Nomura, M, Nagatomo, R, Inoue, K, Doi, K, Shimizu, J, Baba, K, Saito, T, Matsumoto, S, Muto, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2279

1250PExtracellular matrix and tissue derived metabolites in a liquid biopsy identifies endotypes of metastatic melanoma patients with differential response to immune checkpoint inhibitor treatment

Willumsen, N, Bager, C L, Jensen, C, Karsdal, M A, Madsen, D H, Hansen, M, Schmidt, H, Svane, I M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2280

1251PPathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy

Stein, J E, Signoretti, S, Sznol, M, Ishii, Y, McDermott, D F, Choueiri, T K, Taube, J M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2281

1252PPD-L1 expression in uncommon EGFR-mutant non-small cell lung cancer and its response to immunotherapy

Fan, Y, Chen, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2282

1253PCCND1 amplification contributes to immunosuppression in head and neck squamous cell carcinoma and the association with a poor response to immune checkpoint inhibitors

Huang, C, Chen, Y, Gao, X, Li, Y, Lin, J, Chen, L Z, Chang, L P, Chen, G, Guan, Y F, Pan, L K, Xia, X F, Guo, Z Q, Pan, J J, Yi, X, Chen, C B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2283

1254PEfficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer patients with sensitive genes mutation

Cui, H-J, Zheng, S-Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2284

1255PNeutrophil to lymphocyte ratio (NLR) kinetics as predictors of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (NSCLC) patients treated with nivolumab (N)

Simonaggio, A, Elaidi, R, Fournier, L, Fabre, E, Ferrari, V, Borchiellini, D, Thibault, C, Barthelemy, P, Thouvenin, J, Tartour, E, Oudard, S, Vano, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2285

1256PPredictive markers of checkpoint inhibitor activity in adult metastatic solid tumours

Pender, A, Titmuss, E, Pleasance, E, Fan, K, Pearson, H, Bonakdar, M, Taylor, G, Mungall, K, Moore, R, Lavoie, J-M, Yip, S, Lim, H, Renouf, D, Jones, S J, Marra, M A, Laskin, J J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

2286

1257PBlood-based TMB (bTMB) correlates with tissue-based TMB (tTMB) in a multi-cancer phase I IO cohort

Araujo, D V, Wang, A, Torti, D, Huang, J, Leon, A, Marsh, K, McCarthy, A, Berman, H, Spreafico, A, Hansen, A R, Razak, A A, Bedard, P, Wang, L, Plackmann, E, Chow, H, Bao, H, Wu, X, Pugh, T J, Siu, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2287

1258PAnalysis of molecular profile complexities for immunotherapy decision support

Dóczi, R, Tihanyi, D, Filotas, P, Dirner, A, Pálházi, B, Várkondi, E, Farkas, Z, Deri, J, Lengyel, E, Hegedus, C, Petak, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2288

1259PThe role of tumour neoantigens in the differential response to immunotherapy (IO) in EGFR and BRAF mutated lung cancers: Quantity or quality?

Case, K O, Kennedy, K F, Kujtan, L, Subramanian, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2289

1261PComparison 18F-FDG-PET/CT criteria for prediction of therapy response and clinical outcome in patients with metastatic melanoma treated with ipilimumab and PD-1 inhibitors

Vari, S, Annovazzi, A, Giannarelli, D, Pasqualoni, R, Sciuto, R, Carpano, S, Ferraresi, V, Cognetti, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2290

1262PPredictive model for survival in advanced non-small cell lung cancer (NSCLC) treated with frontline pembrolizumab

Rubio, X Mielgo, Garcia, M E Olmedo, Moyano, M Sereno, Aguado, C, Núñez, J A, Gomez, M Domine, Peña, A M Sánchez, Ariza, I Nalda, Gonzalez, S Cerezo, Cabellos, R Alvarez, Gutiérrez, L Cabezón, Mendez,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

2291

1263PExternal validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer

Riedl, J M, Barth, D A, Foris, V, Posch, F, Mollnar, S, Stotz, M, Pichler, M, Stöger, H, Absenger, G, Olschewski, H, Gerger, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2292

1264PChanges of TCR repertoire in metastatic renal cell carcinoma and metastatic melanoma patients treated with nivolumab

Klabusay, M, Skacel, J, Coupek, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

2293

1265PExpression of MHC class I, HLA-A and HLA-B identifies immune activated breast tumours with favorable outcome

López, M D M Noblejas, Nieto-Jiménez, C, Morcillo-García, S, Pérez-Peña, J, Nuncia-Cantarero, M, Galán-Moya, E M, Amir, E, Pandiella, A, Győrffy, B, Ocaña, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

2294

1266PPrognostic significance of tumour tissue NeuGcGM3 ganglioside expression and predictive value of circulating tumour cell count monitoring in patients receiving racotumomab immunotherapy

Üskent, N, Ayla, S, Mandel, N Molinas, Ozkan, M, Teomete, M, Baloglu, H, Aydıncer, C, Yergok, H, Dogan, E, Berk, B, Yazar, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

2295

1267PEvolution of myeloid-derived suppressor cells and objective response rate in relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) patients after receiving immunotherapy

Cortegana, C Jiménez, Carrión, N Palazón, Fernández, E Nogales, García, M A Nieto, Margalet, V Sánchez, de la Gala, M D C Álamo, de Ilárduya, M Suengas Martínez, Burgos, E Montilla, Fernández, I Araúj

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 111 KB

2019

2296

1268PA phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumours or lymphomas

Shen, L, Li, J, Xu, N, Xing, B, Zhang, Q, Zhao, Y, Cao, J, Ding, J, Wang, J, Wang, Y, Dai, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2297

1269PResults from a randomised phase I/II trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)

Voss, M H, Azad, A A, Hansen, A R, Gray, J E, Welsh, S J, Achour, I, Hu, H, Lewis, L, Walcott, F L, Oosting, S F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2298

1271PHigh clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: First results of the AcSé pembrolizumab study

Blay, J-Y, Penel, N, Ray-Coquard, I L, Schott, R, Saada-Bouzid, E, Bertucci, F, Chevreau, C M, Bompas, E, Coquan, E, Cousin, S, Soulié, P, Le Cesne, A, Mir, O, Ryckewaert, T, Brahmi, M, Hoog-Labouret,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2299

1272PLenvatinib plus PD-1 blockade in advanced bile tract carcinoma

Lin, J, Yang, X, Zhao, S, Long, J, Pan, J, Hu, K, Zhao, L, Huo, L, Sang, X, Wang, K, Zhao, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2300

1273PDurvalumab and paclitaxel combination for treatment of metastatic triple negative breast cancer is safe with very promising efficacy

Ghebeh, H, AlSayed, A, Suleman, K, Ajarim, D, Cabangon, L, Tulbah, A, Al-Tweigeri, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2301

1274PA prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients

Hurkmans, D P, Basak, E A, van Dijk, T, Mercieca, D, Schreurs, M W J, Wijkhuijs, A J M, Bins, S, Oomen-de Hoop, E, Debets, R, Joerger, M, Odink, A, Van der Veldt, A A M, Van Der Leest, C H, Aerts, J G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2302

1275PSafety and clinical activity of subcutaneously (SC) administered anti-PD-1 antibody PF-06801591 in phase I dose-expansion cohorts of locally advanced or metastatic non-small cell lung cancer (NSCLC) and urothelial carcinoma (UC)

Cho, B C, Penkov, K, Bondarenko, I, Korozan, M, Kurochkin, A, Pikiel, J, Kulyaba, Y, Ahn, H K, Odintsova, S, Davda, J, Forgie, A, Wang, X, Li, R, Jacobs, I A, Kazazi, F, Chou, J, Johnson, M L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

2303

1276PDevelopment of the functional assessment of cancer therapy-immune checkpoint modulator (FACT-ICM): A scale to measure quality of life in cancer patients treated with ICMs

Hansen, A R, Ala-leppilampi, K, McKillop, C, Siu, L L, Bedard, P, Razak, A R Abdul, Spreafico, A, Sridhar, S, Leighl, N B, Butler, M O, Hogg, D, Sacher, A, Oza, A M, Nisenbaum, R, Webster, K A, Cella,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2304

1277PImmune checkpoint inhibitors (ICIs) as “chemotherapy (Ctx) sensitization” strategy in advanced solid tumours

Montana, F J Ros, Matos, I, Vilacampa, G, Azaro, A, Martin-Liberal, J, Hierro, C, Brana, I, Viaplana, C, Villar, M Vieito, Gardeazabal, I, Saura, C, Madrid, L Fariñas, Mercade, T Macarulla, Saavedra,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

2305

1278PValidation of progression-free survival (PFS) as surrogate endpoint in randomised trials of immune checkpoint inhibitors in advanced solid cancers

Kok, P S, Yoon, W-H, Marschner, I, Lord, S J, Friedlander, M, Lee, C K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2306

1280PA burst of highly differentiated CD4 TL identifies a subset of fast progressors, and correlates with hyperprogressive disease in NSCLC patients treated with ICI

Arasanz, H, Zuazo, M, Aguillo, M Martínez, Marín, B Hernández, Fernández-Hinojal, G, Bocanegra, A I, Ruiz, I Morilla, Gato-Cañas, M, Teijeira, L, Sala, P, García-Granda, M J, Vera, R, Kochan, G, Escor

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2307

1281PNivolumab treatment in advanced non-small cell lung cancer (aNSCLC): A French nationwide retrospective cohort (UNIVOC Study)

Chouaid, C, Levra, M Giaj, Corre, R, Calvet, C, Gaudin, A-F, Grumberg, V, Jolivel, R, Jouaneton, B, Assié, J-B, Cotté, F-E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2308

1282PDissociated responses in patients with metastatic solid tumours treated with immunotherapy

Vaflard, P, Paoletti, X, Servois, V, Pons-Tostivint, E, Sablin, M P, Ricci, F, Loirat, D, Hescot, S, Torossian, N, Borcoman, E, Le Tourneau, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2309

1283PPatterns and outcomes related to rapid progressive disease in a cohort of advanced solid tumours treated with immune checkpoint inhibitors (ICIs)

Ghiglione, L, Galvez, C Cabrera, Reig, O, Soler-Perromat, A, Soler-Perromat, J C, Sánchez, M, Arcocha, A, Viñolas, N, Prat, A, Mellado, B, Reguart, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2310

1284PReal world outcomes of immune-related adverse events (irAEs) among patients receiving immune checkpoint inhibitors (ICIs) in hospital settings

George, S, Zheng, Y, Kim, R, Yu, T, Dreyfus, J, Gayle, J A, Wassel, C, Phatak, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2311

1285PSex-based heterogeneity of efficacy of anticancer immunotherapy

Conforti, F, Pala, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

2312

1286PComparative efficacy and safety of PD-1/PD-L1 inhibitors for patients with solid tumours: A systematic review and Bayesian network meta-analysis

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2313

1287PExcess weight and efficacy of anti-PD-1 antibodies in advanced cancer patients

Rogado, J, Laorden, N Romero, Torres, J M Sanchez, Ramos-Levi, A, Pacheco-Barcia, V E, Garcia, A I Ballesteros, Arranz, R, Lorenzo, A, Gullon, P, Garrido, A, Serra, J M, Donnay, O, Adrados, M, Costas,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2314

1288PSafety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma

Italiano, A, Cassier, P, Roda, D, Lin, C-C, Peltola, K, Gazzah, A, Shiah, H-S, Calvo, E, Tosi, D, Gao, B, warburton, L, Tanner, M, Englert, S, Lambert, S, Parikh, A, Afar, D, Vosganian, G, Moreno, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 107 KB

2019

2315

1289PEfficacy and safety of immune checkpoint inhibitors (ICIs) for treatment of advanced solid tumours in octogenarian patients

Mebarki, S, Gisselbrecht, M, Fabre, E, Mercadier, E, Oudard, S, Paillaud, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

2316

1290PAssociation of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies

Torres, A Z, Mathur, R, Maignan, K, Tucker, M, Ciofalo, K J, Khozin, S, Carson, K R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2317

1291PClinical outcomes of immune checkpoint inhibitors in older and younger patients with advanced solid tumours in a real-life setting

Corbaux, P, Maillet, D, Boespflug, A, Sanchez, M Locatelli, Muzet, M Perier, Duruisseaux, M, Maleka, L Kiakouama, Dalle, S, Falandry, C, Peron, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2318

1292PImpact of corticosteroids and antibiotics on efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer

Martinez, J Mosquera, Riuvadets, M, García- Campelo, M-R, Lopez, J Serra, Palacios, G Anguera, Melo, P Gallardo, Sullivan, I, Joaquin, A Barba, Tarruella, M Majem, Rendo, C Reboredo, González, P Corde

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2319

1293PThe landscape of immuno-oncology clinical trials in China

Wu, D, Huang, H, Li, N, Wang, S, Fang, H, Yu, Y, Bai, Y, Xu, B, Sun, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2320

1294PClinical significance of immune-related creatine phosphokinase increase associated with anti PD1/PD-L1 immunotherapies

Hajem, S S, Baldini, C, Ederhy, S, Berhoune, M, Troalen, F, Romano-Martin, P, Vuagnat, P, Champiat, S, Varga, A, Hollebecque, A, Cauquil, C, Mateus, C, Robert, C, Massard, C, Lambotte, O, Michot, J-M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2321

1295PThyroid toxicity and anti-thyroid antibodies as predictive markers for patients treated with anti-PD1 checkpoint therapy

Meer, W V D, Basak, E A, Hurkmans, D P, Schreurs, M W J, Oomen-de Hoop, E, Van der Veldt, A A M, Bins, S, Joosse, A, Koolen, S L, Debets, R, Peeters, R P, Aerts, J G, Mathijssen, R H, Medici, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

2322

1296PTreatment-related adverse events and tolerability in patients with advanced renal cell carcinoma treated with first-line combination therapy with checkpoint inhibitors

Htut, T Win, Swarup, S, Sultan, A, Mogollon-Duffo, F, Meda, S, Arevalo, M, Adhikari, N, Naing, P T, Hlaing, P P, Myat, Y Mon, Hardwicke, F, D’Cunha, N, Tijani, L, Thein, K Z

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2323

1297PImmune-related adverse events (irAEs) with single-agent PD-1 vs PD-L1 inhibitors: A meta-analysis of 8,730 patients from clinical trials

Sonpavde, G P, Grivas, P, Lin, Y, Hennessy, D, Hunt, J D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

2324

1298PEULAR recommendations for the diagnosis and the management of rheumatic immune-related adverse events due to cancer immunotherapy

Kostine, M, Finckh, A, Bingham, C O, Visser, K, Leipe, J, Schulze-Koops, H, Choy, E, Benesova, K, Radstake, T, Cope, A, Lambotte, O, Gottenberg, J-E, Allenbach, Y, Jamal, S, Marabelle, A, Larkin, J M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2325

1299PRadiographic characteristics and poor prognostic factors of interstitial lung disease (ILD) in nivolumab-treated patients with non-small cell lung cancer (NSCLC)

Sasaki, S, Oikado, K, Saito, Y, Tominaga, J, Sata, M, Sakai, F, Kato, T, Iwasawa, T, Kenmotsu, H, Kusumoto, M, Baba, T, Endo, M, Fujiwara, Y, Sugiura, H, Yanagawa, N, Ito, Y, Sakamoto, T, Ohe, Y, Kuwa

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

2326

1300PUse of checkpoint inhibitors (CPI) in allogeneic stem cell transplant recipients: An institutional experience and a systemic review of the literature

Saberian, C, Abdel-Wahab, N, Suarez-Almazor, M, Al-Atrash, G, Aabudayyeh, A, Diab, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2327

1301PDeep learning radiomics distinguishes intrapulmonary disease from metastases in immunotherapy-treated melanoma patients

Nguyen-Kim, T D L, Trebeschi, S, Pouw, J E E, Milanese, G, Topff, L, Bodalal, Z, Mangana, J, Frauenfelder, T, Haanen, J B A G, Blank, C U, Aerts, H J W L, Beets-Tan, R, Dummer, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

2328

1302PSarcoidosis-like reaction mimics progression in patients treated with immune checkpoint inhibitors

Hans, S, Dercle, L, Champiat, S, Voisin, A-L, Noémie, C, Marabelle, A, Michot, J-M, Sara, L, Corinne, B, Ammari, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

2329

1303PTissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis

Sasson, S C, Cheung, V T F, Gupta, T, Zaunders, J J, Nahar, K, Munier, C M-L, Olsson-Brown, A, Ahlenstiel, G, Palendira, U, Scolyer, R A, Carlino, M S, Long, G V, Menzies, A M, Kelleher, A, Payne, M,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

2330

1304PSignificance of severe immune-related adverse effects (irAE) on patients with advanced tumors treated with immune checkpoint inhibitors being admitted for secondary toxicity: Clinical relevance and next steps

Zubiri, L, Molina, G, Allen, I M, Reynolds, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2331

1305PImplementation of a dedicated immuno-oncology toxicity service reduces the acute impact of immune-related adverse events

Olsson-Brown, A C, Guinan, T, McKay, M, Thurston, K, Chow, S, Lord, R, Sacco, J J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2332

1306PCardiotoxic and pro-inflammatory effects induced by the association of immune checkpoint inhibitor pembrolizumab and trastuzumab in preclinical models

Maurea, N, Quagliariello, V, Passariello, M, Coppola, C, Rea, D, Barbieri, A, De Lorenzo, C, Monti, G, De Laurentiis, M, Ascierto, P A, Botti, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2333

1307PInterstitial lung disease associated with immune-checkpoint inhibitors in malignant diseases

Yamagata, A, Yokoyama, T, Fukuda, Y, Ishida, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

2334

1308TiPA phase I study of intraperitoneal MCY-M11 Anti-mesothelin CAR for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, or subjects with peritoneal mesothelioma with recurrence after prior chemotherapy

Annunziata, C, Dansky-Ullmann, C, Ghobadi, A, Weng, D, Vanas, J, Ekwede, I, Pavelova, M, Keefe, R, Kuo, M, Hassan, R, Thaker, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

2335

1311OLong-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC)

Long, G V, Atkinson, V G, Lo, S, Sandhu, S K, Brown, M, Gonzalez, M, Guminski, A, Scolyer, R A, Emmett, L, Menzies, A M, McArthur, G A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2336

1312PDSafety and efficacy of TRIplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [TRIDeNT] in patients (pts) with BRAF-mutated metastatic melanoma (MM): A single center phase II study

Burton, E M, Amaria, R N, Glitza, I C, Shephard, M, Diab, A, Milton, D, Patel, S, Mcquade, J, Wong, M, Hwu, P, Wargo, J, Davies, M A, Tawbi, H A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

2337

1313PD3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma (OpACIN trial)

Blank, C U, Versluis, J M, Reijers, I L M, Sikorska, K, van Houdt, W J, van Thienen, J V, Adriaansz, S, Mallo, H A, van Tinteren, H, van de Wiel, B A, Grijpink-Ongering, L G, Bruining, A, Haanen, J B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2338

1314PDCell phenotypes associated with response and toxicity defined by high resolution flow cytometry in melanoma patients receiving checkpoint inhibition

Weber, J S, Hodi, S, Wind-Rotolo, M, Woods, D, Winter, A, Chattopadhyay, P, Laino, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2339

1315PDUnsorted single-cell RNA sequencing profiles of metastatic melanoma patients reveal the heterogeneity of melanoma-associated fibroblasts

Homicsko, K, Barras, D, Lopez, V Aedo, Moura, B Gautron, Berthod, G, Matter, M, Gaide, O, Coukos, G, Hanahan, D, Michielin, O A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2340

1319PAvelumab for advanced Merkel cell carcinoma in the Netherlands: A nationwide survey

Levy, S, Aarts, M J B, Eskens, F A, Keymeulen, K, Been, L, Grünhagen, D J, van Akkooi, A C J, Jalving, M, Tesselaar, M E T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2341

1320PHealth-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow-up data

D’Angelo, S P, Nolte, S, Schlichting, M, Henry-Szatkowski, M, Hennessy, M, Bharmal, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2342

1321PA phase II, randomized study of nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and stereotactic body radiation therapy (SBRT) for metastatic Merkel cell carcinoma (MCC, NCT03071406): A preliminary report

Kim, S, Khushalani, N I, Eroglu, Z, Russell, J, Wuthrick, E, Caudell, J, Harrison, L, Aoki, M, Shah, H, Blakaj, D, Markowitz, J, Chen, D-T, Messina, J, Rose, T, Tsai, K, Brohl, A S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 219 KB

2019

2343

1322PReal-world impact of immune checkpoint inhibitors in metastatic uveal melanoma

Bol, K F, Ellebaek, E, Donia, M, Schmidt, H, Bastholt, L, Kiilgaard, J F, Svane, I-M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2344

1323PImmune checkpoint inhibitors in a cohort of 206 metastatic uveal melanomas patients

Saint-Ghislain, M, Geoffrois, L, Gastaud, L, Lesimple, T, Negrier, S, Penel, N, Kurtz, J-E, Le Corre, Y, Gardrat, S, Barnhill, R, Cassoux, N, Mariani, P, Servois, V, Piperno-Neumann, S, Rodrigues, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2345

1324PIncidence and survival of uveal melanoma occurring as single cancer versus its occurrence as a first or second primary neoplasm

Alfaar, A S, Saad, A M, Elzouki, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2346

1325PValidation of a clinicopathological and gene expression profile (CP-GEP) model for sentinel lymph node metastasis in primary cutaneous melanoma

Mulder, E E A P, Dwarkasing, J T, Hollestein, L M, Tempel, D, Bosman, L, Verver, D, Mooyaart, A L, Van der Veldt, A A M, Verhoef, C, Nijsten, T E C, Grünhagen, D J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2347

1327PClinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts)

da Silva, I Pires, Lo, S, Carlino, M S, Scolyer, R A, Menzies, A M, Long, G V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2348

1328PContinental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase II OpACIN-neo trial

Reijers, I L M, Rozeman, E A, Menzies, A M, Versluis, J M, van de Wiel, B A, Sikorska, K, Eriksson, H, Shannon, K, Bierman, C, van Tinteren, H, Gonzalez, M, Spillane, A J, Saw, R P, Scolyer, R A, van

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2349

1329PComparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)

Versluis, J M, Reijers, I L M, Rozeman, E A, van Akkooi, A C J, van Houdt, W J, Bierman, C, van de Wiel, B A, Long, G V, Blank, C U

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2350

1330PAdjuvant therapies for stage III melanoma: Benchmarks for bringing clinical trials to clinical practice

Hieken, T J, Day, C N, Block, M S, Habermann, E B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2351

1331PMixture-cure modeling for resected stage III/IV melanoma in the phase III CheckMate 238 trial

Weber, J S, Kurt, M, Edmondson-Jones, M, Amadi, A, Lobo, M, Moshyk, A, Kotapati, S, Mohr, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2352

1332PAn open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: A subgroup analysis of patients with brain metastasis

Dutriaux, C, Robert, C, Grob, J J, Mortier, L, Dereure, O, Lebbe, C, Mansard, S, Grange, F, Neidhardt, E-M, Lesimple, T, Machet, L, Bedane, C, Maillard, H, Dalac-Rat, S, Nardin, C, Szenik, A, Denden,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 109 KB

2019

2353

1333PAdverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting

Grob, J J, Atkinson, V G, Robert, C, Schadendorf, D, Nathan, P, Davies, M A, Kefford, R, Dummer, R, Kirkwood, J M, Flaherty, K T, Ribas, A, Burgess, P, Gasal, E, Long, G V, Hauschild, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

2354

1334PA single arm, open label, phase II, multicenter study to assess the detection of the BRAF V600 mutation on cfDNA from plasma in patients with advanced melanoma

Rutkowski, P, Pauwels, P, Kerger, J, Jacobs, B, Maertens, G G, Gadeyne, V, Liebert, S, Neyns, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2355

1335PEfficacy and safety of dabrafenib and trametinib in patients with metastatic BRAFV600 mutation-positive melanoma in the real-world setting: Interim results of the non-interventional COMBI-r study

Berking, C, Livingstone, E, Weichenthal, M, Leiter, U, Wittmann, K, Eigentler, T, Mohr, P, Kiecker, F, Loquai, C, Debus, D, Gutzmer, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2356

1336TiPA randomized phase Ib/II study of the selective small molecule Axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma

Straume, O, Lorens, J B, Gausdal, G, Gjertsen, B T, Schuster, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 63 KB

2019

2357

1337PAnalysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials

Robert, C, Schadendorf, D, Dummer, R, Flaherty, K T, Tawbi, H A, Menzies, A M, D’Amelio, A, de Jong, E, Gasal, E, Long, G V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2358

1338PFactors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: An open label, non randomized study

Saiag, P, Robert, C, Grob, J J, Mortier, L, Dereure, O, Lebbe, C, Mansard, S, Grange, F, Neidhardt, E-M, Lesimple, T, Machet, L, Bedane, C, Maillard, H, Dalac-Rat, S, Nardin, C, Szenik, A, Denden, A,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2359

1339PIntegrative RNAseq and target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors

Cheng, P F, Freiberger, S N, Panetti, C, Irmisch, A, Dummer, R, Levesque, M P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2360

1340PEffective treatment with T-VEC monotherapy in stage IIIB/C-IVM1a melanoma of the head & neck region

Franke, V, Stahlie, E H A, Berger, D M S, Klop, W M C, Zuur, L, van der Hiel, B, van de Wiel, B A, Wouters, M W J M, van Houdt, W J, van Akkooi, A C J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2361

1341PRe-introduction of T-VEC monotherapy in recurrent stage IIIB/C-IVM1a melanoma is effective

Franke, V, Stahlie, E H A, van der Hiel, B, van de Wiel, B A, Wouters, M W J M, Van Houdt, W, van Akkooi, A C J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2362

1342PEfficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): Subgroup analysis of the phase III OPTiM study

Middleton, M R, Harrington, K, Ross, M, Ohrling, K, Radcliffe, H-S, Collichio, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2363

1343PReal life use of talimogene laherparepvec in melanoma in centers in Austria and Switzerland

Hoeller, C, Ressler, J M, Karasek, M, Lopez, V Aedo, Koch, L, Kehrer, H, Koelblinger, P, Weihsengruber, F, Kofler, J, Richtig, E, Michielin, O A, Hafner, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

2364

1344POutcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)

Saiag, P, Mortier, L, Dutriaux, C, Benmahammed, L, Morsli, O, Train, C, Spampinato, A, Leccia, M T, Meyer, N, Grob, J J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2365

1346PComparative-effectiveness of pembrolizumab vs nivolumab for patients with metastatic melanoma

Moser, J, Wei, G, Colonna, S, Grossmann, K F, Patel, S, Hyngstrom, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

2366

1347PLong-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: A network meta-analysis

Mohr, P, Toor, K, Goring, S, Chan, K, Besada, M, Johnson, H M, Moshyk, A, Kotapati, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

2367

1348PLong-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study

Dalle, S, Mortier, L, Corrie, P, Lotem, M, Board, R, Arance, A M, Meiss, F, Terheyden, P, Gutzmer, R, Brokaw, J, Le, T K, Mathias, S D, Scotto, J, Lord-Bessen, J, Moshyk, A, Kotapati, S, Middleton, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 97 KB

2019

2368

1349PPrognostic factors for efficacy of Ipilimumab used after anti-PD1 and/or BRAF+MEK inhibitors in melanoma patients: An Italian melanoma intergroup study

Marconcini, R, Nuzzo, A, Manacorda, S, de rosa, F, Fava, P, Astrua, C, Di Guardo, L A, Raimondi, A, Stucci, S L, Todisco, A, Cortellini, A, Bersanelli, M, Nigro, O, Palla, M, Palmieri, G, Falcone, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2369

1350PRechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy

Hepner, A, Carlino, M S, Johnson, D B, Gérard, C L, Lo, S, Pallan, L, Silva, I D, Michielin, O A, Long, G V, Menzies, A M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2370

1351PClinicopathologic characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1 (IPI+PD1) and PD1 monotherapy

Nahar, K J, Rawson, R V, Sandanayake, N, Tattersal, S, Carlino, M S, Palendira, U, Scolyer, R A, Long, G V, Menzies, A M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2371

1353PReal-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands

van Zeijl, M C T, Wouters, M W J M, van den Eertwegh, A J M, de Wreede, L C, Aarts, M J B, van Akkooi, A C J, Van den Berkmortel, F W P J, de Groot, J W, Boers-Sonderen, M J, van der Hoeven, J J M, Ho

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2372

1354PUtilization of real-world data to assess the effectiveness of immune checkpoint inhibitors (ICIs) in elderly patients with metastatic melanoma

Ernst, D S, McConkey, H, Liu, L, Butler, M O, Petrella, T, Baetz, T, Koneru, R, Song, X, Cheng, T, Smylie, M G, Rajagopal, S, Mihalcioiu, C, Gwadry-Sridhar, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2373

1355PTumour mutational burden and response to PD-1 inhibitors: An analysis of 89 cases of metastatic melanoma

Dousset, L, Boussemart, L, Robert, C, Mansard, S, Lebbe, C, Merlio, J-P, Routier, E, Dupuy, A, Rouanet, J, Battistella, M, Capellen, D, Galibert, M-D, Allayous, C, Lespagnol, A, Villechenoux, G, Gerar

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2374

1356PIncrease in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma

Rozeman, E A, Moritz, R, Wilgenhof, S, van Thienen, J V, Haanen, J B A G, van den Heuvel, M, Blank, C U, Van Rossum, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2375

1357PImmune status defined by molecular information layers predicts response to pembrolizumab treatment in advanced melanoma

Prado-Vázquez, G, Trilla-Fuertes, L, Gámez-Pozo, A, López-Vacas, R, López-Camacho, E, Zapater-Moros, A, Arevalillo, J M, Navarro, H, Díaz-Almirón, M, Maín, P, Batlle, J Feliu, Vara, J A Fresno, Espino

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2376

1358PInterim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy

Sandhu, S K, Atkinson, V G, Cao, M Gonzalez, Medina, T, Rivas, A Soria, Caro, I, Roberts, L, Song, Y, Yan, Y, Long, G V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2377

1359PThe impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis

Mandala, M, Legramandi, L, Salvati, L, Rulli, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2378

1361POutcomes of patients with melanoma brain metastases (MBM) treated with standard of care therapy after being excluded from MBM-specific clinical trials

Holbrook, K, Shephard, M P, Haydu, L, Oliva, I Glitza, Amaria, R N, Patel, S, Diab, A, Hwu, P, Brown, C, Arnold, I Boesch, Burton, E, Davies, M A, Tawbi, H A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2379

1362PThe analysis of current treatment outcomes in melanoma patients with brain metastases

Placzke, J, Teterycz, P, Lugowska, I, Morysinski, T, Borkowska, A, Switaj, T, Klimczak, A, Kozak, K, Rogala, P, Kosela-Paterczyk, H, Dudzisz-Sledz, M E, Spalek, M, Czarnecka, A M, Rutkowski, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

2380

1363PA multivariate model to define prognostic groups among patients with melanoma brain metastases: A 10-year retrospective cohort study

Pelizzari, G, Bertoli, E, Vitale, M G, Buriolla, S, Palmero, L, Bartoletti, M, Zara, D, Basile, D, Iacono, D, Pascoletti, G, Cinausero, M, Poletto, E, Bolzonello, S, Freschi, A, Puglisi, F, Fasola, G,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2381

1364PThe immune landscape of melanoma significantly influences survival in patients with highly mutated tumours

Ferguson, R, Morales, L, Simpson, D, Cadley, J, Esteva, E, Chat, V, Martinez, C, Weber, J S, Osman, I, Kirchhoff, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2382

1365PFinal results from phase II of combination with canerpaturev (formerly HF10), an oncolytic viral immunotherapy, and ipilimumab in unresectable or metastatic melanoma in second-or later line treatment

Yokota, K, Isei, T, Uhara, H, Fujisawa, Y, Takenouchi, T, Kiyohara, Y, Uchi, H, Saruta, H, Ihn, H, Inozume, T, Watanabe, D, Takahashi, A, Fukushima, S, Tanaka, M, Yamazaki, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2383

1366PEvaluating polygenic risk score prediction model for melanoma prognosis

Potrony, M, Calbet-llopart, N, Combalia, M, Tell-Martí, G, Puig-Butille, J A, Barreiro, A, Podlipnik, S, Carrera, C, Malvehy, J, Puig, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2384

1367PImpact of sarcopenia in patients with metastatic melanoma treated with immunotherapy

Vitale, M G, Basile, D, Bertoli, E, Giavarra, M, Pelizzari, G, Palmero, L, Zara, D, Targato, G, Pascoletti, G, Cinausero, M, Poletto, E, Iacono, D, Puglisi, F, Fasola, G, Minisini, A M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2385

1368PAncillary evaluation of systemic immune antitumour response (SIAR) and tumour growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase I study Mel-Ipi-Rx

Boutros, C, Chaput, N, Lanoy, E, Larive, A, Mateus, C, Routier, E, Roy, S, Sun, R, Lancia, A, Tao, Y, Ibrahim, N, Khoury-Abboud, R M, Massard, C, Bahleda, R, Schwob, D, Caramella, C, Cassard, L, Soria

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

2386

1369PGenes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma

Svedman, F Costa, Das, I, Tuominen, R, Ramqvist, E D, Hansson, J, Höiom, V, Brage, S Egyhazi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2387

1370PPhase Ib/II study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy

Hassel, J C, Berking, C, Eigentler, T, Gutzmer, R, Ascierto, P A, Schilling, B, Hermann, F, Bartz, R, Schadendorf, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2388

1371PGenomic landscape of primary malignant melanoma of esophagus

Dai, J, Si, L, Cui, C, Sheng, X, Kong, Y, Chi, Z, Mao, L, Wang, X, Lian, B, Li, S, Yan, X, Tang, B, Bai, X, Zhou, L, Guo, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2389

1373TiPILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy

Butler, M O, Robert, C, Negrier, S, In, G K, Walker, J, Krajsova, I, Atkinson, V G, Hansson, J, Kapiteijn, E, Loquai, C, Shaw, H M, Cheng, T, Mansard, S, Grob, J J, Guidoboni, M, Mehta, M, Ascierto, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

2390

1374TiPPRIME002: Early phase II study of azacitidine and carboplatin priming for avelumab in patients with advanced melanoma who are resistant to immunotherapy

Van Der Westhuizen, A, Graves, M, Levy, R, Majid, A, Vilain, R, Bowden, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2391

1375TiPPembrolizumab (pembro) plus lenvatinib (len) for first-line treatment of patients (pts) with advanced melanoma: Phase III LEAP-003 study

Eggermont, A M M, Carlino, M S, Hauschild, A, Ascierto, P A, Arance, A, Daud, A, O’Day, S J, Taylor, M H, Smith, A, Rodgers, A, Moreno, B Homet, Diede, S J, Kluger, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2392

1376TiPProof of concept study with the histone deacetylase inhibitor vorinostat in patients with resistant BRAFV600 mutated advanced melanoma

Huijberts, S C F A, Wang, L, Wilgenhof, S, Rosing, H, Nuijen, B, Beijnen, J H, de Oliveira, R Leite, Bernards, R, Schellens, J H M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

2393

1377TiPA phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumour activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib)

Si, L, Mao, L, Zhou, L, Li, C, Wang, X, Cui, C, Sheng, X, Chi, Z, Lian, B, Tang, B, Yan, X, Li, S, Bai, X, Dai, J, Kong, Y, Lin, L, Zhang, J, Wu, Z, Hui, A, Guo, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2394

1378TiPA phase I clinical trial investigating the therapeutic cancer vaccine UV1 in combination with pembrolizumab as first-line treatment of patients with malignant melanoma

Agarwala, S S, O’Day, S J, Zakharia, Y, Voorhies, B, Milhem, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2395

1379TiPA phase II, open-label, randomized, multicenter trial of encorafenib + binimetinib evaluating a standard-dose and a high-dose regimen in patients with BRAFV600-mutant melanoma brain metastasis (MBM) (POLARIS)

Davies, M A, Weber, J S, Flaherty, K T, McArthur, G A, Reddy, M B, Golden, A, Culbertson, J L, Thomas, C T, Tawbi, H A, Long, G V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

2396

1310OAdjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial

Weber, J S, Del Vecchio, M, Mandala, M, Gogas, H, Arance, A M, Dalle, S, Cowey, C L, Schenker, M, Grob, J J, Chiarion-Sileni, V, Marquez-Rodas, I, Butler, M O, Maio, M, Middleton, M R, Tang, T, Saci,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 106 KB

2019

2397

1381ORNA expression profiles and splicing alterations in grade 1/2 neuroendocrine neoplasms from small intestine origin (siNENs). Final results of the GETNE-NETSEQ study

Capdevila, J, Castaño, J P, Mancuso, F M, Pedraza-Arevalo, S, Matos, I, Palmer, H G, Salva, F, Landolfi, S, Jimenez-Fonseca, P, Garcia-Carbonero, R, Lopez, C, Ogbah, Z, Nuciforo, P G, Casteras, A, Aco

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

2398

1382PDRelation between objective tumour shrinkage and progression-free survival (PFS) in the NETTER-1 population

Pavel, M E, Broberg, P, Caplin, M, Ruszniewski, P, Strosberg, J, Santoro, P, Ravasi, L, Krenning, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 107 KB

2019

2399

1383PDPhase I study of CC-90011 in patients with advanced solid tumours (STs) and relapsed/refractory non-hodgkin lymphoma (R/R NHL)

Hollebecque, A, de Bono, J S, Salvagni, S, Plummer, R, Isambert, N, Niccoli, P, Capdevila, J, Curigliano, G, Moreno, V, De Braud, F G M, López-Brea, M, Martin-Romano, P, Baudin, E, Arias, M, de Alvaro

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2400

1384PDSUNitinib with EVOfosfamide (TH-302) for G1/G2 metastatic pancreatic neuroendocrine tumours (pNETs) naïve for systemic treatment. The SUNEVO phase II trial of the Spanish task force group for neuroendocrine and endocrine tumours (GETNE)

Grande, E, Lopez, C, Alonso Gordoa, T, Benavent, M, Capdevila, J, Teulé, A, Custodio, A, Sevilla, I, Gajate, P, Molina-Cerrillo, J, Hernando Cubero, J, Garcia-Carbonero, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

2401

1386PDLongitudinal increase in Ki67 and high-grade transformation in pancreatic neuroendocrine tumours (PNETs)

Botling, J, Lamarca, A, Bajic, D, Norlen, O, Lönngren, V, Kjaer, J, Eriksson, B, Welin, S, Hellman, P, Rindi, G, Skogseid, B, Crona, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 100 KB

2019

2402

1388PBaseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120 mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen

Ruszniewski, P, Ćwikła, J, Lombard-Bohas, C, Borbath, I, Shah, T, Pape, U-F, Truong Thanh, X-M, Houchard, A, Pavel, M E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

2403

1389PAnalysis of PD-1/PD-L1 blockade biomarker and immune infiltrates in gastroenteropancreatic neuroendocrine carcinoma

Xing, J Z, Bai, C, Cheng, Y, Sun, Z, Gao, Y, Li, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 70 KB

2019

2404

1390PDiabetes is associated with pancreatic neuroendocrine tumours growth and metastasis

Fan, Z, Luo, G, Liu, C, Yu, X

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 70 KB

2019

2405

1391PInvestigation of the reclassification of G1/G2 pancreatic neuroendocrine neoplasms by WHO 2017 classification

Yokose, T, Kitago, M, Shinoda, M, Yagi, H, Abe, Y, Oshima, G, Hori, S, Endo, Y, Hayashi, K, Kitagawa, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

2406

1392PTreatment with somatostatin analogues after radiopeptide therapy

Handkiewicz Junak, D, Syguła, A, Jurecka-Lubieniecka, B, Hasse-Lazar, K, Jarzab, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2407

1393PSafety and tolerability of surufatinib in western patients with solid tumours

Hamilton, E, Wang, J S, Li, D, Dasari, N A, Paulson, S, Cohn, A L, Sauter, N P, Kania, M, Kauh, J, Falchook, G S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2408

1394PThe impact of tumour absorbed dosimetry with survival outcomes after peptide receptor radionuclide therapy in metastatic neuroendocrine tumours

Ladwa, R, Pattison, D, Smith, J, Goodman, S, Burge, M, Rose, S, Dowson, N, Wyld, D K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2409

1395POpportunist and serious infections in patients with neuroendocrine tumours treated with everolimus: A multicenter study of real world patients

Mauro, C D C, de Jesus, V H F, Barros, M, Costa, F P, Weschenfelder, R F, D’Agustini, N, Angel, M, Luca, R, Nuñez, J E, O’Connor, J M, Riechelmann, R P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2410

1396PEstablishment of prognostic nomogram based on the metastatic lymph nodes ratio for patients with gastric neuroendocrine tumour

Lin, Y, Wang, Y, Lin, H, Li, J, Wu, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2411

1397PNeutrophil-lymphocyte ratio as an independent predictive factor in neuroendocrine neoplasms

Ferreira, S C, Conde, R S, Esteves, S, Marques, M T, Claro, I, Moreira, A, Goncalves, M B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2412

1398PFindings from a new specialist remote counselling service for neuroendocrine neoplasm (NEN) patients and family members

Bouvier, C V, Winter, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2413

1400PEfficacy and toxicity of combination chemotherapy with cyclophosphamide, vincristine and an anthracycline in patients with metastatic extrapulmonary neuroendocrine carcinoma

Apostolidis, L, Winkler, E C, Jäger, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2414

1401PAn Australian multi-centre experience of the use of peptide receptor radionuclide therapy for bronchial carcinoid tumours

Lim, L E, Chan, D L, Thomas, D, Wyld, D K, Cehic, G, Macdonald, W, Du, Y T, Tincknell, G, Kuchel, A, Pavlakis, N, Bailey, D, Davis, A, Segelov, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

2415

1402PExtra-pulmonary (EP) high grade (HG) neuroendocrine carcinoma (NEC): Real-life outcomes of fifty-eight patients from a Portuguese cancer center

Conde, R S, Ferreira, S C, Esteves, S, Claro, I, Moreira, A, Marques, M T, Goncalves, M B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

2416

1403PEfficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumours of lung (LCNET)

Sherman, S, Rotem, O, Zer, A, Shochat, T, Dudnik, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

2417

1380O177Lu-DOTATATE plus 166Ho-radioembolization in patients with neuroendocrine tumours: A single center, prospective, interventional, non-comparative, open label, phase II study (HEPAR PLUS study)

Braat, A J A T, van Rooij, R, Bruijnen, R C G, Braat, M N G J A, Wessels, F, van Leeuwaarde, R S, van Treijen, M, de Jong, H W A M, Lam, M G E H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 95 KB

2019

2418

1406PMicrosatellite instability testing and lynch syndrome screening for colorectal cancer patients through tumour sequencing

Liu, L, Garbutt, C, Golkaram, M, Kaplan, S, Martins, M, Casino, S, Mansinho, A, Macedo, D, Alvim, C, Costa, A L, Fernandes, A, Ferreira, C, Aldeia, F, Quintela, A, Costa, L, So, A, Zhang, S, Pawlowski

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2419

1407P"Liquid withdraw" technique in CT-guided cutting needle lung biopsy: Decreased incidence of complications and increased tissue amount for lung cancer molecular testing

Wang, X, Wang, L, Ren, W, Li, R, Liu, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2420

1408PWGS implementation in standard cancer diagnostics for every cancer patient (WIDE)

Roepman, P, Bosch, L, Samsom, K, Schipper, L, de Bruijn, E, Hoes, L, Riethorst, I, Schoenmaker, L, van der Kolk, L, van Snellenberg, H, Voest, E E, Cuppen, E, Monkhorst, K, Meijer, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2421

1409PKnown and unknown gene fusion detection capabilities of solid tumour laboratories conducting next generation sequencing in 6 countries

Finucane, S, Haridas, S, Handley, L, Clark, J, Jack, A, Munksted, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2422

1410PClinical and analytical accuracy of a 523 gene panel next-generation sequencing (NGS) assay on formalin-fixed paraffin-embedded (FFPE) solid tumour samples

Deras, I, Du, T, Zhao, C, Haseley, N, Yazdanparast, A, Jiang, T, Mentzer, A, Purdy, A, Crain, B, Echegaray, C, Lee, D, Lee, J, Silhavy, J, O’Brien, K, Vijayaraghavan, R, Garcia, R, Haigis, R, Pawlowsk

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

2423

1411PMethylation analysis of MLH1 using droplet digital PCR and methylation sensitive restriction enzyme

De Rop, C, Beniuga, G, Radermacher, J, Dahan, K, Vannuffel, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2424

1412PAnalytical performance of the resolution-HRD plasma assay used to identify mCRPC patients with biallelic disruption of DNA repair genes for treatment with niraparib

Pekker, I, Lim, L, Simon, J S, Gormley, M, Li, Z, Pollak, J, Potts, K, Watford, S, Posey, J, Chan, P, Urtishak, K, Garg, K, Hosseini, A, Li, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2425

1413PResults of a global external quality assessment scheme for EGFR testing on liquid biopsy

Normanno, N, Fairley, J, Cheetham, M, Denis, M G, Dequeker, E, Keppens, C, Fenizia, F, Patton, S, Rouleau, E, Schuuring, E, Van Casteren, K, Deans, Z

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2426

1414PClinical impact of plasma next-generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC)

Bonanno, L, Pavan, A, Ferro, A, Calvetti, L, Frega, S, Pasello, G, Aprile, G, Guarneri, V, Conte, P F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2427

1415PFeasibility study of a ctEGFR prototype assay on the fully automated Idylla™ platform

Reijans, M, Gestel, S V, Haes, E D, Vandesteene, C, Castro Gomez, J M, Gouedard, C, Patera, S, Murray, S, Maertens, G G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2428

1416PEnhanced access to EGFR molecular testing in NSCLC using a cell-free DNA tube for liquid biopsy

May, T E, Scudder, S A, Joshi, S J, Kohlmann, M, Shrestha, N, Lee, N, Højbjerg, J A, Lai, J, Madsen, A T, Clement, M S, Meldgaard, P, Tsourounis, M, Sørensen, B, Kohlmann, A, O’Donnell, P, Halait, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2429

1417PAnalysis of circulating tumour DNA in paired plasma and sputum samples of EGFR-mutated NSCLC patients

Grech, C, Hackner, K, Strieder, M, Buder, A, Hochmair, M J, Filipits, M, Errhalt, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2430

1418PLiquid biopsy and array comparative genomic hybridization (aCGH)

Apostolou, P, Ntanovasilis, D-A, Papasotiriou, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2431

1419PNext-generation sequencing panel verification to detect low frequency single nucleotide and copy number variants from mixing cell line studies

Rosas-Alonso, R, Rodriguez-Antolin, C, Esteban Rodriguez, I, Cruz Castellanos, P, de Castro Carpeño, J, Ibanez de Caceres, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2432

1420PAutomated rarefaction analysis for precision B and T cell receptor repertoire profiling from peripheral blood and FFPE-preserved tumour

Quagliata, L, Looney, T, Topacio-Hall, D, Lowman, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2433

1421PA heptamethine cyanine dye is a potential diagnostic marker for myeloid-derived suppressor cells

Jung, C, Cho, Y-S, Kim, H, Ha, H H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2434

1422PMolecular fingerprinting in breast cancer (BC) screening using Quantum Optics (QO) technology combined with an artificial intelligence (AI) approach applying the concept of “molecular profiles at n variables (MPnV)”: A prospective pilot study

Nabholtz, J-M A, Alsaleh, K A, Kullab, S, Abdel-Aziz, N, Abdelwarith, A, Diab, A Al, Hilal, M A, Dabouz, F, Bajic, V, Incitti, R, Bahadoor, M R K, Azeer, A M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

2435

1423PInferring the correlation between incidence rates of melanoma and the average tumour-specific epitope binding ability of HLA class I molecules in different populations

Miklos, I, Molnar, L, Toth, J, Lorincz, O, Csiszovszki, Z, Pales, P, Pántya, K, Megyesi, M, Somogyi, E, Tőke, E R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

2436

1424PThermal liquid biopsy as a valuable tool in lung cancer screening programs

Rodrigo, A, Vega, S, Ojeda Cabrera, J, Sanchez-Gracia, O, Callejo, A, Fernandez, A, Iranzo, P, Cruellas Lapena, M, Quilez Bielsa, E, Velazquez-Campoy, A, Abian, O, Isla, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

2437

1425PTowards a screening test for cancer by circulating DNA analysis

Tanos, R, Otandault, A, Mollevi, C, Bauer, A, Tousch, G, Picque Lasorsa, L, El Messaoudi, S, Colinge, J, Colombo, P-E, Jacot, W, Mazard, T, Sayagués, J M, Gillet, B, Pezet, D, Ychou, M, Thierry, A R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2438

1426PEvaluation of a successful launch of the MammaPrint and BluePrint NGS kit

Delahaye, L, Witteveen, A T, Snel, M, Cavness, T, Chan, B, Mittempergher, L, Glas, A M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2439

1427PAnalysis of prognostic factors on overall survival in elderly women treated for early breast cancer using data mining and machine learning

Heudel, P, Hooijenga, D, Phan, R, Augusto, V, Xie, X, Terret, C, Faure, C, Racadot, S, Tredan, O, Bachelot, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2440

1428PCirculating tumour cell detection in epithelial ovarian cancer using dual-component antibodies targeting EpCAM and FRα

Li, N, Cheng, Y, Chen, L, Zuo, H, Weng, Y, Zhou, J, Liu, H, Peng, M, Song, Q

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2441

1429PCEUS of the breast: Is it feasible in improved performance of BI-RADS evaluation of critical breast lesions? A multi-center prospective study in China

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2442

1430PClassification of abnormal findings on ring-type dedicated breast PET for detecting breast cancer

Sasada, S, Masumoto, N, Nishina, M, Kimura, Y, Amioka, A, Itagaki, T, Emi, A, Kadoya, T, Okada, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2443

1432PNanomaterials augmented LDI-TOF-MS for hepatocellular carcinoma diagnosis and classification

Zhou, J, Liu, W, Zhao, L, Jiang, J, Lu, Y, Hu, J, Zhang, H, Bai, J, Li, X

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2444

1433PDevelopment and validation of an RNA-Seq Assay for gene fusions detection in formalin-fixed paraffin-embedded samples

Dong, H, Peng, H, Wang, C, Guo, Y, Li, B, Chen, C, Xiong, L, Li, F, Tian, L, Xu, Q

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2445

1434PA pilot study to implement an artificial intelligence (AI) system for gastrointestinal cancer clinical trial matching

Jin, Z, Haddad, T, Hubbard, J, Hartgers, M L, Leventakos, K, Cornwell, K, King, K, Franke, B A, Pomerleau, K, Bibeau, V, Coverdill, S, Rammage, M, Helgeson, J, Mahipal, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2446

1435PA blinded comparison of patient treatments to therapeutic options presented by an artificial intelligence-based clinical decision-support system

Suwanvecho, S, Suwanrusme, H, Jirakulaporn, T, Taechakraichana, N, Lungchukiet, P, Thanakarn, N, Decha, W, Boonpakdee, W, Preininger, A, Dankwa-Mullan, I, Solomon, M, Wang, S, Jackson, G, Patel, V, Sh

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2447

1436POncOS: Scalable and accurate next-generation sequencing analytics for precision oncology and personalized patient care

Thompson, J S, Farmery, J H R, Dobson, H, Frost, S, Cassidy, J W, Patel, N, Thompson, H, Clifford, H W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2448

1437PThe association between wearable device physical activity metrics and performance status in oncology: A systematic review

Kos, M, Pijnappel, E N, Kampshoff, C S, Buffart, L M, Wilmink, H W, van Laarhoven, H W M, van Oijen, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2449

1438PSomaticNET: Neural network evaluation of somatic mutations in cancer

Dubourg-Felonneau, G, Rebergen, D, Parsons, C, Thompson, H, Cassidy, J W, Patel, N, Clifford, H W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 64 KB

2019

2450

1440PDJIPANG study: Randomized phase III study of pemetrexed/cisplatin (PEM/Cis) versus vinorelbine /cisplatin (VNR/Cis) for completely resected p-stage II-IIIA non-squamous non-small cell lung cancer (Ns-NSCLC): Outcomes based on EGFR mutation status

Tsuboi, M, Kenmotsu, H, Yamanaka, T, Yoshiya, K, Takahashi, T, Ueno, T, Goto, K, Daga, H, Ikeda, N, Sugio, K, Seto, T, Toyooka, S, Date, H, Mitsudomi, T, Okamoto, I, Yokoi, K, Saka, H, Okamoto, H, Tak

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

2451

1441PDA comprehensive model of genetic-features predicts outcome of personalized adjuvant treatment in resected EGFR-mutant stage II-IIIA NSCLC: Results from a phase III trial (CTONG 1104-ADJUVANT)

Wu, Y-L, Liu, S-Y, Wang, Q, Mao, W, Wu, L, Shen, Y, Cheng, Y, Chen, C, Xu, L, Wang, J, Liu, H-X, Bao, H, Chen, Y-D, Zhang, X, Chen, Z-H, Yan, H-H, Yang, J-J, Shao, Y W, Zhou, Q, Zhong, W-Z

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2452

1442PWedge resection with omission of lymph node dissection as an optional treatment strategy in octogenarians or older with early stage non-small cell lung cancers

Mimae, T, Miyata, Y, Tsutani, Y, Imai, K, Ito, H, Nakayama, H, Ikeda, N, Okada, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2453

1444PPulmonary tumour-draining vein exosomal lincRNA-p21 levels impacts non-small cell lung cancer prognosis

Castellano, J J, Navarro, A, Molins, L, Canals, J, Marrades, R, Viñolas, N, Moises, J, Casadevall, M, Li, Y, Han, B, Martinez, D, Martin, J, Garisoain, A, Muñoz, C, Ramirez, J, Monzo, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2454

1446PImmunological impact of surgery in NSCLC patients

Yanagihara, A, Kagamu, H, Sakaguchi, H, Ishida, H, Nitanda, H, Taguchi, R, Yoshimura, R, Yamaguchi, O, Hashimoto, K, Kodaira, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2455

1447PThe prognostic value of selected immunological panel in predicting the prognosis of early-stage resectable non-small cell lung cancer

Zhao, S, He, Y, Zhang, X, Zhou, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2456

1450PFrequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection

Tsuboi, M, Herbst, R S, John, T, Grohe, C, Majem, M, Goldman, J W, Kim, S-W, Yu, C-J, Miziara, J E A, Novello, S, Urban, D, Akewanlop, C, Öztürk, A, Quang, B V, Kowalski, D, Marmol, D, Marotti, M, Lau

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

2457

1451PEGFR mutation is not a prognostic factor in completely resected lymph node–negative pulmonary adenocarcinoma (LNNPA)

Leeladejkul, N, Chantranuwat, P, Sitthideatphaiboon, P, Teerapakpinyo, C, Shuangshoti, S, Benjacholamas, V, Pornpattanarak, N, Vinayanuwattikun, C, Sriuranpong, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2458

1454PCombined immunoscore for prognostic stratification of early stage NSCLC patients

Pasello, G, Boscolo, A, Fortarezza, F, Lunardi, F, Urso, L, Frega, S, Comacchio, G, Bonanno, L, Guarneri, V, Rea, F, Calabrese, F, Conte, P F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2459

1455PRadiation-induced lung injury and misdiagnosis rate after SBRT

Fu, X, Zhu, X, Li, X

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2460

1456PSignificance of the red blood cell distribution width in resected pathological stage I non-small cell lung cancer

Toyokawa, G, Shoji, F, Yamazaki, K, Shimokawa, M, Takeo, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2461

1439PDBRCA1 expression level as prognostic factor for recurrence in resected NSCLC with adjuvant chemotherapy: SCAT Trial

Massuti Sureda, B, Sanchez Torres, J M, Cobo Dols, M, Moran Bueno, M T, Gonzalez-Larriba, J L, Barneto Aranda, I C, De Castro Carpeno, J, Iglesias, L, Muñoz, M A, López Vivanco, G, Isla Casado, M D, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

2462

1458PDPhase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer: 10-year follow-up of West Japan thoracic oncology group WJTOG0105

Zenke, Y, Tsuboi, M, Chiba, Y, Satouchi, M, Mitsuoka, S, Shimizu, J, Daga, H, Fujimoto, D, Mori, M, Aoki, T, Sawa, T, Omori, S, Saka, H, Iwamoto, Y, Okuno, M, Hirashima, T, Kshiwabara, K, Tachihara, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 107 KB

2019

2463

1459PDEfficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)

Vansteenkiste, J F, Naidoo, J, Faivre-Finn, C, Özgüroğlu, M, Villegas, A, Daniel, D, Murakami, S, Hui, R, Lee, K H, Cho, B C, Kubota, K, Taboada, M, Wadsworth, C, Dennis, P A, Antonia, S J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 108 KB

2019

2464

1460PSurvival outcome of non-small cell lung cancer (NSCLC) patients: Comparing results between the database of the Comprehensive Cancer Center Zürich (CCCZ) and the Epidemiological Cancer Registry Zurich and Zug (KKR)

Stahel, R A, Curioni, A, Rohrmann, S, Dafni, U, Sandner, U, Andratschke, N, Dimopoulou, G, Guckenberger, M, Kohler, M, Matthes, K, Opitz, I, Weder, W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

2465

1461PNORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC)

Guirado, M, Majem, M, Massuti Sureda, B, de las Penas Bataller, R, Ortega Granados, A L, Isla Casado, M D, Domine Gomez, M, Marse Fabregat, R, Sala, M A, Paredes Lario, A, Moran Bueno, M T, Vazquez Es

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2466

1462PA nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators set by principle component analysis

Cheng, B, Meng, X, Yu, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2467

1463PPrognostic and predictive value of 18F-PET/CT on the response to treatment in locally advanced non-small cell lung cancer (NSCLC)

Alfaro Autor, C, Soriano, M, Gómez Bravo, R, Méndez García, M, Royuela, A, Cruz-Bermudez, A, García, J M, Calvo de Juan, V, Franco, F, Provencio, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2468

1464PComparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer

Işıkdoğan, A, Akdeniz, N, Küçüköner, M, Kaplan, M A, Urakçı, Z, Karhan, O, Sezgin, Y, Bilen, E, Ebinç, S, Teke, F, Laçin, Ş, Alan, O, Ercelep, O, Yumuk, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2469

1465PPredicting the first failure pattern in patients with inoperable local advanced non-small cell lung cancer (LA-NSCLC) receiving definitive chemoradiotherapy: Establishment and internal validation of a nomogram based on the clinicopathological factors

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 70 KB

2019

2470

1466PPrognostic impact of neutrophil-to-lymphocyte ratio (NLR) pre and post chemoradiotherapy (CRT) in stage III non-small cell lung cancer (NSCLC)

Palomar Abril, V, Soria-Comes, T, Martin Ureste, M, Maestu Maiques, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2471

1467PMeta-analysis evaluating neutropenia incidence with EGFR inhibitors and chemotherapy in patients with NSCLC

Rapoport, B, Arani, R, Natek, M, Krendyukov, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2472

1468PEffector CD4+ T-cell induction by thoracic radiotherapy for patients with NSCLC

Miura, Y, Kodaira, K, Kenmochi, M, Yamashiro, T, Yamaguchi, O, Shiono, A, Mouri, A, Nishihara, F, Shinomiya, S, Hashimoto, K, Murayama, Y, Kobayashi, K, Kaira, K, Kagamu, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2473

1469PCirculating tumour DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met

Heist, R S, Motwani, M, Naumovski, L, Wu, J, Bach, B A, Lu, X, Kelly, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2474

1470PFirst real life data on durvalumab after definitive concomitant chemoradiotherapy (cCRT) in unresectable stage (St) III non-small cell lung cancer (NSCLC) in France: Analysis of 591 patients (pts) enrolled in the French cohort (c) temporary authorization of use (ATU)

Avrillon, V, Bota Ouchlif, S, Merle, P, Pichon, E, Stancu, A T, Chouaid, C, Sire, C, Boudabous, H, Lagrange, A, Sabatini, M, Eberst, G, Boisselier, P, Gourion, A, Lion, A, Lahouegue, A, Belkhiria, K,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2475

1471PEGFR inhibitor versus chemotherapy as adjuvant treatment for locally-advanced EGFR-mutant non-small cell lung cancer

Xie, P, Tang, W, Li, X, Dong, Y, Sun, X, Zhang, J, Yu, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2476

1472PAfatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: Interim analysis of a phase IIIb, multi-national, open-label study

de Marinis, F, Laktionov, K K, Poltoratskiy, A, Egorova, I, Hochmair, M, Passaro, A, Migliorino, M R, Metro, G, Gottfried, M, Tsoi, D, Ostoros, G, Rizzato, S, Mukhametshina, G Z, Schumacher, M, Novell

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2477

1473PFirst-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis

Tan, D S, Geater, S, Yu, C J, Tsai, C M, Hsia, T C, Zhou, J, Chen, J, Lin, M C, Yu, P, He, J, Li, W, Lu, Y, Sriuranpong, V, Yang, C T, Sen, P, Branle, F, Shi, M, Wu, Y L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

2478

1474PA combined analysis of two phase IIIb studies of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC

de Marinis, F, Tu, H, Laktionov, K K, Feng, J, Poltoratskiy, A, Zhao, J, Egorova, I, Tan, E-H, Gottfried, M, Lee, V, Kowalski, D M, Yang, C-T, Srinivasa, B J, Passaro, A, Clementi, L, Tang, W, Huang,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

2479

1476PDefinition of an afatinib trough concentration threshold in the treatment of NSCLC

Bouchet, S, Favary, C, Frohn, C, Maritaz, C, Lassalle, R, Molimard, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2480

1477TiPA phase Ib trial of neoadjuvant chemoradiotherapy and durvalumab (MEDI4736) for potentially resectable stage III non-small cell lung cancer (NSCLC)

Ahn, B C, Lee, S, Seo, J W, Lee, C Y, Lee, J G, Park, S Y, Kim, D J, Lee, C G, Cho, J, Yoon, H I, Shim, B Y, Cho, D G, Kim, S W, Park, H S, Chun, Y J, Hong, M H, Kim, H R, Cho, B C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 67 KB

2019

2481

1457PDEfficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC: Results from the European Thoracic Oncology Platform (ETOP 6-14) NICOLAS phase II trial

Peters, S, Felip, E, Dafni, U, Tufman, A, Guckenberger, M, Irigoyen, A, Nadal, E, Becker, A, Vees, H, Pless, M, Martinez-Marti, A, Lambrecht, M, Andratschke, N, Tsourti, Z, Piguet, A-C, Roschitzki-Vos

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2482

1479OIntegrated genomic and DNA methylation analyses of non-small cell lung cancer patients with brain metastases

Fan, Y, Xu, Y, Huang, Z, Chen, K, Han-Zhang, H, Ye, J, Han, N, Gong, L, Xu, X, Lu, H, Qin, J, Xie, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 111 KB

2019

2483

1480OCTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC

Zhou, Q, Wu, Y-L, Cheng, Y, Liu, Y, Chen, G, Cui, J, Yang, N, Song, Y, Li, X-L, Lu, S, Zhou, J, Ma, Z, Yu, S-Y, Huang, C, Shu, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 68 KB

2019

2484

1481OClinical development of molecular-targeted therapies for non-small cell lung cancer through nationwide genome screening in Japan (LC-SCRUM-Japan)

Miyamoto, S, Matsumoto, S, Yoh, K, Kato, T, Nishino, K, Sugawara, S, Nakao, M, Ohe, Y, Seto, T, Sakakibara-Konishi, J, Furuya, N, Goto, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2485

1482OOutcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042

Mansfield, A S, Herbst, R S, Castro, G, Hui, R, Peled, N, Kim, D-W, Novello, S, Satouchi, M, Wu, Y-L, Garon, E B, Reck, M, Robinson, A G, Samkari, A, Piperdi, B, Ebiana, V, Lin, J, Mok, T S K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 111 KB

2019

2486

1483PDPembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407

Powell, S F, Abreu, D Rodriguez, Langer, C J, Tafreshi, A, Paz-Ares, L, Kopp, H-G, Rodríguez-Cid, J, Kowalski, D, Cheng, Y, Kurata, T, Awad, M M, Lin, J, Zhao, B, Pietanza, M C, Piperdi, B, Garassino,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

2487

1484PDFinal PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC

Mok, T S K, Shaw, A T, Camidge, R D, Gadgeel, S M, Rosell, R, Dziadziuszko, R, Kim, D-W, Perol, M, Ou, S-H, Bordogna, W, Smoljanović, V, Hilton, M, Peters, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

2488

1485PDSafety and efficacy of WX-0593 in ALK-positive or ROS1-positive non-small cell lung cancer

Shi, Y-K, Fang, J, Zhang, S, Liu, Y, Wang, L, Si, M, Ge, M, Geng, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 103 KB

2019

2489

1486PDExposure-response analyses of ALK-inhibitors crizotinib and alectinib in NSCLC patients

Groenland, S L, Geel, D R, Janssen, J M, Beijnen, J H, Burgers, S A, Smit, E F, Huitema, A D R, Steeghs, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2490

1487PDIntracranial and extracranial efficacy of lorlatinib in the post second-generation ALK tyrosine kinase inhibitor (TKI) setting

Camidge, D R, Solomon, B J, Felip, E, Besse, B, Bearz, A, Peters, S, Toffalorio, F, Abbattista, A, Thurm, H, Peltz, G, Wiltshire, R, Shaw, A T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 97 KB

2019

2491

1488PDEntrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

Braud, F G M De, Siena, S, Barlesi, F, Drilon, A, Simmons, B P, Huang, X, Ye, C, Doebele, R C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2492

1489PDSecondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: Results of the prospective PFROST trial

Landi, L, Tiseo, M, Heukamp, L C, Menon, R, Spitaleri, G, Cortinovis, D L, Delmonte, A, Galetta, D, D’Arcangelo, M, D’Incà, F, Bertrand, M, Jóri, B, Zacher, A, Gridelli, C, Novello, S, Chiari, R, Veru

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

2493

1490PDA phase Ia/IIa trial of Sym015, a MET antibody mixture, in patients with advanced solid tumours

Camidge, D R, Janku, F, Bueno, A Martinez, Catenacci, D V, Lee, J, Lee, S-H, Chung, H C, Dowlati, A, Rohrberg, K S, Felip Font, E, Garralda, E, Kang, Y-K, Moon, Y W, López Criado, M, Chiu, C-F, Poulse

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

2494

1491PPD-L1 expression in primary tumour vs metastatic samples in the phase III MYSTIC study in first-line metastatic (m) NSCLC

Reinmuth, N, Boothman, A-M, Cho, B C, Lee, K H, Luft, A, Ahn, M-J, Scott, M, Whiteley, J, Walker, J, Karwe, V, Mukhopadhyay, P, Thiyagarajah, P, Scheuring, U, Rizvi, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2495

1492PAssessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: Post hoc analyses from the phase III JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC)

Barlesi, F, Özgüroğlu, M, Vansteenkiste, J F, Spigel, D, Yang, J C-H, Bajars, M, Ruisi, M, Manitz, J, Park, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 105 KB

2019

2496

1493PLong-term avelumab treatment in patients with advanced non-small cell lung cancer (NSCLC): Post hoc analyses from JAVELIN solid tumour

Hrinczenko, B, Spigel, D, Iannotti, N, Safran, H P, Taylor, M H, Bennouna, J, Goel, S, Leach, J, Wong, D J, Kelly, K, Verschraegen, C, Bajars, M, Manitz, J, Ruisi, M, Gulley, J L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

2497

1494PEffectiveness and safety of nivolumab in the treatment of lung cancer patients in France: Updated survival and subgroup analysis from the real-world EVIDENS study

Barlesi, F, Dixmier, A, Debieuvre, D, Raspaud, C, Auliac, J B, Benoit, N, Bombaron, P, Moro-Sibilot, D, Audigier-Valette, C, Asselain, B, Lamoureux, P, Cotté, F-E, Allan, V, Daumont, M, Ozan, N, Calve

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2498

1497PSecond-line (2L) real-world treatment (tx) patterns and outcomes in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) treated with first-line (1L) immuno-oncology (IO) monotherapy (mono tx)

Talbot, D, Fish, S M, Jin Ong, T, Flick, E D, Waterhouse, D M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 105 KB

2019

2499

1499PPembrolizumab as first-line treatment in NSCLC with PD-L1 ≥50%: Real life results from an all-comer population

Frost, N, Kollmeier, J, Pultermann, D, Tessmer, A, Schmittel, A, Schmidt, B, Grah, C, de Wit, M, Misch, D, Blum, T, Suttorp, N, Grohe, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2500

1500PPatients with metastatic non-small cell lung cancer without molecular alterations or PD-L1 expression in Germany: Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)

Griesinger, F, Eberhardt, W E E, Bruch, H-R, Rauh, J, von der Heyde, E, Marschner, N W, Jänicke, M, Fleitz, A, Spring, L, Sahlmann, J, Karatas, A, Hipper, A, Weichert, W, Sadjadian, P, Metzenmacher, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2501

1501PImpact of second-line (2L) immune checkpoint inhibitors (ICIs) on the treatment (Tx) of advanced non-small cell lung cancer (NSCLC) in a UK centre: A REAL-oncology analysis from the I-O Optimise initiative

Snee, M, Cheeseman, S, Thompson, M, Bowman, R, Lacoin, L, Sopwith, W, Chaib, C, Daumont, M, Penrod, J R, O’Donnell, J C, Hall, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2502

1502PFirst line pembrolizumab for NSCLC with PD-L1 TPS > 50% in a first French real life cohort

Amrane, K, Geier, M, Corre, R, Léveiller, G, Florence, G, Lamy, R, Bizec, J L, Goarant, E, Robinet, G, Ulrike, S, Quere, G, Bernier, C, Descourt, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2503

1503PInterstitial lung disease induced by immune-checkpoint inhibitors correlates with prognosis of advanced non-small cell lung cancer patients

Sugano, T, Seike, M, Saito, Y, Takano, N, Hisakane, K, Takahashi, S, Tanaka, T, Kashiwada, T, Nakamichi, S, Takeuchi, S, Miyanaga, A, Minegishi, Y, Noro, R, Kubota, K, Gemma, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2504

1504PPhase II study to evaluate the peripheral blood mononuclear cell biomarker for nivolumab efficacy on previously treated non-small cell lung cancer subjects (NEJ029B: IMMUNITY-ONE)

Kawashima, Y, Yamaguchi, O, Kozuki, T, Furuya, N, Kurimoto, F, Okuno, T, Yamada, T, Komiyama, K, Ko, R, Nagai, Y, Ishikawa, N, Harada, T, Watanabe, K, Seike, M, Yoshimura, K, Kobayashi, K, Kagamu, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

2505

1505PEfficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated results of the ongoing non-interventional study (NIS) VARGADO

Grohe, C, Gleiber, W, Haas, S, Krüger, S, Schulze, M, Atz, J, Kaiser, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2506

1506PUpfront atezolizumab chemoimmunotherapy-associated immune-related adverse events in patients with advanced non-small cell lung cancer

Mogollon-Duffo, F, Thein, K Z, Tun, A M, Swarup, S, Jahan, N, Adhikari, N, Htut, T Win, Naing, T W, Hlaing, P P, Myat, Y Mon, Naing, P T, Hardwicke, F, Tijani, L, D’Cunha, N, Awasthi, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2507

1507PNivolumab-induced and radiation recall pneumonitis in patients with non-small cell lung cancer: A multicenter real world analysis of 669 patients

Mamesaya, N, Narita, S N, Naito, T, Udagawa, H, Goto, K, Miyawaki, T, Nakashima, K, Kenmotsu, H, Shimokawaji, T, Kato, T, Hakozaki, T, Okuma, Y, Nakayama, Y, Watanabe, H, Kusumoto, M, Ohe, Y, Horinouc

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2508

1508PRetrospective analysis of immunotherapy prognostic scores in advanced NSCLC at Nottingham University Hospitals (UK)

Lopez Escola, C, Sheikh, O, Franks, H, Mengoli, K, Karim, S, Khan, S, Arora, A, Hennig, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

2509

1509PApplicability of lung immune prognostic index (LIPI) to predict efficacy of first-line pembrolizumab in advanced non-small cell lung cancer (NSCLC)

Mielgo Rubio, X, Gomez Rueda, A, Antoñanzas, M, Falagan, S, Núñez, J A, Sánchez Peña, A M, Gómez-Barreda, I, Martinez Moreno, E, Cerezo Gonzalez, S, Cabezón Gutiérrez, L, Sanchez Torres, J M, Jimenez

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

2510

1510PDelayed onset immune related adverse effects (IRAEs) of pembrolizumab in non-small cell lung cancer

Yan, H, Jiang, Y, Luong, M K, Naban, N, Kane, C, Conibear, J, Papadatos-Pastos, D, Ahmad, T, Chao, D, Asghar, U S, Anand, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2511

1511PClinical implication of multiplex IHC and serologic biomarkers on hyperprogression in NSCLC patients receiving immune checkpoint blockers in real world

Kim, J, Kim, S, Kang, J H, Chun, S, Kim, S-Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2512

1512PLocal ablative treatment and treatment beyond progression for oligo-progression in stage IV non-small cell lung cancer after tumour response to anti-PD1 treatment

Guisier, F, Gervais, R, Husseini, K El, Assié, J-B, Geier, M, Decroisette, C, Corre, R, Descourt, R, Chouaid, C, Salaun, M, Thiberville, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

2513

1514PPrognostic impact of metastatic sites for pembrolizumab efficacy as first-line therapy in patients with PD-L1 tumour proportion score (TPS) ≥ 50% advanced non-small cell lung cancer: A retrospective multicenter study

Kawachi, H, Tamiya, M, Tamiya, A, Ishii, S, Hirano, K, Matsumoto, H, Yokoyama, T, Ishida, T, Ryota, K, Fujimoto, D, Hosoya, K, Suzuki, H, Hirashima, T, Kanazu, M, Sawa, N, Uchida, J, Morita, M, Makio,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2514

1515PImpact of visceral fat area as independent predictive factor in patients with advanced non-small cell lung cancer treated with nivolumab

Sato, Y, Fujimoto, D, Hosoya, K, Nagata, K, Nakagawa, A, Tachikawa, R, Tomii, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2515

1516PEffect and safety of immune checkpoint inhibitors for brain metastases from non-small cell lung cancer

Iuchi, T, Ashinuma, H, Yoshida, Y, Mizuno, S, Hosono, J, Setoguchi, T, Hasegawa, Y, Sakaida, T, Shingyoji, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2516

1517PImpact of radiotherapy on efficacy of anti-programmed death 1 (PD-1) antibodies in metastatic NSCLC

Samuel, E, So, Y J, Hiong, A, Balasubramanian, A, Parakh, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2517

1518PPembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real-world data from a European Cohort with focus on subgroups of interest

Mountzios, G, Signorelli, D, Cobo, J Rey, Banini, M, Economopoulou, P, Russo, G Lo, Baxevanos, P T, Roila, F, de Toma, A, Banna, G, Christopoulou, A, Jimenez, B, Linardou, H, Calles, A, Galetta, D, Ad

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2518

1521POsimertinib in epidermal growth factor receptor (EGFR) T790M advanced non-small cell lung cancer (NSCLC): Analysis of patients with central nervous system (CNS) metastases in a real-world study (ASTRIS)

Metro, G, Provencio, M, Kim, D-W, Cho, B C, Park, K, Pan, Y, Shi, Y, Migliorino, R, Tiseo, M, Yu, J, Zhou, Q, Santo, A, Ardizzoni, A, Hu, Y, Wu, Y-L, Kim, S-W, Miranda, M, Fernandes, A, de Marinis, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2519

EL33Cancer of Unknown Primary

Shibata, Hiroyuki

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 69 KB

english, 2019

2520

1545PBrigatinib in ALK TKI-pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC): The use via expanded access to brigatinib (UVEA-Brig) study

Novello, S, Brustugun, O T, Cadranel, J, Griesinger, F, Hochmair, M J, Pérol, M, Popat, S, Bent-Ennakhil, N, Kruhl, C, Felip, E

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

2521

O2-1-3Mismatch repair-deficient or other molecular subtypes and efficacy of chemotherapy for advanced gastric cancer

Kubota, Yohei, Kawazoe, Akihito, Nakamura, Yoshiaki, Sasaki, Akinori, Mishima, Saori, Kotani, Daisuke, Kuboki, Yasutoshi, Taniguchi, Hiroya, Kojima, Takashi, Doi, Toshihiko, Yoshino, Takayuki, Kuwata,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 97 KB

english, 2019

2522

WS2-4Corporate Viewpoint:Effects of support for balancing work and treatment in small and medium-sized companies

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 82 KB

english, 2019

2523

927PClinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)

Hoffman-Censits, J, Rosenberg, J E, van Der Heijden, M, Dreicer, R, Perez Gracia, J L, Petrylak, D P, Retz, M M, Sabbatini, R, Naglieri, E, Caserta, C, Maruzzo, M, Iacovelli, R, Galli, L, McDermott, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 91 KB

english, 2019

2524

AJS-3Precision Oncology in Clinical Practice in Japan

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 70 KB

english, 2019

2525

AOJS-3 Social Responsibilities of Oncology Medical Association in Taiwan

Chen, Li-Tzong, Wang, Cheng-Su

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

2526

AOJS-4 Challenges of Cancer Care in Singapore

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

2527

EJS-3The Paradigm Shift in Genetic Counseling for Hereditary Cancer

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

2528

JS2-4Unmet Needs of Rare Cancer Patients and New Initiatives of RCJ

Majima, Yoshiyuki

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 82 KB

english, 2019

2529

SY6-3Is Earlier Better? Immunotherapy for Resectable Lung Cancer

Forde, Patrick M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

2530

SY7-3Immune checkpoint inhibitors: a perspective of established and potential combination therapy

Horinouchi, Hidehito

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

2531

O1-2-2Post-marketing survey of safety and efficacy of nivolumab for recurrent or metastatic head and neck cancer in Japan

Kiyota, Naomi, Tahara, Makoto, Nibu, Ken-Ichi, Hoshino, Tomohiro, Iida, Osamu, Hayashi, Ryuichi

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 91 KB

english, 2019

2532

O1-7-1 [Encore]D-index-guided early antifungal therapy for persistent FN in patients with hematological malignancies (CEDMIC trial)

Sakaida, Emiko, Kanda, Yoshinobu, Kimura, Shun-Ichi, Iino, Masaki, Fukuda, Takahiro, Oyake, Tatsuo, Yamaguchi, Hiroki, Fujiwara, Shin-Ichiro, Suzumiya, Junji, Okamoto, Akinao, Fujita, Hiroyuki, Takama

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

2533

O1-9-4A prospective real-world study of eribulin for HER2-negative recurrent breast cancer patients: final results

Mukai, Hirofumi, Inoue, Kenichi, Takahashi, Masato, Yamanaka, Takashi, Egawa, Chiyomi, Sakata, Yukinori, Ikezawa, Hiroki, Matsuoka, Toshiyuki, Ishii, Mika, Tsurutani, Junji

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

2534

PD5-3Comprehensive care for Pediatric and AYA Sarcoma

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

2535

PD5-4Rare Cancer Center - All Activities for Rare Cancer Patients! -

Katoh, Yoko, Kawai, Akira, Shibata, Taro, Goto, Yasushi, Suzuki, Tatsuya, Iwata, Shintaro, Yonemori, Kan, Munakata, Wataru, Satomi, Eriko, Yoshida, Akihiko, Sakurai, Takuro, Takayama, Tomoko, Higashi,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

2536

P2-313Clinical effect of alectinib in patients with ALK-positive non-small cell lung cancer

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 71 KB

english, 2019

2537

SY13-2Immunotherapy with molecular targeted drug for thyroid cancer

Homma, Yoshitaka

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 69 KB

english, 2019

2538

SY19-3CACD: Attitudes of medical staff in cancer care toward symptoms in cancer survivors, and our current approaches

Tanimukai, Hitoshi

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

2539

SY20-3New cytotoxic and target therapies for soft tissue sarcoma

Blay, Jean-Yves

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 82 KB

english, 2019

2540

SY20-5Chemotherapy for Soft Tissue Sarcoma: Development of New Standard Treatments and Clinical Trials in Japan

Tanaka, Kazuhiro

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 83 KB

english, 2019

2541

PS3-2KN100: Results from Japanese patients with advanced recurrent ovarian cancer treated with pembrolizumab monotherapy

Matsumoto, Koji, Nishio, Shin, Takehara, Kazuhiro, Kawamura, Naoki, Hasegawa, Kosei, Takeshima, Nobuhiro, Aoki, Daisuke, Kamiura, Shoji, Arakawa, Atsushi, Kondo, Eiji, Hirakawa, Tomoko, Yamamoto, Keik

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

2542

WS2-3Support for both medical treatment and work∼Perspective of an occupational health physician ∼

Morimoto, Hideki

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 82 KB

english, 2019

2543

PD2-5Care for patients receiving cancer drug therapy at home

Iino, Keiko, Ichikawa, Chisato, Nagaoka, Namiko

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

2544

PD2-6Team work on hazardous drugs exposure handling measures and future prospects

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

2545

LBA23MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)

Tolaney, S M, Wardley, A M, Zambelli, S, Hilton, J, Troso-Sandoval, T, Ricci, F, Im, S-A, Kim, S-B, Johnston, S R D, Chan, A, Goel, S, Catron, K, Yang, Z, Gainford, C, André, F

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 85 KB

english, 2019

2546

PSY2-6Clinical Research and Trial Infrastructure in South-East Asia (Malaysia)

Wan Ishak, Wan Zamaniah

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 83 KB

english, 2019

2547

PSY2-9Management of Breast Cancer in Sri Lanka

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 83 KB

english, 2019

2548

MS2-2Activity on Nationwide Cancer Genome Screening Project for Metastatic Colorectal Cancer in Japan; SCRUM-Japan GI-SCREEN

Yoshino, Takayuki

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

2549

MS4-3Systemic therapy for elderly patients with metastatic renal cell carcinoma

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

2550

MO2-13-1Randomized phase II trial of CBDCA+nab-PTX vs CDDP+GEM in patients with chemo-naïve squamous cell lung cancer: NJLCG1302

Fujita, Yuka, Kawashima, Yosuke, Harada, Toshiyuki, Nakagawa, Taku, Watanabe, Kana, Morikawa, Naoto, Takamura, Kei, Kanazawa, Kenya, Kuda, Tomoya, Usui, Kazuhiro, Sekine, Akimasa, Inoue, Akira, Sugawa

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

2551

PD6-3BRACAnalysis and multigene panel testing needs hereditary cancer care

Kogawa, Takahiro

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

2552

P3-015Assessing the impact of sequence in delivering primary-directed palliative radiotherapy in esophageal cancer

Ho, Shaun Zhirui, Koh, Yen Sin, Wang, Michael, Lim, Faye, Chin, Francis, Yip, Connie, Siow, Tianrui, Wang, Fuqiang

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

2553

P3-129A Young Case of Neoadjuvant Taxane Monotherapy for Breast Cancer toward pCR-Quadruple Neoplasms, Pairing Uterine Sarcoma

Nagata, Yoko, Otani, Yoko, Hagi, Misato, Mizutani, Makiko, Yasojima, Hiroyuki, Mori, Kiyoshi, Manou, Masayuki, Kudawara, Ikuo, Matsumoto, Hisanori, Masuda, Norikazu

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

2554

P3-156Ursolic acid induce anoikis by suppress metabolism in ovarian cancer cells

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

2555

SY20-4Molecular target therapy for soft tissue sarcoma

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 82 KB

english, 2019

2556

MC-2Work Style Reform for physicians at the Cancer Institute Hospital of JFCR by middle-up-down management

Nishimura, Noriko

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

2557

P1-046PF-06439535 (a bevacizumab biosimilar) for non-small cell lung cancer: subgroup analysis

Okano, Yoshio, Ishikawa, Tomofumi, Hiro, Shintaro, Hirano, Yoko, Tajima, Kentaro, Kasahara, Kazuo

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

2558

P1-120Gemcitabine/Cisplatin therapy for an urothelial carcinoma patient undergoing hemodialysis: a case report

Goto, Yumiko, Kanao, Kent, Onishi, Masafumi, Nakamura, Kogenta

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

2559

P2-195L-Arginine metabolism alteration by L-Lysine intervention increased cell death in triple negative breast cancer cell

Yarani, Reza, Jahani, Mozhgan, Tahmasebi, Hadis, Chehri, Javad, Mansouri, Kamran

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

2560

MO2-16-2Irreversible severe cardiotoxicities except for QTc interval prolongation associated with Osimertinib

Kunimasa, Kei, Kimura, Madoka, Oboshi, Makiko, Inoue, Takako, Tamiya, Motohiro, Kuhara, Hanako, Nishino, Kazumi, Yasui, Taku, Shioyama, Wataru, Fujita, Masashi, Imamura, Fumio, Kumagai, Toru

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

2561

O2-5-4Prevalence and prognostic impact of comorbidities in sarcomas: A population-based study of 3746 patients in Hong Kong

Loong, Herbert Hf, Wong, Carlos Kh, Ho, Chu-Wa, Tse, Teresa, Kwan, Sui-Chun Sampson, Lau, Yat-Ming, Leung, Linda Ks

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

2562

117PCorrelation of MRI derived parameters and SUV uptake obtained from FDG- PET-CT with human papillomavirus status in oropharyngeal squamous cell carcinomas

Goyal, S, Koyyala, V P B, Jajodia, A, Chaturvedi, A, Gairola, M, Rao, A, Sharma, M, Pasricha, S, Alhawat, P, Mahawar, V, Amrith, B, Tripathi, R

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

2563

MO1-19-3Final analysis of survival outcomes in the KSCC1501A trial of up-front therapy for HER2-negative advanced gastric cancer

Makiyama, Akitaka, Shinozaki, Katsunori, Kashiwada, Tomomi, Kawanaka, Hirofumi, Tanioka, Hiroaki, Okita, Yoshihiro, Fukahori, Masaru, Hayashi, Naomi, Shimokawa, Mototsugu, Saeki, Hiroshi, Oki, Eiji, B

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

2564

MO2-10-2Aged donor derived CAR-T exhibits enhanced effector functions but shorter persistence and less memory-like phenotypes

Kotani, Hiroshi, Li, Gongbo, Yao, Jiqiang, Mesa, Tania E, Chen, Jon, Yu, Bin, Boucher, Justin C, Yoder, Sean J, Zhou, Jing, Davila, Marco L

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 90 KB

english, 2019

2565

P1-157Pharmacogenetic profile associated with toxicity of fluoropyrimidines in colorectal cancer patients from Kazakhstan

Babenko, Dmitriy, Akhmaltdinova, Lyudmila, Kolesnikova, Evgeniya, Zhumalieva, Vera, Sirota, Valentina, Turmuhambetova, Anar

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

2566

P1-177Clinical and biological significance of thymopoietin-α in gastric cancer

Lin, Kai-Yuan, Fang, Chia-Lang, Uen, Yih-Huei, Sun, Ding-Ping

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 82 KB

english, 2019

2567

P2-049Early detection of pancreatic ductal adenocarcinoma by measuring the abnormal urinary fragmentation ratios of kininogen

Kan, Motoyasu, Mitsunaga, Shuichi, Ohno, Izumi, Ikeda, Masafumi, Tsubouchi, Hironobu, Yanagi, Shigehisa, Matsumoto, Nobuhiro, Okumura, Nobuaki, Takao, Toshifumi, Nakazato, Masamitsu

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

2568

P2-175Polo-like kinase inhibitor with radiation in betel-nuts related HNSCC in Taiwan

Chen, Jo-Pai, Chang, Jui-Ying, Hong, Ruey-Long

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

2569

P3-200Correlation between Social Support Given and its Psychological Effects in Breast Cancer Patients: A Preliminary Study

Claudia, Maria, Reina, Natasya, Octavia, Michelle, Wijovi, Felix, Putri, Helenia, Cindy, Cindy, Kurniawan, Andree

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

2570

P3-201Real State of the Terminal Care of Lung Cancer in the Integrated Community Care System after Medical Fees Revision 2018

Kato, Kan, Koganemaru, Chikage, Oh, Tokuken, Watanabe, Kageaki, Ookuma, Yuusuke, Hosomi, Yukio

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

2571

2OPan-genome cfDNA methylation analysis of metastatic prostate cancer

Wu, A, Cremaschi, P, Wetterskog, D, Conteduca, V, Franceschini, G M, Gonzalez-Billalebeita, E, Giorgi, U D, Demichelis, F, Lise, S, Attard, G

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 107 KB

english, 2019

2572

38PAnti-breast cancer activity of 7-α-hydroxyfrullanolide triggered G2/M arrest and apoptotic induction of triple negative breast cancer cell line, revealed by proteomics

Chimplee, S, Roytrakul, S, Graidist, P, Sukrong, S, Srisawat, T, Kanokwiroon, K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

2573

39PExploring the role of the DDB2 protein as a potent molecular target in pancreatic ductal adenocarcinoma

Gilson, P, Meras, M, Ariztegui, M, Becuwe, P, Merlin, J-L, Harlé, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

2574

120PEarly on-treatment vs pre-treatment tumour transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer

Pernas, S, Goel, S, Johnson, N T, Harrison, B T, Guerriero, J L, Hu, J, Winship, G, Sokolov, A, Regan, M M, Mittendorf, E A, Overmoyer, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2575

511TiPA phase I, open-label study of GSK1795091 administered in combination with immunotherapies in participants with advanced solid tumours (NCT03447314)

Hansen, A R, Strauss, J, Chaves, J, Piha-Paul, S A, Park, H, Garralda, E, Matheny, C J, Carver, J, Moore, A, Hug, B A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

2576

576PImpact of prophylactic systemic antibiotics (SA) on outcome of patients (pts) with RAS-wildtype (RAS-wt) metastatic colorectal carcinoma (mCRC) treated with cetuximab-based first-line therapy. Subgroup analysis of the german non-interventional study ERBITAG

Sahm, S W, Zahn, M-O, Maintz, C, Goehler, T, Janssen, J, Hering-Schubert, C, Rubanov, O, Zander, I, Stenzel, K G, Overkamp, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

2577

789PApatinib combined with docetaxel in second-line treatment of advanced gastric cancer: A prospective clinical study (data updated)

Yang, M, Gao, J, Liu, X, Xu, Z, Lu, H, Yang, W, Li, H, Li, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 729 KB

2019

2578

1208PSafety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumours: Preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts

Conter, H J, MacDonald, L D, Fiset, S, Bramhecha, Y M, Chaney, M, Rosu, G N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2579

1590TiPSafety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study

Reckamp, K L, Akerley, W, Calvo, E, Clarke, J, Edelman, M J, He, K, Moreno, V, Neal, J W, Owonikoko, T K, Patel, J D, Patel, S P, Riess, J W, Sacher, A G, Turcotte, S, Villaruz, L C, Zauderer, M G, Fa

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2580

1831PUpdate of the registry of young women with cancer by the International Network of Cancer, Infertility and Pregnancy

Maggen, C, Van Calsteren, K, Cardonick, E, Shmakov, R G, Gziri, M, Garcia, A C, Fruscio, R, Lok, C A R, Halaska, M, Boere, I A, Zola, P, Ottevanger, P, de Groot, C J M, Scarfone, G, Fumagalli, M, Pain

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2581

2016PModulation of TLR9-dependent autophagy response via inhibition of c-Met signaling influences the survival of HT29 cancer cells

Sipos, F J, Nagy, L, Barta, B, Simon, Á, Dankó, T, Sebestyén, A, Kiss, A L, Műzes, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 69 KB

2019

2582

CN111Cancer patient participation and compliance in microbiome sample collection: An oncology research nurse’s experience

Malo, J, Messaoudene, M, Cauchois, F, Belkaid, W, Frizon-Peresa, D, Ikene, S, Rousseau, L, Lattouf, J-B, Elkrief, A, Mezquita, L, Derosa, L, Besse, B, Blais, N, Alameddine, R, Tehfe, M, Florescu, M, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2583

Introduction

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 65 KB

2019

2584

JS3-1A case of heart failure after radiation therapy for mediastinum

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2585

PSY1-3Precision Medicines in Oncology, European Regulator’s Views

Démolis, Pierre

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

2586

PSY2-4 [Encore]Establishing Comprehensive Cancer Care in Cambodia

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

2587

SY11-5Current status, issue and future perspectives for biosimilars in Japan from the viewpoint of cost-effectiveness

Nanbu, Yoshihiro

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2588

MO1-2-1Temozolomide monotherapy in patient of neuroendocrine carcinoma with resistant to platinum chemotherapy (Final Report)

Kobayashi, Noritoshi, Takeda, Yuma, Tokuhisa, Motohiko, Hiroshima, Yukihiko, Goto, Ayumu, Ichikawa, Yasushi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2589

MO1-8-4Baseline neutrophil to lymphocyte ratio is predictor of longer OS of metastatic BC patients treated with eribulin

Kusuhara, Shota, Kogawa, Takahiro, Shimokawa, Mototsugu, Shingaki, Sumito, Fujimoto, Yumi, Harano, Kenichi, Matsubara, Nobuaki, Naito, Yoichi, Hosono, Ako, Mukai, Hirofumi, Mukohara, Toru

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2590

MO1-9-2Immune microenvironment in clear cell type renal cell carcinoma with loss of PBRM1 protein expression

Miura, Yuji, Motoshima, Takanobu, Inoshita, Naoko, Okaneya, Toshikazu, Takano, Toshimi, Komohara, Yoshihiro

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2591

MO1-11-5Factors that could potentially impact on the initiation time of oncology clinical trials at investigational sites

Sano, Ayaka, Sasamoto, Hiromi, Nakamura, Mitsuyoshi, Ando, Koji, Shimada, Naomi, Kondo, Yayoi, Sawa, Junichiro, Ebisawa, Ryuichi, Suzuki, Hajime, Maruhashi, Akihiro, Tsuda, Takanori, Qiu, Xinbin, Shig

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2592

MO1-11-6The health-related quality of life and Economic burden on Cancer Patients in Japan

Ohno, Shinya, Chen, Yirong, Sakamaki, Hiroyuki, Tsukamoto, Katsura

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2593

MO1-15-2Safety and efficacy of irinotecan administered after nivolumab for advanced gastric cancer

Sasaki, Akinori, Kawazoe, Akihito, Eto, Tetsuya, Mishima, Saori, Kotani, Daisuke, Nakamura, Yoshiaki, Kuboki, Yasutoshi, Taniguchi, Hiroya, Kojima, Takashi, Doi, Toshihiko, Yoshino, Takayuki, Shitara,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2594

MO1-16-1Update on JACCRO CC-11 trial of 1st-line modified-FOLFOXIRI plus bevacizumab for RAS mutant metastatic colorectal cancer

Nakamura, Masato, Sunakawa, Yu, Okuyama, Hiroyuki, Matsuura, Masato, Negoro, Yuji, Yabuno, Taichi, Takahashi, Takao, Tamura, Takao, Takeuchi, Nobumichi, Satake, Hironaga, Miyamoto, Yuji, Kataoka, Masa

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2595

MO2-1-4 [Encore]Association between preanalytical factors and tumor mutational burden estimated by NGS-based multiplex gene panel assay

Nguyen, Quy Pham, Kanai, Masashi, Kou, Takayuki, Kondo, Tomohiro, Yamamoto, Yoshihiro, Matsubara, Junichi, Hiroshima, Akinori, Mochizuki, Hiroaki, Sakuma, Tomohiro, Fukuyama, Keita, Matsumoto, Shigemi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2596

MO2-7-5Quality of medical care in end-of-life lung cancer patients previously received immunotherapy

Kubo, Emi, Ishiki, Hiroto, Yokota, Sayuri, Shimizu, Masaki, Kiuchi, Daisuke, Satomi, Eriko

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2597

MO2-8-5A pharmacokinetics study of edoxaban in NSCLC patients harboring an EGFR mutation combined with venous thromboembolism

Hotta, Takamasa, Tsubata, Yukari, Ishikawa, Nobuhisa, Tanino, Akari, Kobayashi, Misato, Sugisaka, Jun, Nakamura, Atsushi, Okuno, Takae, Umemoto, Junro, Nakao, Mika, Hamaguchi, Megumi, Hamaguchi, Shuni

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2598

MO2-15-4The different frequencies of histologic transformation after different EGFR-TKIs in EGFR-mutant adenocarcinomas

Kang, Jin, Chen, Jun Hua, Yang, Ji Jin, Yi Wu, Long

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

2599

MO3-2-1Correlation between Ghrelin and gastrointestinal stromal tumors/Study on mechanism of Ghrelin regulating GISTs growth

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2600

O1-2-1Phase 1 study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma

Tahara, Makoto, Okano, Susumu, Enokida, Tomohiro, Ueda, Yuri, Fujisawa, Takao, Biel, Merrill

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2601

O1-2-4Efficacy of nivolumab for head and neck cancer arising from subsites which were not included in CheckMate 141

Ueda, Yuri, Fujisawa, Takao, Ito, Kazue, Enokida, Tomohiro, Okano, Susumu, Tahara, Makoto

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

2602

O2-3-2Phase 1 to 3 of the update of the EORTC Quality of Life Gastric module QLQ-STO22

Terada, Mitsumi, Sodergren, Samantha, Blazeby, Jane, Singer, Susanne, Yoshikawa, Takaki, Terashima, Masanori, Lordick, Florian, Vassiliou, Vassilios

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2603

O2-4-4Improvement quality of life in elderly metastatic colorectal cancer patients receiving ambulatory chemotherapy

Chansriwong, Phichai, Sirilerttrakul, Suwannee, Wannakansophon, Nopakan, Tangteerakoon, Patamaporn, Vongterapak, Suluck, Jirajarus, Manmana, Ckumdee, Sineenuch, Muntham, Dittapol, Sirachainan, Ekaphop

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2604

O3-1-1Pembrolizumab vs chemotherapy as 2L therapy for advanced esophageal cancer: Japanese Subgroup Analysis in KEYNOTE-181

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2605

P1-012Primary tumor location and benefit of anti-EGFRs as second or later line treatment in RAS-RAS wild type mCRC patients

Saito, Ayumi, Fukuda, Misao, Ashimine, Hiroya, Miyaji, Yasutomo, Chi, Sunngi, Oyama, Yu

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2606

P1-026Efficacy of nivolumab for advanced gastric cancer

Moriyama, Ichiro, Kawakami, Koshi, Ikejiri, Fumiyoshi, Takahashi, Fumimasa, Matsuda, Shinichiro, Ugata, Norimi, Shimasaki, Yasumasa, Fujii, Yusuke, Tsukano, Kousuke, Yamanouchi, Satoshi, Kusunoki, Ryu

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2607

P1-103Study Pharmacokinetic Behavior of MTX-HD and Rescue with Leucovorine in Human Plasma LC and RMNC13, Children Hospital

Rocabado Calizaya, Guillermo O, Riveros, Astrid S, Leyton Omar, Almazan

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2608

P1-254Expectations and challenges for TeamOncology workshops

Kondoh, Chihiro, Ichinari, Yoko, Morita, Hajime, Suyama, Hisashi, Yoshii, Yumi, Ezura, Mio, Fujisawa, Yoko, Iihara, Hirotoshi, Kariya, Mitsuki, Matsumoto, Natsumi, Nakajima, Sanae, Osato, Yoichi, Tera

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2609

P1-267Cost-effectiveness of pegfilgrastim in prostate cancer patients receiving cabazitaxel

Kondo, Yu, Sakakibara, Takayoshi, Furuta, Misato, Hiraiwa, Izumi, Kato, Jun, Kato, Aki, Miyake, Yoshio

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2610

P2-199A retrospective study of immune-related adverse events in various solid tumors

Shimozaki, Keitaro, Sukawa, Yasutaka, Beppu, Noriko, Kurihara, Isao, Suzuki, Shigeaki, Asoda, Seiji, Ozawa, Hiroyuki, Mizuno, Ryuichi, Funakoshi, Takeru, Ikemura, Shinnosuke, Tsugaru, Kai, Togasaki, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

2611

P2-274Prevalance Geriatric in Hospitilized Cancer Patient

Gunarsa, Ralph, Tryanni, Vania, Iranwan, Cosphiadi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2612

P2-310Two cases of congestive heart failure during osimertinib treatment for EGFR mutant NSCLC

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

2613

P3-030C-reactive protein predicts recurrence after postoperative chemotherapy using S-1 in advanced gastric cancer patients

Shimizu, Takayuki, Ishizuka, Mitsuru, Arakawa, Takao, Suzuki, Takashi, Tago, Kazuma, Hachiya, Hiroyuki, Harada, Yasuhiro, Park, Kyunghwa, Shiraki, Takayuki, Sakuraoka, Yuhki, Mori, Shozo, Abe, Akihito

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2614

P3-130Prevalence of BRCA 1 and BRCA 2 in Breast Cancer Patients in India

Pathak, Abhishek

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2615

SY16-4Countermeasures against delirium during cancer treatment-from the standpoint of a physical therapist-

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 70 KB

2019

2616

DL3Breast Cancer in Young and Premenopausal Women

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 70 KB

2019

2617

EL30Treatment of Multiple Myeloma: Current Status and a Future Perspective

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 69 KB

2019

2618

PS1-3Alpelisib (ALP)+fulvestrant (FUL) in patients from Japan with advanced breast cancer: Subgroup analysis of SOLAR-1 trial

Iwata, Hiroji, Yamashita, Toshinari, Inoue, Kenichi, Takahashi, Masato, Masuda, Norikazu, Yamauchi, Teruo, Yamamoto, Yutaka, Takano, Toshimi, Niikura, Naoki, Nakayama, Takahiro, Takashima, Seiki, Mats

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

2619

SY2-3Investigator-Initiated Registration Directed Trials, or Advanced Medical Care conducted by GOTIC and NRG-Oncology Japan

Fujiwara, Keiichi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2620

SY18-4Chemotherapy for patients with cancer and pulmonary comorbidities

Takiguchi, Yuichi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2621

WS2-1Support for working cancer survivors: toward collaboration among stakeholders in hospitals, workplaces, and communities

Takahashi, Miyako

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

2622

1021PThe prognostic impact of monocyte to lymphocyte ratio (MLR) in advanced epithelial ovarian cancer (EOC)

Salamero, M Cucurull, García, I Teruel, Arroyo, A J, Pardo, B, Gil, M, Piulats, J M, Pla, H, Fina, C, Ginesta, M P Barretina, Angelats, L, Falgas, E Felip, Lecuona, C Erasun, Mosquera, J J García, Rom

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

2623

1279PPharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies

Migden, M R, Paccaly, A, Papadopoulos, K P, Yang, F, Davis, J D, Rippley, R, Lowy, I, Fury, M G, Stankevich, E, Rischin, D

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

2624

MO1-12-6A pilot survey on the outpatient chemotherapy unit of national university hospitals in Japan for early palliative care

Takahashi, Hidenori, Satomi, Yuji, Suzuki, Takeshi, Uneoka, Shogo, Ishii, Takeo, Nanba, Aritomo, Iguchi, Natsumi, Takemura, Katsuya, Nakajima, Nobuhisa, Masuda, Masato, Arasaki, Akira

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

2625

MO2-4-1Sequential Anthracycline-Taxane Chemotherapy in Node-positive Breast Cancer Amongst Asian Patients - Real-world Outcomes

Shariff, Nisha, Wan Ishak, Wan Zamaniah Binti

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 90 KB

english, 2019

2626

MO3-13-6 [Encore]Characterization of Immunosuppressive Cells Using MultiOmyx in Hematological Malignancies

Au, Qingyan, Hanafi, Arezoo, Parnell, Erinn, Kuo, Judy, Leones, Eric, Sahafi, Flora, Padmanabhan, Raghavkrishna, Hoe, Nicholas, William, Josette

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 63 KB

english, 2019

2627

P1-022Clinical response to subsequent chemotherapy after nivolumab in patients with advanced gastric cancer

Tsugaru, Kai, Sukawa, Yasutaka, Shimozaki, Keitaro, Togasaki, Kazuhiro, Kawasaki, Kenta, Hirata, Kenro, Hayashi, Hideyuki, Hamamoto, Yasuo, Kanai, Takanori, Takaishi, Hiromasa

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

2628

P3-076Retrospective study of immune-related adverse events in NSCLC patients treated with PD-1 inhibitors

Otsubo, Aya, Ota, Takeshi, Okajima, Masaaki, Tanaka, Hiroshi, Ishida, Takashi, Iwashima, Akira, Watanabe, Satoshi, Sato, Kazuhiro, Matsumoto, Naoya, Miyabayashi, Takao, Terada, Masaki, Sato, Ko, Ishik

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 89 KB

english, 2019

2629

P3-222Cancer-oriented comprehensive nursing-caregiving service in Korea: 1 year report

Kim, Hyojin, No, Boram, Ko, Ara, Choi, Miso, Lee, Seol, Park, So Young, Ahn, Yongchel, Kim, Moon-Ho

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 91 KB

english, 2019

2630

73POverexpression of EGFR, COX2 and p53 in oral squamous cell carcinoma patients of Pakistan and correlation with prognosis

Ali, S M A, Mirza, Y

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 84 KB

english, 2019

2631

MO2-4-5ROLE OF POST MASTECTOMY RADIOTHERAPY (PMRT) IN T1,T2 LESIONS WITH 1-3 POSITIVE AXILLARY LYMPH NODES

Sadhwani, Manish A, Garg, Nikhil B, Tankshali, Rajen A, Pandya, Shashank J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

2632

MO2-5-6Palbociclib (PAL) + cetuximab (CET) vs CET in patients (pts) with head and neck cancer: Asian subgroup analysis

Tahara, Makoto, Lin, Jin Ching, Sacco, Assuntina, Ley, Jessica, Oppelt, Peter, Shen, Qi, Kern, Kenneth, Thurm, Holger, Wang, Shaw Ling, Martini, Jean Francois, Hoffman, Justin, Melichar, Bohuslav, Adk

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

2633

MO3-2-6Correlation study between c-kit, ETV1, FOXF1 and clinicopathological data of gastrointestinal stromal tumors

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

2634

P2-055FOLFIRINOX for advanced pancreatic cancer patients after nab-paclitaxel plus gemcitabine failure: retrospective analysis

Matsumoto, Toshihiko, Kimura, Shogo, Himei, Hitomi, Okazaki, Ukyo, Kurioka, Yusuke, Tsuduki, Takao, Takagi, Shijiro, Takatani, Masahiro, Hiramatsu, Ysushi, Morishita, Hirofumi

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

2635

P3-196Relationship of Mechanism of Coping and Psychological Problems in Breast Cancer Patients

Tancherla, Angeline, Celine, Elizabeth, Dharmaraja, Fernando, Natalie, Friecelie, Putri, Helenia, Nathania, Regina, Kurniawan, Andree

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

2636

11PMolecular determinants of interaction between glioblastoma CD133+ cancer stem cells and extracellular matrix

Bryukhovetskiy, I S, Khotimchenko, Y, Shevchenko, V

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

2637

P-182Clinical importance of colonoscopy in patients with gastric cancer

Yang, H, Park, J, Ryu, S, Lee, S, Kim, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2638

SO-009Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR-T therapy in metastatic colorectal cancer

Cutsem, E Van, Machiels, J, den Eynde, M Van, Prenen, H, Hendlisz, A, Shaza, L, Carrasco, J, Canon, J, Sotiropoulou, P, Breman, E, Alcantar, E, Flament, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

2639

107PHigh proportion of multiple KRAS mutations in circulating tumour DNA and tumour tissue of pancreatic ductal adenocarcinoma

Kim, M K, Woo, S M, Kim, Y H, Park, B, Joo, J N, Yoon, K -A, Park, S J, Kong, S -Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2640

158PPlasma KIM-1 is associated with clinical outcomes after resection for localized renal cell carcinoma: A trial of the ECOG-ACRIN Research Group (E2805)

Xu, W, Puligandla, M, Haas, N B, Flaherty, K T, Uzzo, R G, Sabbisetti, V, Dutcher, J J, DiPaola, R S, Bhatt, R S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 3.80 MB

2019

2641

273PA nomogram to predict pathologic complete response of neoadjuvant chemotherapy in triple-negative breast cancer based on simple blood indicators

Zhang, F, Huang, M, Zhou, H, Chen, K, Jin, J, Ding, X, Su, D, Zou, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 4.47 MB

2019

2642

274PIdentification of GSTP1 transferred by extracellular vesicles responsible for adriamycin-resistance in breast cancer cells

Yang, S, Tang, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2643

288TiPA randomized phase II study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy

McArthur, H L, Comen, E A, Bryce, Y, Solomon, S B, Leal, J H S, Rodine, M, Abaya, C D, Patil, S, Page, D B, Norton, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

2644

408PWhole brain radiotherapy plus simultaneous in-field boost versus whole brain radiotherapy plus fractionated stereotactic radiotherapy for multiple brain metastases of non-small cell lung cancer

Li, L, Feng, M, Xu, P, Yin, J, Huang, Y, Peng, X, lang, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2645

484PThe addition of metformin to systemic anticancer therapy

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2646

501POncogenic mutations at the dimer interface of EGFR lead to formation of covalent homo-dimers and allosteric activation of the kinase domain: A mechanism which alters the selectivity profile of oncogenic EGFR

Buck, E, O’Connor, M, Flohr, A, Iacone, R, Nicolaides, T, Zhang, J, Mayweg, A V, Epstein, D M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2647

543PThe impact of completeness of chemotherapy on the efficacy of irinotecan in the preoperative chemoradiotherapy of (CRT) locally advanced rectal cancer

Wang, J, Fan, J, Li, C, Shen, L, Yang, L, Xia, F, Wan, J, Zhang, Z, Zhu, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 6.31 MB

2019

2648

609PRomidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and exerts synergistic anti-tumour activity with an anti-PD-1 antibody in colon cancer

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 677 KB

2019

2649

727PThe clinical outcomes of systemic chemotherapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinoma (HCC-CCA): Retrospective study of 120 patients

Kim, E, Yoo, C, Ryoo, B-Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 1.40 MB

2019

2650

862PRetrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE

Mintz, H P, Amos, C, Brannan, R, Brawley, C, Calvert, J, Gannon, M R, Hounsome, L, Ingleby, F C, McPhail, S, Parmar, M K B, Parsons, H M, Patel, P, Rauchenberger, M, Sydes, M R, Wu, H, James, N D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

2651

885PSpatial-temporal change in quantitative total bone imaging (QTBI) and circulating tumour cells (CTCs) in metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA)

Liu, G, Kyriakopoulos, C E, Lang, J M, Sperger, J M, Singh, A, Heath, E I, Perlman, S, Mayer, T, Modelska, K, Porcari, A, Duggan, W, Jeraj, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 2.01 MB

2019

2652

903ORedefining the IGCCCG classification in advanced non-seminoma

Gillessen, S, Collette, L, Daugaard, G, de Wit, R, Tryakin, A, Albany, C, Stahl, O, Fizazi, K, Gietema, J A, De Giorgi, U F F, Hansen, A R, Feldman, D, Cafferty, F, Tandstad, T, Garcia del Muro, X, Hu

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

2653

1164PDevelopment and validation a nomogram based on pathological microscopic features to predict survival in nasopharyngeal carcinoma and guide treatment decision

Liu, K, Lv, X, Guo, X, Li, Y, Li, C, Cheng, H, Qiang, M, Chen, X, Zhang, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 1.26 MB

2019

2654

1404TiPHORMONET: Study of tamoxifen in well differentiated neuroendocrine tumours and hormone receptor positive expression

Barros, M, Felismino, T C, de Jesus, V H F, Mello, C A, Silva, V S, Camandaroba, M, Rodrigues, N, Donadio, M D, Nobrega, E, Chinen, L, De Brot, L, Weschenfelder, R F, Rego, J F, Carvalheira, J B, Riec

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 64 KB

2019

2655

1740PDDifferential expression of B7-H4, VISTA, B7-H6, HHLA2, IDO-1, PD-L1 and CD8 in EGFR mutant and wild-type lung adenocarcinoma

Yu, S, Shi, M, Feng, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2656

1475PImpact of plasma EGFR mutation fractions on response to first generation tyrosine-kinase inhibitor in treatment of naïve non-small cell lung cancer patients

Wang, X, Liu, Y, Meng, Z, Wu, Y, Wang, S, Jin, G, Qin, Y, Wang, F, Wang, J, Wang, L, Bai, J, Shi, X, Wen, Z, Jia, X, Fu, X, Wang, X, Qin, Q, Gao, Y, Guo, W, Lu, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2657

1498PReal-world effectiveness of nivolumab monotherapy after prior systemic therapy in advanced non-small cell lung cancer (NSCLC) in the United States

Stenehjem, D D, Lubinga, S J, Gupte-Singh, K, Zhang, Y, Trong, K Le, Penrod, J R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

2658

1513PAtezolizumab in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs)

Mogollon-Duffo, F, Sultan, A, Swarup, S, Jahan, N, Tun, A M, Win Htut, T, Naing, T W, Naing, P T, Mon Myat, Y, Hardwicke, F, Rehman, S, Tijani, L, D’Cunha, N, Thein, K Z

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2659

1649PHealth status of middle-aged and older cancer survivors in China: Results from the China Health and Retirement Longitudinal Study (CHARLS)

Li, J, Zhao, L, Bai, C, Pang, H, Sun, Z

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 375 KB

2019

2660

1764PA phase III trial evaluating olanzapine 5 mg for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin: J-FORCE study

Hashimoto, H, Abe, M, Nakao, M, Mizutani, H, Sakata, Y, Fujita, Y, Nishimura, T, Hirano, K, Okada, H, Inui, N, Sakata, Y, Iihara, H, Zenda, S, Uchitomi, Y, Yamaguchi, T, Hoshina, Y, Yanai, T, Iwasa, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 5.79 MB

2019

2661

1875PDTargeting molecular mediators of T cell exclusion for effective immunotherapy in ovarian cancer

Wang, Y, Desbois, M, Udyavar, A, Ryner, L, Kozlowski, C, Guan, Y, Dürrbaum, M, Lu, S, Fortin, J-P, Koeppen, H, Ziai, J, Chang, C-W, Lo, A, Keerthivasan, S, Plante, M, Bais, C, Hegde, P, Daemen, A, Tur

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 794 KB

2019

2662

1899PThe clinical and transcriptional signatures of human CD204 reveal an applicable marker for tumor associated macrophage in breast cancer

He, Y, Tang, J, Yang, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2663

1730PInfluence of eribulin on proliferation, migration and invasion properties of leiomyosarcoma cell line models

Mendiola, M, Heredia-Soto, V, Escudero, J, Crespo, R, Ruiz, P, Martínez, A Gallego, Martínez-Marin, V, Pozo, J J, Berjón, A, Ortiz-Cruz, E, Bernabeu, D, Redondo, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2664

MO2-18-6Real-World Effectiveness and Safety of Nivolumab in NSCLC pts in Japan: A Multicenter-Retrospective Observational Study

Saito, Haruhiro, Morita, Ryo, Okishio, Kyoichi, Shimizu, Junichi, Sakai, Hiroshi, Kim, Young Hak, Hataji, Osamu, Yomota, Makiko, Nishio, Makoto, Aoe, Keisuke, Kanai, Osamu, Kumagai, Toru, Kibata, Kayo

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2665

PD5-2Medical Cooperation and Total Care for Pediatric Cancer

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

2666

ME13Interpretation the Results of Adjuvant Chemotherapy in Curatively Resected Pancreatic Cancer

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

2667

LBA32Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)

Tabernero, J, Grothey, A, Van Cutsem, E, Yaeger, R, Wasan, H, Yoshino, T, Desai, J, Ciardiello, F, Loupakis, F, Hong, Y Sang, Steeghs, N, Guren, T K, Arkenau, H-T, García-Alfonso, P, Gollerkeri, A, Pi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2668

LBA82Pembrolizumab (pembro) + chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407

Paz-Ares, L, Vicente, D, Tafreshi, A, Robinson, A, Soto Parra, H, Mazières, J, Hermes, B, Cicin, I, Medgyasszay, B, Beatrix, B, Rodríguez Cid, J, Okamoto, I, Lee, S, Ramlau, R, Vladimirov, V, Cheng, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2669

MO1-12-1Clinical introduction of Microsatellite instability (MSI) test for the Solid Tumors at a single institute

Nakayama, Izuma, Shinozaki, Eiji, Kawachi, Hiroshi, Nakajima, Takeshi, Sasaki, Takashi, Kanata, Ryo, Yunokawa, Mayu, Matoda, Maki, Tomomatsu, Jyunishi, Kitazono, Satoshi, Yuasa, Takeshi, Kobayashi, Ko

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

2670

MO3-8-5Efficacy of Low-dose Apatinib in Advanced HER2-negative Breast Cancer

Zeng, Tianyu, Li, Wei

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

2671

MO3-12-5Phase II Study of Cetuximab Rechallenge in Patients with RAS Wild-Type metastatic Colorectal Cancer: E-Rechallenge Trial

Nakamura, Masato

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

2672

P2-126Study of parvociclib administration patients at our hospital

Funakoshi, Mahito, Kitaguchi, Srlouichi, Hirabayashi, Naoki, Okada, Morihito

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 89 KB

english, 2019

2673

3OTemporal dissection of altered pathways during the evolution of cancer

Ahrenfeldt, J, Sokac, M, Birkbak, N

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 101 KB

english, 2019

2674

1067OThe influence of TDM on achieving busulfan target exposure and related determinants, in both children and adults who underwent an allogeneic hematopoietic cell transplantation

Boss, J, Langenhorst, J, Lalmohamed, A, van der Linden, P, Boelens, J J, Van Maarseveen, E

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 90 KB

english, 2019

2675

MO1-5-5 [Encore]Randomized phase II trial of sorafenib, capecitabine and oxaliplatin (SECOX) vs sorafenib in patients with advanced HCC

Yau, Thomas, Kwok, Gin Wai, Tang, Vikki, Leung, Roland, Lee, Ann-Shing, Law, Ada, Chiu, Joanne, Li, Bryan, Cheung, Tan-To

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

2676

MO2-13-5Racial disparities in lung cancer incidence and mortality over the last two decades; a Population-Based Study

wafa, Mahmad, oussama Khoudeir, Ahmad, Ruhban, Inas A, Saad, Anas M, Al-Husseini, Muneer J, Gad, Mohamed M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

2677

P3-112Patritumab augments anti-tumor immune response of adoptive transfer of autologous T cells for breast cancer PDX models

Kotake, Takeshi, Suzuki, Eiji, Pu, Fengling, Kataoka, Tatsuki, Hirata, Masahiro, Nishimura, Tomomi, Iida, Kei, Liu, Li, Toi, Masakazu

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

2678

86PImmune checkpoint molecule V-set Ig domain-containing 4 (VSIG4) expression is associated with poor prognosis in advanced gastric cancer patients

Kim, S-W, Park, C-S, Roh, J, Rhu, M-H, Park, Y-S, Lee, H S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

2679

MO3-11-4Risk assessment of pulmonary embolism using Revised Geneva Score in solid tumor: Relationship with histopathology type

Khorinal, Eka W, Sutandyo, Noorwati, Dewi, Ayu R, Setiawan, Lyana

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

2680

P1-097Peripheral T cell lymphoma not otherwise specified induced by fingolimod treatment for multiple sclerosis

Kawai, Hidetsugu, Matsushita, Hiromichi, Akashi, Hibiki, Kawakami, Shohei, Furuya, Daisuke, Suzuki, Rikio, Ogawa, Yoshiaki, Kawada, Hiroshi, Nakamura, Naoya, Ando, Kiyoshi

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

2681

71PEvaluation of miRNA-135a and miRNA-9 as prognostic markers in breast cancer patients

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

2682

P-272Is the gastroenterologist really necessary in the operating room? Intraoperative rectosigmoidoscopy: how we do it

Amorim, E, Rachadell, J, Cunha, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 80 KB

english, 2019

2683

TRK inhibitors in TRK fusion-positive cancers

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 345 KB

english, 2019

2684

Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion

Bielack, S S, Cox, M C, Nathrath, M, Apel, K, Blattmann, C, Holl, T, Jenewein, R, Klenk, U, Klothaki, P, Müller-Abt, P, Ortega-Lawerenz, S, Reynolds, M, Scheer, M, Simon-Klingenstein, K, Stegmaier, S,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 305 KB

english, 2019

2685

Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer

Amatu, A, Sartore-Bianchi, A, Bencardino, K, Pizzutilo, E G, Tosi, F, Siena, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 814 KB

english, 2019

2686

Identifying patients with NTRK fusion cancer

Solomon, J P, Benayed, R, Hechtman, J F, Ladanyi, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 546 KB

english, 2019

2687

362PPatterns and predictors of first-line (1L) taxane use in US patients with metastatic triple-negative breast cancer (mTNBC)

O’Shaughnessy, J, Emens, L A, Chui, S, Russell, K, Lin, S -W, Avile, C Flores, Luhn, P, Schneeweiss, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2688

EJS-4Interpreting variants of uncertain significance in hereditary cancer genes in cancer genome era

Shimodaira, Hideki

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2689

EJS-1Uses of genetic testing for cancer prevention

Eccles, Diana M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2690

JS3-6Therapeutic strategies for ischemic heart disease

Sueta, Daisuke, Tsujita, Kenichi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2691

PSY1-2Clinical Trial Design Considerations in the Era of Targeted Therapy

Sridhara, Rajeshwari

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2692

PSY2-8National Cancer Grid: a model for collaboration in cancer care and research

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

2693

PPD1-2Patient and Public Involvement in AMED

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

2694

MS3-5Latest development of PARP inhibitors in ovarian cancer

Harano, Kenichi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

2695

O1-4-1Effects of Dose Modifications on Safety and Efficacy of Dacomitinib for EGFR+ NSCLC in ARCHER 1050 Japanese Subset

Kato, Terufumi, Nishio, Makoto, Niho, Seiji, Yamamoto, Noboru, Takahashi, Toshiaki, Nogami, Naoyuki, Kaneda, Hiroyasu, Fujita, Yuka, Wilner, Keith, Yoshida, Mizuki, Isozaki, Mitsuhiro, Wada, Shinsuke,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

2696

O1-8-4 [Encore]Dose justification for [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-positive breast cancer

Takahashi, Shunji, Modi, Shanu, Tsurutani, Junji, Krop, Ian E, Iwata, Hiroji, Wada, Russell, Yin, Ophelia, Garimella, Tushar, Sugihara, Masahiro, Zhang, Lin, Lee, Caleb, Saito, Kaku, Kawasaki, Yui, Yv

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2697

PD4-4Clinical development of chemotherapy for uterine leiomyosarcoma

Nishikawa, Tadaaki

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2698

P1-007The difference in the effects on chemotherapy following primary tumor resection and olostomy in colorectal cancer

Nagata, Yusuke, Sawada, Ryoichi, Ohkuma, Masahisa, Nishimura, Takashi, Noguchi, Masaaki, Takeda, Yasuhiro, Ito, Daisuke, Nagasaki, Eijiro, Amano, Katsushi, Eto, Ken, Yanaga, Katsuhiko, Saruta, Masayuk

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2699

P1-107Rapid improvement of secondary myelodysplastic syndrome from essential thrombocytosis (ET) treated by Azacitidine(AZA)

Yamazaki, Masahide

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2700

P3-074Efficacy of immune checkpoint inhibitors in driver mutation-positive non-small lung cancer patients

Shiraishi, Kazuhiro, Sugiyama, Keiji, Sato, Mariko, Torii, Atsushi, Yamada, Arisa, Ishida, Akane, Shigemasu, Fumie, Nozawa, Kazuki, Niwa, Hideyuki, Ise, Yuko, Funahashi, Yoriko, Nakahata, Masashi, Oka

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2701

P3-230Countermeasures for urgent visit of patients treated with immune checkpoint inhibitors in Nagoya Memorial Hospital

Hibi, Satoshi, Shirokawa, Yuko, Nanya, Kengo, Tomomatsu, Yuko, Kayukawa, Satoshi, Yosida, Takashi, Hirade, Kentaro, Kabeya, Megumi, Kataoka, Takae, Yuasa, Shu, Ina, Kenji

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2702

SY4-5Second line chemotherapy for advanced pancreatic cancer patients in Japan

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

2703

MC-3Thinking about how to work - How should our division do its job with a limited number of people?

Yamazaki, Tomoko

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2704

MO3-13-2Relative dose intensity of R-CHOP treatment and febrile neutropenia incidence: A nation-wide survey

Matsuda, Kensuke, Jo, Taisuke, Miyauchi, Masashi, Toyama, Kazuhiro, Nakazaki, Kumi, Yasunaga, Hideo, Kurokawa, Mineo

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 83 KB

english, 2019

2705

P3-014Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation Therapy for Oesophageal Cancer Patients

Maung, Maung Kyaw

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

2706

84PCombination treatment of astragalus membranaceus, dose-modified chemotherapy, and anti-PD1 checkpoint inhibitor for patients of advanced malignancy with initial cachexia or poor performance status: A single-institute experience

Lai, H C, Lin, W, Po, T L, Yang, M J

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

2707

1687PReal-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma

Gounder, M M, Merriam, P, Ratan, R, Patel, S R, Chugh, R, Villalobos, V, Thorton, M, Van Tine, B A, Abdelhamid, A H, Joshi, P, Whalen, J, Yang, J, Rajarethinam, A, Duh, M S, Bobbili, P J, Cavanaugh, C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 90 KB

english, 2019

2708

MO2-16-2Irreversible severe cardiotoxicities except for QTc interval prolongation associated with Osimertinib

Kunimasa, Kei, Kimura, Madoka, Oboshi, Makiko, Inoue, Takako, Tamiya, Motohiro, Kuhara, Hanako, Nishino, Kazumi, Yasui, Taku, Shioyama, Wataru, Fujita, Masashi, Imamura, Fumio, Kumagai, Toru

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2709

O2-5-4Prevalence and prognostic impact of comorbidities in sarcomas: A population-based study of 3746 patients in Hong Kong

Loong, Herbert Hf, Wong, Carlos Kh, Ho, Chu-Wa, Tse, Teresa, Kwan, Sui-Chun Sampson, Lau, Yat-Ming, Leung, Linda Ks

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2710

117PCorrelation of MRI derived parameters and SUV uptake obtained from FDG- PET-CT with human papillomavirus status in oropharyngeal squamous cell carcinomas

Goyal, S, Koyyala, V P B, Jajodia, A, Chaturvedi, A, Gairola, M, Rao, A, Sharma, M, Pasricha, S, Alhawat, P, Mahawar, V, Amrith, B, Tripathi, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2711

MO1-19-3Final analysis of survival outcomes in the KSCC1501A trial of up-front therapy for HER2-negative advanced gastric cancer

Makiyama, Akitaka, Shinozaki, Katsunori, Kashiwada, Tomomi, Kawanaka, Hirofumi, Tanioka, Hiroaki, Okita, Yoshihiro, Fukahori, Masaru, Hayashi, Naomi, Shimokawa, Mototsugu, Saeki, Hiroshi, Oki, Eiji, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2712

MO2-10-2Aged donor derived CAR-T exhibits enhanced effector functions but shorter persistence and less memory-like phenotypes

Kotani, Hiroshi, Li, Gongbo, Yao, Jiqiang, Mesa, Tania E, Chen, Jon, Yu, Bin, Boucher, Justin C, Yoder, Sean J, Zhou, Jing, Davila, Marco L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2713

P1-157Pharmacogenetic profile associated with toxicity of fluoropyrimidines in colorectal cancer patients from Kazakhstan

Babenko, Dmitriy, Akhmaltdinova, Lyudmila, Kolesnikova, Evgeniya, Zhumalieva, Vera, Sirota, Valentina, Turmuhambetova, Anar

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

2714

P1-177Clinical and biological significance of thymopoietin-α in gastric cancer

Lin, Kai-Yuan, Fang, Chia-Lang, Uen, Yih-Huei, Sun, Ding-Ping

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

2715

P2-049Early detection of pancreatic ductal adenocarcinoma by measuring the abnormal urinary fragmentation ratios of kininogen

Kan, Motoyasu, Mitsunaga, Shuichi, Ohno, Izumi, Ikeda, Masafumi, Tsubouchi, Hironobu, Yanagi, Shigehisa, Matsumoto, Nobuhiro, Okumura, Nobuaki, Takao, Toshifumi, Nakazato, Masamitsu

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2716

P2-175Polo-like kinase inhibitor with radiation in betel-nuts related HNSCC in Taiwan

Chen, Jo-Pai, Chang, Jui-Ying, Hong, Ruey-Long

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2717

P3-200Correlation between Social Support Given and its Psychological Effects in Breast Cancer Patients: A Preliminary Study

Claudia, Maria, Reina, Natasya, Octavia, Michelle, Wijovi, Felix, Putri, Helenia, Cindy, Cindy, Kurniawan, Andree

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2718

P3-201Real State of the Terminal Care of Lung Cancer in the Integrated Community Care System after Medical Fees Revision 2018

Kato, Kan, Koganemaru, Chikage, Oh, Tokuken, Watanabe, Kageaki, Ookuma, Yuusuke, Hosomi, Yukio

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

2719

2OPan-genome cfDNA methylation analysis of metastatic prostate cancer

Wu, A, Cremaschi, P, Wetterskog, D, Conteduca, V, Franceschini, G M, Gonzalez-Billalebeita, E, Giorgi, U D, Demichelis, F, Lise, S, Attard, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 107 KB

2019

2720

38PAnti-breast cancer activity of 7-α-hydroxyfrullanolide triggered G2/M arrest and apoptotic induction of triple negative breast cancer cell line, revealed by proteomics

Chimplee, S, Roytrakul, S, Graidist, P, Sukrong, S, Srisawat, T, Kanokwiroon, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2721

39PExploring the role of the DDB2 protein as a potent molecular target in pancreatic ductal adenocarcinoma

Gilson, P, Meras, M, Ariztegui, M, Becuwe, P, Merlin, J-L, Harlé, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2722

1021PThe prognostic impact of monocyte to lymphocyte ratio (MLR) in advanced epithelial ovarian cancer (EOC)

Salamero, M Cucurull, García, I Teruel, Arroyo, A J, Pardo, B, Gil, M, Piulats, J M, Pla, H, Fina, C, Ginesta, M P Barretina, Angelats, L, Falgas, E Felip, Lecuona, C Erasun, Mosquera, J J García, Rom

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2723

1279PPharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies

Migden, M R, Paccaly, A, Papadopoulos, K P, Yang, F, Davis, J D, Rippley, R, Lowy, I, Fury, M G, Stankevich, E, Rischin, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2724

MO1-12-6A pilot survey on the outpatient chemotherapy unit of national university hospitals in Japan for early palliative care

Takahashi, Hidenori, Satomi, Yuji, Suzuki, Takeshi, Uneoka, Shogo, Ishii, Takeo, Nanba, Aritomo, Iguchi, Natsumi, Takemura, Katsuya, Nakajima, Nobuhisa, Masuda, Masato, Arasaki, Akira

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2725

MO2-4-1Sequential Anthracycline-Taxane Chemotherapy in Node-positive Breast Cancer Amongst Asian Patients - Real-world Outcomes

Shariff, Nisha, Wan Ishak, Wan Zamaniah Binti

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2726

MO3-13-6 [Encore]Characterization of Immunosuppressive Cells Using MultiOmyx in Hematological Malignancies

Au, Qingyan, Hanafi, Arezoo, Parnell, Erinn, Kuo, Judy, Leones, Eric, Sahafi, Flora, Padmanabhan, Raghavkrishna, Hoe, Nicholas, William, Josette

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 63 KB

2019

2727

P1-022Clinical response to subsequent chemotherapy after nivolumab in patients with advanced gastric cancer

Tsugaru, Kai, Sukawa, Yasutaka, Shimozaki, Keitaro, Togasaki, Kazuhiro, Kawasaki, Kenta, Hirata, Kenro, Hayashi, Hideyuki, Hamamoto, Yasuo, Kanai, Takanori, Takaishi, Hiromasa

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2728

P3-076Retrospective study of immune-related adverse events in NSCLC patients treated with PD-1 inhibitors

Otsubo, Aya, Ota, Takeshi, Okajima, Masaaki, Tanaka, Hiroshi, Ishida, Takashi, Iwashima, Akira, Watanabe, Satoshi, Sato, Kazuhiro, Matsumoto, Naoya, Miyabayashi, Takao, Terada, Masaki, Sato, Ko, Ishik

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2729

P3-222Cancer-oriented comprehensive nursing-caregiving service in Korea: 1 year report

Kim, Hyojin, No, Boram, Ko, Ara, Choi, Miso, Lee, Seol, Park, So Young, Ahn, Yongchel, Kim, Moon-Ho

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2730

73POverexpression of EGFR, COX2 and p53 in oral squamous cell carcinoma patients of Pakistan and correlation with prognosis

Ali, S M A, Mirza, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

2731

753PPrognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)

Zhu, A X, Galle, P R, Llovet, J M, Finn, R S, Kang, Y-K, Yen, C J, Assenat, E, Brandi, G, Motomura, K, Ohno, I, Daniele, B, Vogel, A, Yamashita, T, Hsu, C-H, Meyer, T, Widau, R, Schelman, W, Wang, C,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 93 KB

english, 2019

2732

O2-4-1Multidisciplinary team Management System for Adverse Events Occurring in New Cancer Immunotherapies

Kondo, Miki, Murayama, Akiko, Hayasaka, Kazue, Kimura, Yukie, Miyamoto, Kenichi, Yamauchi, Hirohiko, Yuda, Junichiro, Serita, Ryohei, Kuboki, Yasutoshi, Doi, Toshihiko

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

2733

P1-108An unexpected but successful pregnancy for young lady with CML

Yokota, Hirofumi, Inagaki, Yuichiro, Takeuchi, Yuki, Kuwano, Shihomi, Sawa, Hitomi, Imai, Kanae, Kato, Tomonori, Sawa, Masashi

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 90 KB

english, 2019

2734

P2-198Antitumor effect of immune checkpoint inhibitor for subsequent therapy

Tanaka, Shigeru, Kondou, Masaru, Takahara, Norihiro, Maruyama, Eiichi, Hayashi, Shuuhei, Mukouyama, Nobuaki, Tanaka, Hidehito, You, Shouei, Yamada, Shin, Katsuno, Satoshi, Kashiwagi, Yuuta, Tamura, Ma

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

2735

P3-057Treatment Outcomes after Pulmonary Stereotactic Body Radiotherapy for Oligometastatic or Oligorecurrent Lung Lesions

Sh Chia, Brendan

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

2736

382PDrug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma

Bhatia, S S, Chauhan, V, Vermani, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

2737

482PInterim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC

Marinis, F De, Laktionov, K K, Poltoratskiy, A, Egorova, I, Hochmair, M, Passaro, A, Migliorino, M R, Metro, G, Gottfried, M, Tsoi, D, Ostoros, G, Rizzato, S, Mukhametshina, G Z, Schumacher, M, Novell

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 110 KB

english, 2019

2738

P1-073Re-administration of EGFR-TKI to mutated EGFR NSCLC patients after remission of osimertinib induced ILD

Chikamori, Kenichi, Maeda, Tadashi, Sakamoto, Kenji, Aoe, Keisuke, Utsunomiya, Toshiaki, Murata, Yoriyuki, Nakanishi, Masamoto, Kamei, Haruhito

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

2739

P2-137Association of body mass index and gastrointestinal chemotherapy toxicity in breast cancer patients: A preliminary study

Gunawan, Natasya Reina, Raffaello, Wilson M, Saroso, Olivia J D A, Fahman, Julang, Putri, Helenia, Wijovi, Felix, Dharmaraja, Fernando, Tancherla, Angeline, Cindy, Cindy, Kurniawan, Andree

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

2740

P3-104Eribulin use in MBC (Metastatic breast cancer) in resource limited setting

Roy, Rakesh, Sarkar, Abhijit

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

2741

342OResponse of nivolumab monotherapy in 124 Japanese patients with advanced melanoma: Interim analysis of prospective observational study (CREATIVE study)

Yamazaki, N, Takahashi, A, Namikawa, K, Takenouchi, T, Nakamura, Y, Kitano, S, Fujita, T, Kubota, K, Yamanaka, T, Kawakami, Y

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 91 KB

english, 2019

2742

503PActivity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials

Passaro, A, De Marinis, F, Tu, H, Laktionov, K K, Feng, J, Poltoratskiy, A, Zhao, J, Tan, E-H, Gottfried, M, Lee, V, Kowalski, D, Yang, C-T, Srinivasa, B, Clementi, L, Tang, W, Huang, D C-L, Cseh, A,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 104 KB

english, 2019

2743

MO1-12-1Clinical introduction of Microsatellite instability (MSI) test for the Solid Tumors at a single institute

Nakayama, Izuma, Shinozaki, Eiji, Kawachi, Hiroshi, Nakajima, Takeshi, Sasaki, Takashi, Kanata, Ryo, Yunokawa, Mayu, Matoda, Maki, Tomomatsu, Jyunishi, Kitazono, Satoshi, Yuasa, Takeshi, Kobayashi, Ko

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2744

MO3-8-5Efficacy of Low-dose Apatinib in Advanced HER2-negative Breast Cancer

Zeng, Tianyu, Li, Wei

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2745

MO3-12-5Phase II Study of Cetuximab Rechallenge in Patients with RAS Wild-Type metastatic Colorectal Cancer: E-Rechallenge Trial

Nakamura, Masato

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2746

P2-126Study of parvociclib administration patients at our hospital

Funakoshi, Mahito, Kitaguchi, Srlouichi, Hirabayashi, Naoki, Okada, Morihito

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2747

3OTemporal dissection of altered pathways during the evolution of cancer

Ahrenfeldt, J, Sokac, M, Birkbak, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 101 KB

2019

2748

678PDOutcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)

Rimassa, L, Kelley, R K, Meyer, T, Ryoo, B-Y, Merle, P, Park, J-W, Blanc, J-F, Lim, H Y, Tran, A, Borgman-Hagey, A E, Clary, D O, Wang, E, Cheng, A-L, El-Khoueiry, A B, Abou-Alfa, G K

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 87 KB

english, 2019

2749

O2-2-3 [Encore]Phase II trial of GEMOX for the advanced pancreatic cancer with family/personal history of HBOC related cancer

Tsumura, Hidetaka, Morizane, Chigusa, Nomura, Shogo, Takahashi, Hideaki, Okano, Naohiro, Mizuno, Nobumasa, Satake, Hironaga, Tsuji, Kunihiro, Shioji, Kazuhiko, Asagi, Akinori, Yasui, Kohichiroh, Miyak

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 82 KB

english, 2019

2750

1OTrastuzumab emtansine (T-DM1) vs trastuzumab (H) in Chinese patients (pts) with residual invasive disease after neoadjuvant chemotherapy for HER2-positive breast cancer (BC) in the phase III KATHERINE study

Huang, C, Yang, Y, Kwong, A, Chen, S-C, Tseng, L-M, Liu, M-C, Shen, K, Wang, S, Ng, T-Y, Feng, Y, Sun, G, Yan, I R, Shao, Z

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 102 KB

english, 2019

2751

38OTalazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): Data from phase III EMBRACA

Lee, K-H, Kim, S-B, Sohn, J, Goodwin, A, Usari, T, Lanzalone, S, Im, Y-H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 84 KB

english, 2019

2752

37OSubgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries

Iwata, H, Im, S-A, Sohn, J, Jung, K H, Im, Y-H, Lee, K S, Inoue, K, Tamura, K, Wong, A, Emens, L A, Barrios, C H, Adams, S, Schneeweiss, A, Diéras, V, Winer, E P, Chui, S Y, Henschel, V, Rugo, H S, Lo

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 112 KB

english, 2019

2753

141PA 13-gene signature of DNA repair predicts prognosis in gastric cancer patients

Chang, J, Xu, M, Li, W, Sun, H, Zhu, X

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 85 KB

english, 2019

2754

240PMorbidity and mortality of cervical cancer in the Republic of Kazakhstan

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

2755

252PUterine sarcomas in Qatar: Clinico-pathological characteristics and treatment outcome

Fadlelseid, A A, Ghazouani, H Mr, Saadi, W Al, Omar, N, Al Malik, H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

2756

474O Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC

Cho, B C, Lee, K H, Ahn, M-J, Geater, S Lucien, Ngoc, T V, Wang, C-C, Cho, E K, Lee, J S, Sriuranpong, V, Bui, Q, Clarke, S, Kuyama, S, Nakagawa, K, Liu, F, Clemett, D, Scheuring, U, Peters, S, Rizvi,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 127 KB

english, 2019

2757

299PWeekly versus triweekly concurrent chemoradiation for nasopharyngeal cancer

Sudibio, S, Handoko, H, Auzan, M, Prajogi, G B

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

2758

MO2-12-4Preliminary Phase 1 Results of the PD-1 Inhibitor ABBV-181 in Japanese vs Western Patients With Advanced Solid Tumors

Kuboki, Yasutoshi, Kondo, Shunsuke, Drew, Rasco, John, Powderly, Alexander, Spira, luke Jason, J, Daniel, Afar, Stefan, Englert, Hashiba, Hideyuki, Stacie, Lambert, Apurvasena, Parikh, Shimizu, Eisuke

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

2759

28PCNAs concordance between CRC-PDOs and the original tissue reveals relevant oncogenic pathways alterations

Papaccio, F, Valiente, F G, Gutierrez-Bravo, M F, Cabeza-Segura, M, Gambardella, V, Huerta, M D S, Martinez-Ciarpaglini, C, Alfaro-Cervello, C, Rentero-Garrido, P, Zúñiga-Trejos, S, Rosello Keranen, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

2760

42PPrediction of PFS using a dynamic assessment of ctDNA in patients with EGFR mutated NSCLC with osimertinib therapy

Moiseenko, F, Stepanova, M, Zhabina, A, Myslik, A, Klimenko, V, Rysev, N, Artemieva, E, Shelekhova, K, Bogdanov, A, Volkov, N, Moiseenko, V

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

2761

64PRole of RNF144B in triple negative breast cancer proliferation

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 72 KB

english, 2019

2762

68PC-met mediates invasion and chemotherapy resistance in high grade serous ovarian cancer

Wood, G E, Lockley, M, Kermorgant, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

2763

79PCell lineage context and type of genomic alteration predict for the therapeutic relevance of tyrosine kinase inhibitors in human cancers

Vanacker, H, Cassier, P A, Pérol, M, Saintigny, P, Eberst, L, Carbonnaux, M, Brahmi, M, Verlingue, L, Ray-Coquard, I L, Pérol, D, Blay, J-Y

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

2764

107PRNAi and CRISPR/Cas9-based screens identify mismatch repair genes involved in platinum chemoresistance

Zawadzki, P, Piotrowska, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 68 KB

english, 2019

2765

141P Identifying mechanisms of macrophage-mediated metastasis and treatment resistance in pancreatic cancer

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

2766

160P Novel arginase inhibitor alone and in combination with an immune check point inhibitor reduces tumour growth in murine experimental gliomas

Pilanc-kudlek, P, Cyranowski, S, Wojnicki, K, Ochocka, N, Grzybowski, M, Stańczak, P, Pomper, P, Błaszczyk, R, Gołębiowski, A, Dobrzański, P, Kaminska, B

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 86 KB

english, 2019

2767

78OImmunoscore predicts significant differences in time to recurrence in stage I colon cancer patients

Galon, J, Hermitte, F, Mlecnik, B, Marliot, F, Bifulco, C, Lugli, A, Nagtegaal, I, Hartmann, A, van den Eynde, M, Roehrl, M, Ohashi, P, Zavadova, E, Torigoe, T, Patel, P, Wang, Y, Kawakami, Y, Marinco

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 93 KB

english, 2019

2768

532TiPCANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLC

Tan, D S W, Kim, T M, Solomon, B J, Tan, W L, Yu, C-J, Geater, S, De Castro, G, Greystoke, A, Felip, E, Johnson, B E, Deudon, S, Louveau, A-L, Passos, V Q, Cho, B C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 81 KB

english, 2019

2769

15P Immune escape in acute myeloid leukemia

Kuzelova, K, Brodská, B, Otevřelová, P, Šálek, C, Gašová, Z, Petráčková, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

2770

101PClinical application of routine comprehensive tumour molecular profiling in the management of cancer patients

Mileyko, V, Veselovsky, E, Rozhavskaya, E, Ignatova, E, Kovtun, A, Sharova, M, Ivanov, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 74 KB

english, 2019

2771

MO3-11-4Risk assessment of pulmonary embolism using Revised Geneva Score in solid tumor: Relationship with histopathology type

Khorinal, Eka W, Sutandyo, Noorwati, Dewi, Ayu R, Setiawan, Lyana

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2772

P1-097Peripheral T cell lymphoma not otherwise specified induced by fingolimod treatment for multiple sclerosis

Kawai, Hidetsugu, Matsushita, Hiromichi, Akashi, Hibiki, Kawakami, Shohei, Furuya, Daisuke, Suzuki, Rikio, Ogawa, Yoshiaki, Kawada, Hiroshi, Nakamura, Naoya, Ando, Kiyoshi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2773

71PEvaluation of miRNA-135a and miRNA-9 as prognostic markers in breast cancer patients

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2774

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

Chaput, N, Lepage, P, Coutzac, C, Soularue, E, Le Roux, K, Monot, C, Boselli, L, Routier, E, Cassard, L, Collins, M, Vaysse, T, Marthey, L, Eggermont, A, Asvatourian, V, Lanoy, E, Mateus, C, Robert, C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 142 KB

english, 2019

2775

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors

Brandão, M, Caparica, R, Eiger, D, de Azambuja, E

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 503 KB

english, 2019

2776

MO2-5-2Is prophylactic percutaneous endoscopic gastrostomy necessary for chemoradiotherapy after total laryngectomy?

Kimura, Hidenori, Hamauchi, Satoshi, Kawai, Sadayuki, Onozawa, Yusuke, Yasui, Hirofumi, Yamashita, Aiko, Ogawa, Hirofumi, Onoe, Tsuyoshi, Kamijo, Tomoyuki, Iida, Yoshiyuki, Onitsuka, Tetsuro, Yokota,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

2777

Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy

Park, J H, Jonas, S F, Bataillon, G, Criscitiello, C, Salgado, R, Loi, S, Viale, G, Lee, H J, Dieci, M V, Kim, S -B, Vincent-Salomon, A, Curigliano, G, André, F, Michiels, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 615 KB

english, 2019

2778

LBA15Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia

Nishio, M, Ji, J H, Hotta, K, Chiu, C-H, Lee, J-S, Azuma, K, Kim, S-W, Wu, S-Y, Dvorkin, M, Trukhin, D, Havel, L, Hochmair, M J, Özgüroğlu, M, Bar, J, Chen, Y, Goldman, J W, Byrne, N, Laud, P J, Shire

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 106 KB

english, 2019

2779

24P Multiple KRAS mutations detected by cancer related DNA in patients with resected pancreas adenocarcinoma during treatment with TG01/GM-CSF and gemcitabine (CT TG01-01)

Palmer, D, Møller, A-S, Greenhalf, B, Ma, Y T, Valle, J W, Gjertsen, T J, Kuryk, L

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 93 KB

english, 2019

2780

MO1-8-6Development of diagnostic kit for in vitro diagnostics of the TP53 signature in early breast cancer

Takahashi, Shin, Kakugawa, Youichiro, Nomizu, Tadashi, Saito, Tatsuro, Yuan, Yuan, Ohno, Shinji, Toi, Masakazu, Ishioka, Chikashi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2781

MO1-10-2Lack association between BIM deletion polymorphism and efficacy of EGFR-TKIs in NSCLC based on NGS

Liu, Siyang, Wu, Yilong

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2782

MO1-16-2Update on phase II trial of cetuximab plus S-1/oxaliplatin (SOX) for metastatic colorectal cancer (mCRC): JACCRO CC-06

Sunakawa, Yu, Ichikawa, Wataru, Hagiwara, Ken, Tsuda, Masahiro, Takagane, Akinori, Yasui, Hisateru, Satake, Hironaga, Denda, Tadamichi, Segawa, Yoshihiko, Tanioka, Hiroaki, Kotaka, Masahito, Kochi, Mi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2783

MO3-1-6Geriatric 8 can predict treatment outcomes of elderly patients with de novo AML who received low-dose chemotherapy

Kobayashi, Hiroyuki

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2784

P1-009A case of chemotherapy for unresectable sigmoid colon cancer with severe cardiac dysfunction

Tamai, Tsunenori

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2785

P1-100Impact of Charlson comorbidity index on survival in patients with diffuse large B-cell lymphoma who received R-CHOP

Inagaki, Atsushi, Kusumoto, Shigeru, Masaki, Ayako, Marumo, Yoshiaki, Kikuchi, Takaki, Kinoshita, Shiori, Mori, Fumiko, Komatsu, Hirokazu, Inagaki, Hiroshi, Iida, Shinsuke

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2786

P2-2858 advanced colorectal cancer cases of modified FOLFOXIRI chemotherapy with molecular target drug

Shindo, Yoshiaki

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2787

34PThe importance of p53 signaling pathway in the evolution of gastric cancer

Gurzu, S, Sugimura, H, Van Staden, R I, Yamada, H, Jung, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2788

11PThe prognosis of rare histopathologic subtype of breast cancer

Bae, S Y, Kim, J Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2789

20PDiagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis

Shamshirian, A, Heydari, K, Aref, A R, Alizadeh-Navaei, R, Shamshirian, D, Hamzehgardeshi, Z, Moosazadeh, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2790

62OTepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study

Park, K, Felip, E, Veillon, R, Cortot, A, Mazieres, J, Sakai, H, Reinmuth, N, Viteri, S, Chen, Y-M, Han, J-Y, Jang, T-W, Morise, M, Sakamoto, T, Tokito, T, Cho, B C, Bruns, R, Scheele, J, Straub, J, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 118 KB

2019

2791

72PNovel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2792

122OShould transarterial chemoembolization be continued after non-response to the first two sessions for intermediate-stage hepatocellular carcinoma?

Chen, S, Peng, Z, Chen, M, Feng, S-T, Kuang, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2793

222PDoes tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis

Kanodia, R, Jalan, A, Malhotra, R K, Gurung, S R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2794

283PEffect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: A systematic review and meta-analysis

Cho, J, Kim, J, Park, J, Lim, J H, Lee, M H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

2795

420ORole of cardioprotective therapies for prevention of cardiotoxicity in breast cancer: A systematic review and meta-analysis

Kong, Y C, Sener, M, Subramaniam, S, Bhoo-Pathy, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

2796

459PFish intake, dietary polyunsaturated fatty acids, and lung cancer: systematic review and dose-response meta-analysis of 1.7 million men and women

Cao, C, Li, Y, Jiang, Q

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

2797

327PNeoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution

Liu, X, Li, Z, Cai, Z, Chen, G, Liu, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2798

LBA18Survival and treatment patterns in patients (pts) with locally advanced or metastatic NSCLC treated with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIS): Analysis of US insurance claims databases

Soo, R, Seto, T, Gray, J E, Karimi, P, Taylor, A, Sawyer, W, Thiel, E, Marchlewicz, E, Brouillette, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

2799

753PPrognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)

Zhu, A X, Galle, P R, Llovet, J M, Finn, R S, Kang, Y-K, Yen, C J, Assenat, E, Brandi, G, Motomura, K, Ohno, I, Daniele, B, Vogel, A, Yamashita, T, Hsu, C-H, Meyer, T, Widau, R, Schelman, W, Wang, C,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

2800

O2-4-1Multidisciplinary team Management System for Adverse Events Occurring in New Cancer Immunotherapies

Kondo, Miki, Murayama, Akiko, Hayasaka, Kazue, Kimura, Yukie, Miyamoto, Kenichi, Yamauchi, Hirohiko, Yuda, Junichiro, Serita, Ryohei, Kuboki, Yasutoshi, Doi, Toshihiko

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2801

P1-108An unexpected but successful pregnancy for young lady with CML

Yokota, Hirofumi, Inagaki, Yuichiro, Takeuchi, Yuki, Kuwano, Shihomi, Sawa, Hitomi, Imai, Kanae, Kato, Tomonori, Sawa, Masashi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2802

P2-198Antitumor effect of immune checkpoint inhibitor for subsequent therapy

Tanaka, Shigeru, Kondou, Masaru, Takahara, Norihiro, Maruyama, Eiichi, Hayashi, Shuuhei, Mukouyama, Nobuaki, Tanaka, Hidehito, You, Shouei, Yamada, Shin, Katsuno, Satoshi, Kashiwagi, Yuuta, Tamura, Ma

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2803

P3-057Treatment Outcomes after Pulmonary Stereotactic Body Radiotherapy for Oligometastatic or Oligorecurrent Lung Lesions

Sh Chia, Brendan

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2804

382PDrug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma

Bhatia, S S, Chauhan, V, Vermani, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2805

482PInterim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC

Marinis, F De, Laktionov, K K, Poltoratskiy, A, Egorova, I, Hochmair, M, Passaro, A, Migliorino, M R, Metro, G, Gottfried, M, Tsoi, D, Ostoros, G, Rizzato, S, Mukhametshina, G Z, Schumacher, M, Novell

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 110 KB

2019

2806

P1-073Re-administration of EGFR-TKI to mutated EGFR NSCLC patients after remission of osimertinib induced ILD

Chikamori, Kenichi, Maeda, Tadashi, Sakamoto, Kenji, Aoe, Keisuke, Utsunomiya, Toshiaki, Murata, Yoriyuki, Nakanishi, Masamoto, Kamei, Haruhito

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2807

P2-137Association of body mass index and gastrointestinal chemotherapy toxicity in breast cancer patients: A preliminary study

Gunawan, Natasya Reina, Raffaello, Wilson M, Saroso, Olivia J D A, Fahman, Julang, Putri, Helenia, Wijovi, Felix, Dharmaraja, Fernando, Tancherla, Angeline, Cindy, Cindy, Kurniawan, Andree

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2808

P3-104Eribulin use in MBC (Metastatic breast cancer) in resource limited setting

Roy, Rakesh, Sarkar, Abhijit

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2809

342OResponse of nivolumab monotherapy in 124 Japanese patients with advanced melanoma: Interim analysis of prospective observational study (CREATIVE study)

Yamazaki, N, Takahashi, A, Namikawa, K, Takenouchi, T, Nakamura, Y, Kitano, S, Fujita, T, Kubota, K, Yamanaka, T, Kawakami, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2810

503PActivity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials

Passaro, A, De Marinis, F, Tu, H, Laktionov, K K, Feng, J, Poltoratskiy, A, Zhao, J, Tan, E-H, Gottfried, M, Lee, V, Kowalski, D, Yang, C-T, Srinivasa, B, Clementi, L, Tang, W, Huang, D C-L, Cseh, A,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 104 KB

2019

2811

678PDOutcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)

Rimassa, L, Kelley, R K, Meyer, T, Ryoo, B-Y, Merle, P, Park, J-W, Blanc, J-F, Lim, H Y, Tran, A, Borgman-Hagey, A E, Clary, D O, Wang, E, Cheng, A-L, El-Khoueiry, A B, Abou-Alfa, G K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

2812

O2-2-3 [Encore]Phase II trial of GEMOX for the advanced pancreatic cancer with family/personal history of HBOC related cancer

Tsumura, Hidetaka, Morizane, Chigusa, Nomura, Shogo, Takahashi, Hideaki, Okano, Naohiro, Mizuno, Nobumasa, Satake, Hironaga, Tsuji, Kunihiro, Shioji, Kazuhiko, Asagi, Akinori, Yasui, Kohichiroh, Miyak

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

2813

1OTrastuzumab emtansine (T-DM1) vs trastuzumab (H) in Chinese patients (pts) with residual invasive disease after neoadjuvant chemotherapy for HER2-positive breast cancer (BC) in the phase III KATHERINE study

Huang, C, Yang, Y, Kwong, A, Chen, S-C, Tseng, L-M, Liu, M-C, Shen, K, Wang, S, Ng, T-Y, Feng, Y, Sun, G, Yan, I R, Shao, Z

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 102 KB

2019

2814

38OTalazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): Data from phase III EMBRACA

Lee, K-H, Kim, S-B, Sohn, J, Goodwin, A, Usari, T, Lanzalone, S, Im, Y-H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

2815

37OSubgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries

Iwata, H, Im, S-A, Sohn, J, Jung, K H, Im, Y-H, Lee, K S, Inoue, K, Tamura, K, Wong, A, Emens, L A, Barrios, C H, Adams, S, Schneeweiss, A, Diéras, V, Winer, E P, Chui, S Y, Henschel, V, Rugo, H S, Lo

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 112 KB

2019

2816

141PA 13-gene signature of DNA repair predicts prognosis in gastric cancer patients

Chang, J, Xu, M, Li, W, Sun, H, Zhu, X

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

2817

240PMorbidity and mortality of cervical cancer in the Republic of Kazakhstan

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2818

252PUterine sarcomas in Qatar: Clinico-pathological characteristics and treatment outcome

Fadlelseid, A A, Ghazouani, H Mr, Saadi, W Al, Omar, N, Al Malik, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2819

474O Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC

Cho, B C, Lee, K H, Ahn, M-J, Geater, S Lucien, Ngoc, T V, Wang, C-C, Cho, E K, Lee, J S, Sriuranpong, V, Bui, Q, Clarke, S, Kuyama, S, Nakagawa, K, Liu, F, Clemett, D, Scheuring, U, Peters, S, Rizvi,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 127 KB

2019

2820

299PWeekly versus triweekly concurrent chemoradiation for nasopharyngeal cancer

Sudibio, S, Handoko, H, Auzan, M, Prajogi, G B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2821

MO1-17-2Long-term results of a PII study of chemoradiotherapy with docetaxel, nedaplatin, and fluorouracil for esophageal cancer

Ohnuma, Hiroyuki, Onoyama, Naoki, Hayasaka, Naotaka, Sato, Masanori, Murase, Kazuyuki, Takada, Koichi, Miyanishi, Koji, Hirakawa, Masahiro, Sagawa, Tamotsu, Hori, Masakazu, Someya, Masanori, Nakata, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2822

P1-091Clinical feature of very elderly malignant lymphoma patients unfit for chemotherapy

Takahata, Takenori, Saito, Kensuke, Chen, Yu, Hasui, Kengo, Abo, Emiko, Awatsu, Akemi, Sato, Atsushi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2823

1O100,000 genomes project: Integrating whole genome sequencing (WGS) data into clinical practice

Sosinsky, A, Ambrose, J, Zarowiecki, M, Mitchell, J, Henderson, S, Murugaesu, N, Hamblin, A, Turnbull, C, Walker, S, Perez-Gil, D, Rueda-Martin, A, Fowler, T, Caulfield, M, Rendon, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 101 KB

2019

2824

88PThe Sidra LUMC advanced colon cancer NGS cohort

Hendrickx, W R L, Roelands, J, Kuppen, P, Marincola, F, Bedognetti, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

2825

169PM-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signalling pathways

Wang, Y, Wang, C, Xiao, H, Wu, H, He, H, Cui, J, Li, W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2826

495PTracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib

Buder, A, Hochmair, M J, Setinek, U, Filipits, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

2827

LBA4Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: An update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC)

Untch, M, Geyer, C E, Huang, C, Loibl, S, Wolmark, N, Mano, M S, von Minckwitz, G, Brufsky, A, Pivot, X, Polikoff, J, Fontana, A, Kaufman, B, Alcedo, J C, Boulet, T, Liu, H, Song, C, Mamounas, E P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 104 KB

2019

2828

286OPhase III KEYNOTE-048 study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma: Asia vs non-Asia subgroup analysis

Ngamphaiboon, N, Tanaka, K, Hong, R-L, Wan Ishak, W Z, Yen, C-J, Sriuranpong, V, Takahashi, S, Srimuninnimit, V, Yeh, S-P, Oridate, N, Yang, M-H, Nohata, N, Koh, Y, Roy, A, Gumuscu, B, Swaby, R, Tahar

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 101 KB

2019

2829

99PLikelihood of targeted therapy recommendations for advanced solid tumours

Taghizadeh, H, Prager, G, Müllauer, L, Mader, R M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2830

MO2-4-2Cardiac monitoring among stage 0-III and stage IV breast cancer patients treated with trastuzumab

Ishii, Taisuke, Nakano, Eriko, Watanabe, Tomone, Higashi, Takahiro

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2831

MO3-8-2Characteristics and prognosis of leptomeningeal metastasis in patients with breast cancer

Maeshima, Yurina, Ito, Yoshinori, Shibayama, Tomoko, Hosonaga, Mari, Ono, Makiko, Kobayashi, Kokoro, Kobayashi, Takayuki, Ueno, Takayuki, Oguchi, Masahiko, Takahashi, Syunji, Ohno, Shinji

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2832

MO3-9-3Primary results from Japanese phase I study of pembrolizumab plus chemotherapy as front-line therapy for advanced NSCLC

Kurata, Takayasu, Nakagawa, Kazuhiko, Satouchi, Miyako, Seto, Takashi, Sawada, Takeshi, Han, Shi Rong, Noguchi, Kazuo, Shimamoto, Takashi, Nogami, Naoyuki

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2833

MO3-12-6The efficacy and safety of FOLFIRI+BEV/mXELIRI+BEV by UGT1A1 polymorphisms in metastatic colorectal cancer AXEPT trial

Matsuoka, Hiroshi, Kagawa, Yoshinori, Ota, Mitsuyoshi, Makiyama, Akitaka, Akiyoshi, Kohei, Denda, Tadamichi, Matsuda, Chu, Yamada, Yasuhide, Morita, Satoshi, Sakamoto, Junichi, Muro, Kei, Nakamura, Ma

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2834

29PA retrospective analysis of 66 colorectal cancer cases from Guy’s and St Thomas’ (GSTT) Molecular Tumour Board

Kapiris, M, Josephs, D, Kulkarni, A, Valganon, M, De Souza, B, Campbell, J, Churm, F, Nickless, G, Ross, P, De Naurois, J, Maisey, N, Thillai, K, Roca, J, George, M, Schizas, A, Datta, V, Westcott, E,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2835

48PDevelopment of MDA-MB-231-3D-Spheroid as a reliable model for studying Nav1.5 and nNav1.5-mediated breast cancer metastasis

Murtadha, A H, Mokhtar, N F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2836

219PLong-term outcomes of bladder preservation in muscle-invasive bladder cancer patients

Satiti, A D, Mistry, H, Song, Y P, Choudhury, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

2837

364OClinical utility of ctDNA genomic alterations (GA) based on ESMO scale for clinical actionability of molecular targets (ESCAT) in advanced NSCLC

Mezquita, L, Planchard, D, Suarez, M Dorta, Aldea, M, Naltet, C, Lamberts, V, Grecea, M, Martin-Romano, P, de Kievit, F, Jovelet, C, Lacroix, L, Masip, J Remon, Lavaud, P, Gazzah, A, Morris, C, Howart

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 104 KB

2019

2838

394OKnowledge, attitude and practice of cervical cancer screening and vaccination among female relatives of cancer patients

Mullapally, S K, Gorli, M, Satyavati, V, Digumarti, L, Digumarti, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 104 KB

2019

2839

324PA novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy

Chao, T Y, Ho, C L, Cheng, W H, Chang, C L, Hsieh, Y Y, Jiang, W, Liu, S, Luk, A, Lin, S F, Hsieh, T C, Liu, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 101 KB

2019

2840

MO2-1-6Adoption of multigene panel testing for hereditary cancer "CancerNext" in Tohoku University Hospital

Komine, Keigo, Takahashi, Masanobu, Hiraide, Sakura, Yamada, Hideharu, Tsubata, Mari, Takahashi, Masahiro, Takahashi, Shin, Shirota, Hidekazu, Niihori, Tetsuya, Aoki, Yoko, Ishioka, Chikashi

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2841

P3-234A pivotal role of team medicine for recurrent ovarian cancer patient affected by Clostrioides difficile enterocolitis

Sonoda, Kenzo, Sugimoto, Rie, Ando, Yoriko, Miyamoto, Seiko, Matsukura, Aya, Hashimoto, Yuko, Aiko, Kiyoshi, Maenohara, Shoji, Tomita, Yui, Kitade, Shoko, Nagayama, Rina, Ariyoshi, Kazuya, Okadome, Ma

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2842

95PAnatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases

Wei, Y, Chen, Y, Chang, W, Xu, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2843

144PSevere hypovitaminosis D in metastatic gastric cancer patients from the Northern and Southern hemispheres: Data from the EXPAND phase III trial

Obermannova, R, Valik, D, Hasenclever, D, Zdrazilova-Dubska, L, Hacker, U, Demlova, R, Selingerova, I, Lordick, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2844

351OThe FAFA (FAn on FAce) trial: A randomized clinical trial on the effect of a fan blowing air on the face to relieve dyspnea in Filipino patients with terminal cancer

Ting, F I L, Barbon, C E, Estreller, S, Strebel, H M J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2845

403OThe efficacy of eribulin methylate for patients with taxane-resistant cutaneous angiosarcoma: Final results from a multi-center, prospective, observational study

Fujisawa, Y, Yoshino, K, Fujimura, T, Yamamoto, Y, Uchi, H, Hata, H, Otsuka, A, Miyagi, T, Funakoshi, T, Matsushita, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2846

492PFeasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer

Ahn, H, Kim, Y, Kim, E Y, Kim, K W, Sung, K H, Cho, E K, Kang, S M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 69 KB

2019

2847

317OAssociation of survival and blood-based genomic signature with atezolizumab for patients with second-line and third-line EGFR wild-type non-small cell lung cancer: Pooled analysis of individual patient data from the POPLAR and OAK trials

Yu, Y, Li, A, Chen, Y, Li, Q, Ou, Q, Lin, D, Zhang, W, Li, Z, Hu, H, Yao, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

2848

MO1-17-5Prognostic impact of serum inflammatory markers in oesophageal cancer following chemoradiation

Yip, Connie, Tan, Sze Huey, Wang, Michael, Siow, Tian Rui, Lim, Faye, Chin, Francis, Wang, Fuqiang, Ho, Shaun, Khin, Ni Sann

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2849

49PBiochemical study on modifying role of variants of leptin gene and its receptor on serum leptin levels in breast cancer

Alhanafy, A M, Tayel, S, Ahmed, S, Altorgoman, A, Elsayed, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2850

358PEvaluation of continuous low dose versus standard dose capecitabine monotherapy as second/third-line chemotherapy for metastatic malignancies

Revannasiddaiah, S, Pandey, K C, Madabhavi, I V, Pant, N K, Singh, S, Susheela, S P, Rastogi, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2851

460PMendelian randomization study showed no causality between metformin use and lung cancer risk

Shen, J, Zhou, H, Fang, W, Liu, J, Zhang, Y, Huang, Y, Zhang, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 113 KB

2019

2852

461PBlood trace minerals and lung cancer: A Mendelian randomization study

Xian, W, Zhou, H, Zhang, Y, Shen, J, Liu, J, Zhang, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2853

319OCombined model of frameshift mutations and TMB in predicting response to immunotherapy in NSCLC

Zhou, H, Liu, J, Zhang, Y, Fang, W, Zhang, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 110 KB

2019

2854

320OPBRM1 mutation and preliminary response to immune checkpoint blockade treatment in NSCLC

Liu, J, Zhou, H, Zhang, Y, Huang, Y, Yang, Y, Fang, W, Zhang, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2855

LBA10Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev

Fujiwara, K, Harter, P, Leary, A, Perol, D, Pignata, S, González-Martín, A, Petru, E, van Nieuwenhuysen, E, Colombo, N, Mäenpää, J, Selle, F, de Gregorio, N, Lorusso, D, Guerra Alia, E M, Lefeuvre-Ple

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 109 KB

2019

2856

MO1-4-2Meet the Expert on Rare Cancer - Social Contribution by Rare Cancer Center -

Katoh, Yoko, Goto, Yasushi, Munakata, Wataru, Shibata, Taro, Sakurai, Takuro, Iwata, Shintaro, Kawai, Akira, Nishida, Toshirou

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2857

273PMALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas

Alhanafy, A M, Elshafie, M, Elnour, E S Abou, Genena, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2858

LBA16Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis

Cho, B C, Ohe, Y, Zhou, C, Reungwetwattana, T, Cheng, Y, Chewaskulyong, B, Lee, K H, Planchard, D, Vansteenkiste, J F, Gray, J E, Shah, R, Cheema, P K, Tiseo, M, John, T, Hodge, R, Rukazenkov, Y, Sori

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 104 KB

2019

2859

124OKEYNOTE-181: Pembrolizumab vs chemotherapy in patients (pts) with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line (2L) therapy

Kim, S-B, Doi, T, Kato, K, Chen, J, Shah, M, Adenis, A, Luo, S, Qin, S, Kojima, T, Metges, J-P, Francois, E, Muro, K, Cheng, Y, Li, Z, Yuan, X, Wang, R, Cui, Y, Bhagia, P, Shen, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 108 KB

2019

2860

208OAssociation between kidney function, proteinuria and the risk of kidney cancer: A nationwide cohort study involving 10 million participants

Park, J, Shin, D W, Han, K, Chun, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

2861

161PChitinase 3-Like 1 gene (T/C) polymorphism and serum YKL-40 in hepatocellular carcinoma

Alhanafy, A M, El-Hefnawy, S, Saleh, A, Elbahr, O

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2862

224OPatient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)

Friedlander, M L, Moore, K N, Colombo, N, Scambia, G, Kim, B-G, Oaknin, A, Lisyanskaya, A, Floquet, A, Leary, A, Sonke, G S, Gourley, C, Banerjee, S, Oza, A, González-Martín, A, Aghajanian, C, Bradley

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 104 KB

2019

2863

446PAccuracy of risk scoring system to determine chemotherapy induced nausea and vomiting (CINV) in cancer patients receiving first cycle chemotherapy

Reddy, H, Maka, V V, D, A, Krishna Murthy, M, Mandepudi, A, Paibhavi, P R, K, S P, Vungarala, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2864

70PImproving personalised therapy in metastatic breast cancer by implementing RNA sequencing based gene expression signatures

Schulze, M, Hlevnjak, M, Thewes, V, Elgaafary, S, Mavratzas, A, Fröhling, S, Seitz, J, Zapatka, M, Lichter, P, Schneeweiss, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2865

35TiPRibociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study

Lu, Y-S, Malwinder, S S, Azim, H, Eralp, Y, Im, S-A, Yap, Y S, Alfaro, T Delgar, Gao, M, Saghir, N S El

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

2866

527PA multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing

Li, X, Wang, W, Xu, C, Pu, X, Fang, S, Cai, X, Fang, Y, Zhu, Y, Wang, H, Liang, X, Zhuang, W, Zhang, Y, Wang, L, Cai, X, Li, J, Feng, H, Fang, M, Chen, G, Lv, T, Song, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2867

LBA7Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)

Hsu, C-H, Lee, M S, Lee, K-H, Numata, K, Stein, S, Verret, W, Hack, S, Spahn, J, Liu, B, Huang, C, He, R, Ryoo, B-Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

2868

5P Differential expression patterns of immune checkpoint markers in tumour-stromal microenvironment of primary and chemoreduced retinoblastoma

Singh, L, Singh, M K, Rizvi, M A, Pushker, N, Sen, S, Kashyap, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2869

MO2-16-3Population PK/PD Analysis of Necitumumab: Dose justification for Squamous Cell Lung Cancer (SqCLC) Patients in Japan

Mimura, Hanaka, Long, Amanda, Chigutsa, Emmanuel, Wallin, Johan, Enatsu, Sotaro, Nakagawa, Kazuhiko, Tamura, Tomohide

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2870

O3-1-4The results of Japanese subgroup analyses from TAGS: a phase 3 study of FTD/TPI (TAS-102) in heavily pretreated mGC

Hosokawa, Ayumu, Shitara, Kohei, Nishikawa, Kazuhiro, Fujitani, Kazumasa, Hosaka, Hisashi, Koeda, Keisuke, Makari, Yoichi, Amagai, Kenji, Yukisawa, Seigo, Ando, Takayuki, Ilson, David H, Tabernero, Jo

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

2871

P1-190L-Lysine increased the cytotoxicity effect of doxorubicin in MDA-MB-231 and MDA-MB-468 breast cancer cell lines

Chehri, Javad, Jahani, Mozhgan, Tahmasebi, Hadis, Yarani, Reza, Mansouri, Kamran

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2872

25P Analysis of NGS-based blood immune cell RNA signatures for colorectal cancer detection

Morgenthaler, S, Lindsay, H, Ciarloni, L, Angelino, P, Dorta, G, Delorenzi, M, Ehrensberger, S Hosseinian

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

2873

55P Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study

Nigro, O, Cortellini, A, Giusti, R, Marchetti, P, De Galitiis, F, Di Pietro, F R, Bersanelli, M, Lazzarin, A, Galetta, D, Pizzutillo, P, Santini, D, Torniai, M, De Giglio, A, Russo, A, Silva, R R, Bol

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2874

MO2-4-3Hematological Toxicity in Low Muscle Mass Breast Cancer Patient Underwent Chemotherapy: A Preliminary Study

Wijovi, Felix, Jodhinata, Claudia, Kurniawan, Andree, Raffaello, Wilson M, Halim, Devina A, Putri, Helenia

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2875

LBA8PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations

Sandhu, S K, Hussain, M, Mateo, J, Fizazi, K, Saad, F, Shore, N, Chi, K, Sartor, O, Agarwal, N, Olmos, D, Thiery-Vuillemin, A, Twardowski, P, Mehra, N, Goessl, C, Kang, J, Burgents, J, Wu, W, Kohlmann

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 112 KB

2019

2876

Efficacy of PI3K inhibitors in advanced breast cancer

Verret, B, Cortes, J, Bachelot, T, Andre, F, Arnedos, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 221 KB

2019

2877

32PProfile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019

Aryanti, C, Setiawan, I G B, Sudarsa, I W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2878

MO2-12-4Preliminary Phase 1 Results of the PD-1 Inhibitor ABBV-181 in Japanese vs Western Patients With Advanced Solid Tumors

Kuboki, Yasutoshi, Kondo, Shunsuke, Drew, Rasco, John, Powderly, Alexander, Spira, luke Jason, J, Daniel, Afar, Stefan, Englert, Hashiba, Hideyuki, Stacie, Lambert, Apurvasena, Parikh, Shimizu, Eisuke

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2879

28PCNAs concordance between CRC-PDOs and the original tissue reveals relevant oncogenic pathways alterations

Papaccio, F, Valiente, F G, Gutierrez-Bravo, M F, Cabeza-Segura, M, Gambardella, V, Huerta, M D S, Martinez-Ciarpaglini, C, Alfaro-Cervello, C, Rentero-Garrido, P, Zúñiga-Trejos, S, Rosello Keranen, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2880

42PPrediction of PFS using a dynamic assessment of ctDNA in patients with EGFR mutated NSCLC with osimertinib therapy

Moiseenko, F, Stepanova, M, Zhabina, A, Myslik, A, Klimenko, V, Rysev, N, Artemieva, E, Shelekhova, K, Bogdanov, A, Volkov, N, Moiseenko, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2881

64PRole of RNF144B in triple negative breast cancer proliferation

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2882

68PC-met mediates invasion and chemotherapy resistance in high grade serous ovarian cancer

Wood, G E, Lockley, M, Kermorgant, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2883

79PCell lineage context and type of genomic alteration predict for the therapeutic relevance of tyrosine kinase inhibitors in human cancers

Vanacker, H, Cassier, P A, Pérol, M, Saintigny, P, Eberst, L, Carbonnaux, M, Brahmi, M, Verlingue, L, Ray-Coquard, I L, Pérol, D, Blay, J-Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2884

107PRNAi and CRISPR/Cas9-based screens identify mismatch repair genes involved in platinum chemoresistance

Zawadzki, P, Piotrowska, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 68 KB

2019

2885

141P Identifying mechanisms of macrophage-mediated metastasis and treatment resistance in pancreatic cancer

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2886

160P Novel arginase inhibitor alone and in combination with an immune check point inhibitor reduces tumour growth in murine experimental gliomas

Pilanc-kudlek, P, Cyranowski, S, Wojnicki, K, Ochocka, N, Grzybowski, M, Stańczak, P, Pomper, P, Błaszczyk, R, Gołębiowski, A, Dobrzański, P, Kaminska, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

2887

78OImmunoscore predicts significant differences in time to recurrence in stage I colon cancer patients

Galon, J, Hermitte, F, Mlecnik, B, Marliot, F, Bifulco, C, Lugli, A, Nagtegaal, I, Hartmann, A, van den Eynde, M, Roehrl, M, Ohashi, P, Zavadova, E, Torigoe, T, Patel, P, Wang, Y, Kawakami, Y, Marinco

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

2888

532TiPCANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLC

Tan, D S W, Kim, T M, Solomon, B J, Tan, W L, Yu, C-J, Geater, S, De Castro, G, Greystoke, A, Felip, E, Johnson, B E, Deudon, S, Louveau, A-L, Passos, V Q, Cho, B C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

2889

15P Immune escape in acute myeloid leukemia

Kuzelova, K, Brodská, B, Otevřelová, P, Šálek, C, Gašová, Z, Petráčková, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2890

101PClinical application of routine comprehensive tumour molecular profiling in the management of cancer patients

Mileyko, V, Veselovsky, E, Rozhavskaya, E, Ignatova, E, Kovtun, A, Sharova, M, Ivanov, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2891

12P The expression of PD-1 alone by T cells is associated with cell activation while the co-expression of TIM-3 indicates exhausted subsets both in peripheral blood and bone marrow of multiple myeloma patients

Batorov, E, Sergeevicheva, V, Aristova, T, Sizikova, S, Ushakova, G, Maximova, A, Morenkova, A, Shevela, E, Ostanin, A, Chernykh, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2892

92O Nivolumab plus low-dose ipilimumab as first-line treatment of advanced NSCLC: Overall survival analysis of checkmate 817

Barlesi, F, Audigier-Valette, C, Felip, E, Ciuleanu, T-E, Jao, K, Rijavec, E, Urban, L, Aucoin, J-S, Zannori, C, Vermaelen, K, Frontera, O Arén, Ready, N, Curioni, A, Linardou, H, Poddubskaya, E, Fisc

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 109 KB

2019

2893

114P Targeting the EGF-receptor and CD38 in solid and haematological malignancies with nanobody-based heavy chain antibodies and AAV vectors

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2894

Overview of the relevance of PI3K pathway in HR-positive breast cancer

Vasan, N, Toska, E, Scaltriti, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 525 KB

2019

2895

MO1-2-4IMPACT OF TREATMENT DELAYS IN EWINGS SARCOMA IN A LOW RESOURSE SETTING

Maddumarachchi, Prabani S, Somathilake, Mahendra, Gunasekera, Sanjeeva

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2896

MO1-4-4Investigation on the working status and inhibiting factors during cancer treatment in advanced NSCLC patients

Yoshida, Tatsuya, Kuroda, Hirokai, Kikkawa, Megumi, Hida, Toyoaki

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2897

MO2-3-1Validation of QLQ-BR23 Questionnaire in Measurement of Quality of Life of Breast Cancer Patients: A Pilot Study

Virliani, Cindy, Kurniawan, Andree, Putri, Helenia

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2898

MO2-3-3Analysis of epidemiological characteristics and treatment for male breast cancer patients in Japan

Ishii, Taisuke, Nakano, Eriko, Watanabe, Tomone, Higashi, Takahiro

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2899

P1-221Capsaicin application for prevention of chemotherapy induced neuropathy from paclitaxel or oxaliplatin, phase II study

Upachar, Chutima, Kidwisala, Supatra, Petchdee, Achaporn, Manyanont, Sorrapong, Sukreeyapongse, Orasit, Chompoonuch, Supachat

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2900

P1-230Comparison Between Low and Normal Muscle Mass to Quality of Life in Breast Cancer Patients A Preliminary Study

Kurniawan, Andree, Wijovi, Felix, Putri, Helenia, Halim, Devina Adelia, Saroso, Olivia Adji, Kores, Wilson, Rahman, Julang, Dharmaraja, Fernando, Lugito, Nata Pratama Hardjo

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2901

P3-027Efficacy of chemotherapy following nivolumab in metastatic gastric cancer

Akiyoshi, Kohei, Nakatani, Yuki, Tsuboguchi, Yuko, Yoshii, Yumi, Ueda, Shinya, Okazaki, Shunsuke, Tokunaga, Shinya, Daga, Haruko

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

2902

P3-135Eribulin in Advanced Breast Cancer: Experience from a Tertiary Cancer Care Centre IN India

Agrawal, Chaturbhuj, Goyal, Pankaj, Tripathi, Rupal, Dutta, Kumardeep, Jain, Parveen, Sharma, Manish, Doval, Dinesh Chandra

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

2903

LBA14_PRIMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)

Grande, E, Galsky, M, Arranz Arija, J A, De Santis, M, Davis, I D, De Giorgi, U F F, Mencinger, M, Kikuchi, E, Garcia del Muro, X, Gumus, M, Özgüroğlu, M, Rezazadeh Kalebasty, A, Park, S H, Alekseev,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 104 KB

2019

2904

4OTumour cells mirror embryonic developmental programs to acquire invasive and metastatic capabilities

Saghafinia, S, Michael, I, Homicsko, K, Hanahan, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2905

5OUsing single cell data to validate the cellular origins of a clonal expression biomarker in lung cancer

Biswas, D, Birkbak, N J, McGranahan, N, Swanton, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

2906

6OComprehensive genomic profiling and outcomes among metastatic melanoma patients (pts) treated with first-line cancer immunotherapy (CIT) in a real-world setting

Sadetsky, N, Lambert, P, Julian, C, Chen, J, Yan, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2907

8OTargeting EGFR exon 20 insertions in non-small cell lung cancer by exploiting a dependency on parallel SRC signalling

Vyse, S, Chen, N, Oddy, J, Harrison, P, Le, A, Estrada-Bernal, A, Hermsen, M, Doebele, R, Huang, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2908

9PPlasma gene conversions after one cycle (C) abiraterone acetate (AA) for metastatic castration-resistant prostate cancer (mCRPC): A biomarker analysis of a multi-centre, international trial

Jayaram, A K, Shen, D, Wingate, A, Wetterskog, D, Sternberg, C, Jones, R, Berruti, A, Lefresne, F, Lahaye, M, Thomas, S, Joshi, S, Gormley, M, Tombal, B, Merseburger, A, Ricci, D, Attard, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2909

10PCirculating miR-652-3p as a biomarker of drug resistance in metastatic colorectal cancer patients

Hedayat, S, Lampis, A, Vlachogiannis, G, Khan, K, Cunningham, D, Marchetti, S, Fassan, M, Begum, R, Schirripa, M, Loupakis, F, Valeri, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2910

12PImpact of β-catenin phosphorylation patterns on tumour control/progression in a prospective cervical cancer study (RAIDs)

Scholl, S, Latouche, A, De Koning, L, Popovic, M, de la Rochefordière, A, Berns, E, Gestraud, P, Girard, E, Lecerf, C, von der Leyen, H, Roman Roman, S, Rouzier, R, Kamal, M, Consortium, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2911

14PModulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of response to DNA damage

Lampis, A, Carotenuto, P, Hedayat, S, Previdi, M C, Zito, D, Sclafani, F, Parisi, C, Hahne, J C, Hallsworth, A, Kirkin, V, Young, K, Kouvelakis, K, Azevedo, S X, Vasiliki, M, Scarpa, A, Cunningham, D,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2912

15PMechanistic insight into anti-cancer activity of plumbagin in endocrine resistant and HER2-overexpressed breast cancer cells

Sakunrangsit, N, Ketchart, W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2913

16PDual MGMT inactivation by promoter hypermethylation and loss of chromosome 10q as relevant prognostic marker in glioblastoma

Tachon, G, Richard, S, Milin, S, Wager, M, Karayan-Tapon, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2914

19PJAK3 defines a unique molecular subtypes of East Asian non-small cell lung cancer patients

Xu, C, Wang, W, Zhang, Q, Zhuang, W, Zhu, Y, Huang, Z, Chen, G, Fang, M, Lv, T, Song, Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2915

20PDetecting therapy-guiding aberrations in platelets and plasma at the transcriptome level in non-small-cell lung cancer

Meng, P, Rybczynska, A A, Wei, J, Terpstra, M M, Timens, W, Schuuring, E, Hiltermann, T J N, Groen, H J M, Kok, K, Van der Wekken, A J, Van den Berg, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2916

23PA new quercetin glycoside enhances TNBC immunological profile through TP53/miR-155/MICA/ULBP2

Abdel-Latif, M, Afifi, A, Soliman, R, Elkhouly, A, Abdelmotaal, A, Youness, R A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2917

24PTherapeutic implications of MTH1 inhibitor TH1579 in cutaneous malignant melanoma

Das, I, Gad, H, Bräutigam, L, Pudelko, L, Tuominen, R, Höiom, V, Almlöf, I, Hansson, J, Helleday, T, Brage, S E, Berglund, U W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2918

26PA combination of resistance mechanisms is frequent in non-small cell lung cancer (NSCLC) that progressed to EGFR tyrosine kinase inhibitors (TKIs)

Enrico, D H, Lacroix, L, Rouleau, E, Scoazec, J-Y, Loriot, Y, Tselikas, L, Jovelet, C, Planchard, D, Gazzah, A, Mezquita, L, Ngo, M, Michiels, S, Maillard, A, Massard, C, Facchinetti, F, Soria, J-C, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2919

30PProtein interactome network analysis predicts novel breast cancer candidate genes with molecular signatures

Peer Mohammed, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2920

31PTepotinib inhibits the epithelial-mesenchymal transition and tumour growth of gastric cancers via decreasing MUC5B, MMP7, and COX2

Zang, D Y, Sohn, S-H, Sul, H J, Kim, B, Choi, B Y, Kim, H S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2921

33PCombination of mTOR inhibition and paclitaxel as a personalised strategy in the context of MYC-amplified high-grade serous ovarian cancer

Martins, F C, Couturier, D-L, de Santiago, I, Vias, M, Sanders, D, Piskorz, A, Hall, J, Jimenez-Linan, M, Hosking, K, Crawford, R, Brenton, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

2922

35PPatterns of N-cadherin (N-cad) and vimentin (Vim) expression as a sign of epithelial-mesenchymal transition (EMT) in prostate cancer (PCa)

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2923

36PResults of a first panTRK IHC ringtrial

De Winne, K, Sorber, L, Lambin, S, Keulen, L, Broeckx, G, Pauwels, P, Zwaenepoel, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2924

40PPrognostic role of APOBEC3 genes mRNA expression in lower grade glioma

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2925

43PTargeted high-throughput sequencing for somatic mutations identification in thyroid cancer management

Yakushina, V, Lerner, L, Avdeeva, T, Kazubskaya, T, Kondrat’ieva, T, Lavrov, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2926

45PCirculating tumour associated cells in esophageal cancers are resistance educated per previous chemo treatments

Limaye, S, Crook, T, Ranade, A, Patil, D, Akolkar, D, Datta, V, Schuster, S, Page, R, Sims, C, Patil, R, Srinivasan, A, Khan, S, Patil, S, Mhase, V, Apurwa, S, Datar, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2927

47PThe properties of mitochondria in glioma stem cells

Hong, N, Kim, E-J, Kim, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2928

48PPLSCR1 and XKR8: New markers for low-grade glioma progression and outcome

Havrysh, K V, Bogdanov, M, Kiyamova, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2929

50PAssessing melanoma BRAF status through ddPCR of cfDNA

Passby, L, Silva, S, Brock, I, Wells, G, Cox, A, Danson, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2930

53PZNF518B as a transcriptional factor involved in colorectal cancer progression through the epithelial to mesenchymal transition

Valiente, F G, Tarazona, N, Gambardella, V, Riffo-Campos, Á, Papaccio, F, Cabeza-Segura, M, López-Rodas, G, Cervantes, A, Franco, L, Castillo, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2931

54PInvestigation of the mechanisms of resistance to osimertinib in patients with T790M-associated NSCLC

Stepanova, M, Moiseenko, F, Zhabina, A, Klimenko, V, Rysev, N, Myslik, A, Artemieva, E, Shelekhova, K, Bogdanov, A, Volkov, N, Moiseenko, V

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2932

55PNGS-based multi-gene panel analysis in early-onset colorectal cancer patients

Zhunussova, G, Afonin, G, Abdikerim, S, Jumanov, A, Perfilyeva, A, Kaidarova, D, Djansugurova, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

2933

56PIbrutinib for relapsed/refractory mantle cell lymphoma: 7-year experience

Grilo, I T, Couto, M E, Freitas, J F, Pereira, D P, Moreira, C, Chacim, S, Domingues, N, Santo, A E, Martins, Â, Viterbo, L, Oliveira, I, Moreira, I, Mariz, J M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2934

58PA seven-gene methylation markers panel: An epigenetic predictor of neoadjuvant chemotherapy sensitivity in triple-negative breast cancer

Sigin, V O, Kalinkin, A I, Ignatova, E, Sycheva, A V, Vinogradov, I I, Vinogradov, M I, Vinogradov, I Y, Zaletaev, D V, Strelnikov, V V, Tanas, A S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2935

59PNot only gene mutation matters: Development of flow cytometry panel to determine BRCA2 deficiency for personalised therapy by PARP inhibitors in pancreatic cancers

Chroscicki, P, Tybuchowska, A M, Swatler, J, Samsel, R, Cichocki, A, Podszywalow-Bartnicka, P, Roszkowska-Purska, K, Tenderenda, M, Smiertka, W, Nieborowska-Skorska, M, Skorski, T, Piwocka, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2936

62PIdentification of tamoxifen-resistant microRNA expression profiles in breast cancer: En route to precision medicine through establishing new biomarkers

Andreeva, O E, Semina, S E, Scherbakov, A M, Krasil`nikov, M A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

2937

63PNrf2 expression in surgically resected lung adenocarcinomas: Its association with clinicopathologic features and driver oncogene alterations

Takamochi, K, Hayashi, T, Hara, K, Mitsuishi, Y, Takahashi, F, Suehara, Y, Suzuki, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

2938

66PCustomized hepatocellular carcinoma prediction panel

Abramov, A, Petkevich, A, Ogurtsov, P, Hassan-Kadle, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2939

67PCirculating tumour cells mRNA in treatment strategy for melanoma

Abramov, A, Petkevich, A, Ogurtsov, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2940

69PA laboratory assay for improved prediction of drug responses in acute myeloid leukaemia cells

Aleem, E, Montoya, J, Lee, D, Finch, K, Wai, D, Dubois, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

2941

72PRetrospective study evaluating the impact of genomic profiling on management of patients with metastatic breast cancer

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2942

74PHER2 Ile655Val polymorphism, EGFR expression and cellular proliferation in urinary bladder carcinomas

Dumitru, M, Gruia, M I, Botezatu, A, Mihaila, M, Hotnog, C M, Hortopan, M, Panait, M E, Anton, G, Brasoveanu, L I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 69 KB

2019

2943

75PDynamics of ctDNA in patients with NSCLC

Zhabina, A S, Mjslik, A, Moiseenko, F, Moiseenko, V, Stepanova, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 68 KB

2019

2944

77PMolecular: Genetic analysis of uterine carcinosarcomas

Levitskaya, N, Vostryukhina, O, Poddubnaya, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

2945

78PLy6G+ cells in irradiated tumour tissue promote glioblastoma cell dedifferentiation and tumour recurrence

Seo, S, Jeon, H-Y, Kim, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2946

81PComprehensive genomic and transcriptomic profiling in advanced-stage cancers and rare malignancies: Clinical results from the MASTER trial of the German Cancer Consortium

Horak, P, Kreutzfeldt, S, Mock, A, Heining, C, Heilig, C E, Möhrmann, L, Uhrig, S, Hübschmann, D, Beck, K, Richter, D, Schlenk, R F, Klink, B, Hutter, B, Weichert, W, Stenzinger, A, Schröck, E, Brors,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2947

82PArcagen: An EORTC-SPECTA project to perform a molecular characterization of rare cancers: Results of the retrospective feasibility cohort

Vinches, M, Stevovic, A, Ray-Coquard, I L, Treilleux, I, Meeus, P, Aust, S, Floquet, A, Croce, S, Chalabreysse, L, Girard, N, Blay, J-Y, Morfouace, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2948

83PRadiation-induced change of PD-1/PD-L1 immune checkpoint in mouse colon cancer models

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2949

85PValidation and implementation of a bespoke pan-cancer NGS panel for FFPE solid tumour analysis within an NHS setting

Roberts, H, Wood, S, McNeil, E, White, R, Morgan, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2950

87PInvestigating the role of chromosomal instability in immune cell activation

Sokac, M, Dyrskjøt Andersen, L, Roelsgaard Jakobsen, M, Birkbak, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 88 KB

2019

2951

88PEpithelial-mesenchymal transition of tumour buds: A histopathological parameter with potential implication in oncological therapy of colorectal carcinoma

Jung, I, Banias, L, Bara, T, Kovacs, Z, Fulop, Z, Simu, P, Simu, I, Gurzu, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2952

89PDistribution of somatic mutations in PIK3CA gene in breast colorectal and colorectal Czech cancer patients - selected colorectal cancer patients with angiogenesis inhibitors treatment

Simova, J, Urbanovská, I, Měch, R, Žmolíková, J, Kubová, B, Vaňáková, K, Trombík, L, Dvořáčková, N, Dvořáčková, J, Drábek, J, Uvírová, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2953

90PPatient-derived organoid models of metastatic colorectal cancer to study response to PIK3CA inhibitors

Barros Silva, J D, Wanigasooriya, K, Bermingham, H, Patel, S, Hoare, R, Stodolna, A, Pickles, O, Bryer, C, Whalley, C, Beggs, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2954

91PExploration of biologic significances and mechanisms of combined atorvastatin with PI3K/Akt inhibitor in radiotherapy of colorectal cancer

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

2955

92PDetection of PIK3CA mutation by circulating DNA during chemotherapy: A tool to identify hard-to-treat metastatic breast cancers

Mosele, F, Lusque, A, Tran Dien, A, Droin, N, Le Tourneau, C, Sablin, M P, Lacroix, L, Miran, I, Jovelet, C, Bieche, I, Soria, J-C, Bertucci, F, Bonnefoi, H, Campone, M, Dalenc, F, Bachelot, T, Jacque

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2956

93PPreclinical development of a novel, highly selective PI3Kδ inhibitor, IOA-244, for the treatment of solid malignancies

Johnson, Z, Papakonstanti, E, Tsapara, A, Macqueen, A, Shah, P, Van der Veen, L, Lahn, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2957

94PEncyclopedic tumour analysis guided treatments with conventional drugs outperform available alternatives in refractory cancers

Crook, T, Vaid, A, Limaye, S, Page, R, Patil, D, Akolkar, D, Datta, V, Ghaisas, A, Patil, R, Singh, H, Srinivasan, A, Apurwa, S, Datar, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

2958

97PCommunity-driven development of a modified progression-free survival ratio for precision oncology trials

Mock, A, Heilig, C E, Kreutzfeldt, S, Hübschmann, D, Heining, C, Schröck, E, Brors, B, Stenzinger, A, Jäger, D, Schlenk, R F, Glimm, H, Fröhling, S, Horak, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2959

98PComparison of whole exome sequencing and FoundationOne Heme sequencing panel as tools for precision oncology in paediatric patients with difficult-to-treat solid tumours

Nosková, H, Adamcová, S, Knoflíčková, D, Pál, K, Grioni, A, Horňáková, T, Merta, T, Múdry, P, Pavelka, Z, Vejmělková, K, Štěrba, J, Slabý, O

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2960

100PConcordance between tissue analysis (TA) and liquid biopsy (LB) for RAS/BRAF and the optimization of its clinical application in such a heterogeneous tumour

Grilo, I, Leite, R, Gago, P, Duarte, S, Teira, A, Sarmento, T, Sousa, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2961

102PEncyclopedic tumour analysis (ETA) guided combination regimens of hormone receptor antagonists with other systemic agents for treatment of refractory cancers

Vaid, A, Crook, T, Ranade, A, Limaye, S, Patil, D, Akolkar, D, Datta, V, Page, R, Schuster, S, Sims, C, Patil, R, Srinivasan, A, Apurwa, S, Datar, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2962

103PComparative study of RT-qPCR- and NGS- based platforms for circulating human microRNA biomarker detection

Gargiuli, C, Dugo, M, De Cecco, L, Iannò, M F, Mariancini, A, Marchesi, E, Mancinelli, E, Micali, A, Boeri, M, Sozzi, G, Sensi, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2963

106PA 19-year retrospective analysis of venous thromboembolism trends in chemotherapy-induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration

Bryer, E, Kallan, M J, Chiu, T-S, Scheuba, K, Henry, D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2964

108PTargeted proximity ligation assays combined with sequencing for robust detection of translocations in FFPE samples

Feitsma, H, Yilmaz, M, Swennenhuis, J, Rakszewska, A, Hajo, K, Splinter, E, Simonis, M, Van Min, M, Van Wezel, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

2965

109PAssociation of rs363293 single nucleotide polymorphism in promoter region of miRNA-143/145 with susceptibility to colorectal cancer and with patients’ outcome

Mihaylova, G M, Ivanova, D, Manev, R, Tasinov, O, Nazifova-Tasinova, N, Petrova, V, Petkova- Nelova, D, Mihaylova, Z, Conev, N, Donev, I, Radanova, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2966

111PmTOR inhibitors in combination regimens guided by encyclopedic tumour analysis show superior outcomes compared to monotherapy in refractory cancers

Crook, T, Vaid, A, Limaye, S, Page, R, Patil, D, Akolkar, D, Datta, V, Ghaisas, A, Patil, R, Singh, H, Srinivasan, A, Apurwa, S, Datar, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2967

112PA Bayesian framework to quantify survival uncertainty

Loya, H, Anand, D, Poduval, P, Kumar, N, Sethi, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2968

113PCopy number variations in critical cell-signalling genes with potential targeted therapeutic application

Nikolova, E, Mitev, V, Todorova, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

2969

114PSignal: The home page of mutational signatures

Shooter, S, Czarnecki, J, Nik-Zainal, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

2970

115PDetection of actionable variants in various cancer types reveals value of whole-genome sequencing over in-silico whole-exome and hotspot panel sequencing

Ramarao-Milne, K P, Patch, A-M, Nones, K, Koufariotis, R, Newell, F, Addala, V R, Kondrashova, O, Mukhopadhyay, P, Kazakoff, S H, Lakis, V, Holmes, O, Leonard, C, Wood, S, Xu, C, Pearson, J V, Hollway

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 72 KB

2019

2971

120TiPEORTC SPECTA-AYA: A molecular profiling platform for adolescents and young adults with cancer in Europe

de Rojas, T, Kasper, B, Van der Graaf, W, Pfister, S M, Bielle, F, Ribalta, T, Shenjere, P, Preusser, M, Fröhling, S, Morfouace, M, McCabe, M G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

2972

46PPlasma soluble CD36 of breast cancer based on pathological and clinical characteristics

Romadhoni, A R, Rachman, A, Irawan, C, Koesnoe, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

2973

58PFunctional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy

Ayala Alvarez, J C, Trejo Rosales, R R, Riera Salas, R, Chilaca Rosas, M F, Rivera Rivera, S, Silva Godinez, J C, Salvador Bonilla, B A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2974

53PPhase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report

Altwairgi, A K, Alnajjar, F, Alhussain, H, Alsaeed, E, Balbaid, A, Aldandan, S, Orz, Y, Lary, A, Alghareeb, W, Alsharm, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

2975

125OPembrolizumab + chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study

Chung, H C, Bang, Y-J, Tabernero, J, Van Cutsem, E, Fuchs, C S, Wyrwicz, L, Lee, K-W, Kudaba, I, Garrido, M, Castro, H, Mansoor, W, Braghiroli, M I, Goekkurt, E, Chao, J, Wainberg, Z A, Kher, U, Shah,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 101 KB

2019

2976

180PLHPP inhibit the cell proliferation and EMT via the TGFβ/SMAD3 signaling pathway in iCCA

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2977

75PA parallel deep learning network framework for whole-body bone scan image analysis

Pu, X, Tang, G, Cai, K, Huang, Y, Ping, M, Peng, Z, Qiu, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 86 KB

2019

2978

226OPrevalence of germline BRCA1 and BRCA2 mutations and variants among ovarian, primary peritoneal and fallopian tube cancer patients: A multicentre Indian study

Gupta, S, Rajappa, S, Advani, S H, Agarwal, A, Aggarwal, S, Goswami, C, Palanki, S Dattatreya, Arya, D, Patil, S, Kodagali, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2979

307PLacrimal gland tumours: Clinical and epidemiological patterns in the United States

KhalafAllah, M T, Gouda, M A, Alfaar, A S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

2980

376PAdoption of molecular testing in breast cancer in a tertiary care center in a developing country

Dash, P K, Koyyala, V P B, Suryavanshi, M, Jajodia, A, Pasricha, S, Goel, V, Bothra, S J, Goyal, S, Batra, U, Doval, D C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

2981

399PPrevalence of colorectal cancer risk factors in apparently healthy adults in Suluhan Village, Bali

Trisina, C G, Driansha, C L, Driansha, C L, Martianus, R, Soesilopranoto, L W, Sudarsa, I W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2982

415PAdult soft tissue myoepithelial carcinoma: Treatment outcomes and efficacy of chemotherapy

Chamberlain, F E, Cojocaru, E, Scaranti, M, Noujaim, J, Thway, K, Fisher, C, Messiou, C, Strauss, D C, Miah, A, Zaidi, S, Benson, C, Gennatas, S, Jones, R L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

2983

448PIncidence and severity of chemotherapy induced peripheral neuropathy in geriatric population who are receiving chemotherapy

Mandepudi, A, Paibhavi, P R, M, M K, Maka, V V, Reddy, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2984

475OOverall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)

Wu, Y-L, Mok, T S K, Han, J-Y, Ahn, M-J, Delmonte, A, Ramalingam, S S, Kim, S-W, Shepherd, F A, Laskin, J, He, Y, Akamatsu, H, Theelen, W S M E, Su, W-C, John, T, Sebastian, M, Mann, H, Miranda, M, La

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 81 KB

2019

2985

Targeting PI3KCA pathway to improve patient outcomes in hormone receptor-positive breast cancer: a worthy 20-year wager?

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 100 KB

2019

2986

13P MDSC (myeloid-derived suppressor cells) is an important immunosuppressing factor and functionally related with VEGF and IL-17 in patients with gastrointestinal cancer

Shibata, M, Nakajima, T, Mimura, K, Shimura, T, Kono, K, Takenoshita, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

2987

33P Tumour mutational burden ring trial: Evaluation of targeted next-generation sequencing platforms for implementation in clinical practice

Lambin, S, Lambrechts, D, De Rop, C, D'Haene, N, Froyen, G, Heukamp, L, Huijsmans, C, Maes, B, Melendez, B, Van Campenhout, C, Vanden Bempt, I, van den Brule, A, Vander Borght, S, Vannuffel, P, Pauwel

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2988

43P Enhancing the therapeutic effect of dendritic cell therapy by oncolytic adenovirus 3 encoding CD40-ligand

Zafar, S, Quixabeira, D C A, Hemminki, O, Cervera-Carrascon, V, Santos, J M, Kanerva, A, Hemminki, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

2989

47O Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer or urothelial cancer in routine clinical practice

Drakaki, A, Luhn, P, Wakelee, H, Dhillon, P K, Kent, M, Shim, J, Degaonkar, V, Hoang, T, McNally, V, Chui, S Y, Gutzmer, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 103 KB

2019

2990

53P Immune-related adverse events associated with immune-checkpoint inhibitors: A single center experience

Samanci, N S, Oruc, K, Bedir, S, Celik, E, Degerli, E, Derin, S, Demirelli, F H, Ozguroglu, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 66 KB

2019

2991

58P Risk factors for immune related adverse events: A retrospective study

Parmanande, A Q, Barreira, J V, Spencer, A S, Reis, A F, Sardinha, M, Simão, D C, Luz, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2992

59P Checkpoint inhibitors and conventional therapy for central nervous system lymphoma

Shmidt, D I, Gavrilenko, A N, Polushin, A Y, Kondakova, E, Lepik, K, Medvedeva, N, Klimovich, A, Zalyalov, Y, Mikhaylova, N, Afanasyev, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

2993

99P A platform for extracellular interactome discovery identifies novel functional binding partners for the immune receptors B7-H3/CD276 and PVR/CD155

Husain, B, Martinez-Martin, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

2994

101P Results of the NLG2105 phase I trial using the IDO pathway inhibitor indoximod, in combination with radiation and chemotherapy, for children with newly diagnosed DIPG

Johnson, T S, Aguilera, D, Al-Basheer, A, Berrong, Z, Castellino, R C, Eaton, B R, Esiashvili, N, Foreman, N, Heger, I M, Kennedy, E P, Vahanian, N, Martin, W, Pacholczyk, R, Ring, E, Sadek, R F, Smit

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

2995

105P Discovery of bioactive small molecule inhibitors of human PD1-PDL1 interaction

Patil, S P, Diflumeri, J, Fattakhova, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

2996

130O Association of long non-coding RNA biomarkers with clinically immune subtype and prediction of immunotherapy in patients with cancer

Yu, Y, Zhang, W, Li, A, Chen, Y, Wang, Y, Zhang, Y, He, Z, Ou, Q, Liu, R, Song, E, Yao, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

2997

142P Association of MUC16 mutation with survival of immune checkpoint inhibitor in patients with cancer

Ou, Q, Lin, D, Yu, Y, Li, A, Zhang, W, Chen, Y, Liu, R, Tan, Y, Xu, M, Li, L, Yao, H

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

2998

159P Supportive roles of microglia in breast cancer brain metastases

Kaminska, B, Wojnicki, K, Kochalska, A, Czernicki, T, Matyja, E, Grajkowska, W

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

2999

162TiP A phase I study evaluating BI 765063, a first in class selective myeloid SIRPa inhibitor, as standalone and in combination with BI 754091, a programmed death-1 (PD-1) inhibitor, in patients with advanced solid tumours

Marabelle, A, Cassier, P, Delord, J-P, Jungles, C, Champiat, S, Vinceneux, A, Korakis, I, Huhn, R, Poirier, N, Vasseur, B, Kotecki, N

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

3000

LBA2 First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN

Özgüroğlu, M, Goldman, J W, Reinmuth, N, Chen, Y, Dvorkin, M, Trukhin, D, Statsenko, G, Hotta, K, Ji, J H, Hochmair, M J, Voitko, O, Havel, L, Poltoratskiy, A, Losonczy, G, Verderame, F, Thomas, M, Zh

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 104 KB

2019

3001

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

Chaput, N, Lepage, P, Coutzac, C, Soularue, E, Le Roux, K, Monot, C, Boselli, L, Routier, E, Cassard, L, Collins, M, Vaysse, T, Marthey, L, Eggermont, A, Asvatourian, V, Lanoy, E, Mateus, C, Robert, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 142 KB

2019

3002

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors

Brandão, M, Caparica, R, Eiger, D, de Azambuja, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 503 KB

2019

3003

MO2-5-2Is prophylactic percutaneous endoscopic gastrostomy necessary for chemoradiotherapy after total laryngectomy?

Kimura, Hidenori, Hamauchi, Satoshi, Kawai, Sadayuki, Onozawa, Yusuke, Yasui, Hirofumi, Yamashita, Aiko, Ogawa, Hirofumi, Onoe, Tsuyoshi, Kamijo, Tomoyuki, Iida, Yoshiyuki, Onitsuka, Tetsuro, Yokota,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

3004

Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy

Park, J H, Jonas, S F, Bataillon, G, Criscitiello, C, Salgado, R, Loi, S, Viale, G, Lee, H J, Dieci, M V, Kim, S -B, Vincent-Salomon, A, Curigliano, G, André, F, Michiels, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 615 KB

2019

3005

LBA15Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia

Nishio, M, Ji, J H, Hotta, K, Chiu, C-H, Lee, J-S, Azuma, K, Kim, S-W, Wu, S-Y, Dvorkin, M, Trukhin, D, Havel, L, Hochmair, M J, Özgüroğlu, M, Bar, J, Chen, Y, Goldman, J W, Byrne, N, Laud, P J, Shire

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 106 KB

2019

3006

24P Multiple KRAS mutations detected by cancer related DNA in patients with resected pancreas adenocarcinoma during treatment with TG01/GM-CSF and gemcitabine (CT TG01-01)

Palmer, D, Møller, A-S, Greenhalf, B, Ma, Y T, Valle, J W, Gjertsen, T J, Kuryk, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 93 KB

2019

3007

Prevalence of homologous recombination deficiency (HRD)-related signatures indicates that a wider range of prostate cancer patients may benefit from PARP-inhibitor therapy

Sztupinszki, Z., Diossy, M., Krzystanek, M., Borcsok, J., Pomerantz, M., Tisza, V., Spisak, S., Rusz, O., Csabai, I., Freedman, M., Szallasi, Z.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

3008

First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

3009

82P Real-world survival with first-line (1L) chemotherapy in patients (pts) with advanced non-small cell lung cancer (aNSCLC)

Waterhouse, D, Betts, K A, Zhao, J, Rao, S, Gupte-Singh, K, Rutstein, M, Higashi, M K, Schwartzberg, L

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

3010

131P PD-1 and LAG-3 synergize to drive tumour-infiltration of T cytotoxic cells in NSCLC tumours

Juncker-Jensen, A, Nagy, M, Kuo, J, Leones, E, Sahafi, F, Pham, K, Parnell, E

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 106 KB

2019

3011

133P Tumour immune infiltrate characterization in luminal breast cancer in three distinct age categories and its correlation with frailty

Berben, L, Wildiers, H, Kenis, C, Dalmasso, B, Smeets, A, Vos, H, Neven, P, Floris, G, Hatse, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

3012

Clinical relevance of TNM staging system according to breast cancer subtypes

Park, Y.H., Lee, S.J., Cho, E.Y., La. Choi, Y., Lee, J.E., Nam, S.J., Yang, J.-H., Shin, J.H., Ko, E.Y., Han, B.-K., Ahn, J.S., Im, Y.-H.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

3013

Impact of cytogenetic abnormalities on response to azacitidine in patients with myelodysplastic syndrome

Iizuka, Hiroko, Sugimoto, Keiji, Takizawa, Haruko, Wakabayashi, Mutsumi, Sakajiri, Sakura, Sekiguchi, Yasunobu, Noguchi, Masaaki, Komatsu, Norio

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

3014

Prevalence and associated factor of androgen receptor expression in early and locally advanced female breast cancer

Chompoonuch, Supachat, Wanawong, Panakorn, Angchuan, Siriporn, Petchdee, Achaporn, Manyanont, Sorrapong, Upachar, Chutima

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

3015

Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

Rolfo, C., Dziadziuszko, R., Doebele, R.C., Demetri, G., Simmons, B., Aziez, A., Huang, X., Osborne, S., Paz-Ares, L.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

3016

Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC)

Lee, D.H., Subbiah, V., Gainor, J.F., Taylor, M.H., Zhu, V.W., Doebele, R.C., Lopes, G., Baik, C., Garralda, E., Gadgeel, S.M., Kim, D.-W., Turner, C.D., Palmer, M., Miller, S., Curigliano, G.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 90 KB

2019

3017

Filipinos and lung cancer: An infodemiological assessment using Google trends from 2009 to 2019

Catedral, L.I.G., Berba, C.M., Tan, J.S., Tan, I.T.I.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

3018

Phase II study of atezolizumab for pretreated advanced / recurrent non-small cell lung cancer with idiopathic interstitial pneumonia (TORG1936 / AMBITIOUS study)

Ikeda, S., Kato, T., Kenmotsu, H., Ogura, T., Iwasawa, S., Iwasawa, T., Kasajima, R., Miyagi, Y., Misumi, T., Yamanaka, T., Okamoto, H.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 83 KB

2019

3019

Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601)

Antill, Y., Kok, P.S., Stockler, M.R., Robledo, K., Yip, S., Parry, M., Smith, D., Spurdle, A., Barnes, E., Friedlander, M.L., Baron-Hay, S., Shannon, C., Coward, J., Beale, P.J., Goss, G., Meniawy, T

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 70 KB

2019

3020

Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations

Mok, T.S.K., Cheng, Y., Zhou, X., Lee, K.H., Nakagawa, K., Niho, S., Linke, R., Rosell, R., Corral, J., Migliorino, M.R., Pluzanski, A., Noonan, K., Tang, Y., Wilner, K.D., Wu, Y.-L.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 102 KB

2019

3021

30P Transcriptomic landscape of tumour cells undergoing T-cell attack

Gokuldass, A, Schina, A, Lauss, M, Harbst, K, Chamberlain, C A, Draghi, A, Westergaard, M C Wulff, Nielsen, M, Papp, K, Sztupinski, Z M, Casabi, I, Svane, I M, Szallasi, Z, Jonsson, G, Donia, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

3022

71P Correlation between toxicities and outcomes during treatment with immune checkpoint inhibitors in non-small cell lung cancer patients

de Miguel, P Ayala, Díez, S Arnáiz, García, I Gorospe, Gallego, J López, Varella, A Illán, García, P Borrega

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

3023

74P Cost of adverse events (AEs) with second-line (2L) immuno-oncology agents (IO) and chemotherapy (CHEMO) in advanced non-small cell lung cancer (aNSCLC) in the real-world

Wang, C K, Gupte-Singh, K, Belli, A J, Lane, D C, Lakshmanan, A, Norden, A D

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 84 KB

2019

3024

112P Identification of a novel promiscuous anti-NY-ESO-1 immunogenic CD4+ peptide containing a CD8+ T-cell epitope highly present in metastatic gastric cancer responding to combined radiotherapy/anti-PD-1 immunotherapy

Merhi, M, Raza, A, Inchakalody, V, Sivaraman, S, Panayampilly, F, Mestiri, S, Hydrose, S, Allahverdi, N, Jalis, M, Relecom, A, Al Zaidan, L, Feilchenfeldt, J, Hamid, M S Elkhatim, Mostafa, M, Gul, A R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

3025

LBA5 KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC

Gadgeel, S, Rodriguez-Abreu, D, Felip, E, Esteban, E, Speranza, G, Reck, M, Hui, R, Boyer, M, Garon, E B, Horinouchi, H, Cristescu, R, Aurora-Garg, D, Lunceford, J, Kobie, J, Ayers, M, Piperdi, B, Pie

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

3026

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

Yoon, H.H., Bendell, J.C., Braiteh, F.S., Firdaus, I., Philip, P.A., Cohn, A.L., Lewis, N., Anderson, D.M., Arrowsmith, E., Schwartz, J.D., Gao, L., Hsu, Y., Xu, Y., Ferry, D., Alberts, S.R., Wainberg

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

3027

Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)

Chan, S.L., Miksad, R., Cicin, I., Chen, Y., Klumpen, H.J., Kim, S., Lin, Z.Z., Youkstetter, J., Sen, S., Cheng, A.-L., El-Khoueiry, A.B., Meyer, T., Kelley, R.K., Abou-Alfa, G.K.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

3028

ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer

Fujiwara, K., Vergote, I.B., Sehouli, J., Salutari, V., Zola, P., Madry, R., Wenham, R.M., Korach, J., Pautier, P., Cibula, D., Lheureux, S., Hasegawa, K., Kim, B.-G., Lai, C.-H., Gonzalez-Martinez, A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 82 KB

2019

3029

173TiP PECan study, imaging PD-L1 in cancer: A tool for measuring response to immunotherapy?

Hughes, D J, Chand, G, Josephs, D, Harries, M, Papa, S, Spicer, J, Ting, H H, Goh, V, Cook, G

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 64 KB

2019

3030

LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis

Paz-Ares, L, Ciuleanu, T E, Yu, X, Salman, P, Pluzanski, A, Nagrial, A, Havel, L, Kowalyszyn, R, Audigier-Valette, C, Wu, Y-L, Borghaei, H, Hellmann, M D, Brahmer, J, Reck, M, Ramalingam, S, Zhang, L,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 106 KB

2019

3031

Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

de Braud, F., Siena, S., Barlesi, F., Drilon, A., Simmons, B., Huang, X., Osborne, S., Doebele, R.C.

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 87 KB

english, 2019

3032

Survival outcome and prognostic factors of patients with nasopharyngeal cancer in Yogyakarta Indonesia

Hutajulu, S.H., Howdon, D., Hariadi, K.W. Taroeno, Hardianti, M.S., Purwanto, I., Indrasari, S.R., Herdini, C., Hariwiyanto, B., Ghozali, A., Kusumo, H., Dhamiyati, W., Danarti, S.R.D., Tan, I.B., Kur

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 77 KB

english, 2019

3033

Ventricular–Subventricular zone involvement: A predictive factor for survival in glioblastoma

Pareek, V., Bhalavat, R., Chandra, M.

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

3034

100P Combination of intratumoural double-stranded RNA (dsRNA) BO-112 with systemic anti-PD-1 in patients with anti-PD-1 refractory cancer

Marquez-Rodas, I, Longo, F, Aix, S Ponce, Jove, M, Rubio, B, Blanco, A Calles, Rodriguez-Ruiz, M E, Ponz-Sarvise, M, Castañon, E, Gajate, P, Sempere-Ortega, C, Jimenez-Aguilar, E, Lopez-Casas, P, de M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 93 KB

english, 2019

3035

88P A study on analysis of clinical efficacy factor and exploring prognostic factors for reimbursement policy after immunotherapy being introduced in South Korea

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

3036

166P Insights in the mode of action of a T cell bispecific antibody in tumour bearing mice

Giusti, A M, Sam, J, Karagianni, M, Schneider, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

3037

Preliminary results from fight-102: a phase 1 study of pemigatinib in Japanese patients with advanced malignancies

Kuboki, Yasutoshi, Furukawa, Masayuki, Takahashi, Yasuo, Mizuno, Nobumasa, Hara, Hiroki, Ueno, Makoto, Ioka, Tatsuya, Takahashi, Shunji, Shimizu, Toshio, Lihou, Christine F., Tian, Chenwei, Ji, Tao, F

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

3038

113P A phase I study of an anti-IDO1 inhibitor (LY3381916) as monotherapy and in combination with an anti-PD-L1 antibody (LY3300054) in patients with advanced cancer

Kotecki, N, O'Neil, B, Jalal, S, Massard, C, Wallin, J, Szpurka, A, Wang, D, Galvao, V Regnier, Xia, M S, Crowe, K, Geeganage, S, Doman, T, Gandhi, L, Xu, X, Bendell, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

3039

Current diagnostic strategy for mammographic microcalcification without specific ultrasound abnormality

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 56 KB

2019

3040

Relation between Interleukin -4 (590C/T) gene polymorphism and hepatocellular carcinoma risk in HBV and HCV patients

Gohar, S.F., Montaser, B., Elabd, N., Elhamoly, M., Saleh, A., Salem, E., Abo-Zeid, G., Rizk, M.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 52 KB

2019

3041

Down-staging and histological effects might be predictive factors for DOC+CDDP+5-FU for esophageal cancer

Kobayashi, Kazuma, Kanetaka, Kengo, Yoneda, Akira, Kobayashi, Shinichiro, Yamaguchi, Shun, Tetsuo, Hanako, Okada, Satomi, Enjoji, Takahiro, Kuba, Sayaka, Sakimura, Chika, Kosaka, Taiichiro, Inoue, Yuu

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

3042

50P Predicting onset and continuity of patient-reported symptoms in cancer patients undergoing immune checkpoint inhibitor (ICI) therapies using machine learning

Livanainen, S M E, Ekström, J, Virtanen, H, Koivunen, J P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

3043

94O Safety and antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors: Ovarian cancer cohort data

Gao, B, Goh, J, Markman, B, Voskoboynik, M, Gan, H K, Coward, J, Palmieri, D, So, J, Meniawy, T, Chen, C, Xiang, X, Qiu, J, Xu, Y, Yang, L, Millward, M

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 90 KB

english, 2019

3044

Investigation of the use of a novel S-1 administration method for treating metastatic and recurrent breast cancer

Miki, M., Takao, S., Konishi, M., Shigeoka, Y., Miyashita, M., Suwa, H., Imamura, M., Okuno, T., Hirokaga, K., Miyoshi, Y., Murase, K., Yanai, A., Yamagami, K., Akazawa, K.

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 90 KB

english, 2019

3045

Dental prophylaxis and 5-fluorouracil related oral mucositis in head and neck cancer patients: A population-based cohort study

Huang, Y.-F., Chang, C.-T.

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 66 KB

english, 2019

3046

108P Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances Th1 cytokine production

Gavin, M A, Gragerov, A, Espling, E, Rohde, A, Sexton, T, Doulami, C, Gaitanaris, G

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 73 KB

english, 2019

3047

3O A pre-existing inflammatory immune microenvironment predicts the clinical and immunological response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 peptide vaccination

Abdulrahman, Z, de Miranda, N F C C, van Poelgeest, M I E, van der Burg, S H

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 108 KB

english, 2019

3048

170P Anti-α gal antibodies in the context of blood group and stool and tumour-adjacent microbiome in colorectal cancer patients

Selingerova, I, Budinska, E, Zwinsova, B, Mazalova, B, Bencsikova, B, Valik, D, Dubska, L Zdrazilova

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 76 KB

english, 2019

3049

134P Comprehensive assessment of anti-tumour PDL1 blockade effect in a sarcoma mouse model

Nafia, I, Chaibi, A, Bortolotto, D, Cerf, L, Italiano, A, Bessede, A

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 75 KB

english, 2019

3050

Assessment of efficacy and safety of sorafenib versus no treatment in Egyptian hepatocellular carcinoma patients

El Baghdady, N.S.E.D., El Wakeel, L., Ellithy, M.A., Eltohamy, N., Shaheen, S.M., El Naggar, A.E.R.

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 50 KB

english, 2019

3051

84P Survival outcomes in stage IV small-cell lung cancer (IV-SCLC): Analysis from SEER database

de Castro Carpeño, J, Dols, M Cobo, Gomez, M Domine, Gracia, P Ruiz, Crama, L, Campelo, M R Garcia

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 78 KB

english, 2019

3052

111P Pilot study on the feasibility, safety and immunogenicity of a personalized neoantigen-targeted immunotherapy (NeoPepVac) in combination with anti-PD-1 or anti-PD-L1 in advanced solid tumors

Moerk, S K, Donia, M, Kringelum, J V, Bogenrieder, T, Rønø, B, Sorensen, A B, Draghi, A, Bol, K F, Petersen, N V, Kadivar, M, Hernandez, S S, Hadrup, S Reker, Andreasen, L V, Christensen, D, Andersen,

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 79 KB

english, 2019

3053

37P Chemokine receptor CCR2b expressing anti-Tn-MUC1 CAR-T cells enhanced anti-breast cancer activity

Lin, Y, Yin, H, An, H, Zhou, C, Zhou, L, Chen, S, McGowan, E

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 90 KB

english, 2019

3054

Survival and prognostic factors in cholangiocarcinoma: A single-center experience

Payapwattanawong, S., Maneenil, K., Limtapatip, S., Laohavinij, S.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 50 KB

2019

3055

129O Resistance to immunotherapy is associated with high parenchymal PD1+CD8+/CD8+ T cells (PD1tR) driven by tumour CD155

de Oliveira, A Lepletier, Madore, J, Oâdonnell, J S, Johnston, R L, Eastgate, M, Mallardo, D, Ascierto, P A, Massi, D, Merelli, B, Mandala, M, Wilmott, J S, Bald, T, Stagg, J, Routy, B, Long, G V, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

3056

8P The prognostic value of tumour-infiltrating lymphocytes (TILs) in pancreatic cancer: A systematic review and meta-analysis

Orhan, A, Vogelsang, R P, Andersen, M B, Madsen, M T, HÃ¶lmich, E R, Raskov, H, GÃ¶genur, I

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 91 KB

2019

3057

9P Overall assessment of tumour-infiltrating lymphocytes in early-stage nasopharyngeal carcinoma

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

3058

78P A systematic review and meta-analysis of trials assessing activity of PD-1/PD-L1 immune checkpoint inhibitors (ICIs) for pre-treated advanced malignant mesothelioma (aMM)

Tagliamento, M, Bironzo, P, De Luca, E, Pignataro, D, Rapetti, S G, Audisio, M, Bertaglia, V, Paratore, C, Bungaro, M, Olmetto, E, Artusio, E, Reale, M L, Zichi, C, Capelletto, E, Carnio, S, Buffoni,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

3059

62P Safety and efficacy of allogeneic stem cell transplantation after nivolumab therapy for patients with relapsed/refractory classical Hodgkin lymphoma

Beynarovich, A, Lepik, K, Mikhailova, N, Kondakova, E, Zalyalov, Y, Moiseev, I, Afanasyev, B

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 85 KB

2019

3060

81P Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC) progressing after immune checkpoint inhibitors - AVATAX , a retrospective multicentric study: Preliminary data

Valery, S C, Chouaid, C, Rousseau-Bussac, G, Monnet, I, Bilger, G, BorÃ©, P, Pinsolle, J, Descourt, R, Geier, M, Toffart, A C, Cony-Makhoul, P, Robinet, G, Ennahdi, F, Zaccaria, I, Decroisette, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 75 KB

2019

3061

85P Impact of digital patient monitoring (DPM) on quality of clinical care of cancer immunotherapy (CIT)-treated patients (pts) with advanced/metastatic non-small cell lung cancer (a/mNSCLC)

Schmalz, O O, Jacob, C, Ammann, J, Liss, B, Iivanainen, S, Kammermann, M, Koivunen, J, Giger, M, Klein, A, Popescu, R A

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 87 KB

2019

3062

137P Comparative analysis of the immune microenvironment in histological subtypes of lung and breast cancer using a tissue microarray (TMA) comprising invasive margin (IM) and tumour centre (TC)

Cumberbatch, M, Memeo, L, Womack, C, Kim, W H, Bhagat, M

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 73 KB

2019

3063

146P The dynamics between neo-adjuvant treatment and immune responses in human breast cancer

Thomas, N, Garaud, S, De Wind, A, Pabois, A, De Silva, P, Craciun, L, Boisson, A, Naveaux, C, Duvillier, H, Larsimont, D, Awada, A, Willard-Gallo, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 92 KB

2019

3064

Phase I study of BI 836880, a VEGF/Ang2-blocking nanobodyÂ®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours

Yamazaki, K., Koyama, T., Shimizu, T., Takahashi, T., Watanabe, J., Tanaka, Y., Myobudani, H., Yamamoto, N.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 53 KB

2019

3065

103P Combinatorial unique photothermal tumour immunotherapy against targeted triple negative breast cancer therapy of dual modal nanoplatform

Raju, V, Yasothamani, V, Shyamsivappan, S, Haldorai, Y, Saravanakumar, K

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019

3066

Relationship between QOL and support elderly patients with permanent colostomies

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 50 KB

english, 2019

3067

Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)

Meyer, T., Finn, R., Kudo, M., Kang, Y., Yen, C., Galle, P., Llovet, J., Assenat, E., Brandi, G., Motomura, K., Okusaka, T., Hubner, R., Karwal, M., Baron, A., Ikeda, M., Liang, K., Wang, C., Widau, R

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 89 KB

2019

3068

Efficacy of first-line systemic therapy for left-sided primary metastatic colon cancer: a single-centre retrospective cohort analysis of 186 patients

Prejac, J., Kekez, D., Belev, B., PleÅ¡tina, S.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 94 KB

2019

3069

A Phase Ib Study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction

Chao, Y., Maglakelidze, M., Bulat, L.V., Yau, T., Tanasanvimon, S., Charoentum, C., Arpornwirat, W., Maneechavakajorn, J., Dechaphunkul, A., Ungtrakul, T., Yen, C.-J., Bai, L.-Y., Chou, W.-C., Weiderm

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 55 KB

2019

3070

Prediction of invasiveness in lung adenocarcinoma using machine learning algorithm based on 3D-CT imaging

Saeki, Y., Kitazawa, S., Kobayashi, N., Kikuchi, S., Goto, Y., Sato, Y.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 48 KB

2019

3071

IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy

Peters, S., Kim, A.W., Solomon, B., Gandara, D.R., Dziadziuszko, R., Brunelli, A., Garassino, M.C., Reck, M., Wang, L., To, I., Sun, S.W., Gitlitz, B.J., Sandler, A., Rizvi, N.

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 86 KB

english, 2019

3072

D3 lymph node dissection may be necessary in clinical stage I right colon cancer

Ji, W.B., Chang, Y.W.

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 49 KB

english, 2019

3073

Impact of patientsâ death on oncologists and coping strategies: An online survey

Labidi, S., El Benna, H., Sghaier, S., Nsiri, N., Nesrine, M., Berrazega, Y., Daoud, N., Boussen, H.

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 53 KB

english, 2019

3074

Usefulness for prevention of postoperative cerebrovascular complications in patients with lung cancer using carotid ultrasonography

Takeo, S., Shoji, F., Toyokawa, G., Yamazaki, K., Kozuma, Y.

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 48 KB

english, 2019

3075

An in vitro evaluation of CYP2D6 enzymatic inhibition activities of a Chinese herbal medicine formulation (Xiang Bei Yangrong Tang) for the management of cancer-related fatigue

Yap, N.Y., Ho, H.K., Zheng, H.F., Tan, C.J., Toh, Y.L., Ng, C.C., Chan, A.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 53 KB

2019

3076

Pneumonitis induced antineoplastic agents: Mortality and risk factors in 129 consecutive cases

Kaku, S., Horinouchi, H., Watanabe, H., Tamura, K., Okusaka, T., Boku, N., Yamazaki, N., Ohe, Y., Kusumoto, M.

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 47 KB

english, 2019

3077

Nasopharyngeal carcinoma: A retrospective review of outcome in a single institution

Ch'ng, W.P.P., Law, K.B., Khoo, J.Y.-Y.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 52 KB

2019

3078

Observational study on role of crude cannabis in pain control and quality of life in terminally ill cancer patients: An Indian perspective

Dusi, V., Attili, S.V.S., Singaraju, M.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 49 KB

2019

3079

A multicenter Spanish retrospective study of platinum-based chemotherapy sensitivity in the first line setting after relapse from perioperative platinum based chemotherapy in gastric cancer

del Carpio, L., Calvo, M., Hormigo, G., Serra, Ã., Losa, F., GalÃ¡n, M.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 56 KB

2019

3080

Whole-exome sequencing of non-metastatic anal squamous cell carcinoma: a prognostic genetic variants analysis

Ghanem, I., Trilla, L., GÃ¡mez, A., Mendiola, M., Maurel, J., Campos-Barros, Ã ., PeÃ±a, C., Cuatrecasas, M., G-PastriÃ¡n, L., GarcÃa Alfonso, P., Feliu, J., Fresno, J.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 51 KB

2019

3081

Assessing the quality of life of Filipino cancer patients: A survey of Filipino oncologists

Ting, F.I.L., Callueng, J.M., Vallente, J., Hurtado, R.A., Ramirez, A., Catedral, L.I., King, R.E., Mondragon, K.A., Velasco, R., Ignacio, J., Ngelangel, C.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 51 KB

2019

3082

Correlation between spleenic dose and grade of hematological toxicity in chemoradiation of stomach

Velu, U., Singh, A., Fernandes, D.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 50 KB

2019

3083

Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review

Velasco, R.N., Barbon, C.E., Sacdalan, D.B.L.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 51 KB

2019

3084

Efficacy and safety of isatuximab plus pomalidomide and dexamethasone in East Asian patients with relapsed/refractory multiple myeloma: A subgroup analysis of ICARIA-MM study

Ikeda, T., Sunami, K., Huang, S.-Y., Wang, M.-C., Koh, Y.I., Min, C.G., Yeh, S.-P., Matsumoto, M., Uchiyama, M., Iyama, S., Shimazaki, C., Lee, J.H., Kim, K.H., Kaneko, H., Kim, J.S., Lin, T.-L., Camp

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 54 KB

2019

3085

Pooled analysis of efficacy and safety in Asian patients (pts) in the MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials of ribociclib (RIB) plus endocrine therapy (ET)

Im, S.-A., Yap, Y.-S., Sohn, J., Lee, K.S., Jung, K.H., Tseng, L.M., Lee, S.C., Babu, K.G., Park, Y.H., Gounaris, I., Sondhi, M., Ridolfi, A., Zarate, J.P., Lu, Y.-S.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 59 KB

2019

3086

Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130

Rugo, H.S., Loi, S., Adams, S., Schmid, P., Schneeweiss, A., Barrios, C.H., Iwata, H., Dieras, V.C., Winer, E.P., Kockx, M., Peeters, D., Chui, S.Y., Lin, J.C., Nguyen Duc, A., Viale, G., Molinero, L.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 66 KB

2019

3087

Chief cell in stomach have stem cell activity and potential to develop gastric cancer

Yamamura, A., Matsuo, J., Lim Yi Hui, M., Liana Heng, D., Kofu, K., Md, Z.H., Douchi, D., Yeoh, K.G., Kamei, T., Naitoh, T., Osato, M., Unno, M., Ito, Y.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 51 KB

2019

3088

Daily collection of physical activity via smartphone application and smart band for development of distress screening tools in breast cancer survivors: A feasibility study

Shin, Y., Chung, I.Y.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 49 KB

2019

3089

The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma

Travers, N., Dean, A., Armstrong, K., Peeperkorn, L., Tan, M., Das, A.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 54 KB

2019

3090

Needs of cancer patients in an Asian setting

Bhoo-Pathy, N., Kong, Y.C., Bustamam, R.S., Matin Mellor Bin, A., Zaharah, H., Taib, N.A., Ho, G.F., Yip, C.H.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 53 KB

2019

3091

Combined cellular immunotherapy and chemotherapy improves clinical outcome and displays safety in the treatment of patients with colorectal cancer

Wang, C., Xie, L., Wang, Y., Liang, T., Wu, H., He, H.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 49 KB

2019

3092

Immune-related toxicities in NSCLC: Real-world experience from a tertiary cancer center

d'Arienzo, P.D., Olsson-Brown, A.C., Sallam, M., Ortega-Franco, A., Wong, H., Escriu, C.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 51 KB

2019

3093

Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center

Al-Bairmany, Y.S. Raof

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 64 KB

2019

3094

Pharmacotherapy preceding monocyte harvest interferes with the potency of monocyte-derived dendritic cell anticancer vaccine

Hlavackova, E., Pilatova, K., Fedorova, L., Mudry, P., Mazanek, P., Sterba, J., Dubska, L. Zdrazilova

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 52 KB

2019

3095

Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer

Ryu, H.-H., Ahn, S.H., Son, B.H., Lee, J.W., Ko, B.S., Kim, J., Chung, I.Y., Kim, H.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 51 KB

2019

3096

Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center

Wang, J., Zhu, J.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 50 KB

2019

3097

Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study

Chen, C.-H., Wu, S.-Y.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 50 KB

2019

3098

Clinical features of anorectal cancer in patients with Crohnâs disease: Japanese single center study

Watanabe, K., Kohyama, A., Suzuki, H., Kajiwara, T., Karasawa, H., Ohnuma, S., Musha, H., Kamei, T., Naitoh, T., Unno, M.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 49 KB

2019

3099

Influence of liver metastasis locations on overall survival in patients with colorectal cancer

Sone, T., Murai, T., Itaya, K., Koike, Y., Ono, Y., Nakamura, M.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 62 KB

2019

3100

Results From a Phase I Study of MK-1308 (ANTIâCTLA-4) Plus Pembrolizumab in Previously Treated Advanced Small Cell Lung Cancer

Cho, B.C., Yoh, K., Bar, J., Nagrial, A., Spigel, D.R., Gutierrez, M., Kim, D.-W., Kotasek, D., Rasco, D., Niu, J., Satouchi, M., Ahn, M.-J., Lee, D.H., Maurice-Dror, C., Siddiqi, S., Li, X., Cyrus, J

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 70 KB

2019

3101

The challenge of evaluating new targeted therapies: Opportunities in stratifying the therapeutic response per tumour location

Beaumont, H., Faye, N., Iannessi, A., Klifa, C., Hsieh, C.-Y.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 54 KB

2019

3102

Helicobacter pylori-positive gastric diffuse large B-cell lymphoma: A subset with distinct prognostic features

Cheng, Y., Ma, X., Yang, J.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 49 KB

2019

3103

Treatment of refractory recurrent gastrointestinal stromal tumors with adoptive cellular immunotherapy (TILs) and personalized vaccine

Tavartkiladze, A.A., Khutsishvili, R., Revazishvili, P., Maisuradze, M., Tavartkiladze, L., Tavartkiladze, G.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 52 KB

2019

3104

The Immunoglobulin Superfamily Receptome Defines Cancer-Relevant Networks Associated with Response to Immunotherapy

Martinez-Martin, N., Verschueren, E., Husain, B.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 53 KB

2019

3105

Prognostic implications of residual disease tumour-infiltrating lymphocytes in gastric cancer patients after neoadjuvant chemotherapy

Xing, X., Jia, S., Feng, Y., Zhang, M., Ji, J.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 62 KB

2019

3106

The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy

Bae, S.J., Park, S., Cha, C., Lee, J., Kim, D., Ahn, S.G., Jeong, J.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 66 KB

2019

3107

Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 63 KB

2019

3108

Imatinib induced toxicity and its influence on cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia

Natarajan, H., Kumar, L., Bakhshi, S., Sharma, A., Velpandian, T., Kabra, M., Gogia, A., Biswas, N.R., Gupta, Y.K.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 53 KB

2019

3109

Editorial board

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 131 KB

2019

3110

Title Page

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 143 KB

2019

3111

International Association for the Study of Lung Cancer (IASLC)

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 57 KB

2019

3112

Editorial board

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 108 KB

2019

3113

EACR Board

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 99 KB

2019

3114

The European Association for Cancer Research (EACR)

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 99 KB

2019

3115

Table of Contents

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 158 KB

2019

3116

Table of Contents

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 126 KB

2019

3117

Editorial Board

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 109 KB

2019

3118

Editorial Board

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 155 KB

2019

3119

Table of Contents

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 165 KB

2019

3120

Flavonoids from ethanol extracts of euphorbia hirta inhibit melanoma growth and metastatic potential

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 51 KB

2019

3121

Editorial Board

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 108 KB

2019

3122

INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study

Yang, J.C.-H., Ellers-Lenz, B., Straub, J., Johne, A., Wu, Y.-L.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 41 KB

2019

3123

Title page

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 220 KB

2019

3124

Table of Contents

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 138 KB

2019

3125

Table of Contents

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 151 KB

2019

3126

European Lung Cancer Congress (ELCC) 2019 Organisation and Officers

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 77 KB

2019

3127

Editorial board

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 135 KB

2019

3128

Editorial board

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 108 KB

2019

3129

Editorial board

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 106 KB

2019

3130

Table of Contents

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 134 KB

2019

3131

ESMO Executive Board 2019

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 56 KB

2019

3132

Editorial Board

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 108 KB

2019

3133

The European Society for Medical Oncology (ESMO)

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 47 KB

2019

3134

Molecular Analysis for Personalised Therapy (MAP) 2019 Officers and Organisation

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 76 KB

2019

3135

Table of Contents

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 150 KB

2019

3136

Editorial board

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 109 KB

2019

3137

Artemisia absinthium nanoparticles induce apoptosis in breast cancer cells via inhibiting vesicular trafficking related proteins

Mughees, M., Wajid, S.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 50 KB

2019

3138

Incidence of thyroid carcinoma in the Philippines: A retrospective study from a tertiary university hospital

Caguioa, P.B., Bebero, K.G.M., Bendebel, M.T.B., Saldana, J.S.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 50 KB

2019

3139

Malignant melanoma: A study of clinical profiles and treatment outcomes in Indian patients

Shishak, S.A., Rastogi, S., Pandey, R., Barwad, A., Dhamija, E., Aggarwal, A., Kalra, K., Shamim, S.A., Parisa, M.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 51 KB

2019

3140

Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)

Kubo, T., Nogami, N., Bessho, A., Morita, A., Ikeo, S., Yokoyama, T., Ishihara, M., Honda, T., Fujimoto, N., Murakami, S., Kaira, K., Harada, T., Nakamura, K., Iwasawa, S., Shimokawa, T., Kiura, K., Y

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 67 KB

2019

3141

MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer

Sledge, G.W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P.A., Koh, H., Grischke, E.-M., Conte, P.F., Lu, Y., Barriga, S., Hurt, K., Frenzel, M.,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 69 KB

2019

3142

Personal antigen selection calculator (PASCal) for the design of personal cancer vaccines

Somogyi, E., Csiszovszki, Z., Lorincz, O., Toth, J., Molnar, L., SchÃ¶nharting, W., Urban, S., RÃ¶hnisch, T., PÃ¡ntya, K., Pales, P., Megyesi, M., TÅke, E.R.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 68 KB

2019

3143

Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort

Wu, L., Zhu, J., Yin, R., Wu, X., Lou, G., Wang, J., Gao, Y., Kong, B., Lu, X., Zhou, Q., Wang, Y., Chen, Y., Lu, W., Li, W., Cheng, Y., Liu, J., Ma, X., Zhang, J.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 62 KB

2019

3144

Lessons learnt from treatment of foot sarcomas: Analysis from dedicated sarcoma clinic in North India

Pawar, S.J., Rastogi, S., Dhamija, E., Barwad, A., Kumar, V., Pandey, R., Shishak, S., Kalra, K., Aggarwal, A., Garg, A., Mridha, A.R., Chaubey, J., Khan, S.A.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 50 KB

2019

3145

Table of Contents

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 154 KB

2019

3146

Title Page

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 222 KB

2019

3147

The European Society for Medical Oncology (ESMO)

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 80 KB

2019

3148

ESMO

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 44 KB

2019

3149

Loss of BAP-1 influences the activation of p52 and RelB proteins in the Inflammatory microenvironment of uveal melanoma

Singh, M.K., Kashyap, S., Singh, L., Pushker, N., Bakhshi, S., Sen, S.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 54 KB

2019

3150

Table of Contents

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 180 KB

2019

3151

The European Oncology Nursing Society (EONS)

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 136 KB

2019

3152

Editorial board

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 137 KB

2019

3153

Predictive value of neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) In hepatocellular carcinoma (HCC) patients treated with nivolumab (N)

Dharmapuri, S., Ãzbek, U., Lin, J.-Y., Schwartz, M., Branch, A., Ang, C.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 70 KB

2019

3154

Population-based validation of the risk stratification among prostate cancer patients

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 50 KB

2019

3155

Unusual folding of NaPi2b transporter extramembrane domain 4 during malignant transformation

Minigulova, L., Skripova, V., Nurgalieva, A.K., Ionova, N., Reshetnikova, D., Bogdanov, M., Kiyamova, R.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 314 KB

2019

3156

Efficacy of Cetuximab Based Chemotherapy after Immunotherapy Treatments (IT) in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Patients (pts)

Hernando-Calvo, A., Mirallas, O., Marmolejo, D., Felip, E., Garralda, E., Javierre, G. Villacampa, Feliu, B., MartÃnez, S., Gutierrez, R., Dienstmann, R., BraÃ±a, I.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 55 KB

2019

3157

THOR-707, a novel not-alpha IL-2, promotes all key immune system anti-tumoral actions of IL-2 without eliciting vascular leak syndrome (VLS)

Milla, M.E., Ptacin, J.L., Ma, L., Caffaro, C.E., Aerni, H.R., San Jose, K.M., Pena, M.J., Herman, R.W., Pavlova, Y., Chen, D.B., Ismaili, T.K., Li, S., Nguyen, J., Singh, N., Shawver, L.K., Koriazova

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 51 KB

2019

3158

Evaluation of mouse polyclonal antibody against nNav1.5 to recognize nNav1.5 protein in human breast cancer cells using fluorescence immunostaining

Mokhtar, N.F., Sharuddin, N.A., Che Wahab, N.F.A., Dominguez, A.A., Sarmiento, M.E., Mohd Nor, N., Yaccob, N.S.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 54 KB

2019

3159

Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours

Meric-Bernstam, F., Hanna, D., Beeram, M., Lee, K.-W., Kang, Y.-K., Chaves, J., Lee, J., Goodwin, R., Vaklavas, C., Oh, D.-Y., Rha, S.Y., Elimova, E., Mayordomo, J., Ferrario, C., Cobleigh, M.A., Fort

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 64 KB

2019

3160

Assessments of cancer-free lymph nodes for the prediction of disease progression

Grigoriadis, A., Kurian, N., Ankathi, S., Hardiman, T., Woodman, N., Owens, J., Paharia, S., Meena, S., Coolen, A.C., Ranes, S., Gillett, C., Pinder, S., Sethi, A.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 53 KB

2019

3161

Anti-osteolytic use to prevent skeletal related events in solid tumour bone metastases

Woodard, C.R., Henry, D.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 63 KB

2019

3162

Chronic myelod leukemia in chronic phase (CML-CP) with lymphadenopathy at diagnosis: A retrospective analysis

Prasanna, G. Veni, Boya, R.R., Bendi, C., Voonna, P., Krishna, V. Murali

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 57 KB

2019

3163

Prognostic biomarkers in lung cancer patients treated with immunotherapy

Ferreira, S., Esteves, S., Almodovar, M.T.A.S.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 55 KB

2019

3164

A comprehensive tumour immunogenomics platform for precision immunotherapy: Enabling simultaneous characterization of tumours and the TME from a single FFPE sample

Power, R., Bartha, G., Harris, J., Boyle, S.M., Levy, E., Milani, P., Tandon, P., Li, R., Chinnappa, M., Haddad, A., McNitt, P., McClory, R., Morra, M., Saldivar, S., Clark, M., Haudenschild, C., Newb

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 54 KB

2019

3165

First CAR-T cell immunotherapy against HLA-G: Targeting a unique ICP and TAA

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 66 KB

2019

3166

Applicability of the LIPI score to metastatic microsatellite instability high cancer patients treated with immune checkpoint inhibitors

Vuagnat, P., Auclin, E., Mezquita, L., Alfonso, J. Adeva, Tocino, M.R. Vidal, Munoz, F. Longo, El Dakdouki, Y., Romano, P. Martin, Baldini, C., Varga, A., Garcia-Carbonero, R., Besse, B., Massard, C.,

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 56 KB

2019

3167

Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455)

Grohe, C., Gleiber, W., KrÃ¼ger, S., Mueller-Huesmann, H., Schulze, M., Atz, J., Kaiser, R.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 57 KB

2019

3168

Increasing Responses to T-Cell Therapies in Solid Tumours by the Use of an Engineered Adenovirus Coding for TNFa and IL-2

Cervera-Carrascon, V., Havunen, R., Santos, J.M., Quixabeira, D.C.A., Hemminki, A., Zafar, S.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 49 KB

2019

3169

Development of Advanced Human Immune System Mouse Models for Pre-Clinical Research in Immuno-oncology

Mossu, A., Tschumi, B.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 67 KB

2019

3170

Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors

de Miguel, P. Ayala, Gallego, J. LÃ³pez, GarcÃa, I. Gorospe, Varella, A. IllÃ¡n, Vargas, P.R. Rivera, Restrepo, A. Posada, GarcÃa, P. Borrega

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 54 KB

2019

3171

A population pharmacokinetic model: Assessment of pharmacokinetic similarity of HLX01 and rituximab in diffuse large B-cell lymphoma

Shi, Y., Qin, Y., Zhao, S., Hu, P., Zeng, X., Zhang, X., Jiang, W., Liu, S., Liu, E., Chai, K., Luk, A., Yao, D.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 78 KB

2019

3172

Expression profiles of serum long non-coding RNA in ovarian cancer patients receiving platinum-containing chemotherapy

Gening, S., Dolgova, D., Abakumova, T., Rizvanov, A., Antoneeva, I.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 52 KB

2019

3173

Influence of nivolumab on epidemiology of infectious complications in patients with relapse or refractory Hodgkinâs lymphoma

Rogacheva, Y., Popova, M., Lepik, K., Kondakova, E., Zalyalov, Y., Stelmah, L., Volkova, A., Nikolaev, I., Goloshchapov, O., Barhatov, I., Bondarenko, S., Moiseev, I., Baykov, V., Mikhailova, N., Klim

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 54 KB

2019

3174

Five fractions plus âSRSâ boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)

Rashid, A., Memon, M.A., Hashim, A.S.M.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 49 KB

2019

3175

PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience

Baghmar, S., Agarwal, A., Gauda, C., Qureshi, S., Malik, P.S., Vaibhav, V.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 71 KB

2019

3176

Real-world fusion landscape in advanced Chinese pancreatic cancer using next generation sequecing: A multicenter study

Shen, Y., Fang, S., Cai, X., Fang, Y., Lin, R., Zhang, Y., Li, J., Liang, X., Wang, L., Lin, L., Zhang, L., Feng, H., Lan, S., Cai, X., Xu, C., Wang, W., Fang, M., Zhang, J.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 60 KB

2019

3177

Use of gamma irradiated bone allografts in treatment of various bone tumours

Mishra, A.N., Kapoor, S., Mishra, S.M., Mishra, Y.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 44 KB

2019

3178

Single-nucleotide polymorphism variation (SNV): Possible candidates as predictive biomarkers to response and progression free survival (PFS) in cutaneous malignant melanoma (CMM) patients treated with immune checkpoint inhibitors (ICI)

Svedman, F. Costa, Yang, M., Tuominen, R., Brage, S.E., HÃ¶iom, V.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 274 KB

2019

3179

Biliary cancers: Experience of Medical Oncology Department, University-Hospital Center of Tizi Ouzou, Algeria

Sedkaoui, C., Ammour, H., Ouikene, A.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 48 KB

2019

3180

Multispectral immunofluorescence and computational imaging analysis define the prognostic role of T-cell infiltrates in gastric cancer

Challoner, B.R., von Loga, K., Woolston, A., Griffiths, B., Hewitt, L., Saito, Y., Sivamanoharan, N., Mansfield, D., Melcher, A.A., Grabsch, H., Gerlinger, M.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 52 KB

2019

3181

RNA-seq based transcriptome profiling provides important insights into progression of gastric cancer

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 51 KB

2019

3182

Development of a biomarker-based calculator to predict the probability to achieve a pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer

Marandino, L., Bandini, M., Madison, R., Raggi, D., Gallina, A., Colecchia, M., LucianÃ², R., Giannatempo, P., FarÃ¨, E., Pederzoli, F., Bianchi, M., Colombo, R., Capitanio, U., Ali, S.M., Chung, J.H.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 67 KB

2019

3183

Evaluation of immune response in young patients with sarcoma treated by dendritic cell-based immunotherapy

Fedorova, L., Dubska, L. Zdrazilova, Selingerova, I., Pilatova, K., Mudry, P., Sterba, J., Demlova, R., Valik, D.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 55 KB

2019

3184

Analysis of the immune microenvironment in pre-treatment non-small cell lung cancer (NSCLC) patients with follow-up response data to second-line immunotherapy

Bhagat, M., Warren, S., Elliott, N., Womack, C., Memeo, L., Colarossi, L., Cumberbatch, M.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 53 KB

2019

3185

Correlation between bio-impedance analysis and abdominal CT scan to diagnose decreased muscle mass in adult cancer patients

Kurniawan, A., Hatma, R.D., Adisasmita, A., Soetandyo, N., Witjaksono, F., Panigoro, S.S., Rivami, D.S., Sumantri, R., Tamin, T.Z., Wijovi, F., Putri, H., Raffaello, W.M., Saroso, O.A., Rahman, J., Ha

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 51 KB

2019

3186

Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment

Pareek, V., Bhalavat, R., Chandra, M.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 62 KB

2019

3187

Progressive muscle relaxation and guided imagery techniques and the way of coping of parents of children with malignancies: A randomized controlled trial

Theologia, T.A., Raftopoulos, V., Papastavrou, E., Rousou, E., Charalambous, A.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 55 KB

2019

3188

Investigation of the mechanism of action of anti-PD-1 treatment by systematic depletion of different immune cell populations in syngeneic models

Bourre, L., Jin, Y., Muntel, J., Yu, H., Beeler, K., Bruderer, R., Shan, Y., An, A. Xiaoyu, Ouyang, D. Xuesong, Li, H. Qixiang

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 5.05 MB

2019

3189

The clearance of EGF by tumor-associated macrophages is suppressed by chemotherapeutic agent cisplatin

Larionova, I.V., Liu, T., Riabov, V., Mossel, D.M., Patysheva, M.R., Kiselev, A.M., Kazakova, E.O., Cherdyntseva, N.V., Kzhyshkowska, J.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 1.09 MB

2019

3190

Predictive factors of intensive care outcomes of patients admitted with immune-related adverse events

Paiva, R.V.D.S., Cojocaru, E., Grover, V.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 66 KB

2019

3191

18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma

Rozeman, E.A., Menzies, A.M., Krijgsman, O., Hoefsmit, E.P., van de Wiel, B.A., Sikorska, K., Van, T.M., Eriksson, H., Bierman, C., Gonzalez, M., Shannon, K., Broeks, A., Kerkhoven, R., Spillane, A.J.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 51 KB

2019

3192

EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma

Petrylak, D.P., Rosenberg, J.E., Lee, J., Yonese, J., Duran, I., Loriot, Y., Sonpavde, G., Wu, C., Gartner, E.M., Melhem-Bertrandt, A., Powles, T.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 55 KB

2019

3193

Feasibility of precision cancer medicine in advanced gynaecologic cancers

Taghizadeh, H., Mader, R.M., MÃ¼llauer, L., Aust, S., Polterauer, S., Reinthaller, A., KÃ¶lbl, H., Seebacher, V., Grimm, C., Prager, G.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 52 KB

2019

3194

Treatment outcomes of colorectal cancer patients enrolled in a comprehensive benefits program of the National Health Insurance System in the Philippines: Data from the program pilot site

Sacdalan, D.B.L., Ting, F.I.L., Tampo, M.M., Monroy, H.I., Sacdalan, D.L.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 134 KB

2019

3195

Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer

Oi, H., Yamano, Y., Yokoyama, T., Matsuda, T., Morise, M., Kataoka, K., Kimura, T., Kondoh, Y.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 50 KB

2019

3196

On the right TRK: from oncogene discovery to cancer therapeutics

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 65 KB

2019

3197

A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection

Yan, S., Zhang, Y., Bi, X., Zhao, J., Du, S., Huang, Z., Zhang, Y., Liu, D., Li, Z., Zhou, J., Cai, J., Zhao, H.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 42 KB

2019

3198

Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours

Ziegler, D.S., Doz, F., Geoerger, B., Dubois, S., Grilley-Olson, J.E., van Tilburg, C., Italiano, A., Lissat, A., Kang, J.-H., Tahara, M., Boni, V., Perreault, S., Capra, M., Nanda, S., Brega, N., Hol

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 57 KB

2019

3199

Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study

Huang, W., Chen, Y., Chang, W., Wei, Y., Xu, J.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 51 KB

2019

To build up a library is to create a life. It’s never just a random collection of books.

— Carlos María Domínguez

Official channel

Z-Library Desktop Launcher

Tor version

Z-Library

Z-Library Since 2009 support@z-lib.do

EnglishРусскийEspañolItalianoελληνικάاللغة العربيةBahasa IndonesiaBahasa Malaysiaहिन्दीDeutschFrançaisPortuguêsУкраїнськаPolski中文繁體中文日本語Tiếng ViệtAzərbaycan DiliՀայոց լեզուภาษาไทยTürk Diliქართველიবাংলাپښتوతెలుగుاردو한국어SrpskiБългарски